This is the historic Biotech Daily back copies page.

The current page is at: www.biotechdaily.com.au/back-copies/

 

View recent copies of Biotech Daily with important stories on research and development (R&D), mergers and acquisitions (M&A), finance, government grants and regulation, share price movements, industry news and personnel appointments in Australian Stock Exchange listed biotechnology companies.

All articles include the company name, technology and indication and many have senior personnel in the headline. The easiest way to search is by opening a dialogue box by typing Control F or Command F.

 

 

Friday April 1, 2022

March BDI-40 Up 1.2%, ASX200 Up 6.4%
Big Caps Up 1.4%, NBI Up 4.25%

 

Mar 31, 2022

Dr Boreham’s Crucible: Bio-Bargains; Federal 2040 Health Strategy Committee Appointed; Roger Allen, Patagorang Take 5.5% Of Hydrix; Jason Carroll Takes 11.2% Of Island; Tiffany Olson Replaces Telix Director Oliver Buck; Compumedics Loses Director Tucson Dunn; Nova’s Joe Bankovich Appointed US Glaucoma Society Adviser

Mar 30, 2022

Budget 2022: Further Details, Comment & Response - Ausbiotech, Genesiscare, Insulet, Biotech Daily; Genetic Signatures $5.4m Welsh Easyscreen Deal; Clinuvel Doses 2nd Afamelanotide DNA Repair Cohort; Memphasys: India, China Repeat Felix Cartridge Orders; Recce: 1000mg R-327 ‘Safe, Well-Tolerated’; Race: Astex Free ASTX727 For Zantrene AML, MDS Trial; Argenica ARG-007 ‘Protects Ischaemic Brain Death, In Rats’; Living Cell, University Of Technology Sydney Optimize NTCell; Uscom Unmarketable Parcel Facility Buys Back 269k Shares; Total Brain, Varga Continue $700k Loan Talks; Painchek Appoints Cynthia Payne Director

Mar 29, 30, 2022

Budget 2022 Special Edition

mRNA Vaccines, Women’s Health, Aged Care

Comment & Analyses

Mar 29, 2022

Budget 2022 Special Edition

mRNA Vaccines, Women’s Health, Aged Care

Mar 29, 2022

Tessara Hopes To Raise $10m For Realbrain; UNSW Founders Synbio 10x $840k For Six Start-Ups; Avecho TPM-CBD Gel ‘Highly Significant For OA Pain’; Telix: FDA Orphan Status For TLX66 Transplant ‘Conditioning’; Telix: Xiel Replaces Curium As Illuccix UK, Ireland Distributor; Liquidators Sell Palla UK, Norway; ‘Nothing For Investors’; Nyrada: ‘Oral NYR-BI02 Beats BI01 For Brain Injury, In Mice’; Artrya Opens Los Angeles Office; Dimerix Receives $3.7m Federal R&D Tax Incentive; Credit Suisse Takes 5% Of Mesoblast; Respiri Appoints EAS US Corporate Adviser

Mar 28, 2022

Clarity Opens Prostate Cancer Imaging Trial Recruitment; Oncosil: Germany Funds Pancreatic Cancer Trial; Painchek: NZ’s Summerset Adopts Pain Monitor; Micro-X: MXR Imaging To Distribute Rover X-Ray In US; Inoviq Amends Defence In Performance Share Legal Matter; Recce Receives $3.1m Federal R&D Tax Incentive; Botanix Receives $2.8m Federal R&D Tax Incentive; Creso: Halucenex Upgrade To Grow Psilocybin Mushrooms; ASX Lifts Chimeric Options Suspension; Regal Funds Below 5% In Micro-X; Perennial Reduces To 6.75% In Imex; Cronos Loses Director Kurt Schmidt

Mar 25, 2022

Dr Boreham’s Crucible: Atomo Diagnostics; Doherty Trials 2 Sars-Cov-2 Vaccines; Chimeric Places $2.7m Of $6.4m Shortfall; Total $14.4m; Micro-X: $900k Milestone Payment Due For Stroke Imaging Data; Neuren: FDA Okays NNZ-2591 Pitt-Hopkins IND, Trial; Nuheara 20-To-One Consolidation, Stock Ratification EGM

Mar 24, 2022

Unisuper Invests $75m In Uniseed; Doherty, Moderna Expediate mRNA Vaccine Research; Clarity: US Investigator Copper-64 Prostate Cancer Trial; Servatus Starts Probiotics For Insomnia Trial; Imugene Takes Checkvacc To 2nd Cohort; Immutep: IMP321 For Lung Cancer ‘Safe, Encouraging Activity’; Incannex $125m Scrip For Marijuana Company Apirx; Proteomics: Promarkerd India Patent; Carl Charalambous Takes 8.8% Of Exopharm; Harbour Takes 11% Of Volpara; Mesoblast Appoints Dr Philip Krause Director

Mar 23, 2022

Doherty: Sars-Cov-2 Vaccines Give ‘Lasting’ T-Cell Immunity; Flinders Uni Discovers Gut-Brain Communication Route; Chimeric Rights Raise $4.3m; Total $11.7m; $6.4m Shortfall Halt; Neuren: FDA Approves NNZ-2591 Phelan-McDermid IND, Trial; Telix Approved For TLX101 Glioblastoma Trial; Imugene: US Okay For Phase I Vaxinia Tumor Trial; Chimeric: CHM2101 ‘Eradicates Tumors’, In Mice; Radiopharm: Genesiscare For 1st Australian Cancer Trial; PYC: FDA ‘Concurs’ With Pre-IND Plans; Clime Down To 8.6% Of Mach7; Life Biosciences Reduces To 10% Of Alterity; SG Hiscock Increases, Diluted To 5.1% Of Althea; Anteo To Lose CEO Derek Thomson, Too

Mar 22, 2022

Avita: BARDA Backs Recell Soft Tissue Trial; Noxopharm: Veyonda Soft Tissue Sarcoma FDA Orphan Status; Resapp Claims 92% Covid-19 Detection; Alcidion: $1.35m Herefordshire, Worcestershire NHS Miya Deal; Memphasys: ‘Samson 90% Pregnancy Prediction Rate’; Next Science Share Plan Raises $4.8m; Total $14.8m; Telix Starts Belgium Radio-Pharmaceutical Facility; Total Brain To Repay $3.2m Loans, Expects R&D Tax Incentive; Incannex Requests ‘Acquisition’ Trading Halt; Bio-Melbourne Forum On Cytiva Bio-Challenge; Botanix Appoints Daniel Sharp Director; Mayne Appoints Ann Custin Director

Mar 21, 2022

Federal $28.1m For Geonomics Australia; University Of New South Wales Opens RNA Institute; Baymatob Raises $4.2m For Oli Labor Monitor; Orthocell: TGA Approves Celgro Remplir For Nerve Repair; Living Cell: Shortfall Raises No Funds; Total $3.86m; Anteo Tells ASX Query: ‘Webinar Had No New Information’; ASX Suspends Chimeric Options; Resapp Takes ‘Covid Results’ Halt To Suspension; VGI: Study Backs Delta-Tocotrienol Pharmaco-Kinetics; Immutep Wins Japan LAG525 For Cancer Patent; Creso: Market Share ‘Milestone’; Plant Yield Up

Mar 18, 2022

Dr Boreham’s Crucible: Immutep; Redhill Revenue Up 33% To $116m, Loss Up 28% To $133m; Impedimed: Astrazeneca Extends Sozo Kidney Contract; Polynovo Sells Port Melbourne HQ For $6.4m; Leaseback; Micro-X: $1.9m US Bag Scanner Prototype Milestone; Incannex: Up-To $69m In-The-Money ‘Loyalty’, Piggy-Back Options; IDT Misses Federal mRNA Grant, 2nd ‘Remains Live’; JM Financial Reduces To 8.7% Of Universal Biosensors; Peters Takes 12.7% Of Optiscan

Mar 17, 2022

Garvan $185m Fund For Rare, Untreatable Cancers; Micro-X Sends 4 Rover X-Ray Units To Ukraine; 4D Launches MRFF-Funded XV Lung Scanner; Imagion: Magsense Agent ‘Safe, Well Tolerated’; Paradigm: UK Approves Osteo-Arthritis Trial; Pharmaxis Adds Taiwan To PXS-5505 Bone Cancer Trial; Clinuvel: Neuracthel Batches For Regulatory Approval; Biotron: ‘BIT225 Effective Against Sars-Cov-2, In Mice’; Race: Zantrene ‘Highly Effective’ Against Leukaemia, In Mice; Emyria High Dose Marijuana CBD EMD-RX7; Trial Planned; IDT Requests mRNA ‘Grant Application’ Trading Halt; Orthocell Requests ‘Regulatory Approval’ Trading Halt; Resapp Requests ‘Covid Results’ Trading Halt; Pacific Edge Appoints Tony Barclay Director

Mar 16, 2022

Haemokinesis $17m IPO For Rapid Blood Group Tests; Victoria $10m For 20 Cancer Research Projects; LBT Sells First 5 US APAS Instruments; $2m; Redhill, Kukbo Up-To $10m South Korea Opaganib Covid-19 Deal; Ena Doses 1st INNA-051 Influenza Challenge Participants; Alcidion Signs $1.9m Miya Deal With Tayside NHS; Creso To Ship 35k Marijuana Lozenges To Sierra Sage Herbs; Regal Reduces To 6.5% Of Althea; Immuron Appoints Paul Brennan Director

Mar 15, 2022

Clinuvel: Afamelanotide ‘Safe For Stroke’, Positive Data; Victoria, Intervenn, St Vincent’s Early Cancer Detection; Wearoptimo ‘Multi-Million Dollar Hydration Deal With Aspen’; Imugene To Trial HER-Vaxx, Keytruda For Gastric Cancer; Respiri: Wheezo For Paid Michigan Children’s Program; Cann Group: Mildura Facility ‘Practical Completion’; Opthea: 100% Directors Pay Hike, 2m Directors Options EGM; Pharmaust Manufactures Monepantel For Trials; Radiopharm Appoints Bill Regan Regulatory Strategy Head

Mar 14, 2022

Victoria, South Korea mRNA Vaccine Partnership; Bionomics Receives Cancer Therapeutics CRC $264k; Antisense: ‘ATL1102 Improves Bone Density’; Memphasys: Draft ISO 13485 For Management Systems; EBR: Leadless Pacemaker Included In Solve-CRT Trial; Osteopore, Singular Study AI Design For Cranial Implants; Allegra: ‘Systemic Safety For Sr-Ht-Gahnite Device’; Zelira 175-To-1 Consolidation EGM; Perennial Takes 12.6% Of Lumos; Starfish II Transfers Dorsavi Shares To Nominees; Anteotech: Chair Jack Hamilton To Go; Chris Parker Executive

Mar 11, 2022

Dr Boreham’s Crucible: Mayne Pharma; Victoria $3m For Medical Technology Manufacturers; Neuren: Australia NNZ-2591 For Angelman Trial Approved; Medibio Rights Raise $730k Of Hoped-For $3.4m; Neuroscientific: Emtinb Reduces Cytokines, In-Vitro; IQ3 Requests Administration ‘To Restructure’; Anteo Pleads ‘Presentation’ To ASX43% Fall Query; State Street Takes 7% Of Nanosonics; Auscann Loses CFO Charles Altshuler; New CFO Wanted

Mar 10, 2022

Volpara: Euro Society Backs Breast Density Awareness; Race: Zantrene Kills Kidney Cancer, In-Vitro; Incannex: Marijuana IHL-42X ‘Reduces Sleep Apnoea 44%’; Immutep: IMP321 Breast Cancer Trial FDA Talks ‘Constructive’; Bio-Melbourne Optimizes Medtech Success; Chair Paul Rennie Increases, Diluted To 8.7% Of Paradigm; Sandon Takes 12.2% Of IDT; Geoffrey O’Brien ‘Increases, Diluted’ To 9% Of Hexima; Steven Waller Replaces Cryosite Chair Bryan Dulhunty

Mar 9, 2022

Paradigm: ‘Final USPTO Rejection Not Final’; Eye Co: Omega-3,6 For AMD Trial; Emyria Starts EMD-RX5 Phase I Recruitment; Brandon Renames MRCF ‘Brandon Biocatalyst’; Korda Mentha To Liquidate Palla Pharma; Adalta Receives 2nd Tranche Of $4m Victoria Loan; Regal Takes 17% Of Opthea; L1 Capital Reduces To 8.4% Of Anteris; Fidelity Takes 9.6% Of Medibio; Emvision Appoints 3 Advisors

Mar 8, 2022

Telix Completes TLX250-CDx For Renal Cancer Imaging Dosing; Chimeric Extends Rights Offer; Incannex Requests ‘Trial Results’ Trading Halt; Bio-Melbourne Automates Trials, Management

Mar 7, 2022

Impedimed: ‘Sozo Assesses Bone Mineral Content’; S&P ASX Indices: 7 Biotechs Up; 9 Down; Mach7: $2.4m Trinity, Penn State VNA Orders; Adherium Files US FDA 510k Ellipta, Hailie Application; Chimeric Core-NK (CHM0201): No GvHD, Toxicities; Recce R327 I-V Dose Increase To 1,000mg; Universal Biosensors Appoints Graham McLean Director; Malcolm Thompson Replaces Audeara CFO Peter Harding-Smith

Mar 4, 2022

Dr Boreham’s Crucible: Cochlear; Starpharma Tells TGA: ‘Viraleze A Device, Not A Drug’; CSL Takes 74% Of Vifor, Offer ‘Successful’; Chimeric: Be The Match For Cell Collection; US Patent For Tissue Repair Polysaccharide Manufacture; Director Andrew Kroger Takes 46% Of Cryosite; Micro-X Appoints Ilona Meyer Director

Mar 3, 2022

Redhill Oral RHB-107 ‘Highly Promising’ For Covid-19; Woke: Monash To Develop ‘High Dose Psilocybin’; Avita, Premier Recell Spray-On-Skin Supply Deal; Palla Liquidation: ‘Nothing For Investors’; Truscreen: Zimbabwe Orders 11k Cervical Cancer Sensors; Emyria Ready For Phase I EMD-RX5 O-T-C Marijuana Trial; Incannex: Monash $800k Psychedelic, Virtual Reality For Anxiety; Chair Paul Hopper Increases, Diluted To 21% Of Chimeric; Opthea Appoints Dr Joel Naor CMO; Neurotech Appoints Dr Alexandra Andrews CEO, On $250k PA; Anteris Appoints Dr Karl Poon Medical Adviser

Mar 2, 2022

Anteris ‘20% Discount’ $28m Placement; Perceptive Takes 14%; Medibio, CPS: ‘Ukraine War Ends Underwriting’; Telix ‘Market Conditions’ Cancel Share Plan; Medical Developments: FDA Lifts Clinical Hold On Penthrox; Cardiex: Mobvoi Ticwatch With Atcor Technology; Adalta: China Patent For AD-214; Mitsubishi Takes 6.7% Of Nanosonics; Regeneus Loses Director Dr John Chiplin; Medibio Appoints Dr Matt Mesnik Director

Mar 1, 2022

February BDI-40 Down 12%, ASX200 Up 1%, Big Caps Up 3%, NBI Down 4%; Firebrick To Appeal TGA Nasodine Knock-Back; Avita H2 Revenue Up 37% To $19m, Loss Down 9% To $20m; Imex Revenue Up 22.5% To $13.3m, Loss Up 30% $4.7m; Hydrix H1 Revenue Up 1.5% To $5.2m, Loss Down 50.1% $2.4m; Creso Revenue Up 154% To $6.2m, Loss Down 6.3% To $30m; Epsilon Revenue Down 21% To $5.5m, Loss Down 15.4% To $9m; Cardiex H1 Revenue Down 12.6% To $2.3m, Loss Up 147% To $5.1m; Osteopore Revenue Down 26% To $1.1m, Loss Up 86% To $3.6m; Avecho Begins TPM-CBD Osteoarthritis Trial; Starpharma: ‘SPL7013 Reduces Omicron 95% In 1min, In-Vitro’; Cardiex Completes 10-For-1 Consolidation; ASX Suspends IQ3 On Accounts; Medical Developments Requests ‘FDA Hold Feedback’ Halt; Anteris Requests Capital Raising Trading Halt; Epsilon Requests ‘Valens Partnership’ Trading Halt; Alterity Below Nasdaq $US1 Bid Rule, Again; First Sentier Takes 6.7% Of Nanosonics; Cryosite Director Andrew Kroger Takes 43%

Feb 28, 2022

Clarity: China Grand Option, $1.75 Options Lapse; Hydrix Placement Raises $2.8m; Kazia: Paxalisib, Metformin, Ketogenic Diet Glioblastoma Trial; Patrys PAT-DX3 Stable Production Cell Line; Lumos H1 Revenue Down 38% To $7m, Loss Up 234% To $15m, Febridx; Total Brain H1 Revenue Up 171% To $5.4m, Loss Down 36% To $2.6m; Anteris Revenue Up 10% To $8m, Loss Up 50% To $23m; Nuheara H1 Revenue Down 57% To $3m, Loss Up 614% To $6m; Resonance H1 Revenue Down 8% To $1.9m, Profit To $225k Loss; Osprey Revenue Up 17% To $2.7m, Loss Down 25% To $14m; Universal Biosensors: Xprecia Prime Coagulation Test CE Mark; Dimerix: Remap-Cap Trial Pause; No DMX-200 Implication; Noxopharm Starts Veyonda Combo Sarcoma Trial; Creso: Canada Approves Psilocybin For PTSD Trial; Orthocell Plans 100k PA Striate Dental Membrane Units; China Patent For Cynata Cymerus Stem Cells; Incannex Lists ADRs On Nasdaq; Probiotec CEO Wesley Stinger Sells 1m Shares, Holds 6.4%; Nanomab Takes 10.7% In Radiopharm; Jason Peterson Below 5% In Zelira; Mesoblast Loses 18-Year Director Donal O’Dwyer; Linda Jenkinson Replaces Medadvisor Director, Chair Chris Ridd

Feb 25, 2022

Dr Boreham’s Crucible: Firebrick Pharma; Victoria $470k For Avipep Lymphoma Treatment; Neuren: FDA Approves Angelman Syndrome Trial; Creso Raises $5m; Mayne H1 Revenue Down 6% To $196m; Loss Down 72.2% To $51m; Probiotec H1 Revenue Up 100% To $85m; Profit Up 259% To $4.4m; Medadvisor H1 Revenue Up 199% To $39m, Loss Down 29.5% To $6.7m; Cronos H1 Revenue Up 273% To $27m, Profit Up 1134% To $3.4m; Medical Dev H1 Revenue Down 24% To $10m, Loss Up 549% To $7.4m; Polynovo H1 Revenue Up 44% To $18m, Loss To $1.6m Profit; Compumedics H1 Revenue Down 7% To $17m, Profit Down 78% To $287k; Mach7 H1 Revenue Up 102% To $14m; Loss Down 94% To $419k; Mesoblast H1 Revenue Up 69% To $8m, Loss Down 3% To $68m; Cynata H1 Revenue $6.9m, Loss Down 77% To $1.1m; Impedimed H1 Revenue Up 45% To $5.2m; Loss Down 15% To $9m; Universal Bio Revenue Up 80% To $5.8m, Loss Up 38% To $10.5m; Allegra H1 Revenue Down 26% To $1.7m; Loss Up 967% To $1.3m; Regeneus Up-To $4m Loan For Japan Progenza Manufacture; Clarity Starts 2nd Neuroblastoma Trial Cohort; VGI Appoints Continuum US Distributor; L1 Capital Takes 9.9% Of Anteris; Former Immutep Chair Lucy Turnbull Returns As Director; Lou Panaccio To Replace Adherium Director Matt McNamara; Rhythm Appoints Andrea Steele Co Sec; General Counsel

Feb 24, 2022

Next Science Raises $10m, Plan For $5m More; Japan Approves Avita Recell System; Trajan H1 Revenue Up 17% To $44m, Profit Down 95% To $153k; Cogstate H1 Revenue Up 67% To $32m; Loss To $5.7m Profit; Austco H1 Revenue Up 15% To $16m, Profit Up 83% To $1.5m; Cyclopharm Revenue Up 21% To $18m, Loss Down 17% To $5m; Althea H1 Revenue Up 84% To $9.4m, Loss Down 14.85% To $7m; Visioneering Revenue Up 40% To $10m, Loss Down 75% To $3.2m; Telix Revenue Up 46% To $7.6m, Loss Up 79% To $80.5m; Acrux H1 Revenue Up 80% To $2m, Loss Down 30% To $5.5m; Genetic Technologies H1 Revenue Up To $2m; Loss Up 12% To $3.9m; Micro-X H1 Revenue Down 40% To $1.45m, Loss Up 87% To $9m; Uscom H1 Revenue Down 52% To $1.1m, Loss Up 250% To $943k; Ena, COPD Foundation Partner For Pan-Antiviral Nasal Spray; MTP Connect Adelaide Biomed City ‘Innovation Intermediary’; Zelira To Buy Health House For Scrip; $1.5m Loan; Argenica Completes ARG-007 Genotoxicity Studies; Hydrix Requests ‘Capital Raising’ Trading Halt; Creso Takes ‘Capital Raising’ Trading Halt To Suspension; Antisense, Chicago’s Northwestern Work On ‘Long Covid’; Starpharma Appoints Ex-CSL Executive Dr Jeff Davies Director

Feb 23, 2022

Chimeric Institutional Rights Raise $7.4m; Retail $10.7m To Go; Anteris L1 Capital Options Raise $5m; Clinuvel H1 Revenue Up 57% To $25m; Profit Down 10% To $6m; Alcidion H1 Revenue Up 16% To $13m, Loss Up 360% To $6.3m; IDT H1 Revenue Up 74% To $8.6m, Profit Up 8% To $1.2m; Next Science Revenue Up 160% To $12m; Loss Down 22% To $13m; Cryosite H1 Revenue Up 18% To $5.8m, Profit Up 175% To $782k; Rhinomed H1 Revenue Up 93% To $3.7m, Loss Down 41% To $3.2m; Control Bionics H1 Revenue Up 18% To $2m; Loss Up 193% To $3m; Invion H1 Revenue Up 4.4% To $1.3m, Loss Up 23% To $1.05m; Next Science Requests ‘Capital Raising’ Trading Halt; Brazil Patent For Inoviq Bard1 Cancer Diagnostic; Race: Zantrene Combination ‘Synergy’ For Leukaemia, In-Vitro; Pharmaust: ‘Monepantel Effective For Leukaemia, In-Vitro’

Feb 22, 2022

Cochlear H1 Revenue Up 10% To $821m, Profit Down 28% To $169m; Nanosonics H1 Revenue Up 40% To $61m, Profit Up 165% To $3.9m; Somnomed H1 Revenue Up 10% To $34m, Loss Down 14% To $2.95m; Atomo H1 Revenue Up 17% To $5.3m, Loss Down 5% To $2.4m; Dorsavi H1 Revenue Down 14% To $1.6m, Loss Up 177% To $907k; Bioxyne H1 Revenue Up 12.2% To $1.4m, Loss To $5k Profit; Editorial: Your R&D Tax Incentive Is Not Revenue; Microba Raising $30m For Gut Health Tests, Treatments; Chimeric Rights Offer To Raise $18m; Creso Requests Capital Raising Trading Halt; Proteomics Promarkerd Prepares For Australian Rebate; Emyria Expands MDMA Analogues

Feb 21, 2022

Mesoblast: ‘1st Stem Cell Colitis Cohort Safety, Benefit’; Starpharma H1 Revenue Up 200% To $1.9m, Loss Down 19% To $8m; Pharmaust H1 Revenue Up 52% To $1.7m, Loss Up 48% To $1.2m; Arovella ‘Oversubscribed’ Plan Raises $2m; Total $6.6m; Adherium Hailie CPT Code Rates; Imricor: Münster Uni Hospital Starts ICMR Ablation System; Vectus Ready For 5th VB0004 Dose Cohort; Recce: ‘500mg R327 Safe, Well Tolerated’; Pharmaust Appoints Ergomed For Monepantel Covid-19 Trial; Genetic Technologies ‘NATA, CLIA Okay Genetype Multi-Test’; Chimeric Requests Capital Raising Trading Halt; Copia Takes 5.5% Of Probiotec; Perennial Takes 9% Of Medadvisor

Feb 18, 2022

Dr Boreham’s Crucible: CSL; Redhill ‘Operations Break-Even On Q4 Revenue Of $33m’; Genetic Sigs H1 Revenue Up 16% To $22m; Profit Up 5% To $5m; Avita: FDA Approves Recell Spray-On-Skin Supplement; Medadvisor: Green Cross Deal For New Zealand; Clarity To Release 66m ASX Escrow Shares; Lazard Below 5% In Mayne Pharma; Regal Reduces To 5.6% Of Micro-X; Radiopharm: Antje Wegener Clinical Development Head

Feb 17, 2022

SDI H1 Revenue Up 26% To $46.3m; Loss Down 41% To $2.7m; Nova Eye H1 Revenue Down 1.5% To $6.5m; Loss Up 92% To $3.1m; Cann Group H1 Revenue Up 186% To $3m, Loss Down 12% To $8m; Amplia: AMP945 Ups Chemo 33% For Pancreatic Cancer, In Mice; Anatara Ready For 3FDC For Depression Trial; Firebrick: US Patent For Nasodine Covid-19 Nasal Spray; PYC Takes 93.5% Of Vision Pharma; Cann Group Loses Director Geoff Pearce; Medibio Appoints Stephen Mitchley Director

Feb 16, 2022

CSL Record H1 Revenue Up 5% To $8.5b, Profit Down 3% To $2.5b; Pro Medicus H1 Revenue Up 40% To $44m, Profit Up 53% To $20.7m; BTC Group H1 Revenue Up 12% To $4m, Loss Up 91% To $362k; Woke, Western Australia Uni Work On LSD Analogues; Pharmaust’s Epichem: ‘Promising Results’ On E-Waste Project; Palla ‘Fails To Attract A Buyer; To Begin Wind-Down’; Telix Signs GMSA For Australian Illucix Distribution; Nuheara Expands For US Regulated Hearing Market; Rhinomed Receives $425k Federal R&D Tax Incentive; Cardiex Approves 10-To-1 Consolidation; Medicus Sciences Acquisition Corp Ceases Anteris Holding; Kefford Family Takes 7.3% Of Vectus; Osteopore Loses Director Vlado Bosanac Over Tax Dispute; Lumos Appoints Barrie Lambert CFO

Feb 15, 2022

Anteris ‘Declines’ Medicus Merger Proposal; LBT Receives $825k Federal R&D Tax Incentive; Rhythm Retains Iso 13485 For Colostat Blood Test; Cann Group Trials Marijuana For Sleep Disturbance; Actinogen Appoints Prof Paul Rolan CMO; Bio-Melbourne Women In Leadership Nominations Closing

Feb 14, 2022

CSL Share Plan Raises $750m; Total $7.05b; Opthea: ‘PCV Subset Benefits From OPT-302’; Clinuvel Healthy Adult Afamelanotide For DNA Repair Trial; Cardiex: Andwin $1.3m Atcor XCel Trial For Philip Morris; Resapp: Health Teams To Take Resappdx To Aged Care; Biome Releases Full Results Of Probiotics Acne Trial; Invictus To Raise $2.3m To Demerge From VGI; Amplia Unmarketable Parcel Facility; Adam Leitzes, Karst Peak Take 12.3% Of Pharmaxis; Fil Below 5% In Telix; BCal Releases 21m ASX Escrow Shares

Feb 11, 2022

Dr Boreham’s Crucible: Resmed; Pharmaxis H1 Revenue Down 38%, Sales Up 88% To $3m, $8.8m Loss; Mayne Launches Unnamed Authorized Generic For Acne; Adherium First Production Of New Hailie Sensor; Actinogen Completes Xanamem Dose-Ranging Cognition Trial; Impedimed Trials Sozo For Renal Failure; Immutep IMP321 Australia Patent; Creso O-T-C Marijuana Lozenge For Sars-Cov-2; Lumos To Release 8m Shares From Voluntary Escrow; Lumos M-D Rob Sambursky Off-Board To Focus On CEO Role; Jonathon Gut To Replace Imricor CFO Lori Milbrandt

Feb 10, 2022

Federal ‘Patent Box’ To Cut Tax To 17%; Federal Opposition; Ausbiotech Welcomes ‘Patent Box’ Tax Break; Biotech Daily Editorial: ‘This Is Not A Patent Box’; Firebrick: Nasodine Trials Reduce Sars-Cov-2 Viral Shedding; Anteo: New Eugeni Reader, Sars-Cov-2 Test Trials For TGA; GI Dynamics Back With India Endobarrier Trial; Uscom Unmarketable Parcel Facility; Little Green To Release 55.5m ASX Escrow Shares

Feb 9, 2022

Prota To Raise $20m For Peanut Allergy; Biome: ‘Trial Backs Probiotics For Acne’; Dorsavi Wins ISO27001 Data Security Certification; Actinogen: Worldwide To Manage Xanamem Fragile X Trial; VGI Ethics Approval For IBV001 NAFLD, NASH Trial; Anteris Proposes Merger With SIO-Related MSAC

Feb 8, 2022

Redhill ‘Adjunct Opaganib Reduces Covid Mortality 70%’; Recce: R327 Synthetic Antibiotic ‘Safe At 500mg’; Chimeric: ‘Encouraging CLTX-Car-T Safety Data’; Antisense ATL1102 For Unnamed Muscle Disease Mouse Study; Neuroscientific Completes In-Vitro Emtinb Studies; BCal Breast Cancer Test ‘Backed By Independent Analyses’; Auscann FDA Guidance For CPAT-01 For Dog Osteoarthritis; Nanosonics Revises GE Distribution Deal, Again; Creso’s Halucenex Canada Psilocybin Supplier; Hong Kong Patent For VGI Tocotrienol Delivery; Tessara Hires Peter Girling, Paul Adlard, Mark Greenough; Allegra Loses Director Anthony Hartnell

Feb 7, 2022

MCRI, Prota: Desensitization For Peanut Allergy; Probiotic; Proteomics: Biomarkers For Obstructive Airway Disease; QIMR Exosome Blood Test For Cancer Treatment; Resonance: ‘Eligible For Liversmart Imaging CPT Codes’; Telix EU Illuccix Review Extension; Revenue Delay; Clarity: FDA Approves Prostate Cancer Imaging Trial; Respiri 2nd Access US Distribution Deal; Medlab Closer To UK Nanabis Marijuana Cancer Pain Trial; Althea: Dr Reddy’s To Acquire Distributor Nimbus Health; Emyria To Release 100m ASX Escrow Shares; Bilal Ahmad Takes 6.25% Of Dorsavi; Dimerix Appoints Dr Ash Soman CMO; Robyn Slaughter Replaces Allegra Co Sec Justyn Stedwell

Feb 4, 2022

Dr Boreham’s Crucible: EBR Systems Inc; Proteomics, QIMR Validate Oesophageal Cancer Biomarkers; Federal $15m For Adelaide Cancer Genomics Laboratory; Telix To Be Promoted Into Asx200; Respiri, M-Telehealth $33k 2nd Wheezo Order; Reimbursement; Exopharm Tells ASX: ‘AIRM News Material, Clarification Not’; Clarity Receives $3.3m Federal R&D Tax Incentive; Fil Reduces To 7.3% Of Starpharma

Feb 3, 2022

Adalta Rights Raise $1.25m; Total $5m; Cyclopharm To File FDA Technegas Response In Q3; Starpharma Appoints Etqan & Nazahah Gulf Distributor; Oncosil: German Innovation Funding, Centralized Ethics; Medical Developments Ends CSIRO API Collaboration; Clarity: ‘Unaffected By Failed Belgium Nuclear Reactor’; Creso To Buy Sierra Sage For $29.5m Scrip; Woke Imports Synthetic Psilocybin For Depression Trials; Telix CEO Dr Chris Behrenbruch, Elk River Take 7.5%; Lazard Takes 5% Of Mayne Pharma; Malcom McCusker Takes 5.6% Of PYC; Pharmaust Loses Epichem CEO Colin La Galia; Chimeric Appoints Kelly Thornburg Head Of Quality

Feb 2, 2022

Victoria Supports $17m Lumos Rapid Antigen Test Factory; Vivazome Wins $200k Cytiva ‘Bio-Challenge’ Prize; Biome ‘Probiotic Significantly Cuts Child Asthma Exacerbations’; Avecho, Team Saas $1.4m US TPM-Marijuana Edibles Deal; Opthea $105m At-The-Market Equity Program; IDT To Manufacture Woke Psilocybin For Depression Trials; Audeara Launches A-02 Headphones, TV Bundle; Pharmaust Formulates Monepantel For MND Trial; Jason Carroll Takes 10.15% Of Island; Vale Immutep Director Grant Chamberlain; Director Dr Eric Rose Replaces Mesoblast CMO Dr Fred Grossman; Radiopharm Appoints Hester Larkin Director

Feb 1, 2022

January BDI-40 Down 17%, ASX200 6%, Big Caps 11%, NBI 12%; Firebrick Up 225% On $7m IPO For Nasodine Anti-Viral Spray; Epsilon Receipts Down 28% To $5m; Nova Eye H1 Glaucoma Sales Up 1.6% To $6.5m; Nuheara: ‘Trial Validates Self-Fitted Hearing Aids’; Dimerix: Denmark Okays Phase III DMX-200 FSGS Trial; Clarity To Dose Neuroblastoma 2nd Cohort; Radiopharm: Terrapower To Provide Actinium-225; Chimeric, Pennsylvania Chm2101 Research Deal; Resapp: China Cough Analysis Patent; Carrington Trust Takes 5.2% Of BCal; Imugene Appoints Dr Stephen Cha CMO; Neuren Appoints Gerry Zhao For Corporate Development; Co Sec Tim Slate Replaces Zelira Director Jason Peterson; Medadvisor Appoints Raeann Grossman Cotiviti Director; Lazard Below 5% In Mayne; Correction: MTP Connect

Jan 31, 2022

Clinuvel H1 Receipts Up 79% To $31m; Lumos H1 Receipts $8.2m; Mesoblast H1 Receipts Up 181% To $7.9m; Pharmaxis H1 Receipts Up 101% To $7.2m; Next Science Receipts Up 223% To $13.6m; Imex Receipts Up 25% To $11m; Impedimed H1 Receipts Up 53% To $5.1m; Creso Receipts Up 71% To $6.4m; Nuheara H1 Receipts Down 48% To $2.8m; Pharmaust (Epichem) H1 Receipts Up 31% To $1.7m; Resonance H1 Receipts Down 12.3% To $1.7m; Cardiex H1 Receipts Down 26% To $1.7m; Bioxyne H1 Receipts Up 30% To $1.7m; Dorsavi H1 Receipts Up 112% To $1.6m; Osprey Receipts Up 7% To $2.8m; IDT Federal Supply Deal Ends, ‘mRNA Discussion Ongoing’; Pharmaxis Doses 1st Patients In PXS-6302 Scar Reduction Trial; Allegra Claims Sr–Ht–Gahnite Spinal Cage Sheep Trial Success; Next Science Appoints Zimmer US Xperience Distributor; Exopharm, Astellas $686k Exosome Collaboration; Imugene: CF33, Vaxinia, Checkvacc Japan Patent; Telix Dr Behrenbruch, Elk River; Gnosis, Dr Kluge Reduce To 7.4%; Merchant Funds Takes 8% Of Arovella; MTP Connect Loses M-D Dr Dan Grant; COO Stuart Dignam Interim; Oventus John Cox CEO On $534k; Dr Chris Hart Director, Adviser; Invex: Chair Dr Loveridge $276k; CSO Prof Alex Sinclair $281k; Race Appoints Christina Manfre CFO

Jan 28, 2022

Dr Boreham’s Crucible: Medical Developments; Resmed H1 Receipts Up 16% To Record $2.6b; Medadvisor H1 Receipts Up 198% To $42m; Total Brain H1 Receipts Up 186% To $4.5m; Cann Group H1 Receipts Up To $3.24m; Starpharma H1 Receipts Up 10-Fold To $2.5m; Universal Biosensors Receipts Up 412% To $4m; Control Bionics H1 Receipts Up 25.6% To $1.9m; Osteopore Receipts Down 28% To $1.1m; Imugene, Roche PD1-Vaxx 1 Trial Supply Deal; Imugene: European HER-Vaxx Patent; Anteo Falls 29% On TGA Rapid Sars-Cov-2 Test Data Request; Oventus Receives $417k Federal R&D Tax Incentive; Sg Hiscock Takes 6% Of Althea; Probiotec Appoints Paul Santoro Director; IDT Appoints Dr Jane Ryan Director; Regeneus Appoints Dr Scott Bruder Adviser

Jan 27, 2022

Somnomed H1 Receipts Up 19% To $35m; Cronos H1 Receipts: $29m; Alcidion H1 Receipts Up 52% To $16.4m; Medlab H1 Receipts Up 87% To $4.8m; Anteris Receipts Up 14% To $8.3m; Micro-X H1 Receipts Down 66% To $1.2m; Imricor Receipts Up 27% To $1.5m; Vivazome, Anu Work On Exosomes For Retinal Disease; $283k Hangzhou Zede Deal Takes Resonance To China; NZ Approves Atomo’s Access Bio Covid-19 Rapid Antigen Test; Telix Doses 1st TLX591 Prostate Cancer Treatment Patient; US Patent For Chimeric Chlorotoxin Antigen Receptors; Japan Patent For Cynata Cymerus Stem Cells; Resapp: Prof Antonio Anzueto, Prof Joan Soriano Advisers

Jan 25, 2022

Resonance, VGI Sign $100k Hepafat-AI Trial Deal; Atomo: Covid Tests Push H1 Receipts Up 33% To $7.7m; Visioneering Receipts Up 46% To $11m; Rhinomed H1 Revenue Up 216% To $4.1m; BTNX Rhinoswabs; Austco: H1 Revenue Up 15% To $16m; Profit Up 93% To $1.6m; Opthea Receives $6.6m Federal R&D Tax Incentive; Paradigm 39% Rem Report 2nd Strike, 66% Oppose Chair Shares; Cann Group: TGA GMP Licence; Creso Applies For Canada Psylocibin PTSD Trial; Redmile Reduces To 5.4% Of Avita; Arovella Appoints Dr Mini Bharathan Pre-Clinical Lead

Jan 24, 2022

Telix Raises $175m; Plan For $25m More; Arovella Raises $4.6m; Plan For $1.5m More; Nuheara Plan Raises $1.1m; Total $5.7m; Cyclopharm Expects Revenue Up 22% To $18m; Telix Receipts Up 6% To $4.1m; Uscom H1 Receipts Fall 51% To $1.3m; Clinuvel: German Insurers Continue Scenesse Support; Patrys Receives $1.2m Federal R&D Tax Incentive; 4d Lung Transplantation Validation Trial; Anteris: Duravr Trial Interim Results ‘No Adverse Events’; Visioneering Enrols 1st Contact Lens Trial Patient; Living Cell Signs $1.17m Agreement For Pig Tissue With NZeno; Argenica Completes ARG-007 Toxicology Study; Patrys: Pat-Dx1 Purification Delays Trial 6 Months; Resapp: Doctors On Demand Launches Resappdx; UK MHRA Registers Adherium For Hailie Manufacture; Radiopharm $696k Scrip For 3 ‘Nanobodies’ Ip; Immuron To ASX: ‘Validation, Holiday Email Delayed News’; Australian Ethical Takes 11.3% Of Mach7; Emyria 1.1m Dr Karen Smith Shares, Tattarang Shares EGM

Jan 21, 2022

Cogstate H1 Revenue Up 67% To $29.6m; Genetic Signatures H1 Revenue Up 16% To $22m; Heramed: $220k Joondalup Heracare Contract; Trajan Founder Stephen Tomisich, Family Diluted To 57%; Imugene Loses CMO Dr Rita Laeufle

Jan 20, 2022

Resapp Signs Philippines Homify For Resappdx Telehealth; Althea H1 Marijuana Receipts Up 111% To $9.9m; Starpharma Receives $7.7m Federal R&D Tax Incentive; Emyria Readies For O-T-C EMD-RX5 Marijuana Capsule Trial; Imex: Thailand Approves Aquila, 1st Sale; BJC Distributor; VGI: Amazon To Stock Ne1-Elite, Ne1-Heart Through; Telix Requests Capital Raising Trading Halt; Arovella Requests Capital Raising Trading Halt; Heramed Takes Capital Raising Halt To Suspension; Medibio: Cps Underwrites $1m Of $3.4m Rights Offer; Cann Group: Rua Investors Approve Zalm Acquisition; Optiscan Loses Director Dr Phil Currie

Jan 19, 2022

Genetic Technologies H1 Receipts Up To $2.7m From $15k; Allegra Revenue, Loss Warning; Adherium Receives $1.6m Federal R&D Tax Incentive; Cynata Receives $833k Federal R&D Tax Incentive; Peters Buys Andrew Goodall $1.4m Memphasys Note; Cardiex 10-To-1 Consolidation For US OTCQX Listing; William Blair, Bionomics Chair Dr De Souza, Liz Doolin Take 22%; CEO Dr Peter Meintjes Starts At Pacific Edge

Jan 18, 2022

Universal Biosensors Launches Sentia Malic Acid Wine Test; Recce: ‘150mg R327 Safe, Well Tolerated’; Race Receives $708k Federal R&D Tax Incentive; Heramed Requests ‘Commercial Licence’ Trading Halt; SG Hiscock Takes 7.8% Of Resonance; Compumedics Appoints Paul Jensz Director; Osteopore To Lose CFO Carl Runde; New CFO Wanted

Jan 17, 2022

BDI-40, Cannabis Corner Changes; Immuron Receives $306k Federal R&D Tax Incentive; Resapp: Clinicians Back Resappdx For Covid-19; Memphasys 1st Commercial Felix Sale For Human IVF; Clinuvel Enrols Afamelanotide For Stroke Study; Inoviq: US Patent For Bard1 Cancer Antibody Tests; Mind Medicine Trials Psychedelics Brain Activity; Bod: UK Approves Marijuana For ‘Long Covid’ Trial; Dr Kathryn Macfarlane Replaces Mayne Director Nancy Dolan; Creso Appoints William Lay, Micheline Mackay, Bruce Linton

Jan 16, 2022

Special Summer Catch-Up Edition

Telix: FDA Approves Illuccix For Prostate Cancer Imaging; Pharmaxis ‘Oversubscribed’ Plan Raises $2.6m; Total $9.8m; Actinogen Share Plan Raises $1.3m; Total $13.3m; Avecho, Medterra Marijuana Distribution Deal; Chair Ron Dewhurst, Kroy Wen Take 6.83% Of Rhinomed; Incannex: Phase II IHL-42X Marijuana OSA Dosing Complete; Resonance: EX00A31 Reduces Hepatitis B Replication In-Vitro; Clinuvel: FDA Okays Phase II Scenesse For Vitiligo Study; Invex Receives $186k UK R&D Tax Rebate; CSL Share Plan To Raise $750m; Telix: 1st Patient Dosed In Phase I Bladder Cancer Trial; Genetic Signatures: Variant Kit Differentiates Delta, Omicron; Former Chair Ray Blight Increases, Diluted To 8% Of Alcidion; Director Prof Malcolm Pradhan Diluted To 8% Of Alcidion; Rhinomed: Rhinoswab Junior Meets Equivalence Endpoint; Cogstate Promoted To S&P ASX All Technology Index; Race Share Plan Raises $29.7m; Dr Tillet Increase, Diluted; Bionomics Nasdaq IPO Raises $28m; Lumos: Canada Orders $350k Covidx Sars-Cov-2 Rapid Tests; Audeara Appoints Audika Australia Distributor; Imex: Colombia Police $1.1m Radiology Contract; MGC Starts Artemic ‘Long Covid’ Pilot Study; Neuroscientific: ‘Emtin Peptides Modulate Inflammation In-Vitro’; Niv Dagan Takes 11.38% Of Inhalerx; Total Brain Pays $3.1m For Janssen Depression Research; Antisense Share Plan Raises $2.6m; Total $22.6m; Cynata Starts Phase I CYP-006TK Diabetic Foot Ulcer Trial; Platinum Increases, Diluted To 15% Of Amplia; Dimerix Receives Federal $100k Grant; Platinum Takes 17% Of Adalta; Australian Super Takes 9.5% Of Alcidion; Micro-X Receives $2.1m R&D Tax Incentive; Resapp Appoints Sanrai ‘Emerging Markets’ Distributor; SIO Increases, Diluted To 12.6% Of Anteris; FIL Below 5% Of Cogstate; Mark Lampert, BVF Increase, Diluted To 13% Of Bionomics; Shengli Wang Diluted To 10.63% Of Invion; Lumos Viradx Rapid Test Submissions Ready; Ellerston Below 5%; Regeneus $800k R&D Incentive; Japan Progenza Patent; Anteotech Receives $1.96m R&D Tax Incentive; Exopharm US Patent For Leap Exosome Production; Nyrada Phase I Cholesterol Drug Trial In Late-2022; Avita AGM: 42% Oppose Executive Compensation; Dimerix Approval For Australian Pilot/Phase III Covid Study; Nuheara $4.6m Placement, Rights Offer For $3m; Perennial Reduces To 7.55% Of Medadvisor; Respiri, M-Telehealth Sign 5-Year, $210k Deal For Wheezo In The US; Oncosil: Local Pancreatic Cancer Control In 90.5% Of Patients; Yuuwa Diluted To 18.2% Of Adalta; Inoviq (Bard1): China Patent For Lung Cancer Diagnosis; Universal Biosensors $50k PA For IQ Science Aptamers; Paradigm 2nd Strike, 80% Directors Feel Pool Hike; 525k Shares; Citigroup Takes 22.3% Of Bionomics; Perennial Take 11.5% Of Lumos; Stemcell Further Extends ‘Joint Venture’ Suspension; Andrew Chapman, Merchant Below 5% Of Race; Cynata, Fujifilm Manufacturing Deal; Alcidion Rights Raise $11.6m; Total $55m; Anteris Options Raise $18.9m; LBT Acquires Hettich’s 50% Of Clever Culture Systems; Osteopore: Mark Leong Executive Chair; Vlado Bosanac Director; Living Cell Rights Raise $361k; $3.4m Shortfall; Cann Global AGM: $312k Shares For Ex-Chair Pnina Feldman; Carl Charalambous Takes 7.23% Of Exopharm; Darryl Davies Replaces Inhalerx CEO Matthew Golden; Ex-Director Bernard Hockings Reduces To 6.3% Of PYC; Total Brain $692k Alto Neuroscience Ispot-D Data Deal; Resonance FDA Clearance For Liversmart; Atomo Pleads Schultz, Media, Rats To ASX 36% Price Query; Asia Pacific Healthcare Investments Takes 6% Of Clarity; Trajan Pays $7m, 4.7m Shares For Neoteryx Blood Micro-Sampling; Emyria Appoints Sixty Two Capital Adviser; Mesoblast To File New Remestemcel-L Potency Data To FDA; Trajan Completes Leap Acquisition; Perennial Below 5% In Nuheara; Bionomics Loses BVF Partners Nominee Director Mitchell Kaye; Ecofibre Extends Loan Terms; M-D Robert Wong Takes 6.79% Of Control Bionics; Opthea Appoints Ex-Director Judith Robertson CCO; Imugene Completes Phase Ia PD1-Vaxx Monotherapy Dosing; Imugene Appoints Ursula McCurry, Dr Nimali Withana Executives; Alterity Loses Directors Dr David Sinclair, Tristan Edwards; Hettich Takes 9.6% Of LBT; Bionomics Starts Phase II BNC-210 Social Anxiety Trial; Christian Angemayer, Apeiron Take 19.9% Of Bionomics; Hexima Appoints Phillip Rose US Chief Commercial Officer; Imricor: Athens’ Henry Dunant Hospital Buys Ablation Products; Island Hires Icon For Phase II ISLA-101 Dengue Fever Trial; Anteris Applies For Adapt Sterilisation Patent; Cronos Pleads Schultz, ‘CDA Merger To ASX 42% Price Query; Dr Gisela Mautner Replaces Noxopharm CEO, M-D Dr Graham Kelly; Pharmaxis: NHMRC $1.4m For Drug Pipeline Research; Alterity: US Patent For Neuro-Degenerative Disease; Imugene: South Korea Patent For HER-Vaxx; Nuheara Completes Hearing Aid Clinical Trial; Rhythm: $6.53m Placement To Unnamed ‘Global Funds Manager’; Citigroup Takes 24.73% Of Bionomics; Imugene Receives $6.54m Federal R&D Tax Incentive; Federal $15m For Psychedelics For Mental Health; Israel’s Redhill Appoints Gaelan Emirates Talicia Distributor; Avita: ‘Proof-Of-Concept For GM Skin Cells’; Avita: Recell Soft-Tissue Reconstruction Trial Enrolled; Mesoblast: 1.7m US Warrants For Oaktree Loan Facility; Resapp: Resappdx On Alodokter Telehealth Platform; Recce: Positive Safety Data From Phase I R327 Trial; Creso To Release 47m Shares From Voluntary Escrow; MGC: India Grants Artemic Rescue Import Approval; Noxopharm Receives $5.9m Federal R&D Tax Incentive; Pharmaxis Tells ASX: ‘NHMRC Grants Not Material’; Genetic Signatures: TGA Registers Sars-Cov-2 Saliva Protocol; Resapp Completes US Covid-Cough Study Recruitment; Inoviq $89k For SubB2M Test Antibodies; Chelsea Sherida Replaces Bluechiip Co Sec Lee Mitchell; Race Chair Dr John Cullity Sells 300k Shares; Zelira Receives $348k From DRCN; Polynovo H1 Revenue Up 43% To $18.04m; Dimerix Doses 1st DMX-200 Covid-19 Patients In India; Kim Bradley Replaces Cryosite Chair Bryan Dulhunty As Co Sec; Creso: Halucenex Applies For Canada Special Access Program; BCal Appoints Dr John Hurrell CEO; Starts On $300k; Blackrock Takes 12.2% Of Imricor; SDI H1 Revenue Up 26% To $46m; Compumedics H1 Orders Up 33%, Revenue Down 7% To $17m; Compumedics $4.2m Orion Lifespan Sale To Tianjin Normal Uni; Mesoblast: Rexlemestrocel-L Provides 3-Year Lower Back Relief; KKR Core Investors Takes 6% Of Clarity; Immuron: $6.2m For US Military-Grade Travelan For Diarrhoea; Liverpool Pharmacies Adopt Lumos Febridx; Zelira Receives $1.2m Federal R&D Tax Incentive; Mayne To Sell Generic Protopic For Eczema In US; Nyrada Receives $1.3m Federal R&D Tax Incentive; Federal $25.6m For Cynata, Acrux, Axial; Paradigm Doses 1st Phase III Osteo-Arthritis PPS Patients; Amplia Completes AMP945 Manufacture For Trials; Adherium: US Finalises Remote Therapeutic Monitoring Cpt Codes; Immuron: EU Patent For Traveller’s Diarrhoea; Argenica Appoints Dr Meghan Thomas Clinical Development Head; Artrya Appoints Dr Jacque Sokolov Advisor Board Chair; Kosmas Dimitriou Replaces IQ3 Co Sec Ron Hollands; Korda Mentha Requests Bids For Palla; Redhill: Opaganib Improves Covid-19 Viral RNA Clearance; MTP Connect Awards 10 Fellowships; MTP Connect: $20m For Diabetes, Cardiovascular Disease; Cardiex 1-For-10 Consolidation EGM; Evercore Takes 22% Of Bionomics; Arovella (Suda) Loses Executive Director David Phillips; Stemcell Further Extends ‘Joint Venture’ Suspension

Jan 3, 2022

Special Edition

2021: BDI-40 Up 23%; Big Caps Up 14% ASX200 Up 13%; NBI Down 1%

Actinogen Up 847%, Imugene 387%, Prescient 249%; Oncosil Down 63%, Polynovo 61%
   

 

Dec 17, 2021

Dr Boreham’s Crucible: Imagion Biosystems; Palla Pharma In Administration; Radiopharm Completes Phase I Breast Cancer Imaging; Chimeric Doses 2nd CLTX-Car-T Trial Cohort; Incannex: US Sec ‘Comments’ Delay Nasdaq IPO; Alcidion Director Malcolm Pradhan Diluted To 10.55%; Ex-Chair Ray Blight Diluted To 8% In Alcidion; Uscom Chair Prof Robert Phillips Takes 21.3%; Imagion Chair Robert Proulx 25% Pay Rise To $446k A Year; 4D Appoints Evonne Collier Director; Invex Appoints Prof Michael Wall ‘Evolve’ Trial Chair

Dec 16, 2021

2021 – The Year In Review; CSL Raises $6.3b For Vifor; Federal, Victoria Moderna Deal Hits IDT; Qbiotics Launches Stelfonta For Dog Cancer In Australia; Orthocell: Celgro Tendon Repair ‘Safe, Warrants Further Study’; Proteomics Wins $409k P-K Testing Contract; TGA Knocks Back Psilocybin, MDMA Downgrade - Mind Medicine; Bionomics Requests Nasdaq IPO Trading Halt; Avita Completes Recell For Vitiligo Enrolment; Immutep: Northway To Manufacture Imp761; Mesoblast: FDA OTAT Agree Back Pain Endpoints; Paradigm: PPS ‘Improves Heart Function’, In Rats; Alcidion Completes Silverlink Acquisition; Cronos Completes CDA Health Merger; Cronos: Headley 23.5%, Ben Jansen 24%, Dr Jansen 10%, Rod Cocks 4%; Zelira Appoints Nubu New Zealand Marijuana Distributor; Emyria Requests ‘Partnership’ Trading Halt; Prof Graham Mitchell, Bob Moses, Will Goolsbee Leave Antisense

Dec 15, 2021

Maverick $63m For QIMR ATA188 Multiple Sclerosis Treatment; Uscom Rights Issue Raises $4.4m; Adalta Placement Raises $3.75m, Rights Offer For $2.2m More; Medibio Commitments For $2.25m; Rights Offer For $3.4m More; Pharmaust: Epichem Wins $1m Extension With DNDI; Recce Doses 1st R327 Cohort; Truscreen: Progress In Vietnam, Russia, China, Mexico; Auscann Dermacann APVMA Dog Marijuana Submission, US Launch; Emyria: Marijuana EMD-003 Beats Epidyolex, In Dogs; Palla Takes ‘Review’ Trading Halt To Suspension; Avita: ‘Lack Of Quorum’ Postpones AGM; Imugene Chair Paul Hopper Sells 75m Shares, Down To 5%; Colin Mackinnon, Isle Of Wight Below 5% Of Alcidion; Allan Moss, Blueflag Increase, Diluted To 6.95% In Amplia; Tali Appoints Cochlear’s David Williams Director

Dec 14, 2021

CSL $17b For Vifor; Novartis Terminates $1.9b Mesoblast Deal; Victoria: ‘Home Of mRNA Vaccine Manufacturing’, Moderna; IDT Requests ‘Federal mRNA News Response’ Trading Halt; Bionomics Hopes For $35m Nasdaq IPO; Antisense: UK, EMA Approve ATL1102 For DMD Trial; Alterity: NZ Okays ATH434 Phase II MSA Trial; Proteomics Receives $1.2m Federal R&D Tax Incentive; Polynovo: ‘Sales Up, Morale Up’; Share Price Up; Starpharma: Saudi Arabia Registers Viraleze Nasal Spray; Rhythm $750k To Expand Cancer Diagnostics; Imugene: China Allows Her-Vaxx Patent; Noxopharm: 1st Veyonda Cohort Enrolled; Adalta Takes ‘Capital Raising’ Trading Halt To Suspension; Auscann: Tod McGrouther Chair, Loses Dr Kate Adams, Geoff Starr

Dec 13, 2021

Another Year In The Grass – With Shrooms & E; CSL Confirms Discussions With $12.5b Swiss Vifor; Imugene: FDA Okays Phase II Her-Vaxx, Phase I Vaxinia Trials; Arovella (Suda) Licences MD Anderson DKK1 Monoclonal Antibody; Osteopore Signs $19m Singapore Jaw Implant Partnership; QRX Name, Direction Change, 100% Fee Pool Hike AGM; Argenica To Release 3.3m ASX Escrow Shares; Nyrada To Release 33m Escrow CDIs; Palla Requests ‘Strategy, Operations Review’ Trading Halt; Medibio Requests ‘Capital Raising’ Trading Halt; Selector Takes 6.8% Of Nanosonics; Prof Camile Farah Replaces Optiscan M-D Darren Lurie On $385k; Rhythm Appoints Ex-CSL’s Dr Rachel David Director; Chimeric Loses CMO Dr Syed Rizvi, Promotes Dr Eliot Bourk; Living Cell Appoints Dr Belinda Di Bartolo COO; Kazia Appoints Karen Krumeich As CFO

Dec 10, 2021

Dr Boreham’s Crucible: Visioneering Technologies; Amplia Underwritten Rights Raise $6.97m; Total $12.4m; Telix Expects EU Illucix Approval Decision In March 2022; Race Extends Newcastle Uni Zantrene Collaboration; Adalta Requests ‘Capital Raising’ Trading Halt; Auckland’s Milford Takes 5% Of Neuren; Chair Niall Cairns, CEO Craig Cooper, C2 Take 22% Of Cardiex; Creso Converts 17.5m Halucenex Performance Shares; Stemcell Extends ‘Joint Venture’ Suspension, Again

Dec 9, 2021

MTP Connect $19.7m Medical Device Initiative; Servatus ‘Oversubscribed’ Placement Raises $7.5m; Epsilon Raises $2.9m; 4D Medical: I-Med 1st XV Lvas Commercial Scan; Pacific Edge: Northern Health To Use Cxbladder Cancer Test; Memphasys, Monash IVF Begin Felix Sperm Separation Trial; Adalta: Nebulized AD-214 Reaches Alveolar, In Mice; Antisense Submits FDA ATL1102 Toxicology Protocol; Palla Pleads ‘Shareholder’ To 41.2% Fall; Argenica: USPTO Allows ARG-007 Patent; Auscann: FDA Confirms Dog OA Marijuana CPAT-01 Trial; Macquarie Group Below 5% In Patrys; Copia Below 5% In Probiotec; Atomo Loses Director Connie Carnabuci; Audeara Appoints Dr Elaine Saunders Director; Nathan Jong Replaces Imugene Co-Co Sec Justyn Stedwell; Actinogen Appoints 2 Xanamem Advisory Boards

Dec 8, 2021

Alcidion Raises $43.4m; $11.6m To Go; Orthocell: ‘Ortho-ATI Beats Steroids For Injury’; Trajan Acquires Leap Pal For $10.8m; Race: Zantrene Protects Heart Muscle, In-Vitro; Emyria Screens 1st MDMA Batch; Avecho Study Characterizes Soft-Gel Marijuana CBD; Starpharma Adds To Genentech Research Agreement; Telix Appoints Nucliber Illucix Spain Distributor; Emvision Receives $2m Federal R&D Incentive; Total Brain Takes $2m Mitchell R&D Tax Incentive Loan; Goodbye Bard1, Hello Inoviq; Chair Paul Hopper Takes 23.3% Of Chimeric; Director Michael Stork Diluted To 4.8% In Patrys; Honsue Cho Diluted To 22% Of Invion; Visioneering Loses CEO, Director Dr Stephen Snowdy; Lisa Aubert Replaces Cochlear North America Head Tony Manna; Resapp Appoints Covid-19 Scientific Advisory Board

Dec 7, 2021

Neuren Phase III Trofinetide Rett Trial Success; Up 109%; Alcidion Hopes To Raise $55m For Silverlink; Trading Halt; Actinogen, Oxford Uni Xanamem Cortisol Collaboration; Victoria Backs Compumedics Somfit Manufacture; Recce: ‘R327 Clears Burn Infections In 5 Days’; Imugene: 1st Checkvacc Patient Clears Safety; Anteris: Evolution Underwrites $14.6m Option Exercise; Starpharma, Genentech Dep Research Agreement; VGI Applies For PCT Drug Delivery Patent; Orthocell Requests ‘Ortho-ATI Study Results’ Trading Halt; Epsilon Requests ‘CPS Capital Raising’ Trading Halt; Clarity Releases 6.6m ASX Escrow Shares

Dec 6, 2021

Mesoblast: ‘Rexlemestrocel-L Reduces Adverse Events’; Cardiex Options Raise $7.7m; Nuheara, Sonova Sign Supply Agreement; S&P ASX Indices: Imugene, Cogstate Promoted; Correction: Medicines Development For Global Health; Cann Receives $2.2m Federal R&D Tax Incentive; Anteris Requests Capital Raising Halt; Pie Funds Reduces To 6.2% Of Probiotec; Radiopharm Appoints Prof Sara Hurvitz Adviser; Anatara Appoints Simon Erskine CDO, Michael Pryor BDM

Dec 3, 2021

Dr Boreham’s Crucible: Mesoblast; Redhill: Talicia 50% Better For H Pylori In Obese Patients; CSL Responds To $12.5b Vifor Speculation; Kazia: Paxalisib ‘3-Month Benefit For Glioblastoma; Alcidion Wins $23m Federal Miya Precision Contract; Resonance: US FDA 510k Liversmart Application; Starpharma: 1m Unit Vietnam Viraleze Distribution Deal; Credit Suisse Takes 5.4% Of IDT; Total Brain Loses CFO Emil Vasilev; New CFO Wanted

Dec 2, 2021

Oncology One, WEHI, Curtin Uni Work On Breast Cancer; Patrys Rights Raise $5.33m, Total $7.83m; Imagion Options Raise $4.8m; Osteopore: Hong Kong Approves Bone Scaffold; Memphasys Completes Samson Sperm Data Collection; Immutep: IMP321 ‘Safe’ For 5 Triple Combo Tumor Patients; Amplia: Victoria $2.1m R&D Tax Incentive Loan; Clarity: Cardinal To Manufacture Copper Products For US Trial; Heramed: Heracare Paid Program Enrols 80 Patients; Zelira: Levin Marijuana Ztl-106 Pain Trial Approved; Creso: Halucenex Canada Psychedelics Licence ‘Upgrade’; Montgomery Takes 5% Of Avita; Elixxer Reduces To 10.5% Of Little Green; Hexima: Prof Anderson Off-Board, Dr Sacco CDO Prof Lipner Adviser

Dec 1, 2021

November BDI-40 Up 1%; ASX200 Down 1%; Big Caps Up 1%; Chimeric, Case Western Uni Core-NK Licence Option; Telix: ‘Exceptional Authorization’ For Illucix In Brazil; Clarity Half-Way In ‘Propeller’ Prostate Cancer Imaging Trial; Anteris: Duravr 7-Day Follow Up In 5 Patients; MGC Raises $10m; Audeara: RCM, US FCC Certification For A-02 TV Bundle; Bionomics Wins BNC210 US FDA Fast Track Status For Anxiety; Neurotech: ‘Marijuana Boosts Prednisone, In-Vitro’; Nuheara Receives $1.7m Federal R&D Tax Incentive; Starpharma To Launch Viraleze In Vietnam; Pharmaust Manufactures Small Monepantel Tablets; Resapp AGM 20% Oppose 6m Evolution Capital Options; Epsilon, Valens Deal Extended 2 Months; Viburnum Reduces T0 9.9% In Adherium; M-D Wesley Stringer Takes 7.6% Of Probiotec; Rhythm: Otto Buttula Exec Chair, CEO Glenn Gilbert M-D; Cyclopharm Loses Director Tom McDonald

Nov 30, 2021

Victoria, IDT, MIPS Manufacture Sars-Cov-2 mRNA Vaccine; IDT Up 45%; Emvision: ‘98% Accuracy’ In Stroke Classification Trial; Q-Sera Licences Rapclot Blood Collection Tubes To Terumo; Cogstate Tests In Japanese Seniors ’Phones; Bluechiip Wins US FDA, CE Mark For Cryovials; Rhythm Colostat Wins CE Mark; Cann Swaps Zalm Shares For Rua Shares; Mesoblast AGM 26% Oppose Directors Options; LBT Survives Rem Report, 25% Oppose Director Shares In Lieu; Starpharma AGM 8% Oppose Dr Jackie Fairley Rights; Painchek Pleads Schultz To ASX 51% Query; Creso Requests ‘Material Licence Upgrade’ Halt; MGC Requests ‘Capital Raising’ Trading Halt; Stemcell Further Extends ‘Joint Venture’ Suspension; Nanomab Takes 8.3% Of Radiopharm; Dr Paul Cozzi Takes 6.7% Of Visioneering; Roth Capital Takes 14.6% Of Incannex For Nasdaq Listing

Nov 29, 2021

Biome $8m IPO For Probiotics; Mayne: TGA Approves Nextstellis Combination Oral Contraceptive; Resapp Cough Counter Wins TGA Approval, CE Mark; Vectus Approved To 4th VB0004 Dose Cohort; Kazia: GBM Agile Study Takes Paxalisib To Canada; Bard1, Griffith Uni Work On Exosome Ovarian, Breast Cancer Tests; VGI To Use Endra Taeus For Liver Fat Screening, Measurement; Actinogen Enrols Xanamia Trial; Adalta: I-Body Car-T-Cell In-Vitro Data, 2 Patents; Epsilon Requests ‘Valens Agreement’ Trading Halt; Imricor Pays $280k For 2% Of Mirtle Medical; Ellerston Takes 8.7% Of Atomo; Race Founder Dr William Garner Below 5%; Mercator, Washer Family Diluted In Emyria; Emyria Appoints Dr Karen Smith Executive Director

Nov 26, 2021

Dr Boreham’s Crucible: Radiopharm Theranostics; Artrya Up As Much As 24% On ‘Over-Subscribed’ $40m IPO; Correction: Actinogen Medical; Nominations Open For $40k Victoria Premier’s Awards; Hexima ‘Over-Subscribed’ Share Plan Raises $1m, Total $11m; Palla Pharma Sells Coolaroo Site For $33m, Leaseback; Immutep AGM 20% Oppose 3.6m CEO Marc Voigt Rights; Medadvisor 20% Oppose Placement Capacity; Peter Bennetto; Somnomed AGM 14% Oppose Remuneration Report; Perennial Takes 15% Of Micro-X

Nov 25, 2021

Radiopharm Down 35% On ‘Oversubscribed’ $50m IPO; Aroa H1 Revenue Up 95% To $17m, Loss Down 62% To $5m; Pacific Edge H1 Revenue Up 62% To $5m, Loss Up 27% To $8.6m; Actinogen Raises $12m; Plan For $3m More; Xanamem For Depression; Creso ASIC Query; Raided Chair Adam Blumenthal Stands Aside; Biotron ‘BIT225 Kills Sars-Cov-2 In Mice - Game-Changer’; Starpharma: ‘Positive Interim Results’ For Dep-Cabazitaxel; Nuheara Completes Clinical Trial Recruitment; Imagion: Mercer Underwrites $808k Options; Nova Eye AGM: 45% Oppose 700k M-D Tom Spurling Options; MGC Avoids 2nd Strike, 25% Oppose Director Fee Pool Hike; Regal Funds Reduces To 6.6% In Micro-X; Jason Carrol Takes 9% Of Island; PYC 1-Year US CEO Sahm Nasseri, Steps Down As Director; Medadvisor Loses Director Peter Bennetto; Nominations Open For Bio-Melbourne Women In Leadership Gongs

Nov 24, 2021

Tissue Repair Falls 41% On $22m Wound Healing IPO; Total $29.5m; Race Share Plan For $30m; Imricor Applies For FDA IDE For ICMR Products; Emvision Wins $240k Advance Queensland Fellowship; Proteomics: Promarkerd Takes The De-Novo FDA Route; Emyria Receives $1.2m Federal R&D Tax Incentive; Invex Withdraws 2.5m ‘Performance Shares’ AGM Resolutions; Nova Eye Drops 2.25m Options Resolutions; Alex Sundich Goes; Probiotec AGM: 12% Oppose Wesley Stringer Rights; Greg Lan Goes; Austco Avoids 2nd Strike, 23% Oppose Director Brett Burns; Genetic Technologies AGM: 22% Oppose M-D Dr Jerzy Muchnicki; Avita Moves Financial Year To Calendar Year; Invion To Release 220m ‘Unlimited Group’ Escrow Shares; Selector Takes 5% Of Nanosonics; SIO Reduces To 14% Of Anteris; Resonance Appoints Prof John Olynyk CMO

Nov 23, 2021

Breakthrough Victoria $95m Start-Up Incubator; Volpara H1 Revenue Up 30% To $12m, Loss Down 4% To $8m; Proteomics Expands Promarkerd To Britain; 4D Medical: I-Med Adopts XV LVAS; Paradigm: 3-Patient Data Backs PPS For MPS-I; Resapp Completes India Covid-19 Patient Enrolment; Actinogen Requests Capital Raising Halt; Race Requests Capital Raising Halt; Bionomics Files For Nasdaq IPO; Resonance Files 2 More Cyclophilin Protein Patents; Little Green ‘Registers 1st Marijuana In Denmark’; MGC Receives $1m Of $4.2m US Cimetra Order; Creso Requests ‘ASX Price Query Update’ Trading Halt; Biotron 33% Remuneration Report 1st Strike; Allan Gray Reduces To 5.4% Of Impedimed; Chair Prof Robert Phillips Takes 21% Of Uscom

Nov 22, 2021

EBR Raises $110m For ‘Wise’ Wireless Pacemaker IPO; Uscom 3-For-10 Rights Issue For $5.2m; Redhill Falls 27% On Underwritten $21m Raise; Mesoblast Pays Hercules With $124m Oaktree Loan; Emyria $5m From Tattarang, Dr Andrew ‘Twiggy’ Forrest 7%; Total Brain Loan Extension; Memphasys: 1st Felix Sale To China’s Diagens For IVF; Anteris Implants 5 Patients With Duravr Valve; Chimeric: ‘CLTX-Car-T Shows Regional Tumor Control’; Neuroscientific Hires Imeka For Emtinb MS Neuroimaging; Race: ‘Zantrene Protects Heart Muscle, In-Vitro’; Imugene AGM 56% Oppose Director Dr Axel Hoos; Chimeric 17.5% Oppose Remuneration Report; Paradigm: Paul Rennie Chair, Dr Donna Skerrett Interim CEO

Nov 19, 2021

Vale Bioshares David Blake (1.3.1962 – 18.11. 2021); Dr Boreham’s Crucible: Cryosite; MTP Connect: Redi Pilot Entrepreneur Program Opens; Trajan Pays $26.5m For 2 Axel Semrau Businesses; Resapp: ‘Paediatric Study Backs Cough Diagnostic’; Immutep Completes Phase II Tacti-002 Expansion Dosing; Uniquest Licences Marijuana Delivery Sol-Gel To Preveceutical; Micro-X Withdraws Placement Capacity; 13% Oppose Rights; Genetic Signatures 13% Oppose Rem Report, Michael Aicher; Bionomics Withdraws Capital Distribution; Emyria Requests ‘Placement’ Trading Halt; Oventus Loses Founding Chair Dr Mel Bridges; Cryosite Appoints Steven Waller Director; Prescient: Dr Marco Davila, Prof Andrew Tsourkas Advisers

Nov 18, 2021

Illumina $5m ‘Innovation Collective’ Genomics Lab; Impedimed ‘Oversubscribed’ Plan Raises $7.5m; Total $42.5m; Resapp Licences Resappdx To Janssen For RSV Trial; Adalta: 2nd US Patent For AD-214 For Fibrosis; Alcidion: ‘Too Big For 10% Capacity’; Loses Nick Dignam; Oventus: AGM 44% Stop 10% Placement Capacity; Lumos To Release 9.8m Voluntary Escrow Shares; Australian Ethical Reduces To 13% In Cogstate; Paradigm Appoints Bene’s Dr Christian Reiter For R&D

Nov 17, 2021

Radiopharm IPO Raises $50m; Creso Pleads Schultz To ASX 18% Fall Query; ASIC; Pharmaxis Raises $7.2m, Share Plan For $2m More; Amplia: More Data Backs AMP945 For Focal Adhesion Kinase; Pharmaust Monepantel Trials ‘On-Track’ For 2022; Noxopharm’s Pharmorage Licences RNA Tech From Hudson; Althea: 900k M-D Joshua Fegan Performance Rights AGM; MGC Releases 15m Voluntary Escrow Shares; Perennial Reduces To 5.7% In Nuheara; FIL Takes 7.4% Of Immutep; Director Jim Xenos, Kojent Below 5% Of Medadvisor

Nov 16, 2021

AFP, ASIC Raid Everblu Capital; Noxopharm: ‘MRFF Withdraws $8.8m Grant’; Invion $12m Placement, Plan For $3m For Photosoft; Woke ‘Oversubscribed’ Seed Round Raises $1.55m; Redhill Enrols Part A Of RHB-107 For Covid-19 Trial; Resapp, Carepath Deal For In-Home COPD Monitoring; Imugene: Merck KGaA, Pfizer Supply Avelumab For Trials; PYC Completes VP-001 Toxicology Study; Heramed Issues Shares Beyond Approved Capacity; Cynata 30% Oppose Director Dr Paul Wotton; Platinum Takes 17.45% Of Amplia; Acorn Takes 6.5% Of Amplia; Auscann Loses Chair Max Johnston, Director Bruce McHarrie; Proteomics: Dr Robyn Elliott, Neville Gardiner Directors

Nov 15, 2021

Mesoblast: ‘Revised Data Shows Greater Heart Benefit’; Chimeric: CLTX-Car-T ‘3 Of 4 Glioblastomas Stable Disease’; Immuron Prepares For USU Travelers’ Diarrhoea Study; Woke Orders Synthetic Psilocybin For Drug Trials; Resapp Approval For Covid-19 Test Site Recruitment; Orthocell Locks Ortho-ATI Shoulder Tendon Study Database; Immutep: Eftilagimod Alpha China Patent; Posters Published; Noxopharm $8.8m MRFF Grant; Trading Halt; Pharmaust Takes Dog Lymphoma Trial To New Zealand; Heramed Pleads Schultz To ASX 64% Query; Pharmaxis Requests Capital Raising Halt; PYC Requests Non-Human Primate Study Results Halt; Baillie Gifford Reduces To 5.2% Of Cochlear; Allan Moss, Blueflag Increase, Diluted To 7% Of Amplia; Kazia Appoints Dr John Friend CMO

Nov 12, 2021

Dr Boreham’s Crucible: Artrya; Planet Innovation Buys Bit Analytical, Adds $25m To Revenue; Resonance: Thalassaemia Federation Uses Ferrismart; Auscann Plans Marijuana Spinal Cord Injury Symptoms Trial; Optiscan: Completes Breast Cancer Trial Patient Enrolment; Invion Requests Capital Raising Trading Halt; Bard1: US Patent For Lung Cancer Diagnostic Kit; Anteo AGM: 44% Oppose Pac Partners Fee Options; Cronos: CDA Merger, 5m Performance Rights, 18m Options AGM; Macquarie Group Takes 5.15% Of Patrys; Covid-19 Forces Total Brain M-D Louis Gagnon To Resign

Nov 11, 2021

Brandon, MRCF Back $40m Cureator; Kazia Enrols 1st Patient In Diffuse Midline Glioma Trial; Universal Biosensors, Mayo Clinic Work On Tn Cancer Test; Aroa: Study Backs Sheep Stomach Matrix For Wound Healing; Acrux Receives $3m Federal R&D Tax Incentive; Medlab Completes $1.6m Food Additive Sale To Pharmacare; Adalta Hires Spark Plus For Asia Investor Relations; Audeara, Connect Hearing, Blamey Saunders Partnership; Analytica: US Patent For Pericoach Pelvic Floor System; Clinuvel Avoids Remuneration Report 2nd Strike; Vanguard Below 5% In CSL

Nov 10, 2021

Immutep: IMP321 ‘Non-Significant’ Cancer Benefit; Sub-Groups; Correction: Rage Bio; Clarity Recruits Prostate Cancer Imaging Dosimetry; Immuron, US Navy Cow Colostrum Drug Development Resumes; Zucero Begins Phase IIa Pixatimod Trial; Imagion Pleads Schultz, ‘Enrolment’ To ASX 32.5% Query; Impedimed AGM 15% Oppose Placement Capacity; Avita 130k Directors’ Shares, 378k Options AGM; Arovella Appoints Dr Elizabeth Stoner Director

Nov 9, 2021

Redhill: Kukbo Invests Up-To $13.5m For Asian Rights; Rage $3.7m From IP Group, Monash - Dr Chris Wraight CEO; Pharmaxis: FDA Clears PXS-5505 Phase II Liver Cancer Trial; Actinogen: FDA Approves Xanamem For Fragile X Trial; Island Pays NY State University $914k For Dengue Fever Trial; Race: Wollongong Uni To Evaluate Zantrene Formulations; Artrya ‘Preferred Supplier’ To UK NHS Hospitals; Living Cell Receives $381k NZ R&D Tax Credit; Regal Takes 7.7% Of Medadvisor; Creso Loses 3-Day Consultant Dr Brian Walker MLC

Nov 8, 2021

Amplia $5.4m Placement, $7m Rights Issue; Next Science: TGA Approves Xperience Surgical Solution; Living Cell Drops $4m Rights Issue Price To 0.8c; Clinuvel Adds Neuracthel To Melanocortin Portfolio; Clinuvel Pleads Schultz, ‘Research Note’ To 17.2% Fall Query; Paradigm: ‘Zilosul For Knee Osteoarthritis To Cost $3k-$4k PA’; Corrections: Antisense Therapeutics; Uscom: 2 China Patents For Cardiac Monitor; Mach7: AI Visualize Alleges US Patent Infringement; Adalta Receives Net $894k Federal R&D Tax Incentive; Woke To Distribute O-T-C Havn Mushroom Products; Creso: Halucenex Psilocybin Testing For Phase II Trial; Platinum Takes 5.2% Of Antisense; Perennial Reduces To 8.85% Of Medadvisor; Alex Waislitz, Thorney-Tiga, Urban Land Below 5% In Zelira

Nov 5, 2021

Dr Boreham’s Crucible: Antisense; Prevatex Raises $2.2m; Proteomics: ‘Promarkerd Beats Standard-Of-Care Tests’; Pharmaust Rights Options Raise $514k; Visioneering: ‘Naturalvue Reduces Myopia Progression’; Visioneering Launches Naturalvue Enhanced Multifocal Lens; IQ3: 41%-Owned Oncotex Licences Gold Compounds For Cancer; Blackrock Takes 5.8% Of Avita; Vanguard Takes 5.2% Of Avita; Paradice Takes 8.4% Of Impedimed; JM Financial Reduces To 9.8% Of Universal Biosensors; Regal Funds Below 5% In Adherium; Quincy Street Takes 6.3% Of Zelira; Ausbiotech Appoints Geoffrey Kempler Chair; Polynovo Loses 7-Year CEO, M-D Paul Brennan - ‘Differences’; Visioneering Appoints Dr Ashley Tuan CMO

Nov 4, 2021

Vale Peter Turvey (10.10.1951 - 27.10.2021); Kazia Recruits 1st EVT801 Solid Tumor Patient; Avita: Medicare Expands Recell Reimbursement; Trajan $1.3m For Forth Female Hormone Mapping; Impedimed: Astrazeneca Extends Sozo Contract 3 Months; Invex Prepares For Phase III Presendin For IIH Trial; Noxopharm Recruits 1st Daart-2 Patient; Alterity: Studies Back ATH434 For Parkinson’s, In-Vitro, In Mice; Amplia: Cruk Extends AMP886 Milestone Deadline; US Patent For Medlab Nanocelle; Bioxyne Drops Proposed Acquisition; L1 Capital Takes 7.2% Of Anteris; Creso: WA Legalise Cannabis MLC Dr Brian Walker Advisor

Nov 3, 2021

FDA Clears Paradigm Phase III PPS For Knee OA Trial; MTP Connect $450k Backs $1m For 5 WA Companies; Medlab: DISER Approves $27m Offshore RDTI; Correction: Bard1 AGM; Memphasys Completes Felix Validation, Verification; Lumos: Canada Sars-Cov-2 Rapid Test Interim Approval; BCal: Sample Testing ‘Positive Results’, Trial Begins; Nuheara Federal Hearing Services Provider; Uscom Spirosonic Koneska Technical Agreement; Argenica: ARG-007 Reduces Hie Brain Death 50%, In Rats; Race, Newcastle Uni Zantrene Cancer Diagnostic; Zelira Marijuana Technology; $1.35m Upfront DRCN Deal; MGC Builds Malta Cimetra Factory, $4.8m Grant; Vanguard (Just) Below 5% In Cochlear

Nov 2, 2021

Telix: TGA 1st Illuccix For Prostate Cancer Imaging Approval; Medadvisor $4m US Pilot Sars-Cov-2 Vaccination Program; Israel Approves MGC Cimetra Dosing Study; Neuroscientific: Biospective To Run Emtinb MS Studies; Immutep: China Patent For IMP321 Combination; Osteopore: China Patent For Bone Scaffold Method; Hexima 2.8m Director Options AGM; Perennial Takes 7.5% Of Ecofibre

Nov 1, 2021

October BDI-40 Up 0.3%, ASX200 Down 0.1%, Big Caps Up 3%; Antisense Phase II/III DMD EU Okay; Raises $20m, Rights For $16.8m; Hexima Raises $10m, Share Plan For $1m; Patrys Raises $2.5m, Rights Offer For $5.3m; Eye Co: Dry AMD Fludrocortisone Acetate ‘No Adverse Events’; Austco $1.6m Singapore Tacera Maintenance Contract; Next Science, Tela Bio US ‘White Label’ Deal; Biotron Starts 2 Phase II BIT225 HIV Trials; Imugene, Eureka Join Oncolytic Virus, T-Cells For Tumors; Race Applies For Phase II Acute Myeloid Leukaemia Trial; Bionomics: ‘FDA Okays BNC210 Social Anxiety Disorder Trial’; Creso, Innuana To Grow Marijuana, Swiss Distribution; Paradigm Requests ‘FDA Response’ Trading Halt; Medadvisor Requests ‘Customer Agreement’ Trading Halt; Bard1 Name Change To Inoviq, 2m Director Options AGM; Bard1 Founder Dr Irminger-Finger Diluted Below 5%; Ausbiotech Draft ‘Decadal Blueprint’ For Consultation; Ausbiotech To Lose 9-Year Director, Chair Michelle Burke

Oct 29, 2021

Dr Boreham’s Crucible: Uscom; Resmed Record Q1 Revenue Up 20% To $1.2b, Profit Up 14% To $290m; LBT: FDA 501k Approval For APAS Independence; Immutep: EMA ‘Supports’ IMP321 For Breast Cancer; Cann Global Raises $1.8m; Medical Developments Remuneration 1st Strike: Philip Powell Goes; Adalta 6.7m Director Options AGM; Mesoblast 1.6m Chief Executive, 200k Director Options AGM; Starpharma 493k CEO Performance Rights AGM; Bioxyne Takes ‘Acquisition’ Trading Halt To Suspension; Stemcell Extends ‘Joint Venture’ Suspension; Cronos 80m Shares From ASX To Voluntary Escrow; Pacific Edge Appoints Dr Peter Meintjes CEO; 4D Loses Director Lusia Guthrie; Lost Director Heath Lee; Stefan Ross Replaces Patrys Co Sec Melanie Leydin; Claire Newstead-Sinclair Replaces Invion Co Sec Melanie Leydin

Oct 28, 2021

Ecofibre Claims Marijuana Cancer Results; 1.6 Quarters Cash; Invion: INV-043, Photosoft Kills TNBC, Immunity, In Mice; Up 139%; Incannex: Psilocybin Anxiety Trial Approved, FDA Meeting; Hexima 1.3 Quarters Cash; Requests ‘Capital Raising’ Halt; Anteris Less Than 1 Quarter Cash, Loans, Capital Raising; Resapp Has 2 Quarters Cash, RDTI Coming; Patrys Requests ‘Capital Raising’ Trading Halt; SG Hiscock Below 5% Of Atomo; One Funds, Saville Capital Take 12.5% Of Bluechiip; Victoria Appoints Grant Dooley Breakthrough Victoria CEO

Oct 27, 2021

Aroa H1 Revenue Up 37% To $13.2m; Impedimed Raises $35m, Share Plan For $5m More; Anteris: L1 Capital $5m Placement; Tali Receives $504k R&DTI Victoria Loan; Epsilon Extends $4m Loan Repayment; Universal Biosensors Recruits 1st Xprecia Prime Trial Patient; Oventus: Algorithm Accurate For Apnoea; FDA Exvent Trial; Rhinomed: Rhinoswab St Vincent’s Trial Approved; Race, Chaim Sheba Analyze Zantrene FTO Biomarkers; Adherium AGM 19% Oppose Remuneration Report; LBT Potential 2nd Strike Spill, 1.75m Directors Options AGM; Opthea: China Patent For OPT-302; Bioxyne Requests ‘Potential Acquisition’ Trading Halt; Perennial Reduces To 12.3% In Medadvisor; Loumea Diluted Below 5% In Rhythm; Regal Funds Below 5% In BCal; Black Rock Takes 11% Of Imricor; Oncology One: Peter Mac CEO Prof Shelley Dolan Director; Speedx, Onko-Innate, David Blake Win Ausbiotech Gongs; Ausbiotech: Regenerative Medicine Foundations Laid; Bio-Melbourne Addresses Freight Logistics, Delays

Oct 26, 2021

Ausbiotech Conference 2021, Biotech Invest Open; Victoria $16m For Brain Cancer Centre; Volpara H1 Receipts Up 40% To $13m; Nova Eye $1.42m US Paycheck Loan Forgiven; Atomo: TGA Broadens HIV Self-Test Sales, Advertising; Resapp Expands India Sars-Cov-2 Cough Diagnostic Trial; Bluechiip Signs Fujifilm Irvine IVF Contract; Noxopharm Doses 1st Patient In Veyonda, Nivolumab Tumor Study; Starpharma: Vietnam Viraleze Distributor; 100k Unit Order; Living Cell: NZeno Auckland Island Pigs For Parkinson’s Trial; Polynovo AGM Avoids Spill By 1.7%, 29% Oppose M-D Incentives; MGC Potential 2nd Strike Spill; 100% Directors’ Pay Pool Hike AGM; Hydrix 5.25m Gavin Coote Rights AGM, Paul Lewis Director; Immutep 3.6m CEO Marc Voigt Performance Rights AGM; Medadvisor: 1.5m M-D Robert Read Options AGM; Proteomics To Lose 7-Year Chair Terry Sweet; Anteotech Appoints Tim Pritchard CFO, Co Sec; 2 Executives; Amplia Appoints Dr José Iglesias Clinical Advisor

Oct 25, 2021

Genetic Signatures $12m Record Q1 Revenue; Universal Biosensors: Vinmetrica To Sell Sentia; $1m Sales; Recce Phase I R327 I-V Trial Approved; Creso $217k Scrip For Impactive Marijuana Joint Pain; Memphasys Receives $1.4m Federal R&D Tax Incentive; Optiscan Receives $770k Federal R&D Tax Incentive; Memphasys: China Sperm Separation Patent; Noxopharm: Australia, Europe Allow Veyonda Patent; Impedimed Requests Capital Raising Trading Halt; Invex 2.5m Performance Shares; 60% Pay Pool Hike AGM; Bluechiip 4.5m M-D Andrew McLellan Performance Rights AGM; Paul Hopper Takes 7% Of Imugene

Oct 22, 2021

Dr Boreham’s Crucible: Avita Medical; Chimeric ‘On The Path To CDH17 Car-T Trial’; Medadvisor Expands Walmart Deal; Clinuvel Doses 1st Xeroderma Pigmentosum DNA Repair Patient; Neurotech: ‘Marijuana NTI164 Beats CBD, THC For MS, In-Vitro’; Goodbye Suda, Hello Arovella Therapeutics; Pharmaust 14% Oppose Incentive Scheme Remuneration Report; Austco 2nd Strike, 80% Director Fee Pool Hike AGM; Mayne: $2m M-D Scott Richards ‘Performance’ Rights AGM; Acrux: 6m M-D Michael Kotsanis Rights AGM; BTC 6m Chair Dr Richard Treagus Options AGM; Vanguard Takes 5% Of Cochlear; Copia Takes 5.4% Of Probiotec; Allan Gray Reduces To 6.5% Of Impedimed

Oct 21, 2021

Federal $25m For Stem Cell Research; Hemideina Raises $10m For Cochlear Implants; Cann Group Plan Raises $8.7m, Total $18.7m; Dimerix: ‘1st Phase III Dmx-200 Approval For FSGS’; Neuren: 2nd FDA ‘Hold’ On NNZ-2591, For Phelan-McDermid; Suda: Chile Approves Teva Zolpimist Application; Avecho, Lambert Trial TPM-Marijuana For Arthritis Pain; Pharmaust Manufactures Trial Batches Of Monepantel; Cannim Hires Epsilon For Hummingbud Marijuana; Rhythm 5.3m Director Options AGM; Nova Eye: 2.25m Director Options AGM; Telix Releases 21m Voluntary Escrow Shares

Oct 20, 2021

Telix: ‘TLX101 Safe, Lengthens Glioblastoma Survival’; Zelira: Quincy Street Placement Raises $6.7m; 54% Premium; Pharmacare Pays $1.6m For Medlab Food Additive Business; Truscreen Claims Cervical Cancer Test Success; China Expansion; Imugene Doses 1st CF33 Checkvacc Breast Cancer Patient; Opthea Takes OPT-302 Wet AMD Trials To Asia-Pacific; Control Bionics: ‘Rent Neuronode For Immediate Use’; Incannex Hires Procaps For IHL-42X Manufacture; Oncosil 50% Deliver 2nd Strike; Spill Fails By 2%; Dr Roger Aston; Neurotech 100% Director Fee Pool Hike AGM; Vectus Pleads ‘Schultz, News’ To ASX 24% Query; Acorn Takes 5.3% Of Micro-X; Jason Carrol Takes 7% Of Island; Perennial Below 5% In Hydrix

Oct 19, 2021

CSL 2021 R&D Briefing: ‘Spending Up, Recombinant Focus’; Impedimed Trial: ‘L-Dex Significantly Reduces Lymphoedema’; Artrya $40m IPO For Salix Arterial Plaque Detection; Living Cell $3.5m For NTCell Parkinson’s Trial; Rights For $4m More; Woke, Monash Formulate Psilocybin For Depression Trial; Queensland Uni’s Jetra $1.3m For Fatty Liver Disease; Clarity Closes Sar-Bombesin C-Bobcat Trial Early; Emyria: Eurofins To Screen MDMA Analogs For CNS Activity; Race Wins 6th US Zantrene Patent; Osteopore, Singular Work On Cranial Implant Design Tool; Opthea AGM 20% Oppose Director Options; Dr Jeremy Levin; Nanosonics 353k CEO Rights AGM; Chimeric 7.5m Director Options AGM; Alterity Expands Biomuse ATH343 Multiple System Atrophy Study; Zelira Requests ‘Capital Raising’ Trading Halt; Oncosil Loses 8-Year Director Dr Roger Aston Before AGM; Adherium Appoints Robert Spurr Interim CFO

Oct 18, 2021

Pacific Edge ‘Oversubscribed’ Plan Raises $22m; Total $99.9m; Alcidion, Sydney Health $1.8m Tele-Health Contract; Heramed Notes Raise $2.4m; Mach7 Sales Orders Up 390% To $16.2m; Cynata: Fujifilm Pays $6.7m For New Deal; Patrys: Deoxymab Increases Breast Cancer Survival, In Mice; Mesoblast: ‘Remestemcell-L Improves Child GvHD Survival’; Neuroscientific Completes Emtinb Pharmacology Studies; Auscann Requests FDA CPAT-01 Meeting; Pharmaust: 24 Dogs, 1 Partial Response To Monepantel; Proteomics: ‘Clinical Utility Study Backs Promarkerd’; VGI: Japan Tocotrienol Patent; Anatara 1.8m Director Options AGM; One Week To Ausbiotech Invest 2021, Conference

Oct 15, 2021

Dr Boreham’s Crucible: A Trip Through Psychedelic Drugs; MTP Connect Covid-19-Related 3rd ‘Skills Gaps’ Report; Nuheara Begins 50-Patient Hearing Aid Clinical Trial; Dimerix Brings Phase III DMX-200 For Covid-19 Trial To Australia; MGC Tells ASX: ‘Director Hayes 3y Wrong, Share Trades OK’; Bod ASX Code Change To ‘Bod’; Living Cell ‘Placement, Rights Offer’ Trading Halt; Micro-X 133% Directors’ Fee Pool Hike AGM; Visioneering Q3 Receipts Up 4.2% To Record $2.7m; Cronos Record Q1 Marijuana Revenue $1.1m; Perennial Reduces To 13.6% Of Medadvisor; Perennial Reduces To 5.2% Of Hydrix; IDT To Lose Director Mary Sontrop At AGM

Oct 14, 2021

Federal $30m For Child Musculo-Skeletal Research; Amplia Receives $1.1m Federal R&D Tax Incentive; Heramed Requests ‘Capital Raising’ Trading Halt; Jason Carroll Takes 6% Of Island; Neurotech Tells ASX: ‘Patent Applications Material’; Nuheara AGM 19% Oppose Remuneration Report; Ausbiotech Invest, Partnering 2021 Registration

Oct 13, 2021

Protagonist Jumps 94% As FDA Lifts Rusfertide Hold; IDT, MIPS $2m Sars-Cov-2 mRNA Vaccine Manufacturing Deal; Pharmaxis Doses First Of 24 Patients In PXS-5505 Phase II Trial; Resonance: ‘Liversmart To Launch This Year’; Auscann: Marijuana Dermacann Safe In Dogs At 5mg/Kg; Paradigm PPS Reduces Ards Lung Inflammation, In Mice; Prescient In-Vitro Data Backs Omnicar; US Patent For Redhill’s Talicia For Helicobacter Pylori; Audeara Appoints Oaktree US Headphone Distributor; Actinogen Receives $1.4m Federal R&D Tax Incentive; Kazia 2.5m M-D Dr James Garner Options AGM; Bio-Melbourne, Cytiva Translation Funding

Oct 12, 2021

Alcidion Signs $630k Queen’s Hospital Burton Deal; Imricor: ‘Oversubscribed’ Plan Raises $1m; Total $17.5m; Imricor ICMR For Hungary’s Semmelweis University; Anteris Appoints Iqvia, CRF For Duravr Feasibility Study; CSL: 26% Oppose $10m Paul Perreault ‘Performance’ Shares; Anteo 100% Directors’ Fee Pool Hike AGM; Neurotech Requests ‘Patent Lodgment’ Trading Halt; Oncosil Appoints Prof Ricky Sharma Director

Oct 11, 2021

Acrux Terminates Harris EMLA Licence On Bankruptcy; Audeara, Amplifon Sign Headphone Supply Agreement; Resapp Files Sleepcheckrx FDA 510(K) Application; Universal Biosensors Receives $2.8m Federal R&D Tax Incentive; Creso: ‘Mernova Highest Legal THC In Canada’; USPTO Allows Neuren NNZ-2591 For Autism Patent; Medlab US NRGbiotic Depression Patent; Neuroscientific 8m Directors Options AGM; CMO Dr Sud Agarwal, Cannvalate Take 8.9% Of Incannex

Oct 8, 2021

Biotech Call To Arms: David Blake - Update; Dr Boreham’s Crucible: Somnomed; Cynata: DSMB Okays Stem Cell Covid-19 Trial Unchanged; Lumos Retracts Febridx $2.5b Economic Value Article; LBT: South Australia Extends Loan Repayment; Starpharma: Admenta Italia To Distribute Viraleze In Italy; Adherium CMS Submission On Remote Therapeutic Monitoring; Immuron IMM124E Increases T-Cells In-Vitro, Mice; Actinogen 53m CEO, Director Shares AGM; Clinuvel Potential 2nd Strike Board Spill AGM; Mach7 402k M-D Rights, 335k Director Options AGM; Daniel Ow Replaces Osteopore Directors Carmichael, Pocock; Resmed Pays Rajwant Sodhi $963k; Consultant

Oct 7, 2021

Ellume Recalls Sars-Cov-2 Home Tests On False Positives; Mayne: US FDA 2nd Nuvaring Rejection; National Facility, La Trobe Uni Develop Nanomslide; Medi-Cal To Reimburse Redhill Talicia (Sydney’s Heliconda); Adalta: BTB $760k Moved To Inhaled AD-214; Nova Eye 5-Year Itrack Results; Cardiex: Conneqt, Fenda Manufacturing Agreement; Emyria Joins Palantir Foundry Builders Program; Impedimed AGM: M-D Rights, Options; Chair Scott Ward Goes; MGC: AMC Orders $4m Of Cimetra; Australian Ethical Diluted To 4.9% Of Immutep; Peter Meurs, Skiptan Take 13.8% Of Dimerix; Honsue Cho Takes 26% Of Invion

Oct 6, 2021

Neuren ‘Over-Subscribed’ Plan Raises $3m, Total $23.3m; Aroa H1 Revenue Up 108% To $16.2m; Lumos: ‘Febridx Can Save US $2.5b PA’; Clarification Halt; Emvision: FDA Wants More Data For Portable Brain Scanner; VGI Takes IVB001 Trial To RMH, $1.5m Drawdown-Equity Facility; Race Granted 5th US Bisantrene (Zantrene) Patent; US Allows Medlab Nanocelle Patent; Patrys 25m M-D Options AGM; Island Releases 6.7m Voluntary Escrow Shares; Merchant Funds Takes 5.6% Of Dimerix; Leanne Ralph Replaces Hexima Co Sec Helen Molloy

Oct 5, 2021

CSIRO Eliminates Dengue, Yellow Fever, Zika Mosquito; Redhill Sub-Group Data Backs Opaganib For Covid-19; Volpara: $3m US Breast Software Contract; Rhythm Receives $2.4m Federal R&D Tax Incentive; Pharmaxis Approved For Phase II PXS-5505 Myelofibrosis Trials; Opthea Starts Euro Enrolment For OPT-302 Wet AMD Trials; Clinuvel Ready For Scenesse Xeroderma Pigmentosum Trial; Anteris Duravr Heart Valve ‘Fully-Functioning’ In Sheep; Atomo, Access Replace Rapid Sars-Cov-2 Self-Test Deal; Creso $809k Marijuana Orders; Goodbye Lifespot Health, Hello Inhalerx; Paul Sherman Replaces Palla CFO Brendan Middleton

Oct 4, 2021

Incannex Options Raise $17.7m; Vivelys To Distribute Universal Biosensors Sentia In France; IMCRC: Stryker, Queensland To Build R&D Facility; Avecho Starts Phase I TPM-Marijuana Absorption Trial; Atomo Requests ‘Access Bio’ Trading Halt; TDM Takes 26.8% Of Somnomed; Argenica To Release 1.3m ASX Escrow Shares; Antisense Appoints Dr Gil Price Director; Mayne Appoints Dr Carolyn Myers Director; Exopharm Appoints David Oxley, Johannes Mühl Executives; Troy Di Domenico Replaces Dorsavi CFO Damian Connellan

Oct 1, 2021

September BDI-40 Down 4%; ASX200 Down 3%; Big Caps Down 8%; Biotech Call To Arms: David Blake; Pro Medicus, Novant $40m, 7-Year Visage 7 Deal; Dimerix Share Plan Raises $4m, Total $24m; Pharmaust: Options Rights Offer For $792k; Report To TGA Cautious On MDMA, Psilocybin; Neuren: FDA ‘Hold’ On NNZ-2591 For Angelman IND; Medibio Launches Luca For Stress; Hamish George Replaces Amplia CFO Jeff Carter; David Franks Replaces Exopharm Co Sec Elizabeth McGregor

Sep 30, 2021

Dr Boreham’s Crucible: Aroa Biosurgery; ENA Trials INNA-051 Nasal Spray For Covid-19, Influenza; Adherium Receives $370k Federal R&D Tax Incentive; Cynata: Fujifilm Pays $6.9m In New Stem Cell Manufacture Deal; Paradigm Doses 1st Brazil PPS For MPS-VI Patient; Recce Ready For R327 Phase I Trial; Amplia: Garvan Backs FAK For Pancreatic Cancer; Clarity: Evergreen To Manufacture Copper Isotope Products; Impedimed: Icon To Install 13 Sozo Units; Volpara, Natera Combine For US Cancer Screening; Race: ‘Zantrene Kills FTO-Producing Melanoma, In-Vitro’; Argenica Appoints Linear For Perth ARG-007 Safety Trial; Antisense: EMA Committee Supports ATL1102 For DMD Plan; MGC: AMC Orders 1,000 Cimetra Units; Regal Funds Reduces To 7.8% In Micro-X; Michelle Wing Increases, Diluted To 9% Of Rhythm

Sep 29, 2021

Victoria $4m Backs Neo-Bionica For Medical Devices; Micro-X Wins 2 US Airport Security Contracts; Up To $5.7m; WEHI: ‘Antibody Combo Blocks Sars-Cov-2 In Mice, Hamsters’; PYC: ‘VP-001 Penetrates Rabbit Retina’; Immutep: $3.4m French R&D Tax Incentive; Mayne Appoints Upsher-Smith US Isotretinoin Distributor; Botanix Trials Cannabinoid BTX1204A For Dog Eczema; Stemcell Takes ‘Joint Venture’ Trading Halt To Suspension; Regal Funds Reduces To 5.8% Of Adherium; Veronique Morgan-Smith Replaces Mach7 Co Sec Jenni Pilcher

Sep 28, 2021

Federal Government: Home Covid Testing From November; Mach7: Trinity Orders $7.4m Software, Services; TGA Issues IDT Sterile Licence For mRNA Production; Imricor To Sell Mirtle 12-Lead ECG System; Telix: $12m Federal R&D Tax Incentive; $139m Offshore OK; 4D Medical 702k CEO Options, 50% Directors Pay Pool Hike AGM; Adherium 149m CEO Rights AGM; SG Hiscock Reduces To 6.6% Of Resonance; LBT Appoints Brian O’Dwyer Director

Sep 27, 2021

Pacific Edge Up 22.5% On ASX IPO For Bladder Cancer Tests; Impedimed: Advocate Health Adopts Sozo Heart Program; LBT Appoints Thermo Fisher US APAS Independence Distributor; Federal $12m For Glioblastoma Agile Trial; Kazia; Adalta: ‘AD-214 Reduces Kidney Fibrosis, In Mice’; Eye Co: ‘FA Effective For Macular Atrophy, In Mice’; Invex Partners With Peptron For Presendin; Paradigm: FDA Trial Concern On Mouse Adrenal Gland Function; Noxopharm: US Patent For ‘Veyonda Abscopal Responses’; Exopharm Pleads US Patent News To ASX 24.5% Price Query; Stemcell United Requests ‘Joint Venture’ Trading Halt; Oncosil Receives $1.1m Federal R&D Tax Incentive; Oventus Pleads Schultz To ASX 30% Query; M&G Below 5% In Medical Developments; TDM Takes 26.7% Of Somnomed
 
Dr Boreham’s Crucible: Testing The Covid Assay Developers; Federal, MTP Connect $9m For Diabetes, C-V; Technologies; Cochlear: University Of Pittsburg Files Patent Infringement; Adherium: Astrazeneca $891k Hailie Deal; Immuron Loses Covid Vaccine Bid, Director Peter Anastasiou; Dimerix: India Recommends DMX-200 Covid-19 Trial; Antisense: ‘ATL1102 Significantly Modifies DMD Biomarkers’; Paradigm Ethics OK For Knee Osteoarthritis Pain Trial; Invex Requests ‘Exenatide Deal’ Trading Halt; HSBC Increases, Diluted To 6.8% Of Pharmaxis, In April; Perennial Reduces To 6.7% Of Nuheara; Botanix Appoints Dr Jack Hoblitzell Drug Development Head
 
Atmo Raises $9.6m For Gut Gas Monitor Capsule; Telix: US FDA Extends Illucix Review 3 Months; Micro-X $8m Stroke Alliance Deal; Anteo: Eugeni TGA Application; Romanian Distributor; Osprey: GE Healthcare Resumes Dyevert Euro Promotion; Uscom: BP+ ‘94% Effective For AF Screening’; Zelira’s Ilera Launches Marijuana Acne Product Line; Chimeric: Euro Patent For Car-CLTX, CHM1101; Visioneering: USPTO Allows Multifocal Lens Patent; Polynovo Potential 2nd Strike Board Spill AGM; Cogstate 1.4m O’Connor Family Incentive Options AGM; FMR Takes 5% Of Somnomed; Medibio Appoints Dr Elizabeth Lombardo Adviser
 
Victoria, Monash Uni ‘1st Cardiovascular Centre’; Rhythm Recruits Colostat Trial; Lumos: US FDA ‘Deprioritizes’ Covidx Emergency Use; Imugene: Japan Patent For HER-Vaxx Immunotherapy; Bod, Woolcock Trial S3 Marijuana For Insomnia; Emyria: Preliminary Analysis Of 1st MDMA Analogue; Harbour Takes 10% Of Volpara; Dorsavi Chair Greg Tweedly To Retire At AGM; Clarity Joins Corar
FDA Hold On Protagonist’s Rusfertide (PTG-300); 62% Fall; Federal $6.5m For Rapid Hepatitis C Test; Federal Industry Ministers: Christian Porter Out, Angus Taylor In; Victoria, Burnet, Doherty Rapid Covid-19 Antibody Test; Biomuse Study Readies Alterity For Phase II Parkinson’s MSA Trial; Universal Biosensors Adds 2 Centres For Tn Antigen Cancer Test; Bionomics Prepares For BNC210 Social Anxiety Disorder Trial; Adalta: Victoria $4m RDTI Loan; Resapp Expands Covid-19 Trial To India; Memphasys On-Track For Samson Horse Semen Test; Island: Curia Replaces Cerrx For ISLA-101 Supply; Cronos Pleads Schultz, $61m Marijuana Deal To ASX 30% Query; Oncosil Potential 2nd Strike Board Spill AGM; Epsilon: Valens 1st Marijuana Order For $540k; Zelira Appoints Adjupharm Germany Marijuana Distributor; Creso, Halucenex, Acadia Uni Work On Psilocybin, CBD Gel Capsules
 
Emvision $8m Stroke Alliance Deal; Volpara, Revealdx Combine For Lung Screen; $341k Note; Anteo: Ramma For Greece, Cyprus Eugeni, Sars-Cov-2 Tests; Neuren: Brazil Trofinetide For Rett, Autism Spectrum Patent; MGC: Germany Approves Natural Artemic; Cochlear $2.4m CEO Options, Rights AGM; Dr Greg Rice Replaces Bard1 CSO Dr Peter French; VGI Appoints Prof Darrell Crawford Adviser; Emyria Appoints Dr Jeremy Tannenbaum Psychedelic Adviser
 
Redhill: Opaganib Phase II/III Misses Covid-19 Endpoints; IDT: $11.5m For Federal Sterile Drug Manufacture Plant; Amplia 1st Line AMP945 Combination Pancreatic Cancer Trial; Telix Supplies Illuccix To Amgen For PSMA Therapy Trial; Patrys: ‘PAT-DX3- MMAE Reduces Breast Cancer Growth, In Mice’; Nuheara: Registration-Directed Hearing Aid Trial; Avecho Recruits 1st Phase I TPM-Marijuana Trial Patient; Orthocell: ‘Celgro Rope Improves ACL Reconstruction, In Rabbits’; Imricor Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Starpharma: US Patent For DEP-Cabazitaxel; Cynata: 2 Russian Patents For Cymerus Stem Cells; Argenica ARG-007 For Stroke Scale-Up, Purity; Suda Name Change To Arovella, 8m Dr Michael Baker Options EGM; Regal Funds Reduces To 7.4% Of Adherium; Atomo Appoints Deborah Neff Director; Adherium Loses CFO Anne Bell, Melbourne CFO Wanted; Chimeric Appoints 3 ‘Cellular Immunotherapy’ Advisers 
 
TGA Approves Micro-X Rover; Telix Files US IND For TLX250 Kidney Cancer Trial; Telix: US Guidelines Include PSMA-PET Imaging; Cronos Takes CDA For $61m Scrip In Marijuana Merger; Universal Biosensors, Peter Mac Work On Tn Antigen Test; VGI Appoints Gallipoli For IVB001 Nash Trial; DISER Approves Resapp Overseas R&D; Expects $820k; Cann Group Tests Gelpell Equipment; Harvest One Payment; MGC: UK Approves Import, Use Of Cannepil+ For Epilepsy; Total Brain: $600k ARR As IBM Signs US Veterans Affairs; Rhythm Files Colostat Manufacturer File To TGA; Opthea 1.6m CEO Rights, 4m Director Options AGM; SG Hiscock Takes 5% Of Atomo; Jencay Reduces To 9.6% Of Universal Biosensors; Regal Reduces To 8.8% Of Adherium; Shimano, Ex-M-D Peter Griffiths Below 5% Of Neurotech; One Funds, Saville Take 5% Of Imricor; Lumos Appoints Trump S-G Dr Jerome Adams Adviser
 
Neuren Raises $20m, Share Plan For $2m More; Telix Appoints Radius Illuccix Italy Distributor; Impedimed: 2 Abstracts Back Sozo For Heart Failure; Heramed: ‘Pilot Program Women Approve Foetal Monitoring’; Acrux: US FDA Accepts Dapsone Gel Application; Paradigm: ‘PPS Improves Grip In Mice With Chikungunya’; VGI NE1-Elite Muscle Soreness, Swelling Trial; Creso: MHG Orders $338k Marijuana Products; Universal Biosensors 7.5m CEO, CFO, Staff Performance Rights; Paul Hopper Takes 5.4% Of Imugene
 
Dr Boreham’s Crucible: IDT Australia; Rhinomed: Victoria Orders 1m Rhinoswabs; Distributors; QRX Hopes To Return To The ASX; Correction: Epsilon; Neuren Requests Capital Raising Trading Halt; Sun Hung Kai Increases, Diluted In Total Brain; Consolidation; Polynovo Loses Coo Dr Anthony Kaye; Oventus Appoints Michael Sisk Head Of Finance
 
Haemalogix Raises 10m For Multiple Myeloma; Adherium: FDA Approves ‘Next Generation’ Hailie Sensor; Telix Images Last Patient In Japan TLX591-CDx Trial; Epsilon, Valens Facility Deal; Buys Alternamed For $4.3m Scrip; Auscann Appoints Knoell CPAT-01 Advisor; Clime Takes 10.5% Of Mach7; Australian Ethical Takes 10.2% Of Mach7; Director Andrew Kroger Diluted To 41.5% In Cryosite; Steve Parkes Replaces Mach7 CFO Jenni Pilcher
 
Imricor Raises $16.5m, Plan For $1m More; Volpara, Riverain Deal For Lung Cancer Screening; IDT Tells 2nd ASX Aware Query ‘Federal Deal Not Material’; Showa Denko Evaluates Exopharm Leap Technology; Epsilon Takes ‘Partnership’ Trading Halt To Suspension; FIL Reduces To 5.8% In Cogstate
 
Vale Dr Kevin Healey (May 26, 1952 – Sep 3, 2021); Rhythm Raises $4.3m, Placement For $1.275m More; Vectus Completes Second VB0004 Cohort; Ecofibre, Southern Cross Uni Start Marijuana Sleep Trial; Orthocell: Canada, Hong Kong Patents For Celgro; Little Green WA Psilocybin Licence, Stephen Bright Advisor; Imricor Requests ‘Capital Raising’ Trading Halt
 
S&P ASX Indices: 2 Biotechs Up, 2 Down; Queensland Grant For Analytica Pericoach Manufacture; Anteo: Pera Medikal Turkey Eugeni Covid Test Distributor; Little Green Danish Marijuana; Morten Snede, Tony Roberts; Epsilon Requests ‘Partnership’ Trading Halt; CMO Dr Matthew Myntti Reduces To 7.1% Of Next Science; Perennial Takes 6.5% Of Ecofibre; Anteris Appoints Dr Chris Meduri CMO; Radiopharm Appoints Riccardo Canevari CEO, M-D; Creso Appoints Dr Miri Halperin Wernli, William Lay
 
Dr Boreham’s Crucible: Nanosonics; BTC Revenue Up 17% To $7m, Loss Down 53% To $464m; Neuren: FDA Orphan Status For Nnz-2591 For Prader-Willi; BCal: Sydney Breast Clinic Collects Blood For Cancer Test; Federal DISER Approves Neuroscientific Overseas R&D; Osprey EGM Approves 100-To-1 Consolidation; Nova Eye Buys Back 388k Unmarketable Parcel Shares; CSL $9.8m CEO Performance Rights AGM; MGC: India Approves Cimetra Import; Peter Meurs Increases, Diluted To 10.7% Of Dimerix; Regal Funds Management Takes 7.5% Of Althea; Suda Appoints Dr John Maher Scientific Advisor 
 
Kazia: France Approves Phase I EVT801 For Cancer Trial; Chimeric, Oncobay Partner To Develop CHM1101; Audeara Revenue Up 24% To $1.1m, Loss Up 176% To $1.25m; Immutep Doses Last 2nd-Line NSCLC IMP321-Keytruda Patient; FIL Reduces To 6% Of Telix; TDM Takes 26% Of Somnomed; Australian Ethical Takes 8.7% Of Mach7; Ausbiotech: Regenerative Medicine Manufacture, Trials; Lung Health Initiative: Theodora Elia-Adams Director
 
Imugene: HER-Vaxx Misses Gastric Cancer Secondary Endpoint; Palla Pharma H1 Revenue Down 43% To $7m, Loss Up 267% To $33m; Hydrix Revenue Down 50% To $7.4m, Loss Up 204% To $9.8m; Epsilon H1 Revenue Down 7% To $3.2m, Loss Down 26% To $4.1m; Creso H1 Revenue Up 109% To $3m, Loss Up 9% To $19m; Cardiex Revenue Up 14% To $5.3m, Loss Up 67% To $5.5m; MGC Revenue Up 43% To $3m, Loss Down 28% To $14m; Emyria Revenue Up 95% To $2m, Loss Down 6% To $4.9m; Cann Global Revenue Down 17% To $1.5m, Loss Down 41% To $5m; 4D Medical Continues I-Med Radiology Program; Neuren: Acadia Trofinetide Under-5 Rett Trial; Angelman Ind; Resapp: Indonesia Approves Resappdx; Memphasys: Hydrix To Pay $500k, 1m Shares For Felix Flaw; Althea: Boston Beer Deal For Canadian Marijuana Drinks; Hexima Appoints Jake Nunn Director; Medibio M-D Claude Solitario Pay Rise To $200k: Co-Sec Change
 
Althea Record Revenue Up 128% To $11.5m, Loss Up 1.9% To $15m; Mesoblast Revenue Down 77% To $10.2m, Loss Up 27% To $135m; Stemcell Revenue Up 11-Fold To $8.5m, Loss Up 107% To $3m; Regeneus Revenue Up 325% To $7.1m, Loss To $2.15m Profit; Little Green Revenue Up 218% To $7m, Loss To $24.6m Profit; Medlab Revenue Down 3.7% To $5.2m, Loss Down 7.9% To $12.4m; Bioxyne Revenue Down 6.6% To $2.1m, Loss Down 28% To $426k; Incannex Revenue Up 211% To $1.9m, Loss Up 74% To $8.2m; Proteomics Revenue Down 8% To $1.3m, Loss Up 64% To $2.9m; Oventus Revenue Up 160% To $1.1m, Loss Down 2.9% To $9.8m; Orthocell Completes Ortho-ATI Rotator Cuff Follow-Up; Pharmaxis: PXS-6302 For Burns Scars ‘Safe, Well-Tolerated’; Neuroscientific: Emtinb ‘Significantly Reduces Ms Biomarkers’; Immutep: China’s EOC Plans IMP321, PD-1 Trial; Pharmaust: Epichem Repays Lab Expansion Loans; Cynata: Canada Patent For Cymerus Stem Cells; Creso, Red Light Holland End Merger; Aims At Nasdaq; Movac Fund 3 Below 5% In Aroa; Exopharm Appoints Dr Jennifer King Director
 
Medadvisor Revenue Up 304% To $39m, Loss Up 49% To $15.4m; Austco Revenue Down 1% To $31m, Profit Up 37% To $3m; Lumos Revenue Up 198% To $25m, Loss Up 50% To $20m; Next Science H1 Revenue Up 272% To $5.4m, Loss Down 37% To $4m; Imex H1 Revenue Up 15% To $5.2m, Loss Up 18% To $3m; Resonance Revenue Up 3% To $3.8m, Loss To $586k Profit; IQ3 Revenue Down 58% To $3m, Loss Up 156% To $6m; Orthocell Revenue Up 48% To $1m, Loss Up 47% To $9m; Federal Diser Approves Neuren Overseas R&D; Expects $6.5m; Anteris Extends Lemaitre Manufacturing Deal; Althea Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Imricor To Sell Nordicneurolab Monitors; ASX Removes TBG From Official List; Credit Suisse Below 5% Of IDT; Merchant Reduces, Diluted To 12.6% Of Bard1; SG Hiscock Takes 9.6% Of Bod; Chimeric Appoints Jennifer Chow CEO, M-D; Starts On $754k; David Austin Replaces Cann Global Chair Pnina Feldman 
 
Dr Boreham’s Crucible: Clarity Pharmaceuticals; Mayne Revenue Down 12% To $401m, Loss Up 125% To $208m; Redhill H1 Revenue Up 92% To $58m, Loss Up 57% To $72m; Clinuvel Revenue Up 43% To $48m, Profit Up 68% To $24.7m; Avita Revenue Up 66% To $43m, Loss Down 37% To $36.5m; Atomo Revenue Up 25% To $6.7m, Loss Down 35% To $6m; Anteris H1 Revenue Down 20% To $3.2m, Loss Up 74% To $10m; Allegra Revenue Down 10.2% To $4.5m, Loss Down 50% To $579k; Micro-X Revenue Down 11% To $3.8m, Loss Up 46% To $14.7m; Total Brain Revenue Down 4.7% To $3.7m, Loss Up 9% To $8.3m; Cronos Revenue Up 14-Fold To $1.7m, Loss Up 3% To $4m; Imugene Dosing 3rd PD1-Vaxx Cohort; Rhinomed: Royal Children’s Hospital Trials Rhinoswab Junior; Osteopore Sponsors 2 PCL-TCP Reconstruction Trials; Immutep: China Patent For LAG525; Painchek Disputes $1.4m NSW Tax Assessment; Next Science: Irrimax Xperience Surgical Wash Legal Action; Emyria: Calvert For EMD-003 Synthetic Cannabidiol Studies; MGC Claims $33m AMC Marijuana, Cimetra Deal; Frank Condella Replaces Mayne Chair Roger Corbett
 
Compumedics Revenue Up 2% To $36m, Loss To $1m Profit; Polynovo Revenue Up 32% To $29m, Loss Up 10% To $5m; Kazia Revenue $15m, Loss Down 32% To $8m; Control Bionics Revenue Up 28% To $4m, Loss Up 253% To $3.5m; Rhinomed Revenue Up 9% To $3.9m, Loss Up 18% To $8m; Starpharma Revenue Down 67% To $2m, Loss Up 34% To $19.7m; Dorsavi Revenue Down 7% To $1.8m, Loss Down 73% To $2m; LBT Revenue Down 5% To $1.4m, Loss Up 28% To $7m; Oncology One, Children’s Cancer Institute Work On Solid Tumors; Dash Launches Acrux Generic Testosterone In The US; Nova Eye Pays $2.8m For US Glaucoma Patents; USPTO Allows Cynata Cymerus Stem Cell Patent; Suda Appoints Dr Reuben Benjamin Advisor
 
Clarity Opens Up 18% For Cancer Radio-Pharmaceuticals; Althea Raises $10.6m; Probiotec Revenue Up 12% To $121m, Profit Down 21% To $5m; Trajan Revenue Up 7% To $77m, Profit Down 28% To $2m; Cogstate Revenue Up 44% To $45m, Loss To $7.2m Profit; Genetic Signatures Revenue Up 151% To 28m, Loss To $1.8m Profit; Medical Developments Revenue Up 9% To $26m, Profit To $13m Loss; IDT Revenue Up 19.5% To $17m, Loss To $2m Profit; Cryosite Revenue Up 12% To $10m, Profit Down 56% To $653k; Impedimed Revenue Up 47% To $8m, Loss Down 3% To $21m; Acrux Revenue Up 7% To $1.3m, Loss Up 33% To $13m; Medlab: TGA Okays Nanabis Marijuana Cancer Pain Trial; Dimerix Files Phase III DMX-200 FSGS Study Ethics Application; Bayer Increases Cardiex Trial Contract $682k; Chimeric Releases 19m Shares From Escrow; Credit Suisse Takes 6% Of IDT; Perennial Takes 15% Of Medadvisor; Deborah Ambrosini Replaces Cann Group CFO Greg Bullock
 
Nanosonics Revenue Up 3% To $103m, Profit Down 15% To $8.6m; Somnomed Revenue Up 9% To $63m, Loss Up 147% To $1.2m; Alcidion Revenue Up 39% To $26m, Loss Down 27% To $2m; Impedimed Receives $1.8m Federal R&D Tax Incentive; Adalta, Carina Work On I-Body, Car-T-Cell For Cancer; Suda: ‘Stada Zolpimist Licence For Insomnia In Australia’; Invion EGM For Cho Deal, 138m Thian Chew Options; Imugene Pleads Schultz To ASX Listing Rule 15.7 Leak Query; Perennial Takes 8% Of 4D Medical; Health Management Sells Medadvisor Shares To Cotiviti; China Patent For Hexima Pezadeftide (HXP124) For Toe Fungus; Antisense Dr Gil Price Joins US Duchenne Advocacy Board; Neuroscientific: Dr Peter Hnik, Dr Frank Bonner Advisors
 
Mach7 Revenue Up 1% To $19m, Profit To $9m Loss; Cyclopharm H1 Revenue Up 47% To $8.5m, Loss Down 31% To $4m; IDT: Victoria Buys $1m mRNA Nanoassemblr - Federal Facility; Bod Revenue Up 25% To $7.5m, Loss Up 12% To $4m; Cann Group Revenue Up 369% To $4m, Loss Up 48% To $25m; Bard1 ‘Oversubscribed’ Plan Raises $3.4m; Total $18.4m; Polynovo Starts Novosorb Syntrel Hernia Repair Trial; Impedimed: FDA Sozo Breakthrough Status For Kidney Failure; Telix, Lightpoint Work On Radiation-Guided Surgery; Island, Griffith Uni Repurpose Anti-Virals; Noxopharm: NOX66/Idronoxil/Veyonda Benefit For Covid-19; Lumos Releases 10m Escrow Shares; Actinogen: Brazil Patent Completes Xanamem Protection; Mitsubishi Tanabe Pharma Korea Ends Suda Zolpimist Licence; Vectus Doses 1st VB0004 Blood-Pressure Cohort; Starpharma: ‘Viraleze Kills Sars-Cov-2 More Than 99.9% In Mice’; Althea, Canopy Growth Marijuana Manufacturing Deal; Suspended TBG Suspended For Non-Payment Of Listing Fees; Co-Founder Dr William Garner Takes 27% Of Island; Cotiviti Tales 11.7% Of Medadvisor; Pro Medicus Appoints Alice Williams Director; Anteo Loses CFO Gail Jukes; Duncan Cornish Interim CFO
 
Dr Boreham’s Crucible: Rhinomed; Cochlear Revenue Up 10% To $1.5b, Loss To $327m Profit; SDI Revenue Up 21% To $82m, Profit Up 111% To $9m; Cellmid Revenue Down 14% To $7m, Loss Down 31% To $3m; Visioneering H1 Revenue Up 53% To $4m, Loss Down 71% To $2m; Imugene ‘Oversubscribed’ Share Plan Raises $5m; Total $95m; IDT Tells ASX: Good mRNA News May Have Pushed Price 49%; Federal $79m For New Technologies; Fellowships; Osprey 100-To-1 Consolidation, Director Options EGM; Chimeric: FDA Approves CHM1101 Glioblastoma IND; Imricor Releases 13m Escrow Shares; Anatara Launches IBS-D Trial Recruitment Website; Alcidion Appoints Victoria Weekes, Daniel Sharp Directors; Emyria Appoints Dr Mat Martin-Iverson MDMA Advisor
 
Nova Eye Revenue Up 5% To $13m, Profit To $4.4m Loss; Uscom Revenue Up 11% To $3.9m, Loss Down 31% To $924k; Telix H1 Revenue Up 81% To $2.9m, Loss Up 78% To $32.5m; Oncosil: 1st Pancreatic Cancer Device Revenue $213k; Telix Adds Phase I, Phase II Trials To Phase III Prostact Trial; Rhythm Starts Filing Colostat Blood Test To TGA; Dimerix Tells ASX: ‘No Leak, Try Broker Or Investors’; Biotech Daily Editorial: Confidential Means Confidential; Neuroscientific: Emtinb ‘Reduces Covid-19 Biomarkers In-Vitro’, Halt; Epsilon, Tetra, Terry White Melbourne Marijuana Clinic; Noxopharm Requests ‘Veyonda Covid’ Trading Halt; Incannex Nasdaq IPO EGM; Robins Super Fund Takes 5.9% Of Cryosite; Niv Dagan, 10 Bolivianos Take 9% Of Lifespot; Volpara Appoints Ann Custin Director; Prescient Appoints Prof Donald O’Rourke Advisor 
 
CSL Revenue Up 7.2% To $12.6b, Profit Up 9.6% To $2.9b; Pro Medicus Revenue Up 20% To $68m, Profit Up 34% To $31m; Editorial: Your R&D Tax Incentive Is Not Revenue; Nuheara Revenue Up 374% To $10.7m, Loss Down 38% To $7.2m; Pharmaust Revenue Down 33% To $2.1m, Loss Down 2% To $1.3m; Total Brain $1.9m Of $4m Rights Applications; Total $6.5m; Australian Patent For Island ISLA-101 For Dengue Fever; Telix, Merck KGaA Work On Cancer; 2 Breast Cancer Trials; Tali: ‘Akili Up To $51m ADHD Deal’; Incannex Files US SEC Registration For Nasdaq IPO; Volpara AGM 32% Dissent; Loses Director Dr Monica Saini; Lifespot EGM To Become Inhalerx Marijuana Vape Company
 
Burnet Sells 360 Biolabs To Bioagilytix; Baymatob: ‘FDA Approves Oli For Postpartum Haemorrhage’; Queensland Uni Looks For Sport Concussion Biomarkers; South Australia Uni Nano-Polymer Micelles For C Albicans; Elixinol H1 Revenue Down 39% To $4.8m, Loss Down 87% To $11m; Osprey H1 Revenue Up 33% To $1.5m, Loss Down 30% To $7.1m; Telix: Great Ormond Street Trials TlLX66 For Paediatric Leukaemia; Avita: FDA Approves Recell For Vitiligo IDE Amendment; Pharmaxis $3.8m Aptar Option To Develop Orbital Inhaler; Starpharma: Nasal Viraleze, SPL7013 Safe, Not Systemic; Bard1: Proof-Of-Concept Sub-B2M Elisa Ovarian Cancer Test; Nuheara Plans Hearing Aid Clinical Trial; CSL: Melbourne Uni V-C Prof Duncan Maskell Director; PYC Ophthalmology Clinical Advisory Board
 
Dimerix Placement Raises $20m, Share Plan For $2m More; Radiopharm Raises $20m Seed Capital For Nuclear Medicine; Correction: Painchek; Genetic Technologies Completes Easydna Acquisition; Creso: Halucenex Wins Canada Psychedelics Dealer Licence; Tali Requests ‘Licence’ Trading Halt; Suda, Imperial College Inkt Deal; Prof Karadimitris Sab Chair; Invex: Europe Exanatide Patent For ICP Treatment; Living Cell Cuts Costs, Loses COO Dr Janice Lam; Founder Dr Graham Melrose Reduces To 22% Of Recce
 
 
Pharmaxis Revenue Up 207% To $22.7m, Loss Down 79% To $3m; Antisense: FDA Wants More Data For ATL1102 DMD Application; Proteomics Hires Biotem For Promarkerd Kidney Disease Kits; Imagion, GCT Work On Nano-Scintillator For Breast Cancer; Australia Allows Eye Co Patent For Geographic Atrophy; VGI: Informed Sport Certifies NE1-Elite ‘No Banned Substances’; Dimerix Requests ‘Capital Raising’ Trading Halt; Creso Requests ‘Canada Health Licence’ Trading Halt; Factor To Hold 10-To-1 Consolidation; Jason Carroll Takes 5% Of Island; Osprey Appoints Martin Emerson Director
 
Rhinomed: ‘NSW Orders 1m Rhinoswab Sars-Cov-2 Tests’; Venstra Raises $2m For ‘Next Gen Miniature Heart Pump’; Noxopharm Adds Detail To US NCI Collaboration; Recce Wins 2nd R327 Federal Grant Of $50,000; Uscom: China Awards 5 BP+ Software Copyrights; Creso: Canada Approves Medical Marijuana Licence; Doherty’s Prof Sharon Lewin To Open Ausbiotech 2021; Perennial Below 5% Of Atomo; BCCL Reduces To 6.9% Of Tali 
Mach7 Up-To $2.4m Eunity Imaging Licence To Idaho’s St Luke’s; Aroa: ‘Myriad Matrix’s Efficacy For Pilonidal Sinus Disease’; Ecofibre Revenue Down 43% To $29m, Profit To $7m Loss; TBG H1 Receipts Up 2.7% To $3m; Mayne To Defend ‘Misleading, Deceptive Conduct’ Class Action; Paradigm: FDA Requires Further Ind Clarification; Patrys: Covid-19 Delays PAT-DX1 Manufacture, Trial 6 Months; Pharmaust’s Epichem Waste-To-Fuel Reactor ‘Operational’; Perennial Takes 13.5% Of Micro-X; Regal Funds Reduces To 9% Of Micro-X; Race Founder Dr William Garner Reduces To 6%; Perennial Takes 9% Of Lumos; Zoltan Varga Increases, Diluted To 18.5% In Total Brain; Anteotech: CEO Derek Thomson Extended On $395k; Mike Tonroe Replaces Genetic Tech Co Sec Justyn Stedwell; Elizabeth Spooner Replaces Stemcell Co Sec Chow Yee Koh
 
BDI-40 Down 6%; Big Caps Up 4%, ASX200 Up 1%, NBI Down 0.2%; Orthocell ‘Celgro Helps Develop Lymphatic Tissue’; Anteris To Raise $9m; Anteris H1 Receipts Down 6% To $3.5m; Stemcell United Receipts $7.7m; Epsilon H1 Receipts Down 2% To $3m; Creso H1 Receipts Down 21% To $2m; Resonance Receipts Up 2.2% To $3.7m; Dimerix: Remap-Cap Covid-19 Pneumonia Trial On-Track; Biocurate Funds Monash Early Breast Cancer Research; Bionomics ‘Possible Nasdaq IPO’, Merck Royalty Return; Resapp Requests ‘Licencing Agreement’ Trading Halt; Lifespot AGM Up-To 97% Block 7m Director Options; Hydrix: Angel Medical Implants 1st US Guardian Patient; Thorney, Tiga Take 19.9% Of Oventus; Mark Leong Replaces Osteopore Chair Brett Sandercock; Epsilon Appoints Dr Rob Jenny, Simon Rowe Directors; Adrian Sturrock Replaces Bod CFO Alan Dworkin; Suda Appoints Dr Sandhya Buchanan Manufacturing, Quality
 
Bard1 Raises $15m, Share Plan For $2m More; Rhythm 1-For-40 Rights Offer For $4.3m; Dr Boreham’s Crucible: Alcidion Group; Psychae: Unnamed Company $40m For Psychedelic Research; Medadvisor Receipts Up 306% To $38m; Kazia Posts Licencing Receipts Of $12.7m; Imex H1 Receipts Up 1.5% To $4.5m; Mesoblast Receipts Down 20% To $6m; Medlab Receipts Down 22.5% To $5m; Total Brain Receipts Down 22% To $3.9m; Rhinomed Receipts Down 7% To $3m; Universal Biosensors H1 Receipts Up 441% To $1.3m; Starpharma Receipts Down 66% To $2.4m; Incannex Receipts Up 56% To $2.2m; Dorsavi Receipts Down 32% To $1.6m; Proteomics Receipts Down 17% To $1.5m; Oventus Receipts Up 168% To $1.05m; Telix: Shuts Belgian Cyclotrons, To Build New Cyclotrons; Medadvisor API Deal Adds 250 Pharmacies, Revenue; Paradigm Requests ‘FDA Response’ Trading Halt; TBG AGM 24% Oppose Remuneration Report; Nyrada: US Patent For Pcsk9 Cholesterol Program; 4D Releases 1.7m ASX Escrow, 38.6m Voluntary Escrow Shares; Starpharma Loses Director Peter Turvey
 
Imugene Placement Raises $90m; Share Plan For $5m More; Aroa ‘Oversubscribed’ Placement Raises $47m; $5m Plan; Clinuvel Receipts Up 32% To $39m; Genetic Signatures Receipts Up 241% To $30m; Pharmaxis Expects Revenue Up 82% To $24m, Loss Down 79% To $3m; Hydrix Receipts Down 39% To $9.7m; Atomo Receipts Up 202% To $8m; Regeneus Receipts $7.7m; Osprey H1 Receipts Down 3% To $1.5m; Cronos Receipts Up 970% To $1.2m; Queensland Uni Develops Intranasal Spray-To-Gel; Volpara: US FDA Clears VIS 3.2 Algorithm, Architecture; Epsilon 64% Vote Off Directors Alan Beasley, Lou Cattelan; Anteris Requests Capital Raising Trading Halt; Australian Ethical Takes 19% Of Nova Eye; Mason Stevens Takes 6% Of Patrys; Karen Borg Replaces Optiscan Director Graeme Mutton
 
Little Green Pharma Receipts Up 271% To $6m; Micro-X Receipts Up 104% To $5m; IQ3 Receipts Down 56% To $3.2m; Pharmaust Receipts Down 30% To $2.5m; Emyria Receipts Up 110% To $2m; Bluechiip Receipts Up 42% To $1.2m; Acrux: US FDA Approves Generic EMLA Local Anaesthetic; Clarity Starts Cu-64/Cu-67 Sar-BIS-PSMA Prostate Cancer Trial; Anteo Appoints Apacor UK Eugeni Distributor; Regeneus, Kolling Work On Progenza For Osteo-Arthritis, In Mice; Bard1: Queensland Uni Uses Exo-Net For Ovarian Cancer Test; Chimeric Licences Pennsylvania Uni Car-T For Solid Tumors; Rhythm Requests ‘Capital Raising’ Halt; Dr Charmaine Gittleson To Replace Antisense Chair Bob Moses; Starpharma Appoints Lynda Cheng Director; Resonance Appoints Ajay Nair Sales, Marketing G-M
 
Prescient: Safety Takes PTX-100 To Cancer Expansion Study; Somnomed Receipts Down 3% To $60m; Alcidion Receipts Up 54% To $32m; Althea Receipts Up 126% To $10.3m; Impedimed Receipts Up 44% To $8m; Control Bionics Posts $3.3m; MGC Receipts Up 26.5% To $2.7m; Audeara Posts $1.2m Receipts; Control Bionics Appoints DNR Wheels Singapore Reseller; US Allows Medlab Nrgbiotic For Depression Patent; Incannex Starts Phase I IHL-675A Safety Trial; Patent; Starpharma: ‘SPL7013 Kills 99.9% Of Delta, Kappa Sars-Cov-2’; Aroa Requests ‘Capital Raising’ Trading Halt; Imugene Requests ‘Capital Raising’ Trading Halt; CTXone Renames Itself Oncology One; Factor To Buy Powerlime, Become Dominion Minerals; Dr Alan Finkel, Nebula, Howitt Below 5% Of Cogstate; Sean Williams Replaces Lifespot Chair Rodney Hannington 
 
Cann Group Placement, Share Plan For $20m; Nuheara Receipts Up 162% To $8.85m; Cardiex Receipts Down 12.5% To $4.5m; Cann Group Receipts Down 20% To $1.4m; Imex Pays $8.5m For ‘Related Party’ Rimab; Visioneering To Distribute Innovatus Lenses In North America; Patrys: ‘PAT-DX1 Slows Pancreatic Tumor Growth 26%, In Mice’; Pharmaust: 3 Labs Back Monepantel For Sars-Cov-2, In-Vitro; Hexima Completes Hxp124 Nail Fungus Trial Enrolment; Australian Patent For Anteris Sterilization System; One Funds Takes 11.7% Of IDT; Dr David Brookes Replaces Anatara Chair Sue MacLeman; Cynata Appoints CSL’s Dr Jolanta Airey CMO
 
Dr Boreham’s Crucible: The Life Sciences IPO Olympiad; Bard1 Placement Raises $15m; Share Plan For $2m More; Creso: Landing Strong To Provide PTSD Trial Support; Richmond Hill Below 5% Of Universal Biosensors; Regal Takes 6% Of BCal; Mercer Street Below 5% Of Anteris
 
Omniscient Raises $40m; FDA Clears Quicktome Brain Mapper; Cogstate Receipts Up 46% To $58m; Next Science H1 Receipts Up 83% To $6.3m; Elixinol H1 Receipts Down 28% To $5m; Telix H1 Receipts Down 6% To $2m; Invion Receipts Down 26% To $2.6m; Bioxyne Receipts Down 26% To $2.1m; Proteomics: Abcam To Manufacture Promarkerd Reagents; Island: Cerrx, Curia Manufacturing Agreements; US Patent For Recce R327, R529; Incannex Patent Application; IHL-42X Trial Extension Approved; Pharmaust Applies For Monepantel Patent For Viral Diseases; Cann Group Requests ‘Placement’ Trading Halt; FIL (Fidelity) Takes 6% Of Medical Developments; Browns Island Below 5% In Truscreen; BCal: Jayne Shaw 13%, Ronald Phillips 13%, Merchant 8%, Mera Vale 6%
 
BCal Climbs 10% On $10m IPO For Breast Cancer Screening; Immutep ‘Over-Subscribed’ Plan Raises $7.2m; Total $67.2m; Total Brain $6.5m Placement, Rights Offer; Amplia: ‘AMP945 Safe, Well-Tolerated, Appropriate For FAK’; Ecofibre Receipts Down 24% To $23m; Micro-X New Generator: ‘Half The Price, 4 Times The Power’; Hydrix Takes Guardian Cardiac Arrest Device To TGA; Argenica’s Prof Bruno Meloni Wins $290k Grant For Rat Study; MGC Tells ASX: ‘June 23 Slovenian Patent Material At Jul 15’; Bard1 Requests ‘Capital Raising’ Trading Halt; Australian Ethical Takes 7.55% Of Mach7; Milano Topco, HMS Increase, Diluted To 11.7% Of Medadvisor; Hanno Cappon Replaces Bod Director Patrice Malard; Stemcell United Appoints Francesco Cannavo Director
 
Clarity $92m IPO For Cancer Radio-Pharmaceuticals; Mach7 Receipts Up 23% To $21m; Redhill Completes Opaganib For Covid-19 Pneumonia Trial; ENA Starts INNA-051 Nasal Spray Covid-19 Prevention Trial; Nova Eye Unaudited Revenue Up 6% To $13.5m; Cellmid Receipts Down 32% To $5.6m; Osprey: Dyevert Canada Approval, GE Healthcare Distributor; Emvision Prepares Commercial Portable Brain Scanner; Telix: On-Track For TLX250-CDx FDA Biologics Application; China Patent For Recce R327, R529; Auscann Starts Marijuana Dermacann For Dogs Application; Incannex Requests ‘Patent, Ethics Approval’ Trading Halt; Correction: Adalta; Cochlear Loses Director Abbas Hussain; Otto Buttula Replaces Oncosil’s Chris Roberts, Michael Bassett; MTP Connect Appoints Dr Amanda Ruth ‘Guest Of The Chair’; Lifespot: Saich, Davies In; Stedwell, Cannavo Out
 
Compumedics: Revenue Up 1.4% To $36m; Vaccines The Key; Mesoblast: ‘Remestemcel-L Cuts Under 65s ARDS Mortality 48%’; Recce: R327 Kills ‘Flesh-Eating’ Bacteria, In-Vitro; Mach7 Licences Eunity To Advocate Aurora For $4.3m; Volpara Distributes Invitae Genetic Breast Cancer Test; Genetic Technologies Buys Easydna For $5.4m; Dimerix: FDA Confirms Phase III DMX-200 FSGS Trial Design; Adalta Closes Phase I Trial, To Take Inhaled AD-214 To Phase II; Anteo: Australia, SE Asia Eugeni Sars-Cov-2 Distributors; Heramed: Obstetrix Heracare Foetal Heart Pilot Study; Medlab: WEP To Run UK Marijuana Distribution Programs; Respiri: Adherium Offer Lapses; Total Brain Requests ‘Capital Raising’ Trading Halt; Rain Maker Reduces To 9% In Osteopore
 
Dr Boreham’s Crucible: Lumos Diagnostics; Medical Developments Expects 2020-’21 Loss Up To $5.2m; Visioneering H1 Receipts Up 36% To $4.3m; Nova Eye Unmarketable Parcel Facility; Proteomics: Janssen Drug ‘Significantly Reduces’ Test Scores; Incannex: Procaps To Manufacture Soft-Gel Ihl-675a; MGC Applies For Slovenian Marijuana Delivery Patent; Creso Launches 2 Marijuana Sport Products In Switzerland; Aroa To Release 118m Voluntary Escrow Shares; Living Cell Chair Bernie Tuch Replaces CEO Ken Taylor
 
Victoria $643k Extends J&J Monash Office 2 Years; Volpara: Euro Patent For Breast Care Platform; Actinogen Enrols 1st Xanamia Trial Patient; Bod Marijuana Customer Receipts Up 82% To $6.6m; Total Brain, Eastman $250k Mental Health Contract; Creso Completes Halucenex Acquisition; Anteris AGM 12% Oppose Director Dr Wenyi Gu; Rhythm Director David White Joins US Subsidiary Ichordx
 
Doherty, Peter Mac Stop Sars-Cov-2 Replication, In-Vitro; Planet Innovation Opens $1m Clean-Room; Uscom Receipts Up 20% To $5m; Nuheara Welcomes US President Biden O-T-C Hearing Aid Order; Proteomics Requests ‘Promarkerd Study’ Trading Halt; PYC Trials VP-001 For Retinitis Pigmentosa, In Rabbits; Hexima Expects Euro Patent For Pezadeftide For Toe Fungus; I’rom Below 5% Of IDT; Azure (Invictus) Changes Name To VGI
 
Polynovo Increases US Sales Staff; Expects Record Revenue; Uniquest, CSL Develop ‘Molecule’ For Blood Vessel Damage; WEHI: Immune Boost Kills TB, In Mice; Orthocell: Samson Striate+ (Celgro Dental) Distributor; MGC Starts Phase III Cimetra (Artemic) Covid-19 Trial; Copia, IOOF Take 5% Of BTC Health; BCCL Reduces To 8.45% Of Tali; Lifespot Appoints Elizabeth Spooner Co-Co Sec
 
Recce Doses 1st Patients In R327 Topical Burns Trial; Argenica: ARG-007 Stable With Stroke Drugs; Cronos Expects Marijuana Revenue Of $1.2m; Medlab: Australian Approval For Phase III Nanabis Pain Trial; Patrys: ‘PAT-DX3 Crosses Blood-Brain Barrier, In Mice’; Pharmaust, WEHI Study Monepantel For HTLV-1, In Vitro; Zelira US ‘Observational’ Marijuana Pain Study Approved; Anteris Machines Cow Heart Tissue For Valves; Thorney, Tiga Take 18% Of Oventus; Telix Appoints Kyahn Williamson Comms, Investor Relations
 
Dr Boreham’s Crucible: Polynovo; LBT Presents Data From 5 Studies At European Meeting; Cann Group Recovers $1.2m Of $3.5m ‘Cyber Security Incident’; Althea’s Peak $1.3m 48north Marijuana Manufacture Deal; Creso Completes Anibidiol Uruguay Import Procedures; MGC 64.2m Director Rights EGM; Imugene Issues 119m Vaxinia Milestone Shares; Life Biosciences Diluted To 11.2% In Alterity; Ellerston Capital Takes 5.4% Of Lumos; Invion Executive Chair Thian Chew On $399k pa
 
Australia Approves Qbiotics Stelfonta For Dog Cancer; Brandon $13m For Amaroq Long Non-Coding RNA Cancer Trial; Imex Expects H1 Annual Recurring Revenue Up 12% To $1.1m; Immuron Acquisition Suspension; Chair Adam Blumenthal Reduces To 10% Of Creso; Ausbiotech Talks Patent Box
 
Cogstate Sales Contracts Up 14.5% To $47m; Russia Approves Uscom 1a; Eureka Report Interviews Biotech Daily; Medadvisor’s Adheris To Work With Ehealth Inc; Pharmaust Monepantel Tablets ‘Stable At 24 Months’; Neurotech Dolce Marijuana Beats CBD For Cox-2, In-Vitro; Elixxer Diluted To 12% Of Little Green; Madhukar Bhalla Replaces Incannex Co Sec Glenn Fowles; Polynovo M-D Paul Brennan LTIs Up 20%, Pending Hurdles
 
US Fast Track Status For Opthea Opt-302 For Wet AMD; Cartherics Swaps Collaboration From Hudson To ARMI, CCRM; US FDA Approves Immutep Phase IIb Tacti-003 HNSCC Trial; Bionomics Begins Phase IIb BNC210 PTSD US Trial; Creso: Red Light Holland Orders $219k Netherlands Marijuana; Fil Reduces To 8% In Telix; Planet Innovation Takes 27% Of Lumos; RPS Diagnostics Takes 10% Of Lumos; Perennial Takes 8% Of Lumos; Acorn Capital Takes 6% Of Lumos; CEO Fleta Solomon Increases, Diluted To 8.7% Of Little Green; Bianca Rinehart (Hancock Trust) Takes 11.5% Of Little Green
 
Lumos Opens Up 20% For P-O-C Diagnostics; Correction: Argenica Therapeutics; Proteomics Retracts Promarkerd ‘$506b Savings’ News; TGA: Starpharma Fined $93k For Viraleze ‘Illegal Advertising’; Living Cell Pleads Schultz To ASX 46% Query; Respiri Tells ASX: ‘Lawyers Investigating News, M-D Shares’; Prescient: ‘Immunogenicity Tests De-Risk Omnicar’; Medlab: ‘NRG Biotic Boosts Anti-Depressant Activity’; Nova Eye Files US 2RT For Macular Degeneration Trial IDE; Austco, KTPH $3.3m Supply Deal For Tacera Nurse Call; Recce Receives $177k Canadian R&D Tax Incentive; Resapp: Resappdx, Sleepcheck For Doctors On Demand; Zelira: Finclear Takes Pershing; Lifts Marijuana Investment Ban; Cann Global Receives 2 Canntab Marijuana Products; Thorney, Tiga Take 7% Of Little Green Pharma; Chimeric Appoints Ex-Celgene Dr George Matcham Director; Memphasys Appoints Prof John Aitken Research Director
 
Dr Boreham’s Crucible: Argenica Therapeutics; FDA Approves Imugene CF33 ‘Checkvacc’ Breast Cancer Trial; Cyclopharm H1 Revenue Up 45% To $8.1m; BTC Raises $2.5m For Pharmaxis Bronchitol, Aridol Acquisition; Ellume, Azova, Alaska Airlines Sars-Cov-2 Test Partnership; US Patent For Alterity Excess Iron Redistribution; Creso: ‘H1 Marijuana Revenue Up 113% To $3.1m’; Proteomics Extends ‘Presentation’ Suspension; Esense ASX-Delisting AGM; Allianz Takes 9% Of Starpharma; Gina Rinehart, Hancock Take 11.5% Of Little Green; Perennial Takes 7.6% Of Atomo; Visioneering Appoints Dr Dwight Akerman Director
 
15-Year BDI-40 Up 633% To Record $26b; Big Caps Up 1031%, ASX200 Up 44%; BTC Pays $2m To Distribute Pharmaxis Bronchitol, Aridol; Halt; Mesoblast To Meet FDA For Rexlemestrocel-L For Back Pain; Micro-X Launches Veterinary Rover Mobile Dr; Auscann Marijuana For Tasmania Department Of Health; Argenica ‘ARG-007 Safe, Well Tolerated, In Rats’; Neuroscientific: Emtinb Safe In Monkeys; FDA Approves Noxopharm Darrt-2 Cancer Trial Ind; Truscreen: Serbia Orders Cervical Cancer Screening Device; Memphasys Completes Verification, Validation To Go; Resonance Increases Acuity Facility To $7.75m; Bellwether Super Below 5% Of Bluechiip; Regal Funds Below 5% Of Hydrix; Joanne Moss To Replace LBT Chair Kate Costello; Osprey Appoints Steven Brandt Director; Hang Ling Leung Replaces Regeneus Co Sec Sandra Mcintosh; Miles Davis Replaces Bionomics Dr Rao; Dr Errol De Souza On $702k
 
Cynata Readies For Diabetic Foot Ulcer Stem Cell Trial; Paradigm Responds To FDA PPS Osteo-Arthritis Questions; Avita In US Russell 3000 Index; Universal Biosensors 23% AGM Dissent; Neuroscientific Requests ‘Study Results’ Trading Halt; Vanguard Below 5% Of Cochlear; APG Asset Takes 5.5% Of Cochlear; Adam Leitzes, Karst Peak Take 11% Of Pharmaxis; Australian Ethical Diluted To 5.6% Of Immutep; Perennial Takes 14% Of Medadvisor; Noxopharm Diluted To 24% Of Nyrada; Nyrada Director Dr Ian Dixon Increases, Diluted To 6.5%; Alcidion Loses Co-Founder Ray Blight
 
Federal $19m For Stem Cell Research; Gilead $300k Fellowship Grants For 5 Projects; 4D Medical: Johns Hopkins Joins XV Lung Trial; Pharmaxis: Low Dose PXS-5505 Safe, Inhibits Lox, Loxl2 Enzymes; Biotech Daily Editorial Policy: Respiri’s Adherium Bid; Genetic Technologies Tells ASX: ‘Late May Launch Expected’; Elixinol Terminates Cannacare Acquisition; Nyrada: NYX-PCSK9I Reduces LDL 46%, In Mice; Noxopharm Wins European Patent For Veyonda; Lifespot 7m In-The-Money Director Options, Potential Spill AGM; Proteomics Takes ‘Presentation’ Halt To Suspension; Creso Takes ‘Sales, Revenue Update’ Halt To Suspension; Emyria Appoints Dr Eli Kotler For MDMA-PTSD Trial
 
Cyclopharm: FDA Letter Delays Technegas ‘9 Months’; Qbiotics Raises $35m For Cancer, Wound Drugs; Total $85m; Atomo: Access Bio Covid-19 Antibody Test US Emergency Use; WEHI, Boehringer Ingelheim Partner On Cancer Proteins; Brandon $10m For Currus Car-T-Cell Solid Tumor Drugs; Cartherics Licences Toolgen Crispr/Cas9 For Gene-Editing; Hydrix: Angelmed FDA Approval For Guardian Battery; Amplia, Garvan Trial AMP945, Gemcitabine In Pancreatic Cancer; Nanosonics To Launch Auditpro Digital Data Flow; Antisense, MCRI Work On ATL1102 For Multiple Muscle Diseases; Cynata Appoints Datapharm For MSC Diabetic Foot Ulcer Trial; Pharmaust: 1 Of 15 Dogs MPL Tumor Regression; 6 ‘Stable’; Probiotec Completes $4m H&H Acquisition; Painchek Receives $1.25m Federal Milestone; Elixinol Requests ‘Proposed Acquisition’ Trading Halt; Visioneering Completes 100-To-1 CDI Consolidation; Probiotec Appoints Simon Gray Director; Resonance Appoints Exec Director Mitchell Wells M-D; Ecofibre Appoints Vanessa Wallace Director
 
Dr Boreham’s Crucible: Imugene; Proteomics: ‘Promarkerd Test Could Save $51b Per Year’; Halt; J&J, Navbit Launch Sprint Navigation For Hip Replacement; Ellume, Delta Air Lines Deal For Sars-Cov-2 Test Kits; Cronos: Saiph Marijuana Skin Products For Japan, Hong Kong; Total Brain $1.8m Loan; Adalta Takes $1.7m Radium RDTI Loan; Hydrix Requests ‘Angelmed Distribution’ Trading Halt; Creso Requests ‘Material Sales, Revenue Update’ Halt; State Street Takes 5% Of Cochlear; Dr Alan Finkel, Nebula, Howitt Reduce To 5% Of Cogstate; Esense Considers ASX Delisting; CSL Loses Director Abbas Hussain; Biocurate Appoints Dr Lindner Director; Ms Wu Investment; Chimeric Appoints Dr Li Ren For Technical Operations; Medibio Appoints R&CPMK For Marketing 
 
Patrys Tells ASX: ‘Journal Embargoed Despite 21% Price Jump’; Labcon Pays Bluechiip $2.1m For Resolution; New Deal; Next Science, Zimmer Talks On Xperience Distribution; Prescient: Omnicar Parts Manufacture Completed; Kazia Wins US, India Paxalisib Composition Patents; Trajan $1.3m US Paycheck Loan Forgiven; Jencay Capital Takes 5.3% Of Bluechiip; Perennial Takes 12% Of Medadvisor
 
CMRI, Gyroscope Work On Capsids For Gene Therapies; Telix Doses 1st TLX250-CDx Bladder Cancer Patient; Actinogen: FDA Okays Xanafx Phase II Fragile X Study Plan; Alterity: EMA Backs ATH434 MSA Trial Biomarkers, Design; Neuroscientific Appoints Linear Clinical For Emtinb Trial; Europe, Canada Patents For Medlab Nanocelle; Palla Completes Ireland, Germany Co-Codamol Submissions; Althea Ships Marijuana To South Africa; Respiri: Sigma To Sell Wheezo Asthma Monitors; Invex To Release 21m ASX Escrow Shares; Regal Funds Takes 17% Of Opthea; Richmond Hill Reduces To 6% Of Universal Biosensors
 
Zucero: FDA Cancer Trial Approval Delays $30m IPO; IDT: Talks With mRNA Victoria, State Government, MIPS; FDA Approves Acrux Generic Jublia; Little Green Raises $27m For Denmark Marijuana Facility; Suda Raises $3.7m For T-Cell Platform; ‘Potential’ Clarity IPO For Cancer Diagnostics, Therapies; Micro-X Appoints Roesys EMEA Rover Distributor; Cardiex, Lifeq Deal For Wearable Band; IDT, Clever Leaves Marijuana THC Flower Supply Deal; Antisense: EMA Requires Additional DMD Trial Information; Baker Brothers Reduces To 8.5% Of Opthea; Chair Dr Michael Monsour Takes 23.7% Of Analytica; Neuroscientific Appoints Paradigm CEO Paul Rennie Chair; Nuheara Appoints Nick O'Loughlin, Kathryn Penno Executives
 
Immutep Raises $60m, Plan For $5m; Triple Combination Trial; Victoria: MIPS, Doherty mRNA Vaccine Trial ‘This Year’; Telix: Early Data Takes TLX101 To 1st-Line Glioblastoma Trial; Orthocell: ‘Celgro Early Data Shows Nerve Regeneration’; Starpharma: UK Sars-Cov-2 Questions Halt Viraleze Sales; St Vincent’s Institute, Pfizer Cancer Collaboration; Actinogen Appoints 2 CROs, Cogstate For Xanamia; Emvision, MSH Research, Innovation Deal; Mayne Licences Solaraze, Actkerall; US Nextstellis Launch; Palla Appoints Alloga UK Pre-Wholesale Co-Codamol Supplier; Incannex: Vectura To Formulate IHL-216A For TBI; Little Green Requests ‘Acquisition, Capital Raising’ Halt; Unisuper Below 5% Of Kazia; Cryosite Director Andrew Kroger Holds 43.3%; Joanna Johnson Replaces Acrux CFO, Co Sec Deborah Ambrosini; Epsilon: Louisa Ho In, Philip Leighfield Out, Nicholas Marshall CFO
 
Dr Boreham’s Crucible: Actinogen Medical; Suda To Raise $3m For Imperial College T-Cell Cancer Therapy; Starpharma: ‘SPL7013 Kills Sars-Cov-2 Variants, In-Vitro’; Brazil Okays Paradigm PPS For MPS VI Trial; Zelira, Curtin Uni Improve Marijuana Brain Delivery, In Mice; Clime Takes 9% Of Mach7; Nicholas Marshall Replaces Cardiex Co-Sec Philip Leighfield
 
Brandon, Minderoo, Uniseed $32.5m For ENA Sars-Cov-2 Spray; Telix FDA Meeting For Illucix: ‘No Substantive Issues’; 4D Medical: Michigan Uni Buys $787k Permetium Scanner; Creso, Red Light Holland Marijuana Merger For Highbrid Lab; Victoria: All-Star mRNA Advisory Group; Auscann Leases R&D Facility To Source Certain; Cellmid: Record $1.4m Japan TV Hair Loss Sales; Bod: 2 UK Online Retailers To Distribute Marijuana CBII; Little Green 4.6m ‘Rights’ EGM; Little Green Appoints Medezin Polish Marijuana Distributor; Immutep Requests ‘Capital Raising’ Trading Halt; One Funds Takes 11% Of IDT; Jencay Reduces To 10.6% Of Universal Biosensors; Bio-Melbourne AI Medical Technology Forum; CMRI Wins NHMRC Ideas 2020
 
Patrys: ‘PAT-DX1 Reduces Brain Metastases 93% In Mice’; Avita Q4 Guidance Up 14% To $12.5m; CSIRO Appoints Prof Bronwyn Fox Chief Scientist; Bionics Queensland Prizes; Orthocell: China, NZ Celgro Patents; Rhythm: Sonic Healthcare Joins Colostat Trial; Creso Requests ‘Material Acquisition’ Trading Halt; CSL Appoints Alison Watkins Director
 
Invex: US FDA, EMA Differ On Presendin IIH Trial Endpoints; Kazia, Cornell Trial Paxalisib, Ketogenesis For Glioblastoma; Oventus Rights Raise $4.9m; Total $10m; Cogstate $3.2m US Paycheck Loan Forgiven; Nyrada Selects NYR-Bio1 For Traumatic Brain Injury Study; Anteris: Adapt Carotid Artery Conduit Works In Sheep; Respiri Withdraws $6m-$8m Revenue Guidance; Genetic Technologies US Patent For Genomic Analysis; Azure Food Additives NE1-Elite, NE1-Heart Ready For US Sale; MGC: Cannepil On Irish Reimbursement Scheme; Zelira: Health House Marijuana Toothpaste UK Distributor; Australian Ethical Reduces To 16% Of Cogstate; PYC US Office At J&J San Diego; Neuren Appoints CEO Jon Pilcher Managing-Director; Opthea Appoints Karen Adams Co Sec; MGC Loses Co Sec Nadine Barry
 
Dr Boreham’s Crucible: Trajan Group Holdings; Argenica IPO Opens Up 35%; Next Science H1 Revenue $4.5m To $5.2m, Beats Last Full Year; Avita: FDA Expands Recell To Children, Extensive Burns; India Approves Starpharma Viraleze Nasal Spray; Respiri: UK Approves Wheezo; Cellmid To Release 4.5m Voluntary Escrow Shares; Creso US O-T-C Dual Listing; Australian Super Takes 6% Of Trajan; Thorney, Tiga Take 5% Of Little Green
 
Argenica $7m IPO For ARG-007 For Stroke; Medadvisor: 9-Month Revenue Up 40%; Pharmaxis: 1st PXS-5505 Myelofibrosis Dose-Escalation Cohort; Patrys Receives $626k R&D Tax Incentive; Austco Pleads Schultz To ASX 30% Query; Noxopharm ‘Clarifies’ Darrt-2 Trial; Proteomics Appoints Jacqueline Gray CFO, Vik Malik CCO; Imugene Appoints Dr Monil Shah CBO
 
Lumos $63m IPO For Point-Of-Care Diagnostics; Epsilon To Supply CBD For Youth Severe Behavior Trial; Probiotec Guidance: Revenue Up 12% To $120m, Ebitda $21.5m; Elixinol Appoints Health House Distributor, Pharmacann Out; Cryosite Director Andrew Kroger Takes 43%; Probiotec Jonathan Wenig Replaces Chair Sandy Beard; MGC Appoints David Lim Joint Co Sec
 
Cogstate Earns $26m On Esai, Biogen FDA Alzheimer’s Approval; Redhill Opaganib Phase II/III Covid-19 Study Enrolled; Immuron Acquisition Suspension; ASX Activities Questions; Immutep, Cardiff Work On Cheaper, Oral Cancer Drugs; Almirall Challenges Acrux Generic Aczone; Race Contracts Trialog For Israel AML Combination Trial; Clarity: Dallas Joins Cu64-67 Paediatric Neuroblastoma Trial; Visioneering Loses 10% Capacity, Tom Dooley; Consolidation; Creso, Halucenex Expand Mushroom Psylocibin PTSD Trial; Avecho: ‘TPM Increases Cannabidiol Absorption Up To 5.4 Times’; Cellmid Supply, Collaboration Agreement With Pump Haircare; PYC 2nd Drug Candidate Works For ADAO, In-Vitro
 
Trajan Climbs 20% On $90m IPO; Emyria: ‘Marijuana Reduces Opioid Use, Significantly’; Telix, ATS $1.6m Eurostars Anti-Cancer Alpha Grant; Immutep: ‘Encouraging’ Insight-004 IMP321 Combo Tumor Data; Immutep: ‘Positive’ Tacti-002 IMP321, Keytruda Cancer Data; Dimerix: UK Innovation Passport, ILAP Status For DMX-200; Clinuvel Doses 1st Afamelanotide Stroke Patient; Kazia Enrols 1st Phase II Paxalisib Lymphoma Patient; Universal Biosensors 1st European Sentia Wine Test Sales; Azure Appoints Altipure Manufacturer; Helen Fouras, Velocimetry ‘Reduce’, Diluted To 43% In 4D; 4D Founder, CEO Prof Andreas Fouras Diluted To 22%; TBG Sells 5% Of TBG Inc To Beijing’s Dong Yuan For $1.1m; Tali: Detect Has 20k India Downloads; PYC Requests ‘Pre-Clinical Results’ Trading Halt; Veritas Below 5% In Cochlear; Trajan Appoints Mark Licciardo Joint Co-Sec; Mach7 Appoints David Madaffri Head Of Sales
 
Dr Boreham’s Crucible: Universal Biosensors; Russian Patent For Exopharm Leap Technology; Creso Appoints Route2 Ecuador Marijuana Distributor; Resonance Loses CEO Alison Laws; Mitchell Wells Executive; Polynovo Appoints Andrew Lumsden Director; Don Brumley Replaces Acrux Director Norman Gray; Oventus: John Cox COO; Jim Hunter Acting CFO, Dan Parry Out
 
Pro Medicus, Mayo Work On AI Visage Imaging; Qbiotics Raises $22.5m; 1st Patient In EB46, Merck Cancer Trial; Correction: Trajan; Painchek Takes 60% Of Local Market; Cynata, Tekcyte Diabetic Foot Ulcer Trial; Telix, Eckert Ziegler US Co-Promotion Deal; Dimerix: EMA Confirms Phase III Dmx-200 FSGS Trial Design; Resapp, Medgate Resappdx Trial Extended 2 Months; Zelira Licences Marijuana ZTL-106 To Levin For Pain Trial; Up To 19% Oppose $2 Somnomed Director Options EGM; Anteris Receives $1.5m Federal R&D Tax Incentive; Respiri Rebuts Adherium Rejection Claims; Cronos Launches Marijuana Gel Cleanser, Moisturiser; Prescient Pleads Schultz To ASX 23% Query; Sally McDow Replaces Painchek Co Sec Ian Hobson
 
Trajan To List On ASX On Monday; 300+ Staff Investors; Amplia: AMP945 Improves Pancreatic Cancer Chemo, In Mice; Oncosil Withdraws TGA Application On Data; Race Appoints Parexel For Phase I/II Bisantrene AML Trial; Invion, RMW Cho $4.5m Placement, Photosoft Deal; Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved; Pharmaust Phase I Monepantel MND Trial Approved; European Patent For Immutep Cancer Combinations; Regal Below 5% Of Genetic Signatures; Cryosite Director Andrew Kroger Takes 42%; Mercer Street Takes 5.5% Of Anteris; Opthea: Prof Julia Haller, Judith Robertson Directors; Avita Appoints James Corbett, Jan Stern Reed Directors
 
Imugene 117% Jump Takes May BDI-40 Up 4%; ASX200 Up 2%, Big Caps 5%; Applications Open For $2.5m CSL Centenary Fellowships; Immutep, Merck IMP321-M7824 Phase I/IIa Solid Tumor Trial; Antisense: ‘FDA Expects 9-Month ATL1102 Monkey Tox Trial’; Imagion Receives $2.6m Federal R&D Tax Incentive; Neuren: FDA ‘Minor Modifications’ For 3 Phase II Trials; Starpharma: ‘Viraleze Active Against UK Sars-Cov-2 Strain’; Adherium: US Hailie FDA Submission; Genetic Technologies, Infinity Launch Covid-19 Test; Avecho AGM 17% Oppose 14m Director Options; Medadvisor Loses Joint Co-Sec Carlo Campiciano; Epsilon Appoints Edward Jones Marijuana Manager
 
Truscreen Revenue Down 12% To $1m, Loss Down 33% To $3m; Correction: Audeara; Avecho, Ab Vista Partner On TPM For Pigs; Bard1 Receives $644k Federal R&D Tax Incentive; Neuroscientific Receives $584k Federal R&D Tax Incentive; Acrux Receives Further $175k Federal R&D Tax Incentive; Invion Requests ‘Placement, Technology’ Trading Halt; Immuron Takes ‘Acquisition’ Trading Halt To Suspension; Allan Gray Reduces To 9% Of Impedimed; TDM Takes 26% Of Somnomed; Eleanore Goodridge Takes 5.3% Of Noxopharm; Alison Deans To Replace Cochlear Chair Rick Holliday-Smith; Audeara Appoints Finlay ‘Fin’ Robb US Sales Manager; Respiri Appoints Theo Antonopoulos Chief Commercial Officer; Micro-X Opens Seattle Facility
 
Dr Boreham’s Crucible: Audeara; Respiri Files Replacement Adherium Bidder’s Statement; Austco Expects Profit Up 12%-32% To $2.8m-$3.3m; Cann Group Halves 2020-’21 Revenue Forecast To $4m-$5m; Azure Opens Up 25% At 25c On NSX; Imagion AGM 23% Dissent, Avoids Rem Report 1st Strike; Genetic Technologies Requests ‘Covid-19 Risk Test’ Halt; Perennial Reduces To 6.6% Of Hydrix; Alcidion Appoints Matthew Gepp CFO
 
Victoria Appoints Michael Kapel mRNA CEO; Bluechiip Boxtracker Wins Isber Gong; Volpara Revenue Up 57% To $19m, Net Loss Down 14% To $16.5m; Dimerix: ‘FDA Travere FSFG Knock-Back No Change To Program’; TGA Approves 2 Uscom Monitors; TGA Approves Next Science Blastx Anti-Microbial Wound Gel; Mayne: FDA Grants Nextstellis 5-Year Exclusivity; MTP Connect: Biointelect, Cicada For Redi Industry Training; Recce: ‘R327 Efficacy Against E Coli, In-Vitro’; Little Green $2.5m Demecan Marijuana Order; Invion To Release 1.1b Voluntary Escrow Shares; Immuron Requests ‘Acquisition’ Trading Halt; Imugene’s Paul Hopper, Leslie Chong Sell Shares, Exercise Options; Vanguard Below 5% Of Polynovo; Smart Top, Xianhui Meng Increase, Diluted To 21% Of Uscom; Pokies Bruce Mathieson Increases, Diluted To 9.2% Of Respiri
 
Havah $53m T+AI Deal With Clarus For Mastitis, Breast Cancer; Imagion Enrols 1st Patient In Magsense Breast Cancer Trial; Micro-X: 2nd US FDA Approval For Rover Bedside X-Ray; Epsilon Receives $1m Federal R&D Tax Incentive; Memphasys Notes Raise $3m; Avecho, TGA To Meet On O-T-C Soft-Gel CBD For Insomnia; Antisense ATL1102 Manufactured For DMD Trial; Immutep: China Patent For IMP321, Chemo Combination; Chinese, Hong Kong Patents For Orthocell Celgro; Palla Appoints GW Executive Giles Moss CEO, On $536k
 
Vivazome, Renerve Work On Exosome Spinal Cord Repair; Anteris Placement To Raise $2.3m; Paradigm: FDA Questions PPS For Osteoarthritis Trial; Telix: ‘TLX66 Amyloidosis Trial Meets Endpoints’; Telix Doses 1st Patient In Japan TLX591-CDx Prostate Imaging Trial; Invion: INV-043 Effective Against Multiple Cancers, In Mice; Clarity Signs Cu-67 Supply Deal With Northstar; Aroa Revenue Down 11% To $21m; Loss Up 222% To $18m; Imugene Chair Paul Hopper, M-D Leslie Chong Exercise $2.6m Options; Chimeric Doses 1st Patient In Glioblastoma 2nd Cohort; Visioneering 100-To-1 Consolidation AGM; Bard1: Preliminary Sub-B2M Test Shows ‘Feasibility’ For Cancer; Neurotech Dolce Beats CBD For MS Neuro-Markers, In Vitro; Actinogen Pleads Schultz To ASX 54% Query; Impedimed Releases Sozo Version 4; Memphasys Requests ‘Capital Raising’ Trading Halt; Mercer Street Below 5% In Anteris
 
Cynata: 1st Patient Enrolled In Cymerus Lung Trial; CE Mark For Uscom Spirosonic Air; Adalta, GE Work On Pre-Clinical Granzyme B Imaging; Emvision Improves Brain Scanner; Anteo Adds Brisbane Eugeni Test Strip Manufacturing; Resonance Applies For Antisense Oligonucleotides Patent; Bard1 Applies For Exo-Net, Sub-B2M Patents; Creso 15m Director, Staff, Everblu Shares; Halucenex AGM; TDM Takes 25% Of Somnomed

May 21, 2021; Dr Boreham’s Crucible: Genetic Signatures; MTP: Clinical Trials Worth $1.4b To Australia & Growing; Avecho Completes Marijuana Soft-Gel Design; Creso Polvet Poland Anibidiol For Livestock Distributor; Anteris Requests ‘Capital Raising’ Trading Halt; Veritas Below 5% In Cochlear
 
Anteo Plan: $32m Applications, Raises $8m; Total $20m; 4D Recruits 1st VQ Lung Imaging Cohort; Painchek Wins CE Mark, UK MHRA Approval; Rhinomed Wins CE Mark For Rhinoswab; Azure To List As VGI On NSX; Medlab Move To Synthetic Nanabis For Cancer Pain Trial; Cronos: Marijuana Sales Up, ECS Terpene Distribution; Hexima Renames HXP124 ‘Pezadeftide’; Race Appoints Prof Michael Kelso Principal Scientist; Neurotech Appoints Prof Allan Cripps Director
 
Victoria $245m For Institute Of Infectious Disease; Paradigm Claims 1st ‘Modest’ PPS (Zilosul) Revenue; Bard1: ‘Exo-Net High-Yield Pure Exosomes For Tests, Therapies’; Japan Patent For Adalta; US Patent For Island ISLA-101 Program; Recce: R327 ‘Effective, Not Highly Toxic For Sars-Cov-2, In-Vitro’; Neuroscientific Loses Chair Brian Leedman
 
LBT Sells 2 APAS Independence Units To UK; Audeara Opens Down 5% On $7m Specialist Headphones IPO; Imugene, City Of Hope Deal For CD19 Car-T-Cell Tumor Therapy; Biocurate, Monash Launch Pio For Cancer Immunotherapy; Proteomics, Avance PK Testing Contract; Telix Appoints Eckert Ziegler German Illucix Distributor; Bard1 Launches Exonet At Extracellular Vesicles Meeting; PYC: Unnamed Drug Candidate 2nd For ADOA; Bod Launches Marijuana Cannabigerol CBG50 In UK; MGC Applies For ‘Cimetra’ Slovenian Patent; Emyria 1.5m Consultant Options, Placement EGM; CEO Kate Quirke Below 5% In Alcidion; Cole Mackinnon, Isle Of Wight Diluted To 5.6% Of Alcidion; Resapp Re-Appoints Brian Leedman Exec Director On $187k
 
Immvirx $22m For IVX037, Targeted Oncolytic RNA Viruses; Correction: Island Pharmaceuticals; GSK $80k Australian Research Excellence Awards Open; Anteo Appoints Operon Eugeni Sars-Cov-3 Test Manufacturer; Resonance Selects Lead Component AS3 For Hepatitis B; Botanix: BTX1204A ‘Encouraging Efficacy’ For Eczema, In Dogs; Resapp Enrols 1st Covid-19 Cough Study Participant; Cardiex Launches Conneqt Consumer Brand; Elixinol 23% Oppose 43% Directors’ Fees Pool Hike; Analytica 50m Director Options, Placement EGM; Veritas Takes 5% Of Cochlear, Again; Mithra, Estetra Take 9.6% Of Mayne; Thorney, Tiga Take 17% Of Oventus
 
Dr Boreham’s Crucible: Island Pharmaceuticals; Queensland Uni Dengue Vaccine ‘Immune Response In Mice’; Perennial Takes 11% Of Medadvisor; BCCL Worldwide Takes 9.8% In Tali; Creso: Halucenex Secures More Synthetic Psilocybin; Rhinomed Appoints Prof John McBain Director; Pharmaust Dr Kim Agnew To Lead Monepantel Dog Trial
 
Pro Medicus, Vermont Uni $14m Visage 7 Deal; MTP Connect: $400k For WA Medical Product Manufacturing; Rhinomed: Rhinoswab Beats Standard-Of-Care For Sars-Cov-2; Proteomics Seeks US CPT-PLA Code For Promarkerd; Immuron: ‘IMM-124E Shows Novel Inhibition Of Sars-Cov-2’; Heramed, Obstetrix 100-Subject Herabeat Pilot Study; Imex AGM: 17% Oppose Director Options; Adherium Rick Legleiter, George Baran In; Mike Motion Out; Medlab Appoints Kerem Kaya CFO, Co Sec; Immuron Appoints Dr Dan Peres CMO
 
Budget 2021: Comment & Response - Biotech Daily, Ausbiotech, CSL; Bio-Melbourne Women In Leadership 2021 Gongs; Dimerix: India DMX-200 Covid-19 Trial Delayed By Covid-19; MTP Connect: Dr Staudacher, Dr Kulis Win $250k Redi Grants; Noxopharm Enrols Part 2 Veyonda Covid-19 Trial; Cardiex: US Sphygmocor Patent; Australian Patent For Hexima HXP124 For Toe Fungus; Emyria: ‘TGA Approves Smartphone Heartrate Monitor’; Creso Requests ‘Halucenex Acquisition Update’ Trading Halt; Regal Takes 10.5% Of Adherium
 
Funds For Patent Box Tax Cut, R&D, ANSTO
 
Trajan $90m IPO Oversubscribed; Speedx Wins Carb-X $1.8m For STD Diagnostic; Starpharma: Viraleze For UK Harlequins Rugby Team; Ellume: Sars-Cov-2 Home Test US Facility, US Executives; Emyria Requests ‘Openly Registration’ Trading Halt; Heramed Requests ‘Commercial Partnership’ Trading Halt; Incannex Adds UWA To IHL-42x Marijuana Sleep Apnoea Trial; Australian Super Takes 5.2% Of Micro-X; Blueflag Increases, Diluted To 7% Of Amplia; One Funds Diluted Below 5% In Adherium; Medical Developments Appoints Richard Betts Director; Clarity Appoints Shaemus Gleason Head Of US Operations
 
Audeara $7m IPO For Specialist Headphones; TGA Okays Telix Prostact TLX591-CDx Prostate Cancer Trial; Adherium Rejects Respiri Offer; Oventus Placement To Raise $5m, 1-For-4.4 Rights For $5m; Prescient, Peter Mac Research Omnicar For Cancers; Nuheara Ships 1st Hewlett Packard Elite Earbuds; Bionomics Adds Social Anxiety Disorder To BNC210 Trials; Race: Bisantrene Combinations For AML, In-Vitro; Osteopore: Product Variants CE Mark; Shelf-Life Extended; TDM Takes 25% Of Somnomed; Clime Reduces To 8% In Mach7; Peters Investments Takes 11.4% Of Optiscan; Phillip (Bioscience Managers) Takes 23.5% Of Adherium; Viburnum Takes 11% Of Adherium; FIL (Fidelity) Takes 10% Of Adherium
 
Dr Boreham’s Crucible: Control Bionics; Regeneus Placement To Raise Up-To $4.5m; Noxopharm Veyonda Sarcoma Trial To Enrol 40 Patients; Oventus Takes ‘Capital Raising’ Trading Halt To Suspension; Polynovo Appoints Dr Joshua Cheetham Head Of R&D 
 
CSL $583m Uniqure Deal For AMT-061 For Haemophilia-B; Medadvisor Raises $5.25m; $11.7m Loan; Nyrada Receives $976k R&D Tax Incentive; Mach7 $730k Vermont Uni Medical Centre Eunity Deal; Starpharma: Viraleze Online In Europe; Zelira Launches Marijuana Hope For Autism In US; Rhythm Improves Colostat With Lifestyle Risk Factors; Clarity: US Sar-BIS-PSMA For Prostate Cancer Patent; Creso: Halucenex, Nucro-Technics Psilocybin R&D Deal; MGC Requests ‘Further Artemic Findings’ Trading Halt; Optiscan Appoints Orchid’s Prof Camile Farah Director
 
SDI Expects Revenue Up 18% To $80m, Profit Up 77% To 101%; Alcidion ‘Over-Subscribed’ Share Plan Raises $3m, Total $18.4m; Race ‘Over-Subscribed’ Placement Raises $5.4m; Oventus Requests ‘Capital Raising’ Trading Halt; Hong Kong Approves Oncosil Pancreatic Cancer Device; Memphasys: New IVF Products Include Stallion Sperm Test; Neurotech Starts Phase I/II Marijuana For Autism Trial; Emyria Ecstasy Program For PTSD; Neuroscientific: Emtinb Dose Found In Rabbit Eyes To 14 Days; Nyrada: New Compounds Improve NYX-PCSK9I, In-Vitro; Regeneus Grants CEO Karolis Rosickas 25m Incentive Options; Avecho Loses Director David Segal
 
Amplia Placement Raises $3.8m; Clarity: US FDA Approves Phase I/IIa Prostate Trial; Recce: ‘R327 Kills 99.9% Of Six Pathogens, In-Vitro’; Impedimed: ‘Sozo Measures Heart Readmission Risk’; Uscom Develops Uscom-O2, Basic; Botanix Plans BTX1801 Dialysis Trial; Palla, M&A Legal Issues Settled, Production Begins, Launch; MGC Receives $996k Artemic Rescue Order; Total Brain, Hamptons Life $6m Agreement; Resapp Appoints Ilara Resappdx Kenya Distributor; Medadvisor Requests ‘Funding Facility’ Trading Halt; Medibio: US Patent For Mental State Assessment; Memphasys Prof John Aitken Wins Andrologist Gong; Nuheara Appoints John Luna Business Development Manager; Ron Hollands Replaces IQ3 4-Month Co Sec Aysha Hollingdale
 
Imagion, Patrys Collaborate On Brain Cancer Imaging; Pharmaxis: Teo $187k For Pre-Clinical PXS-5505 GBM Study; WEHI: Natural Antibodies Block Malaria Parasites; Bionomics Repays $6m Equipment, Bank Loan Early; Race Requests ‘Capital Raising’ Trading Halt; Total Brain Requests ‘Commercial Contract’ Trading Halt; Veritas Below 5% In Cochlear; Perennial Takes 15% Of Genetic Signatures; Inov8 Increases, Diluted To 7.8% Of Analytica; Chair Dr Michael Monsour Diluted To 19.99% Of Analytica; Telix Promotes, Appoints Executives For APAC, EMEA
 
Dr Boreham’s Crucible: Anteotech; Epidyolex For Epilepsy - 1st Marijuana On Pbs; Respiri Offers $19m, 1-For-7 Share Takeover Of Adherium; Mesoblast: ‘Remestemcel-L Cuts Subgroup Ards Mortality 46%’; Nova Eye Enrols 1st Patient In Itrack‘Magic’ Glaucoma Trial; Auscann (Cannpal) ‘CPAT-01 Improves Osteoarthritis In Dogs’; Analytica US Patent For Pericoach Vaginal Muscle Strength; Amplia Requests ‘Capital Raising’ Trading Halt; Acrux Receives $406k Overseas R&D Tax Incentive; Micro-X Repays $3m South Australian Government Loan; Cellmid Chinese Import Permit For Jo-Ju, Lexilis Shampoo; Cann Group Sends 20k Bottles Of Marijuana Oil To Iuvo; Avecho 18m Director Options AGM; Australian Ethical Takes 17.5% Of Nova Eye; Exopharm CEO Dr Ian Dixon Increases, Diluted To 18%; Atomo Appoints Joe Hockey, Bondi Partners Advisors; Medadvisor Loses Director Jeff Sherman
 
Federal $2.2m For Queensland Uni mRNA Vaccines, Cancer Drugs; Cellmid To Sell Lyramid For $500k Plus Royalties; Cann Recalls 250 Units Of 50ml Marijuana Oil; Atomo, Unitaid, Viatris Partner For Lower-Cost HIV Tests; Proteomics Files FDA 513(G) Applications For Promarkerd; Regeneus $300k Department Of Defence Grant For Sygenus; Bard1 Assays + CA125: Higher Accuracy For Ovarian Cancer; IQ3: Oncotex Manufacturing Deal With Sterling Pharma; Canada Patent For Neuren Trofinetide For Rett, Autism; Memphasys: 2 US Patents For Felix Sperm Separation Device; Biotron Receives $1.4m Federal R&D Tax Incentive; Universal Biosensors: Grapeworks Sentia NZ Distributor; Medibio To Meet FDA For Mebsleep 510(K) Re-Submission; Australian Super Takes 5% Of Alcidion; Oventus Has Less Than 2 Quarters Cash; Staff Cuts
 
Piper Alderman: Pharmalex Acquires Brandwood CKC; Allegra $2m Loan For Bone Substitute Research; Respiratory Compromise Institute Trials 4d Medical XV LVAS; Anteo Raises $12m For Eugeni Covid-19 Test; Plan For $4m; Emvision: Potential Stroke Detection Analysis Techniques; Amplia Plans Amp945 Combination Pancreatic Cancer Trial; Respiri: Terry White Chemmart To Stock Wheezo; Orthocell: ‘Celgro Nerve Repair Beats Market Leader’ In Rats; Race, Newcastle Uni Study Bisantrene Cardiac Impact; MGC Submits Artemic To Health Canada
 
Victoria: ‘Funding Returns 366% GSP, 454% Income In 10 Years’; Telix: GMS To Manufacture, Supply Radiation Unit Doses; Euro Patent For Osteopore Magnesium Composite Filler; Invion Selects INV-043 For Photo-Dynamic Therapy For Cancer; Anteris Completes ‘Commissural Alignment’ Design Concept; Memphasys Felix Sperm Separator Fix On-Track; Pharmaust Monepantel Dog Plasma Levels ‘Supportive’; Genetic Technologies Files US Covid-19 Risk Test Application; Blackrock Takes 7% Of Cochlear; Cann Group Appoints John Sharman Director
 
FDA Approves Next Science Xperience No Rinse Anti-Microbial; Paradigm: Further US FDA PPS Osteoarthritis Trial Questions; Universal Biosensors: Vicard Sentia South Africa Distributor; Anteo Battery Link Commercialization; Capital Raise Halt; Mackinnon, Isle Of Wight Diluted To 6.8% Of Alcidion; Caledonia, MKMS Below 5% Of Alcidion; Race Founder Dr William Garner Reduces To 7.4%; Regal Below 5% Of Alterity
 
Dr Boreham’s Crucible: Pharmaxis; WEHI, J&J Collaborate On New Malaria Drugs; Analytica Placement For $3.8m; Proteomics Wins ISO 13485 Quality Certification; Prescient: ‘No PTX-200 Dose-Limiting Toxicities’; Dimerix: Remap-Cap Recruits 1st DMX-200 Covid-19 Patients; Antisense: FDA Meeting ‘Constructive’ For ALT1102 For DMD; Auscann Receives $1.6m Federal R&D Tax Incentive; Somnomed 2.2m Director Options, 100% Pool Hike EGM; Regal Reduces To 6% Of Genetic Signatures; Somnomed CEO Neil Verdal-Austin 5-Year Extension On $530k; Auscann CEO Layton Mills Starts On $275k; Anteotech Loses Director Matt Sanderson 
 
Actinogen Plans 3 Phase II Cognition Trials For 2022; Chimeric: ‘No CLTX-CAR-T Dose-Limiting Toxicities’; Patrys: PAT-DX1, PAT-DX3 ‘Favorable’ P-K Profile; Impedimed: US FDA Okays Sozo Heart Failure Index; Oventus: Sleep Metrics To Promote O2vent; Noxopharm Claims ‘Positive’ Interim Noxcovid Results; Incannex: FDA Talks Lead To 3 IHL-675A Applications; Invex: FDA Meeting For Presendin For IIH; Heramed, Joondalup Heracare Pilot Program; MGC Buys Israel’s Medicanl CRO For $6m In Shares; Medibio Begins 2nd Mental Health Application Test; FIL Takes 10% Of Resapp
 
Victoria $50m For mRNA Research, Manufacture; Emyria Raises $5m; Nuheara Starts Elite Earbud Hewlett Packard Production; Factor Therapeutics: From Wounds To Limestone Mining; Incisive Wins Federal $1m For Bluecheck For Tooth Caries; Telix Phase I Japan Trial: TLX250-CDx Safe, Tolerable; Bioxyne Pleads Schultz To ASX 50% Query; Imugene: PFS Endpoint Met In Phase II HER-Vaxx Trial; Ecofibre: Hemp Research Completed 15 Months Early; Analytica Requests ‘Capital Raising’ Trading Halt; Investors Mutual Reduces To 7.5% In Mayne; Founder Dr Mel Bridges, Parma Reduces To 7% Of Anatara; Freeman Road Below 5% Of Resapp
 
Austin: Marijuana ‘No Low Back Pain Benefit With Oxycodone’; Genieus ‘Discovers ALS Biomarker; Potential Treatment’; Exopharm Raises $12m; Azure Raises $2.5m; Name Change To VGI; Ellume: CVS Stocks Sars-Cov-2 Rapid Test Kit; Kazia Potential $478m Evotec Licence For EVT801; Amplia: FAK Inhibitors Reduce Nash Fibrosis, In Mice; Anatara: Ethics Approval For CSIRO 3FDC Psychology Trial; Analytica Appoints Marwa Middle East Infusion Distributor; Little Green Appoints Balancial Danish Marijuana Distributor; Heramed Requests ‘Commercial Partnership’ Trading Halt; Osprey 111m CEO, Director Options AGM; Ausbiotech: Patrys CEO Dr James Campbell Director; Race Appoints Dr David Fuller CMO; Karst Peak Takes 9% Of Pharmaxis
 
Trajan Potential IPO For Precision Manufacturing, Chemistry; China Approves Uscom BP+; Telix Launches TLX599-CDx ‘Noble’ Registry; Adalta Begins Part B Of AD-214 Phase I Study; Ecofibre Marijuana Sleep Trial Approved; Creso: Halucenex, Sixth Wave Psilocybin Extraction Deal; Immutep Receives $1.2m R&D Tax Incentive; Emyria Requests ‘Placement’ Trading Halt; Mitsubishi, Morgan Stanley Below 5% In Cyclopharm; Optiscan: Robert Cooke Chair, Darren Lurie M-D On $375k; Allegra Appoints Robert Bell Technology, Innovation Head
 
Dr Boreham’s Crucible: Volpara Health Technologies; WEHI Discovers How Cancer-Fighting Immune Cells Develop; FDA Approves Mayne, Mirtha Nextstellis Contraceptive; Australian Patent For Anatara Detach For Animal Diarrhoea; Stemcell United Placement Raises $3.8m; Kazia Requests ‘In-Licencing Transaction’ Trading Halt; Exopharm Requests ‘Capital Raising’ Halt; Thorney, Tiga Increase, Diluted To 25% Of Visioneering; Race Appoints Prof Jianju Chen Advisor 
 
Alcidion Raising $18m For $9.6m Extramed; $21m Defence Deal; Amplia Completes Phase I AMP945 Dosing; Race: Bisantrene Inhibits FTO Cancer - Independent Study; Clarity Doses 1st Patient In Phase II Cu64-Sartate Trial; Victoria $2.4m For Bone Marrow Syndrome Research; Acrux Files Dapsone For Acne Anda To FDA; Recce: R327 For Burns Added To Trial Registry; Universal Bio: Wine & Beer Sentia Wine Test US Distributor; Total Brain Adds Heart Variability To Mental Health Monitor; Elixinol Name Change, 43% Directors Fee Hike AGM; Mitsubishi, Morgan Stanley Take 5% Of Cyclopharm; Credit Suisse Takes 5% In IDT; Mercer Street Reduces To 5% In Anteris
 
RMIT: Black Phosphorus Kills Bacteria, Fungi; Pharmaxis $4.4m Placement; GEN Pays Pharmaxis $2m For Russian Bronchitol Rights; Paradigm Doses 1st Phase IIb PPS Osteoarthritis Patient; Telix: TGA Starts Illuccix (TLX591-CDx) Priority Review; Universal Bio: Singularity Sentia Wine Test Chile Distributor; Imex 142k Free CEO, Directors’ Options AGM; Alcidion Requests ‘Acquisition, Capital Raising’ Trading Halt; Stemcell United Requests ‘Placement’ Trading Halt; Creso, Cannabis Queen Bilateral Distribution Deal; Dr Tracey Mynott, Myeng Reduce To 5% Of Anatara; Apeiron, Christian Angermayer Takes 12% Of Bionomics; Peter Mercouris To Replace IQ3 Director Monika Pawel
 
Island Opens Up 100% At 50c, Climbs To 67c; Bard1 Licences Liverpool Uni Type 3C Diabetes Biomarkers; Rhythm: Clinitrials Joins Colostat Trial; Universal Biosensors, Deakin, Swinburne Tn Antigen Deals; Rhinomed Receives $185k Federal R&D Tax Incentive; Avecho Approval For Phase I Marijuana Trial; Pharmaxis Requests ‘Capital Raising’ Trading Halt
 
Resapp Placement To Raise $5.5m; Redhill DSMB 4th Okay For Opaganib For Covid-19; Medlab: ‘Nanabis Reduces Cancer Pain 55%’; CE Mark For Anteotech Sars-Cov-2 Antigen Rapid Test; Imugene Data Back HER-Vaxx Combo, CF33 For Cancer; Tali, Indian Times Group Partnership Commenced; Creso: Halucenex, GTR Mushroom Genome Sequencing Deal; Telix 40% Directors Pool Hike, $100m Revenue CEO Options AGM; PYC: ‘PPMO Delivers RNA Therapeutic To Mouse Brains’; Anteris Takes New $2.7m Mercer Draw-Down Equity Facility; Allan Gray Increases To 10% Of Impedimed; Paradice Diluted To 7% Of Impedimed; Thorney, Tiga Take 15% Of Oventus; Mark Lampert, BVF Take 15.5% Of Bionomics; Amplia Appoints Jane Bell Director; Bod Appoints Medlab’s Alan Dworkin CFO; Genetic Technologies Appoints Opthea’s Michael Tonroe CFO
 
Dr Boreham’s Crucible: 4D Medical; Universal Biosensors Tn Test For Most Cancers; Lubris Deal; Kazia PK Data Confirms Paxalisib Dose; Next Science To Release 73m ASX Escrow Shares; Australian Ethical Takes 5.8% Of Impedimed; Platinum Reduces To 5.6% In Kazia; Anteo Joins Battery CRC Super Anode Project; Genetic Technologies Finalizes US Covid-19 Risk Test Launch; MGC Appoints Nadine Barry Co-Co Sec; 70m ‘Performance’ Rights
 
Impedimed: Sozo BIS Indicates Heart Risk; Visioneering ‘Oversubscribed’ Share Plan Raises $1.2m; FDA Grants Immutep Imp321 Fast-Track Status For HNSCC; Pharmaust Receives $756k R&D Tax Incentive; Resapp Requests ‘Capital Raising’ Halt; Universal Biosensors Requests ‘Agreements’ Halt; Credit Suisse Below 5% In IDT; Nick Allan Replaces Resonance CFO, Co Sec Agha Shahzad; Bionomics Appoints Suzanne Irwin Co Sec
 
Varonis Warns Of Healthcare Cyber Attacks; Island: $44m Bids For $7.5m IPO; Impedimed Options Raise $17.9m; Control Bionics Appoints Numotion US Trilogy Distributor; Imugene Begins 3rd Cohort PD1-Vaxx Dosing; Mayo Joins Trial; Recce ‘R327 Clears Drug-Resistant Infection’; US Patent For Volpara Enterprize, Live Software; Immutep Euro Patent For IMP701 Combination Therapy; Medlab Euro Patent For Nanocelle Drug Delivery; Pharmaust: Monepantel Anti-Viral Against Sars-Cov-2, In-Vitro; Bod: H&H Orders $312k Marijuana Oil For US; MGC Receives $425k Artemic Rescue Order; Perennial Reduces To 7.7% Of Hydrix; Suda Appoints Prof Gunnar Birgegård Scientific Advisor
 
CSL Covid-19 Hyperimmune Immunoglobulin Misses Endpoints; Bionomics Rights Raise $20.4m; Total $22.9m; Exopharm ‘Positive’ Phase I Plexaris Trial Results; Aroa: Myriad Morcells Wound Treatment FDA 510(K) Approval; Noxopharm Veyonda Patent Application; Allegra: Sr-Ht-Gahnite Spinal Cage Sheep Study ‘Successful’; Total Brain Receives $1.4m US ‘Paycheck’ Funding; Control Bionics To Release 7k ASX Escrow Shares; Cann Global Trials Marijuana For Multiple Sclerosis; Pharmaust Requests ‘Monepantel Sars-Cov-2 Results’ Halt; Genetic Signatures Appoints Dr Neil Gunn Director; Opthea Loses Co Sec, CFO Mike Tonroe; Creso Appoints John Griese US Business Development Head; Neurotech Appoints Krista Bates Director
 
March BDI-40 Up 0.2% - Record $18.5b, ASX200 Up 2%, Big Caps Down 1%; 4D Share Plan $32m Applications, Raises $6m; Total $46m; Perron: 3rd US-Approved Drug For Duchenne MD; Recce: ‘R327, R111 Kills Streptococcus Pneumoniae In Mice’; Exopharm Plexaris, Cevaris Safe In Rats, Efficacy Unknown; Universal Bio: Canada Distributor For Sentia Wine Test; Adherium 7.1m Directors Shares In Lieu Of Fees EGM; Creso Launches Marijuana Tea In Switzerland; Cronos FCTR Marijuana Gels For Japan, Hong Kong
 
Pharmaxis, Prof Fiona Wood Trial Pxs-6302 For Scar Inhibition; Opthea: FDA Opt-302 For Wet AMD Paediatric Waiver; Cellmid Rights Raise $4.5m; Medibio ‘Over-Subscribed’ Plan Raises $1m; Total $4m; Telix Appoints Grand River Illuccix (TLX591-CDx) Manufacturer; Memphasys Tests Felix Engineering Fix; Paradigm, Bene Agree New PPS Indications; Invex, FDA Meeting For Phase III Presendin IIH Trial; US Patent For Patrys Deoxymab Combination For Cancer; Creso Pays $70k For Mushroom Psilocybin Extraction; Pharmaust Monepantel Dog Cancer Trial Underway; Phillip Increases, Diluted To 19.6% Of Adherium; Summatix Diluted Below 5% In Adherium; Medlab Loses CFO, Co Sec Alan Dworkin; 4 Appointments; Anteotech Appoints CFO Gail Jukes; Neuroscientific Appoints Dougal Thring, Dr Alexandra Heaton
 
Kazia $382m+ Simcere Paxalisib Brain Cancer China Deal; Dorsavi, Medtronic $432k Wearable Sensors Extension; Swanson Reed: RDTI Registration Closes April 30; Analytica China Pericoach J-V; Race Trials Bisantrene For Extra-Medullary AML; Botanix Btx1702 For Inflammatory Rosacea Trial Approval; Dimerix Takes $5m Peter Meurs Loan; Avita: 15 Recell Abstracts At American Burn Meeting; Recce Granted European R327, R529 Patent; Cann Global: Canntab Marijuana Export Licence; Noxopharm Diluted To 24% Of Nyrada; Altnia Diluted To 7% Of Nyrada; Eleanore Goodridge Below 5% In Nyrada; Trudell Takes 19% Of Adherium; One Funds Diluted To 6% Of Adherium
 
Christian Porter Minister For Industry, Science, Technology; Cann Group, Er Ya Trade In Hong Kong Court For $3.5m; Cynata Expands Stem Cell Ards Trial Beyond Covid-19; Anteris: ‘Adapt Tissue Beats Medtronic For Calcification’; Uscom: Bp+ In China’s Final Review Phase; Living Cell Ends Peptide Research, Pays Auckland Uni $366k; Oventus Signs Inhome As 1st VGM Apnoea Contract; Cann Group, Emyria Plan Fast TGA O-T-C Marijuana; Pharmaust’s Epichem Joins WA Business Program; Respiri, Kevin Chan Trial Asthma Telehealth Program; Althea Launches Cheaper 20ml ‘Flexi’ Marijuana Oil Products; CEO Dr Sean Hall Diluted To 18% Of Medlab; Chair Michael Hall Diluted Below 5% Of Medlab; Director Drew Townsend Below 5% Of Medlab; Regal Takes 6% Of Adherium; Mesoblast Appoints Surgcenter Philip Facchina Director; PYC Appoints Jason Haddock Director; Mark Compton Replaces Next Science Chair George Savvides; Suda Appoints Prof Anil Sood Advisor
 
Dr Boreham’s Crucible: Cynata Therapeutics; Paradigm Files Ind For PPS Knee Osteoarthritis Trial; Immutep: BMS Trial Data Backs Lag3; Creso Placement Raises $18m; LBT Directors Take 25% Of Fees In Shares; Kazia Requests ‘Regional Licence’ Trading Halt; Cann Global Requests ‘Regulatory Milestone’ Trading Halt; Credit Suisse Takes 6% Of IDT; Regal Funds Takes 19.8% Of Visioneering; PYC Loses Director Dr Bernard Hockings
 
4D Access To US Defense, Veterans Contracts; TGA Okays Resapp Wearable Cough Monitor; Palla Retail Rights Raise $5.8m, Total $18m; Race, Newcastle Uni Study Bisantrene For Kidney Cancer; Dimerix: Nasogastric Dmx-200 For Remap-Cap Covid-19 Trial; Medadvisor $6.2m US Vaccine Adherence Contract Extension; Polynovo Appoints Premier Novosorb BTM US Distributor; Starpharma Appoints Lloyds UK Viraleze Distributor; Incannex, FDA Meet On Ihl-675a For Ards, Saards; Cellmid Receives $646k Federal R&D Tax Incentive; Elixinol Hemp Products Ok In UK; Toxicology Study Pending; Jencay Takes 5% Of Medadvisor; Eleanore Goodridge Reduces To 5.4% In Nyrada; Respiri Appoints Dr Andrew Weekes, Dr Mark Levy Advisors
 
Federal $3.2m For Medical Devices; Clinuvel Expands Scenesse To Xeroderma Pigmentosa-Variant; Alcidion $2.2m East Lancashire Nhs Patientrack Deal; Dimerix: Dmx-200 Combination Inhibits Inflammation In-Vitro; Truscreen Cervical Cancer Screening ‘Covid-19 Safe’; Creso Requests ‘Capital Raising’ Trading Halt; One Funds Takes 6% Of Idt; Actinogen CEO Dr Steven Gourlay Appointed M-D; Vale Bionomics Jack Moschakis; Adrian Hinton Interim Co Sec
 
Redhill Opaganib For Swiss Covid-19 ‘Compassionate Use’; Respiri: US FDA O-T-C Approval For Wheezo Asthma Monitor; Pharmaust’s Epichem, Thermaquatica Waste-To-Fuel Deal; MGC Cimetra (Artemic) Phase III Covid-19 Trial Approval; Creso US O-T-C Listing; More Psilocybin; Tdm Takes 24% Of Somnomed; Thorney, Tiga Increase, Diluted Below 5% Of Little Green; Bing-Cheng Liu Replaces TBG Director His-Kai Wang
 
Nyrada Commitments For $11m; Anteo: ‘Rapid Sars-Cov-2 Test 97.3% Sensitive, 99.6% Specific’; Medadvisor Repays Syneos $6.5m Convertible Note In Cash; Auscann $648k Instalment For Chile J-V Dayacann; Antisense Appoints Dr Charmaine Gittleson Director; Avita Appoints Michael Holder CFO 
 
Dr Boreham’s Crucible: Compumedics; Redhill Revenue Up 923% To $83m, Loss Up 80% To $98.5m; Medlab Raises $15m, Appoints Cheryl Maley Director; Pharmaxis Begins US Bronchitol Distribution; Race, Newcastle Uni Study Bisantrene For Melanoma; Noxopharm Begins Veyonda, Nivolumab Cancer Study; Palla: 1st UK Order For Codeine-Paracetamol Pills; IDT: Federal Assessment For Covid-19 Vaccine Production; Creso Launches Marijuana ‘Ritual Sticks’, $73k First Order; Medibio To Supply Ilumen To 1000 UK Compass Employees; Respiri Requests ‘Wheezo FDA Application’ Trading Halt; Ecofibre To Release 192m ASX Escrow Shares; Merchant Funds Takes 13% Of Auscann
 
Monash, Et Al Embryo Models For Pregnancy Studies; Volpara Density ‘Reduces Breast Cancer False Positives’; Amplia, Garvan Work On AMP945 For Pancreatic Cancer; Adherium Placement Raises $18m; Visioneering $1m Share Plan; ITM To Supply Telix Radio-Isotopes; Chimeric Doses 1st Glioblastoma Trial Patients; Osprey: 3 More US Distribution Deals; Bod, Drug Science Study Medicabilis For ‘Long Covid’; Oventus Appoints Connect DME, Circadian Distributors; Nyrada Requests ‘Capital Raising’ Trading Halt; ASIC Restricts TBG Capital Raising; Goodbye Cannpal; Auscann Expands, Board Changes
 
TDM Invests $50m In Qbiotics, Takes 12%; WEHI: Genetic Defect Linked To Mactel Eye Disease; UQ: ‘Anakinra Reduces Worst Chemotherapy Side-Effects’; Federal $15m For Psychedelics, PTSD, Mental Illness; Creso Phase II Psilocybin Trial For PTSD; Amplia Completes Ascending Dose AMP945 Trial; Painchek Wins CE Mark, TGA Approval; Bionomics Additional $3m Placement; Medlab Requests ‘Placement’ Trading Halt; Medadvisor To Release 15m Voluntary Escrow Shares; Universal Biosensors Loses Director Marshall Heinberg; Bill Fleming To Replace Creso’s Dr Miri Halperin Wernli; PYC Appoints Dr Michael Rosenblatt Director
 
Bard1, Minomic Work On Pancreatic Cancer Blood Test; Starpharma: ‘DEP-HER2-Lu Beats Herceptin For Breast Cancer In Mice’; Micro-X Terminates Thales IED Deal; Immutep Starts IMP321-Keytruda Head, Neck Cancer Trial; Azure Manufactures NE1-Elite, NE1-Heart Food Additives; Rhythm Colostat Blood Test 84% Sensitivity, 95% Specificity; Incannex: IHL-675A Beats CBD, HCQ For Arthritis In Rats; Imex: 54 Aquila Deals, $1.2m Annual Recurring Revenue; Imagion Receives Federal $50k Grant; Bluechiip Receives $1.6m R&D Tax Incentive; Adherium Requests ‘Placement’ Trading Halt; European Patent For Regeneus Progenza Stem Cells; Brandon, MRCF, Hesta Hold 27% Of Osprey; Naos Takes 29.5% Of BTC; FIL Reduces To 8.4% Of Resapp; Regal Reduces To 6.6% Of Alterity; Elixinol Appoints Kim Bradley-Ware Co-Co Sec
 
Victoria $17m For La Trobe Uni ‘Digital, Bio Innovation Hubs’; Opthea Treats 1st Phase III Wet AMD Patient, 1979 To Go; S&P ASX Indices: 11 Biotechs Up, 8 Down; Bard1 Granted hTERT Australian Patent; Recce: Pew Adds R327 To Its ‘Non-Traditional’ List; Elixinol To Pay Up To $37m For Germany’s Cannacare; Little Green $7.5m Land Purchase; Marijuana Order; Creso To Pay $500k, 47m Shares For Psychedelic Halucenex; Perennial Takes 5.35% Of 4D Medical; Race Founder Dr William Garner Reduces To 8.45%; Merchant Reduces To 6.4% Of Race; DMX Takes 6% Of Cryosite; Actinogen Appoints Dr Steven Gourlay CEO On $400k
 
 
 
 
  
  
  
  
  
Mesoblast Raises $142m; Emvision Wins $8m Of MRFF Stroke Funding; Palla $4m Placement, $8m Institutional Rights Issue; Neurotech To Raise $3.6m; Expands Dolce Cann Licence; Oasmia Licences Kazia’s Cantrixil For Cancer For $59m; Alcidion Wins $600k NZ Contracts; Nova Eye Starts Itrack Ab-Interno Glaucoma Study; Cynata Cymerus Idiopathic Pulmonary Fibrosis Mouse Study; PYC Claims VP-001 Pre-Clinical ‘Success For RP11’; Osprey Expands US Sales; Noxopharm Receives $4.6m Federal R&D Tax Incentive; CE Mark For Resapp Wearable Respiratory Test; 4D Takes ‘Capital Raising’ Halt To Suspension; Genetic Technologies Requests ‘Material Distribution’ Halt; Creso Appoints Ceres US Anibidiol Distributor; Merchant Funds Takes 14% Of Bard1; Jeffrey Emmanuel Below 5% In Bard1; M-D Fleta Solomon Diluted To 11% Of Little Green; Elixxer Reduces, Diluted To 16% Of Little Green
 
Feb BDI-40 Up 1.5% - Record $18.5b, ASX200 Up 1%, Big Caps Down 0.6%; $99m For Melb Uni-Micro-X Stroke, 4D Lung, Florey Epilepsy; Island $7.5m IPO For ISLA-101 For Mosquito-Borne Viruses; Kyocera Takes Regeneus H1 Revenue To $7m, Loss To $4m Profit; Mesoblast H1 Revenue Down 82% To $4.6m, Loss Up 67% To $65m; Cardiex H1 Revenue Up 16% To $2.7m, Loss Up 6% To $2m; TBG Revenue Up 38% To $4.6m, Profit To $3.5m Loss; Creso Revenue Down 33% To $2.4m, Loss Up 101% To $31m; Pharmaust H1 Revenue Down 37% To $1m, Loss Up 72% To $832k; Osteopore Revenue Up 266% To $1.5m, Loss Down 18% To $2m; Cynata, Tekcyte Work On Stem Cells For Diabetic Ulcers; ASX Delists Invitrocue For Reports, Medigard For Fees; JM Financial, No Plan B Reduce To 12% Of Universal Biosensors; Regal Funds Reduces To 7.5% Of Alterity; Dr Graham Kelly, Milligene Increase To 13% Of Noxopharm; Botanix ‘Terminates’ Dr Michael Thurn, Hires 3 Executives
  
Dr Boreham’s Crucible: Neuren Pharmaceuticals; Avita Hopes To Raise $88m In US; Austco H1 Revenue Down 17% To $14m, Profit Up 2% To $826k; Medical Dev H1 Revenue Up 15% To $12.6m, Profit To $1.1m Loss; Palla Revenue Down 60% To $22m, Loss Up 355% To $35m; Palla Trading Halt For $18m Placement, Rights; Elixinol Revenue Down 51% To $15m, Loss Up 26% To $104m; Imex Revenue Up 41% To $11m, Loss Down 40% $3.6m; Hydrix H1 Revenue Down 38% To $5.1m, Loss Up 188% $4.8m; Cryosite H1 Revenue Up 18.5% To $5m, Profit Down 77% To $285k; Telix Revenue Up 50% To $5.2m, Loss Up 61% To $45m; Resonance H1 Revenue Up 8% To $2m, Loss To $770k Profit; Incannex H1 Revenue $1.2m, Loss Up 31% $2.9m; Osprey Revenue Down 54% To $2.1m, Loss Down 26% To $17m; Polynovo Novosorb Synpath Ulcer Study Approved; 4D Requests ‘Material Grant’ Trading Halt; Emvision Requests ‘Funding Application’ Trading Halt; Mesoblast Requests ‘Private Placement’ Trading Halt; Micro-X Requests ‘Funding Application’ Trading Halt; Neurotech Requests ‘Financing Transaction’ Trading Halt; LBT Receives $826k R&D Tax Incentive; Invex Wins US Trademark For Presendin; Resapp, WMA Medetective Launch Delayed; Suda Contracts Medpharm To Improve Anagrelide Oral Spray; Cogstate Appoints David Franks Co-Sec; Resapp Loses 3-Month Co-Co Sec Stephen Hewitt-Dutton
  
Probiotec H1 Revenue Down 3.5% To $43m, Profit Up 79% To $1.2m; Cogstate H1 Revenue Up 59% To $17m, Loss Down 84% To $563k; Medadvisor H1 Revenue Up 192% To $13m, Loss Up 80% To $9.5m; Alcidion H1 Revenue Up 36% To $11m, Loss Down 23% To $1.4m; Cyclopharm Revenue Up 4% To $14.7m, Loss Up 107% To $6m; Nova Eye H1 Revenue Down 11% To $6.6m, Loss Down 45% To $1.6m; Althea H1 Revenue Up 175% To $5.1m, Loss Down 1% To $8.3m; Bod H1 Revenue Up 114% To $2.5m, Loss Down 8% To $1.3m; Micro-X H1 Revenue Up 190% To $2.4m, Loss Up 15% To $4.8m; Control Bionics H1 Revenue Up 22% To $2m, Loss Up 101% To $1m; Total Brain H1 Revenue Down 9% To $2m, Loss Up 3.5% To $4m; Invion H1 Revenue Down 33% To $1.2m, Loss Down 28% To $852k; Bioxyne H1 Revenue Down 10% To $1.2m, Loss Up 11% To $285k; Antisense Files ATL1102 Duchenne Plan To EMA; CSIRO Medicinal Marijuana Manufacturing Licence; Polynovo Appoints Medinamedical Nordic Novosorb Distributor; Avita Requests US Capital Raising Trading Halt; LHC Reduces To 9% In BTC; SIO Reduces To 19.96% In Anteris; Regeneus Loses Director Dr Alan Dunton; Antisense Appoints Alicia Mellors Co-Co Sec
  
Mayne H1 Revenue Down 8% To $209m, Loss Up 842% To $182m; Nanosonics H1 Revenue Down 11% To $43m, Profit Down 74% To $1.5m; Compumedics H1 Revenue Down 1% To $18m, Profit Up 717% To $1.3m; Clinuvel H1 Revenue Up 58% To $16m, Profit Up 420% To $6m; Little Green H1 Revenue Up 427% To $3.8m, Loss To $484k Profit; Medlab H1 Revenue Down 9% To $2.5m, Loss Up 89% To $7.1m; Uscom H1 Revenue Up 232% To $2.3m, Loss Down 82% To $270k; IQ3 H1 Revenue Down 48% To $2.2m, Loss Up 130% To $2.2m; Allegra H1 Revenue Down 1.6% To $2.3m, Loss Down 86% To $188k; Rhinomed H1 Revenue Up 17% To $1.9m, Loss Up 3.5% To $5.5m; Universal Bio Revenue Down 54% To $3.2m, Loss Up 58% To $7.6m; Emyria H1 Revenue Up 165% To $1.15m, Loss Down 3% To $2.1m; Osprey Options Raise $14.5m; $1.4m US Government Loan; US ‘Forgives’ $1.44m Impedimed Covid-19 Loan; Founders Sue Bard1 For Performance Shares; Opthea: 1,980-Patient Phase III OPT-302 Wet AMD Trials; Resonance Adds CE Mark To Hepafat-AI Australian, US Approvals; Adalta: FDA IPF Orphan Status For AD-214; Malaysian Patent For Azure Tocotrienols; Recce To List On Frankfurt Exchange; Selector Funds Below 5% In Nanosonics; Director, CSO Dr Daniel Tillett Increases, Diluted To 7% Of Race; Cell Care Reduces To 17% Of Cryosite; Noxopharm Dr Graham Kelly Reduces To 11% For Options; Apeiron, Christian Angermayer Take Profit To 10% Of Bionomics
  
  
Editorial: Your R&D Tax Incentive Is Not Revenue; Genetic Sigs H1 Revenue Up 411% To $19m, Loss To $4m Profit; Impedimed H1 Revenue Up 26% To $3.6m, Loss Down 19% To $10.4m; Next Science Revenue Down 15% To $4.4m, Loss Down 17% To $15m; Cann Group H1 Revenue Up 36% To $1m, Loss Up 12% To $9.4m; Micro-X ‘Oversubscribed’ Share Plan Raises $3.5m; Total $34m; Azure Hopes For $3m NSX Listing; Noxopharm: Canaccord Underwrites $3.7m Options; Cynata Receives $1.4m Federal R&D Tax Incentive; Pharmaxis Enrols 1st PXS-5505 Myelofibrosis Patient; Japan Approves Telix TLX591-CDx Prostate Cancer Trial; Bionomics Reformulated BNC210 Pharmacokinetics; BTC To Distribute GPX Neola Lung Volume, Oxygen Monitor; Invion To Release 1.4b Voluntary Escrow Shares; CEO George Syrmalis Increases, Diluted To 20% Of IQ3; Emyria Appoints Dr Karen Smith Advisory Board Chair; Auscann: Charles Altshuler CFO, Maria Alexakis Med Director; Bod To Lose CFO Charles Altshuler; Medigard Faces ASX De-Listing On Fees
  
 
  
Pro Medicus H1 Revenue Up 8% To $32m, Profit Up 12% To $13.5m; BTC $19k H1 Revenue, Speciality Unit $3.6m, BTC Loss $179k; Visioneering Raises $22m, Share Plan For $1m More; Cyclopharm ‘Over-Subscribed’ Share Plan Raises $3m, Total $33m; Mesoblast: Remestemcel-L-Treated Children Recover From MIS-C; Amplia Begins AMP945 Multiple Ascending Dose Study; Bionomics, Empathbio MOU For BNC210-EMP-01 For PTSD; Proteomics Pleads Schultz, Good News To ASX 31% Price Query; Federal Court Grants Cann Group Cleansing Notice Extension; Resonance Requests ‘Regulatory Approval’ Trading Halt; Credit Suisse Takes 5% Of Bard1; Cell Care Reduces To 18.55% Of Cryosite; Jimmy Thomas, Ivy Ponniah Take 8.5% Of Living Cell; Burnet Opens Diagnostics Initiative, Jennifer Barnes Director; Stemcell Appoints David Plattner Sustainability Advisor
 
Dr Boreham’s Crucible: Chimeric Therapeutics; Glaxosmithkline: $6.9m For Australian Research; CSL: Astrazeneca Vaccine Manufacture ‘In Final Stage’; Imugene Begins 2nd Cohort PD1-Vaxx Dosing; Avita H1 Revenue Up 56% To $13m, Loss Up 11.5% To $20.5m; Starpharma, Merck Dep-Antibody Drug Conjugates Deal; Recce R327 ‘Reduces Sars-Cov-2 99.9%’ - In-Vitro; Botanix Receives $6.9m R&D Tax Incentive; Living Cell Pleads Schultz, Talks To ASX 39% Price Query; Tali Requests ‘Capital Raising’ Trading Halt; Incannex Requests ‘IHL-675A Results, Further Studies’ Trading Halt; Auscann Buys Back 8m Unmarketable Shares, 8k Parcels; Platinum Reduces To 6.8% Of Kazia; Orthocell CSO Ming Hao Zheng, Ying Fan Below 5%; BVF Partners Diluted To 15% Of Actinogen; Cochlear Appoints Stu Sayers CFO; Biointelect Appoints Four Executives
Optiscan Starts Breast Cancer Margin Microscope Study; Cann Group: $3.6m ‘Cyber Security Incident’; Proteomics Files FDA Promarkerd Pre-Submission; Telix Terminates Pi Medical Netherlands Distribution; Heramed: Sheba Herabeat Foetal Heart Monitor Trial; Anatara Ready For Garp IBS Diarrhoea Trial; Little Green: 1st German Commercial Marijuana Shipment; Creso Takes-Back Swiss Marijuana Distribution; Respiri: Pharmacy Catalyst To Sell Wheezo Asthma Monitor; Exopharm Pleads Schultz To ASX 30% Query; Stemcell Pleads Schultz To ASX 59% Query; Avecho Requests Capital Raising Halt; Medibio Requests Capital Raising Halt; Anglo Australian Christian Diluted To 14% In Cyclopharm; Perennial Holds 12% Of Micro-X; Regal Funds Takes 10% Of Elixinol; McRae Diluted To 27% In Neuroscientific; Actinogen Loses 6-Year CEO Dr Bill Ketelbey; Race Appoints Mary Harney Director; Neale Java To Replace Control Bionics CFO John Bell
January BDI-40 Down 1%, ASX200 Up 0.3%, Big Caps Down 4%, NBI Up 6%; Redhill: ‘DSMB Backs Opaganib For Covid-19 Trial’; Micro-X Raises $30.5m, Share Plan For $2.5m More; Althea H1 Receipts Up 204% To $4.7m; TBG Receipts Up 119% To $7.3m; THC Receipts Up 44% To $6.9m; Cardiex Suspended; H1 Receipts $2.3m; Polynovo Appoints Medival Novosorb BTM Italy Distributor; UK Approves Palla Norway Codeine Facility; Osteopore, Terumo Collaborate On Regenerative Medicine; Nyrada, Walter Reed, Uni NSW Brain Injury Collaboration; Anatara: Anr-Pf ‘Success’ For Poultry Necrotic Enteritis; Dorsavi Requests ‘Shortfall Placement’ Trading Halt; Botanix Requests ‘BTX1801 Trial Results’ Trading Halt; Suda EGM 36% Oppose Employee Option Plan; LBT To Lose Chair Kate Costello, Director Caroline Popper; Adherium Loses Director Bryan Mogridge; Chimeric Appoints Cindy Elkins Director; Emyria Appoints Dr Richard Magtengaard Advisor
 
Dr Boreham’s Crucible: Orthocell; Resmed H1 Revenue Up 9.5% To $2b, Profit Up 26% To $511m; Imex Receipts Up 25% To $8.7m; Regeneus H1 Receipts, Milestone $7.7m; Hydrix H1 Receipts Down 46% To $5m; Pharmaxis H1 Receipts Down 9.3% To $3.6m; Little Green H1 Receipts $3.3m; Mesoblast H1 Receipts Down 91% To $2.6m; Telix Receipts Up 8.5% To $3.9m; Creso Receipts Up 32% To $3.7m; Osteopore H1 Receipts Up 110% To $1.5m; Incannex H1 Receipts Up 192% To $1.4m; Rhinomed H1 Receipts Down 17% To $1.3m; Bioxyne H1 Receipts Down 37% To $1.3m; Cann Global H1 Receipts Up 85% To $1.1m; Correction: Next Science; Volpara Requests ‘Corporate Acquisition’ Trading Halt; Nyrada ‘Brain Injury Collaboration’ Trading Halt; Australian Ethical Takes 11.5% Of Cyclopharm; Karst Peak, Leitzes Increase, Diluted To 9.7% Cyclopharm; Peter And Helen Jones Below 5% Of BTC; Chimeric Appoints Prof Yvonne Chen Advisor
 
 
Cyclopharm $30m Placement, Share Plan For $1.5m; Genetic Signatures Easyscreen STI Wins CE-IVD; Telix Doses 1st US Zircon Renal Cancer Imaging Patients; Adventist Health Expands Mach7 Pacs Contract To $7.9m; Aroa Q3 Receipts $14.9m; Elixinol Receipts Down 57% To $14m; Atomo H1 Receipts $5.8m; Anteris Receipts Down 61% To $7.3m; Uscom H1 Receipts Up 146% To 2.7m; Medlab H1 Receipts Down 37% To $2.6m; IQ3 H1 Receipts Down 42.5% To $2.5m; Cellmid H1 Receipts Down 27% To $3.5m; $530k China Order; Pharmaust H1 Receipts Down 27% To $1.3m; 4D Starts XV LVAS US Pilot Program; Hapvida $58k, 2-Year Renewal Of Heramed Heracare Deal; Immutep Wins Safety Approval For IMP321 Covid-19 Trial; Universal Biosensors Appoints Enartis US Sentia Distributor; Emvision: FDA Advises De-Novo Path For Brain Scanner; Mitsubishi Singapore Ends Suda Zolpimist Licence; Little Green 2-Year French Government Marijuana Deal; Naos Takes 27% Of BTC; Mercer Street Takes 5% Of Anteris; Living Cell To Lose CEO Dr Ken Taylor; CSL Loses 4-Month Astrazeneca Director Dr Pascal Soriot; Factor Appoints Taylor Collison Advisor
  
  

Jan 17, 2021 

Special Summer Catch-Up Edition: 

Acrux Raises $7.8m, Share Plan For $2m More; Next Science: Blastx Wins CE Mark; Pharmaust: Epichem Extends Up-To $1m DNDI Contract; Nyrada NYX-PCSK9I ‘Reduces Cholesterol In Mice’; Vivazome, BIA Separations Work On Exosome Purification; Rainmaker, Marcus Liew Reduce In Osteopore; Perennial Takes 8.8% In Hydrix; Incannex Starts IHL-42X Marijuana Sleep Apnoea Trial; Elixinol Terminates Pet Releaf Agreement; Creso: Anibidiol Approved In Uruguay, $89k Purchase Order; Director Paul Benhaim, Raw With Life Diluted To 9% In Elixinol; Volpara 5-Year Queensland Breastscreen Contract; Starpharma Starts Viralese Covid-19 Nasal Spray Study; Universal Biosensors, J&J Lifescan Animal Diabetes Test; Alterity, Uniquest Licence For PBT2 Antimicrobial; M&G Reduces To 9% Of Starpharma; K1W1 Below 5% In Adherium; Bod: H&H Orders $871k Of Swisse Hemp Seed Oil For Italy; Director Michael Stork Diluted To 5.5% In Patrys; Stemcell Responds To ASX 172% Price Query; Palla Loses Founder, CEO Jarrod Ritchie; Pharmaust Ethics Approval For Dog Cancer Trial; MGC Wins $5m Malta Grant For Artemic For Covid-19; Cann Group: 1st UK Marijuana Oil Shipment; Genetic Signatures: Boston Medical Easyscreen Distributor; Palla Appoints Iain Ross Director; Avecho Begins ‘Observational’ CBD-TPM Study; Recce: R327, R529 Anti-Viral Effect In Hamsters; TGA Approves Orthocell Celgro; Resapp Ends Reckitt Benckiser Cough Diagnostic Deal; Noxopharm Approved For Overseas R&D Expenditure; Althea Appoints Lyphe UK, Jersey Distributor; Telix: ‘TLX101 Lengthens Glioblastoma Survival’; Invex To File Euro Application For Presendin For IIH; Pharmaust Begins Manufacturing Human-Grade Monepantel; Redhill Opaganib Covid-19 Trial Passes Safety Review; Simavita Extends $1.4m Convertible Notes; Resonance: Blackford Includes Hepafat-AI In Imaging Deal; Blackrock Takes 5% Of Immutep; Elixinol 17% ASX Price Drop Query; Phillip Thematic Below 5% In Adherium; Anteo Appoints Covid-19 Rapid Test Part Manufacturer; M&G Reduces To 8% Of Starpharma; Bruce Gordon Replaces Cellmid Chair David King; Nuheara $11.5m For Hewlett Packard Deal; End Lind Facility; Chiesi Pays Pharmaxis $9m Bronchitol Approval Milestone; Esense $812k Loan Agreements; Medibio: FDA Wants More Data For Medsleep Approval; Analytica Receives $649k R&D Tax Incentive; Phillip Asset Management Takes 15% Of Acrux; Samuel Terry Below 5% In Acrux; Phillip Asset Management Takes 10% Of Cynata; Blackrock Takes 6.6% Of Immutep; Mach7 Appoints Philippe Houssiau Director; Universal Biosensors, Bayer $1.3m Lab Service Deal; Anteris Placement Raises $1.1m; US Patent For Immutep IMP321 Combination For Cancer; Exopharm Pleads Schultz To ASX 68% Query; Regal Funds Reduce, Diluted To 10.5% Of Elixinol; Blackrock Takes 8% Of Immutep; Simon Harradence, DDH Graham, Lugarno Below 5% Of Acrux; Lifespot Rights Raise $1.6m, $793k Shortfall; Probiotec Completes $52.5m Multipack LJM Acquisition; Redhill: Topline Data Shows Opaganib Benefit For Covid-19; Federal Government: $10m For Covid-19 Related Trials; Federal $1.5m For Doherty Sars-Cov-2 Vaccine; Bionomics Starts BNC210 Dosing Study; Anteris Takes $1.2m Mitchell R&D Tax Loan; Genetic Tech: Simon Morriss CEO, Dr George Muchnicki CMO; Indira Naidu Replaces Immutep Joint Co-Sec Tom Bloomfield; Nova Taylor Replaces Lifespot Co-Sec Justyn Stedwell; Blackrock Below 5% In Immutep; Carl Charalambous Takes 6% Of Exopharm; Regal Funds Reduces To 9.5% Of Elixinol; Emyria To Take Marijuana EMD-003 To TGA; Imex Signs 41 Aquila Deals Worth $945k ARR; Cann, Iuvo Supply Deal, 19k Unit First Order; Rhythm Pleads Schultz, Fool, Tim Boreham To ASX 46% Query; FIL Takes 7% Of Somnomed; Elizabeth McGregor Replaces Exopharm Director David Parker; Eleanore Goodridge Reduces To 6.4% In Nyrada; Goodbye Tasmanian Alkaloids, Hello Extractas Bioscience; Anteris ‘Funding Package’: $1m Placement, $19m Loans; Nuheara Placement Raises $11.5m, Debt Repaid; Cardiex Share Plan Raises $3.2m; CMRI, Logicbio Extend Viral Vector Gene Therapy Program; Immutep: Patient Dosing Complete In Part C Of Tacti-002 Trial; Imugene Completes HER-Vaxx Patient Recruitment; Kazia Begins Glioblastoma Agile Trial Recruitment; Mayne Launches Generic Microgestin 24 FE In The US; Dr David Stamler Alterity CEO, Geoffrey Kempler Chair; Pharmaust, Leiden Uni Monepantel Water Solubility Research; Cann Group Receives $3.2m R&D Tax Incentive; Micro-X Receives $1.95m R&D Tax Incentive; Painchek Receives $980k R&D Tax Incentive; Viburnum Reduces To 15.5% In Universal Biosensors; Richmond Hill Takes 7% In Universal Biosensors; Australian Ethical Below 5% In Impedimed; Cannvalate Takes 19% In Lifespot; Auscann: Cannpal’s Layton Mills Replaces CEO Nick Woolf; Mesoblast: ‘Revascor Reduces Cardiac Events By 30%’; Impedimed Completes 1,100 Patient ‘Prevent’ Lymphoedema Trial; Neuren: EU NNZ-2591 Orphan Status For 3 Neuro Syndromes; Cogstate: $29m H1 Sales; Althea Hits $1m Marijuana Sales In Month Of December; Medibio Begins Mental Health Detection Testing; Paradice Takes 8% Of Impedimed; Allan Gray Reduces To 6% Of Impedimed; Loumea Reduces To 5.5% Of Rhythm; Chair Adam Blumenthal, Anglo, Atlantic Take 16% Of Creso; Platinum Below 5% In Antisense; Perennial Takes 8% Of Nuheara; Resapp Appoints Mike Connell Commercial Activities Head; Federal, MTP $38m For Diabetes, Heart Disease; Nuheara Launches HP Elite Wireless Earbuds; Acrux: FDA Approves Generic Testosterone; Creso: Pharma Dynamics $320k Purchase Order For Cannaqix; Optiscan: $350k Carl Zeiss Microscopes Order; Noxopharm: Safety Review Approves Veyonda Dose Increase; Jimmy Thomas, Ivy Ponniah Take 6% Of Living Cell; MGC Appoints Nicole Godresse Head Of Sales; Pro Medicus, Intermountain $40m Visage 7 Deal; Cyclopharm Targets FDA Technegas Approval For July; Orthocell FDA 510(K) Clearance For Celgro; Total Brain Receives $1.1m R&D Tax Incentive; C2, Cardiex Chair Cairns, CEO Cooper Increase, Diluted To 21%; Regal Funds Reduces To 12% Of Alterity; Respiri Begins Wheezo Sales Through Superchem; Aysha Hollingdale Replaces IQ3 Co Sec Gerado Incollingo; Bard1 Loses Director Dr Irmgard Irminger-Finger; Wasagi Corp, David Cannington Diluted Below 5% In Nuheara
 

 

 

 

 

 

Jan 1, 2021
2020: BDI-40 Up 24%, ASX200 Down 1.5%, Big Caps Up 6%, NBI Up 26%;
Amplia Up 550%, Alterity 271%, Telix 170%, Immutep 166%, Cyclopharm 119%
 
Dr Boreham’s Crucible: Micro-X; Mesoblast: DSMB Halts Remestemcel-L Covid-19 Ards Trial; 4D: XV LVAS Scans 1st Commercial Patient; Austco Receives $489k Legal Settlement; Impedimed Wins Hitrust Certification For Cyber Security; Paradigm Prepares FDA Ind For PPS For Osteoarthritis; Mayne Extends Debt Facility, Reduces Debt To $208m
 
Biotech Daily Editorial: 2020 - The Year In Review; Pro Medicus, Medstar $18m, 5-Year Deal For Visage 7; Micro-X, ADF $1.3m Deal For Rover Mobile X-Ray; Race Receives $387k Federal R&D Tax Incentive; Imugene Recruits 1st PD1-Vaxx Lung Cancer Cohort; Orthocell Celgro Passes TGA Conformity Assessment; Medadvisor $4m Shortfall, Total $42.2m; $6.5m New Contracts; THC Raises $2.75m For Medimar And Manufacturing; Neurotech $366k Placement, 38m Employee, Manager Options; Rhythm US Patent For Colostat Biomarkers; Immutep Expands IMP321 Manufacturing Capability; FIL (Fidelity) Increases, Diluted To 9% In Telix; Uniquest Below 5% In Emvision; Acrux Requests ‘Capital Raising’ Trading Halt; Visioneering To Release 6.6m Voluntary Escrow Shares; Anteris Loses Star Bright Director Dr Yanheng Wu; Emvision Appoints Prof Stuart Crozier CSO; Prescient Appoints Prof Henry Miles Prince Scientific Advisor
 
Ellume: FDA Sars-Cov-2 Test Emergency Use Approval; Mesoblast Requests ‘Corporate Update’ Trading Halt; Telix, Muana Kea Partner For Prostate, Kidney Cancer; Telix Files TLX591-CDx Prostate Imaging NDS To Health Canada; Aroa: 6-Patient Myriad ‘100% Healing’ For Bone, Tendon; Imagion Enrolment Opens In Magsense Breast Cancer Trial; Heramed, Mayo Herabeat, Heracare Study; Elixinol Plan Raises $12.3m Of Hoped-For $2m; Total $20.5m; Suda Raises $2.76m, Ordesa Terminates Co-Development Deal; Emyria Placement Raises $1.2m; Optiscan Appoints J&H Taiwan Microscope Distributor; Respiri: Pharmacy 4 Less To Sell Wheezo Asthma Monitor; Creso Marijuana Deal With Ontario Cannabis; Cronos Launches Hemp Soap In Japan, Hong Kong, Australia; THC Requests ‘Capital Raising’ Trading Halt; Credit Suisse Takes 7%, Ceases In Dorsavi; Perennial Below 5% In Immutep; Dr John McBain, Picton, 52nd Celebration Take 17% Of Rhinomed; Bod Appoints Medical Marijuana Advisory Board 
 
Mesoblast: ‘Revascor Misses Endpoint, Reduces Heart Events’; Clarity Placement Raises $25m; Althea Placement Raises $6m; Share Plan Hopes For $3m; Cochlear: US Supreme Court Denies Appeal; $472m Claim, Fees; Cardiex H1 Sales Up ‘More Than 30%’; TGA Drops Cannabidiol To O-T-C Schedule 3, But No Products; MGC: ‘Artemic Covid-19 Trial Meets Endpoints’; Incannex: IHL-216A Beats CBD For Brain Injury In Rats; Immuron, Monash Test Cow Colostrum Against Sars-Cov-2; Heramed: Teleperinatal To Distribute Foetal Monitors; Australian Ethical Takes 15% Of Nova Eye; Credit Suisse Takes 5% In Dorsavi; Regal Funds Reduces To 14% Of Elixinol; Regal Funds Below 5% In Medadvisor; Director Jim McDowell Rejoins Micro-X; Cochlear Appoints Stu Sayers Acting CFO
 
Medical Developments Raises $25m; Share Plan Capped At $5m; Telix, Kanazawa Start TLX591-CDx Japan Ethnicity Study; Alcidion $2m South Tees NHS Extension; Austco $1.3m Singapore Nurse Call Contract; Antisense Wins EU Orphan Status For ATL1102 For DMD; Safety Data Board Okays Adalta AD-214 Dose Escalation; Telix Completes Therapharm, Southampton Uni Deals; S&P Promotes 4D Medical, Demotes Avita, Resapp; Emvision Receives $1.3m Federal R&D Tax Incentive; Kazia Receives $1m Federal R&D Tax Incentive; Stemcell Raises $1.9m; Rhinomed Sars-Cov-2 Swab Equals Comparator; Botanix Completes Btx1801 MRSA Study Treatment; Zelira Appoints Hope Marijuana Washington Dc Distributor; Cellmid: Ourui To Distribute Hair, Skin Products In China; Emyria Requests Placement Trading Halt; Suda Requests Capital Raising Trading Halt; Exopharm Releases 35.7m Escrow Shares; Anatara Unmarketable Parcel Facility; Perennial Below 5% In 4D Medical; Jimmy Thomas, Ivy Ponniah Below 5% In Stemcell; Imex Loses Co-Co Sec Peter Webse; Reena Minhas Co Sec
 
Dr Boreham’s Crucible: Imex Health Services; CSL, UQ Close V451 Covid-19 Vaccine Trial; ANU, Janssen Work On Type 1 Diabetes Tests; Chimeric ‘Over-Subscribed’ $35m IPO Closes Early; Cynata Placement Raises $15m, Rights Offer For $5.5m More; Bod Placement Raises $8m; Patrys Rights Raise $2.4m, $2.4m Shortfall; Total $7.3m; L1, Obsidian Convert $3m Cann Global Notes For Shares; Zelira Receives $1.4m R&D Tax Incentive; Althea Requests Capital Raising Trading Halt; Regal Funds Increases, Diluted To 5% Of Medadvisor; Creso Marijuana For Martin & Pleasance
 
A Year In The Grass - Medical Marijuana Review; Immutep: Aipac Breast Cancer Sub-Group ‘Statistical Significance’; Ellume Sars-Cov-2 Home Test 96% Accurate; FDA Application; Starpharma: Viraleze For EU, Study Planned; Immutep, EOC China IMP321, Paclitaxel Breast Cancer Trial; Hydrix 1st Human Phyrari Heart Sensor Trial; Correction: Cynata Therapeutics; PNOC Includes Kazia Paxalisib In Brain Tumor Trial; Imugene Receives $4.8m R&D Tax Incentive; Medical Developments Requests Capital Raising Trading Halt; Bod Requests Capital Raising Trading Halt; Stemcell Requests Capital Raising Trading Halt; Noxopharm CEO Dr Graham Kelly Diluted To 14%; Telix To Release 2.8m Voluntary Escrow Shares; 4D To Release 10.9m ASX Escrow Shares; PYC: Sahm Nasseri US CEO, Director; Starts On $663k; Race CMO Prof Borje Andersson Steps Down From Board
 
Queensland Grant For Ellume Sars-Cov-2 Test Expansion; Resonance: FDA Clears Hepafat AI Liver Test; Uscom H1 5-Month Revenue Up 183% To $2.2m, Loss To $180k Profit; Anteo Options Raise $3.9m For Covid-19 Tests; Cann Global Raises $3.75m For Convertible Note Liabilities; India Approves Aroa Wound Treatments; MTP Connect $10m Fellowships Program Opens Next Week; Kazia: Results Confirm Cantrixil Ovarian Cancer Responses, Dose; Telix: TLX591-CDx NDA Ready For FDA Review; Dorsavi 12-Month Medtronic Evaluation; Cynata Requests $20.5m Capital Raising Trading Halt; Respiri Drops Wheezo Price 67% For Volume; Orders For 7k Units; Prescient: Covid-19 Screening ‘Inconclusive’; Japan Patent For Tali Detect, Train, Maintenance; Correction: Eleanore Goodridge, Nyrada; Creso Wins $288k In Recreational Marijuana Orders; MGC Sells $1.3m Unmarketable Parcel Shares; Stem Cell Pleads Schultz To ASX 128% Query; Simavita Postpones AGM To June 2021; Paradigm Appoints Amos Meltzer Director
 
Control Bionics $15m IPO Opens Up 87%; Anatara Develops 3FDC For Mood; Garp IBS Trial Delayed; Incannex Plans Psilocybin For Anxiety Trial; Redhill Increases Talicia For Helicobacter Pylori Coverage; Nuheara: ‘Record Monthly Direct-To-Customer Unit Sales’; Althea: ‘November Record Revenue Of $847k’; Tali $9.4m Deal With Times, Brand Capital For India; Antisense Receives $651k Federal R&D Tax Incentive; Recce: DIIS Approves Further $4.2m Offshore RDTI; Resonance Requests ‘Regulatory Clearance’ Trading Halt; Eleanore Goodridge Reduces To 8.3% In Nyrada; Geoff Hollis Replaces Imagion Co Sec Jovanka Naumoska
 
Doherty’s Dr Simone Park Wins $20k Victoria Premier’s Award; TGA Priority Review For Telix Prostate Cancer Imaging TLX591-CDx; CSIRO, Anatomics Collaborate On Smart Helmet For Seizures; Mesoblast: Biomarkers Back Remestemcel-L For GvHD; Lifespot 1-For-4 Rights Issue For $2.4m; Medadvisor: H2 Adheris Revenue Up 14.5% To $21m; Neuren: ‘EMA Positive Opinions For Orphan Status’; Noxopharm Finds Hard-To-Treat Cancer Candidates; Cann Global Requests ‘Capital Raising’ Trading Halt; Azure Applies For Tocotrienol Delivery Patent; Atomo: Prep Health Distributes HIV Self-Test; Ease Of Use Study; Universal Biosensors: Grapeworks Australia Sentia Distributor; Emvision Releases 16.8m Escrow Shares; Cogstate Appoints Darren Watson CFO, Ben Bloomfield CTO
 
Dr Boreham’s Crucible: Palla Pharma; Victoria $60m For Genomics Hub; Hexima Re-Opens On ASX With ‘Oversubscribed’ $3m IPO; Uscom Listed As China ‘High Technology Enterprise’; Medadvisor Retail Rights Raise $3.2m Of $20m, Total $38.2m; Cardiex Share Plan For $1m; Allegra Up 100% On Revised Spinal Cage Beating Previous Design; Medical Developments To Take Back EU Penthrox By March; Australia Backed UN Commission Marijuana Downgrade; Emyria Plans 200-Patient IBS Marijuana Observational Study; Althea, Africann $650k South Africa Marijuana Deal; Medibio: FDA Rejects Depression Test ‘Breakthrough Status’; Tali Requests ‘Partnership, Investment’ Trading Halt; Incannex Requests ‘Psychedelic Drug Trial’ Trading Halt; Unlimited Innovation (Cho Group) Distributes Invion Shares; Medibio To Release 15m Voluntary Escrow Shares; Yoav Elishoov Replaces E-Sense 9-Month CEO Itzik Mizrahi; Resapp Appoints Stephen Hewitt-Dutton Joint Co-Sec
 
Noxopharm Placement Raises $23m; FDA Wants More Data For Telix TLX591 Prostate Cancer Trial; UK Wants More Palla Data For Norwegian Codeine Plant; Imex: Aquila In-The-Cloud $675k Revenue In 6 Months; Telix Appoints Duchembio South Korea TLX591-CDx Distributor; Goodbye Avita Therapeutics, Hello Avita Medical; UN Narcotic Drugs Commission Downgrades Marijuana; Bod: H&H $200k Hemp Oil Order For Europe; Leon Serry, City Castle Below 5% In Antisense; Medical Developments Gordon Naylor Chair; David Williams
 
FDA Approves Academic Use Of Telix 68Ga-PSMA Prostate Imaging; TGA Okays Telix Prostate Cancer Therapy Trial; FDA Fast Track For Mesoblast Remestemcel-L For Covid Ards; 4D, Miami Uni ‘Breakthrough’ Lung Program; Rhythm: Biotem To Manufacture Colostat Colorectal Cancer Test; Bard1 Clarifies hTERT Test Texas Customer; China Patent; Simavita Loses Delisting Vote, Capital Reduction Passed; Zelira, Sprinjene US Marijuana CBD Toothpaste Launch; Creso $414k Animal Marijuana Orders Take 2020 Total To $975k; Genetic Technologies Revises Taliaz Predictix Deal; Amplia Receives $533k R&D Tax Incentive; Perennial Takes 12% Of Micro-X; Merchant Reduces To 9% Of Race; Kim Hogan, JK Below 5% Of Invex; Oncosil ‘Terminates’ CEO Daniel Kenny; Dr Chris Roberts Executive
 
November BDI-40 Up 15%, ASX200 Up 10%, Big Caps Up 2%, NBI 11%; Polynovo Details US Burns Trial; Polynovo Takes Back Breast Program; Correction: Telix; Imugene Starts Phase I PD1-Vaxx Lung Cancer Study; Spain CE Mark For Imex Hiruko Imaging; Noxopharm Requests Capital Raising Trading Halt; Bard1 Requests ‘ASX Information’ Trading Halt; Althea, Peak Deal For Canada Marijuana Drinks; Genetic Technologies To Sell Taliaz Anti-Depressant Predictix Test; Life Biosciences Diluted To 13% Of Alterity; Regal Funds Reduces To 15% Of Elixinol; Memphasys Chair Alison Coutts On $350k; Avita Appoints Kathy McGee COO
 
 
Dr Boreham’s Crucible: LBT Innovations; Control Bionics $15m IPO To Convert Thoughts To Speech; Federal $4m For Covid-19 Research; Anteo Receives $1.2m R&D Tax Incentive; Opyl Receives $249k R&D Tax Incentive; Resapp AGM 35% Oppose Director Options, 10% Capacity Fails; Somnomed AGM 12% Oppose Director Hilton Brett; Bard1 Withdraws Helen Fisher Re-Election Ahead Of AGM; Little Green AGM 9% Oppose 10% Placement Capacity; Nuheara AGM 96% Halt Warwick Sauer Board Bid; Tali Pleads Schultz, AGM To ASX 43% Price Query; Telix Requests ‘Commercial Acquisition’ Trading Halt; Australian Ethical Diluted To 6.75% Of Immutep; Regal Funds Takes 13% In Alterity; Peter And Helen Jones Reduce To 6% Of BTC; Jimmy Thomas, Ivy Ponniah Take 5% Of Living Cell; Neurotech Takes ‘Marijuana Cell Studies’ Halt To Suspension; Esense: ‘Marijuana Terpenes Kills Coronavirus, In-Vitro’
 
 
Volpara H1 Revenue Up 38.3% To $9.0m, Net Loss Up 10.7% To $8.4m; Nova Eye: 4-Month Glaucoma Sales Up 12.8% To $4.4m; Alcidion Expands Nextgate Deal For UK, Ireland; Telix: US FDA Reviews Phase III Plan For TLX-591; TGA Registers Rhinomed Nasal Swab; Emyria Launches Marijuana Mental Health Program; Cann Group Details $50m Debt Facility Terms; Licences; Prescient AGM 47% Oppose CEO, Directors Options; Pro Medicus AGM 10.45% Oppose Anthony Hall Re-Election; Nanosonics: AGM 8% Oppose CEO Michael Kavanagh Rights; IQ3 Corp Postpones AGM; Neurotech Requests ‘In-Vitro Marijuana Cell Studies’ Halt; Regal Funds Takes 16.15% Of Elixinol; Macquarie Group Takes 5% Of Nanosonics; Azure Becomes Austco; Bard1 Loses (Sienna) Director Helen Fisher 
 
Victoria Budget $13b For Health, Innovation; Telix: US FDA Accepts TLX591-Cdx Prostate Cancer NDA; Analytica: Pericoach Costs ‘Significantly Less’ Than Physio; Imugene Additional Data For HER-Vaxx Gastric Cancer Claim; Race: Bisantrene Combo Breast Cancer Efficacy, In-Vitro; Universal Biosensors: Wine Analyzer Accuracy Study; Bod Receives $1m H&H Hemp Seed Oil Order For Italy; Adherium Hailie Inhaler Sensor At 8 US Centres; MGC, Mercer $3.5m Draw Down Convertible Note; Suda Receives $662k R&D Tax Incentive; Immuron Receives $358k R&D Tax Incentive; Resapp Takes US FDA 510(K) Path For Sleepcheck; Azure: 36% Rem Report 1st Strike, 37% Placement Capacity Loss; Cann AGM 27% Defeat 10% Placement Capacity; Cynata: AGM 24% Oppose Director Options; Mayne: AGM 13.6% Oppose Election Of Chair Roger Corbett; Mesoblast: AGM 10.6% Oppose Donal O’Dwyer Election; Creso 198m Blumenthal, Everblu Shares, 109m Options EGM; Heramed Releases 40m ASX Escrow Shares, 20m Options; Australian Ethical Takes 8.4% Of Immutep; Sandon Capital Takes 10% Of IDT; Perennial Below 5% In Medadvisor; Oventus: Sue MacLeman Replaces Chair Dr Mel Bridges
 
Imagion ‘Heavily Oversubscribed’ Placement Raises $6m; Cann Group Takes NAB $50m Mildura Marijuana Loan; Imugene Claims HER-Vaxx Cancer ‘Statistical Significance’; Correction: Actinogen Medical; Azure $1.6m Tacera Nurse Call Sale To Canada Hospital; Redhill Begins Phase III RHB-204 Study For Lung Disease; Redhill: Safety Board Backs Opaganib Covid-19 Study; Osteopore Appoints MTG Germany, Austria Distributor; Next Science, 3m Drop Blastx Distribution Deal; Recce: Japan R327, R529 Patent For Viral Infections; Bard1: Texas hTERT Bladder Cancer Test Customer; Oventus: VGM To Promote O2vent; Visioneering Launches Shared Vision Education Platform; Incannex: ‘IHL-675A Outperforms CBD For Ards, In Mice’; Medibio: Compass Licence For Ilumen Mental Health Platform; Oventus: 10% Placement Facility Falls On 35% Opposition; Medadvisor 6m CEO, Director Options AGM; Antisense Dual Lists On Frankfurt Exchange; IQ Responds To Media Reports; MGC Completes $1.4m Medicinal Cannabis Clinics Acquisition; Elixinol Director Paul Benhaim, Raw With Life Diluted To 12.3%; Chimeric Appoints Jennifer Chow Coo, Dr Syed Rizvi CMO; Anteris Duravr Valve Wins ‘Best Innovation’ Gong
 
Dr Boreham’s Crucible: Actinogen Medical; Mesoblast, Novartis $1.9b Remestemcel-L For Ards Deal; I-Med Upgrades More Than 200 Nanosonics Trophon Systems; Analytica: Study Backs Pericoach For Stress Incontinence; Rhinomed Nasal Swab For URTI Registered With FDA; Orthocell Celgro: ‘Consistently Restores’ Upper Limb Use; Eye Co Phase Ib D-AMD Trial Cleared To Proceed; Neuroscientific Partners For Pre-Clinical Post-Covid Fibrosis; Genetic Signatures AGM: 14% Dissent To M-D Options; Starpharma AGM 18% Dissent, Director Richard Hazelton Goes; Bionomics AGM 18% Dissent, Director Peter Turner Goes; Platinum Increases, Diluted To 7.8% Of Kazia; Australian Ethical Below 5% In Prescient; Ebos Diluted To 7.8% In Medadvisor; Romida, Roxanne Da Gama Below 5% In Medadvisor; Elixinol To ASX: ‘Pet Releaf Paid $1.5m Of $27m; Benhaim Trade OK’
 
Immutep Raises $30m, Expands Tacti-002 Trial, HNSCC Trial; Queensland Uni: Prana’s PBT2 ‘Kills Resistant Bacteria’ In Mice; Pro Medicus, Zwanger Pesiri $8.5m Visage-7 Deal; Polynovo Novosorb In Benelux, Sweden; Telix $885k Belgium Grant For Prostate Cancer Imaging; Neuren Final NNZ-2591 Trial Approval; Canada Approves Painchek Pain Assessment; Micro-X, Carestream Nano Distribution ‘Non-Exclusive’; Starpharma SPL7013 Nasal Spray ‘Active Against RSV’ In-Vitro; Bionomics Licences BNC101 To Dr Deborah Rathjen’s Carina; Resapp, WMA 2-Year Respiratory Diagnostics Deal; Paradigm 35% Rem Report AGM Strike, Loses Chris Fullerton; Emyria, Mind Medicine Psychedelics For Mental Health; Little Green Exports $600k Of Marijuana Oil To Germany; Neurotech Readies Dolce Marijuana For Phase I Neuro Trials; Imagion Requests ‘Capital Raising’ Trading Halt; Incannex Requests ‘IHL-657A In-Vivo Results’ Trading Halt; Neuroscientific Requests ‘Covid-19 Fibrosis Results’ Halt; Platinum Investments Takes 6% Of Antisense; Medadvisor Director Jim Xenos, Kojent Diluted To 6%; Perennial Takes 5% Of Medadvisor; Medadvisor Director Josh Swinnerton, Wavey Below 5%; David Sietsma Reduces To 9% In PYC
 
Kazia: New Data Backs Paxalisib For Glioblastoma; CMRI, Alia Partner For Usher Syndrome; Redhill: FDA Clears Phase II/III RHB-107 For Covid-19 Trial; Dorsavi Rights Raise $300k Of Hoped-For $1.85m; Total $2.15m; Impedimed Sells 1st Heart Failure Sozo To Phoenix; Orthocell Requests ‘Celgro Nerve Results’ Trading Halt; Genetic Signatures Receives $2.6m R&D Tax Incentive; Anatara, Ridley, Murdoch Uni Study Bromelain For Piglet E Coli; Rhythm: AGM 24% Oppose Director Eduardo Vom Election; Micro-X 21% Oppose 10% Placement Capacity; Imugene Releases 106m ASX Escrow Shares; Althea Germany Marijuana Licence; Mid Wealth Takes 9.7% Of Lifespot; Pyxis Increases, Diluted To 6.6% Of Lifespot; Incannex Appoints Canary Capital Corporate Advisor; Federal Government Covid-19 Global Innovation Summit
 
Qbiotics: US FDA Approves Stelfonta For Dog Skin Cancer; Chimeric $30m IPO For Car-T Glioblastoma Therapies; Brandon MRCF $8.2m For UK’s Myricx Pharma; Redhill Completes Phase II Covid-19 Enrolment; Volpara Launches Breasted Breast Density Training Tool; Cardiex 160.5m Directors Performance Rights AGM; Credit Suisse Below 5% In Alterity; Cannvalate Diluted To 18% Of Lifespot; Niv Dagan, Freedom Trader, 10 Bolivianos At 7.1% Of Lifespot; Immutep Requests ‘Institutional Placement’ Trading Halt; MGC: ‘Marijuana Kills Glioblastoma, In-Vitro’
 
 
Dr Boreham’s Crucible: Telix Pharmaceuticals; Victoria $155m For $550m Infectious Disease Institute; Burnet; Mach7 $5.3m Trinity Deal For Eunity Platform; PYC Rights Raise $5.4m, $14.2m Shortfall; Total $40.6m; Polynovo Wins FDA IDE For 150-Patient Novosorb Trial; Medadvisor Extends US Messaging Pilot Program; Actinogen Rights Raise $1.4m Of Hoped-For $4.9m; Total $7.4m; Elixinol Requests ‘Capital Raising’ Trading Halt; Auscann Requests ‘Material Transaction’ Trading Halt; Pie Funds Takes 7.6% Of Probiotec; Allan Gray Reduces To 7.6% Of Impedimed; Credit Suisse Takes 5% In Alterity; Elixinol’s Paul Benhaim, Raw With Life Reduce, Transfer To 15%; D&G, David Newman, Gabriel Ettenson Below 5% In Elixinol; Respiri 65m Director Options, $2.3m Cash Bonuses AGM; Hydrix 500k Chair Gavin Coote Performance Rights AGM
 
 
Data Board Backs Mesoblast Remestemcel-L Covid-19 Trial; Antisense Raises $7.3m, EMA Committee Backs ATL1102 For DMD; Neuroscientific: Alphaswisse Placement Raises $2.4m; Avita Q1 Revenue Up 55.7% To $6.9m; Correction: Avita AGM; Cynata Starts Phase III Cyp-004 Osteoarthritis Trial; TBG: Sars-Cov-2 Rapid Antigen Test Wins CE Mark; Medlab: UK National Institute Accepts Nanabis Phase III Trial; Botanix: FDA Okays Cannabidiol BTX1801 Anti-Microbial Plan; Prescient Receives $1m R&D Tax Incentive; Regal Funds Takes 7.5% Of Hydrix; Exopharm CEO Dr Ian Dixon Diluted To 20%; Visioneering Appoints Thorney’s Andrew Silverberg Director
 
Probiotec $52.5m Multipack LJM Acquisition; Victoria $50k For Kynetyka DVT Diagnostic; TGA Approves Atomo HIV Professional Test; TGA Approves Optiscan Convivo Microscope; Immutep: 5 Complete Responses In Tacti-002 Cancer Study; Anteris: Duravr Aortic Valve Anti-Calcification; Recce: Recce-327 ‘Encouraging Inhibition’ Of Sars-Cov-2; Auscann To Sell Chile J-V Dayacann For $2.1m; Avita: AGM 47% Oppose Executive Compensation; Little Green, Health Insurance Fund Partner For Marijuana; Antisense Requests ‘Orphan Drug, Capital Raising’ Halt; Medadvisor Extends ‘Capital Raising, Acquisition’ Suspension; Elixinol Pleads Schultz To ASX 61% Price Query; Grand Decade (China Grand) Takes 7.6% Of Telix; Mayne To Lose Chair Roger Corbett, Pokies Bruce Mathieson; PYC Loses US Operations Head Douglas Huey
 
Prime Minister Appoints CSIRO’s Dr Cathy Foley Chief Scientist; Alcidion $9.5m South Tees Hospital Management System Deal; Astrazeneca Leases 200 Impedimed Sozos For 2nd Trial; ASX Approves Simavita Delisting; Patrys $2.5m Placement, Rights Issue For $4.8m More; Truscreen To Apply For ASX Dual Listing, Raise Up-To $1.9m; Antisense Applies To Dual List On Frankfurt Exchange; Avita, Houston Methodist Pre-Clinical Skin Collaboration; Immuron Vaccine Shows Infection Immune Response, In Cows; Noxopharm Veyonda, Nivolumab Cancer Study; Dimerix: Remap-Cap Covid-19 Trial Protocol Approved For DMX-200; Emyria, Zelira Hope Marijuana Autism Study; Resapp, Medgate Integrate Respiratory Diagnostic; Heramed, Ecare21 To Market Heracare; Immutep Granted IMP701 Australian Patent; Actinogen Files Xanamem Cognition, Manufacturing Patents; Neuroscientific Requests Placement Trading Halt; Recce Extends ‘Antiviral Results’ Suspension; Genetic Technologies 125m Directors Rights AGM; Regal Funds Reduces, Diluted To 7.8% Of Visioneering; Somnomed Appoints Karen Borg Director
 
Dr Boreham’s Crucible: Mach7 Technologies; Medadvisor Drops Price For $45m Raising; Suspension; Palla Files UK Application For Codeine Tablets, Caplets; Pharmaust AGM: 21% Oppose 10% Placement Capacity; Visioneering To Release 4.4m Voluntary Escrow Shares; Avita Loses CFO David McIntyre; All Change At GI Dynamics; Mark Lampert, BVF Reduce To 19.5% Of Pharmaxis
 
 
Micro-X Wins $5.6m US Airport Security Scanning Contracts; Nanosonics Covid Recovery, Unit Purchases Up 4%; Universal Biosensors Receives $2.8m R&D Tax Incentive; Lifespot: Mid Wealth Placement Raises $721k; Dr Ashray Gunjur Wins $210k Monash Foundation Scholarship; Actinogen: US FDA Requests Additional Xanamem Data; Avecho: ‘Improved TPM-Propofol Safe In Rats’; Adherium, HGE Evaluate Hailie Remote Monitoring; Pharmaxis: AGM 45% Oppose CEO Gary Phillips Rights; Cogstate Partner Eisai China J-V; Willoughby Capital Increases, Diluted To 16% Of Kazia; Richard Mann, Associates Take 5.7% Of Imugene; Starfish, Michael Panaccio, John Dyson, Trujon Have 35% Of Dorsavi; Esense Director Benjamin Karasik Resigns
 
Clarity Treats First 67Cu-Sartate Neuroblastoma Patient; Proteomics Receives $1.1m R&D Tax Incentive; Kazia Unmarketable Parcel Facility; Azure Rethinks ASX Listing Application; Micro-X Requests ‘US Funding Award’ Trading Halt; Recce Requests ‘Anti-Viral Results’ Trading Halt; Incannex Requests ‘Ards Animal Trial’ Trading Halt; THC Rebrands To Epsilon Healthcare; Arix Quits Pharmaxis; Proteomics CEO Dr Lipscombe Diluted To 18%, John Dunlop 5.5%; Osteopore: Dr Carl Runde CFO, Geoff Pocock Non-Executive; Regeneus CEO Karolis Rosickas Starts On $250k; Stemcell Appoints Paul Rosen Chair
 
October BDI-40 Down 5%, ASX200 Up 2%, Big Caps Up 3%, NBI Down 4%; US FDA Approves Pharmaxis Bronchitol For Cystic Fibrosis; Telix, China Grand Up-To $450m Radiotherapy Partnership; Imugene: US FDA IND Approval For Phase I PD1-Vaxx Cancer Trial; Emyria Receives $954k R&D Tax Incentive; Medadvisor $45m Capital Raise For Adheris Acquisition; Neurotech $2.5m Placement; Positive Pre-Clinical Results; Polynovo Appoints Biogenesys Greek Novosorb BTM Distributor; Painchek, Medi-Map Partner For NZ Aged Care Pain Management; Cellmid Lyramid Midkine Divestment AGM; Recce 7.65m Directors Options AGM; Neuroscientific 3m Directors Options AGM; Opyl 1.2m Directors ‘Incentive’ Options AGM; Thorney, Tiga Take 9.3% Of Anatara; Karolis Rosickas Replaces Regeneus CEO Leo Lee
 
Dr Boreham’s Crucible: Amplia Therapeutics; Resmed Q1 Revenue Up 10% To $1.1b, Profit Up 37% To $263m; Ausbiotech, J&J: Queensland Uni Wins 2020 Industry Gong; Hydrix Placement Raises $10m; Medical Developments, Mundipharm End Penthrox Deal; Osteopore Appoints LMT Surgical Distributor; Hydrix To Distribute Phyzhon’s Phyrari FFR-Wire; Immutep, Labcorp $177k For Immuno-Oncology Products; Simavita To Delist From ASX; ‘Covid-19 Impact’; Immuron AGM Faces 18% Dissent, Passes All Resolutions; Avita Adjourns AGM, 1% Short Of Quorum; Mach7 378k M-D Performance Rights, 63k Director Shares AGM; Exopharm 200,000 M-D Bonus Shares AGM; Telix Requests ‘Material Transaction, Investment’ Halt; Quest Takes 9% Of Kazia; Unisuper Takes 6%; Perennial Takes 11% Of Micro-X; Regal Funds Reduces To 6% Of Medadvisor; Jimmy Thomas, Ivy Ponniah Reduce 0.07% To 5% Of Stemcell
 
 
Biocurate, Abbvie Accelerate Drug Commercialization; Emvision Pilot Stroke Study Meets Primary Endpoint; Clinuvel Pilot Phase IIa Scenesse For Stroke Study; Telix, DKFZ Prostate Surgery Imaging Licence; Volpara H1 Receipts Up 33.2% To $9.1m ‘Despite Covid-19’; MTP Connect $300k For Ausbiotech Regenerative Medicine Body; Taiwan Approves Polynovo Novosorb BTM For Burns; Painchek Extends Alayacare Licence To Canada; Resapp Launches Resappdx On Samsung Devices; Perennial Takes 13.5% Of Genetic Signatures; Dr John McBain, Picton, 52nd Celebration Take 15% Of Rhinomed; Impedimed AGM 16% Oppose 10% Capacity; Race 5.6m Directors Options AGM; Auscann Hires Kidder Williams; Advisors; Suspends Facility; Hydrix Requests Capital Raising Trading Halt; Ausbiotech Appoints Linda Peterson Director; Race Loses Directors Dr Bill Garner, Chris Ntoumenopoulos
 
TGA Approves Clinuvel’s Scenesse For EPP; TGA Approves Atomo, Access Bio Sars-Cov-2 Rapid Antigen Test; Dimerix: ‘DMX-200 Reduces Kidney Disease Proteinuria’; Alterity Starts MSA Natural History Study; Telix Completes Phase I Renal Cancer Study Enrolment; Adalta: AD-214 Safe In 21 Phase I Volunteers; Zelira Launches Hope Marijuana For Autism In Australia; Rhythm Adds 7th Colostat Trial Site; Opthea Receives $8.5m R&D Tax Incentive; Actinogen Receives $2.9m R&D Tax Incentive; Acrux Receives $521k R&D Tax Incentive; Cogstate: 19% Oppose Remuneration Report; Bard1 30-To-1 Consolidation AGM; Suda 3m Director Dr Michael Baker Options AGM; Optiscan 35.7m Director, Investor Options AGM; Emvision 1.5m Director Options AGM; Nuheara 6m Directors Options AGM; Karst Peak, Adam Leitzes Take $21m Genetic Signatures Profit
 
Eisai $63m Global Cogstate Licence; FDA Orphan Status For Antisense ATL1102 For DMD; Clinuvel: ‘Scenesse Safe For 1st XP Patient’; Regulatory Halt; Mayne Suba-Itraconazole ‘Higher Uptake At Lower Dose’; Nova Eye - Alpharet Pty Ltd For 2RT Lasers, FDA IND; Prescient: US Patent For PTX-100 Breast Cancer Biomarker; Adherium Takes $3m Viburnum Convertible Note; Volpara, Veloz Explain Breast Scan Results; Noxopharm Enrols 1st Covid-19 Trial Cohorts; Cann Global Launches Marijuana Tablets In Australia; Avecho Pleads Schultz To ASX 100% Price Query; Cynata 4.5m Director ‘Incentive’ Options AGM; Mesoblast 1.2m CEO Prof Silviu Itescu Options AGM; Bod 500k Director Options, 462k CEO Rights AGM; Nanosonics CEO Michael Kavanagh 371k Rights AGM; Dorsavi 2.7m CEO Shares, Directors Options In Lieu AGM; Life Biosciences Diluted To 19.9% Of Alterity; BVF Partners Increases, Diluted To 17.3% Of Actinogen; Invion Appoints Alistair Bennallack Director; Bio-Melbourne ‘Covid-19 Progress Update’ Symposium
 
Dr Boreham’s Crucible: Rhythm Biosciences; Kazia $2.8m Retail Rights Applications, Raise $8.8m; Total $25.2m; Proteomics ‘Heavily Over-Subscribed’ Placement Raises $6m; Biosceptre, CMRI Work On Car-T For Multiple Cancers; Immutep, University Hospital Pilsen IMP321 Covid-19 Trial; Painchek, Nulsen Disability Pain Monitoring Study; FDA Wants More Data For PYC VP-001 Orphan Status; Patrys Pleads Schultz To ASX 26% Price Query; Neurotech Pleads ‘Marijuana Study’ To ASX 59% Query; Pro Medicus 100% Director Fee Pool Hike AGM; Althea: 5.5m M-D Joshua Fegan Performance Rights AGM; Baker Brothers Increases, Diluted To 10% Of Opthea; Arix Reduces To 9% Of Pharmaxis; Pokies Bruce Mathieson Reduces To 10% Of Respiri
 
Mesoblast Trials Endoscopic Stem Cells For Crohn’s Disease; Oncosil ‘First Commercial Sale In New Zealand’; Antisense Requests ‘ATL1102 DMD Orphan Status’ Halt; Movember Plans Global Prostate Cancer Database; PYC Rights Offer, Placement Raise $35.2m; $19.6m To Go; Dorsavi Raises $1.85m; Rights Offer For $1.85m More; Resapp: Astrazeneca Licences Cough Monitor Software; Exopharm Doses 1st Plexoval Patient; $2.1m R&D Tax Incentive; Hydrix Implants 5th Angel Guardian, 1st Woman Patient; Genetic Signatures Q1 Record $10.5m Revenue; Cellmid: ‘Australian Q1 Revenue Up 47%’, Receipts Down 20% To $2.1m; Rhinomed Q1 Revenue ‘Up 95%’ To $1.2m, Receipts Up To $641k; Auckland Trust, Lang Walker Diluted To 39.5% Of Next Science; Thorney, Tiga Take 5.7% Of Little Green Pharma; Azure Healthcare ‘Austco’ Name Change AGM; LBT 6m CEO Brent Barnes ‘Incentive’ Options AGM; Walter And Eliza Hall Institute ‘Brand’ Change To ‘WEHI’
 
US Law Firms Start Mesoblast Class Actions; Biotech Daily Editorial Comment; Correction: Amplia Therapeutics; Anatara Raises $1.7m, Share Plan For $750k More; Somnomed: ‘Q1 Improves Despite Covid-19’; Anteotech Sars-Cov-2 Antigen Test ‘Highly Sensitive’ In-Vitro; Emyria, Sapphire Partner For Marijuana Patient Data; Respiri, Cipla Launch Wheezo In Australian Pharmacies; Resapp Adds Health Engine To Sell Sleepcheck; Starpharma Receives $5.7m R&D Tax Incentive; Dimerix Receives $2.3m R&D Tax Incentive; Oncosil AGM: 38% 1st Strike Rem Report, 30% Oppose CEO Shares; Proteomics Requests Capital Raising Trading Halt; Regal Funds Takes 15.2% Of Opthea; Australian Ethical Below 5% In Antisense; Walker Reduces To 6.7% Of Atomo; Cellmid Loses Chair, Director, Lyramid CEO; Alternate Director; One Week To Ausbiotech Conference, Invest 2020
 
CSL R&D Briefing: Spend Up, Covid-19 Programs; Oncosil: Resected Pancreatic Cancer Survival 31 Months; Respiri ‘Over-Subscribed’ Placement Raises $12.5m; Impedimed Receives $2.6m R&D Tax Incentive; Bionomics Retail Rights Raise $1.2m; Total $2.2m; Cochlear Covid-19 Recovery; Stephen Mayne AGM Bid Lost; Amplia Pleads ‘1st Cancer Patient Dosing’ To ASX 22% Price Query; PYC Hopes To Raise $55m In Placement, 1-For10 Rights Offer; Ecofibre Profit Warning; Rhinomed 12.7m CEO Michael Johnson In-The-Money Options AGM; Micro-X $263k Peter Rowland Performance Rights AGM; Dorsavi Requests Capital Raising Trading Halt; Arix Reduces To 9.9% Of Pharmaxis; Ecofibre Appoints Kristi Woolrych Director; Auscann Loses CFO Quentin Megson; Stemcell To Buy 50.1% Of Shenzen Lentene For Sea Grapes 
 
Federal $30m For University, Business Covid-19 Collaborations; Avecho: ‘TPM Marijuana Increases CBD Bio-Availability In Rats’; Nuheara Iqbuds Boost On UK NHS; Q1 Defies Covid-19; Opthea US IPO Priced At $2.38, Expects To Raise $181m; Adalta Receives $806k R&D Tax Incentive; Anatara Requests Capital Raising Trading Halt; Patrys 14.6m Director Options AGM; Starpharma 973k CEO Performance Rights AGM; Alcidion 3.1m Executive Incentive Performance Rights AGM; Nyrada 1.8m Director Dr Ian Dixon Options AGM; Bionomics 500k Director Dr Jane Ryan Options AGM; Anatara Loses Director Dr Tracie Ramsdale; Neurotech Change: Brian Leedman, David Cantor, Peter Griffith; Geoff Hollis Replaces Imagion CFO Brian Conn
 
Dr Boreham’s Crucible: Impedimed; Kazia Pays GCAR $7.1m For Paxalisib Glioblastoma Trial; Recce Phase I/II Recce-327 Burns Trial Approved; Alterity Raises $35m; Cann Global Shortfall $859k; Total $2m Of Hoped-For $4.7m; Proteomics Appoints Italian Promarkerd Distributor; Rhythm Receives $1.1m R&D Tax Incentive; Anteris (Admedus) Extends $1.3m SIO Loan; Genetic Signatures 250k CEO Options, 80% Director Fee Hike AGM; Opthea Requests ‘US IPO Capital Raising’ Trading Halt; PYC Requests ‘Capital Raising’ Trading Halt
 
Pro Medicus, LMU Klinikum 7-Year, $10m Visage 7 Deal; Actinogen Up-To $11m Capital Raising For Xanamem Trials; FDA Orphan Status For Redhill RHB-204 For NTM; Acrux Receives $1.8m R&D Tax Incentive; Paradigm 1.1m Director Loan Shares AGM; Prescient 17m Director Options AGM; Cann Global Pleads Schultz, ‘Low Price’ To ASX 100% Query; Lazard Takes 5% In Mayne; Correction: Medical Developments; Cryosite: John Hogg CEO On $250k, Bryan Dulhunty Non-Exec
 
Next Science Share Plan Raises $5m; Total $15m; Pharmaxis Receives $5m R&D Tax Incentive; Tali Detect, Train On Sale In India; BTC Wins ISO 1345 Quality Certification; Recce Requests ‘Recce-327 Ethics Approval’ Trading Halt; Respiri Requests ‘Capital Raising' Trading Halt; Mayne $1.6m Shares, $3.1m Loan To CEO Scott Richards AGM; Noxopharm 3.25m Directors Options AGM; Allan Gray Reduces To 8.9% Of Impedimed; Quest Takes 6.3% Of Kazia; John McBain, Picton, 52nd Celebration Take 14% Of Rhinomed; Medical Developments: Brent Macgregor CEO, Gordon Naylor Ned; Little Green WA Facility Wins TGA Marijuana GMP Licence; L1 Below 5% In Creso; Amber Schwarz, Jamber Below 5% In Creso; MGC: Artemic ‘Not Toxic In Rats’ For Covid-19; Stemcell, Blue Aqua J-V For Singapore Sea Grapes
 
Mesoblast Phase III Remestemcel-L Covid-19 Trial Half-Way; Immuron Restarts Imm-124E Phase III Diarrhoea Program; Bionomics Receives $2.9m Federal R&D Tax Incentive; Actinogen Requests ‘Capital Raising’ Trading Halt; Invex 800k Director Dr Thomas Duthy Options AGM; Creso Cancels L1, Lind, Chifley Convertible Notes; W Whitney George Reduces To 40% Of Rhinomed; L1 Reduces To 10.5% Of Creso; Paradigm Appoints Three Executives
 
Biotech Daily Comment: ASX ‘Upgrade’; Opthea Hopes For $221m Nasdaq IPO; LBT Sells APAS Independence, MRSA To Limbach; Nuheara Earns Hewlett Packard $2m Ear Bud Milestone; Acrux: Dash To Sell Unnamed Generic In The US; Adalta Pleads Schultz, $8m Capital Raise To ASX 42% Query; Opthea 8% Oppose 4m Director Options; Polynovo 42% Directors Fees Pool Hike AGM; PYC Claims Compound For Autosomal Dominant Optic Atrophy; Noxopharm Treats Last Prostate Cancer Trial Patient; MGC Ships ‘High THC’ Marijuana To Brazil; Alterity Requests ‘Potential Capital Raising’ Trading Halt; Aurora Sells Cann Group 12%; PYC Loses 9-Month US CEO Doug Huey; Lifespot Appoints Matthew Golden CEO
 
Dr Boreham’s Crucible: Oventus Medical; Proteomics, QIMR Partner For Oesophageal Cancer Test; Anteris: ‘Duravr Aortic Value Exceeds Expectations’; Optiscan Invivage Oral Cancer Scope On-Track For FDA 510(K); Memphasys: Felix Sperm Separator Sales ‘On-Track’; Dorsavi Pleads Schultz To ASX 36% Price Query; Anteotech 6.9m Director Options AGM; Emyria 8.5m Director Options AGM; Medibio 14.15m Solitario Options AGM; Allan Gray Reduces To 11% Of Starpharma; FIL Takes 8% Of Starpharma; Creso: Nova Scotia Liquor Corp Orders $187k Marijuana
 
Federal $1.7b For CSL-UQ, Astra Zeneca Covid-19 Vaccines; Federal $17m For Doherty Research; Volpara H1 Revenue Up 27% To Record $18m; Amplia Doses 1st Phase I AMP945 Cancer Fibrosis Trial Subjects; Redhill Passes 2nd US Review Of Opaganib For Covid-19; Heramed Herabeat ‘Comparable To Hospital CTG Machines’; WEHI Slows Motor Neuron Disease, In-Vitro; Simavita Revenue Down 76% To $43k; ASX Suspension Lifted; Atomo To Release 19.8m Voluntary Escrow Shares; M&G Reduces To 10% Of Starpharma; Allianz SE Takes 7% Of Starpharma; Auckland Trust, Lang Walker Take 42% Of Next Science; Mark Lampert, BVF Take 17% Of Bionomics; Pyxis Increases, Diluted To 7% Of Lifespot
 
Budget Response: Swanson Reed, Ausbiotech, Australian Academy Of Science, Medicines Australia; US NIH $42m For Ellume Sars-Cov-2 At-Home Test; Creso Commitments For $9m; US FDA Rejects Mayne Nuvaring, Contraceptive Pill; Cellmid Disputes Call To Remove Chair Dr David King; Imagion: Phase I Magsense Breast Cancer Trial Approved; Dimerix: ‘DMX-700 Inhibits COPD Receptor Signals, In-Vitro’; PYC: ‘VP-001 Effective For Retinitis Pigmentosa In-Vitro’; Regeneus: Canada Patent For Sygenus Acne Treatment; Medibio, Medridge Depressive Burden Sleep Trial; MGC Launches Cannepil Application, ‘Library Of Cannabinoids’; Meurs Takes 7.3% Of Adalta; L1 Takes 12% Of Creso; Creso Appoints Bruce Linton Advisor
 
 
MTP Connect 2nd Covid-19 Impact Report; Telix 18f-Fet Wins FDA Orphan Status For Glioma Imaging; BARDA Pays Vaxxas $31m For ‘No-Needle’ Pandemic ’Flu Vaccine; Resonance Develops Alert-PE AI For Pulmonary Embolism; Universal Biosensors: Promedeus Xprecia Stride Distributor; Australian Patent For Patrys Deoxymab For Cancer; Rhythm 1.5m M-D Trevor Lockett Options AGM; Noxopharm Amends $4.2m Nora Goodridge Loan; Alterity Files $70m US SEC Registration Form
 
Bio’s Dr Jeremy Levin Replaces Opthea Chair Geoffrey Kempler; Bio-Melbourne, LSQ Governance, Directors Program; PYC Claims VEGF Inhibitor ‘2nd Potential Blockbuster’; Federal Research & Development Tax Incentive Survey; Recce Receives $640k R&D Tax Incentive; Former Optiscan Director Ian Mann Increases, Diluted To 7%; Shimano, M-D Peter Griffiths Take 6.2% Of Neurotech 
 
Dr Boreham’s Crucible: Osteopore; Mesoblast Falls 45% On FDA GvHD Trial Requirement; Antisense: New ATL1102 DMD Data ‘Statistically Significant’; Kazia Institutional Rights Raise $16.4m, $8.8m To Go; Incannex Options Raise $10m; Lifespot $960k Placement, Cannvalate Takes 19.7%; Painchek, Ramsay, Edith Cowan Pain Research Deal; Noxopharm Doses 1st Veyonda Covid-19 Patient; Medibio Files MEB-001 For FDA Breakthrough Status; US Patent For Imugene Immunotherapy Platform; Pharmaxis 942k CEO Performance Rights AGM; Australian Ethical Reduces To 5.5% Of Antisense; John McBain, Picton, 52nd Celebration Take 12.6% Of Rhinomed; Orchid Capital Takes 15% Of Optiscan; Julian Jarman, Troy Valentine Below 5% In Incannex; CSL Appoints Joy Linton CFO, Replacing David Lamont; Invex Appoints Dr Tom Duthy Executive Director, On $125k; Cogstate: Dr Chris Edgar CSO, Prof Paul Maruff To CIO; Race Appoints Prof Borje Andersson CMO, Executive Director
 
 
Antisense Wins FDA Rare Paediatric Disease Status; Starpharma Placement Raises $45m, Plan For $5m More; Micro-X: W.H.O. $1.4m Rover X-Ray Order For Pacific Islands; Astrazeneca $2m To Lease 175 Impedimed Sozos For Trial; TGA Approves 4D Lung Ventilation Analysis Software; Adalta: Study Backs AD-214 For Lung Fibrosis; Emyria, Zelira Deal For Zenivol (ZLT-101) Insomnia Study; Recce, Murdoch Children’s Test Recce-435 For Helicobacter; Kazia Requests ‘Entitlement Offer’ Trading Halt; FMR Below 5% In Somnomed; Little Green Releases 1.4m ASX Escrow Shares; Dr Rita Laeufle Replaces Imugene CMO Dr Mark Marino
 
Federal $9m For Paediatric Cancer Research; Paradigm: Bene Pharmachem 25-Year PPS Supply Deal; Atomo To Distribute Access Bio’s Sars-Cov-2 Antigen Test; Neuren Files NNZ-2591 EU Orphan Drug Applications; Rhythm Validates Final Colostat Biomarkers; Regeneus Receives $677k R&D Tax Incentive; Pharmaust: Monepantel Selective For Cancer Cells; 4D Requests ‘Regulatory Approval’ Trading Halt; Botanix Pleads Schultz To ASX 46% Price Query; Kazia 2m Directors Options, 25% Fees Hike AGM; Uscom 1.4m Chair Prof Rob Phillips Rights AGM; Osprey Wins Supplier Horizon Gong; Prof Phillip Dubois Replaces Emvision Director Ryan Laws; Mayne Appoints Interim CFO Peter Paltoglou CFO; Bio-Melbourne Corporate Governance Program
 
 
Dr Boreham’s Crucible: Suda Pharmaceuticals; Opthea Registers Up-To $212m Nasdaq IPO With US Sec; TGA Okays Starpharma OTC Vivagel For Bacterial Vaginosis; Allegra 3m Director Options AGM; Cogstate 1.25m CEO Options, 44% Director Fee Pool Hike AGM; Exopharm 340k M-D, Chair Rights, 75k COO Shares AGM; Immutep 1.3m Director Rights In Lieu AGM; Impedimed 7.4m CEO Rights, 6.2m Options AGM; Medical Developments 100% Directors’ Fee Pool Hike AGM; Probiotec 1.3m CEO Options AGM; Optiscan Receives $701k R&D Tax Incentive; Visioneering To Release 6.6m Voluntary Escrow Shares
 
Telix Files US NDA For TLX591-CDx; Chimeric $4.3m Baker Young Convertible Note; Incannex Ready For Phase IIb IHL-42X Marijuana Apnoea Trial; Osprey: Regional Health Care Australia, NZ Distributor; Cardiex, Mobvoi Partner For Heart Health Smartwatch; Cynata: Stem Cells Regenerate Cardiac Blood Vessels In Rats; Bionomics $2.2m 1-For-12.54 Rights Offer; Trading Halt; Azure: Canada Patent For Transmucosal Tocotrienols; Pharmaust, Leiden Uni Test Monepantel For Sars-Cov-2, Ex-Vivo; Invitrocue J-V Completes ACE-2 Lab Mice For Covid-19 Testing; Lifespot Requests ‘Placement’ Trading Halt; John McBain, Picton, 52nd Celebration Take 11% Of Rhinomed; Drs Washer Increase, Diluted To 23% In Emerald; Bionomics Loses Peter Turner; Gains Dr Srinivas Rao, Dr Jane Ryan
 
 
Roche Pays $617m For Queensland Uni, Dublin Inflazome; Chimeric, City Of Hope Chlorotoxin Car-T For Glioblastoma; Optiscan $9.8m Placement, $7.4m From Clermont Group; Kazia, Dana-Farber Trial Paxalisib For CNS Lymphoma; Neuren Manufactures NNZ-2591 For Phase II Trials; Suda: Dog Study Backs Lower Dose Anagrelide; Little Green: CBD Content Below TGA Minimum; Respiri Appoints Entech Wheezo Manufacturer; G Medical EGM Votes To Delist, Suspended From ASX; Cardiex Requests ‘Material Commercialization Deal’ Halt; Incannex Appoints Dr Paul Liknaitzky Scientific Advisor
 
Telix Doses 1st 89-Zr-Apomab Lung, Ovarian Cancer Patients; Azure Ready For IVB003 Tocotrienol Pancreatic Cancer Trial; Federal $3m For 2 Doherty-MIPS Covid-19 Vaccine Candidates; TBG: Medigen Distributes Sars-Cov-2 Test Kits; Adalta Progresses GE Healthcare I-Body Collaboration; Resapp Requests FDA Sleepcheck Pre-Submission Meeting; Pharmaust: $881k For Monepantel For Motor Neuron Disease; Creso: Nova Scotia Liquor Corp Orders $187k Marijuana; Invion Director Shares, Options In Lieu Of Cash AGM; Recce Requests ‘Capital Raising’ Trading Halt; THC Requests ‘Federal Court Orders’ Trading Halt; Optiscan Requests ‘Capital Raising’ Trading Halt; Allan Gray Reduces To 12% Of Starpharma; Constellation, Lishan Zhang Below 5% In Anteris; Opyl: Mark Ziirsen Director, Damon Rasheed Executive; Auscann Loses Director Dr Marcel Bonn-Miller
 
Dr Boreham’s Crucible: Proteomics International; Immutep: 3 Complete Responses To IMP321, Keytruda; Immutep: 5 Of 12 Solid Tumor Patients Have Partial Response; Cochlear Opposes Advocate Stephen Mayne Board Bid; Emerald Clinics EGM Backs Name Change To Emyria; Cardiex Sphygmocor Granted European Patent; Australian Ethical Takes 15% Of Nova Eye; Craig Darby Increases, Diluted With Washer Family In Emerald; M-D Dr Ian Dixon Diluted To 23% Of Exopharm; Race Appoints CSS Clinical, FDA Advisors; Noxopharm Appoints Destum Immuno-Oncology Advisor
 
Medadvisor Launches Electronic Prescriptions; Emerald, Mt Sinai Partner For Openly Remote Monitor; Avecho Receives $615k R&D Tax Incentive; FIL Takes 7% Of Starpharma; Eye Co Appoints Alison Coutts Director
 
Next Science $10m Underwritten Placement, $5m Share Plan; Rhythm Validates 2 Colostat Test Biomarkers; Zelira: Zenivol For Insomnia Through TGA Access Scheme; Heramed Herabeat Foetal Heart Monitor On Ecare21; Ausbiotech Invest 2020, Conference Go Online
 
Cyclopharm: Technegas US Trial Meets Endpoints Early; Clinuvel Doses 1st Scenesse XP Patient; IP Group: $650k For Augmented Bionics Non-Invasive Hearing Aid; Rhinomed Develops URTI Nasal Swab; Osteopore, Singapore Uni Study 3-D Jaw Implants; Emerald: TGA Registers ‘Openly’ For Remote Monitoring; Medlab Directors 12m Options, 100% Fees Pool Hike AGM; Yuuwa Capital Diluted To 22% Of Adalta; Avita Loses Director Damien McDonald; Cann Group Confirms Jenni Pilcher Director; Exopharm Hires Alison Mew, Canary Capital Corp Advisor
 
Dimerix Falls 76% On Dmx-200 Missing DKD Primary Endpoint; 3 Companies: ‘Covid-19 Recovery Ahead Of Expectations’; GI Dynamics Raises $13.7m In Crystal Amber Financing; Orthocell Treats 300 Access Patients With Celgro; Avita Enrols 1st Recell For Vitiligo Trial Patient; Starpharma: ‘SPL7013 Kills Sars-Cov-2, In-Vitro’; Auscann: Neuvis Marijuana Capsules Meet Endpoints; Orthocell 10m Director Options AGM; Althea Canada Marijuana Licence; Blum Manufacturing Deal; AGC Asahi Glass Takes 7.5% Of Regeneus; Althea To Release 81.6m Voluntary Escrow Shares
 
Dr Boreham’s Crucible: Kazia Therapeutics; Doherty Institute: ‘Covid-19 T-Cell Immune Response Low’; Federal $3.7m For 3D Meditech Covid-19 Nasal Swab Deal; Pro Medicus, NY Uni $25m Imaging Contract; Research Deal; Ellume Adds Qiagen Sars-Cov-2 Antigen To Antibody Test; FDA Suggests Improvements For Polynovo Novosorb Trial; Genetic Technologies Breast Cancer Risk Test On Sale In Us; Opthea 4m Director Options AGM; Regeneus 15.3m Director Options AGM
 
CMRI Challenges AAV2 As Liver Gene Therapy Vector; Morningside Funds Hudson Ovarian Cancer Therapy; Clinuvel Trials Scenesse For XP Skin DNA Regeneration; Rhythm Adds Newcastle Hospital To Colostat Trial; Resonance Licences Cystic Fibrosis Data For AI Analysis; Anteotech Wins ISO 13485 Quality Certification; Recce Appoints CMax For Recce-327 Trial; Cellmid Hires C14, Pharmaventures For Lyramid Midkine Sale; MGC: Up To $15m Mercer Equity-Drawdown Facility; Dimerix Requests ‘DMX-200 Kidney Trial Results’ Trading Halt; Australian Ethical Takes 14% Of Nova Eye; Sandon Capital Takes 9% Of IDT; Bonvoyolo Diluted Below 5% Of Neurotech; Opthea Appoints Daniel Spiegelman Director; Helen Wiseman Replaces Elixinol Chair Paul Benhaim; Ausbiotech, J&J Awards For Best Covid-19 Responses
 
Cyclopharm, McMasters Partner On Technegas For Covid-19; Clarity: 64-Cu-Sartate Wins FDA Rare Kids Disease Status; Pharmaust: Elanco Drops 2018 Monepantel Option; Covid-19; Imugene: Bell Potter Underwrites $5.7m Options; Memphasys Receives $1.3m R&D Tax Incentive; Anteotech Develops Covid-19, Influenza A, Influenza B Test; TGA Joint Session Drops Marijuana CBD To O-T-C Schedule 3; Memphasys, Hydrix Good Design Gong For Sperm Separator; Loumea Increases, Diluted To 6.9% Of Rhythm; Viburnum Takes 22% Of Universal Biosensors; Naos Takes 26% Of BTC; Kirman 2, Brian Sherman Take 5.7% Of Regeneus; Noxopharm Appoints Fred Bart As Non-Executive Chair
 
Opyl Picks Covid-19 Vaccine Winners; Amplia Phase I AMP945 Cancer Trial Approved; Emvision Pilot Stroke Imaging Study Enrolled; Recce: ‘327, 529 Reduce Sars-Cov-2, In-Vitro’; Botanix: BTX1801 ‘Eliminates MRSA Ex-Vivo, In-Vitro’; Noxopharm Hires Paraxel For Veyonda Prostate Cancer Trial; PYC Combines CPP, Lipid Nanoparticles For Drug Delivery; Zelira Subsidiary For Marijuana Toothpaste; Suda: Australian Patent For Anagrelide For Cancer; US Patent For Anteris (Admedus) Adapt Tissue Process; Optiscan Pleads Schultz To ASX 35% Price Query; MGC Requests ‘Financing Facility’ Trading Halt 
 
Federal $1.7b For CSL For UQ-CSL, Oxford-AZ Covid-19 Vaccines; Boehringer Ingelheim Hands Back Pharmaxis PXS4728A; Next Science: FDA Wants More Data For Xperience Surgical Rinse; Adalta Rights Raise $4.1m; Total $8.1m; Victoria $252k For Polynovo Hernia Cleanroom; Cynata: Cymerus Stem Cells Improve IPF In Mice; Cardiex, China’s Andon Partner For Remote B-P Monitor; Opyl Tells ASX: Covid-19 ‘1st Use’ For AI Trial Software; Biotron: ‘15 Compounds Show Activity For Sars-Cov-2’; Pharmaust Requests ‘Elanco Option’ Trading Halt; Recce Requests ‘Anti-Viral Testing Results’ Trading Halt; M&G Reduces To 8.8% Of Mesoblast; Elixxir Reduces To 21% Of Little Green Pharma; Neurotech Takes 80 Marijuana Samples To In-Vitro Testing; Bio-Melbourne Forum On Burnet Covid-19 ‘Optimise’ Study
 
Dr Boreham’s Crucible: Mayne Pharma; Safety Board Backs Mesoblast Restemcel-L Covid-19 Trial; Pennsylvania $412k For Redhill Opaganib For Covid-19; S&P Promotes Mach7 Into All Technology Index; CSL $9.5m CEO Performance Rights AGM; Allan Gray Reduces To 13% Of Starpharma; One Funds Takes 10% Of Bluechiip
 
Opyl: ‘A I Predicts Trial - Including Covid-19 - Results’; Telix, Varian Prostate Cancer Collaboration; Federal, MTP Connect $10.4m For 13 ‘Early Stage’ Projects; Imugene: US Approves PD1-Vaxx Lung Cancer Trial; Heramed Expands Completed Herabeat Foetal Monitor Study; Regeneus Pays CEO Leo Lee $325k Kyocera Bonus; Neurotech: Brain Therapeutics Greece Mente Autism Distributor; Biotron Requests ‘Compound Testing’ Trading Halt; Australian Ethical Diluted To 5.5% In Prescient; Chris Retzos Reduces, Diluted Below 5% In Prescient; Pie Funds Increases, Diluted To 5% Of Probiotec; Chair Otto Buttula Takes 13.6% Of Rhythm; Correction: Althea, SG Hiscock; SG Hiscock Takes 8.6% Of Bod
 
Rhythm Rights Raise $3.6m; Total $6m; Mesoblast Australian Approval For Phase III Covid-19 Trial; TBG Wins US FDA Covid-19 Rapid Antibody Test Emergency Use; G Medical: ASX Confirms Delisting; M&G Reduces To 9.1% Of Mesoblast; SG Hiscock Takes 5.1% Of Althea; Race: Phil Lynch CEO, Dr Daniel Tillett Back To CSO, On $200k PA; THC Loses CEO Ken Charteris, Jarrod White Interim; Executives; MGC Appoints Evan Hayes Director, 2 Executives
 
August BDI-40 Up 8.3%, ASX200 Up 2.2%, Big Caps Down 0.2%; THC H1 Revenue Up 63% To $3.5m, Loss Down 3.2% To $5.6m; G Medical H1 Revenue Down 31% To $2.7m, Loss Down 30% To $6.7m; Cardiex Revenue Up 13.7% To $4.6m, Loss Up 11.5% To $3.3m; MGC Revenue Up 210% To $2m, Loss Up 124.6% To $19.4m; Creso H1 Revenue Up 58.3% To $1.5m, Loss Up 177.3% To $17.4m; Immuron Revenue Up 5.5% To $2.5m, Loss Down 37.1% To $2.9m; TBG H1 Revenue Up 22.9% To $1.9m, Profit To Loss Of $1.2m; Cann Global Revenue Up 271% To $1.8m, Loss Down 12.8% To $8.1m; Emerald Revenue Up To $1m, Loss Up 95.2% To $5.2m; Telix: Ire Elit To Distribute TLX591-CDx In French Territories; Dorsavi: Study Links Improved Low Back Pain, Vimove Data; Medlab Signs CRO George Clinical For Phase III Nanabis Trials; Starpharma: Water-Soluble Dep-Remdesivir For Covid-19; Noxopharm Starts East Europe NOX66 Covid-19 Trial; Resapp Extends Morayfield Clinic Diagnostic Evaluation; Esense Israel Trial Of Terpenes For Sars-Cov-2 Sanitizers; Recce Wins Federal $37.5k Innovation Connections Grant; Respiri: Wheezo Detects 74% Of True Positive Wheezes; Pharmaust, Obsidian Partner For Waste To Fuels Tech; Bod: Lyphe Appointed Project Twenty21 Marijuana Dispenser; Genetic Technologies $22.1m Regains Nasdaq Compliance; Dimerix 100% Director Fee Pool Hike AGM To $500k; FIL Takes 6% Of Starpharma; Invion Appoints Rob Merriel Director
 
Compumedics Revenue Down 16% To $35m, Profit To Loss Of $6m; Palla H1 Revenue Down 55% To $12.3m, Loss Up 121% To $9.0m; Elixinol H1 Revenue Down 54% To $7.9m, Loss Up To $82m; Nova Eye Revenue Down 21% To $12.8m, Loss To Profit Of $35.7m; Atomo Revenue Up 10-Fold To $5.4m, Loss Up 82.4% To $9.2m; Pharmaust Revenue Down 5.5% To $3m, Loss Down 12.2% To $1.4m; Bioxyne Revenue Up 2.2% To $2.4m, Loss Down 53% To $593k; Nuheara Revenue Down 2.6% To $2.3m, Loss Up 16.6% To $11.7m; Little Green Pharma Revenue $2.2m, Loss Up 69% To $9.3m; Proteomics Revenue Down 3% To $1.4m, Loss Down 16% To $1.7m; Optiscan Revenue Up 14.3% To $1.2m, Loss Down 24.7% To $1.8m; Telix: FDA Orphan Status For TLX102 For Multiple Myeloma; Antisense Applies For EMA ATL1102 For DMD Orphan Status; Immutep, Monash Uni Win $671k ARC Linkage Grant; Clinuvel Opens Singapore Vallaurix Research Centre; Nova (Ellex) Reappoints Tom Spurling, Loses Mike Mangano; Recce Appoints Exec Dir James Graham CEO On $300k PA; Noxopharm, Nyrada Swap Dr Ian Dixon, Dr Graham Kelly; Amplia Appoints Dr Mark Devlin CSO; Anteris Appoints Prof Bernard Prendergast TAVR Advisor
 
Dr Boreham’s Crucible: Prescient Therapeutics; Cochlear: Consensus Paper Backs Implants; Avita Revenue Up 61% To $26m, Loss Up 68% To $58m; Genetic Signatures Revenue Up 132% To $11.3m, Loss Down 40% To $2m; IQ3 Revenue Up 12% To $6.9m, Loss Up 101% To $2.2m; Medlab Revenue Down 10% To $5.5m, Loss Up 65% To $13.5m; Micro-X Revenue Up 120% To $4.3m, Loss Up 2% To $10m; Total Brain Revenue Up 49% To $4m, Loss Down 11% To $7.6m; Adherium Revenue Down 20% To $2.2m, Loss Down 3% To $11.4m; Regeneus Revenue $1.7m, Loss Down 82% To $1.1m; Kyocera Pays Regeneus $1.3m Progenza Milestone; 4d Revenue Up 77% To $1.2m, Loss Up 239% To $22m; Emerald Raises $2.2m; Malaysia Approves Oncosil Radiation For Cancer; US Safety Committee Okays Redhill’s Opaganib For Covid-19; Optiscan: Advanced Microscopy North America Distributor; Anteris (Admedus) Ends Covid-19 Director, Executive 25% Pay Cut; Perennial Reduces To 6.35% Of Atomo; Cann Global: Marion Lesaffre COO, Franc Zvonar Sales
 
Probiotec Revenue Up 46% To $107m, Profit Up 72% To $6m; Mesoblast Revenue Up 92.3% To $44.5m, Loss Down 13% To $108m; Clinuvel Revenue Up 5% To $32m, Profit Down 8% To $17m; Mach7 Revenue Up 102% To $19m, Loss To Profit Of $170k; Alcidion Revenue Up 10% To $18.6m, Loss Up To $4m; Medadvisor Revenue Up 16.5% To $9.6m, Loss Up 21% To $9.8m; Cellmid Revenue Up 2.4% To $8.5m, Loss Up 17% To $5m; Starpharma Revenue Up 142% To $6.6m, Loss Up 3% To $15m; Althea Record Revenue Of $5.7m, Net Loss Up 66% To $8.6m; Dorsavi Revenue Down 27% To $3.2m, Loss Up 8% To $4.0m; Cann Revenue Down 72% To $911k, Loss Up 55% To $17m; Exopharm Raises $10m; WEHI Investigates Compounds For Covid-19; Ellume, Qiagen Partner For Covid-19 Diagnosis; C19 Licences AR-12 For Covid-19; Emerald Clinics Requests ‘Capital Raising’ Trading Halt; Hydrix: ‘Heart Warning Devices Programmed, Switched-On’; G Medical To Remote Monitor TAVR Patients; Nuheara, Hewlett Packard Develop ‘New Audio Experiences’; Respiri, Carlton Women’s Football Team Partner For Wheezo; Blackrock Reduces To 6% Of Cochlear; Australian Ethical Takes 7% Of Prescient; Bionomics Pleads Schultz To ASX 23% Query
 
Queensland Uni, CSL Covid-19 Vaccine ‘Positive Indications’, In-Vivo; Cogstate Revenue Up 8.5% To $32.9m, Loss Down 47% To $1.8m; Polynovo Revenue Up 54.6% To $22.2m, Loss Up 31.5% To $4.2m; Hydrix Revenue Up 12.2% To $16m, Loss Down 24% To $3.2m; Cyclopharm H1 Revenue Down 11% To $5.8m, Loss Up 87% To $5.6m; Immutep Revenue Of $7.5m, Loss Down 26.6% To $13.5m; Impedimed Revenue Up 38% To $5.7m, Loss Down 11.4% To $21.4m; Visioneering H1 Revenue Down 12% To $2.8m, Loss Down 23% To $7.2m; Cynata Revenue Of $4.5m, Loss Down 57% To $3.6m; Rhinomed Revenue Up 8.5% To $3.6m, Loss Up 22.3% To $7.3m; Next Science H1 Revenue Down 55% To $1.5m, Loss Down 22% To $9.3m; Prescient Placement Raises $7m, Total $13.5m; Neurotech $500k Placement For Dolce Marijuana; Platinum Takes 12.3% Of Adalta; Australian Ethical Below 5% In Prescient; Visioneering Pleads Schultz To ASX 87.5% Price Query; Incannex: ‘IHL-675A Ards Anti-Inflammatory Response, In-Vitro’
 
Nanosonics Revenue Up 19% To $100m, Profit Down 25.5% To $10m; IDT Revenue Up 17% To $14.2m, Loss Up 68.5% To $1.9m; Osprey H1 Revenue Down 56% To $1.1m, Loss Down 19% To $10.4m; Acrux Revenue Up 33% To $1.6m, Loss Up 14% To $9.5m; Biodiem Launches LAIV Influenza Vaccine In China; Emvision, Queensland Uni $180k Advance Fellowship; Bluechiip Pleads Schultz To ASX 52% Price Query; Platinum Reduces To 9% Of Kazia; Lazard Below 5% In Mayne; Aurora Cannabis Diluted To 12% Of Cann Group; Medadvisor Appoints Naomi Lawrie Co-Sec, General Counsel; Starpharma: ‘Spl7013 Inhibits Sars-Cov-2 Infection’; Pharmaust: ‘Monepantel Suppresses Sars-Cov-2 Up-To 95%’; MGC: ‘Russia J-V For Artemic For Sars-Cov-2’ 
 
Vale Living Cell’s Prof Bob Elliot (3.1.1934 - 21.8.2020); Correction: Adalta; Somnomed Revenue Down 2.7% To $57m, Loss Up 1013% To $438k; Kazia: US Orphan Status For Paxalisib For Glioma, DIPG; 61 Medical, 41 Medical, Queensland Accelerate Devices; Opthea Plans Nasdaq IPO; Cynata Begins Cymerus Covid-19 Trial; IDT Lists Vaccine Manufacture Info For Federal Government; Bosch Automatic Materials Line For CSL Behring; Azure Begins Food Additives Manufacture; Ecofibre Completes $59m Texinnovate Acquisition; Exopharm Requests Capital Raising Trading Halt; M&G Claims To Reduce To 9.9% Of Mesoblast; Australian Ethical Below 5% In Pharmaxis; Perennial Takes 7.6% Of Micro-X; Peter Meurs Takes 5% Of Adalta; Lazard Reduces To 5% Of Mayne; Immuron Exec Vice Chair Peter Anastasiou Reduces To 5.3%; G Medical ASX Delisting EGM 
 
 
 
CSL Revenue Up 7.2% To $12.6b, Profit Up 9.6% To $2.9b; BTC $295k Revenue, Speciality Unit $5.8m, BTC Loss $283k; Cann Group ‘Oversubscribed’ Plan Raises $25.9m, Total $40.2m; Imagion Raises $1.3m From 2018 Rights Options; Pharmaxis Plans US Pxs-5505 For Myelofibrosis Trial; Aroa: ‘Endoform Attracts Stem Cells For Tissue Repair’; US Patent For Regeneus Sygenus Platform For Skin Conditions; Medical Developments Buys-Back Penthrox From Mundipharma; Respiri, APA Wheezo Referral Agreement; Volpara: 30% Oppose 405k Director Karin Lindgren Options; Osteopore Requests ‘Capital Raise’ Trading Halt; Australian Ethical Reduces To 6% Of Pharmaxis; Yuuwa Capital Diluted To 26.5% Of Adalta; Trudell Diluted To 13.4% Of Adherium; Pyxis Takes 9% Of Lifespot; PYC Dr Rohan Hockings Back As CEO; Prof Sue Fletcher CSO; MGC Requests ‘More Artemic Covid-19 Results’ Trading Halt; Neurotech Requests ‘Price Query, Lab Results’ Trading Halt
 
Cochlear Revenue Down 6.5% To $1.4b, $238m Loss; Telix Doses 1st TLX250-CDx Renal Cancer Patient; Immutep Doses Stage 1, Part B IMP321, Keytruda Tacti-002 Study; Anteotech: Mahe Underwrites $3.76m Options; Medical Developments Requests ‘EU Distribution’ Trading Halt; KFT, GJK, Kepper Family Below 5% In Universal Biosensors; Regal Funds Takes 5.2% (Or 11%) Of G Medical; SG Hiscock Takes 7.2% Of Bod; Christine McLoughlin Replaces Cochlear’s Donal O’Dwyer; Dr Geoff Brooke Replaces Cynata Chair Dr Paul Wotton; Osprey Loses Director Andy Jane; Analytica Loses Director Dr Thomas Lönngren; Phillip Hains Replaces Suda Co-Sec Joseph Ohayon
 
Biotech Daily Editorial: R&D Tax Incentive Is Not Income; Uscom Revenue Up 18% To $4.3m, Loss Down 4.2% To $1.3m; Cochlear Settles Patent Case Interest, Fees For $104m; Starpharma, Chase Sun Partner For DEP Anti-Infective; Hydrix Up 260% On 1st Guardian Heart Warning Device Implants; Memphasys, Newcastle Uni Partner For Fertility; Painchek Expands CMS Partnerships In Australia, UK; Althea: 740 New Marijuana Patients In July For $692k; Bionomics Pleads Schultz To ASX 39% Query; Merchant Funds Takes 10.4% Of Race; Zelira Director Jason Peterson Diluted To 6.5%; Deputy Chair Harry Karelis, Gemelli Below 5% In Zelira; Phillip, Bioscience Managers Take 25% Of Adherium; Damon Crowe, K One W One (K1W1) Increase, Diluted To 5.1% Of Adherium; Emerald Change Name Change To Emyria GM; CFO Tom Howitt Replaces Cronos Co-Sec Lior Harel
 
 
Qbiotics, Merck EBC-46, Keytruda Melanoma Trial; Pharmaxis Revenue Up 12% To $7.4m, Loss Down 31% To $14m; Osprey Wins CE Mark For Dyevert Power XT; Imagion Pleads Schultz To ASX 29% Query; Pharmaxis 942k CEO Performance Rights For AGM; Bio-Melbourne: ‘Manufacturing’s Covid-19 Rapid Response’
 
Victoria Keeps Regenerative Medicine Centre; LBT Share Plan Raises $367k Of Hoped-For $1m; Total $8.4m; Race: Williams, Emmanuel, Merchant Exercise $1.5m Options; US Patent For Immutep IMP321 Combination Therapy; Prescient Increases PTX-100 Cancer Trial Dose; Botanix Starts Phase IIa BTX1801 Surgical Infection Study; Respiri, APA Partner For ‘Real World’ Wheezo Asthma Study; Creso: DHS Portugal, Spain Marijuana Distributor; M&G Mostly Corrects Mesoblast Substantials; Emvision: Forough Khandan Program Management Head
 
Mesoblast Falls On FDA Remestemcel-L For GvHD Questions; Regeneus: Kyocera $26m Progenza Knee Osteoarthritis Deal; Painchek Raises $10m; Adalta Placement Raises $4m, Rights Offer For $4.1m More; Suda Places $533k; Total $3.56m; Acrux: Harris For US Generic Emla Anaesthetic Cream Sales; Telix Submits TLX101 Glioblastoma Drug Master File To FDA; Nuheara Wins ISO 9001:2015 Certification; Paradigm PPS Orphan Approvals, Regulatory Feedback; Perennial Takes 5.5% Of 4D Medical; Regal Funds Reduces, Diluted To 8.9% Of Visioneering; Impedimed Promotes Timothy Cruickshank To CFO 
 
Atomo: TGA Approves Rapid Sars-Cov-2 Antibody Test; Anatara Uni Of New England Work On Poultry Enteritis; Bard1 Euro Patent Validated In 6 Countries; Medibio Ilumen For Stress US Patent; Emerald, Canopy Deal For ‘Real-World Evidence’ System; M&G: Claims To Reduce To 11% Of Mesoblast; Allan Gray Reduces To 10.1% Of Impedimed
 
Dr Boreham’s Crucible: Exopharm; 4D Opens Up 98% In Oversubscribed $56m IPO For Imaging; Kazia: FDA Rare Kids Disease Status For Paxalisib For DIPG; G Medical $5m Placement; Allegra Improves Spinal Fusion Cage In Covid-19 Delays; South Korea Allows Cynata Cymerus Stem Cell Patent; M&G Reduces To 11% Of Mesoblast; Karst Peak, Adam Leitzes Reduce To 11% In Genetic Signatures; Director Michael Stork Diluted To 7% In Patrys; Painchek Requests ‘Capital Raising’ Trading Halt; Adalta Requests ‘Capital Raising’ Trading Halt; Regeneus Requests ‘Japanese Licencing Deal’ Trading Halt; Prescient Appoints Prof Phillip Darcy Advisor; MGC: ‘In-Vitro Study Backs Artemic For Covid-19’
 
Resmed Revenue Up 13% To $4.1b, Profit Up 32% To $963m; Alcidion: NHS To Use Smartpage For In-House Communication; Imugene Pre-Ind FDA Meeting On Vaxinia (CF33) Pathway; Neuren Plan Raises $200k Of Hoped-For $3m; Total $20.2m; Platinum Diluted To 16% In Amplia; Blueflag, Allan Moss Diluted To 7% Of Amplia; Total Brain Appoints Melissa Frieswick ‘Chief Revenue Officer’
 
Imagion Applies For Magsense Phase I Ethics Approval; Pharmaxis: $9.7m Bronchitol Milestone Payable On US Approval; Heramed Shortfall Raises $1.35m; Total $3.9m; Nova (Ellex) Claims Molteno ‘Utility’ For Glaucoma; Lifespot: ‘Apple Approves Fevertel Thermometer’; Imugene CEO Leslie Chong Exercises 27m Options; Credit Suisse Below 5% In Suda; Uniquest Diluted To 8.6% Of Emvision; G Medical Requests ‘Capital Raising’ Trading Halt; MGC Requests ‘Artemic Pre-Clinical Results’ Trading Halt; Auscann Appoints Nick Woolf CEO; Medlab Appoints Laurence McAllister Director; Adherium Appoints Geoff Feakes CTO 
 
Applications For $300k Gilead Grants Close August 14; Monash Uni, Janssen Oxytocin For Postpartum Haemorrhage; Patrys Underwritten Rights Raise $4.3m; Uscom Ventitest Calibrates Ventilators; Resapp Sleepcheck For Apnoea Available On-Line; Recce: ‘Recce-435 Reduces Helicobacter Pylori In Rats’; Alterity: ATH434 MSA Mouse Safety, Efficacy Presentations; Alterity 49m Director ‘Incentive’ Options EGM; Merchant Funds Takes 12.3% Of Bard1; Stephen Dobson Below 5% In Neurotech; Volpara: Katherine Singson US CEO, Mark Koeniguer Goes
 
July BDI-40 Down 2.4%: Big Caps Down 2.4%, ASX200 Up 0.5%; Hatchtech: FDA Okays Xeglyze For Head Lice (19 Years); Zelira ‘Oversubscribed’ Placement Raises $8.75m; Suda: ‘Oversubscribed’ Rights Raise $3.6m; $533k Placement; Redhill: FDA Allows Phase III RHB-204 For NTM Trial; Prescient Completes 1st PTX-200 For AML Cohort Dosing; Medlab: Nanabis 60% Reduction In Pain; Antisense Files ATL1102 For DMD FDA Orphan Application; Cogstate: Eisai To Link Nouknown With Easiit; THC H1 Receipts Up 123% To $3.2m; Creso H1 Receipts Up 314% To $2.9m; TBG H1 Receipts Of $2.8m; Adherium Receipts Down 22.5% To $2.7m; Regeneus Receipts Of $1.6m; Cann Global Receipts Up 54% To $1.3m; Perennial Takes 6% Of Micro-X; Credit Suisse Takes 9.6% Of Suda; Dr Paul Cozzie Increases, Diluted To 14.2% Of Cardiex; Bard1 Founder Dr Irmgard Irminger-Finger Diluted To 5.16%; Imagion To Release 2.5m Voluntary Escrow Shares; Esense Appoints Winton Willesee Director; Non-Compliance
 
Dr Boreham’s Crucible: Dimerix; Clinuvel Receipts Down 9% To $29m; Pharmaxis Receipts Up 13% To $7.8m; G Medical H1 Receipts Down 13% To $2.2m; Nuheara Receipts Up 44% To $3.4m; Bioxyne Receipts Up 61% To $2.8m; MGC Receipts Up 27% To $2.1m; Optiscan Receipts $1.3m; Correction: Dorsavi; Rhythm Rights For $3.6m To Take Total To $6m; BTC Sells Bio101 For $500k; Azure Completes Phase II NASH, NAFLD Protocol; Scott Kirkland Increases, Diluted To 5% In Emvision; Ryan Laws, Skaha Investments Below 5% In Emvision; Simavita: Tiga 17%, Fifty-Second 16%, Dussman 10%, Chevron 9%; McRae Diluted To 31% In Neuroscientific; Volpara 852k CEO, Director Options AGM; Anteris Pleads Schultz To 31% Fall, But No ASX Query
 
Mark Sullivan Wins Clunies Ross Entrepreneur Award; Cynata CYP-001 2-Year GvHD Follow-Up: 60% Survival Rate; Osprey: GE Healthcare To Distribute Dyevert; Paradigm 10 US Access PPS OA Patients Report Reduced Pain; Starpharma Starts DEP Docetaxel Combination Study; Antisense Plans Euro, US Trials Of ATL1102 For DMD; Aroa: Myriad CE Mark; Symphony FDA Approval; Orthocell Files Celgro Nerve Repair To TGA; Tali Supplies Detect To 1.6k Primary School Children; Mesoblast Receipts Down 18% To $35m; Hydrix Receipts Up 29% To $16m; Starpharma Receipts Up 158% To $7.2m; IQ3 Receipts Up 29% To $7.2m; Elixinol H1 Receipts Down 57% To $7m; Medlab Receipts Up 11% To $6.5m; Cardiex Receipts $5.1m; Bionomics Receipts Down 59% To $3.6m; Dorsavi Receipts Down 36% To $2.4m; Amplia Retail Rights Raise $1.83m; Total $4m; Zelira: 1 Quarter Cash; Capital Raising Trading Halt; Hemideina Wins Federal $660k For Hera Cochlear Implant; Elixinol AGM: 19% Oppose Duff, Ellery Rights; Neuren Appoints Lauren Frazer CFO, Co Sec; Neuroscientific Appoints Prof Dao-Yi Yu Advisor
 
Dimerix: DMX-200 Safe, Reduces FSGS Proteinuria 29%; Clarity Starts Cu-64 Sar-Bombesin Breast Cancer Trial; Ecofibre Revenue Up 42% To $51m, Profit Up 119% To $13m; Total Brain Receipts Up 81.5% To $5m; Proteomics Receipts Up 1.3% To $1.8m; Incannex Receipts Up 18% To $1.4m; Imagion ‘Oversubscribed’ Placement Raises $5m; Nova Eye (Ellex) Pays Investors $61m From Lumibird Sale; Nyrada Receives $1.1m R&D Tax Incentive; Ecofibre Pays $59m For Texinnovate; Cann Global Rights Raise $2.2m Of Hoped-For $4.7m; TBG Exprobe Sars-Cov-2 Test Wins Taiwan Emergency Use; Suda: TGA Approves Zolpimist For Insomnia; Invion Investigates Anti-Cancer Compounds; Bard1 Completes Sienna Acquisition; Cann Group Notes Convert To 17m Shares; Invion Loses CEO Craig Newton, Co-Sec Melanie Farris 
 
Genetic Signatures Receipts Up 85% To $8.8m; Impedimed Receipts Up 21% To $5.4m; Resonance Receipts Up 2% To $3.6m; Pharmaust Receipts Down 7.7% To $3.5m; Osprey: H1 Receipts Down 42% To $1.5m; Hydrix Rights Raise $2m, $1m Placement To Go; Atomo, Access Bio 2m North America Covid-19 Antibody Tests; Optiscan $350k For Microscopes To Unnamed China Customers; Visioneering: Oculus Naturalvue Asia Distributor; Oncosil FDA HDE Application For Bile Duct Cancer; Redhill: Envisionrx Takes Talicia For Helicobacter; Cellmid: Tru Beauty To Distribute Évolis Hair Care In The US; Elixinol Japan Marijuana Deal
 
CSIRO, Doherty Distance From ‘Tier 1’ Sars-Cov-2 Claims; Alcidion Receipts Down 3.2% To $20.8m; Mach7 Receipts Up 65.3% To $17.1m; Medadvisor Receipts Up 16.4% To $9.3m; Telix H1 Receipts Up 27.1% To $2.1m; Respiri: ‘Up To $8m Revenue In 2021’; Cardiex Raises $2.5m; Prescient Share Plan For $6.5m; Proteomics Patents, Trademarks, Secrets & Pricing; Opthea: ‘DME Subgroup Benefits From OPT-302’; Oventus Signs 2 Ontario O2vent Optima Deals; G Medical IDTF In 13 Unnamed US University Hospitals; Heramed Starts Herabeat Trial Recruitment; Respiri Completes Unmarketable Parcel Sale; Imagion Requests ‘Capital Raise’ Trading Halt; Dimerix Requests ‘DMX-200 FSGS Trial Results’ Trading Halt; Ecofibre Requests ‘Acquisition’ Trading Halt; Esense ‘Israeli Research Agreement’ Suspension; Noxopharm ASX Listing Rule 10.11 Breach; Anteris (Admedus) Pleads Schultz To Share Sales; Elixinol Appoints Pharmacann For Australia Marijuana Sales; Little Green Pharma Releases 22.4m Escrow Shares; Elixxir Reduces To 22.1% Of Little Green Pharma; Neurotech Pivots From Autism To Dolce Marijuana; MGC: Mice Survive Artemic For Sars-Cov-2 Toxicology Study; Pro Medicus Appoints Deena Shiff Director 
 
Dr Boreham’s Crucible: Aroa Biosurgery; Aroa IPO Opens Up 87% For Endoform Soft Tissue Regeneration; Immuron Raises $28.1m; Emvision To Raise $9m; Universal Bio H1 Revenue Down 73% To $1m, Loss Up 29% To $4.5m; Alcidion $1.5m Scotland NHS Patientrack Contract; Visioneering: 1st Canada Naturalvue Contact Lens Sale; Dimerix Doses Last DMX-200 Kidney Disease Patient; Factor To Acquire Longmile Vet Tech; David Brookes Chair; Adherium 20% Oppose 20m Chair, CEO Options; Bionomics: Aperion, Angermayer Acquisition AGM; Australian Ethical Reduces To 6.5% Of Prescient; Prescient Requests ‘Capital Raising’ Trading Halt; MGC Takes ‘Artemic Sars-Cov-2 Results’ Halt To Suspension; Mesoblast Appoints Dagmar Rosa-Bjorkeson New York COO; Opthea Appoints Lawrence Gozlan Director; Bard1 Appoints Dr Peter French CSO
 
Clarity Starts 67Cu-Sartate Neuroblastoma Trial; Pharmaxis Submits FDA INDA For PSX-5055 Myelofibrosis Trial; Amplia Appoints Nucleus Networks For Phase I AMP945 Trial; Adalta Begins Dosing AD-214 Lung Disease Trial; Invex: FDA, EMA Advice On Presendin For IIH; Incannex Starts Marijuana IHL-216a Rat Trail For Brain Injury; Cogstate Cognitive Assessments For ERT Trials; Rhythm $2.4m Placement, Rights For $3.6m; Cogstate Receipts Up 4.3% To $41m; Immutep Receipts $7.7m; Anteris (Admedus) H1 Receipts Down 62% To $3.8m; Next Science H1 Receipts Up 31% To 3.6m; Rhinomed Receipts Up 5% To $3.1m; Avecho Pleads Schultz To ASX 86% Price Query; Cardiex Requests ‘Capital Raising’ Trading Halt; Esense Requests ‘Israel Coronavirus Deal’ Trading Halt
 
Qbiotics Doses 1st Australian Head, Neck Cancer Patient; Immuron To Raise $28m; Somnomed Receipts Down 5.6% To $61.5m; Cellmid Receipts Up 29% To $8.2m; Atomo Receipts Up 456% To $2.7m; Micro-X Receipts Up 11% To $2.6m; Little Green Pharma Receipts Of $1.8m; Correction: Respiri; Impedimed Launches Sozo For Heart Failure; Emvision Imaging Algorithms Classify Strokes; Imagion: Iron Oxide Nanoparticles Enable Low-Field MRI; Osteopore, QUT Licence For 3-D Printed Bone Implant; Zelira, CVSCM Marijuana Deal For PAD, Diabetic Neuropathy; PYC Completes CPP Toxicity, Mouse Studies; Race Granted 4th US Bisantrene Patent; Botanix Tells ASX 22% Aware Query: FDA Info Held For 10 Days; Invex Requests ‘Regulatory Advice’ Trading Halt; MGC Requests ‘Artemic Pre-Clinical Results’ Trading Halt; Noxopharm Receives $130k From Lind, CST Facility; Adalta Appoints Dr David Fuller Director; Tali Appoints Expert Advisory Board
 
Mesoblast: US FDA Remestemcel-L Paediatric GvHD Review; Telix Receives $11.4m R&D Tax Incentive; Genetic Technologies Raises $7.3m; Bod Receipts Up 205.1% To $3.6m; Clarity, Imaginab Work On Antibodies For Cancer; Heramed Expands Mayo Pregnancy Platform Deal; G Medical, Homestay Deal For Remote Patient Monitoring; Invex: Exanatide US Patent For Intracranial Pressure; Immuron: ‘IMM-124E Antiviral Activity Against Sars-Cov-2’; Up 250%; Prescient: Doherty Tests 2 Unnamed Drugs For Sars-Cov-2; Respiri: Zip Co Wheezo Price $336 Over 6 Months; Zelira EGM: 22% Dissent To 150% Directors’ Fees Hike; Neuroscientific To Release 19.3m Escrow Shares; Everbest, Constellation Take Loss, Below 5% In Anteris (Admedus)
 
Uniquest, CSL Collaborate On Sjögren’s Syndrome; Micro-X: US FDA 510(K) Approval For Rover Mobile X-Ray; Ecofibre Receipts Up 27% To $43.0m; Optiscan: Federal $971k For Oral Cancer Screening Trial; Uscom: 1a Detects Early Pre-Eclampsia; Adalta: Data, Phase I Design ‘Sufficient For FDA Application’; Immuron: FDA Guidance To US Navy For Campylobacter, E Coli; Federal Court Okays Sienna, Bard1 Merger; Goodbye Sienna; Noxopharm: ‘NOX66 Increases Immune Cells In Tumors’; Patent; Correction Recce: 327 For CSIRO Sars-Cov-2 Program, Not 529; Genetic Technologies To ASX: ‘Covid-19 Details In Prospectus’; GI Dynamics: Crystal Amber $14m, 4 Directors To Go, Quit ASX; MGC: $1.4m For Cannvalate’s Medicinal Cannabis Clinic; Respiri: Buy-Now-Pay-Later Zip Co For Wheezo; Little Green Marijuana Permit; Prescient Requests ‘Collaboration’ Trading Halt; Zelira Requests US Licence Agreement Trading Halt; Heramed Takes ‘Material Collaboration’ Halt To Suspension; Peter Meurs Diluted To 12.6% Of Dimerix; Credit Suisse Below 5% In Kazia; Everbest, Constellation Take 5.5% Of Anteris
 
Dr Boreham’s Crucible: Hydrix; Federal $32.5b Takes MRFF To $20b Target; AAMRI Response; Russia, Israel Approve Redhill Opaganib Covid-19 Trial; Alcidion: ACT Health $1.3m 2-Year Contract Extension; Cann Group Raises $14.3m, Plan For $10m More; Receipts Up 17%; Genetic Technologies Placement For $7.3m; Palla: $8m UK Contract; Norway Facility Applies For Approval; THC Share Plan Raises $1.5m, Total To $8.1m; Respiri Appoints Cipla Australia, NZ Wheezo Distributor; Imugene: 2nd PD1-Vaxx Lung Cancer Trial Approval; Auscann Unmarketable Parcel Facility; Ecofibre: 2 US Trials Of CBD For Neuropathy, Agitation; Botanix, FDA Agree BTX1503 Acne Phase III Endpoints; Incannex IHL-675a Reduces Ards Sepsis, In Mice; Rhythm Requests ‘Capital Raising’ Trading Halt; Factor Takes ‘Potential Acquisition’ Halt To Suspension; G Medical AGM 57% Block 75m CEO Dr Yacov Geva Shares; HK’s Star Bright Takes Loss To 12% Of Anteris (Admedus); Cann Group Appoints Jenni Pilcher Director; Biotron Appoints Dr Stephen Becker CMO; Bio-Melbourne Hosts Regenerative Medicine Webinar
 
Bluechiip: ‘Labcon Unlawfully Terminates Supply Deal’; LBT Installs First UK APAS Independence; Biointelect: ‘Malaria Tafenoquine Kills Sars-Cov-2, In-Vitro’; Anteotech: Sars-Cov-2, Influenza A, B 3-In-1 Test; Recce, Path To Study Recce 327, 529 For Sars-Cov-2; Althea Full Year Marijuana Customer Receipts $4.6m; G Medical IDTF In 4 Unnamed US University Hospitals; Bod: 500-Patient ‘Observational’ Marijuana Medicabilis Study; Cronos Prepares Asia Marijuana Launch; Genetic Technologies Requests 200% Price Hike Trading Halt; Heramed Requests ‘Collaboration’ Trading Halt; Avita: ATO Class Ruling On US Move; Mason Stevens Takes 5% In Patrys; CSL Appoints Dr Pascal Soriot Director; Leanne Ralph Replaces Visioneering Co Sec Julian Rockett
 
Nyrada Delivers I-V NYX-242, NYX-1010 For Brain Injury, In Rats; Visioneering H1 Receipts Down 4.7% To $3.3m, Pandemic Effect; Osprey Halts $2.7m Rights Shortfall; Total Raised $12.8m; Sienna EGM Overwhelmingly Backs Bard1 Acquisition; Immutep Granted US Patent For IMP701 For Cancers; GI Dynamics: Crystal Amber Converts $7.7m Note; To Delist; Factor Requests ‘Potential Acquisition’ Trading Halt; Incannex Requests ‘IHL-675A Ards Animal Results’ Trading Halt; Cann Group Requests Capital Raising Trading Halt; Respiri Requests ‘Commercial Agreement’ Trading Halt; Merchant Funds Takes 9.3% Of Race; Naos Takes 24.8% Of BTC; W Whitney George Takes 41.5% Of Rhinomed; Bonvoyolo Reduces To 5.85% Of Neurotech; L1 Below 5% In Creso
 
Polynovo: Barda $21.6m For Novosorb BTM Trial; Pharmaxis: FDA Orphan Status For PXS-5505 For Myelofibrosis; Queensland Uni: 1st Covid-19 Volunteer Dosed; Vaccine Next Year; Alcidion $686k Murrumbidgee Miya Precision, Memre Contract; Mach7 Completes $41m Client Outlook Acquisition; Zelira Phase I ZTL-103 Marijuana Pain Trial ‘Safe, Tolerable’; Imugene Phase I PD1-Vaxx Trial For Lung Cancer Approved; Neuroscientific: Emtin B Increases Myelin Formation, In-Vitro; Heramed Share Plan Raises $233k, Total $2.55m; Nuheara Pleads Schultz To ASX 75% Price Query; ATO Sienna-Bard1 Merger Capital Gains Tax Relief; MGC Licence To Grow Marijuana For RMIT Research; Bluechiip Takes ‘Labcon Agreement’ Halt To Suspension; Anteotech Requests ‘Life Sciences Development’ Trading Halt; GI Dynamics Requests Crystal Amber Note Trading Halt; Regal Funds Below 5% In Medical Developments; Recce’s Dr Graham, Olga Melrose Take 25.3%; Platinum Takes 19.89% Of Amplia; Allan Moss, Blueflag Take 8.7% Of Amplia; Race Director Dr William Garner Diluted To 11.4%; Recce Appoints Dr Alan Dunton Director; Imagion Loses CFO Brian Conn; CFO Wanted
 
Avita: Barda Orders $13.2m Recell Systems; Uscom Customer Receipts Up 59% To $4m; Correction: Cynata Therapeutics; MTP To Run Federal $47m Diabetes, C-V Program; Federal $50k For Patrys, ONJCRI PAT-DX1 For Breast Cancer; Race: Williams, Emmanuel, Merchant Commit To $3m; Luina, Xing Work On Point-Of-Care Sars-Cov-2 Test; Imagion Joins Boston Uni’s Nanosystems Research Centre; Clinuvel: Prenumbra For Unnamed Acute, Systemic Diseases; Heramed: Ready For Joondalup Herabeat Trial; LBT Appoints Oneservice APAS Service Provider; Pharmaust: Monepantel Dog Cancer Trial Report With Elanco; Avecho: 31% Opposition To Equity Incentive Plan; Living Cell Tells ASX: ‘Not Material Info Sent Price 50%’; Cann Global Releases 706m Shares From ASX Escrow; Nuheara 6m Director Options AGM; Zelira Issues 12.5m Chairman, Director Performance Rights; Regal Funds Reduces To 5% Of Medical Developments; Jamber, James Schwarz Sells All 10m Esense Shares; Chifley Reduces To 8.7% Of Esense; Cochlear Loses CFO Brent Cubis; CFO Wanted; Invion Appoints Melanie Leydin CFO; Melanie Farris Director
 
Dr Boreham’s Crucible: Cynata Therapeutics; Compumedics ‘Covid-19 Hits Revenue’ Down 15% To $36m; Avita Unaudited Revenue Up 164% To $21m; Polynovo: FDA Requests More Novosorb Trial Information; Polynovo: ‘Record Novosorb US Sales’ In June, First UK Sale; Correction: Rage Biotech; Creso: Mernova $901k Israeli Marijuana Order; Memphasys: Canadian Felix Approval Vests 11.2m Options; Bluechiip Requests ‘Labcon Agreement Trading Halt; JM Financial, No Plan B Take 14% Of Universal Biosensors
 
Rage: IP Group, Monash, UWA Up To $10m For Lung Disease; LBT Placement For $8m, Share Plan For $1m More; Medibio Applications For $513k, $1m Shortfall; Total $2m; Orthocell Ortho-ATI Tendon Injury Survey: 87.5% Satisfied; Race Requests ‘Placement’ Trading Halt; Kinghorn Joins Starpharma Dep-Irinotecan Trial; Incannex Applies For Marijuana IHL-42X Sleep Apnoea Trial; Cellmid Tells ASX: ‘Wondfo Extension Not Material’, Up 30%; Cellmid To Distribute Immunodiagnostics Sars-Cov-2 Tests; Eleanore Goodridge Reduces To 9.6% In Nyrada
 
Greenlight: Trials Resilient Despite H1 18% Fall; Telix, Reflexion Combine Cancer Technologies; Telix: FDA Supports, Clarifies TLX591 Prostate Cancer Trial; 4D: $56m IPO For XV Respiratory Imaging; Recce 327, 529 In CSIRO, Doherty Sars-Cov-2 Program; Medlab Share Plan Raises $1.6m Of Hoped For $4m, Total $7m; Allegra Details Sr-Ht-Gahnite Patents; Visioneering Pleads Schultz To ASX 100% Price Query; Althea: Concierge For Online Marijuana Sales; MGC Granted Australian Marijuana Import Licence; CVC Sells All 24m Universal Biosensors Shares; Esense Issues Blue Science 10m CDIs
 
CSL Enrols 1st Patient In CSL312 Phase II Covid-19 Trial; LBT: Beckman Coulter Markets APAS In Europe; Trading Halt; Cyclopharm: H1 Sales Down 13.8% To $5.6m, Underlying Up; Esense: Blue Science US Terpenes Sanitizer Distributor; Total Brain: 3.8m Louis Gagnon, Dr Evian Gordon Options EGM; Cellmid Requests ‘Distribution Agreement’ Trading Halt; Life Biosciences Diluted To 25% Of Alterity; Lazard Takes 6% Of Mayne; Pyxis Takes 8% Of Lifespot
 
Mesoblast: US Allows Remestemcel-L For Covid-19 Children; Nyrada: ‘Oral NYX-PCSK9I Equals Injectables For LDL, In-Vitro’; Cogstate: $66m Clinical Trials Sales Contracts; Biotron: ‘BIT225 Enhances HIV-1 Immune Response’; Mayne: Novast Supply Agreement For 13 Contraceptives; Dimerix Advances DMX-700 Program For COPD; Allegra Acquires Sydney Uni Sr-Ht-Gahnite Patents; Cardiex Restructures Inhealth Collaboration; Creso Redeems 1.2m Kunna Non Performance Shares; Recce Requests ‘Research Agreement’ Trading Halt; Thorney, Tiga Increase, Diluted To 27% Of Visioneering; Eleanore Goodridge Below 5% In Noxopharm; Erlyn Dale, Winton Willesee Replace Esense Co-Sec James Bahen
 
Dr Boreham’s Crucible: Mesoblast; FDA Approves 4 Cochlear Nucleus, Custom Sound Products; Amplia Institutional Rights Raise $2m, $2m Retail To Go; Suda Rights Offer For $3.6m; Neurotech $500k Placement For Marijuana For Autism; Ecofibre: US Marijuana Neuropathy Trial Starts; Osprey Pleads Schultz To ASX 77% Price Query; GTG Tells ASX: ‘Early Media Release No Material Impact On Price’; Cann Receives $2m Victoria Regional Jobs Grant; Cann Global Rights Offer For $4.7m; MGC EGM: 23.5% Oppose Share Ratification; Oventus: 50% Directors Pool Hike, 6.9m Director Options EGM; Naos Takes 24% Of BTC Health; Anthony Grist, Oaktone, Denlin Below 5% Of Invex; David Hunnon, Chifley Take 12% Of Esense; Recce Founder Dr Graham Melrose Retires; Paradigm Appoints CMO Dr Donna Skerrett Director; Bionomics Appoints Apeiron’s Aaron Weaver Director; Peter Hatfull Replaces Esense Director Piers Lewis
 
Affinity Claims ‘Antibodies Block Sars-Cov-2’, In-Vitro; Alterity Placement Raises $1.6m; Ellex (Nova Eye) Pays $921k For Molteno-3 Glaucoma Device; Dorsavi: QBE $250k, 12-Month Visafe Deal; Actinogen Pleads Schultz, Alterity To ASX 59% Query; Resapp Raises $1.4m From M-D Dr Tony Keating Options; Osteopore Appoints Bioplate US Distributor; Oncosil Files For TGA Pancreatic Cancer Device Approval; Bod Q4 Marijuana Revenue Up 100% To $2.5m, YTD $6m; Incannex (Impression): $1.5m Maiden Marijuana Sales Revenue; THC: Medleaf Pays $260k; Expects Canada, European Orders; Neurotech Requests ‘Acquisition, Capital Raising’ Halt; Paul, Eleanor Stephens Below 5% In Rhinomed; Apeiron, Christian Angermayer Take 13% Of Bionomics; Mark Lampert, BVF Diluted To 17% Of Bionomics; Creso Chair Boaz Wachtel Below 5%; MGC Expands Artemic Covid-19 Trial To India; Cellmid Extends Wondfo Covid-19 Distribution
 
14-Year Data: Big Caps Up 963%, BDI-40 Up 450%, ASX200 Up 16%; Telix: FDA TLX250-CDx Renal Cancer ‘Breakthrough’ Status; LBT: Johns Hopkins - Apas Independence ‘No False Negatives’; TGA Approves Next Science Bactisure Surgical Lavage; Alterity Pleads Schultz To ASX 2,077% Query; ASX Misses 300%; Mach7 Retail Rights Raise $11.4m; Total $34.8m; Alcidion $560k Sydney Miya Precision Deal; Amplia Under-Written Rights For $4m; Resapp Partners With Coviu, Phenix; Medadvisor, Hms Integrate Health Platforms; Gi Dynamics Extends $6.6m Crystal Amber Note, Again; Cronos Launches 2 Medical Marijuana Oils In Australia; Creso CEO Miriam Halperin Wernli Below 5%; Suda Appoints Phillip Hains Joint Co-Sec; Alistair Warren Replaces Little Green Co-Sec Craig Basson
 
Race: Independent Mouse Study Backs Bisantrene For Cancer; Alterity, FDA Discuss Phase II ATH434 MSA Study Endpoints; Amplia: No Toxicities To Prevent AMP945 Phase I Trial; Redhill: UK Approves Opaganib Phase II/III Covid-19 Trial; Invion Receives 1st Guilin Pavay Cosmetics Order; Ellex Completes $97m Lumibird Laser, Ultrasound Sale; Orthocell Recruits Ortho-ATI Rotator Cuff Trial; Elixinol 1.36m Oliver Horn, Helen Wiseman Rights AGM; Factor Potential 2nd Strike Board Spill AGM; Resapp: Kenya’s Ilara Health Evaluates Resappdx; Australian Ethical Takes 12% Of Ellex; Pyxis Takes 6% Of Lifespot 
 
Neuren Raises $20m, Share Plan For $3m More; Immutep Doses Tacti-002 Study Part A; Avita US Move Completes July 1; Resapp US Defence Health Analytics Program Closes; Starpharma: DEP-Irinotecan Anti-Tumor Activity, In Mice; Amplia Requests ‘Tox Studies’ Trading Halt; Medlab: UK Orders 5k MG Optima Relax Marijuana Units; Resapp Launches Sleepcheck Apnoea Risk Application; Creso: 15m Shares To Mernova For Sales Licence Milestone; Thorney, Tiga Increases, Diluted To 13.9% Of Oventus; L1 Capital Takes 7.4% Of Creso; Little Green Pharma Ships Marijuana Oil To UK; Dr David Brookes Replaces Tali Director Mark Simari; Suda CEO Dr Michael Baker Appointed Director
 
Dr Boreham’s Crucible: Race Oncology; Zucero: ZU545 ‘Potent Activity’ Against Covid-19, In-Vitro; Respiri, Edinburgh Uni Partner For Data; Ellex $100m Lumibird Laser, Ultrasound Sale Finalized; Lifespot: 42% Remuneration Report 1st Strike; Cogstate Appoints John Glueck Co-Co Sec
 
CSL Pays $656m+ For Uniqure’s AMT-061 For Haemophilia-B; Visioneering Share Plan Raises $1.1m; Total $6.1m; Suda: ASX Halts Cancer Drug Acquisition, Back-Door Listing; Lifespot: TGA Registers Fevertel Thermometers; Neuren Requests ‘Capital Raising’ Trading Halt; Adherium 23m Director Options EGM; THC To Supply Marijuana To Medleaf NZ; Antanas Guoga Sells All 3.4m Opyl Shares
 
Pfizer $720m For Clinical-Stage Biotechs; Federal $36m For Rare Disease Projects; Rhinomed Underwritten Rights Raise $6.5m; Aroa 2-Day $45m IPO For Endoform Soft Tissue Regeneration; Mayne: US FDA Accepts E4/DRSP Contraceptive NDA; G Medical: 1st Italian Prizma Order; Botanix Resumes BTX1801 Recruitment; Althea: Drug Science Referral For UK Marijuana; Creso Ups Canada Medical, Party Marijuana Production; ‘Freeman Road’, Dr Ti Wan Ng Take 5% Of Heramed; Paradigm Loses Chair Graeme Kaufman; Simon Gray To Replace Ellex Co Sec Kimberley Menzies
 
Tali: Tali Detect Valid, Reliable Attention Diagnostic; Anatara: No Detach Partner By July; Invion: NZ Patent For Photodynamic Cancer Therapy; Clime Takes 9.1% Of Mach7; Australian Ethical Takes 5.5% Of Mach7; Eleanore Goodridge Reduces To 6.4% Of Noxopharm; MGC: 3-Year GMP Licence For Slovenian Facility
 
Victoria: Jaala Pulford Innovation, Medical Research Minister; Vic Aamri Welcomes 1st Dedicated Minister For Medical Research; THC Raises $6.6m, Share Plan For More; Dimerix Placement Raises $5.8m; Kazia: ‘Paxilisib Beats Temozolomide For Glioblastoma’; Tali Competes Monash Uni Research; Works With Duke; Imagion: 1st Magsense Breast Cancer Trial; Azure Prepares For IVB003 Pancreatic Cancer Trial; Emerald To Use Binah Tech For Covid-19 Vaccine Trial Monitoring; Patrys 1-For-3 Rights For $4.3m; Immutep Receives $1.4m R&D Tax Incentive; Federal Court Approves Avita US Move; GI Dynamics: EGM Backs ASX Delisting; Genetic Technologies: US Genetype Breast Cancer Test Patent; Althea, Collective To Manufacture Marijuana Beverages; MGC Unmarketable Parcel Facility; Medlab: Sean Hall 22%; Michael Hall 6%, Drew Townsend 6%; Star Bright Reduces To 21.6% Of Anteris (Admedus); Bionomics Chair Dr Errol De Souza Full-Time, Pro-Rata Pay Cut
 
Dr Boreham’s Crucible: Emvision Medical Devices; Redhill Expands Euro Opaganib Covid-19 Trial, US Trial Begins; Opyl Raises $739k; Nuheara Begins Shipping 5k Iqbuds Max; Noxopharm: East Europe Covid-19 Trial; Immuron, CSIRO Work On US Defense Bacterial Preventatives; Sienna Appoints Aenorasis For hTERT In Greece, Cyprus; GI Dynamics $1.1m Crystal Amber Convertible Bridge Note; Imagion: 10m CEO ‘Performance’ Rights, 6m Options AGM; Director Peter Anastasiou Reduces To 7% Of Immuron; Cronos Loses Director, COO Peter Righetti
 
Victoria, First State, Roc $250m Business Fund; Oventus ‘Over-Subscribed’ Share Plan Raises $2m, Total $6.65m; Cynata 440-Patient, Phase III Cymerus Osteoarthritis Trial Approved; Anteris (Admedus) Receives $735k R&D Tax Incentive; Lifespot Placement Raises $300k; Telix Resumes Phase III Zircon Trial In Europe; Acrux, Amring Unnamed Generic Drug Deal; Resapp, Reckitt Benckiser Cough Diagnostic MOU; Dimerix Requests Capital Raising Halt; Patrys Requests Capital Raising Trading Halt; Opyl Requests Capital Raising Trading Halt; Emerald Requests ‘Real World Evidence Platform’ Halt; Pie Funds Takes 5% Of Probiotec; Director Dennis Eck Takes 10% Of Cellmid; Noxopharm Chair Dr Graham Kelly Increases, Diluted To 17%; Eleanore Goodridge Takes 8% Of Noxopharm; Esense, Wise Wine J-V For Terpene-Infused Sanitizer; MGC Sells Nutraceuticals To Onassis For $9m In Shares; Pharmaust: ‘WEHI Confirms Monepantel For Sars-Cov-2 In-Vitro’; Respiri Pays Ex-CEO Mario Gattino ‘Immaterial’ Settlement
 
MTP Claims Sector ‘Hit Hard’ By Covid-19; Biocurate, Uniseed Join Forces For Commercialization; Speedx: Roche To Distribute Infectious Disease Tests; Dimerix Completes Phase IIa DMX-200 For FSGS Trial Dosing; Starpharma: DEP-Lutetium ‘Significant For Cancer’ In Mice; Anteris (Admedus) Heart Valve Feasibility Pig Study; Prescient: 2 US PTX-200 Patents For Leukaemia, Breast Cancer; Zelira, Levin Marijuana For Athletes With Chronic Pain; Zelira 150% Directors Fees Hike EGM; Rhinomed: FIRB Okays Whitney George To Underwrite $6.5m; Race Agrees To Buy-Back $800k Dr Peter Molloy Loan Shares; GI Dynamics Extends $6.6m Crystal Amber Note, Again; Kenneth Biddick, Authentics Australia Below 5% In Immuron; Regal Funds Increases, Diluted To 10% Of Visioneering; CSL To Lose CFO David Lamont; Bio-Melbourne Network Appoints Jeff Malone CEO; Bio-Melbourne Forum On Fast Coronavirus Vaccine Project
 
Race: Bisantrene For AML ‘40% Overall Response’; Neuren: Acadia Resumes Phase III Trofinetide Rett Trial; Starpharma: Vivagel BV In Central, Eastern Europe; Memphasys: Felix Sperm Separator Sales ‘On-Track’; Resapp: Phenix Licences Resappdx-EU For Telehealth; Cellmid: $1.2m From Japan TV Hair Loss Sales; Respiri, Pharmacy Guild Asthma Management Course; G Medical CEO Dr Yacov Geva 10m Shares, 65m Rights AGM; Lifespot Requests Capital Raising Trading Halt; THC Requests Capital Raising Trading Halt; Cynata CEO, Director Sell Shares; Australian Ethical Takes 11% Of Ellex; Investors Mutual Below 5% In Ellex; Australian Ethical Takes 17% Of Cogstate; FIL Takes 5% Of Starpharma; PYC: Chair Alan Tribe Aust Land 30%, Director Dr Hockings 9%; L1 ‘Below 5%’ In Creso; Holds 6.3%; Dr Darryl Maher Replaces Cynata Director Peter Webse, Co Sec; Ancila Desai Replaces IDT CFO, Co-Sec Joanna Johnson; Sinead Teague Replaces Exopharm Co Sec David Parker
 
Proteomics: ‘Promarkerd Significantly Predicts Renal Decline’; Avita Overwhelming Backs US Move; Noxopharm Underwritten Rights Raise $7.9m; Medlab Raises $5.4m, Share Plan For $4m More; Azure (Invictus) Prepares IVB001 Nafld, Nash Study; Cellmid: Wondfo Covid-19 Test 86% Sensitive; Doherty Says 69%; Perennial Takes 7.4% Of Atomo; One Funds Takes 8.4% Of Bluechiip; Cann Group Issues CSIRO 325k Shares For Marijuana R&D; Cann Global: ‘Marijuana Strain Stops MS In-Vitro’, Mice; MGC, IM Cannabis To Sell Marijuana Cannepil In Israel; THC: Cannatrek To Supply Dried Marijuana Flower; Esense, ANC J-V For Skin Care, Hair Care, Sanitizer; GI Dynamics Requests ‘Crystal Amber Note’ Trading Halt; Pharmaust Takes ‘Sars-Cov-2 Test Results’ To Suspension 
 
Dr Boreham’s Crucible: Alcidion Group; S&P Indices: 14 Biotechs, Australian Ethical Up; 4 Down; Scopus: City Of Hope Drug, Paul Hopper’s Bioscience Oncology; TBG: ‘FDA Approves Sars-Cov-2 Test Emergency Use’; Exopharm Licences NY State, Santa Clara Uni Exosome IP; Mach7 Placement, Insto Rights Raise $23.4m; $11.4m To Go; Ellex: Lumibird $100m Laser, Ultrasound Sale By June 30; Race Requests ‘Trial Results’ Trading Halt; Esense Requests ‘Joint-Venture’ Trading Halt
 
ACCC Allows Lumibird Ellex Lasers, Ultrasound Acquisition; Azure Acquires Invictus; Redhill Applies For Russia Opaganib Covid-19 Trial; Medlab 1st Nanocbd Patient; ‘Capital Raising’ Halt; Creso Welcomes Israel Marijuana Legalization Proposals; Sienna, Bard1: Federal Court Approves Merger; Lifespot Appoints Bodytel Software Distributor; Proteomics Requests ‘Results’ Trading Halt; Pharmaust Requests ‘Sars-Cov-2 Test Results’ Trading Halt; Cann Global: 3rd ‘Research Initiatives’ Suspension Extension; Fil Increases, Diluted To 7.4% Of Adherium; Jamber Increases, Diluted To 8.5% In Creso
 
Opthea Claims OPT-302 DME ‘Non-Significant’ Success; Bio-Melbourne: Dr Andrea Douglas Wins Leadership Award; Adalta Ready For AD-214 For Lung Disease Trial; Telix: New TLX591-CDx Data For US NDA; Immuron Pleads Schultz To ASX 442% Price Query; Mach7 Capital Raise To Buy Client Outlook For $41m; Micro-X Submits 510(K) To FDA For Rover Mobile X-Ray; Medibio Placement Raises $500k, Rights For $1.5m More; Rhinomed: Unnamed US Drug Store Orders Pronto Clear; Painchek Applies For Canada Pain Assessment Clearance; Avita Scheme Meeting To Move To The US; Osprey Option Exercise Dates; Creso Completes Due Diligence To Sell Marijuana In Canada; Adherium: Trudell 15%, One Funds 8%, Phillip Thematic 5.5%; Orthocell Appoints Dr Leslie Wise Executive Director
 
 
Dr Boreham’s Crucible: Volpara Health Technologies; CSL, UQ, CEPI Collaborate On Covid-19 Vaccine Candidate; Atomo: Rapid Covid-19 Test Australasia Distribution Rights; Heramed Raises $2.3m; Share Plan For $1.5m More; Painchek Receives 2nd $1.25m Federal Payment; LBT Cuts Costs, Reduces Work Week, Pay 20%; FIRB, Federal Approval For Avita US Move; Cyclopharm AGM Votes On 1m M-D Incentive, Loan Shares; Medibio Requests ‘Capital Raising’ Trading Halt; Suda Takes ‘Licencing, Capital Raising’ Halt To Suspension; Proteomics Requests ‘Clarification’ Trading Halt; JM Financial, No Plan B Increase, Diluted To 14% Of Mach7
 
Dimerix DMX-200 Joins Remap-Cap Global Covid-19 Ards Study; ASIC: Insider Trading - Ex-Sirtex CEO Gilman Wong 3 Year Bond; Azure Notes Raise $1.7m For Invictus; Correction: Paradigm; Clarification: Impedimed; LBT Apas Independence For MRSA 6-Month FDA Delay; Osprey Requests ‘Shortfall Placement’ Trading Halt; Pfizer Australia Hosts ‘Post-Covid-19’ Webinar; Lazard Takes 5% In Mayne; Regeneus Loses 5-Year Director Dr Glen Richards; Zelira US CEO Dr Oludare Odumosu Starts On $217k; Cellmid: ‘Emergence Deal For Covid-19 Tests’; Pharmaust: ‘Monepantel Suppresses Sars-Cov-2 50-95% In-Vitro’
 
Clarity: 67cu-Sartate FDA ‘Rare Disease’ For Neuroblastoma; Impedimed: BIS ‘Significant Lymphoedema Detection’; Nuheara: $2m In Iqbuds Max Pre-Orders; Medlab Receives 1st Nanabis From Tasmanian Alkaloids; Creso: DHS To Distribute Cannaqix Marijuana In Brazil; Impression Drops Mouthguards For Marijuana; Cann Global 2nd ‘Research Initiatives’ Extension Suspension; Regal Funds Reduce To 6% Of Medical Developments; Regal Funds Reduce To 10.7% Of Opthea; Perennial Takes 6.4% Of Atomo; Paradigm: Dr Jeannie Joughin COO, Dr Michael Imperiale Safety; Mayne Appoints Toni Nesci Head Of Contract Services
 
Federal $66m For Covid-19 Projects; Applications Open For $2.5m CSL Centenary Fellowships; Avita Submits Pivotal Recell For Vitiligo IDE To US FDA; Bionomics Apeiron, Rights To Raise $22m, 2 Directors, 50% Fee Hike; Resapp: German Hospital To Evaluate Resappdx-Eu; COPD Study; Sienna: Triolab Sweden hTERT Bladder Cancer Test Distributor; Respiri Unmarketable Parcel Facility; Lazard Below 5% In Mayne; Anthony Grist, Oaktone Reduce, Diluted To 5.3% Of Invex; Invex Chair Dr Jason Loveridge Below 5%; Regal Funds Reduces To 11.4% Of Visioneering; Elixinol Chair Paul Benhaim, Raw With Life Diluted To 28%; D&G, David Newman, Gabriel Ettenson Reduce To 6% Of Elixinol; Telix Appoints Dr Colin Hayward Chief Medical Officer; Clarity Appoints Dr Michael Ironside Director Of Operations; Dimerix Requests ‘Covid-19 Trial Opportunity’ Trading Halt; Pharmaust Takes ‘Sars-Cov-2 Results’ Halt To Suspension; Impression Marijuana, Hydroxychloroquine Ards Mouse Trial
 
Biotech Fully Recovered: May BDI-40 Up 14%, ASX200 4%; Big Caps Down 6%; Vaxxas: Merck $18m For No Needle Vaccine, Harro Höfliger; Protagonist Early Data Backs PTG-300 For Polycythemia Vera; Pro Medicus $22m Northwestern Memorial Visage 7 Deal; Mesoblast: 2010 Osiris Data Backs Stems Cells For COPD, Ards; Nuheara Share Plan Raises $4.5m; Oncosil: Singapore Approval For Pancreatic Cancer; Kazia: 1 Paxilisib Glioblastoma Patient Progression-Free; Immutep: Tacti-002 - IMP321 Improves Efficacy For Cancers; Immutep: 4 Of 12 Patients Partial Response To IMP321, Avelumab; Noxopharm: 10 Of 16 Reduce Pain In Veyonda Prostate Study; Creso Placement Raises $2.1m; Micro-X Completes Rover Mobile X-Ray Tests For Military Hospitals; Heramed Requests ‘Capital Raising’ Trading Halt; Suda Requests ‘Licencing Transaction’ Trading Halt; THC Completes Tetra Medical Marijuana Acquisition; Visioneering: 22% Oppose Placement Facility; Regal Funds Reduces To 7% Of Medadvisor; Prescient Appoints Dr Allen Ebens Director; Race Appoints Phillip Lynch Director; Cellmid Appoints Dr Dominic Burg COO
 
Dr Boreham’s Crucible: Nanosonics; Volpara Receipts Up 153% To $12m, Loss Up 73% To $19m; Immutep Receives $3.6m French R&D Tax Incentive; Acrux: Trupharma 6 Products US Distributor; Micro-X Ships $500k Nano Units In May; Mayne: Mithra To Supply E4/DRSP Contraceptive In Australia; THC Prescribes 1st Australian Marijuana; Niv Dagan, Freedom Trader, 10 Bolivianos Take 9.4% Of Lifespot; Micro-X Loses Co Sec Georgina Carpendale; Medadvisor Loses Simon Chamberlain, Victor Kovalev; Osprey 250% ‘Incentive’ Shares Hike In Lieu Of Fees AGM; Pharmaust Requests ‘Sars-Cov-2 Pre-Clinical Results’ Halt 
 
Federal $9.5m For Endometriosis; Mesoblast YTD Revenue Up 113% To $48m, Loss Down 34% To $68m; Imugene: Mimotope Vaccine Identifies PD1 Cancer Antibodies; CSL Leases Swiss Facility To Thermo Fisher; Osprey: Dyevert Reduces Contrast-Induced Kidney Injury; Cryosite Pleads Schultz To ASX 57% Query; ASX Misses 57%; Palla Tells AGM: $1.3b EU Codeine Market; G Medical Clarifies News Article: Not ASX Delisting; Stemcell, Temasek Seagrape Farming Deal; Esense, Sealaria J-V For Terpene, Red Algae Sanitizer; Invex: Forrest, Tattarang 11%; JK, Tisia 6%; McAuliffe Below 5%; Mark Licciardo Replaces Palla Co Sec Jaime Pinto; Situations Vacant: Medical Developments - International BDM
 
Cynata ‘Pleased’ By $11m Bids For $2m Plan; Total $8.4m; Genetic Technologies Raises $12m; CSL Rolls Out Additional Influenza Vaccine Supplies; Cyclopharm: FDA Approval To File NDA For Technegas; Neuren Loses Chair Dr Richard Treagus To BTC Health; Suda: ‘Spray Increases Anagrelide Bioavailability’; Recce Pleads Schultz To ASX 54% Price Query; Respiri: 65% Refuse Director Termination Benefits; Medibio, Partners For Health Settle Legal Action; GI Dynamics: ASX Consent To Delist; Acrux Requests ‘Licence’ Trading Halt; Creso Requests ‘Capital Raising’ Trading Halt; M&G Reduces To 12% Of Mesoblast 
 
Prescient Licences U-Penn, Oxford Uni Tech For Omnicar; Cyclopharm: 1st Technegas Sales In Russia; Imagion: ‘Magsense Manufacture On-Time Despite Covid-19’; Oncosil Rights, Shortfall Raise $5m; Total $19m; Elixinol Rights Raise $5.6m; Total $10.9m; Bioscience Managers Raise $5m For Adherium; LBT Draws Down Final South Australia Government $1.5m; Tasmanian Alkaloids Manufactures Zelira Marijuana Products; MGC: Israel Phase IIb Cannepil Epilepsy Trial; Palla Terminates UK Codeine Customer Acquisition; Owed $3.5m; Cann Group, IDT Supply Marijuana Products To Astral, Iuvo; Shunho Terminates Elixinol Hemp Foods Acquisition; Impression Name Change, 7.5m Shares, 205m Options, 32m Rights EGM; GI Dynamics ‘ASX Delisting’ Trading Halt; Allianz Takes 5% Of Starpharma; Lazard Takes 5% Of Mayne; Medical Developments Appoints Christine Emmanuel Director
 
Uniseed $3.5m For Ferronova Cancer Detection; Exopharm: ‘Plexaris Improves Anti-Cancer Drug In-Vitro’; Correction: Invex; Mesoblast: 3 Trials Support Ryoncil (Remstemcel-L) For GvHD; Medical Developments: Hungary Approves Penthrox For Pain; Resonance Files Provisional Patent For Liver Disease; Nyrada: ‘Compounds Reach Mouse Brain, Block Calcium Build-Up’; Goodbye Admedus, Hello Anteris; Proteomics Receives $200k For Covid-19 Research; Aeroflow Hires Regional Health For Oventus O2Vent; Blackcrane Reduces To 6% Of Avita; Carestream Below 5% In Micro-X; Anteotech Progresses Silicon Lithium Batteries; Prescient Takes ‘Material Licence’ Trading Halt To Suspension; Cann Global Extends ‘Research Initiatives’ Suspension
 
Dr Boreham’s Crucible: Invex Therapeutics; Antisense: ‘ATL1102 Duchenne Muscular Dystrophy Success’; Invex Placement Raises $26.2m; Applications Open For $316k Victoria Prizes, Fellowships; Botanix 39m Directors ‘Incentive’ Options EGM; Cellmid EGM Faces 13% Dissent Against Broker Options; Impedimed Pleads Schultz, ‘Broker Reports’ To ASX 37% Query; G Medical Receives $1.35m US Paycheck Protection Loan; Paul Cozzi Takes 14.5% Of Cardiex; Opyl Takes ‘Contracts’ Trading Halt To Suspension; Probiotec: Sandy Beard Chair, Jonathan Wenig Director; Cardiex Appoints CFO, Co Sec Jarrod White Director
 
4D: FDA Clears XV Lung Ventilation Analysis Software; Vivazome, Cytiva Deal For Exosome Purification Technology; TBG: CE Mark For Sars-Cov-2, Covid-19 Tests; Sienna Appoints Zotal For hTERT Bladder Cancer In Israel; Alterity: ‘ATH434 Potential MSA Efficacy In Humans’; Prescient Requests ‘Material Licence’ Trading Halt; Caledonia Reduces, Diluted To 6.6% Of Alcidion; THC: Canndeo Marijuana Available By Script In Australia
 
Federal $400m For 267 Medical Research Projects; Invex: ‘Exanatide Significant Reduction In ICP’; Clarity: 64Cu-Sartate For Neuroblastoma FDA Orphan Status; G Medical ECG Patch Wins FDA Covid-19 ‘Emergency Use Status’; Imagion, Siemens Work On Nanoparticle MRI Contrast; Mach7: Qatar’s Hamad Medical $4.2m Imaging Renewal; Suda: Japan Patent For Anagrelide For Cancer; Opyl: ‘Covid-19 Puts Focus On Digital Data’; Trading Halt; Heramed, Freeman Road, Phi Pilot Foetal Heart Monitor Studies; Antisense Requests ‘ATL1102 DMD Trial Results’ Trading Halt; Cann Global Takes ‘Research Initiatives’ Halt To Suspension; Regal Funds Below 5% Of Oncosil; Race Loses Founder, CEO Dr Peter Molloy
 
US Court Denies Cochlear Patent Appeal, To Pay $429m; Amplia: AMP945 Wins FDA Orphan Status For IPF; Imagion Nanoparticles For HIV Treatment; BTC Infusion Kit Orders Follow Elective Surgery Rules; Admedus Starts Adapt Anti-Calcification Rat Trial; M&G Reduces To 12.5% Of Mesoblast; Oneventures Appoints Dr John Westwater, Kelly Constable; Justyn Stedwell Replaces Lifespot Director Andreas Empl; Impression Appoints Rugby’s James Graham TBI Advisor; Noxopharm: ‘FDA Pre-IND NOX66 For Covid-19 Trial Submission’
 
MTP Connect: ‘Apply Now For Federal Covid-19 Funds’; Patrys: $2.85m US Grant For PAT-DX1 Inventor; Kyocera Pays Regeneus $1.5m For Progenza OA Due Diligence; Canada’s Careica Health To Refer Oventus O2Vent For Apnoea; Imugene Releases 22m Escrow Shares; GI Dynamics Extends $6.6m Crystal Amber Note To June; Perennial Takes 5% Of Micro-X; Race Requests ‘M-D Dr Peter Molloy Tenure’ Trading Halt; G Medical Requests ‘Product Registration’ Trading Halt; Cann Global Requests ‘Research Initiatives’ Trading Halt; Genetic Technologies Nasdaq Extension; Board Changes
 
Dr Boreham’s Crucible: Telix Pharmaceuticals; Cellmid Responds To Article, Extends Response Suspension; Telix: Pharmalogic To Distribute TLX591-CDx In The US; Thorney, TIGA Take 7% Of Micro-X; GI Dynamics Receives $302k US Covid-19 Paycheck Loan
 
Race, Newcastle Uni Work On Bisantrene Breast Cancer Combo; Anteotech, Axxin Develop Sepsis Multiplex Assay; Nuheara Surpasses 4k Iqbuds Max Pre-Orders; Mach7 $4.8m HAHK Software Order; Telix, FDA Meet For Phase III TLX591 Prostate Cancer Trial; Emvision Restarts Portable Brain Scanner Stroke Trial
 
 
Industry: ‘Federal Jobkeeper For Pre-Revenue Companies’; AAMRI: Research Losing Non-Government Funding; Orthocell Submits Celgro FDA 510(K) Application; Pharmaust: Monepantel ‘Success’ - 1 Dog Tumor Reduced; Suda Adds Drug Supplier To Zolpimist TGA Application; Memphasys Share Trading Increases In Germany; Simavita Extends $1.4m Notes Date To December; THC Acquires Tetra Health For $3m In Cash, Equity; Bod Receives UK Scripts From Project Twenty21 Patients; Paradigm Directors Sell 4.5m Shares To ‘Offshore Investors’; Clime Takes 7% Of Mach7; MGC Extends ‘Distribution Agreement’ Suspension
 
Micro-X ‘Underwritten’ Rights Raise $1.8m Of $6.25m; Rhinomed 1-For-2 Rights Offer For $6.5m; Mesoblast Requests ‘Financing’ Trading Halt; Cochlear: 60% April Sales Fall, Some Reopening, Kids First; Emerald Data Platform Earns $100k For Covid-19 Analyses; Admedus Implants 2nd SAVR Heart Valve Trial Patient; Queensland Clinic Evaluates Resappdx-EU Respiratory Test; Prescient Gains IP Rights To Carina Car-T Cell; Cellmid Takes ‘Media Article’ Trading Halt To Suspension; Bionomics: $10.4m Loan Repayments Deferred 6 Months; Avita: Court Approves Move To US EGM; Karst Peak, Adam Leitzes, Vermillion Below 5% In Avita; FIL Takes 8% Of Genetic Signatures; Walker Reduces To 8% Of Atomo; Allan Gray Reduces To 11% Of Impedimed; FIL Increases, Diluted To 9.5% Of Resapp; Creso Starts Canada Marijuana Sales; Trading Halt; Elixinol: Product Label Class-Action Dismissed; Little Green To Begin Marijuana Extract Production; MGC Takes ‘Distribution Agreement’ Halt To Suspension; Imagion Appoints Dianne Angus Director; Patrys Appoints Dr Peter Ordentlich Advisor
 
Dr Boreham’s Crucible: Cyclopharm; Federal $16.2m For Ovarian Cancer Research; Cynata Cymerus Stem Cell Covid-19 Trial Approved; South Australia Extends LBT $4m Loan Date; Australian Patent For Painchek Smartphone Pain Assessment; Heramed Appoints Medtech Edge Heracare Distributor; Elixinol Sells Nunyara Land For $2.6m; Pharmaust Requests ‘Trial Results’ Trading Halt; THC Requests ‘Acquisition’ Trading Halt; M-D Peter Rowland Below 5% In Micro-X; CM Capital, Australian Super Below 5% In Osprey; Noxopharm Appoints Fred Bart Director
 
CSL $1.2b Loan; Atomo: NG Biotech Orders 422k More Covid-19 Tests; Neuren Starts 1st NNZ-2591 Clinical Trial; Starpharma: DEP-Irinotecan ‘Safe’, Phase II Cancer Trial; Japan Patent For Immutep IMP321 Cancer Combination; Total Brain Receives $1.4m In US, Australian Covid-19 Relief; Cellmid Requests ‘Media Article’ Trading Halt; Noxopharm Requests Capital Raising Trading Halt; MGC Requests ‘Distribution Agreement’ Trading Halt; Australian Ethical Reduces To 10.3% Of Antisense; Australian Ethical Takes 6.6% Of Immutep; Jimmy Thomas, Ivy Ponniah Take 6.6% Of Stemcell United; Auscann To Lose 12-Month CEO Ido Kanyon; Stemcell United Appoints Alan Dronkers ‘Marijuana Advisor’ 
 
Tessara Raises $2.7m To Grow 3-D Brain Tissue; Kazia Share Plan Raises $1.8m; Total $9m; CSL Develops Covid-19 Immunoglobulin For Sars-Cov-2; Mesoblast Doses 1st Remestemcel-L Covid-19 Ards Patients; Cogstate $3.8m US Paycheck Protection Loan; Impedimed $1.8m US Paycheck Protection Loan; Respiri $1m Share Plan Raises $3.14m; Total $5.14m; Elixinol Institutional Rights Raise $5.3m; Retail For $5.6m More; Sienna Appoints Scientle NZ hTERT Bladder Cancer Test Distributor; Resapp Receives Handheld, Wearable Device Files; G Medical: Florida’s All County To Distribute Prizma; Bod: Health & Happiness Orders $1.4m Marijuana For UK; Emvision CEO Dr Ron Weinberger Promoted To M-D
 
Vivazome Licences Adelaide Uni Stem Cells For Exosomes; Pharmaxis Resubmits Cystic Fibrosis Bronchitol NDA To FDA; TBG: China Lifts Export Ban On Covid-19 Tests; Medical Developments Penthrox For Netherlands, Bosnia; Elixinol 1-For-2.51 Rights To Raise $11m At 48% Discount; Rhinomed Requests ‘Capital Raising’ Trading Halt; G Medical: TGA Approves Vital Sign Monitor Patch; Impedimed Appoints David Anderson Director; MGC Starts Artemic For Covid-19 Trial
 
Recce-327: ‘Significantly Reduces Gonorrhoeae In Mice’; IDMC Okays Imugene Phase II Her-Vaxx Cancer Study; Oncosil Placement, Rights Offer To Raise $19m; Oncosil Files For Approval In Singapore, Hong Kong, Malaysia; Nuheara 60% Underwritten Share Plan For $2.5m; Carl Zeiss Pays Optiscan Final $171k Convivo Milestone; Kazia Extends Share Plan For Late Applications; GI Dynamics Potential Delisting, Extends Crystal Amber Note; Neuroscienfitic: ‘Emtinb Not Toxic’; Bod: 1st UK Marijuana Medicabilis Prescriptions; Allan Gray Reduces, Diluted To 12% Of Impedimed; Paradice Investments Diluted To 6.5% Of Impedimed; Regal Funds Reduces To 12% Of Visioneering; Noxopharm Chair Dr Graham Kelly Increases, Diluted To 21%; Eleanore Goodridge Increases, Diluted To 7% In Noxopharm; Pharmaxis Appoints Dr Neil Graham Director; Oncosil Appoints Nigel Lange EMEA Head
 
Biotech Bounces Back: April BDI-40 Up 28%, ASX200 9%, Big Caps 3.5%; Correction: Atomo Diagnostics; Federal Government, Minderoo $67m For Childhood Cancer; Resmed Q3 Revenue Up 16% To $1,191m, Profit Up 47% To $291m; 4DX, Adelaide Uni, SAHMRI Develop Covid-19 ‘Field’ Ventilators; Telix Submits TLX591-CDX Prostate Cancer Euro File; Clinuvel Prepares US Scenesse For Vitiligo Application; Ellex: ‘ACCC To Review Lumibird Acquisition’; Oventus $4.65m Placement, Share Plan For $2m More; G Medical ‘Oversubscribed’ Placement Raises $6m; Neurotech Pleads ‘Covid-19 Tests’ To ASX 71% Query; Opyl Receives $201k R&D Tax Incentive; Medigard: ‘Lack Of Cash Threatens Kunovus KT009 Licence’; Althea: Nimbus To Sell Marijuana In Germany; Baillie Gifford Reduces To 6% Of Cochlear; Australian Ethical Diluted To 6% Of Impedimed; Perennial Reduces To 5% Of Atomo
 
Dr Boreham’s Crucible: Atomo Diagnostics; Mesoblast Starts Remestemcel-L Covid-19 Trial; Genetic Signatures: Sars-Cov-2 Test Record $1.8m Q3 Revenue; Paradigm Completes Zilosul US Program, MPS-1 Orphan Status; Cogstate Wins $1.3m For Memory Impairment Test; Uscom, A&D Partner For New Uscom BP+ Module; THC $4m Mitchell Loan; Nuheara Requests Capital Raising Trading Halt; Elixinol Requests Capital Raising Trading Halt; Australian Ethical Takes 7.8% Of Impedimed; Bellwether Takes 5% Of Bluechiip; Medibio Files FDA 510k Medsleep ‘Sleep Stage’ Application; Respiri Talks Wheezo With Practice Innovators; Noxopharm Claims: 4 Of 15 Patients ‘Abscopal Response’
 
Cochlear $50m Share Plan Raises $220m; Total $1.1b; Immutep Placement Raises $12m; Osprey Wins $2m US Covid-19 Paycheck Protection Loan; Osprey Rights Raise $10.2m Of Hoped-For $15.5m; Visioneering: $5m Placement; Share Plan For $1m More; Adherium, Monaghan US Sales Deal For Hailie Sensors; Oncosil Requests Capital Raising Trading Halt; G Medical Requests Capital Raising Trading Halt; Allan Gray Reduces To 17% Of Impedimed
 
Immutep: 9 Of 17 Tacti-002 Patients Respond To IMP321, Keytruda; Impedimed Retail Rights Raise $8.2m; Total $18.2m Of $24.9m; Pharmaxis Plans Phase II PXS-5505 Myelofibrosis Trial; Thailand Approves Medical Developments Penthrox; Qbiotics Euro Launch Of Stelfonta For Dog Cancer; Imagion Follow-On Placement Scaled-Back; Total Raised $2.5m; Azure, Invictus Fail Spread Rule For $10m Raising; Probiotec: Covid-19 Swings & Roundabouts; MGC $3.5m Placement; Auscann THC, CBD Marijuana Study Begins; Oventus Requests ‘Capital Raising’ Trading Halt; GI Dynamics Has One Quarter Cash; Neurotech 2nd Extension Of ‘ASX Price Query’ Suspension; Australian Ethical Reduces To 11% Of Antisense; Regal Takes 6% Of Micro-X; MGC Claims 2nd Israel Artemic ‘Covid-19’ Trial Site
 
Imugene To Start Phase I Vaxinia, PD1-Vaxx Trials This Year; Telix, Osaka Develop 2nd Generation TLX101 For Cancers; Immutep Requests Placement Trading Halt; Medadvisor Launches Telehealth, Home Delivery Service; Heramed: FDA Allows Herabeat Sales Amid Covid-19; Oventus Claims Covid-19 Benefits Sales; 6 New Sites; Australia, Japan Allow Cellmid Évolis Patent For Alopecia; Tasmanian Alkaloids Supplies Marijuana To Avecho; Australian Ethical Reduces To 12% Of Antisense; Elixinol CEO Oliver Horn Starts On $395k; Immuron Directors Cash Cut, Replaced With Shares; Avecho Appoints Dr Paul Gavin CEO, Dr Roksan Libinaki COO
 
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals; Mesoblast: MSCs Show Ventilator-Dependent Covid-19 Benefit; Correction Onko-Innate; Cardiex: 4 New Waveforms A ‘Major Milestone’; Botanix: Cannabinoid BTX1801 For Infections Wins FDA QIDP; Ellex EGM Backs Asset Sale, Name Change To Nova Eye Medical; Imagion Requests ‘Placement Correction’ Trading Halt; MGC Requests ‘Capital Raising’ Trading Halt; Adherium Appoints Mike Motion CEO, Anne Bell CFO; Global Health Takes 11% Of Atomo; Peter Rubinstein, Irwin, Rip Below 5% In Genetic Technologies
 
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies; Imagion ‘Oversubscribed’ Rights Raise $3m; Clinuvel, Winhealth Launch Scenesse For EPP In China; Canada Special Access Use Of Polynovo’s Novosorb BTM; SDI: Covid-19 50% Profit Warning, Cost Cutting; Admedus: More Than Two Quarters Cash; Recce: ‘Recce-327 Reduces MRSA Load, Heals Wounds In Rats’; Visioneering Requests Capital Raising Trading Halt; Cryosite Director Andrew Kroger Takes 40.3%; TDM Growth Partners Takes 23% Of Somnomed; G Medical Hires Fosun, Boustead For Nasdaq IPO; Polynovo Appoints CEO Paul Brennan Managing Director; Impression To Trial Marijuana IHL-216A For Brain Injury; Noxopharm Claims Isoflavonoid For Glioblastoma
 
 
Doherty Starts 2,500 Patient ‘Ascot’ Covid-19 Trial; Redhill Provides RHB-107 To US Agency For Sars-Cov-2; Emvision: ‘Preliminary Brain Images Correlate With CT, MRI’; Polynovo Novosorb BTM: ‘Up To 100% Wound Closure’; Volpara Placement Raises $28m; $7m Share Plan To Go; Genetic Technologies Raises $2.3m, Total $5.3m; Avita To Move To Us; Visioneering Receives $1.6m US Covid-19 Relief Loan; NSW Expands Impedimed Sozo Lymphoedema Prevention Program; Invitrocue Wins CE Mark For Onco-PDO Cancer Test; US Patent For Tali Attention Deficit Products; Adherium, Planet Innovation Develop Remote Sensors; Livecare To Distribute G Medical Prizma Device; Cardiex Requests ‘Sensor Development’ Trading Halt; Platinum Diluted To 10% Of Kazia; Cann Group 5-Year Marijuana Supply Agreement With Pure Cann; Neurotech Extends ‘ASX Price Query’ Suspension; Noxopharm Receives $409k From Cancelled Loan; Elixinol: Oliver Horn In, Stratos Karousos Out, Helen Wiseman; More Covid-19 Claims: Medlab, Noxopharm
 
Biotech Daily Editorial: Covid-19 Spruikers, Please Stop !
TGA Approves Osteopore Bone Void Fillers; Sienna Licences Sub-B2m For Cancer From Adelaide Uni; Recce-327 ‘Significant’ Anti-Influenza Activity In Mice; Neuroscientific: Mitsubishi To Manufacture Emtinb; Rhinomed Receives $337k R&D Tax Incentive; Bard1 Receives $464k R&D Tax Incentive; Re-Analysis Backs Impedimed BIS For Lymphoedema Prevention; Cynata Requests ‘Capital Raising’ Trading Halt; Avita Requests ‘Re-organization’ Trading Halt; Atomo: Kelly 13%, Walker 10%, Perennial 6%, Ellerston 6%; Craig Darby Takes 12% Of Emerald Clinics; Creso Pays Cohen $409k, Takes $1m Lind Facility; Abby Macnish Replaces Neuroscientific Co Sec Thomas Spencer
 
 
 
Atomo IPO Opens Up 95% With Covid-19 Antibody Test Orders; Starpharma: ‘SPL7013 Inhibits Sars-Cov-2 Infection Of Cells’; Recce Requests ‘Anti-Viral Results’ Trading Halt; Osteopore Requests ‘Regulatory Approval’ Trading Halt; Goodbye Benitec; Proteomics CE Mark For Promarkerd Immunoassay; Mayne US NDA For E4-DRSP Oral Contraceptive; Clinuvel Launches Scenesse In US; Botanix Drops Dermatology For Antimicrobial Targets; Acrux Corrects ‘Non-Material’ TGA Deficiencies; Batavia Develops Immutep Imp761 Cell Line; Adherium, HGE Work On Remote COPD Management; Anteotech Receives $967k R&D Tax Incentive; Regal Funds Takes 11% Of IDT
 
Volpara, Ambry Partner For On-Line Genetic Testing Orders; Impression: Marijuana, Hydroxychloroquine For Covid-19 Ards; Invion: ‘Photosoft Anti-Tumor Response In Mice’; Allegra Has Orders For 105k Face Shields; Nuheara: Malaysia Resumes Post-Covid-19 Iqbuds Production; Impedimed Launches Heart Failure, Kidney Disease Sozo Software; Bionomics Recruits 90-Patient BNC105 Colorectal Cancer Trial; MGC: Swiss Micelle Deal ‘Nothing To Do With Covid-19’; TBG Tells ASX: ‘Miscommunication’ On Now-Banned Covid-19 Test; Anteotech Pleads Schultz, RDTI To ASX 42% Query; Micro-X Requests Capital Raising Trading Halt; Little Green Exports ‘1st Australian Marijuana Oil’; Simavita: Dussman 21%, Thirty-Fifth 6%, Chevron Diluted To 13%; Stemcell Appoints Dr Kevin Yee Chang Chinese Medicine Advisor; Benitec Appoints Edward Smith Director
 
TGA Approves Genetic Signatures Sars-Cov-2 Test Kit; Cellmid Receives 12k Wondfo China Covid-19 Antibody Tests; FDA Waives Cyclopharm $4.5m Technegas NDA Fee; Avecho, Purisys Deal For TPM Marijuana; Painchek FDA Pre-De Novo Application; Bioxyne Directors 50% Pay Cut, Revenue Up 7%; Respiri, Phenix Partner For Wheezo Telehealth; Esense Everblu Loan Notes, Placement Raise $1.15m; Creso Issues 10.8m Collateral Shares To L1 Capital; Bod Launches 4 Marijuana CBD Capsules In UK; Admedus 2nd Name Change (To Anteris), Staff Incentives AGM; Telix 200k CEO Options AGM; Creso, Highnoon, Route 2 Pakistan Marijuana Distributors; G Medical Reconsidering Nasdaq Listing; Jencay Takes 8% Of Ellex; Neurotech Takes ‘ASX Price Query’ Trading Halt To Suspension; Adherium Appoints James Ward-Lilley Chair, Mike Motion COO
 
CSL, SAB Partner For Covid-19; Plasma, Finance Update; Mesoblast Trials Remestemcel-L For Covid-19 Ards; Bard1 To Acquire Sienna; Kazia Raises $7.2m, Share Plan For More; Platinum Takes 12.6% Of Kazia; Recce Phase I Safety Trial Of Recce-327 Antibiotic; Eye Co: Covid-19 Puts Fludrocortisone Study On Hold; Medibio Completes 4th Compass Ilumen Pilot Study; Neurotech Requests ‘ASX Price Query’ Trading Halt; Esense-Lab Extends Everblu $50k Notes Loan Suspension; Cryosite Director Andrew Kroger Takes 40.2%; Genetic Technologies Chair Dr Muchnicki, MJGD, JCM Below 5%; Probiotec Chair Geoff Pearce Retires
 
Adherium: ‘Untimely Death Of Chair Thomas Lynch’; US EPA Approves Next Science LMN8 Surface Disinfectant; FDA Expedites Cochlear Nucleus 7 Remote Check; Paradigm Raises $35m; Imagion Receives $2.2m R&D Tax Incentive; Telix: Cardinal For TLX591-CDx For Prostate Cancer US Sales; Polynovo: Australia Grants 4 Novosorb Patents; Immutep: EOC Advances IMP321 For Breast Cancer In China; Uscom, Uni Of Tasmania Partner For ‘Ideal’ BP Study; PYC: ‘CPP Safe, Less Toxic In Mice’; ASX Suspends MGC For Swiss Marijuana Covid-19 J-V Queries; G Medical Extends Magna Notes To April 30; US FDA Grants G Medical Prizma O-T-C Approval 
 
Micro-X Wins $1.2m Covid-19 Orders For Nano X-Ray Systems; CSL, Takeda Lead Covid-19 ‘Hyperimmune’ Alliance; Redhill: Italy Okay For Opaganib For Covid-19, Israeli Treated; Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’; Polynovo: ‘Novosorb BTM Beats Burns Benchmark’; Polynovo: ‘Despite Covid-19, Q3 Sales Up’; $9m Loan Facility; Proteomics Expands To Sars-Cov-2, Retinopathy, Cancer; Nuheara Iqbuds Max US, EU, Canada, Australasia Approvals; Volpara: 2020 ‘Annual Recurring Revenue’ Up 172%; Kazia: Paxalisib ‘Meaningful Extension Of Life’; Finance; Cellmid Pleads ‘Ignorance’ To ASX Query; $6m Placement; Cochlear: Up To 30% Covid-19 Director, Executive Pay Cuts; Optiscan Pleads Schultz To ASX 87% Query; Althea’s Peak Processing Canada Marijuana Application; Creso Delivers $215k Of Anibidiol To Virbac; Esense-Lab Takes $50k Everblu Loan Halt To Suspension; Amplia Releases 18.5m Voluntary Escrow Shares; Lumyna Below 5% In Oncosil
 
FDA Clears Mesoblast Remestemcel-L For Covid-19 Ards; FDA Clears Admedus Adapt Cardiac Expansion; Genetic Technologies Raises $3m; Resonance Files FDA 510(K) For Hepafat-AI; Avita: Treatments Continue Despite Covid-19; Q3 Revenue Up; Rhinomed Expands US Products, Distribution; Medlab, Randall Food Additives Deal; FDA Tells Paradigm: ‘2 Phase III Trials’, Capital Raising; China Bans TBG Unregistered Covid-19 Test Export; Rhythm Passes ISO13485 Audit; G Medical Prizma Italian Registration, Taiwan Permit; Cellmid Takes Capital Raising Trading Halt To Suspension; Perennial Takes 9% Of Genetic Signatures; Regal Funds Takes 8% Of Medadvisor; Elixinol: Benhaim Chair; Horn In; Duff, Ellery Out; Resapp Appoints Dr Michael Stein Director; MGC Reduces Salaries Up-To 50%
 
Dr Boreham’s Crucible: TBG Diagnostics; Atomo ‘Oversubscribed’ IPO Raises $30m, EU Covid-19 Test Sales; Impedimed: Pay Cuts, US SEC ‘No Action’, Opportunity Talks; Impedimed Institutional Rights Raise $10m; Osprey Part-Underwritten Rights Offer For $15.5m; Telix Completes Belgium Facility Purchase; Dimerix Takes $1m Radium R&D Tax Incentive Loan; Emvision: ‘Covid-19 Pauses Patient Enrolment’; Factor Rebuffs Ramcap J-V ‘Preliminary’ Proposal; Polynovo Requests Trial Result, Funding Trading Halt; Veritas Takes 5.6% Of Cochlear; Tribeca Below 5% In Bod Australia; Azure Extends Invictus Raising Closing Date, Delisting; Esense-Lab $50k Everblu Capital Loan For Working Capital; MGC 7th Marijuana Covid-19 J-V Suspension Extension
 
CSIRO Begins Testing Covid-19 Vaccines; Impedimed Rights For $25m; Genetic Technologies $3m US Placement; Orthocell: ‘Ortho-ATI Patient Symptom-Free At 12 Months’; Bard1, Griffith Uni Work On Cancer Diagnostics; Rhythm Colorectal Cancer Test ‘Key Biomarker’ Validated; Neuren: Israel Patent For Trofinetide; Avita: 9 Recell Burns Abstracts Published; IDT Completes Marijuana Oil Stability Testing; Cellmid Requests Capital Raising Trading Halt; Paradigm Requests ‘US FDA Update’ Trading Halt; Australian Ethical Reduces To 13.5% Of Antisense; Medadvisor Director Josh Swinnerton Reduces To 6%; TDM Takes 23% Of Somnomed; Visioneering: ‘Covid-19 Cuts Staff, Delays Launches’; MGC 6th Marijuana Covid-19 J-V Suspension Extension 
 
Covid-19 Hits All Indices: March BDI-40 Down 23%, ASX200 21%, Big Caps 5%; CE Mark For Genetic Signatures Sars-Cov-2 Detection Kit; Alcidion $1.5m, 5-Year Extension To NHS Fife Patientrack Deal; US FDA Accepts Mesoblast Ryoncil GvHD Application, Priority; Osprey Requests Capital Raising Trading Halt; Dorsavi, Theranow Deal For Physiotherapy Telehealth; Genetic Technologies: 100 Breast, Colorectal Cancer Kit Sales; Oncosil Pancreatic Cancer Device CE Mark, UK ‘Breakthrough’; PYC In-Vitro Models ‘Effectively Treat Retinitis Pigmentosa’; Medlab Completes Depression Trial, Results By July; Resapp Sleepcheck At-Home Sleep Apnoea Test; Exopharm: ‘Covid-19 Halts Plexoval Wound Healing Study’; Noxopharm Claims Idronoxil ‘Blocks Covid-19 Cytokine Storms’; Palla UK Business Option Expires, Talks Continue; China Trademark For Tali Train, Detect; Bod Receives $851k R&D Tax Incentive; Creso Wins $896k Univo Israel Order For Canadian Marijuana; GI Dynamics Extends Crystal Amber Note; Perennial Ceases In Rhinomed; Karl Pechmann Replaces Oncosil CFO, Co Sec Nicholas Falzon; Paul Stephenson Replaces Stemcell Director Ee Ting Ng
 
Proteomics, Janssen Expand Diabetic Kidney Study; Impedimed 1st US Cancer Centre Sozo Order; Medadvisor Launches Telehealth Service; Bye-Bye Benitec; Auscann Starts THC-CBD Dose Study; Nuheara: ‘Covid-19 Cuts Staff, Executive Salaries 50%’; Pharmaust: ‘Covid-19 Halts 3 Dog Trial Sites’; G Medical ‘Product Registration’ Halt, Report Suspension; Elixinol ‘Rebrands, Refreshes’ Products; MGC 5th Marijuana Covid-19 J-V Suspension Extension; Clarity Appoints Clinical Development Group 
 
Genetic Signatures Sars-Cov-2 Test ‘In Use, Pending Approval’; Cellmid Sells China Covid-19 Antibody Test; Sales Guidance; Cyclopharm Files FDA NDA For Technegas; LBT Files FDA 510(K) For APAS Independence MRSA Module; Mesoblast: 70-Patient Sub Study: Revascor Beats Saline; Opthea Completes OPT-302 Combo Trial For DME; Resapp, Coviu Integrate Tele-Health Respiratory Diagnostic; Suda: ‘Artimist On Hold Indefinitely’; Benitec: Court Approves US Move, FIRB Trading Halt; Pro Medicus Buys-Back 34k Shares, Renews 10% Buy-Back; Bod, Swisse Launch 9 Hemp Seed Oil Products; Lifespot Pleads Schultz, Fever Talks To ASX 306% Query; Impedimed Requests Capital Raising Trading Halt; PYC Requests ‘Material Results’ Trading Halt; Micro-X Appoints David Knox Director; GI Dynamics Loses Director Timothy Barberich; Resapp Loses Director Nathan Buzza; Esense Loses 5-Month Director Michael Edwards 
 
Dr Boreham’s Crucible: Zelira Therapeutics; Resmed Ramps Up Covid-19 Ventilator, Mask Production; Anteo Rights Raise ‘Excellent’ $2.15m Of Hoped-For $3.2m; Admedus Implants 1st SAVR Trial Aortic Stenosis Patient; Regal Funds Reduces To 6% Of Medadvisor; Morgan Stanley, Mitsubishi Cease In Opthea; Adalta Loses Dr Wilson, Dr Williams, $805k R&D Loan, Fees Cut; MGC 4th Daily Marijuana Covid-19 J-V Suspension Extension; G Medical Requests ‘Product Registration’ Trading Halt
 
Cochlear Placement Raises $880m Above Expected $800m; Somnomed Institutional Offer Raises $9.7m; Respiri Placement Raises $2m, Plan For $1m More; Alterity Placement Raises $123k; Immutep: IMP321, Paclitaxel Fails Breast Cancer Endpoints; MCRI 4k Health Worker Tb Vaccine Trial For Covid-19; Micro-X: Covid-19 Ramps Demand For DRX Nano, Production Up; Medadvisor Covid-19 Delivery Service For At-Risk Patients; Tali Digital: 13.9% Of Children Show Inattentive Performance; Cardiex Increases Bayer Contract $423k; Allegra: ‘Covid-19 Hits Revenue’; BTC Withdraws H1 Guidance Due To Covid-19 Restrictions; Actinogen: ‘Covid-19 Halts Occupancy Study Enrolment’; Exopharm: ‘Covid-19 Revises Development Programs’; Genetic Signatures Requests ‘Covid-19 Testing’ Trading Halt; Creso Delivers 1st Cannaqix Shipment To South Africa; Benitec Meeting Approves US Move; Avecho Defers AGM; ASIC Covid-19 Advice; Karst Peak ‘Takes’ Auckland Trust’s 14% Of Neuren; Lifespot Requests ASX Price Query Trading Halt; Little Green Pharma WA Facility Commissioned; MGC Daily Marijuana Covid-19 J-V Suspension Extension; Ferris, Knowles Replace MRCF Stockdale; Beattie Director; Noxopharm Appoints Boris Patkin Director
 
Prevatex, Barwon: ‘Mum’s P Copri Prevents Food Allergies’; Cochlear Placement, Share Plan For $850m; $150m Loan; Immutep: ‘IMP321 Improves Paclitaxel For Breast Cancer’; Amplia: FDA Orphan Status For AMP945 For Pancreatic Cancer; Botanix BTX1204 For Eczema Fails Endpoints; Zucero Investigates ZU545 Covid-19 Efficacy; Impression Plans Phase IIb IHL-42X For Sleep Apnoea Trial; Somnomed $15.5m Rights Offer For Covid-19 Impact, Working Capital; Imagion $2m Rights Issue, Director Bronwyn Le Grice Goes; Cardiex $1.5m Mitchell R&D Loan; Dorsavi: Covid-19 Cuts Staff Hours 30%, Expenses 20%; Medibio, DXC Partner For Ilumen Opportunities; Lifespot Adapts Bodytel For (Covid-19) Temperature; MGC Extends Marijuana Covid-19 J-V Suspension, Again; Vanguard Group Takes 5% Of Avita; Tali Appoints 3 Executives; Covid-19 Benefit; Jerry Kanellos Replaces Immuron CEO Gary Jacob - Covid-19
 
Doherty Institute Joins Covid-19 Trials; Pharmalex Trial List; Paradigm Doses 10 US Osteoarthritis Access Patients; Cyclopharm: ‘Covid-19 Boosts Technegas Use’; Compumedics Withdraws Guidance Due To Covid-19; Neuren: ‘Covid-19 Defers Trofinetide Rett, NNZ-2591 Trials’; Heramed: ‘Covid-19 Increases Herabeat, Heracare Demand’; Resapp, Phenix Tele-Health Deal; Ellex EGM For $100m Lumibird Sale; Cellmid ‘Potential Material Contract’ Voluntary Suspension; Creso To Launch Cannaqix Marijuana Instant Tea; Botanix Requests ‘BTX1204 Dermatitis Results’ Trading Halt; MGC Extends Marijuana Covid-19 J-V Suspension; Morgan Stanley, Mitsubishi Take 7% In Opthea
 
Impedimed: Unnamed 470 US Centre Sozo Lymphoedema Deal; Proteomics Identifies Biomarkers For Endometriosis; Regeneus: US Progenza Patent, ‘Covid-19 Link’; Suda: Up-To $870k Mitsubishi Tanabe Zolpimist Insomnia Deal; Clinuvel: April US Scenesse For EPP Launch; Cogstate, Eisai To Launch Nouknow For ‘Brain Health’ In Japan; Auscann Receives $1.2m Federal R&D Tax Incentive; GI Dynamics Proposed Funding EGM; Imagion Requests ‘Capital Raising’ Trading Halt; MGC Takes Marijuana Covid-19 J-V Halt To Suspension; Admedus Quotes $5m, 435k Director Options; Althea Extends Voluntary Escrow Of 10m Shares; Anthony Barton Takes 5% Of PYC, Again; IQ3: Dr Syrmalis, Ms Xu In; Mr Dimitriou, Mr Coolentianos Out; IDT Appoints Director Michael Kotsanis
 
Dr Boreham’s Crucible: Starpharma; Immutep: China’s EOC Recruits IMP321 Breast Cancer Trial; Kyocera Pays Regeneus $1.6m Progenza Milestone; Resonance ‘Controlled Placement Facility’ Raises $2.75m; Impedimed Expands Sozo Texas Lymphoedema Program; Vanguard Takes 5% Of Polynovo; Chair Ron Dewhurst, Kroy Wen Take 5% Of Rhinomed; Cellmid ‘Potential Material Contract’ Trading Halt; Neuren Requests ‘FDA Covid-19 Trial Guidance’ Trading Halt; Rhinomed CFO Sean Slattery Replaces Co Sec Phillip Hains; Total Brain Appoints Simon Poidevin Australasia CEO; Paltoglou, Loftus Replace Mayne CFO, Co Sec Nick Freeman; Timothy Cruickshank Replaces Impedimed CFO Morten Vigeland
 
Luina Bio, Griffith Uni ‘Collaborate On Covid-19 Vaccine’; Atomo: ‘To Develop Covid-19 Rapid Self-Tests’; Victoria Reopens 2 Hospitals For Covid-19; Painchek: 25k Bed Licences Triggers $1.25m Milestone; LBT Study To Validate APAS Independence VRE Module; Biotron Receives $753k R&D Tax Incentive; ASX Suspends TBG, Responds To ASX CE Mark Aware Query; Medibio Completes Sleep Stage Algorithm Test; Cann Global: Obsidian Refinances L1 Notes; Impression: Marijuana Inhalers For Lung Disease; Somnomed Takes Capital Raising Halt To Suspension; Respiri Takes Capital Raising Halt To Suspension; MGC Requests Swiss Covid-19 Marijuana J-V Trading Halt; Regal Funds Takes 13% Of Opthea; Clarity Appoints Prof Oliver Sartor Advisor 
 
TBG: CE Mark For Covid-19 Test, ‘Schultz’ To ASX 1,054% Query; Oncosil: Pancreatic Cancer Device ‘FDA Breakthrough Status’; Race Completes Phase II Bisantrene AML Trial Recruitment; Antisense Trial Database Lock, Results In April; Azure Wins ASX Listing Removal Extension; Neuroscientific: Emtinb Re-Myelinates Ms, In-Vitro; Lumyna Substantials In IDT, Oncosil; Cryosite Director Andrew Kroger Takes 40%; Pendal Group Below 5% In Althea; Next Science Launches On-Line Acne Cream 
 
Bio-Melbourne Covid-19 Breakfast Goes Virtual; US Appeal Court: Cochlear To Pay $437m On Patents; Neuren Defers Partnering For Trofinetide Rett Results; Next Science: Products ‘Kill Covid-19-Like Viruses’, Sales Hit; MGC Share Plan Raises $1m Of Hoped-For $3m; Total $2.1m; Recce: Recce-327 Antibiotic Trial ‘This Quarter’; Noxopharm Veyonda Australian Patent; Clime Takes 6% In Mach7; Investors Mutual Reduces To 8.7% Of Mayne Pharma; TBG Up 93%, Requests ‘Covid-19 Diagnostic Kit’ Trading Halt; Respiri Requests $2m Capital Raising Trading Halt; Somnomed Requests ‘Covid-19 Impact’ Trading Halt; Cann Global Takes ‘Investment’ Halt To Suspension 
 
Cochlear Withdraws Guidance, Freezes Hiring, Spending; Polynovo Files Novosorb BTM Burn Study Results To FDA; Patrys: PAT-DX1 Blood Brain Barrier Mechanism Confirmed; Telix: $500k R&D Grant For Radiation Cancer Drugs; Genetic Technologies Appeals Nasdaq Equity Non-Compliance; Neuroscientific Requests ‘Positive Results’ Trading Halt; Regal Funds Takes 7% Of Medical Developments; CEO Paul Rennie Increases, Diluted To 12% In Paradigm; Mason Stevens Below 5% Of Patrys; W Whitney George Takes 29% Of Rhinomed; Sienna Appoints Prof Geoff McCaughan Advisor
 
Dr Boreham’s Crucible: Qbiotics Group; Cardiex: Astrazeneca, Bayer Expand Xcel In Trials $984k; Visioneering: Canada Approves Naturalvue Myopia Lenses; Botanix: ‘BTX1801 Kills MRSA’; Surgical Infection Trial; Cann Global Requests ‘Institutional Investment’ Trading Halt; Harbour Takes 8% Of Volpara; Director Andrew Kroger Takes 39% Of Cryosite; Zoltan Varga Takes 19.99% Of Total Brain; Paul Wright Replaces Memphasys Director Marjan Mikel; Impedimed Loses Director Gary Goetzke 
 
Federal, Victoria, WEHI National Drug Discovery Centre; Painchek: ‘Business Model Minimizes Covid-19 Impact’; Biotech Daily Editorial: Covid-19 Coronavirus Claims; Biotron: BIT225 ‘Unmasks HIV-Infected Cells’; Little Green Pharma Expands Australian Marijuana Licences; L1 Capital Ceases Substantial In Creso; Auscann Appoints Dr Marc Russo Chief Medical Advisor; Bio-Melbourne Breakfasts On Covid-19 Coronavirus
 
Resapp: FDA Refuses Resappdx-US De Novo Approval; Orthocell: Celgro, Implant Regenerate Bone In Dogs; Admedus: Belgium Approves 1st Human Study Of …; Osteopore To Release 5m ASX Escrow Shares; Mach7 Completes Sentara PACS Installation; Neuroscientific: ‘Potential Emtinb Glaucoma Effect In Pigs’; China ‘Requests Respiri Wheezos For Covid-19’; Cynata Receives Extra $619k R&D Tax Payment; MSCs For Covid-19; Medlab: Marijuana Nanabis Cancer Pain Reduction ‘Significant’; G Medical Prizma Phone Case Blood Glucose Module; Race Director Dr William Garner Reduces To 13%; Merchant Funds Takes 7% Of Race; Medadvisor Appoints Steve Watt Chief Revenue Officer; Creso Appoints Jack Yu, Isaac Allen To Subsidiary Mernova
 
CMRI Collaboration Repurposes Stemetil For Cancer In Mice; Brandon Et Al $53m For George Institute For Chronic Diseases; Redhill Launches Talicia For Helicobacter Pylori; Japan Allows Cynata Cymerus Stem Cell Patent; Mesoblast To Evaluate Stem Cells For Covid-19 Coronavirus; Neuren: NNZ-2591 Phelan-Mcdermid Mouse Trial Significance; Adalta: ‘Targeting CXCRA Could Be Effective In Fibrosis’; Medadvisor: UK Pharmacy Association Backs Reminder Service; Creso Requests ‘Mernova Management’ Trading Halt; Medadvisor: Swinnerton, Wavey, Kojent, Romida Substantials; One Funds Management Takes 7% Of Bluechiip; Race Appoints Prof Didier Blaise Advisor
 
Medlab: ‘Marijuana Nanabis Safe, Efficacy For Cancer Pain’; FDA Grants Immutep IMP321 For Breast Cancer IND; Anteo, Merck KGaA Develop Antobind Europium P-O-C Tests; MGC Doses 1st Patient In Cognicann Marijuana Trial; L1 Capital Takes 5.5% Of Creso; Naos Takes 23% Of BTC; Resapp Requests ‘Regulatory Update’ Trading Halt; Neuroscientific Requests ‘Pig Glaucoma Study’ Trading Halt; Telix Appoints Prof Frederik Giesel Advisor; Medibio Appoints Kelly Trupovic, Dr Stephen Addis
 
Dr Boreham’s Crucible: Covid-19 Coronavirus Special; Neuren: NNZ-2591 Phelan-McDermid Dose Response In Mice; Kazia Completes II GDC-0084 Glioblastoma Trial Recruitment; Race Raises $1.8m; Gilead $300k Fellowship Grants For 7 Projects; Eyepoint Revenue Up 346% To $31m, Loss Down 34% To $86m; Redhill Revenue Down 25% To $9.5m, Loss Up 9% To $64m; Federal Government: 3rd Regional Health Innovation Centre; Azure EGM 99.91% Backs Invictus Acquisition; Director Andrew Kroger Takes 39% Of Cryosite; Universal Biosensors Appoints John Sharman CEO On $480k; Dr John Cullity Replaces Race Chair Dr Bill Garner; Dimerix Appoints Medical Advisory Board; Esense-Lab: Itzik Mizrahi CEO On $236k, James Bahen Co Sec
 
WEHI: WM382 Kills Drug Resistant Malaria Parasite In Mice; Avita Enrols 1st Recell Paediatric Scald Trial Patient; Atomo $30m IPO For HIV Professional, Self-Tests IPO; Micro-X $1m DRX Revolution Nano Orders, Covid-19; Cogstate Claims $9.1m Clinical Trial Contracts In 2 Months; Medadvisor: $825k From 2 US Patient Programs; Respiri Receives 1st 500 Wheezo Asthma Devices; Medlab Requests ‘Nanabis Cancer Results’ Trading Halt; Simavita: Dussman Diluted To 19.9%, Chevron 14%, Heggin 6%; Medical Developments To Lose 10-Year CEO John Sharman
 
Neuren, Acadia FDA Trofinetide Rett ‘Rare Paediatric’ Status; Starpharma Expands Okamoto Vivagel Condom Licence; Race Requests Placement Trading Halt; Botanix Data Analysis: ‘BTX1503 Beats Vehicle For Acne’; Servatus: Hugh Alsop Director, Dr Jessica Allegretti PI
 
Avita Starts Recell Soft Tissue Reconstruction Pivotal Trial; Next Science Bactisure Wins CE Mark; Dimerix DMX-200 Compassionate Use; Canada Patent For Cynata; Clinuvel, FDA Scenesse For Vitiligo Meeting; Bionomics Completes $3m French Subsidiaries Sale To Domain; Correction: Patrys; Noxopharm Doses Last Veyonda Cancer Trial Patient; Cohen Group Ends Creso Israel J-V; Potential Legal Action; Probiotec CEO Wes Stringer Sells 1.7m Shares; THC Expands Medical Marijuana Supply For 6k Patients; Pharmaust Opens 2 More Dog Cancer Trial Centres; Creso Appoints Farmagon Scandinavia Marijuana Distributor; MGC Extends, Amends Onix Brazil Distribution Agreement; Dr David Mazzo Replaces Visioneering Chair Fred Schwarzer; Chow Yee Hok Replaces Invitrocue Director Geoffrey Thomas
 
February BDI-40 Down 14%, ASX200 Down 8%, Big Caps Up 0.3%; Compumedics H1 Revenue Down 2% To $18m, Profit Down To $161k; Admedus Revenue Down 33% To $17m, Loss Down 75% To $6m; IQ3 H1 Revenue Up 46% To $4.3m, Profit To $950k Loss; G Medical Revenue Up 81% To $8m, Loss Down 8% To $23m; THC Revenue Up 80% To $4.8m, Loss Up 36% To $11.7m; Avecho Revenue Up 204% To $4.2m, Loss To $850k Profit; Creso Revenue Up 550% To $3.6m, Loss Down 9% To $15m; TBG Revenue Up 6% To $3.3m, Loss To $620k Profit; Rhinomed H1 Revenue Up 24% To $1.7m, Loss Up 85% To $5.3m; Uscom H1 Revenue Up 4% To $1.5m, Loss Up 97% To $1.5m; Anteotech Rights Offer For $3.2m; Regeneus, Kyocera $1.4m Progenza Deal, $4m Directors Loan; Patrys PAT-DX1-NP Across Blood-Brain-Barrier In Mice; Adalta: Dose Range Confirmed For Phase I AD-214 Study; Heramed: Heracare To Begin Pilot, Clinical Trials; Little Green Launches 4th Marijuana Oil Product CBD50; GI Dynamics Appoints Dr Praveen Tyle Director; Jonathan Hart Replaces Heramed Co-Sec Stephen Buckley
 
Dr Boreham’s Crucible: Immutep; Cryosite H1 Revenue Up 6% To $4.2m, Profit Of $1.2m; Next Science Revenue Up 43% To $6.2m, Loss Up 4% To $22m; Cardiex H1 Revenue Up 15% To $2.3m, Loss Up 44% To $2m; Pharmaust H1 Revenue Down 9% To $1.8m, Loss Up 439% To $485k; Bionomics H1 Revenue Down 40% To $1.8m, Loss Down 43% To $6.4m; Adherium H1 Revenue Up 44% To $1.4m, Loss Down 48% To $4.5m; Bioxyne H1 Revenue Down 4% To $1.4m, Loss Up 11% To $195k; Bod H1 Revenue Up 73% To $1m, Loss Down 50% To $1.4m; Nuheara ‘$1m Iqbuds Max Orders In 2 Months’; Clime Takes 5% Of Mach7; THC Requests ‘Marijuana Permit’ Trading Halt
 
Ex-CEO Mario Gattino, Respiri In Court On Pay; Zelira, Emerald Enrol Marijuana Opioid Reduction Trial; TBG: Zhang Ye Labs Approved Coronavirus Testing Lab; Palla Revenue Up 18% To $54.8m, Loss Up 32% To $7.6m; Mesoblast H1 Revenue Up 43% To $29.4m, Loss Down 32% To $46m; Elixinol Revenue Down 16% To $27.2m, Loss Up To $83.3m; Medadvisor H1 Revenue Up 14% To $4.4m, Loss Up 18% To $5.3m; Medibio Ilumen To Assess Stantec Mental Health; Little Green Appoints Demecan Distributor; Antisense Appoints Dr Gil Price US Consultant
 
Nanosonics H1 Revenue Up 19% To $49m, Profit Down 20% To $6m; Cogstate H1 Revenue Down 13% To $15m, Loss Up 5% To $3m; Polynovo H1 Revenue Up 80% To $10.2m, Loss Up 26% To $2.4m; Clinuvel H1 Revenue Up 11% To $10m, Profit Down 74% To $1.1m; Genetic Sigs H1 Revenue $3.7m, $2.3m Loss; Covid-19 Test; Cyclopharm Revenue Up 5% To $14m, Loss Up To $2.9m; Cellmid H1 Revenue Up 6% To $3.7m, Loss Down 60% To $1.4m; Universal Biosensors Revenue Down 90% To $6.9m, $4.8m Loss; Medlab H1 Revenue Down 18% To $2.5m, Loss Up 89% To $7.1m; Althea H1 Revenue $1.9m, Loss Up 253% To $8.4m; Immuron H1 Revenue Up 59% To $1.6m, Loss Down 6% To $1.5m; Redhill $174m Healthcare Royalty Loan For AZ’s Movantik; Simavita Raises $2.9m; Imagion Nanoparticles For HER2 Breast Cancer Trial; Admedus EGM: 78% Oppose SIO Shares; Admedus 2nd Consolidation – 100-To-1; MGC Supplies Marijuana For Polish Research; Elixxer Takes 23% Of Little Green Pharma
 
Osprey Revenue Up 46% To $5.5m, Loss Up 3% To $24.5m; Total Brain H1 Revenue Up 98% To $2.2m, Loss Down 14% To $3.9m; Invion H1 Revenue Up 58% To $1.9m, Loss Down 10% To $1.2m; Dorsavi H1 Revenue Down 25% To $1.4m, Loss Down 207% To $5.9m; FDA Gives Telix ‘Feedback’ For TLX591-CDx NDA; M-D Fleta Solomon Takes 15% Of Little Green Pharma; Michelle Burke Replaces Ausbiotech Chair Julie Phillips; Biointelect Expands To Melbourne, Hires Staff; Oventus Appoints Jake Nunn Director 
 
Mesoblast: 66% GvHD Patients Respond To Ryoncil At Day-28; Probiotec H1 Revenue Up 33.5% To $44m, Profit Up 65% To $1.8m; Alcidion H1 Revenue Up 12.5% To $8.2m, Loss Up 213% To $1.8m; Starpharma H1 Revenue Up To $5.7m, Loss Down 19% To $5.9m; Resonance H1 Revenue Up 3% To $1.9m, Profit To $1m Loss; Telix Revenue $3.5m, Loss Up 102% To $28m; Uscom: ‘Critical Care Guidelines Back Uscom 1A For Sepsis’; Stryker Leibinger Evaluates Dorsavi Sensors; Clinuvel Singapore Laboratory Expansion; Oventus Appoints Aeroflow Oventus Distributor; Little Green Pharma $10m More Marijuana IPO Opens Down 7%; Simavita Requests ‘Placement’ Trading Halt; Auscann: Clifford Hallam Replaces API As Distributor; Exopharm Clarifies Cevaris Statement; Neurotech Mente Discount Code Referral Program; Regal Funds Below 5% In Oncosil
 
Dr Boreham’s Crucible: Cochlear; Mayne H1 Revenue Down 17% To $227m, Profit To $18.6m Loss; Ellex H1 Receipts Down 6% To $42m, Loss Down 1% To $2.7m; Mach7 H1 Revenue Up 158% To $9.1m, $675k Profit; IDT H1 Revenue Up 10% To $7.2m, Loss Down 51% To $1.2m; Allegra H1 Revenue Up 26% To $2.3m, Loss Up 70% To $817k; Immutep H1 Revenue $7.5m, Loss Down 31% To $6m; Cynata H1 Revenue $4.5m, Loss Down 15% To $2.5m; Resapp Raises $5m; Sienna Rights Raise $2.1m Of $2.5m; Total $3.8m; Paradigm Meets US FDA For PPS Osteoarthritis Trial IND; Noxopharm: ‘FDA Approves Veyonda, Combo IND For Sarcomas’; Telix Loses Odile Jaume, Gains Christian Davis
 
Aroa Launches Myriad For Soft Tissue Repair In US; Impedimed H1 Revenue Up 58% To $2.8m, Loss Up 7% To $12.9m; Mesoblast: GvHD Study Takes Remestemcel-L To Pivotal Trial; Emvision, UQ Win $360k Fellowships; Life Sciences Queensland, India’s Able Collaborate; Resapp: TGA Approves Resappdx-EU Version 2; Exopharm: ‘Cevaris Works For Bladder Dysfunction, Ex-Vivo’; Race Appoints Prof Jaap-Jan Boelens Advisor; Bio-Melbourne Devices, Diagnostics Lab
 
Zelira: ‘Marijuana Reduces Insomnia Severity’; Immutep 8 Of 17 Cancer Patients Respond To IMP321, Keytruda; Medical Dev H1 Revenue Up 14% To $11m, Profit Up 82% To $240k; Avita H1 Revenue Up 95% To $13.5m, Loss Up 35% To $21m; Resapp Requests Capital Raising Trading Halt; G Medical Raises $350k; Opyl: Clinical Trial Predictor ‘Proof Of Concept’; Exopharm: ‘Cevaris Significant For Erectile Dysfunction Ex-Vivo’; Regal Funds Reduces To 5.5% Of Oncosil; Micro-X Appoints Kingsley Hall CFO, Co-Co Sec; Melbourne March Medical Marijuana Meeting
 
Cochlear H1 Revenue Up 9% To $778m, Profit Up 23% To $158m; Somnomed H1 Revenue Up 15% To $33m, Loss To $816k Profit; Paradigm Doses 1st US Zilosul Access Patient; Resapp Completes Handheld, Wearable Prototypes Tests; Bio-Melbourne Loses CEO Dr Julie-Ann White; OBJ Votes For ‘Welfully’ Back Door Listing; Noxopharm, Genesiscare Veyonda Compassionate Access; Auscann Tests Low-Dose Cannabinoid Capsules; Bod Fills 2k Medicabilis Marijuana Scripts In 12 Months; Blackcrane Reduces To 8% Of Avita; BV Healthcare, Ex-Chair Damien Lim Below 5% In Mach7; Amber Schwarz, Jamber Take 11% Of Creso; Ellex Interim CEO Maria Maieli Resigns; Chris Ridd Replaces Medadvisor Chair Peter Bennetto
 
FDA Approves Compumedics Orion Lifespan Meg; Memphasys: ‘Felix Validation On-Track For Clinical Trial’; Nuheara H1 Revenue Down 4% To $1.4m, Loss Up 43% To $5.7m; PYC, Murdoch Uni, Lions Eye $1.2m NHMRC Grant; Zelira Raises $54k, Total $4.6m; Results Trading Halt; Actinogen Receives Extra $650k R&D Tax Incentive; Total $5m; Creso Milestone: To Pay Mernova $900k, 8.3m Shares Vest; MGC Placement, Share Plan For $4m; Cann Global To Raise $419k In Placement; Heramed Details Mayo Monitor Study; Kemper Shaw Below 5% In Imagion; Race Appoints Dr Marinella Messina Clinical Program Head
 
Dr Boreham’s Crucible: CSL; SDI H1 Revenue Up 8% To $40m, Profit Up 12% To $3.5m; Uscom: China Backs Haemodynamic Monitor For Coronavirus; More Mouse Data Backs Invion Photosoft For Cancer; Recce: ‘Recce 327 Beats Kidney, UTI E Coli In Rats’; Noxopharm: Veyonda Prostate Cancer Benefit; Exopharm: ‘Exosomes Could Treat Erectile Dysfunction’; Oventus: US Approves O2vent Optima Reimbursements; Medibio Plans FDA De-Novo, 510(k), CE Mark For Depression, Again; Noxopharm $3m Placement, $5m Loan; MMJ Share Plan For $5m; Proteomics Pleads Schultz To ASX 9% Query; Up 18%; Benitec US Scheme Of Arrangement Meeting; Anthony Huntley Takes 5% Of IDT; Private Portfolio Managers Below 5% In Imugene; Respiri CEO Marijan Mikel Starts On $450k
 
Pro Medicus H1 Revenue Up 16% To $29m, Profit Up 33% To $12m; Micro-X $780k DRX Revolution Nano Orders For Covid-19; MTP Connect Translation Fund Closes March 6; Victoria Innovation Taskforce; Visioneering Revenue Up 74% To $8.5m, Loss Down 25% To $19m; Pharmaxis H1 Revenue Up 36% To $4m, Loss Down 18% To $10m; Cochlear Increases Nyxoah Investment By $13m; Starpharma Vivagel BV In Unnamed Asian Countries; Oventus Launches 3 More US O2Vent ‘Lab In Lab’ Sites; Paradigm PPS For MPS - 9 Months Behind Schedule; MGC Requests Capital Raising Trading Halt; Prof Paul Timpson Joins Amplia Scientific Advisory Board
 
CSL Record H1 Revenue Up 9% To $7.3b, Profit Up 7.5% To $1.85b; CSL Adjuvant For Queensland Uni Covid-19 Vaccine; Uscom Tells ASX: ‘Material Rise In China Orders Not Material’; North Star To Supply Clarity Copper-67; Invictus: US Patent For Tocotrienol Delivery; Exopharm: Plexaris, Cevaris Exosomes ‘Safe’ In-Vitro; Noxopharm Requests ‘Capital Structure’ Trading Halt; Allan Gray Reduces To 13% Of Impedimed; W Whitney George Takes 27% Of Rhinomed; One Funds Management Takes 6% Of Bluechiip; Starpharma Appoints David Mcintyre Director; Doug Huey Replaces PYC CEO Dr Rohan Hockings, On $892k; Respiri Re-Appoints Dr Thomas Duthy Director
 
Cochlear: ‘Up To 7% Coronavirus Profit Warning’; Federal $300k For Melbourne Innovation Summit; Uscom To ASX: ‘China Orders Up 124% From 17 To 38 Units’; Starpharma Receives $4.5m Astrazeneca Milestone; Nyrada: ‘3F Reduces Cholesterol In Mice’; G Medical Hopes To Raise $10m, Cancel $5m Magna Notes; Invitrocue Brazil Joint Venture; Creso To Launch Marijuana Horse Feed; Bod Licence To Import Additional Marijuana CBD Isolates; Opyl, Huumun Digital Products Deal; Unisuper Below 5% In Impedimed; LBT CFO Ray Ridge Replaces Co-Sec Dan Hill; Director Matt Callahan Returns To Botanix, Orthocell; Respiri Loses Director Prof Bruce Thompson
 
US Court: Innate Chris Collins 26 Months Jail; Takeovers Panel; Uscom: Coronavirus China Demand For Uscom 1A; ASX Halt; Clinuvel, FDA To Discuss Scenesse For Vitiligo; UK Nice Briefing Backs Osprey’s Dyevert; Impedimed: NCCN Guidelines Recognize Lymphoedema; Recce: Recce-327 ‘Well-Tolerated In Rats, Dogs’; Heramed, Mayo To Start Herabeat Study; Total Brain Receives $1.3m Federal R&D Tax Incentive; THC To Launch Canndeo Marijuana
 
Dr Boreham’s Crucible: Resmed; Cann Group Convertible Notes Raise $8m; Benitec US Scheme Meeting Court Order; Correction: Opyl; OBJ Extends Export Corp Takeover Date; Alterity Below Nasdaq $Us1 Bid Rule; Cronos COO Peter Righetti Resigns, Continues As Director 
 
Biotech Daily Editorial: 2019-nCoV Coronavirus; Biotron: ‘Evaluating Coronavirus Compounds’; Uscom Pleads ‘Coronavirus Speculation’ To ASX 59% Query; CMRI, GE Healthcare Optimize Gene Therapy Manufacturing; Antisense: ‘DMD Results Open ATL1102 Indications’; Invitrocue: Validation Study, Xylonix, New Cancer Platform; Israel Patent For Cynata Cymerus Mesenchymal Stem Cells; Sienna Appoints Immuno Diagnostic Oy For Finland; G Medical Appoints Meditel Italy Distributor; Creso Develops Oil-Free, Water-Based Marijuana Lozenges; Sienna Promotes CFO, Co Sec Tony Di Pietro To Director; Amplia Board: Lambert On; Behrenbruch, Cooke, Wilkinson Off; Brett Tucker Replaces G Medical Co Sec Steven Wood
 
Federal $32m For Research Innovation Partnerships; Azure Up-To $10m For Invictus Backdoor Listing; Zelira Placement Raises $4.6m; Probiotec: ‘H1 Revenue Up 34% To $44m, Ebitda Up 68% To $6m’; Creso Takes $17.5m L1 Capital Convertible Note; Visioneering 1st Naturalvue Singapore Sale; Memphasys: ‘Felix Sperm Separator Positive KOL Feedback’; Orthocell Canada, Japan Celgro Soft Tissue Patents; Pyxis, Mapletree Below 5% In Neurotech
 
Admedus Sells Adapt Technology To 4C Medical For $1.5m; Resonance Appoints 3DR For Ferrismart In The Us; Cellmid: China Patent For Évolis Hair Growth; Medlab Begins Pay-To-Play Nanabis ‘Observational Study’; Adherium: Trudell 18%, One Funds 10%, Fil 9%, Summatix 7%; Adherium Founder Garth Sutherland Diluted Below 5%; Dorsavi CEO Dr Andrew Ronchi Takes 5%
 
BDI-40: YTD - Up 125%, Big Caps 62%, ASX 20%, NBI 4% - January BDI-40 Up 13%, Big Caps 12% - All Records Broken; Adherium Completes $5.4m Raising; Painchek Receives $798k Federal R&D Tax Incentive; Invion To Supply Skin Care Product To China’s Pavay; Mesoblast Completes US FDA GvHD Application; TGA Reviews Clinuvel Scenesse For EPP; PYC Adds 6 Retinal Drug Delivery Programs; Cronos Takes 51% Of Cannadoc Health; Invictus Euro Patent For Tocotrienols Delivery; Zelira Requests Capital Raising Trading Halt; Elixinol Receipts Down 8% To $33m, Asset Sales; G Medical Receipts Up 106% To $8.1m; Cann H1 Receipts $1.6m; Less Than 2 Quarters Cash; Opyl H1 Receipts Down 3% To $464k; Neurotech H1 Receipts Down 58%; Less Than 2 Quarters Cash; Respiri Has Less Than Two Quarters Cash; Medigard Has Less Than One Quarter Cash; Phillip Thematic Takes 6.7% Of Adherium; James Middleweek Increases, Diluted Below 5% In Adherium; Correction: Crystal Amber Has 73% Of GI Dynamics; Heramed Appoints Alexander Radke US Executive; Respiri Appoints Ludekens, Van Hoof, Dr Shirazi Executives; Neuroscientific Appoints Abby Macnish As Co-Co Sec
 
Dr Boreham’s Crucible: Invion; Resmed H1 Revenue Up 14% To $2.1b, Profit Up 22% To $418m; Avita H1 Revenue Up 95.4% To $13.5m; Clinuvel H1 Revenue Up 2% To $13.5m; Admedus Receipts Down 35% To $18.4m; Medadvisor H1 Receipts Up 33% To $4.8m; IQ3 H1 Receipts Up 17% To $4.4m; Medlab H1 Receipts Up 63% To $4m; Pharmaxis H1 Receipts Up 27% To $4.0m; Osprey Receipts Up 52% To $5.5m; THC Receipts Up 83% To $4.7m; Bioxyne H1 Receipts Up 105% To $2m; Total Brain H1 Receipts Up 12% To $1.7m; Rhinomed H1 Receipts Up 59% To $1.6m; Nuheara H1 Receipts Down 2% To $1.4m; Dorsavi H1 Receipts Down 39% To $1.2m; Noxopharm Less Than 1 Quarter Cash; $26m Facility; Medibio Has 2 Quarters Cash; Esense-Lab Has Less Than Two Quarters Cash; Regeneus Has 1 Quarter Cash; MGC Has Less Than 1 Quarter Cash; Optiscan Meets US FDA For Invivage; Carl Zeiss Orders; EGP Capital Takes 5% Of Adherium; Paul Cozzi Takes 13% Of Cardiex; C2 Diluted To 21%
 
Federal $5m For Lung Cancer Genomics Research; Biotech Daily Appendix 4C Quarterly Reports Policy; Cellmid H1 Receipts Up 54% To $4.8m; Genetic Signatures H1 Receipts Up 25% To $2.9m; Pharmaust H1 Receipts Down 5.6% To $1.9m; Heramed Has Less Than Two Quarters Cash; US Patent For Adalta AD-214 For Fibrotic Disease; Sienna Appoints Dr Raoul Concepcion Advisor
 
Mesoblast H1 Receipts Down 26% To $31.2m; Cogstate H1 Receipts Down 25% To $18m; Next Science $6m Sales, $4.8m Customer Receipts; Telix Receipts Up 44% To $3.6m; Starpharma H1 Receipts Down 3% To $2.1m; Resonance H1 Receipts Up 9% To $1.7m; Adherium Rights Raise $526k Of $5.4m; Expects $2.5m; Botanix Receives $7.6m R&D Tax Incentive; Cann Group Cuts Staff 25%, Costs By $7m; Mildura Facility; Dorsavi, Heathrow Airport Renew Visafe Contract; Emvision Starts Brain Scanner Pilot Stroke Trial; Exopharm Begins Exosome For Wound Healing Study; Cardiex Hires Medl Mobile For Software; Medlab: Tasmanian Alkaloids To Manufacture Nanabis; Respiri Prepares Wheezo US FDA 510(K) Submission; Perennial Value Management Takes 8% Of Genetic Signatures; Platinum Investment Takes 9% Of Amplia; Amplia’s Dr Christian Behrenbruch, Elk River Below 5%; Esense Loses CEO Haim Cohen, Piers Lewis Interim CEO
 
TGA Cancels Neurotech Mente Autism; Imugene Readies For 2020 PD1-Vaxx Lung Cancer Trial; GI Dynamics Enrols 1st Patient In Endobarrier US Trial; Polynovo: 1st UK Novosorb Patients; Somnomed Revenue Up 15% To $33.3m; Alcidion Revenue $15.4m, Customer Receipts $9.2m; Immuron H1 Travelan Sales Up 55% To $1.7m; Lifespot Raises $330k; Admedus: 44m Director Options, 62m Loan Shares, 100-To-1 Consol EGM; Zelira, Parkinson’s Foundation Develop Marijuana Survey; MGC: 5-Year Deal With Anden For Bolivia, Peru Marijuana Sales; Creso Sells More Than 100,000 Cannaqix Packs; Jeremy Green, Redmile Reduce To 9.5% Of Avita; Crystal Amber Takes 76% Of GI Dynamics; Race Appoints Prof Borje Andersson Director; Imagion Appoints Dr Oliver Steinbach Clinical Head
 
Dr Boreham’s Crucible: Polynovo; Resmed Pays $60m To Resolve US ‘Kickback’ Allegation; Viralytics Back As Immvirx For Cancer Immunotherapies; Nuheara: $2.5m Lind Partners Draw-Down Equity Facility; Nuheara Sells Gold Mine Royalty For $292k, Cash, Scrip; Universal Biosensors H1 Receipts Up 149% To $60m; Jeffrey Emmanuel Takes 8% Of Sienna; Amber Schwarz, Jamber Reduce To 9% Of Creso; Neurotech Requests TGA Registration Trading Halt
 
Emerald Raises $6m Of $8m For Marijuana, Data IPO; US FDA Okays Telix Zircon Renal Cancer Trial; Mach7 H1 Receipts Up 89% To $8.3m; Uscom H1 Receipts Up 21.6% To $1.1m; Biotron Pleads Schultz, Directors, Meeting To ASX 40% Query; Australian Ethical Takes 5% Of Impedimed; Merchant Takes 16% Of Sienna; David Daglio Increases, Diluted To 6% Of Total Brain; G Medical Lists On OTCQB; Lifespot Requests Capital Raising Trading Halt; Cann Global Supplies T12 Hemp To Costco; Bard1 Appoints Prof Allan Cripps Director
 
Polynovo: 1st German Novosorb Patient; 1st Polymedics Order; Sienna: South Korea hTERT Cancer Test Validation Study; Impedimed H1 Receipts Up 17% To $2.7m; LBT Receives $1.1m R&D Tax Incentive; Redhill Ends Donnatal, Enteragam Deal For Talicia, Aemcolo; Admedus Starts 1st Human Adapt Aortic Valve Trial; Neuroscientific US Patent For Emtin Technology; Anatara: Garp Preclinical Studies; THC: TGA Grants Southport Facility GMP Licence; Creso Renews Everblu Corporate Advice Mandates
 
Sienna Rights Shortfall Raises $1.8m, Total $3.7m; Elixinol Pleads Schultz To ASX 20% Fall Query; Cogstate Chair Martyn Myer, Family Increase, Diluted To 14%; Alcidion M-D Kate Quirke 34% Pay Rise To $413k; Clarification: Auscann Board Changes
 
Vale Mesoblast’s Prof Peter Ghosh (4.8.1940 – 12.1.2020); Amplia Placement Raises $930k; Europe Okays Qbiotics Stelfonta For Dog Skin Cancer; Heramed Tells ASX: ‘News Followed 52% Share Jump’; Heramed: Mayo Data For Orion Monitor, Hires Uri Merhav; G Medical: Prizma Smartphone Case Approved In Taiwan; Robert Lederer, RTL Take 11% Of Anatara; Eleanore Goodridge Takes 11% Of Nyrada; THC To Sell MGC’s Canndeo Marijuana, 1st Purchase For $40k; THC Requests ‘Receipt Of TGA Licence’ Trading Halt; MTP Connect Appoints Alex Fowkes Director
 
Sienna Rights Raise $263k Of Hoped-For $2.5m, Total $2m; Cardiex $1.5m From C2 Ventures; Auscann: Max Johnston, Krista Bates In; Cheryl Edwardes Out; Australian Ethical Reduces To 15% Of Antisense; Orbis (Allan Gray) Ceases In Pharmaxis; Prescient Claims 91% PTX-200 Breast Cancer Response Rate; Novita Changes Name To Tali Digital; Telix Recruiting TLX101 Glioblastoma Trial; Clinuvel Files Scenesse TGA Registration Application; Allegra Receives Uni Of Sydney, NHMRC $786k Grant; Invion CFO Melanie Farris Replaces Director, Dr James Campbell; Platinum Reduces To 5% Of Antisense; Empery Below 5% In Benitec; Lifespot Starts Slim Line Marijuana Vaporizer Production; Ellex: Lumibird Pays $100m For Laser, Ultrasound Business; IDT Terminates US Temozolomide Mayne Distribution Deal; Imugene Completes Unmarketable Parcel Sale; Micro-X Raises $16.5m In ‘Oversubscribed’ Offer; Invion To Supply Dermatology Compound For China’s Pavay; Telix Files Phase III TLX250-CDx Kidney Cancer FDA IND Application; Kazia Receives $1.4m R&D Tax Incentive; Orthocell Share Plan Raises $1.4m; Total $14.4m; Alcidion $1.9m Deal With Dartford, Gravesham NHS Trust; Telix Submits TLX591-CDx Clinical Briefing Package To US FDA; David Hannon, DRH Super Below 5% In Noxopharm; Pro Medicus, Nines $6m Visage 7 Deal; Visioneering $3m Placement To Thorney; FDA Approves Avita Recell For Vitiligo Study; Dorsavi Raises $187k In Share Plan; Total Raised $1.9m; Starpharma Phase I AZD0466 Trial For Cancer; $4.3m Milestone; Invitrocue Tells ASX Query: Dr Lindner ‘Not Then A Director’; Creso Draws Down $518k Of Convertible Note Facility; Karst Peak, Vermillion, Adam Leitzes Take 12% Of Cyclopharm; Jencay Capital Takes 6% Of Ellex; Imagion Pleads Schultz To 21% ASX Price Query; Prescient Founder, Director Paul Hopper Steps Down; Nuheara Appoints Cheryl Edwardes Chair; Redhill Ends 2014 Salix Licence; Australian Ethical Takes 10% Of Cyclopharm; CVC Reduces To 9% Of Cyclopharm; Mesoblast Files FDA Remestemcel-L Data; Antisense Options Raise $5.5m; Robert Bazzani Replaces Mach7’s Damien Lim, Jennifer Pilcher; Adalta Loses Director Dr John Chiplin; Uscom 5-Year China NMPA Approval For Uscom 1a; Cellmid US, Euro Midkine Patents; Nuheara Launches Iqbuds Max, To Begin Shipping In March; Opthea Recruits OPT-302 Combo Trial For DME; Pharmaust Epichem Client Unity Biotechnology Ends Contract; Polynovo: ‘$2m Novosorb BTM December Sales’; MGC Australia, New Zealand Marijuana Mercury Pharma; Cynata Receives $1.9m R&D Tax Incentive; Dimerix ‘No Safety Concerns In DMX-200 Trials’; Cann Group, IDT Marijuana Resin Extraction Underway; Althea Beats 4k Marijuana Patient Target; Pharmaust Epichem Extends DNDI Contract To Dec 31, 2020; Elixinol Releases 78m Shares From ASX Escrow; Creso Pleads Schultz To ASX 24% Query; Creso Releases 500k Shares From Voluntary Escrow; Immutep Expands IMP321 Tacti-002 Cancer Study; Adherium Appoints Jane Lapon Market Access Head; MGC: 2k Marijuana Scripts; 1st Shipment In Brazil; Eli Lilly Pays $1.6b For Tom Wiggans’ Dermira; Thorney, Tiga Trading Take 15% Of Visioneering; Regal Funds Increases, Diluted To 14% Of Visioneering; Andreas Empl Replaces Lifespot Director Greg Plunkett; Avecho: Ex-Bioscience Managers Matt McNamara Director; Esense Appoints Dr James Ellingford Director; Total Brain Appoints David Daglio Director; Anteotech Pleads Schultz To ASX 72% Query; Anglo Charitable Increases, Diluted To 17% Of Cyclopharm; Race Dr Al-Behaisi Contract Ends - To Recruit Australian CRM; MMJ $2.2m Harvest One Cannabis Loan Agreement; UK Approves Cynata Cymerus Critical Limb Ischaemia Trial; CE Mark For Proteomics Promarkerd Hub; Adalta Phase I AD-214 Trial Delayed For More Data; Euro Orphan Status For Alterity PBT434 For MSA; Imugene: US Grants HER-Vaxx Cancer Immunotherapy Patent; Escrow End Takes Raw With Life, Elixinol’s Paul Benhaim To 40%; Investors Mutual Reduces To 6% Of Ellex; Karst Peak, Adam Leitzes, Vermillion Reduce To 6% Of Avita; Pharmaust Receives $713k R&D Tax Incentive; GI Dynamics Receives $6.7m From Crystal Amber Convertible Note; Reva Files US Ch 11 Bankruptcy; GI Dynamics: Endobarrier ‘Significantly’ Reduces C-V Risk; Karin Lindgren Replaces Volpara Director Prof Mike Brady; Barings Diluted To 15% Of Cyclopharm; Alterity Receives $4.8m R&D Tax Incentive; Orthocell Receives $2.9m R&D Tax Incentive; Japan Patent For Painchek Smart Phone Pain Test; Tali: Google For Education Partner Status; Naos Takes 22% Of BTC Health; Stemcell United Pleads Schultz To ASX 85% Query; ASX Queries Visioneering Cash Burn; Noxopharm’s Nyrada IPO Opens Up 52.5%; Lifespot Capital AG Reduces To 18% Of Lifespot; G Medical Completes China Trials For Prizma Approval; OBJ ‘Wellfully’ $50m Backdoor, 20-To-One Consolidation EGM; Merchant Funds Management Below 5% In Zelira 
 
2019: BDI-40 Up 118%; ASX200 Up 18%, Big Caps Up 46%, NBI Up 24%; Avita Up 919%, Orthocell 543%, Painchek 497%, Opthea 453%, Alcidion 408%

 

 

 
Dec 20, 2019
Dr Boreham’s Crucible: Avita Medical; FDA Approves UWA, Sarepta Vyondys-53 For DMD; Cartherics Raises $12m; Cyclopharm Raises $9.8m In Placement To Karst Peak; Telix, Victoria Cancer Centre Win $500k Grant; Cyclopharm, Cyclotek J-V For NSW Pet Opportunities; Cogstate: ‘Record H1 $19.1m Revenue’; Regeneus, AGC Terminate Japan Stem Cell J-V; Anatara Finalizes Garp Trial Protocol; Adalta, Radium Capital R&D Tax Incentive Loan; W Whitney George Takes 26% Of Rhinomed; Respiri Cancels Two Bulls Shares, Koswani Wall Options 
 
Dec 19, 2019
2019 – Biotech Daily’s Year In Review; Cardiex $1.9m Bayer Trial Contract; Resapp To Test Aboriginal COPD; Immutep Recruits 2nd Cohort For IMP321 Solid Tumor Trial; Alcidion $500k Taunton, Somerset NHS Patientrack Deal; Next Science Appoints Triad As Torrentx US Distributor; Emvision Brain Scanner Ready For Clinical Trials; Memphasys Ships First Batch Of Felix Devices; Anatara: ‘Garp Enhances Anti-Inflammatories In Mice’; Cann Group, IDT 1st Commercial Marijuana Product; Cann Global, Koegas South Africa Marijuana J-V; Palla Negotiates Better Loan Terms; Cyclopharm Requests Capital Raising Trading Halt; Jamber Takes 12% Of Creso; MGC Ships Marijuana Cognicann For Dementia, Alzheimer’s; THC Appoints Angela Macquire COO; Bod Alternative Director Stephen Thompson Resigns
 
 
Dec 17, 2019
Antisense Jumps 46% On ATL1102 For DMD ‘Safety, Efficacy’; Morgans Underwrites Antisense Options For $4m, Total $5.5m; Mesoblast Nears Cardiac Stem Cell Trial Completion; Noxopharm Raises $8.5m For Nyrada IPO; Zelira Completes Marijuana Insomnia Trial Dosing; Race Receives $159k Federal R&D Tax Incentive; Neurotech: Holy Stone Taiwan Mente Autism Distributor; Perennial Takes 7% Of Genetic Signatures; Jeffery Emmanuel Takes 7% Of Sienna; Gayle McGarry, Caperi Reduce To 6% Of Botanix
 
Dec 16, 2019
Telix Up-To $30m Atonco At-211 Bladder Cancer Licence; Polynovo Novosorb For White Island Burns Victims; Medlab ‘Oversubscribed’ Placement Raises $5m; Starpharma Receives $4.9m Federal R&D Tax Incentive; FDA Approves Orthocell Celgro Animal Study; Simavita Borrows $509k Against Federal R&D Tax Incentive; Antisense Takes ATL1102 DMD Results Halt To Suspension; Pharmaxis Requests Boehringer Ingelheim Trading Halt; Nuheara Walgreens Partnership; Bod, H&H Launch CBD In UK; Anteo Lithium Battery On Track For Commercialization; Asia Union Increases, Diluted To 27% Of Genetic Signatures; Karst Peak, Adam Leitzes Diluted To 13% In Genetic Signatures; Fidelity (FIL) Takes 6.7% Of Genetic Signatures; Director Donald Channer Takes 29% Of Medigard; Uscom Appoints Major Shareholder Xianhui Meng Director; Paul Molloy Replaces Oventus Director Neil Anderson; Cann Group Loses Director Neil Belot 
 
Dec 13, 2019
Dr Boreham’s Crucible: Medadvisor; Polynovo Jumps 27% On Novosorb BTM CE Mark Approval; Respiri: ‘Transforms To Software As A Service’; US Grants Next Science Xbio For Acne Patent; Medlab Requests Placement Trading Halt; Bank Of New York Mellon Pershing Reinstates Auscann; Creso Releases 2m Voluntary Escrow Shares; David Lilja Replaces Opyl Co Sec David Hwang
 
Dec 12, 2019
Federal $14.7m Horizon, Bridge Grants For 17 Projects; Prescient: 1 PTX-200 Ovarian Cancer Partial Response, Cost Cuts; WEHI, NIH Link Ripk1 To Cria Syndrome; Resapp Receives $1.8m R&D Tax Incentive; Antisense Requests ATL1102 DMD Trial Results Trading Halt; Ellex Extends Laser, Ultrasound Business Sale Suspension; Medlab, Cultech Expand Orsbiotic, Nanocbd In UK; Bod, Uni Of SA Research ‘Effect’ Of Marijuana Medicabillis; Holista Water Soluble CBD Marijuana Oil; Empery Tax Efficient Reduces To 6% Of Benitec, In 2018
 
Dec 11, 2019
Kazia GDC-0084 Joins ‘GBM Agile' Glioblastoma Multi-Drug Trial; Probiotec Buys Contract Pharma Services For $4.5m; Adherium Hopes To Raise $5.4m In Rights Offer; Bionomics Sells French Subsidiaries To Domain For $3m; Pharmaust Opens 2 More Dog Cancer Trial Centres; Baillie Gifford Reduces To 7% Of Cochlear; Regal Funds Takes 5% Of Medical Developments; Regal Funds Reduces To 12% Of Opthea; Executive Director Dr Ian Dixon Takes 9% Of Medigard; Alterity 587m Options Expire, Voluntary Escrow Release; Cogstate Appoints Keith Hawkins Co Sec 
 
Dec 10, 2019
4DX Pre-IPO Issue Raises $15m; Starpharma ‘Results Take DEP-Cabazitaxel Trial To Phase II’; Qbiotics: ‘EBC-46 Solid Tumor Safety, Efficacy’; Heramed Placement Raises $1.4m; Genetic Technologies: Breast Cancer Genetype Ready; Respiri’s Wheezo Wins CE Mark, TGA Registration; CSL Appoints Carolyn Hewson Director; Cochlear Appoints Michael Daniell Director; Palla $4m Euro Codeine Deal; Cann Global Olivia Newton-John Marijuana Formula Rights
 
Dec 9, 2019
Ausbiotech, Medicines Australia Hit Federal RDTI Change; Invitrocue, Chinalink: $15m Agreement, Hong-Kong J-V; Suda, Sanofi Oromist Feasibility Agreement; Admedus: Lemaitre 12.5k Unit Cardiocel, Vascucel Order; Botanix Readies For Cannabidiol BTX1702 Rosacea Trial; Creso Africa Marijuana Cannaqix Launch By April 2020; Claude Solitario Replaces Medibio’s David Kaysen, Relocation; Ms Farrell, Ms Dahiya Replace Cann Co Sec, CFO Mr Baker
 
Dec 6, 2019
Dr Boreham’s Crucible: Memphasys; Opthea Raises $50m; Sienna Raises $1.7m; Rights Issue For $2.5m More; Russia Accepts Medical Developments Penthrox Application; Elixinol Class Action: ‘Products Correctly Labelled’; Neuroscientific Emtin-B Not Significant For Alzheimer’s In Mice; Heramed Requests Capital Raising Trading Halt; Victoria, Medipharm Open Wonthaggi Marijuana Facility; Lifespot Marijuana Vaporizer, Software Evaluation; Australian Ethical Takes 6% Of Palla Pharma; Peters Takes 10% Of Painchek
 
Dec 5, 2019
Cynata Stem Cells Effective For Sepsis In Rats; Suda, Ordesa Co-Develop Unnamed Oromist Product; Optiscan Appoints Biotimes 2nd China Distributor; Neurotech, Neurofeedback Partner For Mente Autism; Smart Top, Xianhui Meng Take 21% Of Uscom; Capital Group Clients Cease Substantial In Mesoblast; Genetic Signatures 31% Oppose Tranche 1 Shares; Creso 1st Shipment Of Burleigh Heads Cannaqix 50; Pokies Bruce Mathieson Increases, Diluted To 13% Of Respiri; Race Appoints Prof Borje Andersson Advisory Chair; Imugene Appoints Prof Rebecca Auer Advisor 
 
Dec 4, 2019
CSL R&D Spend Up, New Asthma Drug Trial, Pipeline; Orthocell $13m Placement, Share Plan For $5m More; Painchek Confirms $5m Federal Grant; G Medical $30m Gem Global Draw Down Equity Facility; Avecho To Market 6 TPM Drugs; Zelira (Zelda) Takes Hope For Autism To Louisiana; THC Southport Facility 1st Medical Marijuana; Osteopore Appoints Jack O’Mahony Board Advisor
 
Dec 3, 2019
Mach7 Placement For $20m; Dimerix Placement Raises $2.5m; Uscom Commissions 28 US Sales Staff; Painchek 1,000 Bed Licence With PCS UK, 30 Bed Sale; Neuren NNZ-2591 Neurodevelopment EU Patent; Elixinol Sells Elixinol Japan For $346k After Non-Compliance; Ireland Approves MGC Marijuana Cannepil; Viburnum Takes 19% Of Universal Biosensors; Credit Suisse Takes 10% Of Prescient; Australian Land, Director Alan Tribe Take 27% Of PYC; PYC Director Dr Bernard Hockings Increases, Diluted To 13%; Kemper Shaw Diluted To 6% In Imagion; Merchant Funds Below 5% In Rhythm; Noxopharm Extends Lind, CST Equity-Draw-Down Facility
 
Dec 2, 2019
12-Month BDI-40 Up 114%, ASX200 21%, Big Caps 56%, NBI 9.5%; Opthea Placement For $50m; Imugene Placement For $24.6m; Phylogica Doubles Eye Drug Delivery In Mice; Medlab Nanabis ‘Observational’ Study: Pain Reduction; MGC 52% Blocks Founder Nativ Segev Rights, Strong Dissent; GI Dynamics 120k Director Option, $7m Notes EGM; Goodbye Zelda, Hello Zelira; Noxopharm Daart-1 Study: Partial Response In 1 Of 15 Patients; Orthocell Requests Capital Raising Trading Halt; THC Requests Marijuana Production Trading Halt; Blackrock Takes 6% Of CSL; Parker Family, Xylo Diluted Below 5%; Anthony Barton Diluted Below 5% In Phylogica; Sabby Reduces To 5.6% In Benitec
 
 
Nov 28, 2019
Ellex 80% Revenue Laser, Ultrasound Sale Suspension; Federal $20m For Ovarian Cancer Research; Pro Medicus Launches Visage AI Accelerator; Resonance, Siemens Partner For Ferrismart; Creso To Raise Up To $10m For Pharmacielo, Operations; Dorsavi Notes, Placement Raise $1.7m; Plan For $1m More; FDA Okays Impedimed Sozo For Protein Calorie Malnutrition; Resapp To Combine Diagnostic With Coviu Platform; Resapp 40% Oppose Director Options; Optiscan 19% Oppose 10 Percent Placement Facility; Painchek Directors Sell 45m Shares To Fund Tax Liability; Imugene Requests Capital Raising Trading Halt; Sienna Takes Capital Raising Trading Halt To Suspension; Noxopharm Requests NOX66 Cancer Trial Results Halt
 
Nov 27, 2019
Federal Police, ASIC Raid Regal Funds On Investments; Cyclopharm Vanda Gould ‘Guilty’; Disqualified As Director; Prescient: ‘3rd PTX-200 AML Complete Response, Trial Expands’; Invion: ‘Photosoft Reduces Tumor Size 50% In Mice’; Recce’s Recce-327 ‘Reduces MRSA In Rats’; New Phase Orders $300k Of Imagion Nanoparticles; Shareroot Name Change To Opyl, 100-To-1 Consolidation; Noxopharm’s Nyrada Hopes For $8.5m IPO; Cynata 32% Oppose Employee Option Plan; Mesoblast 17% Oppose Remuneration Report; Credit Suisse Takes 5% Of Opthea; Proteomics CEO Dr Richard Lipscombe Diluted To 20.7%; Former Proteomics Director John Dunlop Diluted To 6%; David Sietsma Increases, Diluted To 10% Of Phylogica; Actinogen CEO Dr Bill Ketelbey Repays $360k Share Loan; Benitec Quits Australia For The US; G Medical Requests ‘Funding Facility’ Trading Halt; Osteopore To Release 6.3m Escrow Shares; Suda Appoints Dr Michael Baker CEO, Starting On $250k; Simavita Appoints Dr John McBain Director 
 
 
Nov 25, 2019
Kazia: GCD-0084 Glioblastoma Early Data: ‘Clinical Benefit’; Novita Placement Raises $6.2m; Total $8m; Recce Requests ‘Test Results’ Trading Halt; Micro-X Installs 1st Mini X-Ray At Alfred Hospital; Avita, Gates Center: Spray-On G-M Skin For EB; Imugene Completes CF33 GMP Batches; Cynata Applies For UK CYP-002 Critical Limb Trial; Optiscan To Meet FDA For Oral Cavity Imaging; Dimerix: FDA Phase III DMX-200 FSGS Meeting ‘Provides Clarity’; Up To 13% Dissent At Adherium AGM, 2nd Spill Avoided; Correction: Pharmaxis; CE Mark Approval For Simavita’s Smartz Nappy; Up 480%; Heramed Herabeat For India’s Cloudnine Hospital Group; Auscann, Aspen 3-Year Packaging Agreement; US DEA ‘De-Schedules’ Botanix Synthetic Marijuana; Selector Takes 5% Of Nanosonics; Sienna CEO Carl Stubbings Starts On $327k; Respiri: Marjan Mikel CEO, Director; Mario Gattino Goes
 
Nov 22, 2019
Dr Boreham’s Crucible: Phylogica; Viertel Awards $425k Fellowships, Scholarships; Imagion Rights Raise $3.6m; Anatara Receives $847k R&D Tax Incentive; Prescient Pleads Schultz To ASX 23% Query; OBJ, P&G ‘Harmonize’ Agreements, Higher Royalties; Medibio 70% Oppose New Directors Ide, Wipperman-Heine, Ojala; Oventus 32% Oppose 10% Placement Facility; Pharmaxis AGM: 14% Oppose William Delaat Re-Election; Cann Group ‘Stages’ Mildura Marijuana Facility; MGC, Brasilinvest Expand Marijuana Sales In Latin America; Director Andrew Goodall Takes 23% In Memphasys; Chair Alison Coutts Diluted To 11% In Memphasys; Craig Cooper, Niall Cairns, C2 Convert Notes For Cardiex 20%; Director Dennis Eck Takes 8.5% Of Cellmid; Adherium CEO Dr Peter Stratford Starts On $571k
 
Nov 21, 2019
China Okay For Medical Developments Penthrox Trial; Starpharma EU Approval For Vivagel Condoms; Resonance Develops Automatic Liver Fat Assessment Tool; Phylogica Retail Rights Raise $5.3m, Total $26.8m; Immuron Phase III IMM-124E Trial For Travellers Diarrhoea; Kazia Requests GDC-0084 Glioblastoma Trial Trading Halt; Painchek: $1m Milestone, 30m Director Options Vest; Painchek Expects To Sign $5m Federal Government Contract; Memphasys Wins $549k ARC Grant For Cell Sorters; Memphasys Identifies 5 Countries For Initial Felix Sales; Heramed, Kinderheldin German Herabeat Midwife Service; Health House To Distribute Zelda, Ilera Hope Marijuana; Novita Requests Capital Raising Trading Halt; Anteotech To ASX: ‘IMRA Contract Lodged By Next Trading Day’; Jeremy Green, Redmile Reduce To 11% Of Avita
 
Nov 20, 2019
Volpara H1 Revenue Up 176% To $6.9m; Loss Up 56% To $7.5m; Bluechiip Plan Raises $4.5m; Total $9.1m; Prof Tim Scott Wins $150k Victoria Prize; Bio-Melbourne Women In Leadership Awards Nominations Open; Antisense Completes ATL1102 For DMD Dosing; Resonance Files Provisional Patent For Blood Markers; Visioneering: Cooper FDA Approval Clears Regulatory Path; Clinuvel 40% Oppose $44m CEO Dr Philippe Wolgen Rights; Cellmid: 19% Oppose Remuneration Report; Actinogen Pleads Schultz To ASX 27% Query; Medadvisor 7-To-1 Consolidation; Zelda, Ilera To Launch ‘Hope’ Marijuana For Autism; MGC Requests ‘Latin America Term Sheet’ Trading Halt; Peters Investments Takes 28% Of Memphasys; Bellwether Super Ceases In Bluechiip; Thorney, Tiga Increase, Diluted To 19% Of Palla; Imugene Appoints Prof Prasad Adusumilli Advisor; GI Dynamics Appoints Juan Morera Crystal Amber Observer
 
Nov 19, 2019
Micro-X Raises $16.5m In Placement; Amends Thales Loan; Hemideina Raises $4m For Wireless Hearing Implant; Genetic Signatures Share Plan Raises $2.5m, Total $37.5m; Regeneus Shortfall Raises $755k, Total $5.5m; Alcidion Launches Mobile Electronic Medical Records; Oncosil Submits Updated CE Mark Report; Medlab NRGbiotic Depression Trial On-Track; Mayne Licences Generic Dermatology Product For US; Osteopore, China’s Boao Yiling Nose Job Deal; Admedus Pleads Schultz To ASX 48% Query; Benitec 10-To-1 ADS Consolidation For Nasdaq Compliance; Washington Pattinson, Brickworks Diluted To 19.9% In Palla; Cogstate Appoints Ken Billard Chief Commercial Officer
 
FDA Okays Cochlear Osia 2 For Conductive Hearing Loss; Singapore Approves Visioneering Multi-Focal Lenses; Correction: Palla Pharma; Antisense: 7th Patient Data Backs ATL1102 For DMD; EMA Group Recommends Alterity’s PBT434 Orphan Status; Prescient To Work With Carina For Car-T Cells; Oventus Signs 2 More US O2vent ‘Lab-In-Lab’ Sites; Adherium, ‘Patients Know Best’ Collaboration; Imugene EGM Backs Vaxinia Acquisition; US Patent For Dorsavi Motion Analysis; Suda Receives $928k Federal R&D Tax Incentive; Anteotech, IMRA Deal For Lateral Flow Assays; Heramed Retracts Revenue Forecast, As Well As $13b Typo; FDA Clears Heramed’s Herabeat Foetal Heart Rate Monitor; Polynovo 25% Oppose Chair David Williams; IDT Survives 22.5% Remuneration 1st Strike Vote; Rhythm Releases 38.5m Escrow Shares; Founder Wayne Stringer Decreases To 13% In Probiotec; Avita: David Mcintyre CFO; Tim Rooney CAO; Nathan Jong Replaces Total Brain Joint Co Sec Harvey Bui
 
Nov 15, 2019
Dr Boreham’s Crucible: Uscom; Burnet Prof Brendan Crabb $80k GSK, Research Aust Gong; Palla Retail Rights Raises $10.1m; Total $30.7m; Proteomics ‘Heavily Oversubscribed’ Placement Raises $3m; Allegra Begins Sheep Sr-HT-Gahnite Cervical Fusion Study; Phylogica, Genentech Anti-Microbial Work Cancelled; Resapp, Sanofi Work On Respiratory Smartphone Diagnostic; Dorsavi Staff Cuts, Costs Down; Possible Capital Raise; Australian Patent For OBJ Bodyguard; Elixinol Pleads Schultz, Japan Issue To ASX 17% Fall Query; Novita Tells ASX: ‘NDIS News Published Quickly’; Heramed Requests 2nd ASX Price Query Trading Halt; CEO Dr Behrenbruch, Elk River Diluted To 10% Of Telix; Gnosis, Andreas Kluge Diluted To 10% Of Telix; CEO Paul Rennie Increases, Diluted To 12% Of Paradigm; Anteo Name Change To Anteotech; Respiri: Smedley Chair, Blair-Holt Out; Board Spill Withdrawn
 
Nov 14, 2019
Prescient Doses 1st PTX-100 Cancer Trial Patient; Race Trials Bisantrene For Residual AML Cancer; Combination; Immutep IMP701 Euro Patent For Cancer, Infectious Disease; Heramed Pleads Million-Billion-Schmillion Typo To ASX 52% Query; Sienna Loses 7-Year Director Dr David Earp; AGM Vote Withdrawn; Phylogica Takes 90% Of Vision Pharma With $15m; Simavita Receives $684k R&D Tax Incentive; Uscom Sells 346k Unmarketable Shares; Althea Wins UK Marijuana Licence; Zelda Marijuana For ‘Advanced Cancer Symptoms’ Trial; Australian Ethical Takes More Profit To 16% Of Antisense; Alcidion Director Prof Malcolm Pradhan Diluted To 14%; Former Alcidion Chair Ray Blight Diluted To 10%; Director Peter Anastasiou Reduces To 10.3% Of Immuron; Peter, Diana Diamond Below 5% In Novita 
 
Nov 13, 2019
Avita Raises $120m; Cogstate Retail Rights Raise $1.1m; Total $4m; Imagion: India Patent For Magnetic Nanoparticle Imaging; Proteomics Requests Capital Raising Trading Halt; Starpharma: Vivagel For Bacterial Vaginosis UK Launch; Althea Marijuana For ‘Advanced Cancer Symptoms’ Trial; Pokies Bruce Mathieson Increases, Diluted To 13% In Respiri; Ansila Energy Ceases Substantial In Factor; Alan Tribe, Australian Land Take 25% Of Phylogica
 
Nov 12, 2019
Proteomics: ‘Promarkerd CE Mark For Diabetic Kidney Disease’; US Patent For Orthocell Celgro Collagen Rope; Creso Terminates Sale To Pharmacielo; NDIS Extends Novita’s Tali Health Platform Registration; Impedimed AGM: 44% Back Spill Call; Rem Report Passes; Adherium Clarifies $1.2m Debt Note To $1.1m; Althea Appoints Nimbus German Marijuana Distributor; MGC $25k Federal Grant; London Listing; Uil, Utilico Take 5% Of Starpharma; Peter, Diana Diamond Reduce To 6% Of Novita; Dr Bernard Hockings Increases, Diluted To 13% In Phylogica; Ellume Appoints Joanne Moss Director
 
Nov 11, 2019
Adherium Tells ASX 4C Query: $1.2m Debt Note; Bionomics Receives $5.2m Federal R&D Tax Incentive; Zelda Receives $1m Federal R&D Tax Incentive; Anatara 46% Oppose Dr Ramsdale Rights; 10% Capacity Fails; Anteo AGM: 27% Oppose Placement Capacity; Bod 2.75m Director Options AGM Faces 27% Dissent; Avita Requests Capital Raising Trading Halt; Dorsavi Requests ‘Additional Capital Raising’ Suspension; Micro-X Extends Capital Raising Suspension; Medlab: Record Marijuana Sales In October; Antisense 45m Directors’ Options AGM; THC Southport Marijuana Manufacture Permit; Richard Cashin Diluted To 11% Of GI Dynamics; Creso, Pharmacielo Meetings Delay, Suspension Extended; Industry Holds Melbourne March Medical Marijuana Meeting
 
Nov 8, 2019
Dr Boreham’s Crucible: Genetic Signatures; S&P Promotes Avita To ASX200; Vivazome To Use Sienna Exo-Net For Ischaemia; Total Brain Raises $14m; Biotron: ‘Gleneagle Underwrites 103m Options To $5m’; Prescient Receives $1.6m R&D Tax Incentive; Azure Buys Invictus Food Additives For 35m Shares, $1.2m Debt; Cardiex Appoints Beijing Auden Atcor China Distributor; Bod Joins Project Twenty21 UK Marijuana Study; Crystal Amber Takes 73% Of Gi Dynamics; Suda Loses Andrew Curtis, Joseph Ohayon Part-Time; Michael Edwards Replaces Esense Director Galit Assaf
 
Nov 7, 2019
Export Corp $85m OBJ Backdoor To Be ‘Wellfully’; Zelda Marijuana Insomnia Trial Fully Enrolled; Cann, Symbion Marijuana Deal; Medadvisor, Sigma Prescription Deal - $1m Pa Revenue; Living Cell Board Spill AGM: Dr Kelly In, Laurie Hunter Out; Patrys Receives $672k R&D Tax Incentive; Heramed Software Tested On 750 Pregnancies In 15 Hospitals; Total Brain Takes Capital Raising Trading Halt To Suspension; Australian Ethical Takes Profit To 17% Of Antisense; Asia Union Decreases To 32% Of Genetic Signatures; Karst Peak, Adam Leitzes Diluted To 15% Of Genetic Signatures; Credit Suisse Takes 6.2% Of Kazia
 
Nov 6, 2019
Cellmid Share Plan Raises $1m; Total $2.5m; Acrux Receives Further $1.5m Federal R&D Tax Incentive; Oventus Receives $828k Federal R&D Tax Incentive; Cellmid, API To Sell Évolis At Priceline Pharmacies; Micro-X: ‘Capital Management, Raising’ Halt To Suspension; Eisai Takes 7.2% Of Cogstate; Sico Increased, Diluted To 7.7% In Palla, In 2017; Ellex To Lose Director Giuseppe Canala; Noxopharm Appoints Alexander Hunter CCO
 
Nov 5, 2019
FDA Okays Redhill’s Talicia (Sydney’s Heliconda) For H Pylori; Alcidion Raises $16.2m; Emvision Raises $4.5m; Eye-Co Fludrocortisone Acetate Early Trial Results; Cann Global Convertible Notes For $2.2m; Platinum Diluted To 9% Of Kazia; Peter, Diana Diamond Reduce To 7.7% Of Novita; Creso Takes ‘Pharmacielo Acquisition’ Halt To Suspension; OBJ Takes ‘Material Acquisition’ Halt To Suspension; Total Brain Requests ‘Capital Raising’ Halt 
 
Nov 4, 2019
Pro Medicus: Ohio State Uni $9m Visage 7 Deal; Phylogica Raises $14.3m, $12.5m To Go; Next Science Falls On Wrong Motley Fool 4c Report; Bionomics: FDA Fast Track Status For BNC210 For PTSD; Optiscan: FDA Confocal Microscope Oral Cancer Meeting; Rhythm: China Patent For Colostat; Imugene Receives $4m Federal R&D Tax Incentive; Nuheara Receives $1.7m Federal R&D Tax Incentive; Immuron Receives $532k Federal R&D Tax Incentive; Micro-X Requests ‘Capital Management, Raising’ Trading Halt; Invion Loses 6-Year Director Greg Collier; Elixinol Appoints Teresa Cleary Co Sec; Chris Mews Replaces Auscann Director Dr Paul MacLeman; Stemcell Loses Director Savio Ka Lung Cheung
 
Oct 31, 2019
Ausbiotech Invest, Partnering; Conference Gongs; Victoria AAMRI Wants $20m PA For Research ‘Indirect Costs’; Neuren: Acadia Starts Phase III Trofinetide Rett Trial; Starpharma: ‘DEP-Gemcitabine Best For Pancreatic Cancer In Mice’; Invion, Peter MacCallum Ano-Genital Cancer Studies; Phylogica ‘Underwritten’ Rights Offer To Raise $26.8m; Emvision Assembles 1st Portable Brain Scanner For Stroke Trial; Total Brain, Vault Partner For Mental Health Platform; MGC Prescribes 1,000 Marijuana Doses; Dr Muchnicki, MJGD, JGM Take 5% Of Genetic Technologies; Peter Rubinstein, Irwin, Rip Take 6% Of Genetic Technologies; Nanosonics Appoints Dr Lisa McIntyre Director; Cellmid Appoints Brian McGee US Advangen CEO
 
Oct 30, 2019
Ausbiotech National Conference Opens; Telix $30m To Aushealth For Apomab For Ovarian, Lung Cancer; Biocurate, Takeda Accelerate Therapeutics, Drugs Discovery; Clinuvel: TGA Scenesse Priority Registration; Genetic Technologies Raises $4.5m, Nasdaq Compliance; Sienna, Minomic Work On Pancreatic Cancer Blood Test; Suda $1.5m Cann Pharma Deal For Marijuana Spray; Somnomed, App-Nea Deal For Doctor Software; Medical Developments 18% Oppose Remuneration Report; Respiri Spill Call, Nick Smedley In, Alastair Beard Interim CEO; Mesoblast AGM For 2.4m Options; Neuroscientific 3m Director Options AGM; Althea AGM For 1.2m Joshua Fegan Rights; GI Dynamics: Less Than One Quarter Cash, $US10m Notes; Credit Suisse Below 5% In Opthea; Paradice Increases, Diluted To 7.8% Of Probiotec; Probiotec Chairman Geoffrey Pearce Diluted Below 5%; Merchant Takes 11% Of Sienna; Pendal Group Takes 5% Of Althea; Clarity Appoints Dr Colin Biggin CEO; Vivazome Appoints Dr David Haylock CEO; LBT 13-Year Director Stephen Mathwin Retires; Uscom: Dr Antonio Ferrario Euro Sales, Marketing Manager
 
Oct 29, 2019
Kira Raises $20m For KB312 For Immune Disorders; Imagion Rights Offer For $6.5m; IP Group Backs Uniquest’s Jetra Il-22 For Fatty Liver Disease; Adalta Monkey Study: ‘AD-214 Safe, Well-Tolerated’; Medical Developments, CSIRO Extend Drug Manufacture Deal; Oncosil Submits Updated CE Mark Report; Invion 4C: ‘Cho Group To Fund All Costs’; Proteomics Receives $1.1m Tax Incentive; Nuheara: ‘R&D Tax Incentive Makes Two Quarters Cash’; Telix To Release 67.6m Escrow Shares; Oncosil Withdraws 5m CEO Daniel Kenny Loan Shares; Shareroot: Opyl Name Change, 100-To-1 Consolidation AGM; Greg Plummer, Jetan Take 5% Of Uscom; Merchant Takes 11% Of Bard1; Thorney, Tiga Take 21% Of Palla Pharma
 
Oct 28, 2019
Genetic Signatures Raises $35m, Plan For $2m More; Kazia Raises $4m; Pharmaxis: ‘FDA Larger Clinician Study, 1 Month Delay’; Federal $50k Cynata Coronary Artery Disease Grant; Genetic Signatures Receives $2.1m Federal R&D Tax Incentive; Zelda Name Change To ‘Zelira’, 37.5m Director Options AGM; Resonance 12m Director Options AGM; Rhinomed 10m Directors Options AGM; Resapp 3m CEO, Director Incentive Options AGM; Bioxyne 36m M-D Performance Rights AGM; Benitec 5m Director Options AGM; Acrux 2.7m ‘50% In Lieu’ Directors Rights AGM; Althea Launches CBD100 In Australia; Cann Global Opens Laos Marijuana Subsidiary; David Daglio Takes 6.5% In Total Brain; Aphria Reduces To 5.25% In Althea; Polynovo Appoints CSL’s Dr Robyn Elliott Director; Auscann To Lose Dr Mal Washer, Cheryl Edwards; Noxopharm Appoints Chair Dr Graham Kelly Interim CEO; Exopharm Appoints Dr Christopher Baldwin CCO, On $330k; Genetic Signatures Loses 16-Year Director Phillip Isaacs
 
Oct 25, 2019
Dr Boreham’s Crucible: Elixinol Global; CSL Removes Pharming From Prof Joseph Dr Chiao Case; Resmed Q1 Revenue Up 16% To $999m, Profit Up 16% To $199m; Imagion Needs $1.6m For GMP Nanoparticle; Genetic Technologies Rights Raise $4.5m; Paradigm PPS Treats 10 US Footballers; Canada Allows Cynata Stem Cell Patent; Uscom Consolidates 346k Unmarketable Parcel Shares; Heramed Extends Consultus India Deal, 2nd Herabeat Order; Althea Expects 4k Medical Marijuana Scripts This Year; Respiri Has Less Than Two Quarters Cash; Respiri Opposes Ex-CEO Mario Gattino Re-Election AGM; Adherium 2nd Strike Board Spill AGM; Avita 40m CEO Dr Michael Perry Incentive Units AGM; Novita 14m M-D Options, ‘Tali Digital’ Name Change AGM; Genetic Technologies ‘Genetype’ Name Change AGM; Cynata AGM To Vote On Email Address Requests; Washington H Soul Pattinson Takes 23% Of Palla; Otto Buttula Replaces Rhythm Chairman Shane Tanner
 
Oct 24, 2019
Bluechiip Placement Raises $4.6m; Share Plan For More; Pharmaxis: LOX Inhibitor For Cancer ‘Dose Response, Safe’; Actinogen Receives $4.6m Federal R&D Tax Incentive; Acrux Receives ‘First’ $502k Federal R&D Tax Incentive; Medical Developments: ‘Penthrox 1st Line EU Pain Treatment’; Novita Tali Detect US Reimbursement Code; Up 145%; Genetic Signatures Requests Capital Raising Trading Halt; Kazia Requests Capital Raising Trading Halt; Medibio: PWC Australia To Use Ilumen For Mental Health; Adalta 5m CEO Dr Tim Oldham Options AGM; Credit Suisse Takes 5% Of Opthea; James Schwarz, Jamber Take 5% Of Esense; Nuheara Appoints David Buckingham Director; Invion CEO Craig Newton Starts On $280k
 
Oct 23, 2019
Botanix: Cannabinoid BTX1503 Misses Acne Primary Endpoint; Down 48%; Imugene: $825k US Defense Grant For CF33 Gastric Cancer Research; Medical Developments Launches Penthrox In Italy; Dimerix $50k Federal Dmx-700 COPD Grant; Impedimed Cancer-Related Lymphoedema Prevention Program; Elixinol Investigates ‘Non-Compliant’ Japan Cannabidiol; Oventus 570k CEO Options, 300k Directors Options; Althea Requests ‘Material Supply Agreement’ Trading Halt; Capital Group ‘Clients’ Reduce To 5% Of Mesoblast; M&G Takes Prudential’s 14% Of Mesoblast; M&G Takes Prudential’s 5% Of Medical Developments; M&G Takes Prudential’s 12% Of Starpharma; Wentworth Williamson Takes 8% Of Palla Pharma; Antanas Guoga Takes 13% Of Shareroot; Niv Dagan, Freedom Trader, 10 Bolivianos Take 8% Of Lifespot; Regal Funds Below 5% In Medibio; Clarity Appoints Dr Jennifer Rosenthal For Quality, Regulatory
 
Oct 22, 2019
Cochlear: Forecast OK, EPS Target Down, Going Greener; Cochlear 12.35% Oppose Director Donal O’Dwyer; Volpara H1 Receipts Up 171% To $6.8m; Medical Developments: Penthrox Superior For Pain; Bluechiip Requests ‘Capital Raising’ Trading Halt; Botanix Requests ‘BTX1503 Trial Results’ Trading Halt; Medibio 2nd Strike, 16.6m ‘In Lieu’ Directors Options AGM; LBT 1m Director Options AGM; Medadvisor 13m Director Options, 7-To-1 Consolidation AGM; Bluechiip 856k CEO Performance Rights AGM; Genetic Signatures 2nd Strike AGM; G Medical Responds To ASX Delay Query; Blackrock Takes 7.2% Of Cochlear; Mark Kerr Takes 12.7% Of Avecho; Jimmy Thomas, Ivy Ponniah ‘Below 5%’ In Genetic Technologies
 
Oct 21, 2019
LBT: Wisplinghoff Buys First Euro APAS Independence; Palla Pharma Raises $20.6m, $10.5m To Go; Cogstate ‘Underwritten’ $4m 1-For-10 Rights Issue; Imugene Plans 2 CF33 Trials For 2020; Cann Has One Quarter Cash, ‘Loan Coming’; WIPO Publishes Micro-X Carbon Nanotube Patent; Medibio Completes 1st Compass Ilumen Test; Correction: Cellmid; Orthocell 1m CFO, Director Options AGM; Phylogica Name Change To ‘PYC Therapeutics’ AGM; Purisys To Supply Botanix Synthetic Cannabidiol; Elixinol Requests ‘Japanese Subsidiary’ Trading Halt; Noxopharm Veyonda (NOX66): ‘80% No Cancer Progression’; 9 Days To Ausbiotech Biotech Invest, Conference; Mayne Loses 13-Year Director Ron Best; Matt McNamara Replaces Adherium Director Prof John Mills
 
Oct 18, 2019
Dr Boreham’s Crucible: Clinuvel Pharmaceuticals; CSL: Prof Joseph Chiao, Pharming Lawsuit On HA Data; Oncosil Receives $3.8m R&D Tax Incentive; Clinuvel 1.5m, $48m CEO Dr Phillipe Wolgen Rights AGM; Pharmaxis 927k CEO Gary Phillips Rights AGM; Starpharma 671k CEO Dr Jackie Fairley Rights AGM; Cellmid To Vote On 3m CEO Maria Halasz Options; Bionomics 2nd Strike AGM; Race 5.5m Directors Options AGM; Regeneus CEO Leo Lee 15m Options AGM; Althea Completes Canada Peak Acquisition; Noxopharm: ‘Glutamate-Inhibitor For Brain Cancer’; Merchant Funds Reduces To 5% Of Rhythm; Merchant Takes 12% Of Auscann
 
Oct 17, 2019
Alcidion: ‘Cash Flow Positive, Share Price Up 300% In 6 Months’; WEHI Team Wins $250k Prime Ministers Innovation Prize; Terumo Hands Back Avecho (Phosphagenics) TPM-Propofol; Palla ‘Underwritten’ $31m Placement, Rights Offer; Mesoblast: Lonza To Manufacture Remestemcel-L; Cynata, Sumitomo Quit Acquisition Talks; Pharmaxis Receives $6.2m R&D Tax Incentive; Painchek, Ward Pain Tests For Aged Care Facilities; CSL AGM Passes All Resolutions; 4.9% Dissent; Neurotech 6m Director Options AGM; Creso Delivers First Order Of 10% CBD Oil To Medleaf NZ; THC Receives S4, S8 Narcotics Licences For Marijuana; Recce’s Dr Graham Melrose, Olga Melrose Diluted To 23%; M-D Dr Ian Dixon Increases, Diluted To 29% Of Exopharm; CSL Loses Director Dr Tadataka Yamada; Imugene Appoints Prof Yuman Fong Advisor
 
Oct 16, 2019
Cronos: ‘Fully Underwritten’ $20m IPO For Medical Marijuana; Final Data Backs Immutep IMP321, Keytruda For Melanoma; Neuren NNZ-2591 Phelan-McDermid, Pitt Hopkins Orphan Status; Living Cell: Vertex Pays $1.1m For Semma Shares; Optiscan Appoints Guanzhou Yunxing China Distributor; Nuheara Pleads Schultz To 55% ASX Query; Regal Funds Takes 7% Of Medadvisor; Merchant Takes 5% Of Zelda; Invitrocue Loses Dissident Directors Prof Yu, Lui, Ng; Former IDT Chairman Graeme Kaufman Retires; Carl Stubbings Replaces Sienna CEO Matthew Hoskin; Noxopharm Loses 3 Month Director Dr Beata Edling/Niechoda
 
Oct 15, 2019
Federal, MTP Connect ‘Up To $1m’ Device Grants; Regeneus Receives $1.5m Federal R&D Tax Incentive; Admedus Amends Lemaitre Upfront Payment To $21.2m; Invex Exenatide Intracranial Hypertension Trial Recruited; Federal $50k For Botanix Synthetic CBD Analogs; Cynata Investors Request Email Addresses Resolution; Alcidion $400k Directors Fee Pool Limit AGM; Kazia AGM To Vote On 1.2m CEO James Garner Options; Clarification: Rhinomed, Odd Fellows, Perennial; Director, CSO Dr Daniel Tillett Diluted To 8% Of Race; Ebos Diluted To 10.8% In Medadvisor; Clinuvel To Lose 17-Year Chairman Stan McLiesh
 
Oct 14, 2019
Admedus: ‘Up-To $36m Adapt Lemaitre Distribution Deal’; Correction: Recce Pharmaceuticals; Victoria Boosts Epilepsy Marijuana; Ends IDT, Cann Deals; Cellmid Raises $1.5m; Share Plan For $500k More; Anatara Bromelain Garp Effective For IBD, IBS, In Mice; Cellmid, Australian Shopping Network Evolis Agreement; Telix Integrates GE Healthcare Gallium With TLX591-CDx; Medadvisor 3-Year Chemist Warehouse Deal; Polynovo 50% Director Fee Pool Hike To $600k AGM; Painchek $840k M-D, Directors Performance Rights AGM; Suda 40m Chair Paul Hopper Options, 25-To-1 Consolidation; Bard1 100% Director Fee Pool Hike To $400k AGM; Merchant Takes 11.5% Of Auscann; Canopy Ceases; ‘Odd Fellows’ Below 5% In Rhinomed; Pharmaust Appoints Colin La Galia Epichem CEO; Dr Keenan Director; Imagion Scientific Advisory Board
 
Oct 11, 2019
Dr Boreham’s Crucible: Recce Pharmaceuticals; Opthea OPT-302 Benefit For CNV, Wet AMD Lesions; Truscreen: W.H.O. Cervical Cancer Strategy Benefit; Neuren NNZ2591 Angelman Syndrome FDA Orphan Status; Oncosil: US FDA Humanitarian Use, CE Mark Progress; Oventus 5 O2vent ‘Lab-In-Lab’ Sites In US, Canada; Bluechiip: ‘More Than 2 Quarters Cash’; Invitrocue CEO Dr Steven Fang Survives Spill Meeting; Impedimed 2m CEO Shares, Options, 2nd Strike AGM; Platinum Reduces To 6% Of Antisense; HMS Takes 13% Of Medadvisor; Alcidion’s Ray Blight Increases, Diluted To 11%; Dimerix Loses Director David Franklyn
 
Oct 10, 2019
Recce ‘Strongly Supported’ Placement Raises $6.8m; Dimerix Receptor-Hit Discovers Dmx-700 For COPD; Immutep Receives $2.55m French R&D Tax Incentive; Dr Kamala Thriemer, Prof Daniel Thomas Win $1.25m CSL Grants; Cellmid Requests ‘Capital Raising’ Trading Halt; Emvision Pleads Schultz To ASX 13% Query; Medlab, ANC Expand Food Additive Business To US; Bod 67% Directors Fee Hike, 2.75m Directors Options AGM; M&G (Prudential) Diluted To 13% Of Mesoblast 
 
Oct 9, 2019
Vale Dr John Holaday
(1945 – 2019);
Clinuvel Up 63% On FDA Scenesse EPP Approval; Orthocell: ‘Celgro With Microsurgery Repairs Nerve Damage’; Phylogica: ‘CPP Takes Antisense Drug To Human Retina In-Dish’; Zelda, Ilera Marijuana Merger For Zelira; G Medical Tells ASX: ‘Revenue Awaiting Approvals’; Australian Ethical Takes Profit, Reduces To 18.5% In Antisense; CEO Kate Quirke Takes 6% Of Alcidion; Kennedy, Caledonia Increase, Diluted To 8% Of Alcidion; Mackinnon, Isle Of Wight Increase, Diluted To 8% Of Alcidion; Imugene Unmarketable Parcel Facility; Adalta Appoints Dr Tim Oldham CEO; Starts On $300k; Respiri Loses CEO Mario Gattino; Painchek CEO Philip Daffas 11% Pay Rise
 
Oct 8, 2019
Federal $35m For Macquarie Uni Synthetic Biology Research; Recce $4m Capital Raising Trading Halt; Visioneering Revenue Warning To $8.7m; Dimerix Receives $1.2m Federal R&D Tax Incentive; Neurotech Convertible Loans For Up To $600k; Bard1 Assay Validation Milestone; Sienna Clayton Move For Sien-Net Production; Mach7 810k Director Options AGM; Board Changes; Memphasys Pleads Schultz To ASX 23.5% Query; Zelda Requests ‘Material Control Transaction’ Trading Halt; BVF, Mark Lampert Below 5% In Opthea; M&G (Prudential) Takes 12.7% Of Mesoblast; ‘Odd Fellows’ Takes 5.4% Of Rhinomed
 
Oct 7, 2019
Medadvisor Raises $17m; Jeff Sherman Director; Antisense Pleads Schultz, Publicity To ASX 45% Query; Pharmaust Expects $1.5m Federal R&D Tax Incentive; Respiri Wheezo Passes CE Mark Safety; Feb 2020 Sales; Invex: Japan Patent For Elevated Intra-Cranial Pressure; Uscom Share Facility Price Change; Orthocell ‘Celgro Trial Results’ Trading Halt; Empery Takes 9% Of Benitec; Crystal Amber Takes 71% Of GI Dynamics; Telix Appoints Dr David Cade CBO, IR Head; Clinuvel Renews CEO Dr Wolgen; $1.4m Base Salary
 
Oct 4, 2019
Dr Boreham’s Crucible: Actinogen Medical; Genetic Technologies Rights Issue To Raise $4.5m; Suda: ‘Regulator Concern Over Artimist Use, Adherence’; Pharmaust’s Epichem Wins WA Export, Women’s Awards; Kolabtree: ‘Access To 10,000 Science Freelancers’; Imugene Unmarketable Parcels Facility; Resapp Joins Munich Start-Up Creasphere Program; Althea Prescribes 2,329 Marijuana Patients; Stemcell United, Yunnan Hongyi For Orchid Stem Cells; Living Cell Board Spill AGM; Imugene 100m Director Options AGM; Paradigm 100% Director Fee Hike, $1.1m Staff Shares AGM; Immuron CEO Dr Gary Jacob 5m Options AGM; GI Dynamics Exercises $2.9m Crystal Amber Warrants
 
Oct 3, 2019
Mesoblast Raises $75m; Telix Buys Belgian Radiopharmaceutical Production Site; Cynata Ready For Phase II Cymerus Osteoarthritis Trial; FDA Allows Clarity Sartate Neuroblastoma Trial; Federal $8m For Five Collaborative Trials; Federal Regional Queensland Stem Mentoring Launch; Pharmaust Raises $2.4m; Alchemia Raises $5.7m To Become Australian Primary Hemp; Suda Tells ASX: ‘Accounts In Order, Artimist Worth $5m’; Optiscan Receives $227k R&D Tax Incentive; Cardiex: Sphygmocor Xcell Q1 Sales Up 88% To $900k; MGC: 400 Cannepil, MXP100 Prescriptions; Court Approves Pharmacielo, Creso Acquisition Scheme Meeting; Medadvisor Requests Placement Trading Halt; Bard1 Grants CEO Dr Leanne Hinch 15m Incentive Options; Invex 2.2m Director ‘Incentive’ Options AGM; Sabby Takes 9% Of Benitec
 
Oct 2, 2019
Innate Chris Collins Pleads Guilty, Resigns US Congress; Ausbiotech Melbourne Biotech Invest, Conference; Immuron, US Defense $5.5m Collaboration; Medlab: 1st Export Order For Hemp/Marijuana Nanocbd; Heramed Intmed Brazil Heracare, Herabeat Collaboration; Mayne To Pay Mithra Up To $440m For US Contraceptive Deal; Resapp TGA Approval For Resappdx-EU Diagnostic; US FDA Changes Clinuvel PDUFA Date To October 8; Mach7 US Patent For Dynamic Media Management System; Anteo Buys Back 12.7m Unmarketable Shares; G Medical In Suspension: ‘Preparing ASX Query Response’; Ron Dewhurst, Kroy Wen Below 5% In Rhinomed; Federal Government Appoints Stem Cell Advisors
 
Oct 1, 2019
September BDI-40 Up 0.5%, ASX200 Up 1%, Big Caps Down 1.4%, NBI Down 3% - Paradigm Up 80%, Antisense 57%; Pro Medicus Down 25%, Amplia 20%; Actinogen: ‘Xanamem Improves Cognition In Healthy Volunteers’; Mesoblast ‘$75m’ Trading Halt; Benitec To Raise $3.3m, Warrants; Innate Director Chris Collins Insider Trading Charges; Opthea Receives $14.6m Federal R&D Tax Incentive; Paradigm: ‘PPS Inhibits Nerve Growth Factor Pain Mediators’; TGA Refuses Suda Artimist Appeal; Phylogica, Vision Join Lions Eye; Appoints Prof Sue Fletcher; Neuroscientific: ‘Emtin-B Hits Retina, Optic Nerve In Rabbits’; Visioneering Appoints Menicon Naturalvue Europe Distributor; Cellmid Germany, China Évolis Distribution Deals; Cryosite 1.3m Chairman Options AGM; Pharmaust Requests ‘Capital Raising’ Trading Halt; Resapp ‘Regulatory Approval’ Trading Halt; Race Appoints Director Dr Daniel Tillett CSO; Biotron Appoints Phase II HIV Trial Scientific Advisory Board; Patrys Appoints Dr Pamela Klein Director; Correction: Oncosil
 
Sep 30, 2019
Uscom To Raise Up To $1m In Private Placement; Kinoxis: Up To $7m US Grant For KNX100 For Opioid Withdrawal; Kazia: ‘Cantrixil Partial Response In 2 Of 9 Patients’; Resapp: ‘Algorithm Accurate For Obstructive Sleep Apnoea’; Invion Prepares For 2020 Basal Cell Carcinoma Light Trial; Noxopharm: ‘NOX66 Boosts 177Lu-PSMA For Prostate Cancer’; Invitrocue To Open Hong Kong R&D Laboratory; Immutep: 51m Performance Rights, 1-For-10 Consolidation AGM; Mesoblast To Release 14.5m Voluntary Escrow Shares; Phylogica ‘Partnership’ Trading Halt; Avita To List On Nasdaq; Morgan Stanley Below 5% In Avita; Osteopore: Mr Liew, Rain Maker, Mr Seng, Prof Teoh, Prof Yang; Admedus Requests 8th Funding Suspension Extension; Cyclopharm Appoints Sales, Regulatory, Service Staff; Oncosil CFO Nicholas Falzon In, Tom Milicevic, Dr Ash Soman Out
 
Sep 27, 2019
Dr Boreham’s Crucible: Suda Pharmaceuticals; Cellmid Receives $840k R&D Tax Incentive; Oncosil 4.85m CEO Loan Shares AGM; Actinogen Requests ‘Clinical Trial Results’ Trading Halt; Neuroscientific ‘Pre-Clinical Ophthalmology Results’ Halt; Alchemia Completes 1-For-20 Consolidation; Creso Resubmits Pharmacielo Scheme Booklet; Morgan Stanley Takes 7% Of Avita; Dissident Shareholders Take 5% Of Living Cell; Harry Karelis, Gemelli Below 5% In Auscann; Medibio Eliminates 4.65m Invalid Options/Partly Paid Shares; Truscreen Loses CEO Martin Dillon - Replacement Wanted
 
Sep 26, 2019
Brandon $14m For Denteric Porphyromonas Gingivalis Vaccine; Cynata Receives Fujifilm $4.4m Signing Fee; Immutep: ‘Positive Data, IMP321 Tacti-002 NSCLC Trial Go Ahead’; Adalta Invoices GE Healthcare $183k For Imaging; Visioneering Claims 1st Hong Kong Naturalvue Sale; CE Mark For Resapp Version 2 Respiratory Diagnostic; Dimerix Recruits DMX-200 Diabetic Kidney Disease Trial; FDA Approves Starpharma, Astrazeneca AZD0466 Trial; Bionomics Reformulated BNC210 Achieves Blood Levels; Elixinol Appoints Harmonia Life Finland Hemp Distributor; Probiotec Releases 1.95m Escrow Shares; Genetic Technologies EGM 14% Oppose Share Issue; Pac Partners Reduced To 6% Of Althea; Niv Dagan, Freedom Trader, 10 Bolivianos Take 7% Of Lifespot
 
Sep 25, 2019
Probiotec Raises $10.6m; JCR: Mesoblast Temcell For Epidermolysis Bullosa ‘On Hold’; Invitrocue Onco-PDO Validation Study; Victoria Call For Bio Europe Trade Mission; Phylogica CPP Delivers Antisense Drug In Mice Over 4 Weeks; LBT Finalizes Apas Independence CE Mark For MRSA; Invitrocue Directors Prof Yu, Mr Lui Reply To Spill Claims; Anteo, Axxin Work On Anteobind Assay Readers; Karst Peak Reduces To 8% Of Avita
 
Sep 24, 2019
Heramed Applies For Israel-Mayo Grant; Oventus Pleads Schultz To ASX 16% Query; Suda Loses 9-Year CEO Stephen Carter; Genetic Technologies Loses Chair Paul Kasian; Noxopharm Loses 5-Month CEO Dr Greg Van Wyk; Paradice Investments Takes 9% Of Probiotec
 
Sep 23, 2019
Osteopore IPO Up 263% To 72.5c For 3D Bone Replacement; Victoria: ‘$2b Drugs Top Value Manufactured Exports’; Immutep Earns $7m Glaxosmithkline LAG-3 Milestone; Rhinomed Placement Raises $6m; Optiscan: Confocal Microscope For 2nd Oral Cancer Trial; Sienna Receives $405k Federal R&D Tax Incentive; Genetic Technologies, Tgen Risk Tests Agreement; Universal Biosensors Finalizes Siemens Xprecia Deal; IQ3 Tells ASX Aware Query: ‘IT Glitch Stopped Announcement’; Probiotec AGM: CEO Wesley Stringer $4.9m Loan For Options; Acrux Resolution Calls To Appoint Norman Gray Director; ASX Suspends Oventus On Price Query; Merchant Group Reduces To 6.6% Of Rhythm; Jim Craig, Bellwether Reduce To 5.6% Of Bluechiip; Clinuvel Appoints Susan Smith Director; Mark Masterson Replaces Bod Chairman George Livery
 
Sep 20, 2019
Dr Boreham’s Crucible: Pharmaust; GI Dynamics: ‘Endobarrier Reduces HbA1c, Weight, BP’; Japan Patent For Recce Antibiotics; Respiri India Pre-Market Launch Of Wheezo For Asthma; CVC Below 5% In Probiotec; GI Dynamics CEO $663k Base Salary, 58m Options, 55m Shares
 
Sep 19, 2019
Avita: ‘Recell Improves Dermabrasian Acne Scar Healing’; Novita Rights, Shortfall Raise $2m; Rhythm ‘Colostat Differentiates Cancer, Healthy Tissue’; Bionomics Submits BNC210 PTSD US Fast Track Application; OBJ Establishes ‘Wellfully’ Subsidiaries; Living Cell $1.2m From Vertex Buying Semma; Rhinomed Requests Capital Raising Trading Halt; Anthony Eaton Replaces Invitrocue Director Dr Gary Pace
 
Sep 18, 2019
Cynata: ‘Fujifilm Up-To $67m CYP-001 GvHD Licence’; Antisense Up 100% On ATL1102 ‘Positive Drug Effect For DMD’; Eye Co: Hemp Seed Oil For Dry AMD Steroids In Mice; Adalta Receives $3.5m R&D Tax Incentive; Recce Receives $164k R&D Tax Incentive; Invitrocue EGM To Remove Dissident Directors; Cogstate 1m CEO Brad O’Connor Options AGM; Althea Peak Processing EGM; MGC Passes 200 Cannepil, MXP100 Prescriptions; Creso Takes Pharmacielo Trading Halt To Suspension; Peter, Diana Diamond Increase, Diluted To 9% Of Novita; NSW Uni Bio-Engineering Research Showcase Next Tuesday
 
Sep 17, 2019
Benitec: 3 Dog Studies For FDA BB-301 Phase I OPMD Trial; IQ Acquires Tex Core For Solid Tumors From University Of Texas; Antisense Requests ‘ATL1102 DMD Results’ Halt; Alcidion $895k, 3-Year Healthscope Partnership; Avita US Recell Trial For Skin Injuries; Living Cell Tells ASX 32% Fall Query: ‘Newsletter Not News’; ASX Suspends G Medical For Failure To Respond To Query; Novita: Tali Train Supply Agreement With UK’s Edtech Impact; Proteomics Promarkerd: ‘Validated’; Heramed, Mayo Collaboration For Pregnancy Monitor; Japanese Patent For Immutep LAG525 Antibody; US Patent For Dimerix DMX200 Combination Therapy; Pinnacle Reduces Below 5% In Cochlear; Macquarie Below 5% In Impedimed; Jimmy Thomas, Ivy Ponniah Take 6% Of Genetic Technologies; Invitrocue CEO Dr Steven Fang Replies To Spill Claims; Race Appoints Dr Daniel Tillett Director; Somnomed Appoints Matthew Conlon For North America Sales
 
Sep 16, 2019
LBT: APAS Wins CE Mark, Meets Golden Staph Standards; Adalta, GE Healthcare: Deal For I-Body Diagnostic Imaging; Botanix BTX1702 Papulo-Pustular Rosacea Trial; Novita Shortfall Raises $30k; Total $1.86m; Correction: Imagion, Telix; Cynata Requests ‘Fujifilm Option’ Trading Halt; Proteomics ‘Promarkerd Assay Development’ Trading Halt; Creso ‘Pharmacielo Acquisition’ Trading Halt; Creso Canada Marijuana Facility Licence; Alchemia To Be Australian Primary Hemp; Consolidation; Ed Graubart Replaces Polynovo US Sales Head Kevin Whiteley; Jeremy Green, Redmile Reduce To 12.4% Of Avita
 
Sep 13, 2019
Dr Boreham’s Crucible: Imagion Biosystems; Polynovo, FDA Novosorb Meeting For Burns; Proteomics Launches Promarkerd Kidney Test In Spain; Invitrocue Geoffrey Thomas Spill Call; Kifin Takes 7% Of Opthea; Viburnum Takes 19% Of Universal Biosensors; Phylogica Appoints Dr Fred Chen Advisor
 
 
 
 
Sep 9, 2019
Federal $15m For Reproductive Cancer Trials; Universal Biosensors, Siemens Xprecia Coagulation Deal; Pharmaust Starts Monepantel Dog Cancer Trial; Imagion Magsense ‘MRI Contrast Agent Potential’; Invitrocue Board Fight; Respiri Settles 14m Director Options Legal Action; Race Capital Raising EGM; Cardiex ‘Material Contract’ Trading Halt; Althea: Record Marijuana Scripts In August; Jencay Takes Profit To Below 5% In Bluechiip
 
Sep 6, 2019
Dr Boreham’s Crucible: Antisense Therapeutics; Botanix Synthetic Cannabidiol ‘Disrupts Bacterial Pathways’; CSL $12.4m CEO, CSO ‘Performance Rights’ AGM; S&P Promotes Polynovo To ASX200, Avita To ASX300; Pro Medicus Dr Sam Hupert, Anthony Hall Sell 2m Shares; Kinetic Below 5% Of Osprey; G Medical ‘ASX Query’ Trading Halt
 
Federal $32m For Translational Health Research; Novita Shortfall Raises $250k; Total $1.8m; Micro-X Wins $1.8m UK Defence Contract; Hyperion Below 5% In Cochlear; Crystal Amber Increases, Diluted To 68% Of GI Dynamics; WF Asian Below 5% In Simavita; Creso To Release 2.4m Voluntary Escrow Shares; Painchek Appoints Pete Shergill For UK Business Development; Cardiex Appoints Anthony Sloan, Rhonda Welch Executives; Auscann Appoints Dr Marcel Bonn-Miller Director 
 
Sep 4, 2019
Cynata: ‘MSCs Reduce Organ Transplant Rejection In Mice’; US FDA Lifts IDT Warning Letter; Orthocell: 8 Of 9 Rotator Cuff Patients Pain-Free; Immuron: ‘Travelan Binds To 71 Cholera Strains’; Clarity FDA Ind For Copper Sartate Neuroblastoma Trial; Adalta: I-Body Half-Life Can Be Customized; Respiri Launches Wheezo Asthma Diary; Mitsubishi Takes 5% Of Total Brain; BTC: Sharon Papworth CFO, Co Sec; Stuart Jones Corp Dev
 
Sep 3, 2019
Uniquest, Grünenthal Cone Snail Neuropathic Pain Drug; Phylogica: CPP Delivers Antisense Drug In Mice; Emvision Readies For Brain Scanner Stroke Pilot Trial; Starpharma: ‘One More SE Asian Vivagel BV Approval’; MGC 100-Patient Cannepil, MXP100 Marijuana Epilepsy Study; Bod: August Marijuana Pills Up 95% To 329 Scripts; Morgan Stanley Takes 5% Of Total Brain; Regal Funds Takes 10% Of Medibio; FIL Increases, Diluted To 9% Of Medibio
 
Sep 2, 2019
August BDI-40 Up 13%, Big Caps Up 3%, ASX200 Down 3% - Opthea Up 341%, Polynovo 31%; Osprey Down 32%, Clinuvel 21%; Compumedics Record Revenue $41.5m, Profit Up 43.2% To $4m; IQ3 Revenue Down 5% To $6.5m, Loss From $1k To $1m; Pharmaust Revenue Up 32.5% To $4.4m, Loss Down 36% To $1.6m; G Medical H1 Revenue Up 191% To $4.3m, Loss Down 20% To $10m; Cardiex Revenue Down 2.5% To $3.9m, Loss Up 1% To $3m; Immuron Revenue Up 30% To $2.4m, Loss Up 54% To $4.6m; THC H1 Revenue Up 67% To $2.1m, Loss Up 80% To $5.8m; Stemcell Revenue Up 437% To $1.6m, Loss Down 37% To $2.1m; US FDA Clears Oventus O2vent Optima; Antisense, Regulators Meet On ATL1102 For DMD; Amplia Receives 1kg AMP945 For Trial; Memphasys Receives $1.1m Federal R&D Tax Incentive; Neuroscientific Expects $2m Off-Shore R&DTI Over 3 Years; Director Andrew Kroger Takes 38% Of Cryosite; Allan Gray Reduces To 15% Of Impedimed; Medibio: Clarification; Admedus Requests 7th Funding Suspension Extension; Genetic Technologies Appoints Nick Burrow Director
 
Aug 30, 2019
Dr Boreham’s Crucible: Anatara Lifesciences; Mesoblast Revenue Down 3.6% To $25m, Loss Up 155% To $134m; Avita Revenue Up 50% To $17m, Loss Up 110% To $34.6m; Avecho H1 Revenue Up 409% To $4.2m, Loss To $2.3m Profit; Medlab Revenue Up 41% To $6.1m, Loss Up 72% To $8.2m; Allegra Revenue Down 15% To $4m, Loss Up 38% To $836k; Dorsavi Revenue Down 27% To $3.2m, Loss Up 8% To $4m; Adherium Revenue Down 53% To $2.8m, Loss Up 26% To $11.8m; Total Brain Revenue Even At $2.6m, Loss Down 63% To $8.6m; Nuheara Revenue Down 41% To $2.4m, Loss Up 35% To $10.0m; Micro-X Revenue Up 20% To $1.9m, Loss Down 41% To $9.8m; TBG H1 Revenue Up 21% To $1.6m, Loss To $10.5m Profit; Proteomics Revenue Up 25% To $1.5m, Loss Up 44% To $2.1m; Orthocell Revenue Up 26% To $1.2m, Loss Up 2% To $5.9m; Suda Revenue Up 186% To $1.2m, Loss Up 29% To $7.8m; Optiscan Revenue Down 52% To $1m, Loss Up 15% To $2.3m; Novita Shortfall Raises $1m; Total $1.6m; Regeneus Rights Raise $620k, $1.8m Underwritten; Telix Plans TLX250-CDx Japan Kidney Cancer Imaging Trial; CE Mark For Novita Tali Train; Elixinol: Appoints 25th Group Belgium, Luxembourg Distributor; Medibio, Compass 4th Deal For Ilumen Mental Health Study; Chelodina, Marble Bar Take 9% Of Medibio; Alcidion: Rebecca Wilson Chair, Ray Blight Director; Ingrid Player To Replace Cogstate Director Jane McAloon; Mach7 M-D Mike Lampron Starts On $410k A Year
 
Aug 29, 2019
Ellex Revenue Up 3% To $81.6m, Loss Up 14% To $5.8m; Probiotec Revenue Up 19% To $79m, Profit Up 33% To $4m; Palla H1 Revenue Up 20% To $27.4m, Loss Up 44% To $4m; Elixinol H1 Revenue Up 17% To $17.5m; Profit To $9m Loss; Alcidion Revenue Up 304% To $17m, Loss Down 96% To $84k; Benitec Revenue Up 4,175% To $16.2m, Loss To $4m Profit; IDT Revenue Down 9% To $12m, Loss Down 64% To $6m; Medadvisor Revenue Up 25% To $8.2m, Loss Up 83% To $8.2m; Invion Revenue Up 426% To $3.9m, Loss Up 175% To $2.55m; Rhinomed Revenue Up 51.5% To $3.3m, Loss Up 51.5% To $6m; OBJ Revenue Up 35% To $2.7m, Loss Up 1% To $1.7m; LBT Revenue Down 55% To $2.5m, Loss Up 62% To $4.4m; Starpharma: ‘HER-2 Dep-Drug Reduces Ovarian Cancer In Mice’; Janssen Exercises St Vincent’s Alzheimer’s Molecule Option; Paradigm: ‘PPS Reduces Cartilage Degradation 12%’; Alcidion Reports Chair’s Spouse’s Closed Period Share Sale; ASX Removes 3 Biotechs For Failure To Pay Fees; Total Brain, IBM Partner For Veteran Mental Health; THC Opens Gold Coast Marijuana Facility; BVF, Mark Lampert Take Profit To 5.25% Of Opthea; Bank Of America Reduces To 5.3% Of IDT; Richard Cashin Diluted To 12.7% In GI Dynamics; All Change At Medibio’s Board
 
Aug 28, 2019
Cogstate Revenue Down 25% To $32m, Loss Up 341% To $3.7m; Clinuvel Record Revenue Up 22% To $31m, Profit Up 37% To $18m; Cellmid Revenue Up 29% To $7.4m, Loss Up 58% To $6m; Genetic Signatures Revenue Up 71% To $5m, Loss Up 7% To $3.5m; Starpharma Revenue Down 45% To $2.7m, Loss Up 39% To $14.3m; Bioxyne Revenue Up 4% To $2.3m, Loss Up 4% To $1m; Bluechiip Revenue Up 83% To $1m, Loss Up 31% To $3.3m; Cogstate Raises $2.9m From Japan Distributor Eisai; Global Brands Buys Probiotec Celebrity Slim For $7m; Starpharma DEP-Cabazitaxel, DEP-Docetaxel ‘Early Efficacy’; Novita ‘Shortfall, CE Mark Application’ Trading Halt; FDA Guidance For Telix TLX591-CDx Prostate Cancer Imaging; US FDA Upgrades IDT; Australian Marijuana Licence; PBS Reimbursement For Mayne Pharma Kapanol Morphine; Heramed Herabeat, Heracare Hapvida Brazil Roll-Out; Medigard Cancels $615k Sol-Millennium Notes; Converts Loans; Noxopharm: ‘NOX66 Reduces Tumor Size; Pain, PSA Levels’; Regal Funds Takes 13% In Opthea
 
Aug 27, 2019
Nanosonics Revenue Up 39% To $84m, Profit Up 137% To $13.6m; Cann Revenue Up 174% To $4m, Loss Up 131% To $11m; Resonance Revenue Up 25% To $3.6m, Profit Up 466% To $1.3m; Cryosite $1m Legal Settlement; Novita Raises $485k Of Hoped For $2m; FDA Guidance For 2019 Mesoblast Cardiac Trial; BTC Chair Dr Richard Treagus $125k Bonus, $15k Pay Rise; Brian Leedman Exercises 5m Alcidion 8c Options; Cogstate Requests ‘Contract, Placement’ Trading Halt; Vivazome, Toolgen Collaborate On Crispr-Cas9 Research; Cann Lifts Mildura Marijuana Production By 40% To 70t; MGC Approval For Slovenian Medical Marijuana Research; Westmead Hospital 2019 Hospital Week; Bio-Melbourne ‘Formula For Success’ Conference
 
Aug 26, 2019
Admedus H1 Revenue Down 16% To $11m, Loss Up 3% To $12m; Mach7 Revenue Up 8% To $9.3m, Loss Up 43% To $7m; Acrux Revenue Down 64% To $1.2m, Loss Down 41% To $8.3m; Invitrocue Raises $966k; Exopharm Starts ‘Plexoval’ Exosome Wound Healing Trial; CE Mark Renewal For 3 Uscom Spirosonic Devices; Antisense: Acromegaly Europe Access Program On Hold; Nuheara To ASX: ‘NHS Recategorization Not Material’; Recce: 500% Production Increase; Cann Global, Pharmocann Marijuana Food, Cosmetics Deal; Pharmaust Receives Monepantel Dog Trial Tablets; G Medical Drops $25m Nasdaq IPO For OTCQB Listing; Noxopharm Receives $3.7m Federal R&D Tax Incentive; Crystal Amber Fund Takes 75% Of GI Dynamics; Matt Callahan, Stone Ridge, SRV Transfer Below 5% In Orthocell
 
Aug 23, 2019
Dr Boreham’s Crucible: Somnomed; Mayne Revenue Down 1% To $525.2m, Loss Up 111% To $283.8m; SDI Revenue Up 7% To $79.6m, Profit Up 30% To $7.3m; Next Science Revenue Up 222% To $3.5m, Loss Up 10% To $9.7m; Telix H1 Maiden Revenue Of $1.8m, Loss Up 100% To $10.4m; Oventus ‘Oversubscribed’ Rights Raise $2.3m; Total $9.3m; CE Mark For Resapp Smartphone Respiratory Diagnostic; W.H.O. Names Kazia GDC-0084 For Brain Cancer ‘Paxalisib’; MGC, Swinburne Test Marijuana Driving; Paul Cozzi Takes 10% Of Cardiex; Botanix, Orthocell Director Matthew Callahan Takes Leave
 
Aug 22, 2019
ASX Suspends Five Biotechs For Failure To Pay Fees; Pro Medicus Revenue Up 48% To $50m, Profit Up 92% To $19m; Polynovo Revenue Up 128% To $13.7m, Loss Down 47% To $3.2m; Cryosite Revenue Up 35% To $8m, Loss Up 39% To $1.7m; Cyclopharm H1 Revenue Up 2.5% To $6.5m, Loss Up 342% To $3m; PYC (Phylogica) CPP Delivers Antisense Drug In Mice; Mach7 $950k St Teresa’s Hospital Imaging Contract; GI Dynamics $10m Crystal Amber Notes; Adherium $1.8m One Funds, Summatix Convertible Notes; Immutep Granted European IMP321 Patent; Japan Accepts Orthocell Celgro Patent; European Patent Allowed For Cellmid Midkine Antibodies; Universal Biosensors: ‘Siemens Deal In September’; Resapp Requests ‘CE Mark Application’ Trading Halt; G Medical Requests Nasdaq Listing Trading Halt; Zelda: 103 Of 150 Marijuana Autism Trial Patients Recruited; Creso: Pharma Dynamics Africa Cannqix10 Distributor; Credit Suisse Below 5% In Adalta
 
Aug 21, 2019
Somnomed Revenue Up 12% To $59m, Loss Up 91% To $16.4m; Medical Developments Revenue Up 19% To $21m, Profit Up 327% To $1m; Impedimed Revenue Up 25% To $4.2m, Loss Down 12% To $24m; MGC Raises $4.75m, Plan For $1m More, To List On LSE; Cann Global (Qld Bauxite) Raises $5.95m, Return To ASX; Sloan Kettering Approves Optiscan Microscope For Trial; Noxopharm: NOX66 ‘Abscopal’ Response In Mice; Chair Dr Bill Garner Diluted To 17% Of Race
 
Aug 20, 2019
Visioneering H1 Revenue Up 99% To $3.4m, Loss Down 33% To $6.7m; Bionomics Revenue Down 5% To $4.5m, Loss Down 63.5% To $9m; Race Raises $1.45m At 10% Premium; Dr Daniel Tillett Takes 9%; Telix: 1st Australian Patient In Zircon Kidney Cancer Study; Adherium, Summatix Partner For Hailie Inhaler Sensors; Up To 28% Oppose Volpara Option Resolutions; Up To 17% Of Medibio EGM Oppose Share Issue; Creso: 1st Pharmacielo Columbian Marijuana To Switzerland; Jencay Capital Takes 5.5% Of Ellex; Escrow End Reduces Life Biosciences To 31% Of Alterity; Genera Loses Chair Dr Damian Pethica, Co Sec Melanie Leydin; Cardiex: Chris Dax Atcor Head, Doug Kurschinsky G-M 
 
Aug 19, 2019
Uscom Revenue Up 27% To $3.6m; Loss Down 29% To $1.4m; Telix: ‘$9.6m Applications For $5m Share Plan’; Acrux Files ANDA For Generic Emla Local Anaesthetic; Medibio Extends Share Plan To $1.2m; Ellume To Open Expanded Brisbane Offices; MGC Requests ‘Capital Raising’ Trading Halt; BVF, Mark Lampert Reduce To 9.5% Of Opthea; John Gleeson Below 5% Of Uscom
 
Aug 16, 2019
Dr Boreham’s Crucible: Opthea; Cochlear Revenue Up 7% To $1,446m, Profit Up 13% To $277m; Medlab Marijuana Extract Nanabidial ‘Safe, Fast-Acting’; Japan Patent For Neuren’s NNZ-2591 For Brain Disorders; Exopharm Share Plan Raises $1.1m Of Hoped-For $2.8m; Race Requests Capital Raising Trading Halt; Admedus Tells ASX 4C Funds Query: ‘Working On It’; Regal Funds Takes 12% Of Opthea; Cho, Unlimited Innovation Increase, Diluted To 68% Of Invion
 
Aug 15, 2019
Pharmaxis Revenue Down 74% To $13m, Profit To $20m Loss; Starpharma: 1st SE Asian Vivagel BV Approvals; Federal $3m For SDI Dental Amalgam Alternatives; Oventus: 2 More US Sleep Groups Adopt O2vent; Cynata Talks Take-Over, CYP-001 With Sumitomo, Fujifilm; Noxopharm’s Nyrada Hopes For $8m ASX IPO; Kifin Takes 5% Of Opthea; Walker Group Sells 14m BTC Shares To LHC; LHC Capital Takes 11% Of BTC; SG Hiscock Takes 6% Of Bod Australia; Pharmaxis Issues CEO Gary Phillips 927k Options
 
Aug 14, 2019
CSL Record Revenue Up 8% To $12.5b, Profit Up 11% To $2.8b; Osprey H1 Revenue Up 54% To $2.7m, Loss Up 5% To $12.6m; Mesoblast: Investigator Remstemcel-L For Chronic GvHD Trial; Nuheara NDIS Hearing Equipment Provider; Mach7 Wins 3 US Imaging Contracts Worth $500k; Bod: Human Proteins With Marijuana For Ageing; Baker Brothers Takes 11% Of Opthea; Australian Ethical Diluted To 4.99% Of Immutep; Suda Appoints Dr Richard Franklin Anagrelide Director; Vivazome Appoints Dr David Haylock CSO
 
Aug 13, 2019
MDGH: Novo Nordisk Buys Moxidectin River Blindness Voucher; Federal $1m For Emergency Stroke Treatment; Kazia Completes Phase I Part B Cantrixil Recruitment; Race Granted 3rd US Bisantrene Patent; Regeneus Reduces Staff, Pay, Costs By 50%; MGC: ‘100 Cannepil Marijuana Patients’; Tetra Deal 
 
Aug 12, 2019
Heramed Appoints Duttenhofer Germanic Distributor; ASX Suspends Invitrocue; Alchemia To Australian Primary Hemp AGM; Dr Fred Grossman Replaces Mesoblast’s Dr Donna Skerrett; Adalta Loses Founding CEO Samantha Cobb
 
Aug 9, 2019
Dr Boreham’s Crucible: Shareroot; MCRI Starts Paediatric Influenza Study; Botanix Completes $40m Placement; Suda Lodges TGA Marketing Knockback Appeal; Malta Approves MGC Marijuana Facility; Creso: Medleaf NZ ‘Targets Not Material’; Gayle Mcgarry, Caperi Reduce, Diluted To 7% Of Botanix; Callahan, Horgan, Shenasaby Diluted To 7% On Botanix; Phylogica ‘Re-Brands’ As PYC Therapeutics
 
Aug 8, 2019
Telix TLX591-CDx Tests Enzalutamide For Prostate Cancer; Nuheara Sells Peru Mining Interests For $369k; Invitrocue, Singapore Hospital Work On Onco-PDO; Bioscience Managers $5.5m For CSIRO, Pharmamark Intencap; Phylogica ASX 63% Query: ‘Results Published Next Morning’; Immuron: IMM-124E Fails Alcoholic Hepatitis Study; Singapore Approves Polynovo Novosorb Wound Treatment; Starpharma Begins Dep-Irinotecan Solid Tumor Trial; Recce European Antibiotic Patent; Admedus Loses Arcomed Distribution; Total Brain, Everyday Health Partner; Elixinol $27m Pet Releaf Marijuana Extract Deal 
 
Aug 7, 2019
Opthea Jumps 160% On OPT-302 Wet AMD Result; CSL To Move 3km To Haymarket; Victoria Government; Genetic Technologies Ends Blockshine J-V; Back On ASX; Correction: Cellmid; Novita Rights Offer For $2m; Paradigm Files Zilosul FDA IND, Expanded Access For OA; Althea Prescribes 1,523 Medical Marijuana Patients; Summit Medical Transfers BTC Distribution To Avanos; MGC Completes China Marijuana Food Additive Market Test; Total Brain, CNA Insurance Work On Mental Health; Zhang Lishan, Star Bright Took 23% Of Admedus Last Year
 
Aug 6, 2019
Immutep Rights Offer Raises $6m, Total $10m; Bod Director, Management Options Raise $1.2m; Suda: ‘Zolpimist Spray Beats Tablets For Insomnia’; Painchek: Singapore Approval; Allium Aged Care Licence; Phylogica: ‘Peptide Effective In Retina Tissue In-Vitro’; Imagion Files US FDA Pre-Submission; Cellmid: India’s K2B South Korea Évolis Distributor; Creso Appoints Medleaf NZ Marijuana Distributor; Volpara AGM: 900k Director Options; Bod CEO Joanne Patterson Increases, Diluted To 7.8%; Naos Takes 19.65% Of BTC; BTC Appoints Peter Mears Advisor
 
Aug 5, 2019
Telix, DKFZ Work On Fluoro Dye For Prostate Surgery; Anatara To Licence Detach Piglet Diarrhoea Treatment; Medlab To Expand US Food Additives; Reva Receives Further $1.8m Loan; Opthea Requests Phase IIb OPT-302 Results Trading Halt; Allan Gray Increases, Diluted To 16% Of Impedimed; Alterity (Prana) Releases 18.6m Escrow Shares, 10m Options; Admedus Requests 6th Funding Suspension Extension; BTC Appoints Bruce Hewett Director
 
Aug 2, 2019
Dr Boreham’s Crucible: Regeneus; Proteolytics: $6m For Opal-A, Pl-001 For Wound Therapy; Immutep Underwritten Rights Raise $6m; Total $10m; S&P Dow Jones Promotes Pro Medicus To ASX200; ASX Suspends Genetic Technologies On Chapter 10 Breach; Federal Government ‘Boosts Marijuana Industry’; Cann Global Appoints Austin, Cohen, Easterling Directors
 
Aug 1, 2019
July BDI-40 Up 6%, Big Caps Up 7%, ASX200 Up 3%, NBI Down 3% - CSL Breaks $100b, Pro Medicus Through $3b; Botanix Placement To Raise $40m; Regeneus Raises $2.3m, Rights Issue For $3.2m More; Polynovo Expects Revenue Of $9.4m; Admedus H1 Receipts $10m, Less Than 2 Quarters Cash; Telix: ‘TLX591-CDx Beats Axumin For Prostate Cancer’; Telix, Merck KGaA Combine Unnamed Molecules, Radiation; Probiotec Completes Abs Acquisition; Medadvisor Secures 1st UK Pharmacy Customer; Althea Launches Medical Marijuana In The UK; Creso: 1st Burleigh Heads Cannqix 50 Marijuana Order; Adalta Appoints Dr Rosalind Wilson Director; Botanix Appoints Richard Peterson CFO, Howie McKibbon, CCO; Ausbiotech, J&J Innovation Excellence Awards Open
 
Jul 31, 2019
Amplia Rights Raise $689k Of Hoped For $2.2m; Total $1.2m; Neuroscientific: Emtin-B ‘Statistically Significant’ In Rats; Clinuvel Receipts Up 36% To $32m; Mesoblast Milestones Take Receipts Up 203% To $45m; Avita Receipts Up 73% To $17m; Bionomics Receipts Up 22% To $9m; IQ3 Receipts Down 16% To $6m; Impedimed Receipts Down 3% To $4.5m; Pharmaust Receipts Up 27% To $3.8m; G Medical H1 Receipts Up 312% To $3.7m; Rhinomed Receipts Up 77% To $3.1m; Nuheara Receipts Down 42% To $2.35m; Micro-X Receipts Up 77% To $2.3m; Bioxyne Receipts Down 5% To $1.75m; Telix Posts $1.6m H1 Maiden Receipts; Suda 1st $1m Receipts, Without Westcoast; Invitrocue Less Than 2 Quarters Cash; Capital Raising; Regeneus Has Less Than Two Quarters Cash; Expects Funding; GI Dynamics: Surgical Specialists Of Louisiana Joins US Trial; Platinum Reduces To 7.6% Of Antisense; Tribeca Below 5% Of Cann; Investors Mutual Takes 9.7% Of Mayne Pharma; Memphasys Appoints Shane Hartwig Director
 
Jul 30, 2019
European Patent For Opthea OPT-302; Medibio, Compass Partner For Mental Health Trial; MGC: ‘Additional Information Cannabinoids And Brain Cancer’; Biotech Daily Appendix 4C Reports Policy; Elixinol Receipts Up 18% To $16.4m; Volpara Q1 Receipts Up 137% To $2.2m; Medadvisor Receipts Up 24% To $8m, 2 Quarters Cash, Just; Medlab Receipts Up 24% To $5.8m; Proteomics Receipts Up 111% To $1.7m, Almost 2 Quarters Cash; Cann Receipts Up 140% To $1.5m; Respiri Has 2 Quarters Cash, With $3.4m Placement; Recce Has Cash With Expected Capital Raising; Stemcell Has Two Quarters Cash; Imagion Has Less Than 2 Quarters Cash; ‘Will Raise Capital’; Botanix Requests Capital Raising Trading Halt; Neuroscientific Requests ‘R&D Program’ Trading Halt; Regeneus Requests Capital Raising Trading Halt; Hyperion Takes 5% Of Cochlear; Genetic Technologies To Appeal Nasdaq Notice; Clarity Appoints Ex-Viralytics Robert Vickery CFO
 
Jul 29, 2019
Applications Open For $250k Gilead 2020 Fellowships; Zucero Adds Bowel Cancer To Pixatimod, Opdivo Combo Trial; Alterity: ‘PBT434 Safe, Tolerated In Elderly Volunteers’; Neuren Files 3 NNZ-2591 FDA Orphan Applications; TGA Approves Proteomics Promarkerd; Indonesia Patent; Dorsavi Receipts Down 13% To $3.7m; Resonance Receipts Up 33% To $3.5m; Maiden Cash-Flow Positive; Medibio, Wellteq Partner For Employers, Insurers; Elixinol, Pharmacare Partner For Cannabidiol Capsules; Bod Appoints PCCA UK, Ireland Marijuana Distributor; Respiri Takes Capital Raising Halt To Suspension; Kinetic Increases, Diluted Below 5% In Impedimed; Macquarie Takes 5% Of Impedimed; Leon Serry, City Castle Below 5% In Adalta; Anteo CEO Derek Thompson Starts On $280k
 
Jul 26, 2019
Dr Boreham’s Crucible: Imugene; Resmed Revenue Up 11% To $3.8b, Profit Up 4% To $758m; Cellmid Receipts Up 19% To $6.4m; 6 Months Cash; Profit 2019-’20; Next Science Receipts $2.8m; Oncosil Pleads Schultz To ASX 31% Query; Oventus $7m Placement, $2.3m 1-For-20 Rights Issue; Proteomics $418k Linear Contract; Cann Wins Marijuana Manufacture Licences; Federal Court Grants Micro-X 2 Days For Cleansing Notices; Neuroscientific Releases 1.16m Shares From ASX Escrow; Kemper Shaw Reduces To 10% In Imagion; William Taylor Nominees Reduce To 7% In Imagion
 
Jul 25, 2019
Orthocell: ‘Celgro Repairs Rat Nerves Better Than Sutures’; Mesoblast: ‘Article Supports MPCs For Heart Failure’; Race Treats 1st Bisantrene AML Patient; Pharmaxis Revenue Up 29% To $12m; Genetic Signatures Receipts Up 49% To $4.8m; Redhill H1 Revenue Down 31% To $4.7m; Universal Bio H1 Revenue Down 71% To $4m; Creso: 1 Quarter Cash, Awaiting $122m Pharmacielo Sale; Imagion Receives $2m R&D Tax Incentive; Althea Raising $30m For Canada’s Peak Marijuana Processing; Bod: 220 Medical Marijuana Scripts In 2 Months; Airxpanders Files Liquidation With US Sec; Micro-X Requests Cleansing Notice Trading Halt; Respiri Requests Capital Raising Trading Halt; Benitec Below Nasdaq $US1 Bid Rule
 
Jul 24, 2019
Living Cell NTCell ‘Parkinson’s Benefit, Sans Other Drugs’; Exopharm Placement Raises $4.4m; Share Plan For $2.8m; US Patent For Painchek Facial Recognition Pain Assessment; Visioneering Myopia Contact Lenses Hong Kong Registration; Cynata Tells ASX: $204m Offer ‘Incomplete, Confidential’; Antisense Treats 5 Of 9 Duchenne ATL1102 Patients; Compumedics Pleads Schultz To ASX 9% Query; Althea Takes ‘Acquisition, Capital Raising’ Halt To Suspension; MGC Claims: ‘Cannabinoids Kill Glioblastoma’ - In Vitro; Australian Ethical Takes 10.5% Of Somnomed; FIL Diluted To 14% Of Medibio; Oventus Requests Capital Raising Trading Halt
 
Jul 23, 2019
Amplia: ‘AMP945 Reduces Tumor Sizes And FAK In Mice’; Phylogica: ‘Peptides Deliver 4 Times Antisense Drug In Mice’; Regeneus: ‘Progenza Reverses Allodynia In Rats’; ASX Queries Benitec Xmas Eve BB-401 Trial News; Palla (TPI) $36m Unnamed European Codeine Deal; Somnomed Receipts Up 8% To $65m; Cogstate Receipts Down 7% To $40m; Expanded Alcidion Receipts Up 416% To $21.5m; Mach7 Receipts Up 8% To $10m; Uscom Receipts Up 21.5% To $2.5m; Thomas Jefferson Joins GI Dynamics Endobarrier Trial; Pharmaust Pleads Schultz, Dog News To ASX 26% Query; Tribeca Takes 5% Of Cann; Hybrid Holdings Takes 7.5% Of Pharmaust; New H2 Takes 18% Of Bod, Tribeca 8%, SG Hiscock Below 5%; Sienna To Release 27m Escrow Shares; Medibio Capital Raising, 21.6m Management Options EGM; Simavita Appoints Alan Fisher Director, Michael Spooner Exec; New Elixinol Jobs For Ettenson, Smith, Harrison, Atcha; Bod Appoints Akash Bedi, Patrice Malard H&H Directors
 
Jul 22, 2019
Kazia, Sloan Kettering GDC-0084, Radiation For Brain Metastases; Patrys: ‘PAT-DX1, Radiation Reduces Tumors, No Tox, In Mice’; Corrections: Pharmaxis; Telix: Denmark For Europe TLX591-CDx Reference; Exopharm: Exosome Wound Trial, ‘Capital Raising’ Halt; Bionomics Further $1.3m Federal R&D Tax Incentive; Total $7.9m; Shareroot Shortfall, Placement Raise $780k; Total $1.3m; Regeneus: ‘Progenza For OA Pain Focus, Drop Animal Health’; Euro Patent For Suda’s Anagrelide; Althea Requests ‘Acquisition, Capital Raising’ Trading Halt; Elixinol Buys Microencapsulation IP For Hemp Products; Total Brain Joins American Heart Study; Invion COO Craig Newton To CEO, Dr Greg Collier Director; Anteo Loses CEO Harley Frankfurt, Christopher Parker Back; Simon Glover Replaces Medadvisor CFO Carlo Campiciano
 
Jul 19, 2019
Dr Boreham’s Crucible: Pharmaxis; Cynata Tells ASX: ‘Sumitomo Dainippon Offered $204m’; Impedimed Underwritten Rights Raise $14m; Noxopharm Takes Lind, CST $26m Equity-Draw-Down Facility; Resonance $1m Unnamed US Company Trial Contract; Medibio, Compass 2nd Deal For Ilumen Mental Health Study; FDA Tells Medical Developments: One More Animal Study; Telix Readies For Japan TLX250-CDx Kidney Cancer Trial; Zelda To Acquire Emerald Clinics Marijuana Data; Hong Kong’s Health & Happiness Takes 18% Of Bod; 2 Directors; Impedimed Pleads Schultz To ASX 27% Query; Simavita Lodges H1 Report, Reinstated To ASX; Australian Ethical Takes 5% Of Immutep; Avecho Loses Joint Co-Sec Michael Sapountzis; Maria Maieli Replaces Ellex 3-Month CEO Ged Wallace
 
Jul 18, 2019
Sienna: Building An In-Vitro Diagnostic Portfolio; Telix Receives $9.3m R&D Tax Incentive; Federal $21m For 13 Dementia Projects; Suda Appeals TGA Easter Artimist Regulatory Refusal; Imagion Up 155% On Magsense FDA Breakthrough Designation; Neurotech Pleads Schultz To ASX 32% Query; Visioneering H1 Receipts Up 103% To $3.5m, Two Quarters Cash; Anteo Unmarketable Parcel Facility; Shareroot Requests Shortfall Placement Trading Halt
 
Jul 17, 2019
Imugene - Prof Yuman Fong: ‘Industrial Process To Invent CF33’; Telix Placement Raises $40m; Share Plan For $5m More; Airxpanders Goes Under; Immuron To Raise $1.9m; Trading Halt; Shareroot Rights Raise $510k, $445k Shortfall; FDA Approves Livac Organ Retraction System; US, European Patents For Uscom 1A, BP+ Combo; Patrys European Patent For Doexymab 3E10; Memphasys Pleads Schultz To ASX 21% Query; Cynata Requests ASX Query Trading Halt; Bod Requests ‘Material Strategic Partnership’ Trading Halt; Elixinol’s Nunyara Wins Marijuana Manufacture Licence; Correction: Nuheara, Farjoy; Pinacle’s Hyperion Below 5% In Cochlear; CSL Appoints Anjana Narain Seqirus Head; Nanosonics Appoints Geoff Wilson Director
 
Jul 16, 2019
Biocurate, Servier To Accelerate Drug Discovery; Clarification: Victoria Government, Johnson & Johnson Innovation; Starpharma Receipts Up 1% To $2.8m, $51m Cash; Immuron Revenue Up 29% To $2.6m, 1st US $1m Travelan Sales; Universal Biosensors Siemens Strips Up 156% To $2.3m, $51m Cash; FDA Approves Airxpanders Aerofoam; Director Zeta Peach Resigns; Adalta Starts AD-214 For IPF Toxicology Study; Alcidion To Supply Script System For Dartford, Gravesham NHS; Oventus ‘Lab-In Lab’ Agreements With 3 US Companies; Stemcell United, Malaya Uni Research Agreement; Neuren Receives Final Payment From Lanstead; Total $12m; Nuheara’s Tim Robertson, Farjoy Increase, Diluted To 10%; M&G In And Out Of Medical Developments; Deutsche Bank Below 5% In Genetic Signatures; Bard1 Director Dr Irmgard Irminger-Finger Increases, Diluted To 8%; CEO Miriam Halperin Increases, Diluted To 8.5% Of Creso; Chair Boaz Wachtel Increases, Diluted To 5.5% Of Creso; Elixinol: Stratos Karousos CEO On $338k, Paul Benhaim CIO; Noxopharm: Dr Niechoda Director, Nyrada Board Changes
 
Jul 15, 2019
Victoria’s Innovation Minister Martin Pakula Talks Biotech; Telix: FDA Guidance For Zircon TLX250-CDx Kidney Cancer Trial; Telix ‘Capital Raising’ Trading Halt; Imugene Buys City Of Hope, Vaxinia CF33 Oncolytic Virus; Osprey: H1 Customer Receipts Up 67% To $1.8m; Rhinomed: ‘Pronto Vapor Dilators Win CE Mark’; Oventus: 1st ‘Material Contract’ With Unnamed US Group; Pharmaust Ethics Approval For Dog Cancer Trial; Botanix: ‘AB2367 Kills Clostridium Difficile In-Vitro’; Micro-X To Build Its Carbon Nanotube X-Ray Tubes; Adherium Wins FDA 510(K) Clearance For Hailie Sensors; Cogstate Chair Martyn Myer, Family Increase, Diluted To 15%; William Garner Takes 18.8% Of Race; Race CEO Peter Molloy Diluted Below 5%
 
Jul 12, 2019
Dr Boreham’s Crucible: Nuheara; Osprey Welcomes US Kidney Initiative; Nuheara ‘Kiosks’ In 10 Best Buy Canada Shops; M&G Prudential Takes 11.7% Of Mesoblast; Mason Stevens Takes 6% Of Patrys; Pura Vida Reduces To 10% Of Factor; Freshero, Canadian Nickel Cease Factor Substantial; Genetic Technol: CFO, Co Sec Viney Out; Hains, Stedwell In
 
Jul 11, 2019
Prescient Starts Phase Ib PTX-100 Multiple Cancers Trial; Dimerix Europe, Canada Patents; President Donald Trump; GI Dynamics: ‘Brigham And Women’s Lead Endobarrier Site’; MGC Revenue Up 569% To $1.7m; Two Quarters Cash; Rhinomed: ‘Mute Fastest Growing US Nasal Strip’; Zelda Pleads Schultz To 46% ASX Query; Micro-X Expands Adelaide Production Facility; Shareroot: ‘Opyl Platform Signs 1st Customers’; FIL Increases, Diluted To 8% Of Cogstate; Nebula Neuro, Howitt Diluted To 6% Of Cogstate; Jamber, Amber Schwartz Take 5% Of Creso; Genera Appoints CMO Dr Damian Pethica Chairman
 
Jul 10, 2019
Airxpanders: ‘TGA Lymphoma Fear May Suspend Aeroform’; Bard1 Rights Raise $2.5m; Total $7.5m; Medibio To Raise $4m In Placement, Share Plan; Cardiex: US Expands Blood Pressure Guidelines; Benefit; Dimerix Completes DMX-200 FSGS Recruitment; Total Brain, 3 Unnamed US Companies Partner For Monitoring; Factor Board Spill Group Withdraws Spill Request; Neuroscientific Releases 1.16m ASX Escrow Shares; Australian Ethical Takes 16% Of Cogstate; Dagmar Dolby Increased, Diluted To 15% Of Cogstate; Tom Granger, Anacacia, Wattle Below 5% In Cogstate; Regal Funds Takes 15% Of Visioneering; Willoughby, Hishenk, Abolakian Take 17.5% Of Kazia; Macquarie Below 5% In Patrys; Mason Stevens
 
Jul 9, 2019
Immutep Placement, 1-For-11.8 Rights To Raise $10m; Uscom: ‘Record Uscom1A, BP+, Spirosonic Sales’; Invex $12m IPO For Exenatide For Raised Intracranial Pressure; Mach7 Software Deal With Advocate Aurora Health; Memphasys $4.2m Placement For Felix Device Manufacture; Airxpanders: Q2 Revenue Up 14% To $2.6m; THC Wins Southport Marijuana Facility Licence; Medibio Takes ‘Capital Raising’ Trading Halt To Suspension; Unisuper Below 5% In Impedimed; Mason Stevens ‘Below 5% In Patrys’; Recce: Dr Prendergast Chair; Dr Melrose, Dr Ward Directors; Genetic Technologies Loses Director Sam Lee
 
Jul 8, 2019
Volpara Adds Screenpoint Transpara For Breast Screening; Imugene: ‘HER-Vaxx 80% Tumor Reduction’; Ellex: 4-Year Lead Trial Data Shows ‘2RT Slows AMD’; Cogstate Raises $4m From Australian Ethical; Cellmid Tells ASX 29% Query: ‘No Confidentiality Breach’; Somnomed: 500,000 Patients Treated With Somnodent; Anteo, Unnamed Brand Work On Battery Density; UBS Takes 5% Of Adalta; Crystal Amber Takes 65% Of GI Dynamics; Emvision Releases 300k Escrow Options
 
Jul 5, 2019
Dr Boreham’s Crucible: Orthocell; Nuheara Tells ASX: Samsung’s Harman Bid $82.5m; Nuheara Raises $4m; Shareroot Divests ‘Non-Core’ Ludomade; Cogstate Requests ‘Placement’ Trading Halt; Immutep Requests ‘Capital Raising’ Trading Halt; Memphasys Requests ‘Capital Raising’ Trading Halt; Macquarie Group Below 5% In Impedimed; Yuuwa Capital Diluted To 33% Of Adalta 
 
Jul 4, 2019
Medlab Q4 Revenue Up 135% To $3m; Cellmid Expects Q4 Record Revenue Of $2.45m; Elixinol Appoints Medvec German Distributor; Medibio Requests ‘Capital Raising’ Trading Halt; THC Requests Marijuana ‘Manufacture Licence’ Halt; Australian Ethical Below 5% Of Mach7; Platinum Increases, Diluted To 8.5% Of Adalta; Hishenk Takes 17% Of Kazia; Jimmy Thomas, Ivy Ponniah Take 5% Of Genetic Technologies; Jimmy Thomas, Ivy Ponniah Take 5% Of Stemcell United
 
Jul 3, 2019
Neuroscientific: ‘Emtin-B Grows Nerves, Synapses In Rats’; Sirtex CEO Gilman Wong Pleads ‘Guilty’ To Insider Trading; Unnamed Company Withdraws $83m Nuheara Bid Intent; Nuheara Requests Capital Raising Trading Halt; Uniquest Appoints Ex-WEHI Dr Julian Clark Director; Telix Appoints Grupo RPH For TLX591-CDx In Latin America; Creso Repays $5.15m Convertible Note Debt For Acquisition; BTC Director Peter Jones, Helen Jones Increase, Diluted To 7%; Emvision: Ruth Cremin Head Of Quality, Regulatory Affairs; Stemcell Appoints Theng Dar Teng Advisor
 
Jul 2, 2019
Painchek, MCRI Partner For Infant Study; Nuheara Iqbuds, Iqstream TV On Federal Hearing Program; Zelda Starts Marijuana Opioid Reduction Trial; Telix Signs PI Medical Netherlands TLX591-CDx Distributor; Correction: Probiotec; Micro-X, Thales Complete $10m Note Agreement; Pharmaust’s Epichem Repays $750k Federal Loan For Lab; Creso’s Mernova Sells 1st Marijuana Flower Harvest; E-Sense 300-Litre Vaporspec Marijuana E-Juice Order; CEO Paul Rennie Increases, Diluted To 12% Of Paradigm; Unisuper Reduces To 5.5% In Impedimed; Sigma Takes 10% Of BTC; Walker Group Diluted To 5.6% Of BTC; W Whitney George, Sprott Take 25% Of Rhinomed; Genera Loses 9-Year Chairman Lou Panaccio; Stemcell Loses Director Glenn Davies
 
Jul 1, 2019
13-Year BDI-40 Up 339%, Big Caps Up 681%, ASX200 Up 30%; 12-Month BDI-40 Up 40%, Big Caps Up 13%, ASX200 Up 7%, NBI Down 1%; 12-Month Stars: Avita 792%, Genetic Signatures 268%, Paradigm 236%; Probiotec $28m For Australian Blister Sealing; Profit Up; Avita: ‘Recell Reduces Diabetic Foot Ulcers 83%’; Volpara Retail Rights Raise $4.8m; Total $55m; Visioneering Rights Raise $5.8m, Total $11.1m; Emvision Prepares Stroke Brain Scanner Pilot Trial; Biointelect, Boston’s New Perspectives Partner For Support; US Patent For Sienna hTERT Cancer Test; Resapp Recruits 200 Of 250 Sleep Study Patients; Heramed Foetal Cardiac Monitor At Brazil’s Hapvida Hospitals; Auscann, Tasmanian Alkaloids Marijuana Resin Deal; Medibio Signs Compass For 1st UK Ilumen Test; Crystal Amber Extends Gi Dynamics Convertible Note Date; Admedus Requests 5th Funding Suspension Extension; Regal Reduces To 6.6% Of Oncosil; Director Dr William Garner Reduces To 14% In Race
 
Jun 28, 2019
Dr Boreham’s Crucible: Patrys; Victoria To Appoint Israel Liaison Officer; Rhinomed To Support Monash Uni Sleep-Suicide Study; Anatara Plans Australia Detach For Pig Diarrhoea Sales; Lifespot Requests ‘Product Development, Distribution’ Halt; Blackcrane Takes 9% Of Avita; Dr Errol De Souza Continues As Bionomics Interim Chairman
 
Jun 27, 2019
Impedimed Underwritten Rights To Raise $14m; Novita, Victoria Partner For Tali Attention Deficit Test; Starpharma Betadine Bacterial Vaginosis Europe Launch; LBT Receives Second $1.5m Of $4m SA Government Loan; Cryosite Write-Off; Mark Byrne COO, Bryan Dulhunty Exec; Phylogica ‘CPP Delivers More Drug To Mouse Retinas’; Imagion Loses Director Dr John Hazle, Continues As Advisor; Cardiex Appoints Chris Dax, Dr Sean Merritt Executives
 
Jun 26, 2019
Bionomics BMC210 Fails Agitation Trial; Suda ‘Oversubscribed Rights’ Raise $3.9m; Alcidion Renews $970k Western Sussex Patientrack Contract; Dimerix Opens WA Recruitment For DMX-200 Trials; Rhythm Adds Alfred Hospital To Colostat Trial; Bank Of America Sells, Transfers Shares, Takes 5% Of IDT; Jencay Capital Takes 12% Of Universal Biosensors; Macquarie Takes 5% Of Impedimed, Yet Again; Airxpanders 3rd ‘Debt Agreement’ Suspension Extension; Salesh Balak Replaces Universal Biosensors Rick Legleiter
 
Jun 25, 2019
Immutep Completes IMP321 Aipac Cancer Trial Enrolment; Althea Project Twenty21 For 20k UK Marijuana Patients; Anteo Works With Silicio Ferrosolar For Lithium Batteries; Factor Faces 2nd Board Spill Call; Impedimed Requests ‘Capital Raising’ Trading Halt; Unisuper Takes 7% Of Impedimed; Simon Chamberlain Replaces Alcidion’s Geoffrey Rohrsheim
 
Jun 24, 2019
FDA Orphan Status For Mesoblast’s Revascor; LBT Apas Independence ‘100% Accurate For UTIs In 13 Seconds’; Oventus Signs 2 Canadian Sleep Groups For $1m O2vent; Dimerix Licences Receptor-Hit To Excellerate Bioscience; Shareroot Rights Issue For $1m; 501-Implant Study Backs Admedus Cardiocel; Micro-X, Allora Settle $1.8m Invoice Dispute; Bionomics Requests ‘Trial Results’ Trading Halt; Credit Suisse Takes 5% Of Adalta; Dr John Lambert Replaces Amplia CEO Simon Wilkinson
 
Jun 21, 2019
Dr Boreham’s Crucible: Next Science; CSL Takes Over China Albumin Import; Nuheara: Puretone To Manage 3-Year Scotland NHS Contract; Australia Grants Immutep IMP321 Patent; Althea 1st UK Patient; Frankston Marijuana Plant Permit; Alchemia Quits Biotech To Be Australian Primary Hemp; Bod, Burleigh Heads Medicabilis (ECS315) Marijuana Deal; Morgan Stanley Below 5% In Total Brain
 
Jun 20, 2019
Pharmaxis: ‘FDA Wants Small Clinician Bronchitol Study’; Nuheara Iqbuds Boost On NHS Scotland Hearables Contract; Ashland $3.6m Avecho (Phosphagenics) Vital ET, TPM Licence; Medibio: ‘Heart Algorithm 80% Accurate For Depression’; TGA Registers Oventus Exvent For Sleep Apnoea; Botanix: ‘BTX1801 Kills Super Bugs In-Vitro, Mice’; Jeffrey Emmanuel Takes 8.5% Of Bard1; Merchant Funds Takes 7.7% Of Bard1; David Williams, Moggs Creek, Take 5.5% Of Bard1; Kinetic Takes 5.6% Of Osprey; Kinetic Takes 5.6% Of Impedimed; Immuron Vice-Chairman Peter Anastasiou Takes 11%; Mach7 David Chambers, Damien Lim Swap Chairs, Mike Lampron MD
 
Jun 19, 2019
Federal Frontiers $9.5m For 10 Projects; Painchek Placement Raises $4.15m; Orthocell: ‘Celgro Halves Dental Implant Time’; Botanix BTX1308 ‘Anti-Inflammatory, Immune Response’; OBJ Joins Little Green Pharma For Magnetic Marijuana; MGC Appoints Onix Brazil Marijuana Product Distributor; Next Science Pleads Schultz, Publicity To ASX 46% Query; Heramed Launches Herabeat Foetal Heart Monitor; Airxpanders Pays Oxford Finance $727k For Debt Breach; Invictus: FDA ‘Broadly Supports’ Fatty Liver, Cancer Plans
 
Jun 18, 2019
Editorial: BNYM & Substantial Shareholder Notices; Medlab 2,000 Patient Nanabis ‘Observational’ Study; Bard1 Places $5m, Rights Issue For $2.5m More; Rhythm Signs Monash For Colostat Trial; Cardiex ‘Material Contract’ Halt, Suspension ‘Not Material’; GI Dynamics: Withdraws AGM Delisting Proposal; Bank Of NY-Mellon Reduces To 58% Of Genetic Technologies; Botanix Requests ‘Psoriasis Phase Ib Results’ Trading Halt; Botanix 17m Directors Options, Termination Benefits EGM; Max Johnston, Philip Powel Replace Bard1 Brett Montgomery; GI Dynamics Appoints Prof Steven Opal Advisor
 
Jun 17, 2019
FDA Approves Cochlear Nucleus Profile Plus; Anteo, Lumos Collaborate On Assay Development; TPI, Tasmanian Alkaloids End Poppy Dispute; Medibio, Partnerships For Health Intelligence J-V Writ; Painchek Requests ‘Capital Raising’ Trading Halt; Cardiex Takes ‘Customer Contract’ Halt To Suspension; Thorney Technologies, Tiga Take 11% Of Visioneering; Regal Funds Reduce, Diluted To 9% Of Visioneering; Credit Suisse Below 5% In Prescient; Bank Of New York Mellon Clients Take 21% Of Immuron; Alcidion Releases 160m Escrow Shares
 
Jun 14, 2019
Dr Boreham’s Crucible: Heramed; Burnet, Oxford Find Antibodies To Stop Malaria; Clinuvel: ‘Upgraded To ASX200’; Zoetis Terminates Anatara Detach Licence; Adalta Rights Raise Hoped-For $2m; Optiscan Raises $1.7m; Volpara Completes $21m MRS Acquisition; Bard1 Requests ‘Equity Raising’ Trading Halt; GI Dynamics: ‘Endobarrier Reduces Sleep Apnoea’; Althea Prescribes 1,000 Medical Marijuana Patients; Harbour Takes 6% Of Volpara; Ausbil Below 5% In Bionomics; TPI Changes Name To Palla Pharma; ASX Code To ‘PAL’
 
Jun 13, 2019
Academy Awards Clunies Ross Gongs; Telix Appoints Eczacibasi-Monrol Distributor; Osprey, Premier Quest Kidney Injury Data; Immutep Recruits 1st IMP321 Tacti-002 Cohort Patients; Oventus O2Vent Splint With Valves ‘Reduces Sleep Apnoea’; GI Dynamics Contracts First US Pivotal Trial Sites; THC Wins Marijuana Manufacture Licence; Cardiex Requests ‘Material Customer Contract’ Trading Halt; Phillip, Bioscience Managers Below 5% In Avita; Kinetic Ceases In Osprey; Kinetic Ceases In Impedimed; Crystal Amber Takes 49% Of GI Dynamics; Bank Of New York-Mellon Clients Reduce To 19% Of Immuron; BNY-Mellon Clients Reduce To 59% Of Genetic Technologies
 
Jun 12, 2019
Bod 300-Patient Pay-For Marijuana PTSD Observational Study; BTC Share Plan Raises $1.2m, Total $9.2m; Amplia Placements, Rights For $2.73m; US Patent For Starpharma, Astrazeneca DEP-Bcl2/Xl Inhibitors; Immuron: ‘Travelan Reduces Dysentery Inflammation In Monkeys’; Resapp Receives $1.8m R&D Tax Incentive; Telix, Osaka Uni Extend TLX101 For Cancer Collaboration; Avita: 3 Vitiligo, Acne Posters At Dermatology Meeting; Optiscan Requests Capital Raising Trading Halt; THC Requests ‘Manufacture Licence’ Trading Halt; Credit Suisse Reduces To 6% Of Prescient; Karst Peak, Adam Leitzes Reduce To 9.5% Of Avita; Paul Cozzi Takes 8% Of Visioneering; Paul Benhaim, Raw With Life; D&G Health Diluted In Elixinol; Canopy Growth Takes 13% Of Auscann; Eye Co Appoints Prof William Sponsel Advisor
 
Jun 11, 2019
Mesoblast, JCR Expand Temcell To HIE In Japan; Elixinol, RFI Partner For US Marijuana Expansion; Genetic Technologies Tells ASX: ‘Director Lee Training’; Next Science To Release 711k Escrow Shares; Zelda’s Mara Gordon Reduces To 5.8%; Merchant Takes 3.6%; Ming Hao Zheng, Ying Fan Increase, Diluted To 5% Of Orthocell; Credit Suisse Takes Loss, Reduces To 7.8% In Prescient; Respiri To Issue 10m Management Options
 
Jun 7, 2019
Dr Boreham’s Crucible: Medical Developments; Axovant Terminates Benitec $954m BB-301 OPMD Deal; Bio-Melbourne Women’s Lunch ‘Sold Out’; Nuheara Trades On US OTCQB Exchange; Canada’s Pharmacielo To Buy Creso For $122m In Shares; Imagion To Release 78m Escrow Shares, 9.6m Rights; MMJ 10m Share Buy-Back; Embark Investment Manager; MGC, RMIT Digital Cannabinoids Library; Noxopharm’s Nyrada Receives $486k R&D Tax Incentive; Paul Anderson, Matt Callahan, SRV Diluted In Orthocell; Chairman Dr Michael Monsour Takes 25% Of Analytica; Levenson Takes 7% Of Anteo; James Middleweek Takes 5% Of Adherium; Deborah Ambrosini Replaces Acrux CFO, Co Sec Tim Bateman
 
Jun 6, 2019
Visioneering Placement, Rights, Notes For $11m; Immutep Doses First Patient In Merck, Pfizer Cancer Trial; Benitec Requests ‘Existing Material Contracts’ Trading Halt; GI Dynamics 4 Endobarrier Meeting Presentations
 
Jun 5, 2019
Volpara Placement, Rights Raise $50m; Retail Rights For $5m; Elixinol Placement Raises $50m; LBT Raises $5m In ‘Oversubscribed’ Placement; Anteo ‘Oversubscribed’ Placement, Rights Raise $3.65m; Analytica Rights Raise $913k Of Hoped-For $2.7m; Suda, Cann Pharma $1.5m Plan For Cannabinoid Oral Spray; Global Kinetics Kinetigraph For Parkinson’s Brain Stimulation; Althea Wins Victoria Hemp Licence; Tissue Culture; Neurotech Pleads Schultz, Board Renewal To ASX 208% Query; Neurotech Launches Mente Autism Clinic Website; Regal Funds Takes 10% Of Opthea; Jencay Capital Takes 5% Of Bluechiip; OBJ Appoints Paul Peros Beauty CEO, Starts On $580k; Resapp Appoints Dr Naomi Fried, Dr Joseph Kvedar Advisors
 
Jun 4, 2019
Applications Open For $316k Victoria Prizes, Fellowships; Paradigm PPS Beats Saline For Ross River Virus Joint Pain; Starpharma: ‘Okamoto Launches 003 Vivagel Condom In Japan’; Imugene: ‘High Dose HER-Vaxx Shrinks Tumors’; Visioneering Requests ‘Transaction, Capital Raising’ Halt; Elixinol Requests Capital Raising Trading Halt; GI Dynamics ‘Considers Delisting From The ASX’; Suda Signs US, Hong Kong Companies For Expansion; Pharmaust: Catalent Makes Dog Cancer Trial Monepantel; MGC Receives Bulk Marijuana, Revenue; Admedus Requests 4th Funding Suspension Extension; Adrian Trevisan Sells All 19m Neurotech Shares
 
Jun 3, 2019
May BDI-40 Up 7%, Big Caps Up 4% ASX200 Up 1%, NBI Down 6%; Federal Opposition: Clare O’Neil, Brendan O’Connor Innovation; Volpara To Raise $55m, To Pay $21m For MRS Systems; Suda 3-For-1 Rights Issue For $3.4m; Uniquest, Pfizer Partner For Cancer; Starpharma, Astrazeneca 2nd Oncology Agreement; Clinuvel: FDA Extends Scenesse PDUFA Date; Medical Developments: Mundipharma For Penthrox Australia; OBJ Appoints Parafix Manufacturing Partner; Bard1 Euro Patent Validated In 6 Countries; Smart Top, Xianhui Meng Take 19% Of Uscom; LBT Requests Capital Raising Trading Halt; MGC Requests ‘Customer Contract’ Trading Halt; Alchemia Further Extends ‘Change In Activities’ Suspension; David Torrible Replaces Total Brain Director Stephen Koslow; Recce Appoints Dr David Bowers Advisory Chair
 
May 31, 2019
Dr Boreham’s Crucible: Invitrocue; Ausbiotech: ‘Sector Worried By Threat To R&D Incentive’; Althea Launches UK Concierge Marijuana Platform; Telix, Emory Trial TLX591-CDx For Cancer Imaging, ASX Query; BTC Completes $6.3m Admedus Infusion Acquisition; Up To 22% Oppose Imagion Placement Facility; TPI Backs Palla Name Change, 22% Support Withdrawn Spill; Yuuwa Diluted To 39% Of Adalta; Nanosonics Loses 9-Year Director Richard England; Admedus Loses 5-Month Director Lishan Zhang
 
May 30, 2019
Minister Karen Andrews Talks Biotech; Orthocell Raises $10.6m; Immuron Raises $2.9m; Patrys ‘PAT-DX1 Kills Breast Cancer Brain Metastases In Mice’; Mesoblast Begins FDA GvHD Submission; Noxopharm Enrols Darrt-1 NOX66 Prostate Cancer Trial; Resapp Names UK Consultancy Avanti Med; Universal Biosensors, Siemens Extend Term Sheet; BVF Reduces To 21% Of Pharmaxis; Immuron Chair Peter Anastasiou Increases, Diluted To 10.6%; Alcidion Pleads Schultz To ASX 13.6% Query; Airxpanders Loses CFO, COO Scott Murcray
 
May 29, 2019
Resapp Hires Unnamed UK Group For New Products; Actinogen Higher Dose Xanahes Trial Passes Safety Review; Bionomics Completes Strategic Review; Neurotech Pleads Schultz To ASX 55% Query; MGC, RMIT Win Australian Marijuana Research Licence; Empery, Ryan Lane Below 5% In Immuron; Cardiex Appoints Rhonda Welch Head Of Marketing; Redhill Appoints Prof June Almenoff CSO
 
May 28, 2019
Invion IVX-P02 Hits Cancer, No Cell Toxicity In Mice; Telix, FDA Prostate Cancer Imaging Meeting; Distributors; Paradigm: ‘Osteo-Arthritis Knee Pain Down 51%’; Federal Court Extends Micro-X Cleansing Notice; Orthocell Requests Capital Raising Trading Halt; Medlab Appoints Mega Lifesciences Nanabis Distributor; Sigma Takes 5% Of BTC; Walker Group Increases, Diluted To 8.5% Of BTC; Cellmid Appoints Bart Wuurman Lyramid Midkine CEO; TBG Loses Director, COO Eugene Cheng
 
May 27, 2019
Victoria $267m For Research, Jobs, Investment Funds; Federal Biotech Ministers: Karen Andrews, Greg Hunt; Biotech Daily Comment; Next Science: Grace Medical Distributes Sinus Lavage; TGA Registration For Genetic Signatures Easyscreen; Painchek: UK Contract 1st Offshore Deal; Bard1 Receives $521k R&D Tax Incentive; Cardiex: Presentation Backs Blumio BP Sensor; Chair Dr Richard, Karen Treagus, Diluted To 13.7% Of BTC; Director Peter, Helen Jones Increase, Diluted To 9.8% Of BTC; Micro-X Takes ‘Cleansing Notice’ Halt To Suspension; Eye Co Appoints Prof Jan Provis Advisory Chair; Stemcell Appoints Yanhua Huang, Qi Lu Directors
 
May 24, 2019
Dr Boreham’s Crucible: Oncosil Medical; Immuron To Raise $2.9m; Antisense ATL1102 DMD Trial Enrolled; Starpharma: DEP-Irinotecan, Cetuximab Kill Cancer In Mice; MGC Claims ‘Marijuana Toxic To Glioblastoma’, In-Vitro; Naos Takes 18.5% Of BTC Health; Goodbye Phosphagenics, Welcome Avecho
 
May 23, 2019
Starpharma: ‘Bacterial Vaginosis Trial Possible, FDA Talks’; Adalta Raises $5m, Rights Offer For $2m More; Genetic Technologies ADSs Raise $1.75m; Imagion Toxicology Study: ‘Magsense Safe For Breast Cancer’; Immutep IMP321, Chemotherapy Patent For Europe; Noxopharm Expands NOX66 Prostate Cancer Trial; FMR Takes 5% Of Somnomed; G Medical 2m Director Shares, 14.5m CEO Loan Shares AGM; Micro-X ‘Late Cleansing Notice’ Trading Halt; Creso Harvests First Canadian Marijuana Crop
 
May 22, 2019
Phosphagenics To Be Avecho Biotech; Dr Ross Murdoch; Oventus: Lane Dental, Sleepcues For O2Vent In Nth Carolina; Bio-Melbourne Moves To Collins Street; Rhythm Wins ISO Quality Certification; 2nd Chinese Patent For Sienna Sien-Net Blood Test; Total Brain Test ‘80% Accurate For Depression Drugs’; Investors Mutual Takes 8.5% Of Mayne Pharma; Redhill Hires 3 Staff For Talicia (RHB-105) Sales; Auscann: Ido Kanyon Starts As CEO
 
May 21, 2019
Cardiex Business, Marketing Operations In China; Adalta Requests Capital Raising Trading Halt; Cellmid Buys Back 499k Unmarketable Parcel Shares; Admedus Requests 3rd Funding Suspension Extension; ‘Bank Of New York Mellon’ Takes 26% Of Avita; Macquarie Takes 5% Of Impedimed, Again; Morgan Stanley Takes 7% Of Total Brain
 
May 20, 2019
Longas Morphoseq For DNA Sequencing; Nick McCooke CEO; FDA Approves LBT Apas Independence; Kazia, Alliance Partner On GDC-0084 For Brain Metastases; Noxopharm Claims NOX66 Efficacy For Prostate Cancer; Alcidion $700k NSW Child Health Contract; IDT Medical Marijuana Manufacturing Licence; Medadvisor, Zeullig Pharma Signs 1st Customer; Cardiex Partners With Health160 For China Tele-Health; G Medical Hopes For $24m Nasdaq IPO; Stemcell Takes 51% Of Yunnan Hemp Co For $794k; Alterity (Prana) To Release 270m Escrow Shares, 540m Options; Jason Colquhoun, 0971224 BC Below 5% In THC; Och Ziff Exits Total Brain; Cynata: Dr Brooke Replaces Dr Chiplin; Hires Dr Lipe; Imugene Appoints Dr Jens Eckstein Director; Botanix Appoints Vince Ippolito Executive Chairman On $400k PA
 
May 17, 2019
Dr Boreham’s Crucible: Pro Medicus; WEHI GSK126 For Cancer Targets Cause Of Asthma In Mice; Neuren NNZ-2591 Efficacy For Angelman, Pitt Hopkins In Mice; Immutep IMP321 Reduces Tumor Size At 9 Months; Rhinomed FDA, TGA Pronto Vapor Release Registration; Australian Super 6% Orthocell Notice; Matt Callahan; LBT US FDA Submission Trading Halt; Airxpanders Extends Debt Suspension, Postpones AGM; Suda: David Phillips Director; Joseph Ohayon CFO, Co Sec
 
May 16, 2019
Federal Election 2019: Policies & Comment; Vittail $6m For Peter Mac, CSIRO E6AP Cancer Target; Bionomics BNC210 PTSD Data ‘Justifies Further Evaluation’; Nuheara Iqstream TV On Sale; Canadian Patent For Prescient PTX-200 For Cancer; G Medical US Phone Sensor Deals; News Correction; Botanix ASX Query Retracts ‘Bacterial-Resistant’ Claim; Cann Global: ASX In-Principle Relisting Approval; CSL Appoints Dr Paul McKenzie COO
Opthea Completes OPT-302 Wet-AMD Trial Visits; BTC Raises $8m For Admedus Infusion Business; Share Plan; Cann Australian Marijuana Resin For Victoria; THC Wins Australian Marijuana Export Licence; Elixinol Wins New York Marijuana Authorization; Medibio Faces 23% Opposition To 14.5m ‘In Lieu’ Options; Avita Loses CFO Dale Sander; Tim Rooney Interim CFO; Suda: Paul Hopper Chairman; Steven Carter CEO; Mach7 Appoints Travis Nuzzi Sales, Marketing Head Race Ready For 1st Bisantrene Leukaemia Trial In 25 Years; Mayne Falls On Expected H2 Downturn; Admedus AGM Clears Rem Report, 46% Star Bright Dissent; Blackcrane Takes 8% Of Avita Volpara Density ‘Effective In Breast Cancer Risk Model’; Living Cell: NTCell Shows ‘Benefit’ For Parkinson’s; BTC Health Pays $6m For Admedus Infusion Business; Airxpanders Dumps Revenue Forecast; 2nd Loan Breach; FDA Clears Somnomed Somnodent Avant; DIIS Approves Imagion Overseas R&D; Expects $1.7m; Correction: Next Science; John Gleeson Takes 5% Of Uscom; Regal Funds Again Reduce To 11% Of Visioneering
 
May 10, 2019
Dr Boreham’s Crucible: Rhythm Biosciences; Genetic Technologies: ‘New Colorectal, Breast Cancer Tests’; Analytica $2.7m 1-For-6 Rights Issue; Simavita $3m Convertible Notes; Next Science To Release 2.3m ASX Escrow Shares; FIL Below 5% In Actinogen, Takes Loss
 
May 9, 2019
FDA Committee Backs Pharmaxis Bronchitol For Cystic Fibrosis; Paradigm Completes $78m Capital Raising; Zelda Receives $769k R&D Tax Incentive; Admedus Takes $1m SIO Loan At 12%, $125k Fee; GI Dynamics $4.3m Crystal Amber Note; Osprey Director Options Face 13% Dissent; Airxpanders Hires Cowen For Financial Advice; LBT Receives First $1m Of $4m SA Government Loan; Australian Ethical Takes Loss On Actinogen; Australian Ethical Takes 8.4% Of Ellex; Robert Lederer, RTL Group Take 10% Of Anatara; Och-Ziff Reduces To 6% Of Total Brain; Factor Loses Director Tim Hughes, Directors Fees Back; Genera Loses Director Jim Kalokerinos
 
May 8, 2019
Redhill NDA For Talicia (RHB-105) For Helicobacter Pylori; Clarity Raises $10m; Orthocell: ‘Celgro Regains Muscle Function’; Compumedics Barrow Orion Lifespan Meg ‘Largest Contract’; Osprey Launches ‘Dyeminish’ Patient Registry; Anteo 1-For-5 Rights Issue For $2.6m; Pharmaust Receives 25kg Monepantel For Cancer Trials; Bank Of New York Mellon Files 8 Substantial Biotech Notices; Credit Suisse Takes 10% Of Prescient; Regal Funds Diluted Below 5% In Prescient
 
May 7, 2019
Actinogen: ‘Xanamem Fails Alzheimer’s Endpoints’; THC Share Plan Raises $3m; CSIRO, Genesiscare $5m For Cancer ‘Theranostics’; Medadvisor, Zuellig JV For Asia Script Reminders; Zucero Completes $6m TBG (Progen) PG500 Deal; Admedus Extends Funding Suspension; Adherium Tells ASX: ‘Revenue Coming, Possible Capital Raising’; Australian Ethical Diluted To 11% Of Prescient; Living Cell Appoints Prof Carolyn Sue Director; Shareroot Appoints Dr Julian Chick Chairman
 
May 6, 2019
Alterity: ‘PBT434 Passes Blood-Brain-Barrier, Well-Tolerated’; Kazia ‘60mg GDC-0084 For Glioblastoma Tolerated’; Ellex Launches Eye Prime Diagnostic; Pharmaust Monepantel Dog Cancer Study ‘Flexible Dosing’; TBG Completes Zhangsha Zhangye Acquisition; MGC Appoints Grow Biotech, IPS Specials UK Distributors; W Whitney George, Sprott Take 24% Of Rhinomed; Anteo Requests Capital Raising Trading Halt; Hamish George Replaces Dimerix CFO, Co Sec Ian Hobson; Polynovo Appoints Ashok Srinivasan COO; Invitrocue Appoints Dr Wahab Insurance Advisor; Oneventures Appoints Jim Scopa, Dr Dan Baker
 
May 3, 2019
Dr Boreham’s Crucible: Cynata Therapeutics; Resmed Q3 Revenue Up 12% To $947m, Profit Down 4% To $151m; Actinogen Requests Xanadu Alzheimer’s Results Halt; Impedimed: ‘Study Backs BIS For Lymphoedema’; Respiri, Medachievers J-V For Wheezo India; Genetic Technologies Nasdaq Market Cap Warning; Airxpanders Extends ‘Debt Agreement’ Suspension
 
May 2, 2019
Polynovo: ‘April Revenue $1m, Close To Break-Even’; Airxpanders Cuts 45% Of Workforce, 33% Of Cash Expenditure; Adalta Confirms AD-214 Manufacture; MGC Signs Health House, Cannvalate Australia Distributors; Noxopharm Claims 8 Of 14 Prostate Cancer ‘Progression Free’; Australian Ethical Takes 15% Of Prescient; Regal Funds Take 6% In Prescient; Spill Call Investors Take 14% Of Factor
 
May 1, 2019
April BDI-40 Up 18%, ASX200 Up 2%, Big Caps Up 3%, NBI Down 5%; Brandon $210m For MRCF5; ‘Australia’s Biggest VC Firm’; Novita Tali Attention For Oregon School; 4DX: Lung Health Initiative $960k Federal Grant; Polynovo US Defence Novosorb Contracts; Orthocell Takes Celgro For Ligament Repair To TGA; US Patent For Bard1 Cancer Diagnostics; Recce Receives $204k Radium R&D Tax Incentive Loan; Genera Has $50k Cash; ‘Loans, Placement’; Adherium Has Less Than One Quarter Cash; Invitrocue Has Less Than One Quarter Cash; Placement; Nuheara Has Less Than Two Quarters Cash; ‘More Coming’; Micro-X Has Less Than One Quarter Cash; Thales $10m Note; FIL Below 5% In Starpharma
 
 
Apr 29, 2019
MCRI Trials Marijuana For Behavior Problems; Federal $5m For Painchek Roll-Out; Polynovo Appoints Polymed Novosorb Distributor; Respiri To Start Wheezo Clinical Study; Somnomed ‘Has Two Quarters Cash’; Admedus Has Less Than One Quarter Cash; Dr Chiplin, Dr Dunton Replace Regeneus Dr Aston, John Martin
 
Apr 26, 2019
Dr Boreham’s Crucible: Sienna Diagnostics; Telix: ‘Study Backs TLX591 For Prostate Cancer’; Neuren NNZ-2591 Phelan-McDermid FDA Submissions; Antisense To Issue 45m Director Loan Shares, Options; Prescient Rights Raise $890k; Total $9.1m; EGM 14% Dissent; Cann $6m For 20% Of Pure Cann NZ For Medical Marijuana; Eye Co Files Marijuana For Amd Patent; Imagion Less Than Two Quarters Cash, ‘Possible Capital Raise’; TPI 2nd Strike Board Spill, Name Change AGM; Painchek Requests ‘Government Funded Trial’ Trading Halt; Polynovo Appoints Kevin Whiteley As US Vice President 
 
Apr 24, 2019
Pro Medicus $14m, 7-Year Duke Health Contract; FDA ‘Clinical Hold’ On Race Bisantrene For AML IND; Elixinol Buys 25% Of Altmed Pets For $9m Cash, Scrip; Creso ‘Brazil Cannaqix50 Pain Licence’ Conditions; Airxpanders Postpones AGM To June; Mach7 Q3 Receipts Up 231% To $3.6m; Neurotech Pleads Schultz, Board Renewal To ASX 457% Query; Sebastian Andre Replaces Esense Co Sec Ian Pamensky
 
Apr 23, 2019
Admedus Coridon Sale Fail; ASX Query; Funding Suspension; Resapp Claims 86% Adult Respiratory Diagnostic Accuracy; Alcidion Q3 Receipts Up 50% To $6.2m; Cogstate: ‘Alzheimer’s Trials Hit Q3 Revenue’, Down 28% To $8.5m; Elixinol Q1 Receipts Up 37% To $8m; China Approves Cardiex Oscar 2 With Sphygmocor; Airxpanders Files $21m US Sec Registration Form; Polynovo: ‘Poster Backs Novosorb BTM For Leg Ulcers’; Total Brain Offers Free Trial To Mental Health America; FIL Takes 6% Of Actinogen; Blackcrane, Daniel Kim Take 6% Of Avita; Founder Dr Matthew Myntti Takes 11.5% Of Next Science; G Medical To Release 234m Shares, 20m Options From Escrow; Imugene: Dr Lesley Russell Director; 75m Director Options; Ellume Appoints David Green CFO, Co Sec; Mark Boyle CBO; Noxopharm Dr Graham Kelly Chair, Dr Greg Van Wyk CEO; Ausbiotech Medical Technologies May Melbourne Conference
 
Apr 18, 2019
Dr Boreham’s Crucible: Compumedics; Next Science Opens 40% Above $1 IPO Price; Victoria Supports Trajan Expansion; CE Mark For Analytica Pericoach For Pelvic Prolapse; Total Brain Places $1m Shortfall Shares; Visioneering AGM Faces 12% Dissent; Telix 895k Director Options, 25% Pay Pool Hike AGM; Phosphagenics Name Change AGM, Again; Elixinol: Stratos Karousos CCO; Rights, 46% Pool Hike AGM; Novita Tali Attention Train 1st US School District Sale; Creso: Brazil Licences Cannaqix50 For Chronic Pain; Suda Requests ‘TGA Artimist Malaria Submission’ Trading Halt; Oncosil To Release 6.5m Escrow Loan Shares; THC Releases 37.5m Escrow Shares
 
Apr 17, 2019
Next Science ‘Oversubscribed’ IPO Raises $35m, Lists Tomorrow; Paradigm Places $61.4m, $16.5m To Go; Medibio, Humanitas Uni Collaborate On Mental Illness; MGC Signs Yushop For Marijuana In China; Admedus Takes Coridon Sale Trading Halt To Suspension; Cann To Release 33m Escrow Shares; Renaissance Below 5% In Visioneering; Neurotech Rolls Board, Co Sec; Jumps 237.5%; Immuron Appoints CEO Dr Gary Jacob Director
 
Apr 16, 2019
Cochlear Launches MRI-Friendly Nucleus Profile Plus Implant; Starpharma, Aspen Launch Vivagel BV For Bacterial Vaginosis; FDA Allows Mesoblast Rolling GvHD Application; Rhinomed Pronto Vapor For Sleep, Decongestion; Medlab, Chronic Pain Australia Medical Marijuana Education; Osprey: Q1 Revenue Up 56% To $1.2m; Resonance Pleads Schultz To ASX 37.5% Query; Genetic Technologies Chair Dr Paul Kasian Full-Time, Pay Rise; CFO Robert Meissner Replaces Althea Co Sec Peter Gillis
 
Apr 15, 2019
Paradigm Raising $78m On PPS Osteoarthritis Pain Results; Study Backs LBT APAS For MRSA (Golden Staph); Resapp Files FDA Application For Resappdx-US; Immuron Claims 9-Month Sales Up 23% To $1.7m; Admedus Vaccines Sale, 3m CEO Options, 2nd Rem Strike AGM; Admedus Requests Coridon ‘Immunotherapies Sale’ Halt; Prana ASX Code PBT Changes To Alterity ATH; Karst Peak, Adam Leitzes Take Profit, Reduce To 10.5% In Avita; MMJ Hands Embark Marijuana Investments, Drops Share Plan; Micro-X Loses Richard Hannebery; Harley Frankfurt Replaces Anteo CEO Christopher Parker
 
Apr 12, 2019
Dr Boreham’s Crucible: Osprey Medical; Bio-Melbourne Appoints Dr Julie-Ann White CEO; Nuheara Launches Self-Assessment Hearing Website; Medibio 14.5m Directors Options In Lieu Of Pay EGM; Volpara To Release 51m Voluntary Escrow Shares; MGC: UK Marijuana Import Permit; Australia, UK Sales; Empery Reduces To 6% In Immuron; Renaissance Increases, Diluted To 5% In Visioneering; Elixinol Appoints Greg Ellery Director; Genera Appoints Dr Guillermo Elias For North America
 
Apr 11, 2019
Creso To Raise $5.35m Via Secured Loans; Imagion Supplies Nano-Particles To Israel’s New Phase; Starpharma, FDA Discuss Vivagel For Bacterial Vaginosis; Immuron Takes Travelan For Travellers’ Diarrhoea To FDA; Pharmaust ‘Oversubscribed’ Shortfall Raises $700k; Total $2m; Osprey 13.5m Directors Options AGM; Paradigm Requests ‘Secondary Endpoints’ Trading Halt; JM Financial Group Takes 16% Of Mach7; RACI Dines On ‘Innovation To Impact’ With J&J’s Kathy Connell; Total Brain For Emory Goizueta Coaching Diploma
 
Apr 10, 2019
Admedus Pleads Schultz, Vaccine Sale To ASX 109% Query; Actinogen Investigates Xanamem For Mood Disorders; Noxopharm Plans NOX66, Doxorubicin Sarcoma Trial; Total Brain Rights Raise $897k Of Hoped-For $1.9m; $963k To Go; Chris Retzos Increases, Diluted To 6% Of Prescient; Clarity Appoints Advisor Dr Gillies O’Bryan-Tear Director; Factor Appoints Dr David Brookes Director
 
Apr 9, 2019
Ellume In Pre-IPO Mode For Respiratory Diagnostics; Goodbye Prana, Hello Life’s Alterity; $11.4m Raised; Bio-Melbourne Gongs: Anna Lavelle, Clara Gaff, Evelyn Chan; Painchek Signs Churches Of Christ Queensland Aged Care; Visioneering Q1 Sales Up 104% To $1.6m; Memphasys: 5 More Centres Assess Felix IVF Sperm Separation; Airxpanders Backs Radformation Radiation Software; Oceania, HCI Quit Mach7; Australian Ethical Takes 5% Of Mach 7; SG Hiscock Below 5% Of Neurotech; Creso Requests ‘Capital Raising’ Trading Halt; GI Dynamics Appoints Prof Judith Korner Advisor; G Medical Loses Director Sam Skontos
 
Apr 8, 2019
Volpara: 2019 ‘Annual Recurring Revenue’ Up 85%; Genetic Technologies, Tgen Develop Risk Tests; Dorsavi Wins $540k UK Myvisafe Contract; Novita, Tali, Carestarter Partner For Autism, ADHD; Reva $5.35m Goldman Sachs Loan, $1.1m Fees; THC Share Plan Ahead Of Final Marijuana Licence; Noxopharm To Release 31m Voluntary Escrow Shares; Karst Peak, Adam Leitzes Reduce To 14.5% In Avita; Ged Wallace Replaces Ellex CEO Tom Spurling, On $320k; Somnomed Appoints Hervé Fiévet CFO
 
Apr 5, 2019
Dr Boreham’s Crucible: Starpharma; Avita: ‘Recell To Save Burn Centre $39m PA’; Prana Okays Life Takeover, Alterity Name Change; Atomo HIV Self-Test On Sale In Australia; Creso Tells ASX ‘Sensitive’ News Not New; Ellex Requests ‘Leadership Change’ Trading Halt; THC, Heleogenics Partner For Malaysia Medical Marijuana; Memphasys Pays Monash IVF 4m ‘Consulting’ Shares; Peters Investments Takes 21% Of Memphasys
 
Apr 4, 2019
Airxpanders: Aeroform Breast Expander ‘Superior’; Suda Submits TGA Zolpimist Insomnia Application; Euro Patent For Cynata Cymerus Stem Cells; GI Dynamics Endobarrier Data At NY Diabetes Meeting; Antisense On-Track For ATL1102 For DMD Results This Year; Althea: ‘511 Medical Marijuana Patients; Q3 Sales $183k’; Australian Ethical Takes 11% Of Prescient; Regal Funds Below 5% In Prescient; Kinetic Below 5% In Visioneering; Actinogen Appoints Malcom McComas Director
 
Apr 3, 2019
Budget Comment And Analysis - Biotech Daily, CSIRO, AMRAB, AAMRI, Medicines Australia, Ausbiotech; Nanosonics Welcomes French Disinfection Guidance; Acrux Settles Valeant Jublia Generic Patent Litigation; Correction: Anatara; Allan Gray Takes 17% Of Osprey; Clarity COO Colin Biggin Replaces Matt Harris As Acting CEO
 
 
Apr 2, 2019
Anatara Re-Focusses On O-T-C Bromelain For Human Health; Immuron Lodges Form F-3 To Raise Up To $US100m; Sienna Buys Sevident Exosome Cancer Test For $4m; Airxpanders Debt Suspension For Revenue Shortfall; Imugene Key-Vaxx And B-Vaxx ‘Reduce Tumor Growth In Mice’; Imugene: High Dose HER-Vaxx Tumor ‘Responses, Antibodies’; LBT APAS Independence Golden Staph Control Study; Cardiex To Begin Sphygmocor Cardiovascular Trial; Impedimed Launches Gen 3 Sozo, Improves Security; European Patent For Cellmid Monoterpenoids For Alopecia; Jencay Takes 9.5% Of Universal Biosensors; Oceania, HCI Reduce To 6% Of Mach7; Pro Medicus $150m, 10m-Share Buy Back; GI Dynamics Appoints Dr Allon Friedman Advisor
 
Apr 1, 2019
March BDI-40 Up 6%, ASX200 Up 0.2%, Big Caps Flat; Micro-X $10m Thales Deal For X-Ray Technology; Kazia: Cantrixil For Ovarian Cancer ‘Safe, 1 Response’; Euro Patent For Amplia AMP945 For Fibrotic Diseases; Exopharm Plans Plexaris Platelets For Wound Healing Trial; GI Dynamics Extends Crystal Amber Note; Invion Pleads ‘Research, Social Media’ To ASX 39% Query; Bard1 Tells ASX: ‘Assay Development’ Led To 25% Jump; Memphasys Chair Alison Coutts Increases, Diluted To 14.6%; Director Andrew Goodall Takes 24.6% Of Memphasys
 
March 29, 2019
Dr Boreham’s Crucible: Immutep; GI Dynamics: ‘Endobarrier Reduces Weight, HbA1c, Apnoea’; Micro-X Begins $13.7m Allora Federal Court Proceedings; Resapp Recruits Breathe Easy Study, FDA Submission; Clinuvel To Host EPP Expert Meetings In Europe; Oncosil Meets BSI, Committee On CE Mark; Alchemia Requests Suspension For ‘Change In Activities’; Airxpanders Requests Loan Breach Trading Halt; Spill Call Shareholders Reduce To 12% Of Factor; Total Brain 2m Director Ajay Arora Options EGM
 
March 28, 2019
Mach7 Wins Sentara Picture Archive Contract; Volpara Welcomes FDA Breast Density Changes; Genetic Technologies Opens Hong Kong, China Operations; Pharmaust Monepantel For Cancer ‘Safe In Dogs’; Analytica Receives $745k Tax Incentive; Paradigm Pleads Schultz To ASX 18% Query; John McBain, Picton, 52nd Celebration Take 8% Of Rhinomed; Blue Sky Ceases In Alcidion; Bio-Melbourne Loses 5-Year CEO Dr Krystal Evans; Invictus Appoints Dr Jordan Moon Advisor
 
Mar 27, 2019
Neurotech, Founder Dr Attard Trevisan And His Ph D; Mesoblast, Mt Sinai Revascor New Heart Failure Trial; Dorsavi Tells ASX ‘We Are A Going Concern’, Funding; Memphasys Raises $1.9m, $1.7m To Go; Factor Survives Board Spill AGM; 43% Rem Report 1st Strike; Prescient 5m Director Options EGM; G Medical $35m Nasdaq Shares, 14m Dr Yacov Geva Shares EGM; Genetic Technologies Requests ‘Expansion’ Trading Halt; Phosphagenics Dr Murdoch Steps Down, Dr Collier Steps Up; Suda Appoints David Simmonds Director
 
Mar 26, 2019
Federal $80m For Peter Mac Cancer Centre Car T-Cell; Federal: $66m For Genomics Research Grants; Women Win 4 Of 5 Victoria Premier’s Research Awards; CEO David Kaysen Resets Medibio Heart-Mental Health Test; Final Review Backs Actinogen Xanadu Alzheimer’s Trial; FDA Meets Pharmaxis For Bronchitol Recommendations; Genera: $243k Applications Of Hoped-For $11.4m; E-Sense Lab Cuts Expenditure By $840k; THC’s Vertical Canna Buys 1,858m2 Canada Marijuana Plant; Altium Growth Below 5% In Immutep; Bank Of America Below 5% In IDT; Och-Ziff Reduces, Diluted To 7% Of Total Brain; Clarity Appoints Dr Thomas Ramdahl Director
 
Mar 25, 2019
Oncosil Falls 87% On Pancreatic Cancer Radiotherapy Doubts; Prescient To Raise $9.1m In Placement, Rights Issue; FDA Issues WEHI-Discovered Abbvie Venetoclax Warning; Reva $4.2m Loan; Jeff Anderson Replaces CEO Reggie Groves; Uscom Wins Chinese Medical Device Certificate; Mesoblast, JCR Stem Cell Licence For Epidermolysis Bullosa; Race Files Bisantrene For AML IND With US FDA; Factor Receives $2.5m R&D Tax Incentive; Simple Sleep Services Closes Owing Somnomed $1.1m; UK NHS Moves Nuheara Iqbuds Boost To ‘Hearable’; Thorney, Tiga Take 17% Of TPI; THC Requests Canada Acquisition Trading Halt
 
Mar 22, 2019
Dr Boreham’s Crucible: Rhinomed; Prof Alan Trounson: ‘Australia Handicapped On Cell Therapies’; Federal $25m For Regional Cancer Trials; GE Healthcare To Sell Volpara Density Worldwide; Adheris To Sell, Promote Medadvisor Adherence Program; Pharmaust Rights Raise $1.3m Of $2m; $700k To Go; US Patent For Immutep IMP321, Chemo For Cancer; Smart Top, Xianhui Meng Take 18% Of Uscom; BVF Increases, Diluted To 19% Of Actinogen; Goodridge Takes 8% Of Noxopharm; Mesoblast Appoints Joseph Swedish Chairman; Phylogica Appoints Dr Rakesh Veedu Advisor
 
Mar 21, 2019
Cynata Falls 43% On Fujifilm Option Extension; J&J, Monash Work On Inhaled Oxytocin; Compumedics $1.4m US Adventist Monitor Deal; Alcidion $1m Patientrack Deal With UK Hospitals; Biocelect, 60 Degrees Kodatef For Malaria In Australia; Telix, Cyclotek Complete Visact Manufacture; Prescient Requests Capital Raising Trading Halt; Medibio Reviews Heart-Mental Illness FDA Submission; Spill Call Shareholders Take 19.97% Of Factor; FMR Below 5% Of Resmed; Invictus Appoints Prof Ed Gane Advisor
 
Mar 20, 2019
Next Science Raises $35m For Xbio Antibacterial; GSK Awards $150k, Collaborations To 2 Research Projects; Telix Manufactures TLX250 For Kidney Cancer Trials; FDA Provides Guidance For Imugene Key-Vaxx IND; Factor Responds To Dissident Investor Letter; Eye Co Files Patent For Dry AMD; FIL Below 5% In Impedimed; JM Financial Group Takes 11% Of Mach7; Medadvisor Requests ‘Commercial Agreement’ Trading Halt
 
Mar 19, 2019
Truscreen Back For Cervical Cancer Screening; Cynata Requests Fujifilm Licence Trading Halt; Immuron IMM-529 Clostridium Difficile Trial ‘Slow’; Patent; Kazia Sells Noxopharm Holding For $2.1m; Cann, Aurora Marijuana Deal; $11m Mildura Greenhouse; Cellmid Unmarketable Parcel Buyback; Visioneering To Release 8m Escrow Shares; Regal Funds Below 5% In Medibio; FIL Takes 16% Of Medibio
 
Mar 18, 2019
Resapp Diagnostic ‘Better Than Clinicians For Croup’; Telix Welcomes EAU Prostate Cancer Guidelines; Alcidion $2.1m Miya, Patientrack, Smartpage UK NHS Deal; Rhythm Recruits 1st Colostat Colorectal Cancer Patient; Inside Diagnósticos To Distribute Sienna’s hTER Test In Brazil; Prana Receives $3.3m R&D Tax Incentive; Total Brain Hopes To Raise $7m; GI Dynamics $1.4m Crystal Amber Convertible Note; Medigard Tells ASX ‘Working To Comply With Rules’; KT009; Australian Ethical Takes 19.96% Of Antisense; Platinum Takes 8.6% Of Antisense; Leon Serry, City Castle, Sked Take 6% Of Antisense; Capital Group Reduces To 6% Of Mesoblast
 
Mar 15, 2019
Dr Boreham’s Crucible: Mesoblast; GI Dynamics Endobarrier Study: ‘Significant Weight, HbA1c Drop’; Eyepoint H1 Revenue Up 122% To $4m, Loss Up 280% To $63m; Next Science $35m IPO For Xbio For Biofilm-Protected Bacteria; Suda’s Anagrelide Potential Role For Cancer; Praxis Picks Victoria For Asia-Pacific HQ; Wintermute Moves US Operations To Latrobe Uni; Clinuvel, UK Nice Talk Scenesse Appeal, Managed Access; Dr Errol De Souza Continues As Bionomics Exec Chair; Dorsavi Cuts Costs 40%, CEO Dr Andrew Ronchi Pay Cut; Shareroot Appoints Michelle Gallaher CEO
 
Mar 14, 2019
NHMRC Awards 23 Research Excellence Awards; Hemideina Wins Federal $800k For Hera Wireless Implant; Medlab: ‘Marijuana Nanabis Reduces Pain In 5 Patients’; Imugene Doses 1st HER-Vaxx Gastric Cancer Patient; US Patent For Recce Antibiotics, Recce-327; Pharmaust Monepantel ‘Dog Tumor Suppression, Regression’; Phylogica, Tel Aviv Uni Collab For siRNA Therapies; Medibio Outsources Ilumen To Ex-Staff-Owned Alta; FIL Takes 5% Of Actinogen; Investors Mutual Takes 7% Of Mayne Pharma; Total Brain Requests Capital Raising Trading Halt; Alastair Beard Replaces Respiri Co Sec Julian Rockett 
 
Mar 13, 2019
Antisense Raises $1.6m To Accelerate ATL1102 For DMD; Reva Further Extends Capital Raising Suspension; Genera Further Extends Rights Offer Closing Date; Resapp Expects $1.7m R&D Tax Incentive; Offshore Finding; Spill Call Shareholders Take 19% Of Factor; CEO Dr Philippe Wolgen Takes 7% Of Clinuvel; Clinuvel Takes 9% Of Itself; E-Quits Orders $7k Esense Marijuana Terpenes; MGC Appoints Dr Stephen Parker Director; Respiri Appoints Gerry Bullon Investor Relations Consultant
 
Mar 12, 2019
Ellex Lasers Beat Drops For Ocular Hypertension, Glaucoma; MHRA Backs Cynata Critical Limb Ischemia Trial; Starpharma Receives $4m Federal R&D Tax Incentive; Medibio Rights Raise $923k Of Hoped-For $4m; Cogstate Tests In J&J’s US Spravato CIII Depression Trials; Springboard Program For 6 Australian Biotech Women; US Patent For Imagion Magnetic Nanoparticles For Cancer; Zelda, Ilera Partner To Co-Develop Medical Marijuana; Phylogica ‘Peptides Deliver Antisense Drugs In Mice’; Kit Wei Lui Replaces Invitrocue Director Jamie Gee Choo Khoo
 
Mar 11, 2019
CE Mark For Admedus Cardiocel 3D, Vascucel; Federal $50m For Alfred Traumatic Brain Injury Mission; Victoria Funds Melbourne Uni, Cynata Stem Cell Project; Antisense Requests Duchenne Muscular Dystrophy Funds Halt; Avita: 10 Presentations At American Burns Meeting; Mach7 Restructure: Mike Lampron Replaces CEO Mike Jackman; Sandon Capital Takes 8% Of IDT; Jamore, Danshe Take 5% Of Nuheara; Australian Ethical Takes 8.65% Of Somnomed; Amplia Appoints Prof Lara Lipton, Prof Phil Hansbro Advisors
 
Mar 8, 2019
Dr Boreham’s Crucible: Volpara Health Technologies; S&P ASX All Ordinaries: 6 Biotechs, Aust Ethical In; 7 Out; Immutep: ‘IMP761 Reduces Primate T-Cells’, Clinical Trials; Federal $500k For Griffith Uni Plasprotect Malaria Vaccine; Federal Health Boards ‘50% Women’; Prof Dorothy Keefe; Universal Biosensors Loses 33% Staff, CEO Rick Legleiter; Cochlear: UK Nice Expands Hearing Implant Suitability; Immutep Receives $872k Federal R&D Tax Incentive; Wentworth Williamson Takes 7% Of Tasmanian Poppy; ASX Suspends Medigard On Accounts
 
Mar 7, 2019
DSMB Backs Opthea Phase IIb OPT302 Wet AMD Trial; Immutep Doses 1st IMP321, Keytruda Cancer Patient; Medibio: Ilumen Shows 26% Of Staff Depressed, Anxious; Correction: Orthocell; Employee Sues Neurotech Founder, Subsidiaries; Kinetic Investment Reduces To 5.3% Of Visioneering; Creso To Release 2m Voluntary Escrow Shares; Althea: Aphria’s Jakob Ripshtein Replaces Gregg Battersby
 
Mar 6, 2019
Osprey: ‘Breakeven By 2022’; Prana: Boston Life Biosciences Control, Name Change EGM; Immutep: ‘9 Of 24 Respond To IMP321, Keytruda’; Orthocell To Complete Ortho-ATI Recruitment By July; Reva Further Extends Capital Raising Suspension; Zelda Cannabidiol Breast Cancer Biomarker Patent; Cardiex Bayer Sphygmocor Contract Up $494k; Telix To Release 814k Voluntary Escrow Shares; Pinnacle (Hyperion) Takes 5% Of Cochlear; CVC Takes 13.5% Of Universal Biosensors
 
Mar 5, 2019
Medlab, Pharmascience Nanabis Deal; Total Brain, Blackthorn Partner For Neuro-Behavior; Pinacle’s Hyperion Takes 5% Of Cochlear, Again; Jersey’s D&A Income Takes 7% Of Pharmaxis; Leydin, Polonsky Replace Alchemia’s Gennari, Book; G Medical Appoints Prof Zeev Rotstein Director
 
Mar 4, 2019
Volpara Dense Breast Study: ‘Interval Cancer Drops Dramatically’; Cynata, NSW Uni: ‘Cymerus Heart Disease Efficacy, In-Vitro’; Avita EU Recell ‘Sales Interruption’; M3 To Market, Distribute Avita’s Recell In Japan; Factor Tells ASX: $1.2m R&D Incentive A ‘Forecast Figure’; G Medical Revenue Up 2709% To $4.3m, Loss Down 40% To $23m; Montoya Ceases In Pharmaxis; Jim Surek Replaces Osprey Head Of Sales Hank Butcher; Genetic Signatures Appoints CFO Peter Manley Co Sec; Alcidion: Melanie Leydin, Michael Sapountzis Joint Co Secs; G Medical Loses Director Louis Antoniou
 
Mar 1, 2019
February BDI-40 Up 11%, ASX200 Up 5%, Big Caps Up 0.4%; Dr Boreham’s Crucible: Cochlear; Federal $608m For NSW Children’s Cancer Centre; Admedus Revenue Up 127% To $25.6m, Loss Up 180% To $24.7m; TBG Revenue Down 9% To $3.2m, Loss Up 33% To $4.4m; THC Revenue Up 45% To $2.7m, Loss Up 237% To $8.6m; Cardiex H1 Revenue Up 2% To $2m, Loss Up 26% To $1.4m; Pharmaust H1 Revenue Up 44% To $1.9m, Loss Down 94% To $90k; Dorsavi H1 Revenue Down 18% To $1.8m, Loss Down 3% To $1.9m; OBJ H1 Revenue Down 29% To $1.1m, Loss Up 92% To $788k; W Whitney George Takes 23% Of Rhinomed; Oceania, HCI Reduce To 7.6% Of Mach7; G Medical Requests Final Preliminary Report Suspension; Damian Lismore Replaces LBT Director Dr Glenn Haifer; Clarity Appoints Dr Robert Miller CMO; MGC Loses Joint Co Sec Kate Sainty
 
Feb 28, 2019
Zelda: ‘Endo-Cannabinoid HER2 Breast Cancer Path’; TPI Revenue Up 109% To $47m, Loss Down 65% To $6m; Neuren Revenue Up 49% To $15.2m, Profit Down 7% To $3.1m; Airxpanders Revenue Up 100% To $11m, Loss Down 8% To $37m; Avita H1 Revenue Up 53% To $6.8m, Loss Up 115% To $15.6m; IQ3 H1 Revenue Down 15% To $2.9m, Profit Up 333% To $320k; Uscom H1 Revenue Up 4% To $1.5m, Loss Down 30% To $758k; Phosphagenics Revenue Up 21% To $1.4m, Loss Down 53% To $4m; Adherium H1 Revenue Down 63% To $986k, Loss Up 74% To $8.6m; Total Brain H1 Revenue Up 4% To $1.1m, Loss Down 62% To $4.6m; Micro-X Quits Xinray; Adalta, Excellerate Collaborate On I-Body; Regeneus $2.5m Directors Loans; Harbour Takes 5% Of Volpara, Again; Simon Harradence, DDH Graham, Lugarno Take 6% Of Acrux; Spill Call Shareholders Take 18% Of Factor; Pyxis Takes 6% Of Neurotech; Duncan Cornish Replaces Anteo CFO, Co Sec Julien McInally
 
Feb 27, 2019
Compumedics H1 Revenue Up 16% To $18.7m, Profit Up 27% To $811k; Cogstate H1 Revenue Down 17% To $15.5m, Loss Up 436% To $3.9m; Cyclopharm Revenue Up 2% To $13.4m, Loss Down 98% To $35k; Cryosite H1 Revenue Up 36% To $4m, Profit To Loss Of $1.3m; Redhill Revenue Up 109% To $11m, Loss Down 15% To $54m; Invion H1 Revenue Up 394,450% To $1.2m, Loss Up 14% To $1.3m; Memphasys To Raise $3.64m, Lists On Frankfurt Exchange; Dimerix Two DMX-200 Phase II Trial ‘On-Track’; Regal Funds Reduces To 12.4% Of Visioneering; SG Hiscock Diluted To 7% Of Neurotech; Niall Cairns Replaces Cardiex Chairman Donal O’Dwyer
 
Feb 26, 2019
Aravax PVX108 ‘Safe’ For Peanut Allergy; Imugene B-Cell Vaccine ‘Anti-Tumor Activity’; Optiscan Microscope At Sloan Kettering; Optiscan, Summit Work On Microscopes, Imaging; Elixinol First H1 Revenue $37.1m, Loss $860k; Probiotec H1 Revenue Up 35% To $37m, Profit Up 258% To $1.1m; Benitec H1 Revenue Up 3392% To $14.6m, Loss To Profit Of $9.1m; Clinuvel H1 Revenue Up 27% To $9m, Profit Up 189% To $4.1m; Osprey Revenue Up 54% To $3.5m, Loss Up 22% To $24.5m; LBT H1 Revenue Down 49% To $1.8m, Loss Up 59% To $1.7m; Botanix BTX1503 ‘5 Times Others CBD’; MGC Marijuana ‘More Than 35% THC’; Cardiex Appoints Harry Kim Advisor
 
Feb 25, 2019
Nanosonics H1 Revenue Up 36% To $41m, Profit Up 221% To $7m; Alcidion H1 Revenue Up 479% To $7.3m, Loss Down 47% To $563k; Medadvisor H1 Revenue Up 19% To $3.8m, Loss Up 99% To $4.5m; Genetic Signatures H1 Revenue Up 41% To $3.5m, Loss Up 3% To $1.7m; Mach7 H1 Revenue Down 9% To $3.5m, Loss Up 31% To $4.4m; Resonance H1 Revenue Up 40% To $1.8m, Profit Up 693% To $935k; Alcidion Extends $711k ACT Health Contract; Neurotech Rights Raise $783k Of Hoped-For $3.3m; Pharmaxis: Boehringer Completes PXS‐4728A Nash Enrolment; Reva Extends Capital Raising Suspension; TPI, Tasmanian Alkaloids Codeine Poppy Patent Fight; Total Brain, Onedigital Partner For Brain Health; Memphasys Requests Capital Raising Trading Halt; Auscann Appoints Ido Kanyon CEO; Race Appoints Prof Roland Walter Bisantrene Trial PI
 
Feb 22, 2019
Dr Boreham’s Crucible: Cellmid; Pharmaxis Starts LOX Inhibitor For Pancreatic Cancer Trial; Mayne H1 Revenue Up 13% To $274m, Loss To Profit Of $1m; Universal Bio Revenue Up 176% To $70m, Loss To $38m Profit; Ellex H1 Revenue Up 9% To $41.6m, Loss Down 0.4% To $2.7m; Medlab H1 Revenue Up 17% To $2.3m, Loss Up 60% To $3.7m; OBJ P&G Licence Deal For Olay Magnetic Infuser; Factor Board Spill AGM; Redhill Appoints Director Rick Scruggs COO; Melanie Leyden Replaces Medibio Director Andrew Maxwell; Stephen Denaro Replaces Novita Co Sec John Osborne
 
Feb 21, 2019
Mesoblast H1 Revenue Down 7% To $19m, Profit To $62m Loss; Editorial: Your R&D Tax Incentive Is Not Revenue; Somnomed H1 Revenue Up 15% To $28.8m, Loss Up 90% To $12.4m; Pro Medicus H1 Revenue Up 60% To $25.4m, Profit Up 184% To $9m; Polynovo H1 Revenue Up 109% To $5.7m, Loss Down 41% To $1.9m; Cellmid H1 Revenue Up 12% To $3.6m, Loss Up 221% To $3.5m; Allegra H1 Revenue Down 22% To $1.8m, Loss Up 142% To $481k; Impedimed H1 Revenue Up 19% To $1.8m, Loss Down 16% To $12.1m; Bioxyne H1 Revenue Up 83% To $1.4m, Loss Down 72% To $203k; Proteomics US Biomarker Patent For Kidney Disease Target; Resmed, Fisher & Paykel Settle Patent Dispute; Suda Improving Anagrelide Solubility; Althea: Cannvalate Australia Marijuana Distributor; Auscann To Buy Marijuana Resin From Medipharm; Anteo, Geneodx To Launch Anteobind In China; Noxopharm Review: Prioritize Prostate Cancer, US Listing; Botanix Appoints Dr Stewart Washer Interim Chairman; Julian Rockett Replaces Visioneering Co Sec Leanna Ralph
 
 
Feb 19, 2019
Cochlear H1 Revenue Up 11% To $712m, Profit Up 16% To $129m; Visioneering Revenue Up 214% To $4.6m, Loss Down 1.5% To $23.5m; Hemideina Raises $1m For Hera Wireless Hearing Aid Implant; Takeovers Panel Dismisses Pura Vida Factor Complaint; Victoria $1.5m For ‘Teletrials’ Program; Alcidion Launches Miya Precision At NZ Mid-Central Health; Last Patient Dosed In Phase III Mesoblast Heart Trial; TGA Okays Mayne Kapanol (Morphine) For Breathlessness; Admedus: ‘TAVR Safe, Potential Benefits, In Sheep’
 
Feb 18, 2019
Federal $22m For Early Stage Research; Clarity Raises $9m, Open For $1m More; Emerald Clinics Raises $2.5m For IPO; Pharmaust Rights Issue To Raise $2m; Neuren NNZ-2591 ‘Effective For Phelan-McDermid In Mice’; Bionomics Up 54% On ‘Significant’ BNC210 PTSD Blood Response; J&J Lifescan Pays Universal Biosensors Test Strips $44m; Pharmaust, Epichem Extend DNDI Contract; Suda European, Chinese Patents For SUD-003, SUD-004; Proteomics To Release 3.9m Escrow Shares; Reva Requests Capital Raising Trading Halt; Canada Marijuana Cultivation Licence For Creso; Telix Appoints Gabriel Liberatore Group COO; Invitrocue Appoints Prof Arial Zeng Yi Consultant
 
Feb 15, 2019
Dr Boreham’s Crucible: CSL; Federal $39m For 23 Rare Cancers, Diseases; Victoria Backs Master Of Cancer Sciences; Pharmaxis H1 Revenue Down 91% To $3m, Profit To $13m Loss; Bionomics H1 Revenue Up 3% To $2.4m, Loss Up 19% To $10.6m; Bard1 5-Peptide Good For Mesothelioma, Not Others, In Mice; Neurotech, Anchovy Partner To Deliver Mente Autism
 
Feb 14, 2019
Minomic Appoints Cirrus Dx For Micheck Prostate Cancer Test; Nominations Open For Victoria Manufacturing Hall Of Fame; Federal $26m For Heartkids, Childhood Heart Disease; Paradigm Plans Phase II/III MPS Trial; GI Dynamics Ready For US Pivotal Endobarrier Trial; Colleges Back Althea Medical Marijuana Education; Medlab Expands Nrgbiotic Depression Trial Recruitment; Creso, Hempmate Collaborate On Marijuana For Europe
 
Feb 13, 2019
CSL Record H1 Revenue Up 9% To $6.3b, Profit Up 7% To $1.6b; Orthocell: ‘Ortho-ATI 82% Success’; Invictus Requests FDA Liver, Pancreas Drugs Meeting; Mayne To Sell Lexette For Psoriasis In US; Cross-Party Launch Of Medicinal Cannabis Industry Australia; Creso: Burleigh Heads To Distribute Medical Marijuana; Esense 80% Dump CEO Haim Cohen As Director; Painchek Pleads Schultz, ‘Publicity’ To ASX 71% Query; Race Chair Dr William Garner Reduces To 15.8%; FIL Reduces To 7.1% Of Adherium
 
Feb 12, 2019
Federal $32m For Researcher Entrepreneur Training; Nanosonics: ‘90% Of Japan Vaginal Probes Contaminated’; Invion Completes Chronic Airway Therapeutics Spin-Out; Creso Deals Could Trigger ASX Chapter 11; Volpara Appoints Paul Reid Chair; Botanix Appoints Dr Michael Thurn Executive Director; Zelda Hires ICCI For Marijuana Trials; Victor Kovalev Replaces Medadvisor CTO Dr David Chatterton
 
Feb 11, 2019
Actinogen Begins Xanamem Dose Escalation Trial; Invitrocue, Dr Chen J-V For Immune Mice, Cells; Universal Biosensors, Siemens ‘Modify Relationship’; Beagles Back Pharmaust New Monepantel Taste; Total Brain, Mapmygenome Partner For ‘Brain Optimization’; Capital Group Reduces To 8% Of Mesoblast; Starfish Below 5% In Impedimed; FIL Reduces To 8.5% Of Adherium; Phylogica Loses Sahm Nasseri
 
Feb 8, 2019
Dr Boreham’s Crucible: Adalta; Vale Botanix Chair Graham Griffiths (19.8.1955 – 6.2.2019); Recce Raises $1.8m; Rhythm: Ethics Ok For Colostat Colorectal Cancer Trial; Cryosite, ACCC Agree $1.1m Cartel Penalty; Nucleus Buys Q-Pharm For Early Clinical Trials; Correction: Anatara; Phylogica Peptide ‘Outperforms Zebra Competitor’ In Mice; Goodbye ITL
 
Feb 7, 2019
Cellmid: ‘Midkine Antibodies For Heart Inflammation’; Koligo $7m IPO For Kyslecel For Pancreatitis, Pipeline; Anatara ‘Garp’ For Irritable Gut Proof-Of-Concept; Uscom Appoints Koneska Spirosonic US Distributor; Elixinol Buys $2.6m, 60-Acre NSW Property For Marijuana; E-Sense To Supply Marijuana E-Juice To Vaporspec; Spill Call Pura Vida, Freshero Take 15% Of Factor; FIL Reduces To 5% Of Impedimed; Respiri Appoints Michael Clarke Wheezo Ambassador
 
Feb 6, 2019
Federal Government $20m For Phenomics Research; Recce Requests ‘Capital Raising’ Trading Halt; Noxopharm: Veyonda (NOX66) ‘Well-Tolerated’; Total Brain Launches 40 New ‘Trainings’, Videos
 
Feb 5, 2019
Eyepoint (Psivida) US Launch Of Yutiq (Durasert); Factor Raises $417k; Abu Dhabi, Perth Board Spill Call; Correction: Neuren, Acadia; Respiri ‘Oversubscribed’ Placement Raises $1.6m; Unisuper, BNP Paribas Take 5% Of Impedimed; Creso Takes ‘Share Issue, Transactions’ Halt To Suspension; Nanosonics Hires Renee Salaberry, David Morris, Rod Lopez; Reva Cuts HQ Staff By 44% To 22; Elixinol To Appoint 12-Staff European Team
 
Feb 4, 2019
Federal $55m For Type 1 Diabetes; Neuren, Acadia: ‘Phase III Trofinetide Rett Trial This Year’; Sienna Signs Mediwell As Singapore Distributor; Oventus Launches O2vent Optima In Canada; China Study ‘Validates’ Cardiex Sphygmocor; Niall Cairns Replaces Cardiex Chairman Donal O’Dwyer; Dr Willy Hsu Replaces TBG COO Eugene Cheng; MMJ Loses CEO Jason Conroy
 
Feb 1, 2019
January BDI-40 Up 10%, ASX200 Up 4%, Big Caps Up 1%, NBI Up 13%; Dr Boreham’s Crucible: Resmed; Neuren: Acadia RoW Offer ‘Not In Shareholders Interests’; Genetic Technologies, MSK, Cambridge Uni Breast Cancer Test; Genera Rights Offer For $11.4m; Mesoblast H1 Receipts Up 296% To $28.5m; THC Receipts Up 61% To $2.6m; Nuheara H1 Receipts Down 19% To $1.4m; Invitrocue Has One Quarter Cash; MGC Grows 700kg Marijuana Crop, More Than 35% THC; Cardiex Takes 41% Of Inhealth; E-Sense Lab To Release 44m Escrow CDIs; Creso Requests ‘Share Issue, Transactions’ Trading Halt; Regeneus CEO Leo Lee Starts On $325k; Auscann Appoints CFO, COO Quentin Megson Joint Co Sec; Creso Appoints Colombia’s Dr Ricardo Salazar Advisor
 
Jan 31, 2019
Brandon, Okogen Trial OKG-0301 For Viral Conjunctivitis; FDA Orphan Status For Prana PBT434 For MSA; Cogstate H1 Receipts Up 30% To $23m; Elixinol Posts Receipts Of $36m; Clinuvel H1 Receipts Up 35% To $13m; Bionomics H1 Receipts Up 33% To $4.8m; Mach7 H1 Receipts Down 28.1% To $4.4m; 2 Quarters Cash; IQ3 H1 Receipts Up 64% To $3.7m; Medadvisor H1 Receipts Up 18% To $3.6m; Pharmaust H1 Receipts Up 62% To $1.9m; Adherium H1 Receipts Up 51% To $1.8m; Less Than 2 Quarters Cash; Total Brain H1 Receipts Up 72% To $1.6m; Less Than 2 Quarters Cash; Avita H1 Receipts Up 25.4% To $1.2m; Micro-X Has Less Than Two Quarters Cash; Reva Receipts Up 360% To $886k; One Quarter Cash; Race Receives $229k Federal R&D Tax Incentive; Kemper Shaw, William Taylor Each Take 11% Of Imagion
 
Jan 30, 2019
Federal $37m For Parkinson’s Disease; Airxpanders 2018 Sales Up 211% To $12m; G Medical Less Than 2 Quarters Cash; $30m Hygea Contract; Invion Backs Demerger, 209m Director Options; Mayne Anti-Fungal Tolsura (Suba-Itraconazole) US Launch; API To Sell Medlab Food Additives; LBT Appoints Simon Arkell US Director; Creso Marijuana Beer Licenced To Switzerland’s Einhor Bräu
 
Jan 29, 2019
Visioneering: ‘Naturalvue Reduce Myopic Progression 90%’; Correction: Neuren; Universal Biosensors Sales Down 7% To $24m; J&J To Pay $45m; Osprey 2018 Sales Up 62% To $3.4m; Volpara Q3 Record Receipts Up 192% To $1.8m; Invion 4C: ‘Cho Group To Fund All Costs’; Invion Hires Guilin Xingda For Cancer Equipment Manufacture; Neurotech Rights Issue For $3m; Japan Patent For Opthea’s OPT-302; Adalta AD-214 Manufacturing ‘On-Track’; Pharmaust, Elanco Monepantel Data Sharing Deal; ITL Delists February 8; Nasdaq 3rd Genetic Technologies Non-Compliance Letter; Avita: 9 Abstracts At US Burns Meeting; Impedimed To Present ‘Detailed Prevent Trial Results’; Cynata Presents CYP-001 GvHD Results; G Medical Requests ‘Purchase Orders’ Trading Halt; MGC Completes Derma Sale To Cannaglobal
 
Jan 25, 2019
Dr Boreham’s Crucible: Neuren Pharmaceuticals; Resmed H1 Revenue Up 10% To $1.75b, Profit Up 9.6% To $336m; Botanix BTX-1204 Eczema Trial On-Track; Auscann Buys Perth Marijuana Drug R&D Facility; Cardiex 20m CEO Performance Shares, 3m Director Options EGM; Colin Mackinnon Replaces Alcidion CFO Duncan Craig
 
Jan 24, 2019
Proteomics Axes Prism US Licence; Visioneering 2018 Receipts Up 311% To $4.8m; Creso Placement Raises $3m; Cyclopharm $2.4m R&D Tax Incentive, Recruits 100th US Patient; Telix Licences 99m-Technetium-Ipsma For Prostate Cancer; ITL Unmarketable Parcel Facility Buys Back 166k Shares
 
Jan 23, 2019
Cartherics, Toolgen Gene-Edit Stem Cells For Cancer; Cellmid: ‘December Profit; Cash Flow Positive In 2020’; Invitrocue, Shanghai Inst Develop Breast Cancer Onco-PDO; NZ Allows Elixinol Medical Marijuana; ‘Australia Lags’; MMJ Share Plan For $10m, EGM; Leo Lee Replaces Regeneus CEO John Martin; Anatara Appoints Dr David Brookes Director
 
Jan 21, 2019
Living Cell: ‘4-Year NTCell Parkinson’s Safety Data Positive’; Clarification: Immuron Warrants Over 701.5k US Shares; Pharmaust: ‘Diet, Excipients Improve Monepantel For Cancer’; Biotech Daily Appendix 4C Quarterly Reports Policy; Admedus Has Less Than Two Quarters Cash; New York’s Sio Takes 22% Of Admedus; Acrux Receives $2m Federal R&D Tax Incentive; Creso To Sell Terrascend 100kg/Month Marijuana Flowers; Jeremy Green, Redmile Take 13.4% Of Avita; One Funds Diluted Below 5% In Avita
Benitec Late BB-401 Head, Neck Cancer Trial Closure; Rhinomed Share Plan Raises $95k Of Hoped-For $1m; Phosphagenics: Anna Legg Out; Melanie Leydin, Michael Sapountzis In; Phylogica Loses CSO Dr Robert Hayes; ASX ‘Verbal Confirmation’ Queensland Bauxite Relisting; Race CEO Peter Molloy Increases, Diluted To 5%; FIL Below 5% In Starpharma, Again; Telix Completes $8.3m AMNI SA Acquisition; MGC Exports Cannepil From Slovenia; Micro X Raises $2m; Altium Takes 7.5% Of Immutep; Medibio Loses Christopher Indermaur, Appoints Claude Solitario; Cann Gives Pays CSIRO 91k Shares; Dorsavi CEO Dr Andrew Ronchi Diluted Below 5%; Prudential (M&G) Takes 5% Of Medical Developments; Elixinol Releases 52k ASX Escrow Shares; MMJ Medipharm Receives Canada Approval Marijuana Production; Race Chair Dr Bill Garner Takes 17.5%; Race CEO Peter Molloy Increases, Diluted To 5.2%; FDA Requests ‘Clinical Data’ To Approve Starpharma Vivagel BV; Prana Raises $44.6m From Life Biosciences, Investors; Lanstead Reduces Below 5% In Neuren; GI Dynamics Extends $6.6m Crystal Amber Loan; Resapp Submits CE Mark Tech File For Smartphone Diagnostic; Japan Approves Starpharma Vivagel Condom; Total Brain Releases 474k Shares From Escrow; Creso ‘Takes Advantage’ Of Israeli Marijuana Export Rules; Immuron Receives $1.19m Federal R&D Tax Incentive; Resonance Licences Wisconsin Fat-Diseases Patents; Bionomics Phase II BNC105 Combination Cancer Trial Underway; Leigh Elkolli Replaces Reva CFO, Co Sec Brandi Roberts; GI Dynamics Appoints Stephen Linhares Clinical, Regulatory Head; Australia Accepts Cynata Stem Cell Patent Application; Mesoblast Phase III Trial Completes Recruitment; Starpharma Tells ASX: FDA Data Material, Japan Approval Not; Nuheara Launches Iqbuds Max; Imugene Appoints Prof Michael Caligiuri Scientific Advisor; Immutep $6m Collaboration With Cytlimic; Reva Expands Into Seven European Countries; Creso To Distribute Medical Marijuana In Sri Lanka; FIL Reduces To 6.5% In Impedimed; Polynovo: H1 Novosorb BTM Sales Up 320%; Patrys Receives $556k R&D Tax Incentive; Telix: Huj591 Data Supports Phase III Prostate Cancer Trial; Avita US Launch Of Recell System; Elixinol CFO Ron Dufficy To US, Kim Bradley-Ware Co Sec; Oventus Launches Nylon O2Vent Optima For Sleep Apnoea; ITL Health Votes To Quit ASX; MMJ Appoints Michael Curtis Director; Zelda Pleads Schultz To ASX 20% Query; Medlab: ‘Nanostat Improves Atorvastatin’; Nuheara Launches Hearing Services App, Iqstore; Jencay Capital Takes 8% Of Universal Biosensors; Creso, Medleaf Partner For NZ Medical Marijuana; Cancer Trials Joins Shareroot’s Media Consent; FDA: July 8 PDUFA Date For Clinuvel’s Scenesse For EPP; Niv Dagan, Freedom Trader Take 5.5% Of Lifespot; Invitrocue Appoints Dr Steven Fang Chairman; Nuheara Launches Iqconnect; Invitrocue Appoints Prof Masakazu Toi Clinical Advisor; Memphasys: Uni Of Florence, Isfahan Clinic Test Felix; Federal $25m For WEHI Drug Discovery Centre; Mesoblast Takes $21m From Hercules Credit Facility; FIL Takes 5% Of Starpharma; Zelda Director Jason Peterson Transfers, Reduces To 9.6%; Anatara Receives $1.25m R&D Tax Incentive; CEO Richard Hannebery Takes 13.4% Of Genera; Memphasys: Boston IVF, University Of Munster Test Felix; Pharmaust: ‘Monepantel Shows Anti-Cancer Activity’; Cardiex, Anthem To Co-Market Inhealth; Immuron Offers Warrants Over 701.5k US Shares; Resonance: Envoyai To Distribute Ferrismart In US; Kazia Receives $2.2m R&D Tax Incentive; Prescient Receives $939k R&D Tax Incentive; Mark Fortugno Replaces THC CFO Jarrod White; Invion: Lynda Spelman, Louis Irving, Nathan Lawrenstchuk Advisors; Painchek Works With Allity Aged Care, Ward Medication; Invitrocue Appoints Prof Jesús García-Foncillas Clinical Advisor; Impedimed Signs Ascension For Sozo; Pharmaxis Ready For Phase II LOXL2 Trials; Phosphagenics, FDA Discuss TPM-Oxymorphone Path; EMA Approves Medlab SME Qualification; Genera Receives $438k R&D Tax Incentive; Anteo Works With Sona Nanotech, Ellume; Esense-Lab Ships 2l Cannabidiol Vape Product To E-Quits; Malaysia Approves Polynovo BTM; Buys Production Facility; Cardiex Tells ASX: ‘Jan 5 Anthem News Published Jan 15’; Invitrocue Rolls-Out Onco-PDO Screening Germany; Antisense: ATL1102 For DMD Trial Recruitment Half-Way; Bioxyne Loses Director Maxwell Parkin; Auscann To Release 133m ASX Escrow Shares

 

 

 
 
Dec 21, 2018
Dr Boreham’s Crucible: More Medical Marijuana; Invion Demerger, 209m Director Options EGM, ATO Ruling; Genetic Technologies Pays $250k For Blockshine J-V; LBT Files FDA 510(K) For APAS Independence; LBT Receives $1.85m Federal R&D Tax Incentive; Bionomics Earns $654k From Cancer CRC, Pfizer Deal; Ellex Trades On US OTCQX; THC Wins 2 Australian Medical Marijuana Licences; Creso Completes Kunna Canada Acquisition For 9.4m Shares; Elixinol Welcomes US Hemp Approval; Neurotech: ‘New Strategy For US Mente Autism Sales’; Telix Appoints Nannette Rich Head Of US Sales, Marketing
 
Dec 20, 2018
2018 - Biotech Daily’s Year In Review; Starpharma $142m US Vivagel Bacterial Vaginosis Deal; Patrys: ‘PAT-DX1 Kills Breast Cancer Brain Metastases In Mice’; Qbiotics Raises $15.5m Of Hoped For $26m; Dimerix Receives $1.1m Federal R&D Tax Incentive; Pharmaxis Resubmits US FDA Application For Bronchitol; Universal Biosensors $6.3m US Tax Liability; Cuts, Staff Go; Memphasys: Colorado Centre Tests Felix Sperm Device; Micro-X Requests Capital Raising Trading Halt; Noxopharm Receives $3.3m R&D Tax Incentive; Creso Hails US Hemp Law Change; Neurotech Founder Dr Attard Trevisan Back As Advisor; Esense Loses Director Kobi Zecharia
 
Dec 19, 2018
Cyclopharm: Canada Guidelines Back Technegas For Imaging; Telix Applies For Japan TLX250-CDX Kidney Cancer Imaging Trial; Immutep Raises $7.2m; Suda $1.4m Mitsubishi Tanabe Zolpimist Insomnia Licence; Akaal, Boston Pharma Deal For AKP-11 For Psoriasis, Arthritis; Clinuvel: ‘Scenesse Good For Vitiligo, Dark Skin Rejected’; Alcidion Extends ACT Health Contract; Phosphagenics, Mylan, Strides Settle For $176k, New Deals; Lifespot’s Vaporizer For CBDS US Marijuana Trials; Bard1 Dr Irmgard Irminger-Finger Increases, Diluted To 11%; MGC Trades On US OTCQB; THC Requests ‘Marijuana Permits’ Trading Halt; Mesoblast Promotes Dr Eric Strati To Commercial Head
 
Dec 18, 2018
Paradigm: ‘PPS Reduces Osteoarthritis Pain’; Respiri Places $3.2m; Plan For $1m More; Workplace Wheezo; Merchant Places Bard1 $1.1m Shortfall; Total Raised $3.3m; Dorsavi Raises $2.1m Of Hoped-For $3.2m; Avita Receives $1.4m Federal R&D Tax Incentive; Botanix Ready For Phase II BTX1204 Eczema Trial; Analytica Resumes US Pericoach Sales; OBJ: Procter & Gamble Licence For 1st Integrated Product; Cynata Sends GvHD Results To Fujifilm For Option Decision; Mayne Re-Acquires Suba-Itraconazole Rights From Hedgepath; Cardiex, Unnamed Company Partner For Sleep Disorders; Recce Chair Dr Graham Melrose Lends $200k; Lifespot To Release 28m ASX Escrow Shares; Medical Developments Loses Allan McCallum; ‘Help Wanted’
 
Dec 17, 2018
Imugene: HER-Vaxx For Gastric Cancer ‘Safety, Responses’; Genetic Signatures Easyscreen Respiratory Kit CE Mark; Federal Government $3m For Paediatric Leukodystrophies; Imagion, Planet Innovation To Develop Magsense; Nuheara, UK Specsavers Partner For Iqbuds Sales; Race: Truemed Sells AML Named Patient Bisantrene In Israel; Dorsavi Requests ‘Rights Issue Results’ Halt; TBG Buys Zhangye Medical Lab For China Testing Services; Virbac Orders $350k Creso Animal Marijuana Products; Genera AGM Passes All Resolutions; Vinva Below 5% In Mayne; Grey Innovation, Two Bulls To Take Respiri Stake; China; Neuren CSO Dr Larry Glass Retires As Director; Oventus Appoints Sharad Joshi Director
 
Dec 14, 2018
Dr Boreham’s Crucible: Medadvisor; Admedus Rights Raise $5.4m Of $20m; $13.6m Underwritten; Australian Super Takes 8% Of Osprey; Paradigm ‘OA, Bone Bruising Trial Results’ Trading Halt; Respiri Requests Capital Raising Trading Halt
 
Dec 13, 2018
Cynata: ‘NHMRC $2m For Osteoarthritis Stem Cell Study’; Bard1 Raises $1.2m; $3.3m Expected; Pharmaxis Resumes US Sales Of Aridol, $2m Potential; Geneodx To Distribute Anteo Molecular Glue In China; Perth’s Oncores Wins British Royal ‘Entrepreneur’ Gong; Mesoblast, FDA Agree GvHD Regulatory Pathway; Adherium Loses US CEO Arik Anderson, CFO David Allinson; Paradigm CEO Paul Rennie Increases, Diluted To 16.7%; Regal Reduces To 6.5% In Prescient; Race Chair Dr Bill Garner Reduces To 15%
 
Dec 12, 2018
Federal Government: NHMRC $526m For 682 Projects; Federal $25m Grants For Mental Illness Open; Redhill Raises $28m; FDA Approves Mayne (Halcygen) Suba-Itraconazole; US Patent For Starpharma SPL7013 Conjunctivitis Eye Drops; Cellmid: ‘Record $2.2m Q2 Revenue’; From Glass To Plastic; Cardiex Expands Blumio Wearable BP Monitor Deal; Resonance Pleads Schultz, News, Deals To ASX 29% Query; ASX Suspends MMJ; Phosphagenics Takes ‘Mylan Talks’ Halt To Suspension; Jeremy Green, Redmile Take 9.4% Of Avita; One Funds Increases, Diluted To 5% Of Avita; Robert Lederer, Rtl Group Take 9% Of Anatara; Benjamin Karasik Diluted Below 5% Of Esense; Admedus: Star Bright Lishan Zhang, Dr Yanheng Wu Directors; Factor Loses Director Dr Robert Ryan
 
Dec 11, 2018
Orthocell Raises $1.8m; Birmingham Dental Approves Celgro; Bionomics Share Plan Raises $250k Of $2m; Total $10m; FIL Returns To 5% In Starpharma; Bionomics Receives $6.5m Federal R&D Tax Incentive; Rhythm Receives $284k Federal R&D Tax Incentive; Polynovo Appoints Jan-Marcel Gielen CFO, Co Sec; Gi Dynamics: Charles Carter CFO, Co Sec; Dave Bruce Goes; Genetic Technologies Appoints Paul Viney COO, CFO, Co Sec
 
Dec 10, 2018
Prescient: ‘Breast Cancer Responders Progression-Free’; Pro Medicus Extends Unnamed German Hospital Contract; CE Mark Approval For Speedx Gonorrhoea Test; Impedimed: ‘Study Backs L-Dex For Breast Cancer Lymphoedema’; Medibio Notes Raise $2.5m; Rights Offer For $4m More; Phosphagenics Requests ‘Mylan Negotiations’ Trading Halt; Allan Gray Diluted To 15% Of Osprey; Oncosil Appoints Michael Bassett Director; Painchek, Blamey Saunders Win UK ‘Rocketship’ Travel Grants
 
Dec 7, 2018
Dr Boreham’s Crucible: Mach7 Technologies; Phylogica Claims HSV-1 Vaccine Efficacy In 9 Of 12 Mice; Paradigm New Data Backs Osteoarthritis Pain Reduction; Genetic Signatures Receives $2.6m Federal R&D Tax Incentive; Orthocell Requests Capital Raising Trading Halt; Brandon, MRCF, Australian Super Hold 27% Of Osprey; Adam Leitzes, Karst Peak Increase, Diluted To 17.3% Of Avita; Deutsche Bank (Karst Peake) Quits Genetic Signatures, Again
 
Dec 6, 2018
Federal $240m For ‘Innovative, Transformational Research’; Cardiex Raises $5.5m For Inhealth; Gilead $250k For 6 Research Projects; Mesoblast To ASX: ‘We Did Not Tell Media Of Chair Retiring’; Zelda, Suda Work On Marijuana Oral Spray, $200k Options; Medadvisor, Thrivor Partner For Patient Care; E-Quit Orders Esense Marijuana Terpenes; Deutsche Bank AG Takes 14% Of Genetic Signatures, Again; Vinva Takes 5% Of Mayne Pharma; Medibio Requests ‘Material Capital Raising’ Trading Halt; LSQ Loses CEO Mario Pennisi; Claire Blain Acting; Dr Gopisetty
 
Dec 5, 2018
CSL R&D Spend Up, Approvals, ’Flu Vaccines, Pipeline; Biotron Options Raise $4.7m; Rhythm Completes Colorectal Cancer Test Reagents; Chair Allan Tribe, Australian Land Take 23% Of Phylogica; Prana Registers 1m ADRs; Stemcell: ‘ASX OK Marijuana Cosmetics; Dragon’s Blood’
 
Dec 4, 2018
Redhill Phase III Confirms RHB-105 For Helicobacter Pylori; Avita Raises $40m For US Sales; Atomo: ‘TGA Approves HIV Self-Test’; Federal $10m For MTP Connect; Nuheara ‘Oversubscribed’ Placement Raises $5m; Reva Fantom Encore 1st Italy Implant; Antisense Receives $285k Federal R&D Tax Incentive; Phylogica Peptides Deliver CAS9 To Laboratory Cells; Medlab Europe Subsidiary For EMA Registration; Jencay, Brett Rock Increase To 7% Of Universal Biosensors; Bori Liberman, Jagen Take 7% Of Opthea; Cardiex Requests ‘Capital Raising Activity’ Trading Halt; Admedus Appoints Dr Kiran Bhirangi CMO; Correction: BDI-40 With Market Capitalization
 
Dec 3, 2018
November BDI-40 Down 5%, ASX200 3%, Big Caps 4%, NBI Up 5% - Paradigm Up 42%; Factor Down 95%, Admedus 65%; Resonance Up 139% On FDA Ferrismart Clearance; Osprey Signs Premier For Dyevert; TPI Buys Melbourne Property; China Patent For Regeneus Stem Cell Biomarkers; Pharmaust Scalable Monepantel Kills Cancer In-Vitro; ITL Opens Unmarketable Parcel Facility; Medadvisor, Zuellig J-V For Prescription Reminders In Asia; Neurotech Facility Fail, 23% Oppose Remuneration Report; Phosphagenics Ends US OTCQX Listing; Creso To List On Toronto’s TSX-V
 
Nov 30, 2018
Dr Boreham’s Crucible: Oventus Medical; Mach7 ‘Oversubscribed’ Placement Raises $3m; Mesoblast ‘Renewal’ Starts With Chair Brian Jamieson; Mesoblast 23% Oppose Remuneration Report; Options; Genetic Signatures 31% Remuneration 1st Strike; Optiscan 33% Oppose Director ‘Performance Rights’, Options; Avita Requests Capital Raising Trading Halt; Nuheara Requests Capital Raising Trading Halt; BVF, Mark Lampert Diluted To 15% Of Opthea; Thorney Takes 14% Of TPI; Rhinomed Appoints Sean Slattery CFO, Loses Shane Duncan; Phylogica Board: Dr Rohan Hockings In, Dr Robert Hayes Out; Genera Loses 10-Year Director David Symons; Esense Appoints Piers Lewis Chair, Amit Edri Director
 
Nov 29, 2018
Victoria Appoints Martin Pakula Minister For Biotech; Osprey Rights Raise $4.3m Of Hoped For $10.5m, Total $14.3m; Telix, Nihon Work On Actinium-225 For Kidney Cancer; Noxopharm NOX66 Tolerated, ‘Suspends Tumor Growth’; European Patent For Immutep IMP321; ITL Delisting, Buy-Back EGM; Ellex’s 35% Oppose Director Alex Sundich; Adalta 17% Oppose Dr John Chiplin’s Share Purchase; MMJ Votes 22% Against Remuneration Report; Genetic Technologies Faces Up To 23% Dissent At AGM; 10.5% Dissent For Mayne Pharma Remuneration Report; Correction: GI Dynamics; ATO Delays Invion, Chronic Airway Demerger; Empery Reduces To 7% In Immuron; Richard Cashin Increases, Diluted To 21% In GI Dynamics; Wentworth Williamson Takes 6% Of TPI
 
Nov 28, 2018
Opthea 2014 Options Raise $13.3m; Dimerix To Expand Use, Licence Receptor-Hit Platform; Mach7 Requests ‘Capital Raising’ Trading Halt; Admedus Ends 4-Month Suspension To Raise $20m; Falls 57%; UK NHS Adds Nuheara Iqbuds Boost For Hearing Loss; Immutep 3 Of 6 Patients Respond To IMP321, Keytruda; Patent; Polynovo 5-Month Novosorb Sales $2.8m; Orthocell Treats Last Celgro Dental Implant Patient; Cardiex, Inhealth, Kaiser 7-Year Diabetes Lifestyle Study; GI Dynamics, India’s Apollo Sugar Trial Endobarrier; LBT 24% Avoids Remuneration Report 1st Strike; THC To Market Dutch Medical Marijuana In New Zealand; Cooper Below 5% Of TPI; TPI Appoints Sue Macleman Director; Glenn Gilbert Replaces Rhythm CEO Dr Trevor Lockett, On $260k
 
Nov 27, 2018
Medibio, AIAA Ilumen Mental Health Contract; Phosphagenics $228k Takes R&D Tax Incentive To $833k; Race 21% Oppose Remuneration Report; All Change At Respiri (Isonea, Karmelsonix) - Again; BVF Partners, Mark Lampert Reduce To 22% Of Pharmaxis; Grandlodge, Peter Anastasiou Have 12% Of Immuron
 
Nov 26, 2018
Telix Buys Partner ANMI For $9.3m Cash, Scrip; BTC Licences Episil Oral Pain Relief From Camurus; LBT 1st APAS Independence In The US; Local Sales Delayed; Proteomics, Janssen Work On Diabetic Kidney, Heart Function; Alcidion: MKM $12m Queensland Referral Contract; Opthea Enrols Last Of 366 Patients In OPT-302 Wet AMD Trial; Actinogen Enrols Last Patient In Xanamem Alzheimer’s Trial; Zelda, St Vincent’s Trial Marijuana For Pain; Mesoblast, Tasly Meet For Stem Cell Heart Drug Pathway; Dimerix Wins $100k Federal Grant To Identify Targets; Bluechiip Loses Director Blair Healy; Simavita To Lose Director Warren Bingham, Damien Haakman In; Peter Griffiths Replaces Neurotech CEO, M-D Wolfgang Storf; Admedus Appoints Matthew McDonnell Interim CFO
 
Nov 23, 2018
Dr Boreham’s Crucible: Memphasys; ITL To Delist In February: ‘Low Share Price, Liquidity’; Botanix Receives $4.6m Federal R&D Tax Incentive; Recce Takes Radium $256k R&D Tax Incentive Advance; Mark Kerr Takes 11% Of Phosphagenics
 
Nov 22, 2018
Biotech Daily Victoria Election 2018 Editorial; Dimerix Starts DMX-200 FSGS Trial; Dorsavi $106k Workright NW Workplace Safety Agreement; Paradigm Icahn PPS Licence For Muco-Poly-Saccharidoses; Hidden Hearing Distributes Nuheara Iqbuds Boost In Ireland; Memphasys, Gred To Validate Felix Sperm Separator; MGC 54% Remuneration 1st Strike; Pharmaxis 15% Oppose Malcolm McComas; Resolution Dropped; Vanguard Below 5% In Cochlear; Deutsche Bank Sells Genetic Signatures 14%; Karst Peak 18%; Hydroponics Changes Name To THC Global
 
Nov 21, 2018
Allegra: ‘FDA Okays Sr-HT-Gahnite Spinal Cage Path’; Simavita Raises Further $100k, Total $3.075m; Dorsavi Rights Offer For $3.2m; EU Orphan Status For Dimerix DMX-200 For FSGS; Up To 17% Dissent Against Clinuvel Chair Stan McLiesh; Micro-X AGM Placement Facility Faces 12% Dissent; Vanguard Takes 5% Of Cochlear; Genetic Technologies To Lose CFO, Co Sec Kevin Fischer; Noxopharm Appoints John Moore Director
 
Nov 20, 2018
Pro Medicus Signs $27m Partners Imaging Deal; Eye Co Fludrocortisone Acetate For Dry AMD Trial; Pharmaxis Readies For LOX Inhibitor Pancreatic Cancer Trial; Kazia Plan Raises $800k, Total $4.2m; Resonance Receives $326k Federal R&D Tax Incentive; Nuheara Unveils Iqstream TV For Independent Volume Control; Biotron 43% Remuneration 1st Strike; Options; Adherium 33% Remuneration 1st Strike; Share Plan; Universal Biosensors Repays $21m Athyrium Loan; MMJ Completes Phytotech Sale To Harvest One; Name Change; Adam Leitzes, Karst Peak Take 19.8% Of Avita; Fil Sells, Takes Loss On All 83.3m Factor Shares; Cochlear Appoints CSL’s Abbas Hussain Director
 
Nov 19, 2018
Volpara H1 Revenue Up 53% To $2.5m; Loss Up 22% To $4.8m; Imagion Rights Offer Raises Full $4.3m; Cynata Receives $1.3m Federal R&D Tax Incentive; Allan Gray Sells, Takes Loss On All 123m Factor Shares; Dimerix Starts DMX-200 Diabetic Kidney Disease Trial; Genetic Technologies Files $15m Kentgrove Prospectus; Cellmid Appoints Pharmaceutical Services NZ Distributor; China Copyrights, Trademarks For Uscom 1A, BP+, Spirosonic; Invion To Release 2.75b Escrow Shares; MGC, RMIT, Hebrew University Of Jerusalem To Launch Cannahub; Immuron: Dr Gary Jacob CEO Starts On $479k; Dr Kanellos COO; Invitrocue Appoints Dr Lindner Europe CEO, Prof Waugh Advisor; Somnomed Neil Verdal-Austin Replaces CEO Derek Smith On $480k; Admedus Loses CFO Catherine Costello; Medibio Appoints Mathew Watkins Joint Co Sec
 
Nov 16, 2018
Dr Boreham’s Crucible: Regeneus; CMRI, Logicbio Partner For Viral Vectors; Avita Hires 20 US Sales Staff; Starpharma Dep-Chemo Stops Pancreatic Cancer In Mice; Optiscan To Lose Founding Director, Inventor Peter Delaney; Medibio AGM Repels Elias Leo ‘The Gun’ Khouri Board Spill; Hydroponics 30% Oppose In-The-Money Options; Canada Co; Painchek Receives $751k Federal R&D Tax Incentive
 
Nov 15, 2018
Pharmaxis: LOXL2 Drug ‘Safe, 85% Enzyme Inhibition’; Federal $4m For Autism Research; Prof Georgina Long, Prof Richard Scolyer Win GSK $80k; Paradigm Receives $2.3m Federal R&D Tax Incentive; Suda Receives $745k Federal R&D Tax Incentive; US Patent For Dorsavi Body Orientation Technology; Cynata Survives 24.55% Remuneration Dissent; Suda Survives 22% Remuneration Dissent; Resapp 18% Placement Facility Dissent At AGM; MGC Starts UK Legal Proceedings Against Varm Cosmo; BVF, Mark Lampert Take Profit To 16% Of Opthea; Dimerix Loses Kathy Harrison
 
Nov 14, 2018
Factor Falls 97% On VF001 Venous Leg Ulcer Fail; Victoria $100k For Compumedics, Deakin Sleep Diabetes Study; Exopharm $7m IPO For Exosome Regenerative Medicine; Bionomics 2nd Placement Raises $2m Of $4m; Total $9.8m; Bionomics 37% Remuneration 1st Strike; Opthea Recruits Phase IIb OPT-302 AMD Trial; Painchek Launches On-Line Training Course; Resapp ‘ISO Compliant’ For CE Mark, TGA; Rhinomed AGM For 9m Director Options; Kinetic, Aust Super Increase; Brandon, CM Diluted In Osprey; Proteomics: Adelaide Equity, Scintilla Corporate Advisors; Anatara Appoints Steven Lydeamore CEO On $395k
 
Nov 13, 2018
Qbiotics 1st EBC-46 Solid Tumor Trial: ‘2 Complete Responses’; Cochlear $20m For Nyxoah OSA Hypoglossal Nerve Stimulation; Imugene: ‘HER-Vaxx Safe, Antibodies For Gastric Cancer’; Sienna Receives $443k Federal R&D Tax Incentive; IDT Buys-Back, Cancels 659k Shares; Factor Requests ‘Trial Results’ Trading Halt; Pharmaust: Catalent GMP Monepantel For Dog Cancer Trials; Imugene 18% Oppose 25m Chair Paul Hopper Options; Auscann Hires PCI Pharma For Marijuana Capsules For Pain; MGC Sells Derma To Cannaglobal Canada
 
Nov 12, 2018
Mesoblast Stem Cells Miss Heart Endpoint, Reduce GI Bleeding; Bionomics To Lose CEO Dr Deborah Rathjen; Raise $12m; Immutep IMP321, Keytruda ‘Some Melanoma Efficacy, Safety’; Uscom Establishes Beijing Office; Phosphagenics Loses $416m Mylan Case; Race Chair Dr William Garner Transfers, Reduces To 16%
 
Nov 9, 2018
Dr Boreham’s Crucible: Allegra Orthopaedics; Cochlear, Denmark’s GN Group Expand Collaboration; Proteomics Ships 1st Commercial Promarkerd Kidney Test; Imugene Receives $1.85m Federal R&D Tax Incentive; BVF, Mark Lampert Take 18% Of Opthea; NZ Harbour Asset Management Below 5% Of Volpara
 
Nov 8, 2018
Imagion Readies For 1st Human Magsense Breast Cancer Trial; Federal Government Sets 12 Research, Innovation Priorities; Bard1 To Raise $3.3m In Entitlement Offer; Euro Guidelines ‘Challenge’ Reva; Richard Kimes Goes; Strides Pays Suda $1.4m For SUD-001H For Migraine In US; Visioneering: ‘Lenses Slow Children’s Myopia By 81%’; Optiscan Receives $776k R&D Tax Incentive; Phosphagenics Receives $604k R&D Tax Incentive, $200k More; Cellmid 16% Oppose 33% Director Fees Pool Hike; Genetic Technologies CEO Dr Paul Kasian $47k Pay Rise
 
Nov 7, 2018
Resmed Pays $1b For Matrixcare Software; FDA Okay For Optiscan, Carl Zeiss Convivo Microscope; Biotech Daily 13th Birthday Editorial; South Korea Approves Nuheara Iqbuds, Iqbuds Boost; Europe Allows Cynata MSC Patent; US, EU Patents For Cellmid’s Midkine N-Domain; Botanix Treats 1st BTX1308 Psoriasis Patient.; Invion IVX-P02 Anti-Cancer Gel, Pre-Clinical Studies Partners; Paradigm New 20-Patient Data Backs Osteoarthritis Pain Reduction; Zelda To Release 224m Shares, 40m Options From ASX Escrow; Suda Requests ‘Licence Agreement Negotiations’ Trading Halt; Bard1 Requests ‘Capital Raising’ Trading Halt; MGC Extends ‘Cannaglobal, MGC Derma Sale’ Suspension; Polynovo To Lose Co Sec Greg Lewis; CFO, Co Sec Wanted
 
Nov 6, 2018
Qbiotics $26m IPO For Rainforest Cancer, Wound Drugs; Global Kinetics PKG Improves Parkinson’s; Savings; Investors Mutual Takes 7% Of Ellex; Elixinol Takes 50.5% Of Elixinol Japan; Elixinol CEO Paul Benhaim, Associates Diluted To 63%; David Newman, Gabriel Ettenson, D&G Diluted To 10% In Elixinol
 
Nov 5, 2018
Cochlear Ordered To Pay $372m Over Patent; Appeal; Mach7 Works On Sentara Radiology Upgrade; Japan Patent For Resapp Respiratory Diagnostic; Vanguard Takes 5% Of CSL; MGC Takes ‘Cannaglobal, MGC Derma Sale’ Halt To Suspension
 
Nov 2, 2018
Dr Boreham’s Crucible: Cryosite; Living Cell: ‘18-Month 80-NTCell Benefit For Parkinson’s’; Rhinomed Raises $5m, Share Plan For $1m More; Biocurate, Novartis To Accelerate Drug Discovery; Court Orders Cellmid To Pay Ikon $939k; Mexican, Hong Kong Patents For Orthocell Celgro Scaffold; Optiscan Takes ‘Regulatory Approval’ Halt To Suspension; G Medical To Buy Telerhythmics For $2.7m; Hydroponics Supplies 1st Marijuana Patients; Genera AGM Extended, Rights Issue For $11.2m; Medibio Appoints David Kaysen CEO On $500k, Sacks US Staff
 
Nov 1, 2018
October BDI-40 Down 16%, ASX200 6%, Big Caps 7%, NBI 15% - Volpara Up 52%; Bionomics Down 86%, Airxpanders 39%; Reva Launches Fantom Encore; Post-Market Trial; MTP Connect, Federal Government: ‘$6b Regenerative Medicine’; India Approves Polynovo Novosorb; Myovatec Distributor; Cardiex, Blumio Wearable BP Sensor Trial; Oventus Receives $1m Federal R&D Tax Incentive; Cellmid Repays R&D Loan, Expands US Évolis Availability; Race Appoints Biosynergy For Bisantrene Deals; Credit Suisse Below 5% In Bard1; Creso Launches Cannaqix50 For Chronic Pain In Brazil; MGC Requests ‘Cannaglobal, MGC Derma Sale’ Trading Halt; Micro-X Has Less Than Two Quarters Cash; Avita AGM To Vote On 15m CEO Dr Mike Perry Options; Neurotech AGM For 609k Director Shares; Fisher & Paykel Appoints Neville Mitchell Director; Admedus Appoints Stephen Denaro Director, Co Sec; Dr Dean Moss Replaces Ausbiotech Director Lawrence Gozlan; Ausbiotech J&J Gongs: Dr Anna Lavelle, MDGH, Telix, Microba
 
Oct 31, 2018
Resapp ‘Very Pleased’ With Results; ‘Beats Stethoscope’; Resonance: ‘Unnamed US Pharma $1m Trial Contract’; Opthea Receives $12m Federal R&D Tax Incentive; Biotech Daily AGM Reporting Policy; Mesoblast AGM For 990k Director Options; Stemcell AGM For 18.6m Director Options; Correction: Recce; Optiscan Requests ‘Regulatory Approval’ Trading Halt; Rhinomed Requests ‘Capital Raising’ Trading Halt; Founder Yacov Geva Lends G Medical $9.9m More; Raises $4.5m; Invitrocue Has Less Than Two Quarters Cash; Fund Raising; Stemcell Has Less Than One Quarter Cash; Medical Developments To Lose 12-Year Director Dr Harry Oxer; Bioscience Managers Appoints Dr Kate Rowley
 
Oct 30, 2018
Resapp Misses 1st Primary Endpoint, Mixed US Trial Results; Allan Gray Invests $10m In Osprey; $10.5m Rights Issue; Medlab: From Phase I Nanabis Cancer Pain Trial To Phase II; Cellmid Receives $808k Federal R&D Tax Incentive; Imagion Has One Quarter Cash, ‘More Coming’; Medigard Licences Kunovus KT009 For Disc Degeneration; Biotron Tells ASX: HIV Trial Data ‘Currently Confidential’; Optiscan AGM For 1.94m Director ‘Rights’, 12.8m Options; Recce 250k Director Dr John Prendergast Shares AGM; Invitrocue AGM For 6m Director Options; Zelda AGM For 25m CEO Dr Richard Hopkins Options; Tim Robertson, Farjoy Take 11.5% Of Medlab; MGC Epilepsy Action Online Information, Access Portal; Creso Edible Marijuana R&D Centre Of Excellence
 
Oct 29, 2018
Clinuvel’s Vallaurix Expands Laboratory To Analytics; Anatara Detach For Piglets Approved; Pork CRC Options; Cann Wins Victoria Marijuana Resin Supply Contract; Pharmaust Develops Monepantel GMP Method; Resapp Extends ‘Smartcough-C-2 Trial’ Suspension; Osprey Requests Capital Raising Trading Halt; G Medical Requests ‘China Facility Audit’ Trading Halt; Mayne $6m CEO Loan Shares, 50% Pay Pool Rise AGM; Phil Hodges; Clarification: Opthea AGM; Paradigm AGM For 300k CEO Paul Rennie Loan Shares; Genetic Signatures 200k CEO Dr John Melki Options AGM; Brain Resource Name Change To Total Brain AGM; Mach7 Has One Quarter Cash, ‘Seasonal Costs Down’; Platinum Takes 11.5% Of Kazia; Credit Suisse Takes 6% Of Bard1; Admedus Loses Director, Co Sec Catherine Costello; Prescient Appoints Dr James Winkler For Business Development
 
Oct 26, 2018
Dr Boreham’s Crucible: Biotron; Opthea 12-Week Opt-302 Combination For DME ‘Positive Data’; Cancer Therapeutics CRC $668m Pfizer Collaboration; Neuren, Acadia Negotiate Trofinetide For Rest-Of-World; Mayne $45m For US, Australia Halobetasol For Psoriasis Rights; Cardiex $300k Astrazeneca Sphygmocor Contract; Somnomed One Quarter Cash; Better Quarter Coming; Compumedics AGM Rolls Director Dr Alan Anderson; Uscom AGM For 1.2m Chairman Prof Robert Phillips Rights; Bioxyne AGM For 7.5m Director Rights, 1m Options; Opthea AGM For 7m Director Options; Nuheara AGM For 3m Director Kathryn Foster Options; Auscann AGM For 67% Directors Fee Pool Hike To $500k; Starpharma To Vote On 675k More CEO Performance Rights; Phosphagenics Pleads Schultz To ASX 27% Query
 
Oct 25, 2018
Victoria $1.5m For CSIRO Biologics Manufacturing Facility; Australia-Texas Medical Center Collaboration; Paradigm Raises $9m; PPS Deal To Treat Retired US Athletes; Patrys Receives $3m Pat-Sm6 Settlement; Redhill Assesses Final Phase III RHB-105 Heliobacter Patient; Oncosil: ‘Analysis Backs Brachysil For Pancreatic Cancer’; Avita Begins Recell Trial For Paediatric Burns; Compumedics China JV Talks ‘Stalled’; $1.1m China Order; Cann Collaborates With CSIRO On Medicinal Marijuana; Credit Suisse Takes 5% Of Bard1, Again; Airxpanders EGM 22% Oppose Chair Barry Cheskin Shares; Bluechiip AGM For 2.3m CEO ‘Performance’ Rights; Adalta 375k CEO Replacement Options AGM
 
Oct 24, 2018
Mesoblast Expands JCR Deal To Epidermolysis Bullosa; Proteomics Licences Promarkerd For Spain; Wins WA Gong; Adalta Receives $2m Federal R&D Tax Incentive; Resapp Takes ‘Smartcough-C-2 Trial’ Halt To Suspension; Euro Patent For Invictus Transmucosal Tocotrienols; Bard1 Granted Additional China Patent For Cancer; Memphasys Tells ASX: Anova News ‘Not Material’; Queensland Bauxite, Bonify 3t Import-Export Marijuana Deal; Medibio $30k Unnamed Company Contract; Actinogen 18m Directors Options AGM; Proteomics 800k Director Options, 316k Shares ‘In Lieu’ AGM; Proteomics Founder Director Dr John Dunlop To Retire; Respiri Appoints Dr Tom Duthy Director
 
Oct 23, 2018
Bard 1: ‘Breast Cancer Blood Test 86% Accurate’; Telix Starts Zircon TLX250 Renal Cancer Imaging Trial; Phosphagenics $425m Mylan Case ‘Progress’; Nuheara Receives $1.9m Federal R&D Tax Incentive; Hong Kong Approves Medical Developments Penthrox; Japan Patent For Orthocell Celgro Collagen Device; Fisher & Paykel ‘Court Finds Infringed Resmed Patent’; Resonance Pleads Schultz To ASX 86% Query; Correction: Resapp; IDT Loses 2nd Strike Vote, Wins Spill Vote, Again; Patrys 24m Director Options, 60% Director Fee Pool Hike AGM; Paradigm Requests ‘Capital Raising’ Trading Halt; Esense To Supply E-Quits Marijuana Terpenes; Biotron Appoints Prof Stephen Locarnini Director; Invitrocue Appoints Dr Gary Pace Director; Anatara Appoints Product Development Advisory Board; Neurotech: Prof Emanuela Russo CSO, Advisory Board; Stemcell Glenn Davies, Ee Ting Ng In; Chair Jamie Khoo Out 
 
Oct 22, 2018
One Week To Ausbiotech Melbourne, Brisbane Conferences; Memphasys, Anova To Validate Felix Sperm Separator; Imagion Rights Offer Raises $411k Of Hoped-For $4.3m; Kazia, Dana-Farber Trial GDC-0084 For Breast Cancer To Brain; Antisense Inventor Dr Frank Bennett Shares $4m Prize; Resapp Requests ‘Smartcough-C-2 Trial’ Trading Halt; Invictus: Capstone Supplement Manufacture For US Launch; Actinogen To Close Xanamem Alzheimer’s Trial Recruitment; Peter Manley Replaces Genetic Signatures CFO Mark Langan; Invitrocue: Prof Iyer Advisor Chair, CSO Dr Dasgupta Goes; LBT Loses 12-Month Director Matthew Michalewicz; Erlyn Dale, Winton Willesee Replace Creso Co Sec Sarah Smith; Noxopharm Appoints Dr Greg Van Wyk CMO
 
Oct 19, 2018
Dr Boreham’s Crucible: Redhill Biopharma; MGC Derma Sale To Cannaglobal Delayed; Queensland Bauxite To Distribute Pharmocann Products; Factor Has Less Than 2 Quarters Cash, ‘Pivotal Trial Ending’; Brain Less Than 2 Quarters Cash, ‘Significant Revenue Rise’; Pharmaxis AGM For 690k More CEO Performance Rights; Prescient AGM For 2m CEO Steven Yatomi-Clarke Options; Race 4m Director Options AGM; Living Cell Pleads Schultz To ASX 177% Query; Stemcell Pleads Schultz To ASX 28% Query; Respiri Hires M&C Saatchi To Launch Wheezo Asthma Detector
 
Oct 18, 2018
Telix Starts TLX101, Radiotherapy Glioblastoma Trial; Cynata Stem Cells Impact Brain, Skin Cancers In-Vitro, Mice; Kazia Raises $3.4m, Share Plan; Elixinol To Add Medical Marijuana To OTC Hemp Foods ‘Soon’; Avita 1st US Recell Sales; Oventus Trials Show Significant O2vent Benefit; European Patent For Regeneus Progenza Fat Stem Cells; Esense Tells ASX Aware Query $25k Sales ‘Not Material’; CSL 16% Oppose $8.5m CEO Paul Perreault Shares, Again; Charter Life Sciences Diluted To 20% Of Visioneering; Novita Completes Sale Of Newly To Healthcarelink; Memphasys Pleads Schultz To ASX 65% Query; ASX Misses 148%; Ellex Appoints Dr David Lubeck CMO
 
Oct 17, 2018
Acrux New Generic Testosterone FDA Application; Airxpanders: ‘Radiation OK With Aeroform Breast Expander’; CPS Underwrites $4.7m Expiring Biotron Options; Proteomics Receives $834k Federal R&D Tax Incentive; Telix, Radboud TLX250 Renal Cancer Manufacturing Deal; Prescient, Unnamed US Company New Formulations Work; Nuheara Welcomes US FDA De Novo Device Path; Impedimed 44% Remuneration 1st Strike; Alchemia Pleads Schultz To ASX 187.5% Query; Suda Pleads Schultz, ‘Tweets’ To ASX 100% Query; Resapp Pleads Schultz To ASX 24% Query, Media After; MGC Pleads Schultz, Canada Marijuana Law To ASX 25% Query; Kazia Takes ‘Capital Raising’ Halt To Suspension; Clinical Genomics Mary Padbury, Katherine Kalin To Board
 
Oct 16, 2018
FDA Approves Eyepoint (Psivida) Yutiq (Durasert); Telix: Seibersdorf To Manufacture TLX101 For Glioblastoma; Cardiex To Pay More Than $4.6m For 50.5% Of Inhealth; Factor Hires Taylor Collison For VF001 Leg Ulcer Deals; Medibio Back To Bioprospect Future Board Spill AGM; Phylogica 10m CEO Dr Rohan Hockings Options AGM; Antisense Pleads Schultz To ASX 59% Query; ASX Misses 159%; MGC Requests ‘ASX Price Query’ Trading Halt; Prudential (M&G) Reduces To 14% Of Mesoblast; Australian Ethical Takes 7.4% Of Actinogen; Peter, Diana Diamond Take 12.2% Of Novita; Hydroponics Welcomes Canada Recreational Marijuana; Esense Requests ‘Commercial Supply Agreement’ Trading Halt
 
Oct 15, 2018
Telix: Study Backs Cancer Imaging Trial; ANMI, Cyclotek Deals; Optiscan Starts Breast Cancer Margin Trial; Adalta Ad-214 ‘Major Manufacturing Milestone’; Esense-Lab Raises $3.15m; Medibio Receives $3m Federal R&D Tax Incentive; Biotron Receives $1m Federal R&D Tax Incentive; Pharmaust Monepantel ‘Palatable To Beagles’, Activity; Kazia Requests ‘Capital Raising’ Trading Halt; W Whitney George Takes 22% Of Rhinomed; Tiga Takes 12% Of Simavita; Living Cell AGM For 3.4m CEO, Director Options
 
Oct 12, 2018
Dr Boreham’s Crucible: Novita Healthcare; WEHI: New Mouse Model Mimics Complex Human Cancers; University Of Melbourne, Beijing No 1 Biochemical Partner; Tasly Pays, Invests $57m In Mesoblast For China Heart Deal; Cyclopharm FDA 505 (B) 2 Technegas Path ‘Lower Cost, Risk’; Alcidion Q1 Receipts Up 229% To $5m; Cash Flow Positive; Volpara Sells 1st Public Sector Breast Screen Enterprize; Impedimed Completes Xitron Technologies Sale; Sienna AGM For 1.8m Director Options; Hydroponics 6m Options, 380k Shares, Name Change AGM; Zelda CEO Dr Hopkins Pay Up To $300k, Option Prices Down; Jianfang Wang Below 5% In Stemcell United; Cardiex Requests ‘Material Transaction’ Trading Halt
 
Oct 11, 2018
Pharmaxis: LOXL2 Drug ‘Highly Meaningful Enzyme Inhibition’; Saudi Arabia Approves Medical Developments Penthrox; Resapp Claims Sleep Apnoea Algorithms ‘90% Accurate’; Orthocell Receives $2.5m Federal R&D Tax Incentive; Cardiex: CEO Craig Cooper, Director Niall Cairn $1.5m; Zelda Ends Chile Marijuana Research Program; TGA Approves MGC Marijuana Cannepil For Epilepsy; CVC Takes 12% Of Universal Biosensors; Simavita: Post-Placement Substantial Holders In, Out, Diluted; Suda Appoints Andrew Curtis For US Business Development; Clarity Appoints Prof Jason Lewis To Advisory Board 
 
Oct 10, 2018
Cochlear Investigates ‘Fully Implantable’ Hearing Aid; Clinuvel UK Nice Scenesse EPP Decision ‘Remitted’; Telix, Genesiscare TLX101 Glioblastoma Compassionate Use; Childrens Hospital Foundation $10m For Brain Cancer; MTP Connect $690k For Three Projects; Actinogen Receives $3.2m Federal R&D Tax Incentive; Kazia Completes Cantrixil Ovarian Cancer Dose Escalation; Impedimed Starts US Sozo Heart Failure Trial; Zelda Begins US Marijuana Autism Trial; Queensland Bauxite’s Medcan Wins Marijuana Licences; Immuron 437k Director Shares, 2m Options, 43% Fee Pool AGM; Correction: MGC; LGCc Diluted Below 5% In Bluechiip; Medadvisor Appoints James Rotsart, Lucas Merrow Advisors
 
Oct 9, 2018
Visioneering: Medilens Nordic 1st Naturalvue Euro Distributor; Probiotec Completes $13.5m Branded Products Sale To Inova; Phylogica Receives $2.9m Federal R&D Tax Incentive; Resapp Requests ‘Sleep Apnoea Trial’ Trading Halt; MGC Requests ‘TGA Application Deal’ Trading Halt; NZ Harbour Asset Management Takes 5% Of Volpara; Investors Mutual Reduces To 6% Of Mayne Pharma; Creso To Release 23m Escrow Shares; Marijuana Beer Launch; Nanosonics 54k CEO Michael Kavanagh Rights, 287k Options AGM; Cellmid AGM For 630k Director Shares, 33% Pool Hike; Esense Placement, Share Capital EGM; Nuheara: Ex Microsoft, Doppler Exec Brian Hall Advisor
 
Oct 8, 2018
Victoria Government $300k For Ballarat R&D Collaboration; Medical Developments, Daiichi Sankyo For Penthrox In China; Patrys $50k Federal Grant For Yale Breast Cancer Studies; Volpara Pleads Schultz, Analyst Report To ASX 27% Query; Analytica Appoints Unnamed Pericoach Manufacturer For US; Creso Applies For Canada Marijuana Licence; $2.7m Loan; Ausbil Reduces To 6.4% Of Bionomics; FIL Below 5% In Starpharma; Resonance AGM For 21.5m ‘Employee’ Options; Imugene Leslie Chong Pay Rise, Options, Paul Hopper Options
 
Oct 5, 2018
Dr Boreham’s Crucible: Simavita; Prana: ‘PBT434 Targets Key MSA Pathology’ In Mice; GI Dynamics: Intertek ‘Notified Body’ For Endobarrier CE Mark; Benitec AGM For 10m Executive Chair Dr Jerel Banks Options; MMJ EGM Backs Change, 25% Oppose Director Options; Memphasys: Alison Coutts 16%, Andrew Goodall 24.5%; Clinuvel Stan McLiesh: ‘I’ll Retire On FDA Scenesse Approval’
 
Oct 4, 2018
Simavita Placement, Convertible Notes Raise $3m; Patrys Targets Breast And Brain Cancer For PAT-DX1; Orthocell: ‘Celgro Improves Outer Bone Repair’ In Rats; Factor Last Leg Ulcer Patient Treated; Results Next Month; Airxpanders Aeroform Study Satisfaction, No CO2 Leaks; Adherium Hailie In Smartairla Asthma Program; Neurotech Mente Autism In Netherlands, Yemen; Study Plans; Fatima Dickey, Richard Bayles, Lagoda Below 5% In Clinuvel; Imugene Appoints Dr Josep Tabernero Advisor; Pharmaxis Loses Director Dr Simon Buckingham; Dr Wenyi Gu Replaces Admedus Director Dr Simon Buckingham; Neurotech Appoints Prof Neil Fong Director
 
Oct 3, 2018
Kazia Starts US GDC-0084 Paediatric Brain Cancer Trial; Telix: Cardinal To Prepare, Distribute Prostate Cancer Kit; Bluechiip Share Plan Raises $1.95m, Total $7.45m; Recce Receives $680k R&D Tax Incentive; Painchek, Leecare Aged Care Collaboration; Rhythm Colostat Test On-Track; Pauline Moffatt Co Sec; Medibio Launches Ilumen Corporate Health Platform; Hishenk Takes 14% Of Kazia; Sue MacLeman Starts As MTP Connect Chair
 
Oct 2, 2018
Bionomics Falls 69% As ‘BNC210 Fails PTSD Primary Endpoints’; Que Q-122 Phase II Post-Breast Cancer Hot Flush Trial; Resapp Sleep Apnoea Study Results ‘Within A Week’; Visioneering Appoints Australia, New Zealand Distributors; Neurotech Submits US FDA Mente Autism Application; Auscann Online Medical Marijuana Courses; Lifespot Acquires Seng Vital Cannabis Vaporizer; G Medical Hires Unnamed Underwriter For Nasdaq Offer; Richard Cashin Takes 23% Of GI Dynamics; Australian Ethical Below 5% Of Immutep; Neville Bassett Replaces Pharmaust Director Dr Wayne Best
 
Oct 1, 2018
September BDI-40 Up 11%, ASX200 Down 2%, Big Caps Down 9% - Bionomics Up 106%, Clinuvel 49%; Prescient Down 15%; Rhinomed, Columbia Care Sign 12-Year Nasal Marijuana Deal; Micro-X Notes Raise $3m; Leo ‘The Gun’ Khouri Takes Medibio Back To Bioprospect Future; Clinuvel To Trial Scenesse For Variegate Porphyria; Probiotec Completes $24.5m Facility Sale, Leaseback; Auscann, Dayacann, Khiron To Promote Medical Marijuana; Imugene: Pravin Kaumaya Advisor, Ex-CSO Urusla Wiedermann; Race Appoints Tom Lee For Partnering, Funding
 
Sep 28, 2018
Dr Boreham’s Crucible: Footy Finals Bio-Sports Special; Biotron Up 105% On BIT225 HIV Combo ‘Significant Benefit’; Elixinol Raises $40m; Bionomics Requests ‘BNC210 PTSD Trial’ Halt; Oncosil AGM To Votes On 3.3m CEO Daniel Kenny Loan Shares; CVC Takes 9.4% Of Universal Biosensors; ‘Freeman Road’ Reduces To 6% Of Resapp; MMJ Postpones Phytotech Sale EGM One Week; Anatara Loses Director Iain Ross
 
Sep 27, 2018
Atomo Signs Mylan For Developing World Rapid HIV Test; Clinical Genomics ‘Can’t Confirm, Deny’ AFR $40m IPO; Orthocell: ‘Silver-Coated Celgro Prevents Infection’ In-Vitro; Invion, Chronic Airway Hire R&G For China Nadolol For COPD; Australian Ethical Reduces To 5% Of Immutep; Botanix BTX1308 Psoriasis Trial Approved; MGC To Sell Marijuana Derma Division To Cannaglobal; Micro-X Requests ‘Capital Raising’ Halt; Elixinol Requests ‘Capital Raising’ Halt; Simavita Takes ‘Placement’ Halt To Suspension; Sienna Loses Director Dr John Chiplin; Auscann To Lose M-D Elaine Darby, Gains Dr Paul MacLeman
 
Sep 26, 2018
J&J Lifescan $44m For Universal Biosensors Strip Fee Rights; ASIC: Ex-Sirtex CEO Gilman Wong Insider Trading Charge; Zelda Doses 1st Marijuana Insomnia Patient; Avita Receives $1m Federal R&D Tax Incentive; IDT 10% Share Buy-Back, Unmarketable Parcel Facility; BVF Partners, Mark Lampert Take 23% Of Pharmaxis; BVF, Mark Lampert Reduce To 15.7% Of Opthea; Painchek To Release 254m Escrow Shares
 
Mesoblast MPC-150-IM ‘Safe’ For HLHS In Children; Invion ‘Photosoft Oral, IVX-P02 Kill Cancer Better, In-Vitro’; Paradigm Claims PPS 52% Reduction For OA Knee Pain; MGC: Varm Cosmo $1m Default; Canada Deal Suspension; Probiotec Releases 2m Escrow Shares; Bioxyne Pays $121k For Indonesia PT Gamat Utama For Sales; Simavita Requests ‘Placement’ Trading Halt; Arix Takes 11% Of Pharmaxis; JCP Below 5% Of Nanosonics; JCP Below 5% Of Osprey 
 
Sep 24, 2018
Immutep, Merck KGaA, Pfizer Cancer Trial; FDA Clearance For Volpara Enterprise, Density, Live; Valeant Fights Acrux, 13 Others On Generic Jublia; Oncosil Receives $4.3m Federal R&D Tax Incentive; Dimerix AGM Votes On 6.35m CEO Dr Nina Webster Options; Airxpanders Votes On 29m CEO Frank Grillo Shares; Elixinol Takes 50.5% Of Japan Hemp Company; Elixinol Japan; Noxopharm’s Nyrada Discovers IRAK4 Inhibitor
 
Sep 21, 2018
Dr Boreham’s Crucible: Paradigm Biopharma; US FDA Approves Avita Recell For Severe Burns; Ellex Trial Misses Endpoint, AMD Progress Slowed Trend; Imugene Hires Ambiopharm For Key-Vaxx; Patent Application; Acrux Director ‘Rights’, Potential Spill AGM; IDT AGM To Vote On Directors, Potential 2nd Strike Spill; OBJ 60% Directors Fees Hike, Potential Spill AGM; Cogstate AGM To Vote On 1m CEO Brad O’Connor Options; FIL Takes 10.5% Of Resapp; MGC Requests ‘Canada Marijuana Deal’ Trading Halt; Medibio Director Jack Cosentino Out, Jennifer Solitario In
 
Sep 20, 2018
Biocelect, 60 Degrees Tafenoquine For Malaria FDA, TGA Ok; Mesoblast: ‘69% Day-100 Paediatric GvHD Survival’; GI Dynamics Raises $7m; Crystal Amber Note; Consolidation; Imagion $4.3m Rights Offer; Osprey, GE US Kidney Health Education Program
 
Sep 19, 2018
Medical Developments Plan Raises $7.5m Of Hoped-For $5m; Resapp Raises $7.5m; Cynata ‘MSCs Relieve Cytokine Release Syndrome’ In Mice; Proteomics, Dublin’s Atturos Join Forces For Diagnostics; Brain Expands, Renames Technology ‘Total Brain’; Medical Dev Chair David Williams Increases, Diluted To 14.5%; Benitec Appoints Dr Gregory Reyes Senior Scientific Advisor
 
Sep 18, 2018
CSL: TGA Approves Hizentra For CIDP; Memphasys Works With Monash On Felix Sperm Separation; Pharmaxis: 30% Oppose Placement; Edward Rayner Elected; Italy’s Vision Group Trials Nuheara Iqbuds Boost; Lifespot Buys Seng Vital For Marijuana Vaporizer; HK Julian Biotech, Wu Yanheng 19% Of Admedus; Zhang Overlap; Race Chairman Dr William Garner Transfers, Reduces To 18.5%; Elixinol To Trade On US OTCQX; Imugene Appoints Mayo’s Prof Tanios Bekaii-Saab Advisor
 
Sep 17, 2018
Race Hires NSF For Bisantrene FDA Pathway; Genetic Technologies ‘Invited’ To Market Cancer Test In China; Mesoblast: Tasly Wins China Approvals; Micro-X Receives $4m Federal R&D Tax Incentive; Loan Repaid; Impedimed Votes On 2.5m CEO Options, 3m ‘Performance’ Rights; Resapp Requests ‘Capital Raising’ Trading Halt; Imagion Takes Capital Raising Halt To Suspension; Acorn Below 5% In Telix; Zhang Lishan, Star Bright, Associates Take 19.99% Of Admedus
 
Sep 14, 2018
Dr Boreham’s Crucible: Elixinol Global; Opthea Presents More Phase I/II OPT-302 Wet AMD Data; Qld Bauxite To Be Cann Global, Buy Marijuana Companies; Kazia $1.25m Shares For Paul Hopper, Leslie Chong; CSL $8.5m More CEO ‘Performance Rights’ AGM; Lifespot Requests ‘Acquisition’ Trading Halt; FIL Reduces To 6% Of Starpharma; Jim Craig, Bellwether Take 6.6% Of Bluechiip; Director Dennis Eck Takes 6.4% Of Cellmid
 
Sep 13, 2018
Biotech Revenue Up 17% To $17b; Non-Big Cap Up 6% To $1.6b; Biotech Daily Top 40: Sirtex Out, Starpharma Up, Paradigm In; Genesiscare Invests $5m In Clarity For Cancer Collaboration; Eyepoint Revenue Down 61% To $4.1m, Loss Up 188% To $74m; Redhill Meets FDA For 2 Phase III RHB-102 IBS Trials; Recce Takes Radium R&D Tax Incentive Loan; Imagion Requests Capital Raising Halt; Goodbye 1-Page
 
Sep 12, 2018
CSIRO Fund Raises $232m; 3 Of 9 Investments Biotech; Federal Court OK, Sirtex Departs Tomorrow; Phylogica Raises $9.1m; Mouse Kidney Data Takes Cellmid CAB102 To FDA, EMEA; Proteomics To Receive $928k From Sale Of CPR Shares; Visioneering Plan Raises $334k Of Hoped-For $3m; Total $9.2m; Suda: Priorities; Hunts Business Development Head; Licences; Cochlear $1.7m CEO Dig Howitt Options, Rights AGM; Up To 22% Of Cynata Oppose $1.8m Director Options Loans; 1-Page (European Cannabis Corp) To Delist From ASX; Auscann Trades On US OTCQX; FIL Below 5% In Clinuvel
 
Sep 11, 2018
Telix $14m Cash, Scrip For Atlab, BZL Prostate Cancer IP; Federal Government: $10m For Six Rare Disease Trials; Imugene Phase Ib HER-Vaxx Cancer Trial Recruited; Goodbye Innate, Welcome Amplia; Sirtex Departs ASX On Thursday; Fisher & Paykel Seeks Resmed US Exclusion Order; Medlab Wins Marijuana Product Export Licence; Suda Requests Unspecified Trading Halt; Phylogica Takes 3¢ Capital Raising Halt To Suspension; Inbridge Below 5% Of Invitrocue; Credit Suisse Below 5% Of Bard1; Dr Göran Ando Replaces Eyepoint Chair Dr David Mazzo; Nuheara Appoints Philip Newton ‘Chief Sales Officer’
 
Sep 10, 2018
Bluechiip Raises $5.5m, Share Plan; Sirtex Voters 99.7% Back $1.9b CDH Bid; 92.6% Don’t Vote; Phosphagenics Questions Mylan Generic Daptomycin Sales; Correction: Botanix Pharmaceuticals; Painchek Licences Application To Allity Aged Care; US Okays Novita Tali Train For ADHD; Pharmaust: Cancers Sensitive To Monepantel In-Vitro; Imagion Optimizes HER2 Breast Cancer Test Nanoparticles; Australian Patent For Invion Photosoft Cancer Therapy; Medadvisor To Use Patient Database For Trial Recruitment; Suda Wins Federal Home Affairs ‘Trusted Trader’ Status; Telix Requests ‘Acquisition’ Trading Halt; Anteo’s ‘Short Term’ CEO Christopher Parker Continues
 
Sep 7, 2018
Dr Boreham’s Crucible: Botanix Pharmaceuticals; S&P ASX300: Clinuvel, Polynovo In; Impedimed Out; Osprey, Device Access, Cardiologic Take Dyevert To UK; Sirtex Receives $1.7b From CDH Genetech & China Grand; Micro-X Wins $2.4m Government Funding; Respiri Hires SRX To Manufacture New Wheeze Test; Phylogica Requests ‘Capital Raising’ Trading Halt; Director Simon Panton, Southam Increase To 18% In Resonance; Oventus CEO Chris Hart Starts On $400k, CTO Neil Anderson $225k; Ausbiotech Invest In Melbourne, Brisbane Conference
 
Sep 6, 2018
Federal Government, Movember $12m For Prostate Cancer; Bard1 Ovarian Cancer Test ‘97% Accurate’; Medibio Claims Heart Rhythm Depression Test ‘70% Accurate’; Eyepoint (Psivida) C-Code Reimbursement For Dexycu; Regeneus Receives $2.4m Federal R&D Tax Incentive; Nuheara Receives $145k Export Grants; Factor: Leg Ulcer Trial Results In November; MGC: AM Mangion Europe, Mid East, Nth Africa Distributor; Bluechiip Requests Capital Raising Trading Halt; Vivo Takes 19.9% Of Airxpanders; Novita Appoints Sue MacLeman Chair; Automic’s Lee Tamplin Replaces Cellmid Co Sec Raymond Ting; Suda Appoints Prof Stephen Watson Anagrelide Advisor
 
Sep 5, 2018
Invion Spins-Out INV102, INV104, Dr Mitch Glass To Chronic Airway; Starpharma DEP-Irinotecan Beats Irinotecan In Mice, Again; Immuron: Travelan Protects 6 Of 8 Primates From Dysentry; Opthea: DSMB Backs OPT-302 Wet AMD Trial; Redhill: 2nd Phase III Talicia (RHB-105) Helicobacter Trial Enroled; Goodbye Innate, Hello Amplia; Clinuvel: FDA Requests Scenesse Manufacturing Information; Noxopharm Doubles Prostate Cancer Trial Cohort To 32; Nuheara US Distribution Deal With Adco Medical; Sydney Optometrist 1st Visioneering Non-US Sale; FIL Decreases To 5.45% In Clinuvel; CVC Below 5% In IDT; Dr Chris Hart Oventus CEO, Neil Anderson CTO; Advisors
 
Sep 4, 2018
Telix Ready For TLX101 Glioblastoma Trial; Brandon, MRCF, Yuuwa $16m For Polyactiva Glaucoma Trial; Uni NSW: Switchable Car-T For Pancreatic Cancer, In Mice; Medlab: Sydney Uni Study Backs Nanocelle; Phosphagenics Up-To $416m Mylan Decision ‘Shortly + 3 Weeks’; Pharmaust: Monepantel Tablet For Dog, Human Trials; Zelda Appoints Hapa For German Manufacture, Distribution; Australian Ethical Reduces To 6% Of Immutep; Macquarie Group Takes 6% Of Patrys
 
Sep 3, 2018
August BDI-40 Up 4%, ASX200 1%, Big Caps 14%, NBI 5%; Resapp Claims ‘Outstanding’ Paediatric Diagnostic Results; Star Bright Lends Admedus $5m, Invests $7.7m; 4 Directors; Cellmid ‘Oversubscribed’ Share Plan Raises $1m; ITL Revenue Down 30% To $24m, Profit Down 12% To $3m; Admedus H1 Revenue Up 13% To $13m, Loss Up 31% To $11.5m; IQ3 Revenue Up 10% To $6.5m, Loss Down 98% To $1.1k; Cardiex Revenue Down 7% To $4m, Loss Down 9% To $4.4m; Pharmaust Revenue Down 1% To $3.3m, Loss Up 88% To $2.5m; Optiscan Revenue Up 63% To $2.2m, Loss Down 31% To $2m; Prescient Finds Improved Manufacturing Route For PTX-100; Immutep To Begin Cell Line Development For IMP761; Cynata Meets With Japan Regulators For Cymerus Stem Cells; Fisher & Paykel To Contest Resmed US Patent Case; Investors Mutual Reduces To 7.3% Of Mayne Pharma; Viburnum Funds Takes 7% Of Airxpanders; Peter, Diana Diamond Take 11.7% Of Novita
 
Aug 31, 2018
Dr Boreham’s Crucible: Cann Group; Starpharma: Astrazeneca Applies For DEP-BCL2/XL Patent; Ellex Revenue Up 10% To $79m, Loss Up 463% To $5m; TPI H1 Revenue Up 281% To $23m, Loss Down 58% To $3.7m; Avita Revenue Up 40% To $11.4m, Loss Up 29.4% To $16.5m; Medadvisor Revenue Up 56% To $6.6m, Loss Up 29.9% To $4.5m; Airxpanders H1 Revenue Up 291% To $5m, Loss Down 8% To $19m; Dorsavi Revenue Up 13% To $4.4m, Loss Down 4% To $3.7m; Medlab Revenue Down 3% To $4.3m, Loss Up 24% To $4.8m; Alcidion Revenue Up 21% To $4.2m, Loss Up 1% To $2.1m; Brain Resource Revenue Up 9% To $2.6m, Loss Up 134% To $23m; Rhinomed Revenue Up 26% To $2.2m, Loss Down 9.9% To $4m; Bioxyne Revenue Up 16% To $2.1m, Loss Up 71% To $1.3m; TBG H1 Revenue Down 5% To $1.7m, Loss Up 131% To $2.3m; Hydroponics H1 Revenue Up 295% To $1.3m, Loss Up 339% To $3.2m; Ellex: Novartis Competitor Withdrawal ‘Implications’; CVC Takes 8% Of Universal Biosensors; Merchant Funds Takes 9% Of Sienna; David Williams Takes 7.7% Of Sienna; Mason Stevens Takes 6.5% Of Patrys; John McBain Takes 7% Of Rhinomed; Resapp Requests ‘Trial Update’ Trading Halt; Living Cell Loses Roy Austin; Elizabeth McGregor Co Sec; Genera Appoints Dr Damian Pethica, Seong Chen; $11.2m Rights; Hydroponics CFO Jarrod White Ceases As Joint Co Sec
 
Aug 30, 2018
Cynata CYP-001 Stem Cells Phase I Safety, Efficacy For GvHD; Prescient: 2 PTX-200 AML Complete Responses; Extension Study; Sienna, RMH Study hTERT For Indeterminate Thyroid Cancer; DSMB Okays Medical Developments Youth Penthrox Trial; Compumedics Revenue Up 7.5% To $37m, Profit Up 113% To $2.8m; Clinuvel Revenue Up 52% To $26m, Profit Up 86% To $13m; Mesoblast Revenue Up 619% To $17m, Loss Down 54% To $48m; LBT ‘Rebate Revenue’ Up 0.6% To $6m, Loss Down 47.7% To $2.7m; Cryosite Revenue $5.9m, Loss $1.2m; Impedimed Revenue Down 15% To $5.2m, Loss Down 1.4% To $27m; Resonance Revenue Up 15% To $2.9m, Loss To $225k Profit; Immuron Revenue Up 32% To $1.8m, Loss Down 55.5% To $3m; Micro-X Revenue Up 144% To $1.6m, Loss Up 28% To $16.6m; G Medical H1 Revenue $1.4m, Loss Up 61% To $11.7m; MMJ ‘Loss Of Control’ Revenue Up 40,034% To $49m, Profit $34m; Botanix: FDA ‘Confirms’ Cannabidiol BTX1204 Eczema Trial; Medadvisor, Ebos, HPS Work On Hospital Drug Management; Oncosil Appoints Iqvia Market Advisor For The EU; Cellmid Neiman Marcus, Soft Surroundings Évolis Launch; Innate To Rename As Amplia; Director Niall Cairns, C2, Carnethy Take 15% Of Cardiex
 
Aug 29, 2018
ANU Clot Diagnostic Identifies Cardiac, Stroke Risk; Bluechiip Wins 3-Year, $16m Labcon Supply Deal; Antisense Doses 1st Patient In ATL1102 Duchenne Phase II Trial; China Okays Mesoblast, Tasly $55m Cardiac Stem Cell Deal; Medibio Loses M-D, CEO Jack Cosentino; Sirtex Revenue Down 7% To $221m, Profit Down 2% To $41.5m; Elixinol H1 Revenue Up 111% To $15m, Maiden H1 Profit $120k; Genetic Signatures Revenue Up 39% To $3m, Loss Up 22% To $3m; Proteomics Revenue Up 27% To $1.2m, Loss Up 57% To $1.4m; Medical Developments To Answer FDA Penthrox Questions; Neuren, Lanstead Pause Settlements For 120 Days; MMJ Phytotech Sale, Name Change, 1m Director Options AGM; Deutsche Bank Below 5% In Avita; G Medical Pleads Schultz To ASX 49% Query; Anatara: Sue MacLeman, Jane Ryan In; Jay Hetzel, Paul Grujic Go
 
Aug 28, 2018
Patrys, WEHI Win Victoria $100k For 7D10-PAT-DX1 For Cancer; Probiotec To Sell Impromy To Blackmores For $9m; Nuheara Revenue Up 61% To $4m, Loss Up 53% To $7.4m; Adherium Revenue Up 150% To $6m, Loss Down 27% To $9m; South Australia $4m ‘Low Cost’ LBT Loan Approved; Paradigm: Ross River Virus Phase IIa Recruitment Complete; Inbridge Reduces To 6.3% Of Invitrocue; Medibio Requests ‘Staff Changes’ Trading Halt; Anatara Loses Co-Founder, CSO Dr Tracey Mynott
 
Aug 27, 2018
Atmo, RMIT, Spect Win $300k J&J, Victoria Quickfire Challenge; Airxpanders Placement, Rights Raise $20.3m; Cellmid Revenue Up 23% To $7m, Loss Down 17% To $3.7m; Osprey H1 Revenue Up 69% To $1.6m, Loss Up 31% To $12m; Simavita Signs 1st Major Deal With Belgium’s Drylock; Noxopharm Claims Nyrada NYX-330 ‘Cholesterol Progress’; Medlab Multibiotic Safety, Tolerability Chemotherapy Trial; MGC Marijuana Cognicann For Dementia, Alzheimer’s Trial; Probiotec Sells Property For $24.5m, Leases Back; CSL $8m More CEO ‘Rights’ AGM; Resonance Details Trial Contracts; Dimerix Appoints Dr Nina Webster CEO, M-D; Starts On $300k
 
Aug 24, 2018
Dr Boreham’s Crucible: Visioneering Technologies; Resonance Claims 2 New Trial Contracts Worth $721k; Telix, Melbourne Uni, Peter Mac Work On Colorectal Cancer; Sienna Rights Offer Raises $3.6m, Total $5.2m; Mayne Revenue Down 7% To $530m, Profit To $134m Loss; Mach7 Revenue Down 16% To $9m, Loss Down 7% To $5m; Allegra Revenue Down 5% To $4.7m, Profit To $604k Loss; Probiotec Sells Branded Products To Inova For $13.5m; ITL Extends Blood Bank Contract; ASX Impedimed Aware Question, Ignores Share Jump; Seminars; Adherium Claims To Expand Vitalus Deal; Mitsubishi, Morgan Stanley Take 5% Of Medadvisor; MMJ Loses Joint Co Sec Eryln Dale
 
Aug 23, 2018
Biotech Daily Liberal Leadership Editorial; Telix Applies For European TLX250 Renal Cancer Trial; Publication Backs Impedimed L-Dex For Lymphoedema; Genetic Signatures Expects $417k More R&D Tax Incentive; Biotech Daily Editorial: Reporting, Maths And Tax Incentives; Probiotec Revenue Up 25% To $76m, Profit Up 54% To $4m; Cyclopharm H1 Revenue Up 5% To $6.3m, Loss Down 52% To $685k; Cann Posts Maiden $616k Marijuana Revenue; Burnet, Eliminate Hepatitis C To Eliminate Hepatitis C By 2030; Qatar’s Hamad Medical Corp Upgrades Mach 7 Platform; Proteomics Pipeline Progress, Mesothelioma Discontinued; Avita Begins Manufacturing Recell In US; Brett Crowley Replaces Uscom Director Sheena Jack; Imugene Appoints Dr Mark Marino Chief Medical Officer; Race Loses CSO Dr John Rothman, Gordon Beck; Clarity Appoints Dr Gillies O’Bryan-Tear Advisor; Goodbye Scigen
 
Aug 22, 2018
‘Expert Panels’ Back Global Kinetics PKG For Parkinson’s; St Vincent’s Buys 1st LBT Apas Independence; Victoria $3m For 30 Research Projects; IDT Revenue Up 39% To $13m, Loss Up 2097% To $17m, Impairment; Uscom Revenue Down 18% To $2.8m, Loss Up 9% To $2m; Immutep Posts $2.6m Revenue, Loss Up 36% To $12.8m; Somnomed Revenue Up 29% To $64m, Loss Up 158% To $8.6m; Acadia Pays Neuren $13.6m For Trofinetide Licence; Immutep Receives $1.9m French Tax Rebate; Actinogen: DSMB Backs Xanadu Phase II Trial, Again; Suda Wins SUD-003, SUD-004 South Africa Patent; Regal Takes 13.4% Of Visioneering; Kinetic Takes 6.7% Of Visioneering; Adalta Releases 24m Shares From ASX Escrow; Micro-X Loses Directors Jim McDowell, David Symons; Zelda: Prof David Casarett, Dr Dustin Sulak Advisors
 
Aug 21, 2018
Starpharma Revenue Up 34% To $5m, Loss Down 32% To $10m; Analytica Claims Pericoach Incontinence ‘Significance’; TGA Grants Suda GMP Facility Status; Genetic Technologies ‘Invited To Discuss China Entry’; Creso: Pharmacare UK Marijuana Cannaqix Distributor
 
Aug 20, 2018
Nanosonics Revenue Down 10% To $61m, Profit Down 78% To $6m; Correction: Anatara Lifesciences; Sirtex: China Grand Shareholders Approve Purchase; Admedus Further Extends Capital Raising Suspension; Creso Options Raise $1.2m Of Hoped-For $2.8m; Shortfall; Nuheara: Quantum To Sell Iqbuds Boost On Amazon; Arix Bioscience Takes 5.6% Of Pharmaxis; Adrian Trevisan, Paloma Reduce To 19.9% (18%) Of Neurotech; Australian Trademark For Noxopharm Veyonda (NOX66)
 
Aug 17, 2018
Dr Boreham’s Crucible: Anatara Lifesciences; Pharmaxis Revenue Up 182% To $51m, Loss To $18m Profit; Medical Dev Revenue Down 5% To $18m, Profit Down 87% To $243k; Bionomics Revenue Down 56% To $12.5m, Loss Up 258% To $25m; Acrux Revenue Down 86% To $3.4m, Loss Up 5,736% To $14.1m; Visioneering H1 Revenue Up 289% To $1.6m, Loss $10m; JCP Reduces To 6.2% Of Nanosonics; Tim Robertson, Farjoy Take 10.5% Of Medlab; Robert Lederer, RTL Group Take 8% Of Anatara
 
Aug 16, 2018
Resapp, US DARPA, Lockheed-Martin Partner For Combat Health; Telix, Nihon Partner For TLX250 For Renal Cancer In Japan; Memphasys Receives $593k Federal R&D Tax Incentive; Pro Medicus Revenue Up 14% To $36m, Profit Up 37% To $13m; Polynovo Revenue Up 59% To $6m, Loss Up 20% To $6m; Genetic Technologies, Zishan Health China J-V; Auscann Produces Final Dose Cannabinoid Hard Capsule; Micro-X Clarifies: Carrying Value A Non-Cash Impairment; 1-Page To Buy Back $5m Shares, Toronto IPO; QLD Bauxite Votes On 3 Marijuana Entities, To Be Cann Global; Allan Gray Reduces To 6% Of Pharmaxis
 
Aug 15, 2018
CSL Record Revenue Up 15% To $10.5b, Profit Up 29% To $2.4b; Redhill Raises $35m, Most For Australian Technologies; Visioneering $9m Placement, Share Plan For $3m More; Paradigm Claims ‘60% Reduction In Osteo-Arthritis Pain’; FDA Okays Pharmaxis Aridol Plant; $2m US Sales A Year; Actinogen: Xanamem Alzheimer’s Trial 75% Enrolled, Mindmate; Cann Supplies 1st Patients Aurora Medical Marijuana; Australian Patent For Resapp Respiratory Diagnostic; Regal Funds Reduce To 8% Of Prescient; Regal Reduces Below 5% Of Avita; Robert Peters Takes 18% Of Memphasys
 
Aug 14, 2018
Cochlear Revenue Up 9% To $1,351m, Profit Up 10% To $246m; TGA Approves Polynovo Novosorb For Australian Register; Federal, VC $6m For Paragen Hookworm Auto-Immune Drugs; CVC Reduces To 10.4% Of Cyclopharm; Innate Tells ASX: ‘Trading Halt Followed Trial Bad News’; Adherium Hailie Monitor Direct-To-Customer O-T-C Launch; Creso: Schmidgall For Austria, Northern, Eastern Europe; CSIRO Appoints Dr Cathy Foley Chief Scientist; Cochlear Director Prof Edward Byrne To Retire; Memphasys 15-To-1 Consolidation Record Date
 
Aug 13, 2018
Vale Bard1’s Prof Geoff Laurent: 23.2.1948 – 12.8.2018; FDA Clears GI Dynamics US Endobarrier Re-Start; NHMRC, MRFF, Federal $200m For 337 Research Projects; Sloan Kettering Starts Telix Kit Prostate Imaging Trial; Compumedics, Health 100 JV ‘Unexpected Complexities’ Delay; Cogstate Revenue Up 10% To $40m, Loss Down 12% To $778k; Universal Bio H1 Revenue Up 6% To $13.5m, Profit To Loss; Micro-X Expects Unquantified Xinray Impairment Charge; Cynata Lends Dr Ross Macdonald, Dr Stewart Washer $1.8m; Admedus Further Extends Capital Raising Suspension; Visioneering Technologies Requests ‘Capital Raising’ Halt; Merchant Group Takes 8.1% Of Rhythm; Macquarie Group Takes 6.2% Of Impedimed; Thorney Takes 12% Of TPI; Medicines Australia Appoints Dr Anna Lavelle Chair; MMJ: Medipharm Appoints Sybil Taylor, Michael Perron
 
Aug 10, 2018
Dr Boreham’s Crucible: Dimerix; Telix Kyzeo JV Extends Endocyte Agreement; Neurotech Ships Improved Mente Autism Devices; GI Dynamics Requests ‘Endobarrier FDA IDE’ Trading Halt; Australian Ethical Takes 11.5% Of Cyclopharm
 
Aug 9, 2018
Innate Ex-Director Chris Collins, Family ‘Insider Trading’; Federal $1.3m For 2 Men’s Health Grants; FDA Expands Avita Recell Compassionate Use To 108 Patients; Auscann Raises $1.9m Of Hoped-For $8m; Total $35.3m; Admedus, Summit Extend Distribution To 2026; Qbiotics: Virbac For EBC-46 Dog Cancer Sales In US, EU; Naos Takes 17% Of BTC Health
 
Aug 8, 2018
Federal $18m For 29 Women’s Health Grants; Medical Developments Raises $17m, Share Plan For $5m More; Genetic Technologies, Kentgrove $20m Draw Down Facility; Nanosonics Trophon2 North America, Europe Launch; Cyclopharm H1 Revenue Up 5% To $6m, Loss Up 15% To $1m; Admedus Extends Capital Raising Suspension; Mach7 Distribution Deal With Envoyai; Harvey Nichols Adds MGC Marijuana Derma To 2 More Shops; G Medical To List Chinese Subsidiary On Hong Kong Exchange
 
Aug 7, 2018
Acadia $630m For Neuren Trofinetide North America Rights; Immutep Doses Imp321 Tactimel Trial 4th Cohort; Alcidion: MKM Software For Alfred Health; Sienna Appoints Shaanxi Gaoyuan China Distributor; Canada Patent For Immutep LAG3, IMP731; IDT, Cann Marijuana Manufacturing Deal; JCP Reduces To 7.2% Of Nanosonics; Rhythm Releases 9.75m Escrow Shares; Scigen To Delist From ASX August 28; G Medical Requests Hong Kong Listing Trading Halt
 
Aug 6, 2018
Oneventures $100m Credit Fund; Pharmaxis Raises $24m, 3% Premium; Edward Rayner Director; Invictus, MIPS Tocotrienol Pro-Drug Proof-Of-Concept; Medical Dev Revenue Down 5%, Profit Down 87%; Trading Halt; Reva Amends Rutgers Licence; Paradigm: Phase IIb For Bone Bruising Recruited; Cann, Agriculture Victoria ‘More Marijuana R&D’; Admedus Takes Capital Raising Trading Halt To Suspension; Anteo Battery Material Transfer Agreement
 
Aug 3, 2018
Dr Boreham’s Crucible: IDT Australia; Resmed Revenue Up 13% To $3b, Profit Down 8% To $429m; Telix Eligible For $55m Off-Shore Spending Tax Rebates; Airxpanders Placement, Rights Offer For $20.3m; TPI: $9m Codeine Deal; Allegra Wins $2.4m For Kangaroo Ligaments; Pharmaxis Requests Placement Trading Halt; Genetic Signatures Names Australian Clinical Labs; Volpara: 900k In-The-Money Directors Options AGM; Mach7: Prof Siegel, David Chambers In; Dr Finch, Nobuhiko Ito Go
 
Aug 2, 2018
Medicines Australia Addresses Gender Inequality; La Trobe University $27m Medicinal Marijuana, Opium Hub; Sirtex CDH Genetech, China Grand Scheme Meeting; Acrux First-To-File For Generic Jublia For Nail Infection; Genetic Signatures Gen 2 Easyscreen Sales Contract; Uscom Launches BP+ Reporter Blood Pressure Interface; Polynovo Enrols US Novosorb Feasibility Trial; Resapp Completes Paediatric Respiratory Trial Enrolment; Genetic Technologies Signs Blockchain Agreement; Admedus Requests ‘Capital Raising’ Trading Halt; Adalta Releases 24.6m Escrow Shares; Cryosite Profit Warning; Queensland Bauxite Claims Marijuana Inhibits T-Cells; Israel’s Supermedic To Sell Creso Cannaqix To Middle East
 
Aug 1, 2018
July BDI-40 Up 4%, ASX200 1%, Big Caps 2%, NBI 6%; Federal $3m For Stem Cell Research; Suda Raises $6.8m; Airxpanders Revenue Up 649% To $5.7m; Capital Raising Halt; Pharmaust Receipts Up 0.3% To $3m; Stemcell United Has Less Than 2 Quarters Cash; Resapp Completes Smartcough-C-2 Enrolment; Patrys: PAT-LM1 European Patent; Queensland Bauxite Compliance, Capital Raising Suspension; ASX Approves 1-Page Delisting; Paradigm Wealth, Investment Admin Below 5% In Sienna; Prof Trevor Perrior Dines On Drug Discovery With RACI
 
Cellmid Raises $9m, Share Plan For $1m More; Biocurate Initial $1.5m For 6 Biomedical Research Projects; Redhill RHB-104 (Myoconda) Effective For Crohn’s Disease; Cynata: Cymerus Improves Cardiac Recovery In Rats; Immutep IMP321 Cancer Trial FDA IND Approved; Australian Patent For Recce Antibiotics; Biotech Daily Appendix 4C Quarterly Reports Policy; Admedus Q4 Receipts Up 68% To $7.6m; H1 $14m; Avita Receipts From Customers Up 22% To $9.6m; Mach7 Receipts Up 14% To $9.5m; Mesoblast Receipts Up 207% To $7.6m; Cellmid Revenue Up 21% To $6.7m; Adherium Receipts Up 127% To $5.4m; IQ3 Receipts Up 36% To $4.9m; Medlab Receipts Up 48% To $4.7m; Nuheara Receipts Up 114% To $4.1m; Immutep Receipts Up 313% To $3.5m; Rhinomed Revenue Up 24% To $2m; Uscom Receipts Down 26% To $2.1m; Hydroponics Receipts Up 316% To $1.4m; Micro-X Receipts Up 114% To $1.3m; One Quarter Cash; OBJ Receipts Up 339% To $1.2m; G Medical Has Less Than Two Quarters Cash; Hydroponics: ‘Endoca Medical Marijuana In Australia’; MGC Appoints Prof Wendyl D’souza Medical Marijuana Adviser
 
Jul 30, 2018
Clinuvel Receipts Up 32% To $23.7m, Q4 Cash-Flow Positive; Actinogen Expands Xanamem Indications, 3 New Studies; Regeneus: ‘RGSH4K Safe, Tolerable, Immune Response’; Opthea Doses First Patient In OPT-302 Phase IIa DME Trial; Phylogica Peptide With Cre Outperforms Cre In Mice; Elixinol Marijuana Revenue Up 103% To $14.6m; Brain Resource Receipts Down 3% To $2.4m; Genetic Technologies Appoints Swisstec Asia Distributor; Hydroponics Scraps Biofloral Canada Deal; Merchant Funds Takes 8% Of Sienna; David Williams Takes 5.6% Of Sienna; Empery Reduces To 8.2% In Immuron; Mitsubishi Below 5% In Impedimed; Queensland Bauxite Requests Marijuana Deal Trading Halt; Imagion Appoints Prof John Hazle Director; Bio-Melbourne: Molecules, Medicines & Markets
 
Jul 27, 2018
Dr Boreham’s Crucible: Resonance Health; Saudi Arabia Okays Polynovo Novosorb, Al Mofadaly Distributor; Ellex Sales Up 10.5% To $79m; Genetic Signatures Revenue Up 39% To $2.8m; Visioneering H1 Revenue Up 265% To $1.6m; Phylogica Peptides ‘Stronger’ For Cancer In Mice; Aphria’s ‘Biggest Marijuana Oil Export’ For Medlab Pain Trial; Federal Government Renews Nuheara Contract; FDA 510 (K) Clearance For Adherium Hailie Sensor; Cellmid Requests Capital Raising Trading Halt; Mitsubishi, Morgan Stanley Take 5% Of Impedimed; Deutsche Bank Reduces To 5.7% In Avita; Peter, Diana Diamond Take 11% Of Novita; Botanix Appoints Dr Stephane Levy, Jillian Chapas-Reed
 
Jul 26, 2018
Polynovo: Prof Greenwood, Novosorb For Greek Fire Victims; Orthocell Celgro 1st Sales, Use In Ireland; Opthea OPT-302 For DME ‘Safe, Well-Tolerated’, Phase II Begins; Probiotec: ‘Unaudited Sales Revenue Up 25% To $78m’; Sirtex CEO Andrew McLean To US On $852k, 12-Month Clause; CE Mark For Reva Motiv Peripheral Artery Stent; US Patent For Prescient PTX-200 For Ovarian Cancer; Telix, JFE Partner For TLX-250 Japan Kidney Cancer Trials; Innate Name Change To Amplia, 1.4m Director Options AGM

Jul 25, 2018
Telix: FDA Approves Drug File, Prostate Cancer Imaging Trials; FDA: Medical Developments Penthrox Trial ‘On Hold’; Somnomed Receipts Up 26% To $60.5m; Immuron Sales Revenue Up 29% To $2m; Medadvisor Operating Revenue Up 56% To $6.6m; Medlab Starts Phase IIa NRGBiotic For Depression Trial; Nuheara, Melbourne Uni To Study Iqbuds For Autism; Redhill Recruits 400 Patients For RHB-105 Helicobacter Study; IDT Discusses Remediation Plan With FDA, Products On-Market; David Phillips Replaces Suda BDM Nick Woolf
 
Jul 24, 2018
Cardiex: Blumio Sensor ‘Good For Cardiovascular Monitoring’; Orthocell: Celgro On Track For FDA 510(K); MMJ: ‘Satipharm Marijuana CBD Reduces Paediatric Epilepsy’; Hydroponics Completes Marijuana Property Lease; Brain, Tlex Partner For ‘Ancient Wisdom’; Creso: Adam Blumenthal Converts 1.5m Performance Shares; Edinburgh Uni Below 5% In Actinogen; MMJ ‘Less Than Two Quarters Cash, $1m Coming’
 
Jul 23, 2018
Imugene Key-Vaxx ‘Superior’ For Cancer In Mice; Prof Zielinski; Euro Patent For Innate’s AMP-886 For Cancer, Fibrosis; Impedimed Receipts Down 16% To $4.6m; Dorsavi Receipts Up 19% To $4.25m; Resonance Receipts Up 16% To $2.65m, Q4 Cash Flow Positive; Creso $2.7m Options Rights Offer; Mayne Pharma Buys Efudex For Up To $40m; Creso, Kunna Reduce Purchase Price; 1-Page: From Re-Listing For Medical Marijuana To De-Listing; Regeneus Pleads Schultz To ASX 27% Query; CVC Takes 7% Of Universal Biosensors; Platinum Takes 10% Of Adalta; Wentworth Williamson Takes 5% Of TPI; Antisense Appoints Nuket Desem For Clinical, Regulatory
 
Jul 20, 2018
Dr Boreham’s Crucible: Prana Biotechnology; Sienna Raises $1.6m; $3.6m Rights Issue; Novita Raises $2.8m, To Sell Newly To Healthcarelink; Cogstate Expects Revenue Up 9.6% To $39m, $2.6m Loss; Orthocell Additional Celgro Euro Patent; Kazia Files $136m US Sec ‘Shelf’ Registration; Alcidion One Quarter Cash, ‘Substantial’ Revenue Expected; Renaissance Below 5% In Genetic Technologies; Avita Hires 3 For US Recell Launch; Promotes Dr Katie Bush; Nanosonics Joint Co Sec Robert Waring Retires
 
Jul 19, 2018
Universal Biosensors H1 Revenue Down 6% To $13.5m; Osprey H1 Revenue Up 89% To $1.5m; 15 Quarters Of Growth; Alcidion Signs 3-Year, $2.6m NT Health Extension; Botanix, UQ Collaborate On BTX1801 For Skin Infections; Memphasys To Test Felix For IVF In Europe, Middle East; Nuheara Secures Production For Iqbuds Boost; Auscann Tells ASX: ‘Not Aware Of Funding At Price Drop’; Novita Takes Capital Raising Trading Halt To Suspension
 
Jul 18, 2018
Mesoblast China Cardiac MPC Deal - $54m Cash, Stock Upfront; Dorsavi: Stryker Leibinger Evaluates Vimove2; Federal $50m For Cancer Genome Analyses; Dimerix: Ethics Approval For 2 DMX-200, Phase II Trials; Race Wins Bisantrene FDA Rare Paediatric Disease Designation; Sienna Requests Capital Raising Trading Halt; Anatara To Partner Bromelain Gut Product; Zoetis Detail
 
Jul 17, 2018
Kazia Ready For 1st GDC-0084 Glioblastoma Dosing; Federal $6m For South Australian Research; Actinogen Shortfall Raises $560k; Total $16.6m; Proteomics: Biosanapharma $350k Contract, Near Break-Even; Orthocell 1st Italian Celgro Dental Sale, Use; ITL Expects $24.3m Revenue, $3.5m Ebitda; Recce Designs Phase I Recce-327 Antibiotic For Sepsis Trial; Novita Requests ‘Bookbuild For Newly’ Trading Halt; Creso Lists On Frankfurt Exchange, Hires German Advisor
 
Jul 16, 2018
Auscann Share Plan For $8m, To Take Total To $42.4m; Microba ‘Meta-Genomic Gut Microbiome Sequencing Kit’ Launch; Antisense Begins ATL1102 Duchenne Phase II Trial; Immuron: US Army Travelan Studies; CSIRO Shigella Vaccines; Reva Appoints Bio Vascular For Italy, 1st Fantom Italy Implant; Medical Developments: Spain Approves Penthrox; Factor Completes VF001 Leg Ulcer Trial Recruitment; Medibio Heart Rhythm Depression Test FDA Application; FIRB, US FTC Approve CDH Sirtex Acquisition; Genetic Technologies: Breast, Colorectal Cancer Tests; Race Requests ‘FDA Decision’ Trading Halt; Suda To Focus On US; 12 Term Sheets In Negotiation; MMJ: ‘$153k For 2.5% Of Embark For Marijuana Extraction’; Dr Richard Hopkins Starts As Zelda M-D
 
Jul 13, 2018
Dr Boreham’s Crucible: Cardiex (Formerly Atcor Medical); Federal $22m For Biomedical Translation Bridge Program; Adalta Placement Raises $4.25m, Share Plan; Sirtex Pays Varian $15.8m Break Fee; Kazia Sells Anti-Tropomyosin To Newly-Formed Trobio; Stemcell $13.5m Dragon’s Blood Deal With Rainbow Medical; Founder Dr Bruce Gray Corrects Sirtex Substantial; MGC European Marijuana Facility ‘GMP Certified’; MMJ: ‘Harvest Recreational Marijuana For BC Liquor’; Renaissance Reduces To 5% In Genetic Technologies
 
Jul 12, 2018
Actinogen Plan Raises $952k Of Hoped For $2m, Total $16m; Suda Increases Anagrelide Solubility For Oral Cancer Spray; Resapp Sleep Apnoea Diagnostic Trial ‘On-Track’; Bard1 Granted US Breast, Ovarian Cancer Test Patent; ACCC Starts ‘Cartel’ Proceedings Against Cryosite; JP Morgan Chase, Highbridge Below 5% Of Benitec
 
Jul 11, 2018
Resonance Ferrismart Wins CE Mark, TGA Approval; Admedus Implants First Aortic Heart Valve In Sheep; Founder Dr Bruce Gray Back To 5% Of Sirtex; Immuron Granted European Nash Patent; Adherium: Connecticut Children’s Trials Hailie; Cellmid: New Évolis Products In Japan, Australia, US; Hydroponics $2.5m Southport Facility ‘Worth $14.6m’; Noxopharm To Release 15.9m Escrow Shares; Adalta Requests Capital Raising Trading Halt; MGC Requests ‘Euro Marijuana GMP’ Trading Halt; Stemcell United Requests ‘Entry Into Contract’ Trading Halt; Mesoblast Appoints Shawn Tomasello Director; Hydroponics Appoints Ken Charteris CEO, Starts On $280k; Ellex Appoints Joaquin Wolff Itrack President
 
Jul 10, 2018
Clarity Starts Sartate For Meningioma Trial; Italy, Czech Republic Okay Medical Developments Penthrox; Orthocell Appoints Carrera UK Celgro Dental Distributor; US Patent For Regeneus Progenza Stem Cells; Oventus To Release 37m Shares, 1.2m Options From ASX Escrow; Private Portfolio Managers Take 7% Of Imugene; Anthony Barton, Associates Take 6% Of Phylogica
 
Jul 9, 2018
Benitec Up 124% On Up-To $892m Axovant Gene Therapy Deal; Admedus: Medical Instruments Adapt Italy Distributor; Gi Dynamics: Risk-Benefit Study ‘Endobarrier Safe’; Bionomics Phase II BNC210 For PTSD Trial Treated; Starpharma: FDA Accepts Vivagel BV NDA, Review Starts; Neurotech US 34-Patient Autism Trial Results ‘Positive’; Noxopharm: 3 Of 9 NOX66 Patients ‘Mild’ Adverse Events; Hydroponics Extends Endoca Marijuana Deal; Paradigm Pleads Schultz, Good News To ASX 24% Query; Invictus Appoints Lou Panaccio, Richard Estalella Directors
 
Jul 6, 2018
Dr Boreham’s Crucible: Alcidion Group; Alcidion 5-Year, $4.75m ACT Health Contract; Imugene Underwritten Rights Issue Raises $8.1m; Total $20m; Actinogen: 5 More US Xanamem For Alzheimer’s Trial Sites

Jul 5, 2018; Auscann Raises $33m, Plan For $8m More; Invion Photosoft Kills Ovarian Cancer In-Vitro; Patrys PAT-DX1 Enters Triple Negative Breast Cancer In Mice; Resonance Partners With Blackford For Imaging; Neurotech Requests ‘Trial Results’ Trading Halt; Noxopharm Idronoxil Kills Brain Cancer Cells In-Vitro; Paul Cozzi Increases, Diluted To 6% Of Cardiex (Atcor); MMJ’s Harvest One Appoints Grant Froese CEO
 
Jul 4, 2018
Prana Doses 1st Human Subject With PBT434 For Parkinson’s; GI Dynamics: ‘Endobarrier HbA1C, Weight Loss Post-Explant’; Medlab Recruiting Marijuana Nanabis Cancer Pain Trial; Haemalogix, Takeda Research Multiple Myeloma; Fatima Dickey, Richard Bayles, Lagoda Down To 7% In Clinuvel; Colin Mackinnon, Donald Kennedy Each Take 6.4% In Alcidion; Alcidion Chairman Ray Blight Increases, Diluted To 12%; Genera Takes ‘Convertible Notes Raising’ Halt To Suspension; Nuheara Loses Founder Dr Michael Ottaviano; Neuren: Dianne Angus, Patrick Davies, Jenny Harry Directors; Neurotech Appoints Dr David Cantor Director
 
Jul 3, 2018
Auscann ‘$30m Raising’ Trading Halt; MTP Connect Western Australia; Dorsavi $120k Citipower, Powercor Deal; Patrys: China, Japan Deoxymab 3E10, PAT-DX1 Patents; Memphasys 15-To-1 Consolidation; Hydroponics New Site, Supply Deal Due Diligence Extended; Cardiex: Zihan Lin, Rhonda Welch In, Duncan Ross Out
 
Jul 2, 2018
June BDI-40 Up 1%, ASX200 3%, Big Caps 4% NBI 1%; Y-T-D BDI-40 Up 18%, ASX200 8%, Big Caps 38% NBI 7%; Y-T-D: Volpara Up 303%, Oncosil 206%; Airxpanders Down 86%, Reva 75%; Mesoblast Novaquest $54m Loan, $14m Shares Finance; Orthocell Begins South Africa Celgro Shoulder Study; Opthea: Phase IIb Opt-302 For Wet AMD Trial Half-Way; Cynata, RCSI Partner For Stem Cells For Sepsis; Immutep Files IMP-321 Tacti-002 IND To FDA; Botanix BTX1801 Skin Infection, BTX1308 Psoriasis Trials; Probiotec Buys Next-Door Facility For $3.6m; Suda To Pay HC Berlin $2.6m; Rights Offer For $6m; Genera Requests ‘Convertible Notes Capital Raising’ Halt; Dimerix: Further US Patent For DMX-200; Pharmaust: Epichem Wins NATA Accreditation; Race 10m ‘Performance’ Shares For Chair, CSO, Update Pharma; Dr John McBain Takes 6.5% Of Rhinomed; Botanix To Release 156m Shares, 13m Options From ASX Escrow; Creso To Sell Cannaqix In New Zealand; MMJ Invests $5m In Medipharm Labs; Ellex Appoints Mike Southard, Mike Mangano Directors; OBJ Appoints Cameron Reynolds Director; IDT Appoints Interim CEO Dr David Sparling CEO On $348k; Phylogica CEO Dr Rohan Hockings Starts On $395k; Immuron Loses Joint Co Sec Peter Vaughan; Steven Wood Replaces G Medical Co Sec Stephen Buckley
 
Jun 29, 2018
Dr Boreham’s Crucible: ITL Health; CSL’s Seqirus Joins Human Vaccine Project For Influenza; Raleigh Takes $1m 5-Year Mach7 Licence; LBT: ‘1st Apas Sale Delayed’; Elixinol Welcomes US Hemp Farming Act; MMJ, Dutch Passion Partner; One Funds Increases, Diluted To 6.4% Of Avita; Hybrid Holdings Takes 5% Of Pharmaust; Benitec Appoints Oliver Kidd Company Secretary
 
Jun 28, 2018
Pro Medicus: $15m US Mercy Archive Contract; Compumedics, Fukuda Denshi $3.6m Japan Distribution Deal; Avita ‘Buys’ US Facility; Trading Halt; Changes To ‘Leases’; Resapp Child, Adult Australian Trials On-Track; CDH Genetech, China Grand $49m Takes Sirtex Deposit To $220m; Regeneus Up-To $2m Paddington St R&D Tax Incentive Loan; Hydroponics, Ascent Exchange Marijuana Strains; Esense Wins Israeli Marijuana Permit; Suda Requests ‘HC Berlin, Capital Raising’ Trading Halt; Shenasaby Increases In Botanix, Diluted To 9%; Mayne Pharma Appoints Patrick Blake As Director; Neurotech Founder Dr Adrian Attard Trevisan Retires
 
Jun 27, 2018
Prana Back In The Clinic With PBT434 For Parkinson’s; Starpharma, Mundipharma Take Vivagel BV To Europe; Invitrocue Raises $3.6m; Nanosonics Trophon2 Wins CE Mark; Admedus, Star Bright Closer To Vaccines Deal; Botanix Recruits 1st Patients For BTX1503 Acne Trial; Nuheara: Liveiq Completes Engineering Validation Test; Cann To Build Melbourne Airport Marijuana Facility; SG Hiscock Takes 9% Of Neurotech; Eyepoint Appoints Dr Göran Ando Director; CFO Solution Replaces Brain Resource Co Sec Robert Waring 
 
Jun 26, 2018
Dorsavi Launches Professional Suite In The US; Factor Closing Leg Ulcer Recruitment, Results On-Track; Optiscan Receives $980k Federal R&D Tax Incentive; Visioneering Expands Multifocal Contact Lens Range; Australian Ethical Takes 7.5% Of Somnomed; W Whitney George Takes 20.6% Of Rhinomed; Immuron Appoints New York’s Richard Berman Director; Hydroponics Appoints Katy Day For Marijuana Regulation
 
Jun 25, 2018
Clinuvel Files US Scenesse For EPP NDA; 2019 Response; Telix Appoints Isologic To Manufacture TLX-250; Medical Developments: Penthrox In Switzerland, Portugal; CVC Takes 6.25% Of IDT; Immuron Requests ‘New Director’ Trading Halt; Race To Release 27m Escrow Shares, 10m Performance Shares; OBJ Appoints Cameron Reynolds Director; Orthocell Appoints Dr Jonathan Bell To Advisory Board; Auscann Appoints ‘Master Grower’; Jade Research Agreement; Hydroponics: 1st Marijuana Products From Endoca; MMJ To Sell Phytotech To Harvest One; Creso, Joint Venture Release 2 Marijuana Beers
 
Jun 22, 2018
Dr Boreham’s Crucible: Immuron; Cochlear Launches Nucleus 7 Android Phone Application; OBJ: ‘2 More Procter & Gamble Products’; Clinuvel Requests ‘Regulatory Submission’ Trading Halt; Australian Ethical Takes 5.5% Of Somnomed; Bard1 Releases 230m Escrow, 217m Performance Shares; MMJ Appoints CFO Jim Hallam Joint Co Sec
 
Jun 21, 2018
Mesoblast 75% Day-100 Paediatric GvHD Survival; Cynata 2nd Cohort 86% Day-28 Adult GvHD Improvement; Race Wins UK ‘Unlicensed Medicine’ For Bisantrene For AML; Rhinomed Up 28% As Columbia Takes It To Cannabis Corner; Queensland Bauxite Buys Medcan Australia, Medical Cannabis; European Patent For Uscom Blood Flow, Pressure Monitor; Esense: ‘Marijuana Terpenes Arrest Cell Growth In-Vitro’; Auscann Pleads Schultz To ASX 14.5% Fall Query
 
Jun 20, 2018
Botanix ‘Oversubscribed’ Placement Raises $8m; Medadvisor Appoints PDX For US Pharmacy Entry; Canada Approves Recreational Marijuana; MMJ; Lifespot: Marijuana For Australasia And North America; Race Requests ‘UK Regulatory Developments’ Trading Halt; Rhinomed Requests ‘Product Partner’ Trading Halt; Australian Super Increases To 7% In Osprey
 
Jun 19, 2018
Microbiotica, Adelaide Uni Faecal Drug For Colitis; Kazia Cantrixil: ‘1 Ovarian Cancer Response, 3 Stable’; Immutep Aipac Breast Cancer Trial Enrolment Half-Way; Bard1 Ovarian Test: ‘95% Accurate’; Reva CE Mark For All Fantom Encore Products; TGA Approves Medibio Depression, Mental Health Tests; Genetic Technologies, Swisstec Blockchain J-V; US Patent For Dorsavi Knee Sensor Technology; Correction: Suda; Rhinomed: CVS To Stock Mute Snoring Nasal Dilators; Canada Narcotics ‘Dealer’ Licence For MMJ’s Harvest One; Jencay, Brett Rock Increase To 6% Of Universal Biosensors; Joseph Swedish Replaces Mesoblast’s Dr Ben-Zion Weiner; Telix Appoints Jann Skinner Director
 
Jun 18, 2018
Telix Consortium Wins $1m Bio-Manufacturing Grant; Cynata, Uni Of NSW Work On Coronary Artery Disease; Proteomics Licences Promarkerd To Patia For Mexico; Canada Grants Suda Sildenafil Products Patent; James Mirams, Paradigm Wealth Take 5% Of Sienna; Tim Robertson, Farjoy Take 6% Of Nuheara; Botanix Requests ‘Capital Raising’ Trading Halt
 
Jun 15, 2018
Dr Boreham’s Crucible: Imugene; Sirtex Drops $1.6b Varian Offer For CDH, China Grand $1.9b Bid; All Change As Benitec Loses CEO Greg West, CSO Dr David Suhy; Paradigm: ‘75 OA Patients Report Average 50% Pain Reduction’; Suda Hails Aytu US, Canada Zolpimist For Insomnia Licence; Medadvisor 3-Year Deal With Ebos Zest; JCP Reduces To 8.4% Of Nanosonics; Private Portfolio Managers Below 5% In Bionomics; JP Morgan Chase Decreases, Diluted To 6% Of Benitec; Analytica Chair Dr Michael Monsour Increases, Diluted To 23%; Peter Corr, Inov8 Increase, Diluted To 11% Of Analytica; Merchant Group Takes 7% Of Rhythm; TDM Increases To 19.97% Of Somnomed
 
Jun 14, 2018
US Approves MDGH Moxidectin For River Blindness, Certara; Pharmaxis LOXL2 Fibrosis Drugs ‘Potential Partner Briefings’; Prana Starts Phase I PBT434 Parkinson’s Trial; Antisense Has ATL1103 For 12 Acromegaly Patients; Painchek National Rollout; Orthocell: ‘88% Of Ortho-ATI Patients Return To Work’; Merchant Below 5% In Polynovo; CVC, Stinoc Reduces To 12% Of Cyclopharm; Investment Administration Services Takes 5% Of Sienna; MMJ Invests $510k In Bevcanna Marijuana Drink Manufacturer; Creso Appoints John Griese COO For The Americas; Clunies Ross Award For WEHI’s Venetoclax Researchers; Respiri Appoints Mark Ziirsen Chairman
 
Jun 13, 2018
Cogstate: ‘No Impact From Eli Lilly Alzheimer’s Trial Close’; Australia Approves Botanix Phase II BTX1503 Acne Trial; Optiscan: Slow Viewnvivo Sales, Revenue $250k; Australian Ethical Takes 10% Of Cyclopharm; SG Hiscock Below 5% Of Somnomed
 
Jun 12, 2018
Resonance Reduces MRI Times, Expects Return To Profit; Cardiex ‘Oversubscribed’ Rights Raise $1.1m, Total $5m; Analytica Placement Options Raise $1.5m; Biotron $1.5m Rights Offer ‘Oversubscribed’; Cynata: ‘CYP-001 GvHD 6-Month Follow-Up Positive’; Alcidion: MKM Signs NSW Ehealth Contract; Bioxyne To Sell Rice Cooker In China, Taiwan, Malaysia; Creso’s Kunna Wins Columbian Marijuana License; MGC Marijuana Cosmetics At Harvey Nichols London Shops; Adam Leitzes, Karst Peak Take 15% Of Avita; Merchant Group Takes 5% Of Rhythm; Airxpanders CEO Frank Grillo Starts On $591k
 
Jun 8, 2018
Dr Boreham’s Crucible: Factor Therapeutics; S&P Promotes Cochlear Into ASX50; Nuheara Raises $6m; IDT Responds To FDA Facility Concerns; Imugene Answers ASX Selective Briefing Query; Biotech Daily Comment; US Patent For Oventus Snoring, Sleep Apnoea Airway; Monash Uni, Biotech Resources US Malaria Diagnostic Patent; Sandon Capital Takes 6.6% Of IDT; Lazard Below 5% In Mayne Pharma; Bard1 Releases Escrow Shares; OBJ Elects Antonio Varano Chairman
 
Jun 7, 2018
Imugene $20m For Kaumaya B-Cell Cancer Platform; BDI-40: Viralytics Out, LBT Up, Imugene In; Federal Government To Reduce Clinical Trial Red Tape; Genetic Technologies Signs Omix, Shivom Genetic Database; Third Study Backs Painchek Technology; Pharmaust, Epichem Extend $2.2m Unity Contract To 2020; Admedus Ends Go Medical Relationship; Auscann Joint Venture Harvests 620kg Marijuana Crop; Stemcell Partner Yunnan Hua Fang China Marijuana Licence; Correction: Starpharma; FIL Takes 10% Of Cynata; Marjan Mikel Replaces Memphasys Director John Periera; Melanie Leydin Replaces Medibio Co Sec Robert Lees
 
Jun 6, 2018
Avita Raising $16m For Recell US Launch; Orthocell: Positive Interim Cellgro Shoulder Trial Results; Zelda: ‘Marijuana Extracts Reduce Brain Cancer In-Vitro’; Nanosonics: US Ultrasound Decontamination Non-Compliance; LBT Review Axes Woundvue For APAS Focus; Atomo, Owen Mumford Partner For Rapid HIV Tests; Botanix: ‘Synthetic Cannabidiol BTX1204 For Eczema Safe, Efficacy’; Cann, La Trobe Uni Expand Marijuana R&D; Esense Marijuana E-Liquid For Vaporizing; US Allows Resapp Diagnostic Patent; Admedus Requests ‘Supply Termination’ Trading Halt; Nuheara Requests Capital Raising Trading Halt; Fil Reduces To 7% Of Starpharma; Clarity Appoints Michelle Parker For Clinical Operations; Cameron Petricevic Replaces Alchemia Director David Lamm
 
Jun 5, 2018
Federal, Brandon, Uniseed $25m For Certa Kidney Therapy; Adalta Hires Selexis, KBI For AD-214 Manufacture; Race: ‘Bisantrene 30-Year Efficacy For AML’; FDA Provides Recce ‘Clarity’ For Clinical Trial; CE Mark For Cogstate Cognigram; Noxopharm NOX66 Trial: 1 Partial Response; Imugene Requests ‘Acquisition, Capital Raising’ Halt; Botanix Requests Results Trading Halt
 
Jun 4, 2018
Clinical Genomics Raises $33m For Colorectal Cancer Test; WEHI ‘Sees’ SOCS1 Switch-Off Cell Signals For Cancer Drugs; Goodbye Viralytics; US Patent For Redhill Ebola Drug; Admedus Share Plan Raises $2.8m, Total $8.8m; Applications Open For Federal Global Connections Grants; Italcert Approves Neurotech Mente Autism Upgrade; Avita Requests ‘Capital Raising’ Trading Halt; Painchek Appoints Prof Jennifer Abbey Advisor 
 
Jun 1, 2018
May BDI-40 Up 3%, ASX200 0.5%, Big Caps 8% NBI 5%; Dr Boreham’s Crucible: Genetic Signatures; Cynata Stem Cells ‘Effective For Diabetic Ulcers In Mice’; Benitec Rights Raise $6.2m Of Hoped-For $17.4m; Total $8.8m; Optiscan CE Mark, Delivery Delays, Darren Lurie On $1k/Day; TPI 25% Remuneration Report 1st Strike; Oncosil Pleads Schultz To ASX 34.5% Query; MMJ Takes 13% Of Bien For Marijuana Food, Drink Powder; Paul, Eleanor Stephens Take 8% Of Rhinomed; Robert Peters Takes 13% Of Memphasys; Imagion To Release 3.5m ASX Escrow Shares; BTC Loses Director Bruce Hancox
 
May 31, 2018
Compumedics, China Health 100 ‘$133m Revenue’ JV; Biotech Daily, Commsec, Iress, Chi-X Market Report Changes; Patrys PAT-DX1-Np Kills Brain Cancer Stem Cells In-Vitro; Victoria Government Partners For 5 Conferences; Mesoblast 9-Month Revenue Up 767% To $21m; Orthocell Celgro In Poland; Value Trade Distributes Nuheara Iqbuds In Japan; Resapp Smartcough-C-2 Trial ‘On Track’ With 74% Recruited; Regal Funds Takes 9% Of Opthea; MMJ Invests $600k In Martha Jane For Marijuana Extraction; Neuren Buys-Back $1.56m Dr Richard Treagus Loaned Shares; Josh Muntner Replaces Mesoblast CFO Paul Hodgkins; All Change At Respiri, ‘Significant Milestone’
 
May 30, 2018
Immutep: ‘Keytruda, IMP321 61% Overall Response Rate’; Cynata Places $5.2m With Fidelity; Imagion Nanoparticles Bind To HER2+ Tumor Cells In Mice; Telix, Osaka University $173k Grant; Nuheara Appoints Force Australia, New Zealand Distributor; Atcor Changes Name To Cardiex, New Code CDX From Friday; Court Okays Perkinelmer RHS Acquisition, Delists Today; Blackrock Reduces To 6% Of Cochlear; Mayne Appoints Frank Condella Director; Esense Appoints Kobi Zecharia Director
 
May 29, 2018
Volpara Revenue Up 53% To $2.6m, $8m Loss; $5m Plan; Viralytics 99% Back Merck Takeover, ‘5.5-Bagger’ In 5 Years; Mesoblast, Cartherics Unite For Ovarian, Gastric Cancer; Compumedics Requests ‘China Contract’ Trading Halt; IDT Receives FDA Warning; Oventus Combination Improves Sleep Apnoea; Medical Developments In Iran; 4 Countries Approve Penthrox; Medigard, Bio-Link New Products Agreement
 
May 28, 2018
Immutep IMP321 Melanoma Interim Safety, Efficacy Results; Sirtex Scheme Meeting Delayed Until July; TGA Approves Novita’s Tali Train For Attention Disorders; Proteomics Signs Prismhealthdx For US Promarkerd Launch; Rhinomed Signs Unnamed US Pharmacy Retailer For Mute; Pharmaust: ‘BRI Monepantel Palatable For Dogs, Humans’; Cynata Requests ‘Placement’ Trading Halt; JCP Increases To 9.4% Of Nanosonics; CVC Takes 5.6% Of Universal Biosensors; Dr Dax Marcus Calder Diluted To 11% Of Patrys; Macquarie Group Takes 5% Of Patrys; Dr Warwick Tong, Cancer CRC Take 11% Of Innate; Innate Appoints Dr Warwick Tong Chairman; Uscom: Teresa Guo China Head, Curt Grosse Nth America Sales; Simon Moore Replaced TPI Chairman Peter Robinson On May 1
 
May 25, 2018
Dr Boreham’s Crucible: Antisense Therapeutics; Bio-Melbourne Celebrates 10th ‘Connecting Women’ Lunch; Compumedics $16.5m China Deals; Bob Peters Invests $1m In Memphasys For Horse IVF; Jacobs Adopts Medibio Mental Health Check-In; Factor Survives 24% Remuneration Report Dissent; Phosphagenics Passes Remuneration Report, No 2nd Strike; Director Michael Stork Diluted To 9% In Patrys; CEO Richard Hannebery Takes 11% Of Genera; Queensland Bauxite 4th Marijuana Suspension Extension; Phosphagenics Loses Director Peter Lankau
 
May 24, 2018
Reva Fantom 24-Month Low Mace Rate; Cynata Treats Last Phase I CYP-001 GvHD Patient; Russia Approves Benitec BB-401 Head Neck Cancer Trial; Somnomed Expects 2017-’18 Revenue Up 13%; European Patent For Orthocell Celgro; US Patent For Uscom Spirosonic Lung Function Monitor; Admedus 34% Remuneration Report 1st Strike; Uscom Loses Shanghai Director David He
 
May 23, 2018
CDH Sirtex Bid, Varian Won’t Match; Profit Warning; Actinogen $15m Placement, $2m Share Plan; DSMB Backs Trial; UK NHS Not Nice To Clinuvel Scenesse Reimbursement; Prota Probiotic, Peanut Immunotherapy Trial Enrolled; Australia, US Approve $502m Merck Viralytics Acquisition; Bionomics Starts Phase II BNC210 For Agitation Trial; Admedus Files 3 More US TAVR Provisional Patents; ASX Delists QRX; Imagion Pays MD Anderson $793k Fees As 10.5m Shares; MMJ Sells Cannabis Wheaton For Profit, Esense For Loss; Investors Mutual Takes 6% Of Ellex; JPS, Raff Family Take 9% Of Genera; Mason Stevens Takes 5.5% Of Patrys; Compumedics Appoints Tucson Dunn Director; Admedus Appoints Co Sec, CFO Catherine Costello Director; Adherium Appoints David Allinson CFO
 
May 22, 2018
Orthocell Claims 1st UK, EU Celgro Dental Sales, Use; Oventus: ‘Statistically Significant Apnoea Improvement’; Dorsavi Signs 2-Year Deal With Insurer AIG; Admedus Aortic Valve Replacement Sheep Trials; Victoria, J&J $300,000 Quickfire Device Challenge; Sirtex Requests ‘CDH Bid Developments’ Trading Halt; Sienna Receives $632k Federal R&D Tax Incentive; RHS Votes 99.97% For Perkinelmer Acquisition; Airxpanders 43% Oppose 1.3m Director Options; Minderoo (Metal) Group Below 5% Of Admedus; Zelda Appoints Pharmaust CEO Dr Richard Hopkins M-D On $250k; Rhythm: Glenn Gilbert Coo, Dr Joanne Boag Commercial G-M
 
May 21, 2018
Neuren, Unnamed US Pharma Trofinetide Talks, $5m Investment; Patrys Raises Placement To $4.6m; Atcor, Blumio, Macquarie Uni Study Wearable Pulse Wave Analysis; Adherium Smartinhaler In 2 Astrazeneca Trials; Airxpanders Appoints Spiran Australia Aeroform Distributor; Bioxyne Appoints Asva South East Asia Distributor; Actinogen Requests Alzheimer’s Interim Results Halt; Creso Appoints Mediphos For Marijuana-Based Cannaqix In Benelux; MGC Welcomes Malta Medical Marijuana Laws; Chairman David Williams Takes 16% Of Medical Developments; Lurie, Mutton Backers Cease Optiscan Combined Substantial; Admedus Loses Director Mathew Ratty; Invictus Appoints Dr Richard Pestell Advisor; G Medical Responds To Stockhead Article
 
May 18, 2018
Dr Boreham’s Crucible: Invitrocue; CSL Increases Expected 2017-’18 NPAT 8% To $2.3b; Bard1 Pleads ‘Contract’ To ASX 31% Query; Thermo Fisher; MMJ: Cannabis Wheaton Acquires Dosecann; CEO Dr Yacov Geva $4m G Medical Loan; Queensland Bauxite 3rd Marijuana Suspension Extension
 
May 17, 2018
Federal Fund, Oneventures $2.6m For Bivacor Heart Pump; Paradigm PPS Knee Osteoarthritis Trial ‘80% Recruited’; Orthocell Treats 10th Ortho-ATI Rotator Cuff Patient; Cyclopharm Technegas For Asthma, COPD Trial; Patrys: Yale, Beth Israel PAT-DX1 Breast Cancer Mouse Study; Admedus Appoints Cardiva Spain, Portugal Distributor; Novita: ‘NDIS Approves Tali’; Up To 25% Oppose Reva CEO Dr Regina Groves Stock; Adherium Renames Smartinhaler ‘Hailie’; Fatima Dickey, Richard Bayles, Lagoda Down To 10% In Clinuvel; FIL Reduces To 7.6% Of Clinuvel; Medadvisor To Release 21m Escrow Shares; Anatara Executive Chairman Dr Mel Bridges Retires
 
May 16, 2018
Patrys Placement To Raise $3.5m; Mesoblast 893k, $1.3m IP Shares To Unnamed 3rd Party; China’s Yifan Bids $37.5m For Poland-Singapore Scigen; Reva 1st Turkish Fantom Implants; Alcidion: Patientrack Extends UK Contracts; Mach7, Client Outlook Partner For Radiology Viewing; Creso, Asaf Cohen: Israel Marijuana Joint Venture; Rhythm: Euro Cancer Test Patent Confirmed In 13 Countries; Immutep Pleads Schultz To ASX 21% Query; Robert Lederer, RTL Group Take 7% Of Anatara; Milford Below 5% In Living Cell
 
May 15, 2018
Living Cell: ‘NTCell Long-Term Parkinson’s Efficacy’; Zoetis Licences Anatara Detach For Animal Diarrhoea; TGA Approves Genetic Signatures Superbug Test; Dimerix Prepares For 2 Phase II Kidney Disease Trials; US Best Buy To Stock Nuheara Iqbuds Boost; Race Hires Novotech For US Bisantrene AML Trial; Medlab Nanabis Ready For Cancer Pain Trial; Factor Receives $1.2m Federal R&D Tax Incentive; Up To 22% Of Elixinol Oppose Director Performance Rights; Merchant Funds Reduces To 6% Of Polynovo; Race Appoints Dr Samar Al-Behaisi Chief Medical Officer; Ellex Loses Director Dr Meera Verma, To Consultant; Suda Appoints Dr Nailin Li, Dr Richard Franklin Sud-018 Advisors; Invictus: Dr Douglas Kalman, Dr Susan Hewlings Advisors; MGC CEO Roby Zomer M-D, M-D Nativ Segev Executive Director
 
May 14, 2018
Planet Innovation $400k Takes LBT Raising To $7.9m; Clinuvel 5100 Scenesse Implants Safe; US NDA By July; Federal $6m For Melbourne Academic Health Research Centre; Oncosil Files CE Mark Data To British Standards Institute; Factor On-Track To Complete Enrolment In June; Medical Developments ‘Flat Revenue Expected’; Rhythm Reagents For Colorectal Cancer Test On-Time, Budget; Lifespot Fingerprint Marijuana Vaporizer For Israel Trials; Antisense Pleads Schultz, $5m To ASX 7% Query; Patrys Requests ‘Capital Raising’ Trading Halt; Anatara Requests ‘Detach Deal’ Trading Halt; Creso Requests ‘Israeli Acquisition’ Trading Halt; Bard1 Takes ‘ASX Price Query’ Trading Halt To Suspension; Opthea (Circadian) Below 5% Of Antisense; Mark, Tiffany Devlin, 34th Avenue Take 5% Of Innate
 
May 11, 2018
Dr Boreham’s Crucible: Prescient Therapeutics; MRFF $215m Investments This Year, $20b Fund By 2021, $80m ‘Fees’; Optiscan EGM: Mutton Group Wins, Director Ian Mann Out; Biotron Pleads Schultz To ASX 35% Query; Biotron Tells ASX: $1.5m Rights Issue Will Cover Costs; Kathy Connell Wins Bio-Melbourne Women In Leadership Gong; Prof Iain McGregor Dines On Medical Cannabis With RACI; Dr Christian Behrenbruch, Elk River Take 6% Of Innate; GI Dynamics’ Dave Bruce Appointed Company Secretary
 
May 10, 2018
Admedus Placement To Raise $6m, Share Plan; Biotron Rights Offer To Raise $1.5m; AFL, Rio Tinto, Aurecon-Jacobs Join Medibio Check-In; GI Dynamics: ‘Paper Backs Endobarrier For HbA1c, Insulin’; Osprey 20% Oppose Director Options; MGC Launches 2nd Marijuana Cosmetic; Highbridge, JP Morgan Chase Take 7% Of Benitec; Brendan Moran Increases, Diluted Below 5% Of LBT; Bard1 Requests ‘ASX Price Query’ Trading Halt; Novita Chair Bruce Higgins Goes, Mark Simari In; Glenn Smith M-D
 
May 9, 2018
Budget Qualified Welcome: Ausbiotech, Bio-Melbourne, Biotech Daily, Medicines Australia, AAMRI, Oneventures; Osprey: ‘Hospitals, Clinical Data To Drive Dyevert Sales’; Painchek (Epat) FDA Regulatory Guidance; Optiscan EGM; Darren Lurie Chair, Zelko Lendich Acting G-M; Medibio Signs St John Of God For Check-In; Alchemia Pleads Schulz To Asx 36% Query; Platinum Takes 6% Of Antisense; Invictus Appoints Richard Estalella US Advisor
 
May 8, 2018
Federal Budget Special Edition
 
May 8, 2018
Redhill Completes Phase III RHB-104 Crohn’s Disease Dosing; Botanix: US FDA Approves Phase II BTX1503 Acne Trial; Immuron: IMM-124E ‘Significant Alleviation Of Colitis’ In Mice; Orthocell Appoints Komak Poland Distributor; Genera, Beckman Coulter Move To Distribution Deal; Admedus Requests Capital Raising Trading Halt; Biotron Requests Capital Raising Trading Halt; Australian Ethical Takes 19% Of Antisense; FIL Takes 5% Of Cynata; Brain Appoints Ajay Arora Director
 
May 7, 2018
Cyclopharm Buys Distributor Medicall Analys For $1.3m; Redhill 2nd Phase III RHB-105 For Helicobacter Pylori On-Track; Federal Court Postpones Sirtex Varian Meeting; European Patent For Cynata Cymerus Stem Cell Technology; Suda Artimist Talks With World Health Organisation; Rhinomed: ‘Mute Does Not Fit GNC’s Core Range’; Hydroponics, Canada’s National Access Cannabis End Deal; Medibio 3.6m Directors Options, Prior Share Issue EGM; Jencay, Brett Rock Take 5% Of Universal Biosensors; MTP Connect Appoints Dr Dan Grant CEO; OBJ Appoints New York’s Antonio Varano Director; Dimerix Appoints Prof Simon Roger DMX-200 Lead Investigator 
 
May 4, 2018
Dr Boreham’s Crucible: Innate Immunotherapeutics; China’s CDH Bids $1.9b For Sirtex; Class Action; Asx200; Nanosonics Receives Canadian Clearance For Trophon 2; Resonance Diabetic Retinopathy For Developing Countries; Acorn Below 5% Of Factor Therapeutics; Hydroponics New Marijuana Growing Site, Supply Agreements; MMJ: Harvest One Buys Dream Water For $36m Cash, Scrip; Queensland Bauxite Takes Marijuana Deal Halt To Suspension
 
May 3, 2018
Immutep CEO Marc Voigt: ‘Multiple Trials, Multiple Milestones’; Starpharma, Mundipharma Up-To-$12m Vivagel BV Deal; Antisense $4.5m Rights Offer Completes $5m Raise; CE Mark For Medibio Cardiac Mental Illness Diagnostic; G Medical, Zingmobile $4m Prizma Smartphone Case Asia Deal; Cann Tells ASX: ‘Aurora Talks Confidential Until They Weren’t’; G Medical AGM: 28% Oppose Dr Brendan De Kauwe Election; ASX Lifts Esense Compulsory Suspension
 
May 2, 2018
Mayne Files (Halcygen) Suba-Itraconazole NDA To FDA; Analytica: TGA Approves Pericoach For Pelvic Prolapse; Nuheara To Research Auditory Processing Disorders; Probiotec Buys Next Door For $3.5m; GI Dynamics $2.3m Crystal Amber Notes; Atcor Issues $830k Part 1 Placement Shares; Cellmid To Sell Évolis In China; G Medical Opens Online Store For Prizma Smartphone Case; Paul, Eleanor Stephens Take 7% Of Rhinomed; Queensland Bauxite Requests Marijuana Deal Trading Halt; Dimerix Acquires 989 Unmarketable Parcels, 660k Shares
 
May 1, 2018
April BDI-40 Down 1.4%, ASX200 Up 4%, Big Caps Up 8%, NBI Down 3%; Compumedics $3m China Deal; Pro Medicus $1.4m, 5-Year Visage Deal With I-Med; Orthocell Bone Repair ‘26% Better Than Comparative’; Suda To Meet With HC Berlin; Genetic Technologies, Melbourne Uni $478k Breast Cancer Grant; Clinuvel To Take 100% Of Singapore Vallaurix; Adherium, Vitalus For COPD Smartinhaler Use; Medibio Corporate Mental Health Application Launch; FMR Takes 9% Of Nanosonics; FIL Reduces To 9% Of Clinuvel; Airxpanders 1.3m Directors Options AGM; Lorraine Chiroiu To Replace Ausbiotech CEO Glenn Cross; Admedus Appoints Michael Oswell Development Head; Bioxyne Appoints Peter Hughes-Hallett Director; Cogstate: COO George Hunnewell ‘Concluded’
 
Apr 30, 2018
ARC Funds Queensland Medical Device Research Hub; Volpara Placement Raises $15m; Plan For $3m More; Benitec $2.6m Placement, $17m Rights Issue; Cann: ‘No Aurora Takeover Proposal Received’; Volpara Revenue $2.9m, ‘Best Sales Year, Quarter’; Elixinol 1st Q1 Report: Revenue Up 94% To $6.6m; Japanese Patent For Neuren Trofinetide For Autism; Starpharma Files Final Vivagel BV FDA Module; Orthocell Appoints Bimar Italian Distributor; Creso Swiss Marijuana Anibidiol For Pets Launch; MMJ’s Weedme Wins Canada Cultivation Licence; Avita Has $8m, Expects To Spend $9m, Significant Funds Coming; Respiri Has Less Than One Quarter Cash, $3m Raising; Dimerix CEO Kathy Harrison To COO; New CEO Search; Somnomed Appoints Hamish Corlett Director; Eyepoint (Psivida) EGM For Essex Woodlands 27.5m Share Issue; Atcor Votes On Name Change Placements, 24m Performance Rights
 
Apr 27, 2018
Dr Boreham’s Crucible: Nuheara; Federal, Victoria $1.75m For Buruli Ulcer; NHMRC $20m; Resmed Q3 Revenue Up 15% To $783m, Profit Up 25% To $146m; Universal Bio Q1 Revenue Down 3% To $8m, Profit Down 97%; FDA Clears Nanosonics Trophon2 Probe Cleaning System; Micro-X Wins $133k UK Defence Contract; Hong Kong Star Bright 60% Of Admedus Vaccines (Coridon); Nuheara: One Quarter Cash; Ramp Up, Revenue Up, Costs Cut; MMJ: Dr Sanjay Nijhawan Cannabis Access Medical Director
 
Apr 26, 2018
Victoria: ‘Canopy Makes Melbourne Medical Marijuana Hub’; Prescient Prof Said Sebti: Precision Oncology Treatments; Eyepoint Pleads Schultz To ASX 39% Query; Irish Trial Backs Genetic Signatures Easyscreen; Hydroponics Pays $2.55m For Leo Pharma Facilities; Resapp Receives $689k Federal R&D Tax Incentive; Innate EGM Approves Amplia Acquisition, Directors; Phosphagenics Potential 2nd Strike Board Spill AGM; Factor Entitlement Issue Takes Cash To $8.8m; Biotron Has Less Than 2 Quarters Cash; Benitec Requests ‘Capital Raising’ Trading Halt; Volpara Requests ‘Capital Raising’ Trading Halt; Optiscan: ‘4 Of 5 Staff Withdraw Resignations’; Bronwyn Le Grice Replaces Imagion Director Peter Di Chiara; Dr His-Kai Wan To Replace TBG Director Edward Chang; Medibio Appoints Scientific Advisory Board
 
Apr 24, 2018
Nuheara $649 Iqbuds Boost For Moderate Hearing Loss; Alcidion Buys MKM, Patientrack; Kate Quirke Group CEO; LBT Ships First APAS To Germany; Medical Developments: Penthrox Approved In Finland; Rhythm 2nd Preliminary Test Complete, Finish In May; Bloomingdales Stocks Cellmid Évolis Hair Products; Unnamed German Hospital Trials Resapp Diagnostic; Auscann Licenced To Import Canopy Marijuana Oils; Further CE Mark For G Medical Smartphone Case; 1-Page To Re-List As European Cannabis For Medical Marijuana; Elixinol, Kersey Ag Marijuana Hemp Joint Venture; Allan Gray Takes 15% Of Factor Therapeutics; Hydroponics Takes ‘Material Acquisition’ Halt To Suspension; Recce Appoints Dr John Prendergast Director; G Medical Loses Ashley Krongold; Mach7 CFO Jenni Pilcher Replaces Co Sec Alyn Tai
 
Apr 23, 2018
Vaxart Earns $6.5m For $242m Biota Inavir Sales; Atcor $5m Placement, Rights Offer, Investment; FDA Approves Speedx Mycoplasma Genitalium Test; Zelda Recruits Phase IIa Marijuana Insomnia Trial; Viralytics Votes On $502m Merck Offer On May 28; Recce $862k Federal R&D Tax Incentive; Total $1.3m; MMJ Takes 1.6% Of Marijuana Retailer Fire And Flower; Mutton, Lurie Replace Optiscan Directors Griffiths, Francis; Universal Biosensors Loses Chief Scientist Dr Alastair Hodges
 
Apr 20, 2018
Dr Boreham’s Crucible: Kazia Therapeutics; Resmed $1.4b Revolving Credit Agreement; CE Approval For Genetic Signatures Superbug Test; Cynata Loses Apceth; Files Car-T Side Effects Patent; Respiri Completes Wheeze Prototype For 2019 Launch; MMJ, Target Capital Partner For Marijuana Investments; Queensland Bauxite Deal With Burleigh Heads Cannabis; Up To 13% Oppose Visioneering CEO Dr Stephen Snowdy Options; Admedus Loan Warrants, CEO Performance Options AGM; BTC Dr Richard Treagus, Peter Jones Take Herz Holding; Credit Suisse Takes 5% Of Bard1; Hydroponics Requests ‘Material Acquisition’ Trading Halt; GI Dynamics: Two Go, Dave Bruce Promoted
 
Apr 19, 2018
Prota, Hansen Partner For Phase III Peanut Immunotherapy; Victoria $2m For Maddie’s Vision Bone Marrow Biology Centre; Oncosil Share Plan Raises $4m, Total $16.7m; Impedimed Interim L-Dex Lymphoedema Results ‘Promising’; Euro Patent For Proteomics Promarkerd Kidney Test; Admedus Applies For 3 US TAVR Patents; Cann Signs Aurora For 3rd Marijuana Facility; Atcor Requests ‘Capital Raising’ Trading Halt; Queensland Bauxite Hemp For Coles Supermarkets; CSL Appoints Fiona Mead Company Secretary; Compumedics Appoints Gordon Haid MEG Business Director
 
Apr 18, 2018
Federal Government, MTP Connect $10m For 11 Grants; Applications Open For $1m Victoria Sector Growth Grants; Mesoblast Approved To Continue Phase III Heart Failure Trial; Optiscan Loses Chairman Alan Hoffman; MGC Completes $5m Placement; Nuheara Receives $1.2m Federal R&D Tax Incentive; Pharmaust, Elanco Monepantel Dog Cancer Agreement; Adalta Redesigns AD-114 To AD-214; Trial Delayed 1 Year; Zelda, Curtin To Test Marijuana For Diabetic Dementia; Creso, CLV To Launch Marijuana Beers, Tonics; Queensland Bauxite, Medical Cannabis Hemp Seed Oil Capsules; Mayne Pharma Opens US Manufacturing Facility; Invion Director Dr Mitchell Glass Sells 10m Shares; Avita Releases 3.5m Escrow Shares
 
Apr 17, 2018
FDA Clears Impedimed Sozo For Bilateral Lymphoedema; Mayne US Launch Of 200mg Amiodarone For Arrhythmia; Noxopharm NOX66 Prostate Cancer Trial Enrols 2nd Cohort; Creso Withdraws 1.8m Director, Everblu Rights, Options; SG Hiscock Takes 5% Of Somnomed
 
Apr 16, 2018
Sirtex Soramic Trial: ‘Sir-Spheres No Survival Benefit’; Telix French Translational Nuclear Medicine Partnerships; Resapp Tells ASX: ‘Result Unknown At Trading Halt’; Proteomics Options Dilute Dr Lipscombe, Dr Parker, Mr Dunlop; Pharmaust ‘Global Pharma Agreement’ Trading Halt; Ausbiotech: 12th Medical Technologies Conference In Adelaide
 
Apr 13, 2018
Dr Boreham’s Crucible: Invion; Invitrocue Launches Onco-PDO Personalized Cancer Test; Immutep Plan Raises $6.3m, Total $13.2m; Factor Rights Offer Raises $4.2m; Federal Government $55m For Digital Health CRC; Zelda US Marijuana Autism Study Approved; Avita Claims ‘Potential’ For Recell Facial Burns; Eyepoint (Psivida) Allowed 2 US Patents; Platinum Reduces Below 5% In Imugene; Regal Below 5% In Airxpanders; Scott Dodson 7m Options; Universal Biosensors Loses Head Of Tech Garry Chambers
 
Apr 12, 2018
Prescient ASX Aware Query: ‘Trial Data Published Promptly’; Avita Recell Reduces Skin Harvesting 97.5%, Costs; Cogstate Q3 Customer Receipts Up 60% To $13m; Medibio Completes Vital Conversations Acquisition; Hydroponics Appoints Executive Team; Dimerix Retains Westar As Corporate Advisors
 
Apr 11, 2018
Living Cell Retains NTCell, Pericyte Programs, Cuts Costs; Viralytics: ‘Three Trials Data Continues To Encourage’; Bionomics Phase II BNC210 For PTSD Trial Recruited; Race Appoints Durbin For Bisantrene NPP Distribution; Cynata Granted US Patent For Cymerus; MGC $5m Placement, Malta Marijuana Factory Contract; MMJ Phytotech Renames As MMJ, Operations Update; G Medical Rejects Analyst Report; Australian Ethical Takes 13% Of Antisense; Regal Funds Take 7% Of Medibio; Samuel Terry, Fred Woollard Take 6% Of Acrux; All Change At Phylogica; Dr Hockings 15%, Alan Tribe 19.9%
 
Apr 10, 2018
Prescient PTX-200 Breast Cancer Trial: ‘5 Of 10 Respond’; Brandon, MRCF, Federal Government $8m For Global Kinetics; Factor VF001 Wound Trial 70% Recruited, Results This Year; ASIC: Stefan Boitcheff Avoids Gaol For Anteo Manipulation; Resapp Pleads ‘Clinical Studies’ To ASX 50% Query; Resapp Preliminary Results ‘Excellent’ For Sleep Apnoea Test; Canada Approves Medical Developments Penthrox; Telix Deal With Endocyte For Prostate Cancer Test; Curtin Uni Uses Dorsavi’s Vimove For Low Back Pain Trial; Respiri Raises $3m; MMJ Invests $1m In Cannabis Access Online Portal; G Medical Requests ‘Analyst Report Response’ Trading Halt; Suda Loses Chairman Michael Stewart; Pharmaust: Epichem’s Wayne Best Chair, Dr Martine Keenan CEO 
 
Apr 9, 2018
Ausbiotech: ‘R&D Tax Incentive Cap Will Damage Sector’; Botanix Completes Cannabidiol BTX1204 Eczema Trial Enrolment; Osprey AGM For 2.4m Director Options; Orthocell EGM For 7.5m Director, CFO Options; Resapp Requests ‘Trial Update’ Trading Halt; Phylogica Requests ‘Board, Management’ Trading Halt; MGC EU Marijuana Contract, Capital Raising Halt; DRH, David Hannon Reduce, Diluted To 6% Of Noxopharm; Airxpanders Scott Dodson Goes, Scott Murcray Interim; Sales; Suda Appoints David Phillips Director; Anteo Loses CEO Dr Stefan Enderling, Gains Christopher Parker; Cellmid 5th Midkine Symposium In Munich
 
Apr 6, 2018
Dr Boreham’s Crucible: Painchek; Innate: Amplia Trials, Funding; CEO Simon Wilkinson Stays; Proteomics Options Raise $3.4m; LBT Share Plan Raises $487k, Total $7.5m; Medadvisor: ‘1m Patients Connected Milestone’; Reva 475k Directors Options, 114k ‘Restricted Shares’ AGM; Respiri Requests Capital Raising Trading Halt; MMJ Holds 34% Of Harvest One Cannabis; Nuheara Appoints Advisory Board, Sales Directors; Cogstate Rare Disease, Paediatric Centre
 
Apr 5, 2018
Peter Mac Cancer Centre: Venetoclax Beats Chemo For CLL; Nanosonics: Germany Backs High Level Disinfection; Germany Approves Medical Developments Penthrox; Noxopharm Starts ‘Abscopal’ NOX66 Prostate Cancer Trial; Patrys Receives $293k R&D Tax Incentive; MMJ ‘Doubles Investment’ In Dosecann; Optiscan Board Spill EGM Set For May 10; BVF Partners, Mark Lampert Take 21.5% Of Pharmaxis
 
Apr 4, 2018
IDT Sells 2014’s $21m Sandoz Drugs To Ani For $3.55m; Eyepoint (Psivida) To Delist From ASX; Imagion: FDA Supports Development Plans; Oncosil: 3rd Pancreatic Cancer Patient Surgery; Cellmid To Distribute Labo’s Fillerina; Australian Ethical Reduces To 9% Of Pharmaxis; Regal Funds Increases To 11% Of Oncosil; Mitsubishi, Morgan Stanley Below 5% Of Medlab; Dr John Cullity Replaces Race Director Dr Brendan De Kauwe; Dr Jack Hamilton Anteo Chair; John Hurrell, Rolf Sickman Go
 
Apr 3, 2018
Trump Effect: March BDI-40 Down 2%, Asx200 3%, Big Caps 3%; Optiscan Chair Alan Hoffman ‘Q&A’; Victoria, Cancer Council $2.5m For Poor Survival Cancers; Polynovo Signs $1.6m, Royalties Breast Device Program; Volpara Revenue Exceeds 200% Guidance By 27% To $3.4m; Antisense $582k Australian Ethical Raise, $4.5m Rights Issue; Reva Appoints Kardionet Turkey Distributor; Avita: 6 Recell Safety, Efficacy Presentations; Tribeca Below 5% Of Cann; Esense Board Prevails 60:40 Over De Kauwe Challenge; MMJ; Atcor Loses 10-Year Director Dr David Brookes
 
Mar 29, 2018
Dr Boreham’s Crucible: Patrys; Biotech Daily Editorial: Something Is Rotten In Optiscan; Psivida To Raise $79m, Borrow $26m, Buy Icon, Rebrand, Quit ASX; Cyclopharm Images 1st 40 Technegas US Trial Patients; Dr Misty Jenkins Wins $20k BHP, CSIRO Indigenous Stem Gong; Mesoblast Completes Phase III Low Back Pain Enrolment; Kazia Begins Phase II GDC-0084 Brain Cancer Trial; German Court Dismisses Suda HC Berlin Pharma Appeal; Invion Pleads Schultz To ASX 187% Query; MGC Produces 1st Euro Medical Marijuana Batch; Esense Response To ASX: General Operations Continue; Investors Mutual Increases To 8.5% Of Mayne Pharma; Mitsubishi And Morgan Stanley Take 6% Of Medlab; Dr John McBain Takes 5.5% Of Rhinomed; Webinvest, Otto Buttula Increase, Diluted To 4.6% In Oncosil; IDT Loses Director Reo Shigeno
 
Mar 28, 2018
Optiscan: ‘Business Continues Despite Losing 6 Senior Staff’; G Medical Responds To ASX Missed Milestones Query; Innate $4m Amplia Acquisition, Directors, Consolidation EGM; Micro-X Convertible Notes Raise $5m; First Swiss Implant Of Reva Fantom Encore; US Orphan Status For Cynata CYP-001 For GvHD; ITL Biomedical Launches Safety Sub Culture Unit 2; Auscann: Chile Marijuana Special Access Scheme; Antisense Requests Capital Raising Trading Halt; Recce Expects $853k R&D Tax Incentive, Pauses Lind Facility; CVC Takes 5.2% Of IDT; Chairman David Williams Takes 2.2% Of Polynovo; Imugene Promotes CEO Leslie Chong To M-D; Jim Hallam Replaces MMJ CFO Lisa Dea
 
Mar 27, 2018
Protagonist Falls 57% On PTG-100 Colitis Trial ‘Futility’; Optiscan Loses Founder Peter Delaney, More To Go; 2nd Spill Call; Foreign Investment Review Board Clears Varian Sirtex Bid; Victoria Launches $300k J&J Quickfire Device Challenge; Kerryn Moore Wins $20k Victoria Gongs; Medical Developments Adds 4 Euro Penthrox Approvals; Opthea Doses Opt-302 Wet AMD Patients In Europe, Israel; Painchek, Health Metrics Collaborate For Aged Care; Mayne US Quartette Oral Contraceptive Launch; FDA OK For Adherium O-T-C Smartinhaler For Symbicort; Merchant Reduces To 7.7% Of Polynovo; Alexander Beard, CVC, Stinoc Take 9% Of Probiotec; Director Andrew Kroger Takes 37% Of Cryosite; Dimerix Appoints Prof David Packham CMO
 
Mar 26, 2018
Federal $2m For Florey Epilepsy Research; Telix Files Prostate Imaging Master File; Alcidion Smartpage ‘Goes Live’ At Monash Health; Anteo, ‘Major Battery User’ Sign Confidentiality Agreement; Orthocell Appoints Prof Giuseppe Luongo Advisor; Sienna Appoints Helen Fisher Director; Cellmid Appoints Dennis Eck Director; QRX Appoints Anthony Jefferies Director
 
Mar 23, 2018
Dr Boreham’s Crucible: Medlab Clinical; Innate Back To Buy Amplia For 2 New Cancer Compounds; ASX Suspends Esense; Dr De Kauwe Responds To Claims; Up To 22% Dissent At Hydroponics Post-Spill AGM; Analytica Replaces US Manufacturer; Noxopharm Raises $10.8m For NOX66; Pinnacle Says It Is Below 5% In Cochlear; Regal Reduces To 6% Of Avita; Invion Loses Director Warren Brown
 
Mar 22, 2018
Immutep Starts 4th IMP321 Tactimel Melanoma Trial Cohort; Sienna Adjunct Urinary Cancer Test ‘Increases Sensitivity’; Oncosil Placement Raises $12.7m, Plan For $4m More; Bard1 Raises $1.3m; Applications Open For GSK $75k Discovery Fast Track; Pro Medicus Announces Buy-Back Of 10m Shares; Adherium Tells ASX Aware Query: ‘News Not Material’; Volpara Appoints Paul Reid Director; Psivida Loses Deb Jorn; Esense Starts Legal Action Against Dr Brendan De Kauwe
 
Mar 21, 2018
Federal MRFF $6m For Regional NSW; Oncosil ‘Milestone Surgery’; $16.7m Placement, Share Plan; Noxopharm 2 Patient ‘Abscopal Response’; Funding Halt; Actinogen Alzheimer’s Trial Enrolment Half-Way, On-Target; Israel Patent For Bard1 Lung Cancer Test; Uniquest Appoints John Grant, Richard Moore Directors; Invion Appoints Hudson’s Dr Andrew Stephens Advisor; Mach7 Appoints Per Larsen 1st Advisory Board Member
 
Mar 20, 2018
Phosphagenics, Terumo ‘Focus On TPM Injectables’; Invion, Hudson Collaborate On Photo-Therapy For Cancer; FDA Accepts Psivida Durasert Posterior Uveitis NDA Filing; FDA Accepts Mayne ANDA For Intravaginal Contraceptive; Biotech Daily Editorial Correction, Correction; Micro-X Takes Capital Raising Halt To Suspension; Bard1 Requests ‘Capital Raising’ Trading Halt; NY Empery Takes 9% Of Immuron; Medical Developments David Williams Sells 5m Shares ‘To Meet Demand’; Pro Medicus Dr Sam Hupert, Anthony Hall Sell 2m Shares
 
Mar 19, 2018
Patrys: ‘PAT-DX1 Improves Glioblastoma Survival In Mice’; Bluechiip’s Andrew McLellan: ‘Strategy Change Is Paying Off’; Somnomed Retail Offer Raises $4.5m, Total $10.4m; Avita Starts China Recell Burns Trial; Clinuvel 13-Month Data Backs Scenesse For EPP; Memphasys Settles Platinum Road, Bridge Road Capital Fight; Optiscan Spill Group Holds 13.4%; Hydroponics EGM Simplifies AGM; Orthocell Appoints Prof Massimo Simion Advisor; Invictus Appoints Dr David Kingston Advisory Board Chair; Mark Licciardo, Kate Goland Replace Avita’s Gabriel Chiappini; Australian Ethical Takes 7% Of Immutep
 
Mar 16, 2018
Dr Boreham’s Crucible: Orthocell; Optiscan Board Spill Request; Genetic Technologies, Melbourne Uni Work On Brevagenplus; Race Raises Further $480k, Total $3.6m; Nuheara Approved For Government Hearing Program; Mayne Launches Doxycycline For Acne Capsules In The US; Micro-X Requests ‘Capital Raising’ Halt; Director Andrew Kroger Takes 35.5% Of Cryosite; Crystal Amber Takes 47.5% Of GI Dynamics; Doug Halley Replaces MMJ Director Jason Bednar
 
Mar 15, 2018
Victoria, Dana Farber, Boston Children’s Cancer Deal; Telix, Radboud Work On TLX-250 For Kidney Cancer Imaging; Simavita Secures $1.4m In Convertible Notes; OBJ: Proctor & Gamble Patent, Exclusivity Agreements; Orthocell Welcomes FDA Stem Cell Acceleration; Alan Beasley Spills Hydroponics; CEO David Radford Goes; Creso Partners With Frike On Marijuana For Osteoarthritis; Volpara Moves 51m Shares From ASX To Voluntary Escrow; Catherine Costello Replaces Admedus Co Sec Tanya Mangold
 
Mar 14, 2018
Uscom: Lung Cancer, Infectious Diseases Breath Test; Immuron Raises $5m From Unnamed US Fund, 9.2% Holder; Factor To Raise $4.2m In Underwritten 1-For-7 Rights Offer; Biotech Daily Editorial Correction; Proteomics $3.4m March 31 Options Underwritten; Pharmaust, ONJ, Dr Doug Fairlie Study Monepantel For Cancer; Atcor: Name Change To Cardiex; Blumio Wearable Sensors; US, Germany Clear Varian $1.6b Sirtex Offer; Visioneering Releases 59m Escrow US Shares, CDIs; Brain Sells 99 Unmarketable Parcels, 434k Shares; Thorney Takes 11% Of TPI; Esense Claims Marijuana Terpene ‘Anti-Inflammatory Activity’
 
Mar 14, 2018
Uscom: Lung Cancer, Infectious Diseases Breath Test; Immuron Raises $5m From Unnamed US Fund, 9.2% Holder; Factor To Raise $4.2m In Underwritten 1-For-7 Rights Offer; Biotech Daily Editorial Correction; Proteomics $3.4m March 31 Options Underwritten; Pharmaust, ONJ, Dr Doug Fairlie Study Monepantel For Cancer; Atcor: Name Change To Cardiex; Blumio Wearable Sensors; US, Germany Clear Varian $1.6b Sirtex Offer; Visioneering Releases 59m Escrow US Shares, CDIs; Brain Sells 99 Unmarketable Parcels, 434k Shares; Thorney Takes 11% Of TPI; Esense Claims Marijuana Terpene ‘Anti-Inflammatory Activity’
 
Mar 13, 2018
Biotech Daily Editorial: Doing The Deal; Sienna Claims 1st Euro Sale Of hTERT Bladder Cancer Test; Invion Offer Raises $2.5m; Immuron Ends Trading Halt For More Placement Offers; Dr Brendan De Kauwe Rejects Esense Claims; EGM, AGM; Simavita Takes 2nd R&D Tax Incentive Loan For $610k; Pinnacle (Hyperion) Takes 5% Of Cochlear; Platinum Reduces To 6% Of Imugene; Hydroponics Loses 4-Month COO Debbie Ormsby; MGC Launches Premium Vegan Marijuana Food Supplements
 
Mar 12, 2018
Immutep Raises $7m, Share Plan For $10m; Merck Partnership; Race ‘Oversubscribed’ Placement Raises $3.2m For Bisantrene; Admedus 3-D Aortic Valve Meets ISO Durability Standard; Factor Requests ‘Capital Raising’ Trading Halt; Immuron Requests ‘US Placement’ Trading Halt; Nanosonics Chairman Maurie Stang Sells 5m Shares To 7%; Bernard Stang Reduces To 6% Of Nanosonics; Brain Appoints Patrick Manzo, Christopher Dolan Advisers; Actinogen Alzheimer’s Trial Roadshow
 
Mar 9, 2018
Dr Boreham’s Crucible: Avita Medical; WEHI: Lung Cancer Signature In Mice Could Lead To Blood Test; Federal $10m Million For Low Survival Cancers, Diseases; OBJ Claims Active Kneeguard Success For Osteoarthritis; Admedus Wins 3-Year US Cardiocel, Vascucel Supply Deal; Resapp Smartcough-C-2 Study ‘On-Track’; Dimerix Unmarketable Parcel Facility; Capital Group Takes 9% Of Mesoblast; Mitsubishi, Morgan Stanley Below 5% Of Viralytics
 
Mar 8, 2018
Immuron Up 65% On Mixed Results For IMM-124E For Nash; Recce, FDA Meet To Discuss Recce-327 Antibiotic; GI Dynamics Completes $2m Private Placement; Suda Completes $1.7m West Coast Medical Supplies Sale; Race Requests ‘Capital Raising’ Trading Halt; Alchemia-Related Sandon Capital Takes 5% Of IDT
 
Mar 7, 2018
Mesoblast Takes $96m Loan; Proteomics Dominican Republic Promarkerd Launch; Admedus: Canada Approves Cardiocel, Cardiocel 3D, Vascucel; Victoria, St Vincent’s Launch Clinical Trials Gateway; Prana: ‘PBT434 Prevents MSA Neuron, Function Loss In Mice’; Sharp Healthcare Takes Impedimed Sozo, L-Dex; Adherium: ‘Trial Shows 81% Asthma Adherence’; Immuron Requests ‘Nash Trial Results’ Trading Halt; Immuron Corrects Nasdaq Code, ‘False, Misleading News’; Correction: Noxopharm; Michael Abolakian, Hishenk Take 11.2% Of Kazia; Harvest Lane Takes 5.25% Of RHS (Reproductive Health); Allegra Appoints Dr Nicholas Hartnell Director
 
Mar 6, 2018
LBT Placement Raises $7m, Share Plan For $1m More; Nominations Close For $750k Science Prizes March 26; Zelda, Curtin Trial Marijuana-Chemo For Pancreatic Cancer In Mice; Invictus Licences Monash Pro-Drug Delivery Platform; Bard1: ‘89% Sensitivity, 82% Specificity For Ovarian Cancer’; Up 130%; Micro-X Sells $1.8m Of Nano X-Ray Units And Spare Parts; Genetic Technologies, Omix Deal For Shivom Genetic Database; Cann Granted Australia, Canada Marijuana Permits; Uscom BP+ In US Electronic Health Study; US Patent For Immutep IMP701 Humanized Antibody; Noxopharm: ‘12 Of 14 NOX66 Patients Response’; BVF Partners, Mark Lampert Sell 10m Viralytics Shares To 4%; Ausbil Takes 8% Of Bionomics; Paul, Eleanor Stephens Take 5.5% Of Rhinomed; Atcor Loses 13-Year CFO Co Sec Peter Manley
 
Mar 5, 2018
Blamey Saunders Launches Facett Hearing Aid; Benitec Begins BB-401 Head And Neck Cancer Trial; Factor VF001 Leg Ulcer Trial On-Track, Interim Data; Proteomics Takes 10% Of CPR Pharma Services For $1.2m; Medibio To Buy Vital Conversations For $500k Cash, Scrip; Immutep (Prima) Receives $687k R&D Tax Incentive; Noxopharm Requests ‘Clinical Data’ Trading Halt; Washington H Soul Pattinson, Brickworks Take 19.95% Of TPI; Chairman Geoffrey Pearce Takes 5% Of Probiotec; Mitsubishi, Morgan Stanley Take 7.6% Of Viralytics; Stemcell United Releases 221m Voluntary Escrow Shares; Bryan Dulhunty Replaces Cryosite Chair Stephen Roberts
 
Mar 2, 2018
Dr Boreham’s Crucible: Benitec Biopharma; TGA Approves Visioneering Multifocal Contact Lenses; Phylogica Delivers Proof-Of-Concept Cre Enzyme In-Vitro; Dr Glenn Tong, Invictus Take Gordagen IP; Singapore Patent; MMJ Hails Federal, NSW Single Marijuana Approval Move; Capital Group Makes $10m On Viralytics; LBT Requests Capital Raising Trading Halt; Cryosite Loses Chairman Stephen Roberts; Rhinomed M-D Michael Johnson On $325k PA, Incentives
 
Mar 1, 2018
February BDI-40 Up 4.5%, ASX200 Down 0.3%, Big Caps Break $100b; Bioxyne Tells ASX: International Board Delayed News; Invion Pleads Schultz, Rights Issue To ASX 100% Query; Paradigm: 50% OA Pain Reduction With PPS; Mayne Launches 10mg Methylphenidate For ADHD In US; Hydroponics $1.8m Inaugural Revenue, $2.6m Inaugural Loss; Pharmaust Revenue Up 1% To $1.7m, Loss Up 261% To $1.5m; Brain H1 Revenue Down 17% To $1m, Loss Up 39% To $12m; Telix Appoints Odile Jaume As European COO; Cann Appoints Neil Belot Director
 
Feb 28, 2018
Patrys Up 100%: ‘PAT-DX1 Blood To Brain, Tumor Shrink In Mice’; Oncosil: ‘Pancreatic Cancer Tumor Reduction’; RCH Okays Antisense Duchenne Muscular Dystrophy Trial; Editorial: Your R&D Tax Incentive Is Not Revenue; Mesoblast H1 Revenue Up 1442% To $19m, Loss To $8.6m Profit; TPI Revenue Up 111% To $22m, Loss Up 19% To $17m; Admedus H1 Revenue Down 8% To $11m, Loss Up 38% To $9m; Clinuvel H1 Revenue Up 3% To $7m, Profit Down 44% To $1.4m; Airxpanders Revenue Up 585% To $5m, Loss Up 33% To $37m; TBG H1 Revenue Up 198% To $4m, Loss Up 150% To $6.5m; Cryosite H1 Revenue Down 4% To $3m, Profit To $895k Loss; Medlab H1 Revenue Up 30% To $2m, Loss Up 33% To $2.4m; Atcor H1 Revenue Up 7% To $2m, Loss Down 42% To $1m; Genetic Sigs H1 Revenue Up 44% To $1.6m, Loss Up 28% To $1.3m; Phosphagenics Revenue Down 28% To $1m, Loss Down 51%; Rhinomed H1 Revenue Down 37% To $762k, Loss Up 37% To $1.8m; Pharmaust Receives $354k Federal R&D Tax Incentive; Hydroponics Marijuana Import Licence, Tourette’s Trial; Lazard Takes 5% Of Mayne Pharma; Dr Dax Marcus Calder, Staffwear Take 13% Of Patrys; Resonance Appoints Mitchell Wells Director
 
Feb 27, 2018
Suda To Sell $6m Revenue Westcoast; Cynata 100-Day Data Backs CYP-001 For GvHD; Correction: Allergan Pays A Total Of $331m For Elastagen; Ellex H1 Revenue Up 12% To $38m, Profit To $2m Loss; Cyclopharm Revenue Down 8% To $13m, Profit To $1.5m Loss; IQ3 H1 Revenue Up 33% To $3.4m, Profit Down 56% To $74k; Visioneering Revenue Up 385% To $1.3m, Loss Up 104% To $21.6m; Resonance H1 Revenue Up 3% To $1.3m, Profit Up 233% To $118k; Alcidion H1 Revenue Down 4.2% To $1.3m, Loss Down 32% To $1m; Creso To Launch Cannaqix Marijuana Supplement In March; Peter Meurs Increases To 19.99% Of Dimerix; Tanya Mangold Replaces Admedus Co Sec Maja Mcguire
 
Feb 26, 2018
Perkinelmer Buys RHS For $25m; Reva Fantom Encore CE Mark, 1st Implant; Allergan Pays A Total Of $331m For Elastagen; Invitrocue $100k Northern Ireland Cancer Drug Screen Grant; Universal Bio Revenue Up 34% To $25m, Profit To $765k Loss; Compumedics H1 Revenue Down 1% To $16m, Profit Up 184% To $641k; IDT H1 Revenue Up 2% To $5m, Profit To $3m Loss; Mach7 H1 Revenue Down 19% To $3.9m, Loss Down 14% To $3.4m; LBT H1 Revenue Up 530% To $3.5m, Loss Up 407% To $1m; Medadvisor H1 Revenue Up 111% To $3.3m, Loss Up 11% To $2m; Osprey H1 Revenue Up 179% To $2m, Loss Up 22% To $18m; Resapp Pleads Schultz To ASX 58% Query; Queensland Bauxite $4m For Israel MS Marijuana Study; Antisense Injectable ATL1103 For European Acromegaly Patients; ITL Launches Samplok Adapter Caps; Malaysia Approves Bioxyne Mymana Milk, Honey Product; Carestream Launches Micro-X DRX Revolution Nano X-Ray System; Nuheara Starts Iqbuds Boost Production; Harvest One Conversion Reduces MMJ To 34.5%
 
Feb 23, 2018
Dr Boreham’s Crucible: Cyclopharm; Kazia (Novogen) GDC-0084 Orphan Status For Glioblastoma; Mayne H1 Revenue Down 17.5% To $243m, Profit To $173m Loss; Probiotec H1 Revenue Up 18% To $33m, Profit Up 68% To 1.4m; Nanosonics H1 Revenue Down 17% To $30m, Profit Down 90%; Immutep (Prima) Posts $2.6m H1 Revenue, Loss Up 6.5% To $4.3m; OBJ H1 Revenue Up 12% To $1.6m, Loss Down 83% To $410k; Nuheara Iqbuds Available At 66 Acuitis European Shops; Cann Analytics Deal With Under The Tree; Resonance BDO Alison Laws Promoted To CEO On $165k
 
Feb 22, 2018
Merck $502m For Viralytics’ Cavatak Cancer Immunotherapy; Mesoblast: US Phase III GvHD Trial ‘Met Primary Endpoint’; Starpharma Receives $3.7m Federal R&D Tax Incentive; ITL H1 Revenue Down 25% To $13m, Profit Up 313% To $8.7m; Impedimed Revenue Down 34% To $2.3m, Loss Up 4% To $14.4m; Cellmid H1 Revenue Up 47% To $3.2m, Loss Down 28% To $1.1m; Allegra H1 Revenue Down 11% To $2.4m, Profit To $198k Loss; NAL Validates Nuheara Ear ID; Stryker Adopts Dorsavi Visafe; US Patent For Orthocell ‘Cell Factory’; Imagion Appoints Dr Farideh Bischoff For Clinical Research
 
Feb 21, 2018
Queensland Uni, Zealand Work On Venom For GI Disease; Sirtex H1 Revenue Down 3% To $109m, Profit Up 22% To $25m; Cogstate H1 Revenue Down 8% To $17m, Profit To $1.6m Loss; Nuheara ‘Maiden’  H1 Revenue Up 90% To $2m, Loss Up 151% To $4m; Somnomed Raises $5.9m, $4.5m To Go; Dimerix Raises $4.5m, Total $7.6m; Acrux Quietly Drops Lead Program Acr-065 For Onychomycosis; Second US Patent For Race Bisantrene; Esense Board Spill AGM, EGM To Be Held In Israel; Clarity Appoints Prof Andreas Kjaer Advisor
 
Feb 20, 2018
Universal Biotech, Servier $141k Innovation Prize; La Trobe, Monash: ‘Amniotic Sac Cells Reduce Stroke Damage’; MRCF $7m For Cincera Compounds For Inflammation, Fibrosis; Resonance MRI-Test For Nash; Medical Developments, CSIRO: ‘Better, Cheaper Lidocaine’; Acrux H1 Revenue Down 81% To $2.7m, Profit To $8.7m Loss; Regeneus H1 Revenue Down 96% To $353k, Profit To $3m Loss; Clinuvel: New Identity, Website, Values; Director Michael Stork Increases, Diluted To 11% In Patrys
 
Feb 19, 2018
Volpara UK Breast Cancer Risk Screening Program; Somnomed H1 Revenue Up 33% To $32m, Loss Up 593%; Halt; Adalta: ‘Ad-114 Has Promise For Lung Fibrosis In Mice’; Imugene Arginine Modulator ‘Anti-Tumor Activity In Mice’; Labcon Bluechiip Tracking Enabled Cryogenic Vials On Show; Medical Developments Penthrox: Estonia OK, Austria Order; Kazia Receives $4m R&D Tax Incentive; South Australia $4m ‘Low Cost’ LBT Loan; Creso Completes Mernova Medical Marijuana Acquisition; Cann Renews Marijuana Growing, Production Licences; Dimerix Requests ‘Shortfall Placement, Capital Raising’ Halt; Jason Conroy Replaces MMJ CEO Andreas Gedeon
 
Feb 16, 2018
Dr Boreham’s Crucible: Uscom; Genetic Technologies $15m Blockchain Term Sheet, $4.5m Raise; Pro Medicus H1 Revenue Up 9% To $16.6m, Profit Up 6% To $5m; Medical Dev H1 Revenue Down 3% To $8m, Profit Down 69%; Stemcell United Rights Raise $643k, $1m Underwritten; Noxopharm $4m Notes For Nyrada; Genera, Beckman Coulter Co-Marketing Partnership Delayed; IDT Appoints Dr David Sparling Interim CEO; Bioxyne Loses Director Dr Peter French; Optiscan Begins CEO Search
 
Feb 15, 2018
J&J, Monash Uni Partner; J&J, Victoria $300k Device Challenge; Kinoxis Raises $4m For Substance Abuse Treatments; Vaxart Takes Aviragen (Biota), 11-For-1 Consolidation; BI Payment Takes Pharmaxis H1 Revenue Up 354% To $31m, $6m Profit; Polynovo H1 Revenue Up 31% To $2.7m, Loss Up 64% To $3.2m; Dorsavi H1 Revenue Up 14.5% To $2.2m, Loss Up 56.1% To $1.9m; Recce Submits More Recce-327 Data To FDA; Nuheara Petitions FDA To Accelerate O-T-C Hearing Aid Act; Hydroponics Queensland Marijuana Plant Completes 1st Stage; Kinetic Takes 6.4% Of Impedimed; Nuheara Releases 151m Shares, 50m Options From Escrow; OBJ Appoints Steven Schapera Interim Chairman
 
Feb 14, 2018
CSL Record H1 Revenue Up 13% To $5.3b, Profit Up 35% To $1.4b; Bionomics H1 Revenue Up 0.4% To $7m, Loss Down 9% To $9m; Uscom H1 Revenue Down 25% To $2m, Loss Up 28% To $1.1m; Patrys Rights Issue Raises $2.4m; EMA Grants Regeneus Progenza Advanced Therapy Status; Nuheara, Sonova Begin Iqbud Hearing Health Sales Trial; Creso Kunna Acquisition Due Diligence Expected In March; Cult Beauty Launches MGC Marijuana Cosmetics; Alcidion To Release 249m Shares, 218m Rights From ASX Escrow; Hyperion Below 5% Of Cochlear
 
Feb 13, 2018
Cochlear H1 Revenue Up 7% To $640m, Profit Down 0.5% To $111m; Resonance: 3rd Unnamed Company Order Takes Revenue To $861k; Creso 3.35m Advisor Shares; 1.8m Everblu Rights, Options; Platinum Road Takes Memphasys To Victoria Supreme Court; Esense: ‘Israel Court Backs Board’; EGM, AGM On March 29; MTP CEO Sue Macleman To Replace Chair Dr Bronwyn Evans; Creso Appoints Amit Edri For Business Development; Hydroponics AGM To Overturn EGM
 
Feb 12, 2018
FDA Expands Avita Recell Compassionate Use To 88 Patients; Imugene Anti-PD1 Mimotope Vaccine Pre-Clinical Ready; Invion $2.5m Rights Issue At 93% Discount; Japan Patent For Regeneus Human, Animal Cancer Vaccine; Cas Capitulates For Aviragen 9% More In Vaxart Merger; Actinogen Xanadu Alzheimer’s Trial 41% Enroled; British, Irish Hypertension Society Backs Uscom BP+; Medical Developments Places Spacers At Walgreens; Genetic Technologies, ASX Discuss Blockchain Impact; Nuheara Appoints Ex-Microsoft Kathryn Foster Director
 
Feb 9, 2018
Dr Boreham’s Crucible: Cynata Therapeutics; MTP Connect: Exports Up 30% To $5.2b; Jobs Up 10% To 62k; Latvia Approves Medical Developments Penthrox; Resonance Receives $452k Federal R&D Tax Incentive; Telix To Release 3m ASX Escrow Shares; MGC To Release 63m Shares From ASX Escrow; Immutep DSMB Confirms IMP321 Safety; Imugene IMU-131 Gastric Cancer Trial Investigator Meeting; Regal Funds Reduces To 7.5% Of Oncosil; Analytica Chairman Dr Michael Monsour Takes 25%; Crystal Amber Increases, Diluted To 45% Of GI Dynamics; Ilan Saad Esense Chair; Brendan De Kauwe; Benjamin Karasik; Creso Requests ‘Share Issue, ASX Talks, Update’ Halt; Emma Lawler Replaces Sarah Prince As Simavita Joint Co Sec; Brain Appoints Matt Resteghini, Pablo Sanchez Executives
 
Feb 8, 2018
Psivida 2nd Phase III Durasert Uveitis Trial Meets Endpoint; Factor Recruits 100th Patient In VF001 Venous Leg Ulcer Trial; Oncosil Recruits 1st US Pancreatic Cancer Patient; ASX Query; Aviragen (Biota) Ups Vaxart Offer For Merger Meeting; Hydroponics Responds To Ides Of March Board Spill; AGM; Adherium H1 Revenue Up 92% To $2.7m, Loss Up 4% To $5m; Psivida H1 Revenue Down 79% To $1.7m, Loss Up 63% To $15m; Invion Pleads Schultz To ASX 22% Query; Esense Responds To ASX 9.5m ‘Performance Shares’ Query; Invitrocue Appoints Dr Andreas Lindner Director
 
Feb 7, 2018
Allergan Buys Elastagen For $120m; Imugene IMU-131 Vaccine ‘Shows Promise For Gastric Cancer’; WEHI: Control NOD2 Immune Response For Inflammation; Aviragen (Biota) Delays Vaxart Merger EGM 3 Days; MMJ Hopes For 70 Tonnes Of Cannabis Flower By 2020; Hydroponics To Open Marijuana Clinics By July; Rhythm Develops Reagents For Colostat Cancer Test; Tribeca Takes 5% Of Cann; Naos Takes 16% Of Biotech Capital
 
Feb 6, 2018
Actinogen: ‘Research Backs Stress, Cognitive Decline Link’; Regeneus Fat-Derived Sygenus ‘Effective For Acne’; Cardinal To Distribute Rhinomed Mute Nasal Dilators; Platinum Increases, Diluted To 7% Of Imugene; Genetic Technologies Loses Eutillio Buccilli; Dr Paul Kasian
 
Feb 5, 2018
Orthocell Rabbit Trial Backs Celgro For ACL Reconstruction; Cynata Stem Cells Engineered For Cancer; Botanix Raises $15m; Proteomics Options Raise $111k, $3.3m To Go; Ellex H1 Sales Up 12% To $38m; Clinical Genomics: ‘Insure Fit More Accurate’; Anatara: FDA Okays Detach-Treated Pigs ‘For Human Food’; G Medical China Green Channel Tax Breaks; TPI Completes Portugal Sale; Xianhui Meng, Smart Top Overseas Take 17% Of Uscom; Medlab Director Drew Townsend Increases, Diluted To 8%; OBJ Chairman Glyn Denison Retires After 12 Years; Genetic Technologies Dr Paul Kasian Chairman; Blockchain; Reva Appoints Dr Stephen Oesterle Director
 
Feb 2, 2018
Dr Boreham’s Crucible: Resmed; Admedus Launches Cardiocel 3D In North America; ITL, Myhealthtest Launch Home Prostate Cancer Test; Proteomics To Take 10% Of CPR Pharma Services; Alcidion Completes $2.7m Oncall Acquisition; Japan Patent For Bard1 Lung, Colorectal Cancer Molecules; BTC Dental Perisolv On Therapeutic Goods Register
 
Feb 1, 2018
January BDI-40 Up 4%, ASX200 Down 0.4%, Big Caps Up 5%, NBI Up 7%; Florey Develops Alzheimer’s Blood Test For Clinical Trials; US Surgeons Back Polynovo Novosorb At Hawaii Conference; CE Mark For Visioneering Lenses; Slovakia Approves Medical Developments Penthrox; Acrux, Eli Lilly Q2 Sales Revenue $9m; MMJ: Harvest One Closes $41m Placement; Queensland, Act Approve Medlab Marijuana Drug Sales; EOC Pays Immutep $1m Milestone; Prescient Receives $1m Federal R&D Tax Incentive; Suda H1 Receipts Up 15% To $4m; Nuheara H1 Receipts $1.7m; Hydroponics 2017 Receipts $1.6m; Race Has Less Than Two Quarters Cash; Reva Receipts Up 142% To $123k; Botanix Requests ‘Capital Raising’ Trading Halt; FMR Takes 8% Of Nanosonics; Consonance Takes Profit To Below 5% Of Sirtex
 
Jan 31, 2018
Sirtex Expects $1.6b Varian Offer To Complete By June; Dr Boreham’s White-Hot Crucible: Sirtex Medical; Starpharma Ready For DEP-Cabazitaxel Solid Tumor Trial; Genetic Technologies: 57% Back Board Spill, Suspension; Patrys Files Patent Application For Humanized 3e10, PAT-DX1; Canada Completes Orthocell Ortho-ATI Patent Suite; MMJ 10-Patient Data: ‘PTL101 Reduces Paediatric Epilepsy’; Immuron Enrols 1st IMM-529 Clostridium Difficile Patients; Clinuvel H1 Receipts Down 2% To $10m; Bionomics H1 Receipts Down 49% To $3.4m; Timing; Medlab H1 Receipts Up 63% To $2.4m; Dorsavi H1 Receipts Up 19% To $2.3m; Q2 Cash-Flow Positive; IQ3 H1 Receipts Up 12% To $2.3m; Adherium H1 Receipts Down 27% To $1.2m; Resonance H1 Receipts Up 7% To $1.2m; GI Dynamics Has Two Quarters Cash With Placement; RHS Has Less Than Two Quarters Cash; Grant Applications
 
Jan 30, 2018
CAS Group: ‘Australian Biota Investors Should Oppose Aviragen’; Varian Offers $1.6b For Sirtex; Analytica To Senate: ‘Pericoach Beats Transvaginal Implants’; Immuron: ‘US Army Shows Travelan Reactive To Bacteria’; Avita Heralds 5 Burns Meeting Abstracts; Pharmaust, BRI Reformulating Monepantel Taste For Trials; Painchek Testing Android Pain Assessment Application; Genetic Technologies Loses Directors; EGM Trading Halt; MMJ Takes $2.5m Stake In Toronto’s Dosecann; Admedus Receipts Up 29% To $11.6m; India Launch; Impedimed H1 Receipts Down 21% To $2.4m; Ming Hao Zheng, Ying Fan Increase, Diluted To 6% Of Orthocell; Michael Abolakian, Hishenk Take 9.5% Of Kazia; WEHI’s Prof Jacques Miller Wins $275k Japan Prize For T-Cells
 
Jan 29, 2018
Study Backs Patrys PAT-DX1-NP For Tumors, Metastases In Mice; Correction: Actinogen Medical; Austria Approves Medical Developments Penthrox For Pain; Visioneering: ‘Naturalvue Decreases Myopia Progression’; Botanix Claims Synthetic Cannabidiol BTX1503 Acne Success; MMJ Requests ‘Material Investment’ Trading Halt; Prescient ‘On-Track’ Following PTX-200 Clinical Holds; Cellmid H1 Receipts Up 6% To $2.4m; Oncosil Has Less Than Two Quarters Cash; Proteomics Granted Japanese Patent; US Allows Race Bisantrene Patent; Esense Israeli Board Spill Meeting; Clinuvel Appoints Dr Karen Agersborg US Director
 
Jan 25, 2018
Dr Boreham’s Crucible: Actinogen Medical; Medlab Raises $24m; Living Cell Sells Its 50% JV Share To Otsuka For $3m; Airxpanders Receipts Up 419% To $3.5m; Medadvisor H1 Receipts Up 49% To $3m; Genetic Signatures H1 Receipts Up 46% To $1.5m; Reva Implants 1st Italian Fantom Patient; Aurora Takes 23% Of Cann; MGC Medical Marijuana Plant Wins Interim GMP Certification; Cogstate Joins Global Alzheimer’s Platform Rater Program
 
Jan 24, 2018
Federal Government $69m For Rare Cancers, Diseases; Atomo, Access Bio Partner For HIV Test; Dimerix Raises $3.1m Of Hoped-For $5.5m; Shortfall Meetings; Shareholders Attack Aviragen (Biota) Management, Merger; Denmark Approves Medical Developments Penthrox; Somnomed H1 Receipts Up 26% To $23m; Volpara 9-Month Revenue Up 22% To $2.1m, Market Share Up; Osprey Receipts Up 195% To $1.9m; Race Receives $170k Federal R&D Tax Incentive; Rhythm, CSIRO Begin Colostat Reagent Work; Cynata Doses 1st Higher Dose GvHD Patient; Suda Completes Anagrelide Acquisition From Aluztra Bio; Hydroponics Considers $20m/Year Canada Marijuana Company; Botanix Requests ‘Acne Trial Results’ Trading Halt; ASX To Release 31m Imagion Escrow Shares; Megabay Below 5% In Novita; Federal Government Appoints Brain Cancer Advisory Group; Adherium Loses 4-Month CFO Timothy Marcotte
 
Jan 23, 2018
Resmed H1 Revenue Up 13% To $1.4b, Profit Down 37% To $120m; Probiotec Upgrades H1 Profit 10% To $1.5m; Cynata, Celularity Work On Placental Stem Cell Production; Japan Study Backs Atcor Sphygmocor; GI Dynamics Raising $2.1m; Benitec Receives $4m Federal R&D Tax Incentive; Immuron Receives $2.2m Federal R&D Tax Incentive; Factor Moves Financial Reporting For Trial Results; Medlab Clinical Requests Placement Trading Halt; MGC Requests ‘European GMP Certification’ Trading Halt; Peter Diamond, Crazy Diamond, Dak Drafting Take 8% Of Novita; Dorsavi Dr Andrew Ronchi To Us, Matt May G-M, BDM Wanted; Polynovo Appoints Greg Lewis Coo, CFO, Co Sec; Gavin Smith
 
Jan 22, 2018
‘Safety, Efficacy Data’ Take Cynata To 2nd GvHD Cohort; Iceland Approves Medical Developments Penthrox; Medibio Partners With Striiv For Mobile Mental Health Test; MGC Marijuana Cosmetics Sales Deal With London’s Cult Beauty; API To Distribute Auscann Medical Marijuana; Esense $766k Singapore Marijuana Terpene Deal Starts; Mesoblast Issues 3.9m Kentgrove Shares, 1.5m Advisor Options; Universal Biosensors 2017 Receipts Up 16% To $26m; Cogstate H1 Revenue Down 6% To $19m, Receipts Down 28%; Esense To Release 4.5m ASX Escrow Shares; BTC Sells Biointelect To Herz Family For $700k; Zelda To Trade On US O-T-C Market; Kazia Takes 8% Of Noxopharm For Nox66 Collaboration; SG Hiscock Takes 6% Of Neurotech; Optiscan Loses CEO Archie Fraser; Medibio Appoints Peter Carlisle Director
 
FDA Clears Impedimed Sozo For Fluid Monitoring; Kazia, Noxopharm Collaborate On NOX66 For Cancer; My Capital, Une-Innovation Take 7% Of Hydroponics; Lanstead Reduces To 6% Of Neuren; Brain Chair Evian Gordon Diluted To 8%; Brain Appoints Louis Gagnon Managing Director; Neuren Director Bruce Hancox Steps Down; Nathan Buzza Replaces Resapp Director Brian Leedman; Executive; Impedimed Lymphoedema Trial Enrols Patient 1,100; MMJ Signs $2m Debenture Agreement With Weed Me; Viburnum Funds Takes 18% Of Universal Biosensors; Memphasys Raises $3m; Alison Coutts 19.9%, Andrew Goodall 30%; Orthocell 6-Patient Peripheral Nerve Damage Milestone; Uniquest, Emvision Portable 3D Brain-Scanner; Pharmaxis Receives PBS Reimbursement Approval; Universal Biosensors Extends $19m Athyrium Draw-Down Facility; ITL Chair Bill Mobbs Increases To 39%; MGC Appoints Kate Sainty Joint Company Secretary; Honsue Cho, Unlimited Innovation Take 71% Of Invion; Opthea Starts OPT-302 Trial For Diabetic Macular Oedema; Micro X Releases 28m Escrow Shares; MGC Responds To ASX $1m Varm Cosmo Payment Query; Director Urs Wettstein Transfers 650,000 G Medical Shares; Phylogica Appoints Michael Williams Director; Federal Government Legalizes Medical Marijuana Exports; MGC Launches Marijuana Derma Plus For Psoriasis; Viralytics Raises $30m, China’s Lepu Takes 13%; Allan Gray Below 5% In Phosphagenics; Psivida Granted FDA Waiver; Victoria $7m For 14 Cancer Projects; Elixinol Global Lists On ASX For Marijuana Products; Phylogica Peptide Cancer Vaccine Effective In Mice; Neurotech Completes Mente Autism Trial; Resapp Enrols 1st Patient In Smartcough C-2 Study; Dimerix Completes Dmx-200 Dosage Optimization Trial; Viralytics Receives $6.5m R&D Tax Incentive; Opthea Receives $2.7m R&D Tax Incentive; BTC Dental Carisolv On Therapeutic Goods Register; Nuheara Launches New Hearing Devices; THC Completes $3m Share Plan, Total $11m; Kentgrove Capital Reduces Below 5% In Alchemia; Dorsavi CEO Dr Andrew Ronchi Takes 5%; Uscom Chair Prof Rob Phillips Increases, Diluted To 17%; Cell Care Cancels Cryosite Merger; Nuheara Works With Hearing CRC, National Acoustic Labs; Bard1: ‘Ovarian Cancer Test 88% Accurate’; Genetic Technologies Regains Nasdaq Listing Compliance; Rhythm Bio, CSIRO Collaborate On Colostat Blood Test; Stuttgart Diluted Below 5% Of Brain; Ian Pamensky Replaces Esense Secretary Steven Wood; Medibio Receives Quality Management Certificate; Alcidion Oncall Smartpage In 2 NZ Hospitals; Oncosil: 20th Pancreatic Cancer Patient Implanted; Psivida Submits New Drug Application To FDA For Durasert; Medlab Licenced To Sell Marijuana Products; Nuheara Partners With AMS AG To Launch IQ Buds; Fil Takes 10% Of Factor Therapeutics; SG Hiscock Takes 5% Of Neurotech; Recce Releases 42m Shares From Escrow; MMJ’s Harvest One Increases Placement To $36m; Cellmid FGF5 Hair Products Q2 Sales Up 115% To $2m; Neurotech: ‘Autism Results Not Available Until Published’; Anteo To Lose Chairman Dr John Hurrell, Director Rolf Sickman; Boehringer Ingelheim Pays Pharmaxis $15m For 1st Patient Dosed; RHS: ‘Study Finds Doplify Internationally Competitive’; Physioage To Distribute Atcor Sphygmocor Measurement System; Resapp Receives 3rd Review Board Approval; Holista: ‘Global Biolife Universal Drug Cancer Promise In-Vitro’; Saints Capital Everest Distributes 29m Reva CDIs; Phylogica Receives $2m R&D Tax Incentive; Creso Marijuana Joint Venture With LGC Capital, Baltic Beer; Cynata To Release 8m Shares From Escrow; Orthocell Share Plan Raises $1.5m, Total $3m; Brain Share Plan Raises $1.25m; Deutsche Bank Takes 7% Of Avita; Cormorant Reduces To Below 5% In Viralytics; Resonance To Begin 2 Studies In Early 2018; Phylogica Appoints Shohei Koide To Scientific Advisory Board; FDA Grants Benitec BB-301 Orphan Drug Designation; THC Director Calls Board Spill; Steven Xu Appointed Director; GI Dynamics Prepares US Endobarrier Ide; Telix Launches Telix Japan, Appoints COO And CMO; Avita Issues 30m Employee Options; Patrys 2-For-11 Rights Offer For $2.4m; Recce Receives $5.6m R&D Tax Incentive; Unisuper, BNP Paribas Diluted Below 5% Of Viralytics; Credit Suisse Holdings Takes 5% Of Ellex; Michael Abolakian, Hishenk Take 8% Of Kazia; Invitrocue Releases 349m Shares From Voluntary Escrow; ASX Releases 37m Telix Shares From Escrow; IC Access To Distribute Esense Terpenes In UAE; Paradigm European Patent For Bone Marrow Oedema Treatment; Stemcell To Raise $1.7m In 1-For-5 Rights Issue; Bioxyne To Launch Mustang Weight Shake In Malaysia; Oncosil Receives Additional $600k R&D Tax Incentive; Bionomics Receives $6.8m R&D Tax Incentive; Botanix Receives $1.6m R&D Tax Incentive; Auscann Releases 9m Shares From Escrow; BPH: Cortical Dynamics Brain Monitor At Melbourne Hospital; Auscann: Victoria, Canopy To Cultivate Medical Marijuana; Epat Changes Name To Painchek; Creso Appoints Precision To Market Marijuana Products In The UK; Credit Suisse ‘Returns’ Shares To Below 5% Of Ellex; Phosphagenics Receives $1m R&D Tax Incentive; Oventus Receives $966k R&D Tax Incentive; Noxopharm Receives $856k R&D Tax Incentive; TBG Releases 102m Shares From Escrow; Sirtex H1 Earnings Up 16% To $34m; Cryosite Appoints Mark Byrne CEO; Invitrocue Onco-PDO Grows Liver Tumor Organoids; DNDI Extends Contract With Pharmaust’s Epichem, Worth $1.3m; Recce To Vote On 2nd Strike Board Spill; Smart Top Overseas Takes 13% Of Uscom; Phosphagenics Shortfall Placement Raises $1.37m; Total $4.73m; Australian Patent For Orthocell Celgro Soft Tissue Repair; Ashnev To Distribute Neurotech Autism Test In India; Polynovo, Establishment To Develop Breast Devices; Anatara Receives $1.2m R&D Tax Incentive; Queensland Bauxite Appoints ‘Amazon John’ Easterling Director; Cann Share Plan Raises $16m; Total $75m; Medibio Loses 6-Month Deputy-Chair Adam Darkins; Brain Resource Unmarketable Parcel Facility; Orthocell Directors Increase, Diluted In Placement
 

 

 

 
Dec 22, 2017
Dr Boreham’s Crucible: Admedus; Ellex Plan Raises $583k Of Hoped-For $5m, Total $24m; Creso $2m Underwritten Plan Raises $359k, Total $17.5m; Antisense, Mytomorrows ATL1103 Acromegaly Early Access; Telix Releases 37m ASX Escrow Shares, Voluntary Escrow; Anteo Board Spill Call; Phosphagenics TPM Cow Feed ‘No Better For Milk, Fertility’; Baillie Gifford Reduces To 8% Of Cochlear; Paul Cozzi Takes 7% Of Atcor; CEO Richard Hannebery Takes 9.5% Of Genera; Respiri CEO Mario Gattino Starts On $300k
 
Dec 21, 2017
2017 - Biotech Daily’s Year In Review; Certara, MDGH File Moxidectin Application For River Blindness; Living Cell: ‘Long-Term Data Keeps NTCell Primary Focus’; Nice Fails To Recommend Clinuvel Scenesse For NHS Rebate; US FDA Grants Mesoblast RMAT For LVAD Trial; ACCC Ends Review Of Cryosite And Cell Care Merger; ITL, Myhealthtest Launch Cholesterol Test; Oncosil: ‘20th Brachysil Pancreatic Cancer Patient In January’; Starpharma Files 4th Vivagel Bacterial Vaginosis FDA Module; Hydroponics To Sell Nanolux Marijuana Growing Products; Up To 27% Oppose Psivida Director Options; Genetic Technologies Pleads Schultz To ASX 78% Query; Aurora Takes 22% Of Cann, Chair Allan McCallum Diluted; Mesoblast To Release 20m Escrow Shares; CSL Counsel Edward Baily Quits Co Sec Role, John Levy
 
Dec 20, 2017
Michaelia Cash Appointed Innovation Minister; Biotech Daily Editorial Comment; Mesoblast Phase III Paediatric GvHD Enrolled; US Patent Board Denies Avita Review; Rehearing Request; Uscom: ‘BP+ Eligible For CE Mark’; Cann ‘Northern’ Marijuana Cultivation, R&D Facility Opens; Genetic Technologies Board Spill EGM; Chair Ron Dewhurst, Kroy Wen Diluted To 6% Of Rhinomed; Niall Cairns Replaces Atcor Director Duncan Ross; Visioneering Appoints Jean Franchi Director; Micro-X Appoints Jeff Trost For US Corporate Development; Prescient CSO Prof Said Sebti Makes Nature Top 20 List
 
Dec 19, 2017
Opthea Starts Phase IIb OPT-302, Lucentis Trial For Wet AMD; Antisense Extends Paediatric ATL1102 For DMD Trial; Resapp: ‘Mass General Approves Smartcough-C-2 Trial’; Uscom Raises $3m; Probiotec Expects H1 NPBT Up; Options, Buy-Back EGM; Maurice Blackburn Serves Sirtex 2nd Share Price Class Action; Imugene Rights Raise $460k, $1.6m Underwritten; Total $8.7m; Memphasys Rights Raise $432k; Total $700k; MMJ’s Harvest One Pays $962k For 161ha To Grow Marijuana; Baker Bros Increases, Diluted To 8% Of Opthea; Nicholas McDonald Below 5% In BTC Health (Biotech Capital); Anteo Jumps 43% On Hiring Polaris For Lithium Batteries
 
Dec 18, 2017
Resapp: ‘Further Analysis Shows Algorithm 90% Accurate’; Botanix Phase Ib BTX1503 Cannabidiol Acne Trial Enrolled; Auscann Joint Venture Plants 2nd Chile Marijuana Crop; Creso To Pay Kunna Up To $11m For Colombia Marijuana; China’s Steven Meng Takes $1.8m, 10% Stake In Uscom; Investors Mutual Takes 5% Of Ellex; Active Immunity, Spiro Sakaris Sell 19.75m IQ3 Shares (19%); Bioworx, Anthony Tsigounis Take 19% Of IQ3; Pharmaust Appoints Prof Barbara Kitchell Vet Advisor
 
Dec 15, 2017
Dr Boreham’s Crucible: Dorsavi; Tigenix Pays Mesoblast Up To $30m For Stem Cell IP; Psivida Pilot Trial Backs Durasert Dexamethasone For OA; Medibio Ready For Mayo Clinic Depression Trials; Atcor Wins $1m Heart Failure Trial Contract; Cellmid Raises $1m From Advisor Dennis Eck; Orthocell European Patent For Ortho-ATI Manufacture; Phosphagenics TPM-Chicken Feed Beats Heat Stress; Uscom Receives $492k R&D Tax Incentive; Capital Raising Halt; Epat EGM To Change Name To Painchek; Respiri 29% Remuneration 1st Strike; Board Spill Defeated; Regal Funds Down To 7% Of Avita; Auscann Loses Executive Director Harry Karelis
 
Dec 14, 2017
Pharmaxis Pays $9m To Take-Back LOXL2 From Synairgen; Proteomics, Dimerix Partner For Kidney Disease; Telix, Sloan Kettering Partner For Kidney Cancer; Cynata Receives $1.3m Federal R&D Tax Incentive; Hydroponics Raises $8m, Plan For $3m More; Allegra To Distribute Waldemar Link Joint Replacements; Noxopharm Pleads Schultz, News To ASX 83% Query; Falls 24%; Bioxyne: ‘New Image Group $1m Claim Without Foundation’; JCP Below 5% Of Viralytics; Cryosite, Cell Care Asset Sale, Share Buy-Back EGM; MGC To Launch Marijuana Herbal Repair Cream For Psoriasis; Creso Pharma Requests ‘Latin America Acquisition’ Halt; Dr Jay Hetzel Replaces Uniquest Chair Mary Boydell; Alcidion Appoints Kevin Moynihan For Business Development
 
Dec 13, 2017
Telix, JFE Partner For TLX-250 For Cancer Imaging In Japan; Immutep Recruits 3rd IMP-321, Keytruda Melanoma Cohort; Oventus Raises $7.6m; Orthocell Placement Raises $1.5m, Share Plan; Cann Share Plan For Up To $10m, To Take Total To $78m; Brain Placement For $10m, Share Plan For $1.25m; Pharmaust: ‘Monepantel Safety, Efficacy For Dog Lymphoma’; Second Study Backs Epat Painchek; Nanosonics: ‘More UK Guidelines Back Probe Cleaning’; Clarity Sartate For Kids Meningioma Trial Ethics Approval; Resapp Prepares For Smartcough-C-2 Trial; Suda: ‘Data Backs Anagrelide Platelet Reduction For Tumors’; Brian Mcnamee Replaces CSL Chair John Shine, Abbas Hussain; Clinical Genomics Appoints J&J’s Roy Davis Director, Advisor
 
Dec 12, 2017
Cynata Cells Beat Steroids, Combine Well For Asthma In Mice; 22 Euro Countries Okay Medical Developments Penthrox; Nuheara To Launch Two Hearing Products In 2018; Hydroponics Requests ‘Capital Raising’ Trading Halt; Esense, Young Henry’s Marijuana Terpene Beer; MMJ Invests $2m In Toronto Marijuana Grower Weed Me; Fisher & Paykel Files Australian Patent Case Against Resmed; Genetic Technologies: ‘Board Spill Could Impact Sale’; OBJ Wins Proctor & Gamble Partner Of The Year Gong
 
Dec 11, 2017
Melbourne Uni, IBM Collaborate To Predict Epileptic Seizures; Patrys: ‘PAT-DX1, Olaparib Synergistic For Cancer In-Vitro’; Zelda, Philadelphia Children’s Marijuana Autism Study; CSL Renews National Blood Authority Supply Agreement; ITL Launches Segment Sampler For Lab Blood Sampling; Prescient Resumes PTX-200 For Breast Cancer Recruitment; Bioxyne: ‘Early Data Backs Probiotic Progastrim For Gut Health’; Admedus Moves Financial Year To Dec 31, Next AGM May 2018; Orthocell Requests Capital Raising Trading Halt; Oventus Requests Capital Raising Trading Halt; MMJ Requests ‘Material Investment’ Trading Halt; Hydroponics To Release 14.7m Escrow Shares; Regeneus Appoints Japan-Based Leo Lee Director
 
Dec 8, 2017
Dr Boreham’s Crucible: Living Cell Technologies; Victoria Opens Tel Aviv Trade, Investment Office; Invitrocue Raises $1.5m; Orthocell Case Study Backs Ortho-ATI For Tendon Repair; US Veterans Affairs Joins Medibio Depression Study; Chairman Prof Robert Phillips Takes 19.96% Of Uscom; W Whitney George Takes 19.6% Of Rhinomed; Zelda Requests ‘US Partnership’ Trading Halt; Mesoblast Wins Frost And Sullivan Stem Cell Gong
 
Dec 7, 2017
CSL Opens $230m Advanced Albumin Manufacturing Facility; WHO Approves Atomo HIV Self-Test; Medigard Share Plan For $640k; Biotechs Win 5 Of 15 Federal $33m CRC Grants; LBT, Partners Win Federal $2.5m CRC Project Grant; Novita Wins $1.2m Federal CRC Grant; Adalta Collaborator Wins $768k NHMRC Grant For AD-114; Orthocell Treats 1,000th Patient; Alcidion To Acquire Oncall For $2.7m; Cellmid Signs Soft Surroundings For US Évolis Distribution; US Patent For Cynata Cymerus Stem Cells; Auscann, Tas Alkaloids Marijuana Manufacturing Licence; Hydroponics Licence With Canada’s National Access Cannabis; Bioxyne Launches Health, Beauty Products In Asia; Anteo CEO Dr Stefan Enderling To Start On $260k; Houry Youssoufian Replaces GI Dynamics James Murphy
 
Dec 6, 2017
NHMRC Increases Funding For Women Lead Investigators; Melbourne Biotechs Ego, Leica Take 2 Of 12 Export Awards; Pharmaust ‘Oversubscribed Placement’ Raises $1.9m; Dimerix 1-For-2 Rights Issue For $5.5m; Genera, Beckman Coulter Unite For Diagnostics; Teva Files Application For Suda Zolpimist For Insomnia; Clarity Licences Melbourne Uni Prostate Antigen IP; Auscann Requests ‘Update’ Trading Halt; Novita Requests ‘Government Grant’ Trading Halt; Zelda Tells ASX: ‘Marijuana Trial Requires Complex Approval’; Regal Takes 12% Of Visioneering; UWA Prof Elizabeth Rakoczy Wins $50k CSL Florey Medal
 
Dec 5, 2017
CSL R&D Spend Up, New Assets, Transplant Portfolio; Marinova Seaweed Reduces Tumor, Backs Chemo In Mice; Bluechiip Wins $1m US Order For Tracking Technology; Botanix Cannabidiol BTX1503 ‘Potent’ Against Acne; Factor Therapeutics Receives $3m Federal R&D Tax Incentive; US Patent For Neuren’s NNZ-2591 For Autism; Prudential (M&G) Increases To 15% Of Mesoblast; FIL Takes 10% Of Cogstate; Dimerix Takes Capital Raising Trading Halt To Suspension; Avita Appoints Dale Sander CFO, Tim Rooney Cao; Spiro Sakiris Resigns As IQ3 Director, Continues As Executive
 
Dec 4, 2017
CE Mark For Burnet, Omega Visitect PoC HIV Test; Burnet, Oil Search Partner For PNG Health; Proteomics, Busselton Collaborate On Lung Diagnoses; TBG, Xiamen Hiacang Joint Venture Medical Lab; Phosphagenics: Rodan + Fields TPM Cosmetics Licence; Phylogica Drops Programs To Focus On Penetrating Peptides; Doetsch Grether To Distribute Creso Cannaqix10 Supplement; Noxopharm: ‘Compassionate Use Patient NOX66 Response’; Morgan Stanley ‘Returns Collateral’ Below 5% Of Viralytics; Cormorant Reduces To 5% In Viralytics; Renaissance Takes 6% Of Genetic Technologies, ‘Coding Error’; Adherium Quietly Loses Founder Garth Sutherland; Telix Appoints Dr Bernard Lambert Head, COO Telix US; Imugene Appoints Peter Schmid Advisor
 
Dec 1, 2017
November BDI-40 Up 1%, ASX200 1%, Big Caps 3%, NBI 0.55% - Avita Up 83%, Compumedics 34%; Living Cell Down 85%, Viralytics 21%; Dr Boreham’s Crucible: Probiotec; Noxopharm Subsidiary Nyrada To Raise $6m; Nanosonics: ‘European Recommendations Back Trophon’; Genetic Technologies Takes Legal Advice On Board Spill Call; Orthocell Wins Euro Patent For Ortho-ACI Cartilage Repair; Impedimed: ‘4 Abstracts Back L-Dex For Lymphoedema’; Nuheara Iqbuds Approved In 9 Countries; Dimerix Requests Capital Raising Trading Halt; Pharmaust Requests Capital Raising Trading Halt; Tom Granger, Anacacia, Wattle Take 5.5% Of Cogstate; Morgan Stanley, Mitsubishi Borrow, Take 5% Of Viralytics; Invion Appoints Thian Chew Chair, Dr Greg Collier Back To CEO; Analytica Loses Directors Warren Brooks, Carl Stubbings; MMJ: Phytotech CEO Dr Daphna Heffetz To Resign; Cogstate Co Sec Claire Newstead-Sinclair Returns
 
Nov 30, 2017
Cann $60m Marijuana Production Capital Raising; Victoria $2m For MCRI 100k Baby Five-Year Study; Aviragen Teslexivir (BTA074) Anogenital Warts Trial Enrolled; CE Mark For G Medical Patch; Suda Receives $662k Federal R&D Tax Incentive; Antisense AGM Loses 2nd Strike Vote, Wins Spill Vote; Atcor AGM Up To 48% Dissent, 43% Remuneration 1st Strike; Medigard AGM 28% Remuneration 1st Strike; Avita AGM Survives 20% Remuneration Report Dissent; Invion AGM Backs Cho Group, Drops 100-To-1 Consolidation; Memphasys Director Andrew Goodall Diluted To 34%; Atcor Appoints Craig Cooper CEO On $395k, Duncan Ross Stays; Resonance: Agha Pervez, Adrian Bowers, Sander Bangma; Goodbye Medical Australia; Respiri Moves Board Spill AGM
 
Nov 29, 2017
Volpara Launches Enterprise Live For Quality, Risk Software; Actinogen Raises $5.3m; Rhinomed Raises $3.6m; LBT APAS Passes St Vincent’s Hospital Lab Assessment; Factor Therapeutics VF001 Leg Ulcer Trial ‘Half Recruited’; Zelda Marijuana Insomnia Trial; Creso Joint Venture For Marijuana Beer; Noxopharm: ‘NYX-104 Protects Brain Post-Stroke In Mice’; Up To 32% Of Suda AGM Oppose Director Options; LBT 20% Oppose Placement Capacity, 19% Remuneration Report; Adherium 18% Oppose Director Jeremy Curnock Cook; Genera Takes ‘Partnering Agreement’ Halt To Suspension; Suda Appoints Bioscience Managers David Phillips Advisor; Recce Replaces Co Sec, CFO Peter Williams; Avita Moves Australia, Europe Offices
 
Nov 28, 2017
Suda Acquires Anagrelide For Cancer; Creso Raises $15.5m, Plan For $2m More To Grow Marijuana; ITL, Myhealthtest Launch Consumer Thyroid Test; Australia, NZ Approve G Medical Prizma Vital Signs Sensors; Up To 21% Oppose Ellex Placement Capacity; Up To 17% Dissent Against Clinuvel Performance Rights; Cellmid, YPB To Market Evolis Hair-Loss Treatment In China; Peter Diamond, Dak Drafting Take 5% Of Novita; Prima Trades As Immutep From December 1; Clinical Genomics Bowel Cancer Test Wins CSIRO Gong
 
Nov 27, 2017
Proteomics Dominican Rep Promarkerd Kidney Test Launch; Benitec Applies For Orphan Status For BB-301 For OPMD; Orthocell Welcomes US Regenerative Medicine Framework; Optiscan 45% Oppose Option, Performance Rights Plan; Eemagine To Enhance Neurotech Mente Autism Headband; Actinogen Requests Capital Raising Halt; Rhinomed Requests Capital Raising Trading Halt; G Medical Requests ‘Regulatory Approvals’ Trading Halt; Genera Requests Capital Raising Trading Halt; Creso Suspension For Capital Raising, Marijuana Chocolate; Lai Danny Kong Sang Reduces To 7% Of Stem Cell
 
Nov 24, 2017
Dr Boreham’s Crucible: Psivida; Bio-Melbourne: ‘Victoria Needs A Physical Biotech Hub’; ITL Launches Transfer Cap Set Blood Culture Test; Medigard Raises $150k, Total $300k; Memphasys Wins $400k NSW Medical Devices Grant; Oncosil 3m CEO Loan Shares To Be Released From Escrow; Asia Union ‘Decreases’ To 37% Of Genetic Signatures; GI Dynamics Loses Directors Anne Keating, Graham Bradley
 
Nov 23, 2017
Prima Loses Chair Lucy Turnbull, Director Albert Wong; Imugene Placement, Rights Offer For $8.7m; Botanix Starts Cannabidiol BTX1204 Atopic Dermatitis Trial; Acrux, Eli Lilly Lose Axiron Appeal; Pharmaust: ‘AAD Compounds Kill Cancer 6 Times Monepantel’; Noxopharm’s Dr Graham Kelly: ‘I Invented NOX66 Pre-Novogen’; Medlab Welcomes New TGA Marijuana Licencing; Creso Pharma Requests Capital Raising Trading Halt; Viralytics Loses 10% Placement Vote; Cellmid Survives 23.5% Remuneration 1st Strike; Resonance Directors Face 24% Dissent; Opthea 11% Oppose Increased Placement Capacity; Probiotec 13% Oppose Remuneration Report; Dorsavi: Caroline Elliott Director, Chair Herb Elliott Retires
 
Nov 22, 2017
Spain Reimburses Sirtex Sir-Spheres; Pro Medicus Adds Artificial Intelligence To Visage 7 Imaging; India Okays Admedus Cardiocel; Syncronei Distributor; Study Backs Uscom BP+; European Patent For Prima’s IMP321; MMJ To Raise $21m, Lease For 35 Tonnes Marijuana Buds; Memphasys Rights, Notes, Placement For $3.75m; Cryosite Cord Blood Closure To Cost $1m, H1 Profit Warning; Correction: Recce; Auscann Dayacann Wins 2nd Chile Marijuana Growing Licence; MGC To Supply Marijuana Extract To Macedonia’s Mabsut Life; Kazia (Novogen) ‘IP Legal Discussions With Dr Graham Kelly’; Creso Appoints Health House Cannaqix 50 Distributor; Zelda Pleads Schultz To ASX 30% Query; Dr Yacov Geva Diluted To 58% In G Medical; IDT: Alan Fisher Chair, Graeme Kaufman Exec Director; Medigard Appoints Dr Ian Dixon Executive Director On $240k; Proteomics Appoints Paul House Director; Us, Japan Consultants
 
Nov 21, 2017
Starpharma Files ‘Rolling’ Vivagel BV US NDA; US Patent For Evado Clinical Trials Management Software; Auscann Requests ‘Chilean Joint Venture’ Trading Halt; Imugene Requests Capital Raising Trading Halt; Zelda Requests ‘ASX Price Query’ Trading Halt; Recce Loses 2nd Strike Vote, Spill Motion; Stemcell Pleads Schultz To ASX 59% Query; ASX Misses 16%; One Funds Diluted To 7.5% Of Avita; Director Simon Panton, Southam Take 17% Of Resonance; Noxopharm Share Transfer Establishes Nyrada; Phylogica Founder Prof Paul Watt Retires As Director; Hydroponics Appoints Debbie Ormsby CCO
 
Nov 20, 2017
Simavita Raises $1.35m Through Convertible Notes; Genera Receives $489k Federal R&D Tax Incentive; Hydroponics: Breath Of Life To Supply Marijuana Products; Noxopharm: 10 Of 11 NOX66 Patients ‘No Cancer Progression’; Novogen Now Kazia, Code Change November 29; Creso Appoints China Marijuana Distributor; FMR Takes 6% Of Resmed; Dr Dax Marcus Calder, Staffwear Take 11% Of Patrys; Biotron Loses 7-Year Director Dr Denis Wade
 
Nov 17, 2017
Dr Boreham’s Crucible: Telix Pharmaceuticals; Rhythm Bio $9m IPO For Colostat Bowel Cancer Blood Test; Mach7 $2.4m Sentara Data Migration Deal; Pro Medicus $18m Yale New Haven Health Visage 7 Contract; Stanford Evaluates Optiscan Viewnvivo; Australian Patent For Adalta AD-114; Mesoblast Tells ASX Query ’52-Week RA Data Not Material’; Medlab Chair Michael Hall Takes 8%; Prima AGM Backs Name Change To Immutep; Neuren 20-To-1 Consolidation; Hydroponics Releases 4.5m Shares, 2.25m Options From Escrow; Noxopharm Requests Georgia NOX66 Trial Data Trading Halt
 
Nov 16, 2017
Patrys, WEHI Collaborate On 7D10, PAT-DX1 For Cancer; US QIDP Status For Recce-327 For E Coli, Golden Staph; US Patent For Pharmaust AADS For Cancer; Prima Expects To File US IMP321 IND By July 2018; Noxopharm Treats 1st NOX66 Prostate Cancer Patient; Esense, Healthy Chocolate Develop Marijuana Chocolate; Medadvisor To Release 89m Shares From Escrow; Stemcell Hopes To Raise $2.3m; Anteo AGM Loses Director, Survives Rem Report, Again; Factor Avoids AGM 1st Strike By 0.75%; Up To 19% Of Mesoblast Oppose Remuneration Report; Credit Suisse Returns, Sells Below 5% Of Mesoblast; Paradice Investments Takes 6% Of Impedimed; W Whitney George Takes 19% Of Rhinomed
 
Nov 15, 2017
Telix $50m IPO Up 25% For Molecular Targeted Cancer Radiation; G Medical Raises $13.5m; Cynata Half Way In Phase I CYP-001 GVHD Trial; Biotron ‘Pre-Clinical Compounds Active Against Hepatitis B’; Epat Painchek Children’s App ‘On-Track’; Universal Biosensors Hits J&J $45m Fee Buy-Out Trigger; Medical Australia Votes For ICU Acquisition; MMJ Gelpell-CBD Marijuana Capsules Available In Australia; Hydroponics Distributes Endoca Medical Marijuana In Australia; Actinogen Receives $1.2m Federal R&D Tax Incentive; 35% Of Impedimed Oppose 1.6m CEO Options, 1.3m CEO Rights Okay; Living Cell Withdraws 6 Director Fees, 3m Options AGM Resolutions; Up To 23% Oppose Novogen AGM Resolutions, Name Change Approved; Challenger Takes 8.6% Of Airxpanders; Paradigm M-D Paul Rennie, Kzee, Ear At 19%; Oceania Capital Takes 9% Of Mach7; Atcor Appoints Craig Cooper Director
 
Nov 14, 2017
Dendright Starts DEN-181 Rheumatoid Arthritis Phase Ib Trial; XL-Protein’s Pasylation Extends Adalta’s AD-114 Activity; Paradigm Claims PPS Success For Bone Bruising; Viralytics: Early Cavatak, Keytruda Cancer Data ‘Promising’; Mach7 Adds Zebra Artificial Intelligence To Radiology; Admedus Cardiocel 3D North America Sales In February 2018; Recce Requests ‘FDA Correspondence’ Trading Halt; US Patent For Immuron Nash Colostrum Treatment; Esense Raising $2m, $500k From MMJ; Harvest One Marijuana Deal; Creso Launches Anibidiol Marijuana For Swiss Dogs; Respiri Board Spill, 34m Director Options AGM; Regal Funds Takes 8% Of Avita; Robert Lederer, RTL Group Take 6% Of Anatara; Greencape Takes 8.5% Of Airxpanders; Michael Abolakian, Hishenk Take 6.6% Of Novogen; Naos Takes 12% Of Biotech Capital; Cochlear Appoints COO Dig Howitt Executive Director
 
Nov 13, 2017
Optiscan Claims 1st China Microscope Sale; Japan Approves Volpara Enterprise; Mach 7 Raises $2m From Oceania Capital Partners; GI Dynamics Endobarrier Conformity Certificate Withdrawn; ITL Launches Clinical Brand; Uscom Wins US Government Listing; Mesoblast: Stem Cells ‘Durable’ For RA At 52-Weeks; Court Orders Gordagen Wind-Up, Creditors Meeting; Both Resmed, Fisher & Paykel Claim UK Patent Win; G Medical Requests ‘Capital Raising’ Trading Halt; Novogen Licences Trilexium To Heaton-Brown; China Advisor; Creso Welcomes Canada $1/gm Recreational Marijuana Tax; Consonance Takes Loss On 5% Of Airxpanders; Credit Suisse Borrows, Buys To 7% Of Mesoblast; Auckland’s Milford Reduces To 5.3% Of Living Cell
 
Nov 10, 2017
Dr Boreham’s Crucible: Nanosonics; Living Cell Tumbles 89% On NTCell For Parkinson’s Results; Invitrocue Raises $1m; G Medical: ‘First Channel $527m Taiwan, India Distribution Deal’; Redhill Completes RHB-104 For Crohn’s Disease Enrolment; Phosphagenics, Terumo Take TPM-Propofol To Rat Studies; Paradigm CEO Loan Shares Face 20.5% Opposition; MMJ Requests ‘Investment, Collaboration’ Trading Halt; Esense Requests ‘Investment, Collaboration’ Trading Halt; JM Financial Takes 8% Of Mach7
 
Nov 9, 2017
Prima: IMP321 With Keytruda ‘Safe, Tumor Reduction’; Epat Hails 1st Painchek Residential Aged Care Licence; Orthocell Celgro Dental Scaffold Wins CE Mark; IDT, Victoria $2m Unnamed Drug Development Deal; Allegra 2nd Tranche $500k Takes Total To $1.7m; Mayne US Launch Of ‘Full Range’ Of Anti-Psychotic Clozapine; Antisense Receives $399k Federal R&D Tax Incentive; Immuron Completes IMM-124E For Nash Patient Visits; OBJ 58% Remuneration 1st Strike; Living Cell Requests ‘NTCell Parkinson’s Results’ Halt; Creso, LGC Cannabis Collaboration
 
Nov 8, 2017
Johns Hopkins Completes Sienna Bladder Cancer Test Study; Clarity Starts Sartate Kids Neuroblastoma Imaging Trial; Luina Wins Queensland Health, Biotechnology Export Award; Four Studies Back Impedimed L-Dex For Lymphoedema; Cryosite: More ACCC Questions On Asset Sale To Cell Care; Orthocell Requests Celgro CE Mark Trading Halt; G Medical Takes India, Taiwan Distribution Halt To Suspension
 
Nov 7, 2017
Biotech Daily 12th Birthday Editorial; Avita Rights Issue Raises $12.4m, Total $16.9m; Living Cell US Pericyte Patent Application For Neurology; Clinuvel Pleads Schultz To ASX 11% Query; Creso, Wollongong Uni Study Cannabis Effect On CNS
 
Nov 6, 2017
Paradigm ‘Oversubscribed Placement’ Raises $5.75m; FDA Lifts Hold On Prescient PTX-200 Ovarian Cancer Trial; Correction: Reva; Analytica Hires Navigant For Licencing; OBJ Micro-Array Doubles Delivery Of Anti-Cancer Vitamin B3; Mylan Arbitration Ends, Phosphagenics Awaits Result; TPI Sells Portugal Subsidiary For $4.3m; US Increases Impedimed L-Dex Hospital Reimbursement 7%; G Medical Requests India, Taiwan Distribution Trading Halt
 
Nov 3, 2017
Dr Boreham’s Crucible: Reva Medical; Ellex Placement Raises $23m, Share Plan For $5m More; Wearable Sensor Project Wins $10m ANU Grant; Noxopharm: ‘NYX-104 Inhibits Loss Of Brain Function In Mice’; Nanosonics 21% Oppose Director Richard England; Resapp Passes Remuneration Report, 2nd Strike Averted; Merchant Reduces To 9% Of Polynovo; Visioneering Loses Gary Stevenson; Nuheara Appoints Dave Thompson Business Development
 
Nov 2, 2017
Dimerix Analysis Backs DMX200 For Diabetic Nephropathy; Federal MTP Connect $5m Biomedtech Horizons Program Open; MTP Connect, MTAA Partner For Industry; Admedus: ‘No Change To Vaccines, Immunotherapies Funding’; Redhill Resubmits Rizaport For Migraine FDA Application; Factor: ‘All Phase II VF001 Leg Ulcer Trial Sites Recruiting’; IM Medical Votes To Become Babylon Pump & Power; Paradigm Requests Capital Raising Trading Halt; Regal Funds Reduces To 5% Of Avita; Allan Gray Reduces To 6% Of Phosphagenics; Actinogen Appoints Dr George Morstyn Director; Cann Moves HQ To La Trobe Uni Tech Enterprise Centre
 
Nov 1, 2017
October BDI-40 Up 7%, ASX200 4%, Big Caps 6%; Records Fall- Neuren Up 62%, Benitec 41%; Cellmid Down 15, Avita 14%; Reva: New Thinner Stent; Fantom Low Mace Rate At 2 Years; Pharmaust’s Epichem Wins 5th WA Exporter Of The Year Award; Biotron Receives $1.6m Federal R&D Tax Incentive; Medigard Places $150k; Ellex Requests ‘Placement’ Trading Halt; Suda AGM For 19m Director Options, Notes, Name Addition; Mark Kerr Takes 7% Of Phosphagenics; MGC Hl Marijuana Deal: ‘$10k Per Epilepsy Patient Per Year’; Zelda To Release 111.6m Escrow Shares; Bioscience Managers Appoints Three Directors; Rhinomed Loses Co Sec Justyn Stedwell, Phillip Hains Stays
 
Oct 31, 2017
Federal Government Launches $200m CSIRO Innovation Fund; Victoria Research Acceleration Fund $3m For 13 Projects; Vaxart Takes Over Aviragen (Biota); Adherium Q1 Delivers 7.5k Smartinhalers, 6.2k To Astrazeneca; Bionomics Recruits Phase I BNC101 Colorectal Cancer Trial; Botanix Ready For Cannabidiol BTX1204 Atopic Dermatitis Trial; Impedimed Appoints Regional Health For Sozo Australia, NZ; UK Phoenix To Distribute Rhinomed Mute; LBT Has Two Quarters Cash, Despite Projected Burn; Pro Medicus To Lose 7-Year Director Roderick Lyle; Clarity Appoints Prof Richard Wahl Advisor
 
Oct 30, 2017
WEHI’s Jane Visvader, Geoff Lindeman Win $50k Victoria Prize; Credit Suisse Takes, Disposes 8.7% Of Mesoblast; Admedus Shelves Prof Ian Frazer DNA Vaccine Funding; Antisense: ‘ATL1102 Significantly Reduces Nerve Fibre Loss’; Uscom Releasing Upgraded BP+ Monitor; G Medical Buys Texas Cardiostaff For $4.2m Debt, $1.3m Scrip; Paradigm Starts Phase IIb PPS Osteoarthritis Trial; MGC Signs $8m Of Varm Cosmo $40m PA Marijuana Cosmetics Deal; Hydroponics Wins Federal Marijuana Growing Licence; Invion AGM Votes On Cho Group, Light Therapy, Consolidation; Medigard 6m Directors Shares AGM; Avita Votes On 50m CEO Dr Mike Perry Incentive Shares; ITL Director Shares In Lieu, Fees Pool 33% Hike, Name Change AGM; Invitrocue Has Less Than Two Quarters Cash; Allan Gray Takes 17% Of Impedimed; FIL Reduces To 7.5% Of Impedimed
 
Oct 27, 2017
Dr Boreham’s Crucible: Prima Biomed; Polynovo Share Plan Raises $16m, Takes Total To $23m; Luina Wins $405k Queensland Grant; Cann Federal Marijuana Import-Export Licence; Resmed Q3 Revenue Up 12.5% To $686m, Profit Up 13.2% To $113m; LBT Sells Microstreak To China’s Autobio For $2m; Medical Developments 26% Oppose Directors Fees Hike; Starpharma AGM For 1m More CEO ‘Performance Rights’; Antisense Votes On Potential 2nd Strike Board Spill; Analytica AGM For 20m Euro, US Licence Director Options; Ellex AGM For 150% Directors Fees Pool Hike To $500k; JCP Takes 5% Of Osprey; Clarification: Oventus; Regal Funds Reduces To 8.6% Of Oncosil
 
Oct 26, 2017
MTP Connect $7m, Generates $22m, 20 Projects, 200 Partners; Admedus $10m Facility; Uniquest, Merck Collaborate On Immuno-Oncology Therapies; Ausbiotech, J&J: Lusia Guthrie, Planet Innovation, Canceraid; Oventus: ‘O2Vent T Reduces Sleep Events 30%’; Cellmid Opens Tokyo Advangen ‘Concept Store’; Correction: Phosphagenics; Biotron Pleads Schultz, Again, Olds To ASX 27% Query; Acrux 55% Remuneration 1st Strike; 40% Oppose CEO Shares; MMJ Votes On 12m Directors ‘Performance Rights’; Platinum Reduces To 8% Of Imugene; Melbourne Uni Appoints Duncan Maskell Vice-Chancellor; Cogstate Loses 13-Year Director David Simpson
 
Oct 25, 2017
STC Actuator Up To $75m For 40 Medical Technology Companies; Ausbiotech Adelaide Conference; Prof Jan Tennent Director; TGA Approves Starpharma Vivagel For Bacterial Vaginosis; Japara Adopts Dorsavi Myvisafe; Sirtex Sir-Spheres, Nivolumab Liver Cancer Trial; Permits Expand Cann Medical Marijuana Facilities; Acrux, Eli Lilly Axiron Q1 Revenue Down 80%; Brain Raises $10m For ‘Aggressive US Growth’; Phosphagenics Raises $3.4m Of Hoped-For $4.7m; Medibio Receives $3.3m Federal R&D Tax Incentive; Bioxyne Wins Malaysia Direct Sales Licence; Teva Sells 29m Mesoblast Shares, Below 5%; Regal Funds Take 6% Of Medibio; UBS ‘Returns’ 4m IDT Shares To 6%; Anthony Barton, Associates Take 5% Of Phylogica, Again; Up To 30% Oppose Micro-X Director Patrick O’Brien; Phylogica Appoints Judy Lieberman, Stephen Doberstein Advisors
 
Oct 24, 2017
Ausbiotech Invest Starts Conference Week; Telix $50m IPO For Targeted Radio-Pharmaceuticals; Admedus Develops Trans-Catheter Heart Valves; Ebos Invests $10.5m, Takes 14% Of Medadvisor, Up 39%; Dimerix Ready For Propagermanium PK Trial; Orthocell Receives $2.3m Federal R&D Tax Incentive; Aphria Ships Medlab Cannabis Oil For Sydney Cancer Pain Trial; IDT 49% Remuneration 1st Strike; Placement Vote Lost; Sirtex Dissent On CEO Performance Shares, Remuneration; Invion Pleads Schultz To ASX 125% Query; Novita Pleads Schultz To ASX 22% Query; Actinogen Votes On 5m Director Dr Geoff Brooke Options; Viralytics Votes On 20% Directors’ Fee Pool Hike; Benitec Loses 7-Year Director Dr John Chiplin; Sahm Nasseri Replaces Phylogica Director Dr Rick Kendall
 
 
Oct 20, 2017
Dr Boreham’s Crucible: Polynovo; Airxpanders Q3 Revenue 23% Above H1 At $1.5m; Innate Closes Auckland Science, Drug Manufacturing; MGC Up 100% On Varm Cosmo $40m PA Marijuana Cosmetics Deal; Simavita Receives $964k Federal R&D Tax Incentive; Medadvisor Requests ‘Capital Raising’ Trading Halt; Unnamed American Chain Completes Rhinomed Mute Trial; Deutsche Bank Takes 6% Of Avita; David Sietsma Takes 11% Of Phylogica 
 
Oct 19, 2017
Prof Jenny Graves Wins $250k PM Science Prize; Carl Zeiss 60 Sales Staff Back Optiscan Microscopes; Dimerix Faces 27% Dissent Over 20-To-1 Consolidation; Regal Funds Takes 7% Of Avita; Medadvisor Issues 203m (18%) ‘Founder Performance’ Shares; Esense Requests ‘Material Agreement’ Trading Halt; Hydroponics CEO David Radford Starts On $325k, Board Moves; Anteo Appoints Matthew Sanderson Director; CEO Wanted; Pharmaxis Appoints Dr Dieter Hamprecht; Advisors; Polynovo Loses Co Sec Andrea Goldie
 
Oct 18, 2017
CSL CEO Faces 18% Dissent Over $7m More Performance Shares; Analytica Raises $1.3m Of Hoped-For $1.6m; Mexico Approves Medical Developments Penthrox; Resonance, Perth Clinic Work On AI-Ferriscan; Alison Laws; US Issues Benitec RNA-I Hepatitis B Patent; Anteo Up 178% On Nano-Coating Silicon-Lithium Batteries; Immuron AGM: 875k Grandlodge Shares, 1m Director Options; Resonance AGM For 7m Director Options; BPH, Cortical Dynamics French Bar Monitor Trial; Visioneering Releases 1.7m Escrow Shares; Dimerix Appoints DMX-200 Chronic Kidney Disease Advisors
 
Oct 17, 2017
Biotech Wins $9.6m Federal Advanced Manufacturing Grants; Respiri Faces Board Spill; Uscom BP+ Climbs Everest: ‘Better Than Conventional Arm BP’; Volpara H1 Revenue Up 7% To $1.5m; ‘Total Contract’ Up 339% To $2m; Dimerix Receives $546k Federal R&D Tax Incentive; MMJ Canada Green Light For Medical Marijuana Sales; RHS Claims 98% Pre-IVF Testing Accuracy For Aneuploidy; Prima AGM For Name Change, 50m CEO ‘Performance’ Rights; Yarra Funds Below 5% Of Sirtex; Imugene Pleads Schultz To ASX 38% Query; Race AGM Votes On 4m Director Options
 
Oct 16, 2017
Polynovo Novosorb Breast Devices Unnamed Company Deal; Neurotech Raises $4m For Mente Autism; Universal Biosensors $7.5m Federal R&D Tax Incentive; Reva Fantom Stent 1st Swiss Implant; Federal $50k Patrys Garvan PAT-DX1 Pancreatic Cancer Grant; Canadian Patent For Orthocell Celgro Collagen Scaffold; Oncosil Pancreatic Trial: 28 Recruited, 14 Implanted; Novogen Votes On Name Change To Kazia, 10-To-1 Consolidation; Impedimed Votes On 1.6m CEO Options, 1.3m ‘Performance’ Rights; Living Cell AGM For 3m Director Options In Lieu; 33% Fees Hike; Prana AGM To Vote On 11m Directors Options ‘In Lieu Of Pay’; Bioxyne Pleads Schultz, Malaysian Sales To ASX 37% Query; Medical Developments David Williams Sells 4m More Shares; Peter Diamond, Dak Drafting Take 5% Of Novita; Scott Ward Impedimed Chair; Cherrell Hirst; Robert Graham; Cellmid Appoints Dr Martin Cross Director; Respiri Hires Mario Gattino CEO On $300k, Dr Tim Oldham Goes; Imugene Hosts Immuno-Oncology R&D Briefing
 
Oct 13, 2017
Dr Boreham’s Crucible: Bluechiip; Clarification: Imugene AGM; FDA Meeting Takes Neuren To Phase III Trofinetide Rett Trial; Medibio Raises $14m; Resmed Wins German Fisher & Paykel Patent Case; MGC Harvesting Marijuana In Czech Republic, Slovenia; TPI Processes 1st Batch Of Customer Poppy Straw; Nuheara Iqbuds Available In 600 Shops; Biotron Has Less Than Two Quarters Cash; Pengana (Hunter Hall) Below 1% In Avita; Rhinomed AGM For 100% Directors Fee Poll Hike To $400k; Bluechiip AGM For 3m CEO ‘Performance’ Rights; Factor Therapeutics 1m John Michailidis Options AGM; Probiotec Loses Director Graham Morton; Medibio Loses Founding Director Kris Knauer; MMJ Requests ‘Canada Marijuana Licence Amendment’ Halt; Neurotech Takes Capital Raising Halt To Suspension
 
Oct 12, 2017
Life Sciences Queensland Bioproducts, Bioenergy Symposium; Imugene Votes On 2nd Strike, Board Spill, Axel Hoos Options; Adalta 2m Director Options AGM; Pharmaxis AGM For 770k More CEO ‘Performance Rights’; Dr Jerel Banks Replaces Benitec Chairman Peter Francis
 
Oct 11, 2017
Medibio ‘Misunderstanding’ Leaks News Before ASX Told; Biotech Daily Editorial: Selective Briefings; Paradigm Tells ASX: ‘Olds, Not News Leak, Pushed Price 20%’; Prana Refreshes $64m At-The-Market Facility; Azura Raises $21m For Meibomian Gland Dysfunction; Avita Raising $17m; Imugene Receives $1m Federal R&D Tax Incentive; Respiri Pleads ‘Alan Kohler’ To ASX 50% Query; Oventus: O2vent Reduces Sleep Apnoea Events 80%; Psivida, Nicox Work Bio-Erodible Nitric Oxide Delivery For IOP; Actinogen Xanamem Canada Patent For Metabolic, Neuro; US Patent For Patrys PAT-LM1; Orthocell Appoints Surgical Specialties Aust, NZ Distributor; Robert Peters Takes 10% Of Optiscan; Benitec To Lose COO Dr Cliff Holloway
 
Oct 10, 2017
Paradigm: ’20 Of 24 (83%) OA Patients Report Reduced Pain’; Carl Zeiss Unveils Optiscan ‘Convivo’ Microscope; MMJ To Be Marijuana Company Incubator, Name Change; Epat Registers Pain Application As ‘Painchek’; Imagion Hires Chemconnection For Cancer Trial Particles; Correction: Uscom; US Non-Cancer Patent For Pharmaust Monepantel; Proteomics Receives $786k Federal R&D Tax Incentive; Memphasys Receives $432 Federal R&D Tax Incentive; Cynata 2m Director Dr Paul Wotton Options AGM; Consonance Takes 8% Of Sirtex; FIL Takes 9% Of Factor Therapeutics; G Medical Co Sec Peter Webse Goes, Stephen Buckley Stays; Adherium Appoints Vik Panda Head Of Marketing 
 
Oct 9, 2017
Ausbiotech Invest, Conference A Fortnight To Go; LBT Receives $4m Federal R&D Tax Incentive; Resmed Claims Sleep Mask Patent Wins Over Fisher & Paykel; More Data Backs Airxpanders Aeroform Breast Expander; Uscom: ‘Study Backs Monitor For ICU Fluids’; Botanix, FDA Pre-IND Cannabidiol BTX1503 For Acne Meeting; Medibio, Otsuka Work On Heart Test For Mental Illness; Cynata Hires Finantec To Raise Japan Profile; Starpharma, Peter Mac Win $50k Federal DEP-Oncology Grant; Avita Requests ‘Capital Raising’ Trading Halt; ASX Lifts Anteo Suspension On Accounts; Nuheara Justin Miller, Wasagi, David Cannington Diluted To 8%; Adalta Appoints Dr Dallas Hartman COO
 
Oct 6, 2017
Dr Boreham’s Crucible: Optiscan; CSIRO, Cann Work On Marijuana Oral Drops, Inhaled Vapor; Uscom Withdraws Prof Rob Phillips Share Issue; Optiscan’s Ian Mann, Ibsen, Ezahc Increase, Diluted To 10%; Prof Tim Hughes Wins $80k Research Australia GSK Award
 
Oct 5, 2017
CSL Closes $894m Loan Facility; US Patent For Phylogica Blood-Brain Phylomers; Factor Therapeutics VF001 Leg Ulcer Trial Delay; MMJ: TGA, German Approvals, $184k Revenue In 3 Months; Alexander Beard, CVC, Stinoc Take 8% Of Probiotec; Bath Road, Tony Giam Take 6.5% Of Probiotec; Honsue Cho (Cho Group) Takes 15% Of Invion; Andrew, Skye Leicester Take 6% Of Allegra
 
Oct 4, 2017
Redhill Bekinda (RHB-102) Meets Phase II IBD Trial Endpoints; Medibio Signs 2nd Mayo Clinic Deal For Psych Trials; Optiscan $1m Placement Takes Total To $3.5m; FDA Eases Restrictions On Avita Recell Burns Protocol; Polynovo Appoints AMI Israel Distributor; Micro-X Delivers 1st Nano-X-Ray To Carestream; Alcidion Signs 3-Year, $389k Monash Health Deal; Court Okays Medical Australia, ICU Scheme Booklet, Meeting; Neurotech Tells 112% ASX Aware Query: ‘We Needed Time’; Resapp 2nd Strike Board Spill AGM; Noxopharm Spin-Out Nyrada EGM; Creso To Release 2m Escrow Shares; Clinuvel Loses Director Elie Ishag
 
Oct 3, 2017
ITL Sells Melbourne Medical Supplies To Merit For $14m; Redhill Cuts RHB-104 For Crohn’s Trial, Saves $18m, One Year; Ellex Claims 5 Quarters Of Rising Itrack Revenue; TPI Completes $26m Vistin Pharma Opiate Acquisition; Probiotec Completes $12m South Pack Acquisition; Prescient PTX-100 For Lymphoma Trials, Patent Application; Cellmid Receives $947k Federal R&D Tax Incentive; MGC 5-Year Euro Medical Marijuana Deal With Lenis; Living Cell Pleads Schultz To ASX 14% Query; CEO Richard Hannebery Takes 7% Of Genera; Novita Appoints Glenn Smith CEO, Starts On $274k; Pharmaust: Angela Frimberger, Christian Schirvel Advisors
 
Oct 2, 2017
September BDI-40 Up 4%, ASX200 Down 0.6%, Big Caps Up 3.5% - Living Cell Up 45%, Polynovo 36%; Acrux Down 44%; FDA Lifts Antisense Phase IIb ATL1102 MS Trial Hold; G Medical Appoints Medtl Greece, Cyprus Distributor; ITL Requests ‘Transaction Update’ Trading Halt; ASX Suspends Anteo On Accounts
 
Sep 29, 2017
Dr Boreham’s Crucible: OBJ Limited; LBT Shelves Microstreak, APAS Distribution Deal Late; TPI Adds Marijuana To Opium Assets; Uscom AGM For 1.2m Chairman, Director Shares In Lieu Of Pay; Novita AGM For 14m Director Options; Stemcell United Loses ‘King Of Cannabis’ Nevil Schoenmakers; Anteo Loses 12-Year Director, Co Sec Richard Martin; Allan Gray Takes 6% Of Sirtex
 
Sep 28, 2017
Mesoblast Recruits Phase II End Stage Heart Failure Trial; Avita Files Recell For Burns FDA Application; Airxpanders Completes Costa Rica Aeroform Plant; Oventus Relaunches O2 Sleep Apnoea, Snoring Device; Volpara Signs Imaging Associates For Enterprise Software; Astrazeneca Names Starpharma DEP AZD0466 For Tumors; MTP Connect, Medical Alley US-Australia Collaboration; Aviragen (Biota) Nasdaq Share Price Warning; Faces Delisting; Australian Ethical Reduces To 6.4% Of Ellex; Invitrocue Appoints Dr Sunny Tan, Dr Ramanuj Dasgupta 
 
Sep 27, 2017
CNBP Computer-Assisted Cystoscopy For Bladder Cancer; Aus Bio Single Drop Drug Prevents Influenza In Mice, Ferrets; Psivida $1.2m Deal For Glaucoma Drugs; Optiscan Plan Raises $1.2m, $2.3m To Go; Recce Share Plan For Up To $1m; LBT Automated Plate Assessment System Trial Begins; Neurotech: Mente Autism ‘Incredible Preliminary Results’; Noxopharm To Begin Phase Ib NOX66 Prostate Cancer Trial; US Patent For Cynata Stem Cell Scalability; Memphasys Settles $4.5m Prime, Pulau Manukan Dispute
 
Sep 26, 2017
Regeneus: ‘Stem Cells Beat Morphine For Pain In Rats’; Phosphagenics Licences TPM-Diclofenac To Sichuan Credit; Phosphagenics Rights Offer To Raise $4.7m; Cyclopharm Enrols Patients In US Phase III Technegas Trial; Epat Pain Software Launch At Alzheimer’s Meeting; IM To Become Babylon Pump & Power, Depart Biotech
 
Sep 25, 2017
Medical Developments: ‘Penthrox For UK Ambulance’; Polynovo Placement Raises $7m, Share Plan; Sienna: Axlab Bladder Test Distributor For Denmark, Sweden; Novogen, FDA Meeting - GDC-0084 Brain Cancer Trial On-Track; GI Dynamics: ‘Endobarrier Equals Gastric Plication’; Oncosil Receives $2.9m Federal R&D Tax Incentive; Noxopharm, Director Dr Ian Dixon Spin Out Nyrada; FMR Takes 7% Of Nanosonics; Pengana (Hunter Hall) Reduces To 11% In Avita; Neurotech Requests ‘Mente Austism Trial Update’; Mach7 CEO Michael Jackman Appointed M-D; Ausbiotech Launches ‘Roadmap To A Successful IPO’
 
Sep 22, 2017
Dr Boreham’s Crucible: Acrux; Starpharma Safety, Efficacy Takes Dep-Docetaxel To Phase II; Mach7 Imaging Deal With Vermont Uni Medical Centre; Oncosil Pancreatic Trial: 23 Recruited, 10 Implanted; Atcor Share Plan Raises $350k Of Hoped-For $500k, Total $1.2m; Invion Pleads Schultz To ASX 33% Query, ASX Misses 34%; Phosphagenics Requests ‘Capital Raising’ Trading Halt; Sirtex $1.4m CEO ‘Performance Rights’ AGM; Acrux $620k CEO ‘Performance Rights’ AGM; CLJE Takes 10% Of Allegra; Narhex Director Ian Reynolds Takes 6% Of Resapp
 
Sep 21, 2017
Avita Signs $30m BARDA Paediatric Burns Extension; Carl Zeiss Unveils Optiscan In-Vivo ‘Digital Biopsy Tool’; Compumedics Signs $1m German Epilepsy Monitor Contract; Probiotec Buys South Pack For $8m Cash, 7.9m Shares; Australian Patent For Orthocell Celgro Repair Platform; Genetic Technologies D-I-Y Brevagenplus Breast Cancer Test; Polynovo Requests Capital Raising Trading Halt; Psivida $14m Available Through FBR ‘At Market’ Facility; Macquarie Uni, CSIRO Hold Synthetic Biology Conference
 
 
Sep 19, 2017
Cyclopharm, Ansto, Cyclotech, Macquarie Imaging Agreement; Paradigm Ready For Phase IIb PPS Osteoarthritis Trial; Clinuvel Preparing Submission; FDA EPP Workshop; Adalta AD-114 Safe In Monkeys; Simavita Takes $695k R&D Tax Incentive Loan; Adherium: Timothy Marcotte CFO, Rob Turnbull VP Finance; Volpara Appoints Radiologist Dr Monica Saini Consultant; G Medical Appoints Ashley Krongold Director; MTP Connect, Life Sciences Queensland Collaboration; Rhinomed Sells 425 Unmarketable Parcels, 436k Shares
 
Sep 18, 2017
Telix To Raise $50m, Appoints Kevin McCann, Dr Mark Nelson; Patrys: ‘PAT-DX1 Plus Nanoparticles Targets Tumors In Mice’; Epat Raises $3.75m; Analytica 1-For-8 Offer To Raise $1.6m; Recce Says TV News Led To ASX 79% Query; Zelda Claims Marijuana Benefit For Paediatric Autism; CE Mark For G Medical Prizma; Australian Patent For Medlab Nrgbiotic For Depression; Prolog Reduces To 4.9% Of Airxpanders; Proteomics Founder William Parker, Xylo Reduce To 9%; Stuttgart Takes 8% Of Brain Resource
 
Sep 15, 2017
Dr Boreham’s Crucible: Rhinomed; Mesoblast Completes $50.7m Capital Raise; FDA Approves CSL Privigen For CIDP; Mayne Australia Launches Monurol, Urorec, For UTIS; OBJ, Proctor & Gamble SK-II Magnetic Booster Taiwan Launch; CSL 2nd Strike Rem Report, $7m More CEO ‘Rights’ AGM; Consonance Takes 5% Of Airxpanders; Bruce Higgins To Replace Novita Chairman Iain Kirkwood
 
Sep 14, 2017
Patrys PAT-DX1 Kills Cancer Cells, In-Vitro, In Mice; Up 400%; Polynovo: ‘Two More US Novosorb Orders Worth $300k’; Médecins Sans Frontières Cancels Resapp Field Evaluation; Paradigm Treats 6 Ross River Virus Patients, New Trial Sites; Addendum: Paradigm Case Study Published; Optiscan Signs China Gate Scientific As Viewnvivo Distributor; Rhinomed Appoints Brojaw To Distribute Mute In Taiwan; Viking Yacht Adds Atcor Sphygmocor To Health Program; Medical Australia, ICU Scheme Of Arrangement; Epat Requests Capital Raising Trading Halt; Neurotech Appoints Medilink Australian Distributor; Auscann Appoints 3 ‘Medical Liaison Managers’
 
Sep 13, 2017
WEHI Shows How Viruses Trigger Immune System; Amgen, Sydney Uni Launch $11m High School ‘Biotech Experience’; Biotech Capital, Bioimpact Licence RLS Dental Products; Dimerix 20-To-1 Consolidation, 11m Directors Options AGM; Visioneering Releases 53m Shares, CDIs; Anatara Extends Pork CRC Options 12 Months; Sirtex Appoints Helen Kurincic Director; Certara Appoints Dr Andreas Wallnöfer Advisor; Zelda Appoints Dr Kuester, Dr Sasso, Ms Vergara For Trials
 
Avita: ‘Surgeons Say Recell Reduces Skin Harvested’; Psivida Revenue Up 365% To $9m, Loss Down 14% To $23m; Antisense ATL1102 Dystrophy Trial, Funds Depend On FDA; Euro Patent For Pharmaust Monepantel For Cancer; Race Produces 1st Bisantrene For AML Batch; Noxopharm: NOX66 For Cancer ‘Well-Tolerated’; Respiri (Isonea), Grey Work On New Airsonea Wheeze Meter; Consonance Takes 7% Of Sirtex; FMR Takes 6% Of Nanosonics 
 
Sep 11, 2017
Imagion Preparing For Human Cancer Imaging Trials; Funding; Federal, Bioscience Managers BTF $13m For 3 Projects; Paradigm: ‘Case Study Backs PPS For OA Bone Bruising’; TDM Takes 15% Of Somnomed; Micro-X Appoints Jim McDowell Director
 
Sep 8, 2017
Dr Boreham’s Crucible: Clinuvel; Boehringer 2nd Pharmaxis PXS-4728A Trial Triggers $15m; Allegra Raises $1.3m, Second Placement For $1.4m More; Memphasys, Transocean Settle Dispute; Japan Patent For Prima IMP731 For Transplant Rejection; David Neate Takes 10.5% Of Sienna; DRH, David Hannon Increase, Diluted To 8% Of Noxopharm; Pro Medicus Appoints Dr Leigh Farrell Director
 
Sep 7, 2017
Epat Pain Diagnostic 1st Sale To Dementia Support Australia; Recce Starts FDA Application For Recce 327 Antibiotic; Actinogen: ‘1st Patient Treated In Xanamem Alzheimer’s Trial’; Mesoblast’s Prof Silviu Itescu Increases, Diluted To 15%
 
Sep 6, 2017
FDA, Generics Kill Acrux, Eli Lilly $1b Axiron; Pharmaxis, Synairgen Ready For LOXL2 Fibrosis Trial; Orthocell: ‘Early Data Backs Celgro Safety, Tolerability’; G Medical Awards Directors 70m ‘Performance’ Rights; Prudential (M&G) Increases To 14% Of Mesoblast; Brandon, MRCF, Australian Super Take 27% Of Osprey; Lusia Guthrie Dines On Entrepreneurship, AI With RACI
 
Sep 5, 2017
Orthocell Treats 1st Ortho-ATI Rotator Cuff Patient; Starpharma: Ansell China Condom Sale ‘Vivagel Opportunity’; Prima Japan Patent For IMP321 For Infectious Diseases; Dimerix Extended Release Propagermanium For Trials; Invion Proceeds With Cho Group Control, NGPDT For Cancer; Phylogica Functional Peptides: ‘More Drug To More Targets’; Victorian Comprehensive Cancer Centre 1st Conference; Lifespot Appoints Ex-Simavita CEO Philippa Lewis Chairman
 
Sep 4, 2017
Biotech Revenue Up 194% In 8 Years To $1.4b; FDA Lifts Hold On Prescient PTX-200 For AML Trial; Resapp Upgrades Protocols, Algorithms For Study Re-Run; FDA Approves G Medical Prizma; 70m ‘Performance’ Rights; OBJ Responds To 2nd ASX Aware Query; Pharmaust Takes 100% Of Nihon Amino-Acetonitrile IP; Stemcell United To Release 248m ASX Escrow Shares; Cochlear Appoints Sirtex’s Dr David Cade CMO; Nuheara Iqbuds Win 2 Berlin Radio Show Awards
 
Sep 1, 2017
August BDI-40 Down 1%, ASX200 Down 0.1%, Big Caps Up 2% - Starpharma Up 37%, Osprey 18%; Actinogen, Dimerix Down 27%; Dr Boreham’s Crucible: Pro Medicus; Polynovo: ‘1st US Sales Of Novosorb Wound Treatment’; Anteo Sells Recent Acquisition Diasource For $24m Cash; IQ3 Revenue Up 178% To $6m, Loss Down 98% To $50k; Alcidion Revenue Down 14% To $3.5m, Loss Down 19% To $2m; Pharmaust Revenue Up 21% To $3.3m, Loss Down 66% To $1.3m; Phylogica Revenue Up 1477% To $2.8m, Loss Down 51% To $2m; Brain Resource Revenue Down 18% To $2.4m, Loss Up 145% To $10m; Bioxyne Revenue Up 1.5% To $2m, Profit To $766k Loss; Ellex Takes Itrack Production From 20k To 50k, 100k Planned; FMR Takes 5% Of Nanosonics; Invion Requests ‘ASX Compliance’ Trading Halt; FDA Approves Adherium Smarttouch Symbicort Monitor; Phosphagenics Part-Return Of Mylan ‘Pay-Out’ To Investors; Cann, Hydroponics Partner Medicinal Cannabis Portal; Brandi Roberts Replaces Reva CFO, Co Sec Katrina Thompson
 
Aug 31, 2017
CSIRO, Monash M2 For Prototypes, Imaging; Admedus Revenue Up 57% To $22m, Loss Down 49% To $13m; Clinuvel Revenue Up 165% To $17m, $7m Maiden Profit; Suda Revenue Up 23% To $7m, Loss Down 46% To $1.2m; Cellmid Revenue Up 21% To $5.6m, Loss Up 28% To $4.5m; Medlab Revenue Up 70% To $4.4m, Loss Up 3% To $4m; Atcor Revenue Down 14% To $4.3m, Loss Down 9% To $4.4m; Immuron Revenue Up 40% To $1.4m, Loss Up 21% To $6.8m; Alcidion, Monash Negotiating Miya Clinical Task Management; Admedus To Supply Adapt Tissue To 4C For Mitral Valve Repair; Prima, Monash Win $360k ARC Grant For LAG-3; Imugene Doses 1st HER-Vaxx Gastric Cancer Patient; MTP Connect, India To Collaborate On Life Sciences; US Patent For Opthea OPT-302 For Eye Diseases; Clinical Genomics Wins J&J Eureka Prize For Cancer Test; OBJ To Lose Chairman Glyn Denison; Cho Group Takes Control Of Invion, Light Therapy For Cancer; Avita Appoints Erin Liberto Chief Commercial Officer
 
Aug 30, 2017
Osprey Rights Offer Raises $10.3m, Total $32.5m; Mesoblast Revenue Down 94% To $3m, Loss Up 1761% To $96m; Medical Australia Revenue Down 7% To $13m, Loss To Profit; Allegra Revenue Down 1.5% To $5m, Loss To $501k Profit; Medadvisor Revenue Up 198% To $4m, Loss Up 12% To $3m; Resonance Revenue Down 4% To $2.5m, Loss Down 21% To $304k; Genetic Signatures Revenue Up 12% To $2m, Loss Up 5% To $3m; Optiscan Revenue Up 330% To $1.4m, Loss Up 120% To $3m; Antisense: ‘ATL1102 Reduces Nerve Fibre Loss’; Micro-X Receives $7m Federal R&D Tax Incentive; Monash Licences Lymphatic Drug-Targeting To Puretech; BVF Partners, Mark Lampert Take 19.97% Of Pharmaxis; Allan Gray Reduces To 7% Of Pharmaxis
 
Aug 29, 2017
Mesoblast Raises $38m, $12.7m To Go; Atcor Share Plan For $500k; OBJ Ready For Transdermal Ibuprofen Pain Study; Cyclopharm H1 Revenue Up 6% To $6m, Profit  To $1.4m Loss; Avita Revenue Up 129% To $8m, Loss Up 50% To $12m; Adherium Revenue Up 12% To $2.3m, Loss Up 103% To $13m; Rhinomed Revenue Up 70% To $1.7m, Loss Down 26% To $4.4m; TBG (Progen) H1 Revenue Up 30% To $1.8m, Loss Down 62% To $1m; Genetic Techno Revenue Down 54% To $518k, Loss Down 1%; Euro Patent For Ellex 2RT Laser Treatment For AMD; Regeneus Receives $2.6m Federal R&D Tax Incentive; Zelda Priority For $6m Cannpal IPO; Noxopharm: Idronoxil Kills Brain Cancer In Laboratory; Yarra Funds Back Below 5% Of Mayne Pharma, Again
 
Aug 28, 2017
CSL Buys Calimmune Stem Cell Gene Therapy For Up To $524m; ASIC: ‘Stefan Boitcheff Pleads Guilty To Anteo Manipulation’; Compumedics Revenue Down 8% To $34m, Profit Down 60% To $1m; Mach7 Revenue Up 452% To $10m, Loss Up 35% To $17m; Dorsavi Revenue Up 20% To $4m, Loss Down 26% To $4m; Starpharma Revenue Down 18% To $3.6m, Loss Down 29% To $15m; Nuheara Maiden Revenue $2.5m, Loss Down 72% To $5m; Cann Harvests 1st Medical Marijuana Crop; Immuron Ready For IMM-529 Clostridium Difficile Trial; Dorsavi Loses Chairman Herb Elliott, Greg Tweedly Chair; Anteo Appoints Julien McInally Company Secretary; Bio-Melbourne Medical Technologies US Sales Briefing 
 
Aug 25, 2017
Dr Boreham’s Crucible: Sienna Cancer Diagnostics; Boehringer Phase II NASH Trial Triggers Pharmaxis $27m; Mesoblast $51m 1-For-12 Rights Offer, Trading Halt; Ellex Revenue Down 2% To $72m, Profit To $894k Loss; Mayne Revenue Up 114% To $573m, Profit Up 137% To $89m; Probiotec Revenue Down 5% To $63m, Loss To $4m Profit; Nanosonics, GE Sign Resale Deal To 2022; Allegra Sheep Trial Takes Sr-HT–Gahnite To Neck Spine Cages; Genetic Technologies ‘Strategic Review’; China, Singapore Patents For Visioneering Contact Lenses; Cann Licences Cannakorp Vaporizing System, Marijuana Pods; LBT Appoints Ray Ridge CFO, Dan Hill To Co Sec
 
Aug 24, 2017
Clinical Genomics Hails 25m Bowel Cancer Test Kits; MRFF 1st Grants For Antimicrobial Resistance, Clinical Trials; One Week To Apply For STC $160k Medtech’s Got Talent; Noxopharm Raises $5.5m; Nanosonics Revenue Up 53% To $67.5m, Profit Up 2,134% To $26m; Somnomed Revenue Up 12% To $49m, Profit To $3.5m Loss; Cryosite Revenue Up 0.3% To $10m, Profit Down 26% To $225k; Polynovo Revenue Up 8% To $4m, Loss Up 64% To $5m; Impedimed: ‘Independent Study Backs L-Dex For Lymphoedema’; Six Months To Acrux, Eli Lilly Axiron Appeal Decision; OBJ Explains $3.5m Staff, Consultant Performance Milestones; Consonance Takes 6% Of Sirtex; Bluechiip Appoints Blair Healy Director
 
Aug 23, 2017
Clarification: Phosphagenics; Sirtex Revenue Up 1% To $237m, Profit Down 21% To $42m; Optiscan Underwritten Plan, Placement For $5m; Novita Rights Issue Raises $1m, Takes Total To $3.5m; Acrux Revenue Down 16% To $24m Profit To $243k Loss; IDT Continuing Revenue Up 25% To $9.5m, Loss Down 81% To $773k; Impedimed Revenue Up 3% To $6m, Loss Up 6% To $28m; OBJ Revenue Up 29% To $2m, Loss Up 56% To $5.5m, SKII In Japan; Noxopharm Takes ‘Capital Raising’ Trading Halt To Suspension; Cynata: ‘Cymerus Cells Beat Steroids For Asthma In Mice’; MGC Signs RMIT Medical Marijuana Deal; Australian Patent For OBJ ‘Personalized Transdermals’; GI Dynamics Appoints Juliet Thompson Director; Resapp Appoints Dr Philip Currie Advisor; Nuheara Appoints Gr Media Solutions For Middle East, Africa
 
Aug 22, 2017
Terumo Takes Phosphagenics Oxymorphone, Not Oxycodone; Cogstate Revenue Up 28% To $35m, Profit To Loss Of $824k; Regeneus Revenue Up 436% To $10m, Loss To $3.3m Profit; Uscom Revenue Up 19% To $3.5m, Loss Down 6% To $1.8m; St Vincent’s, Janssen Small Molecules For Alzheimer’s; Clinical Genomics, Qiagen Blood Test For Colorectal Cancer; Oncosil Recruits 1st UK Patient In Pancreatic Cancer Trial; G Medical Pleads Schultz To ASX 44% Query; NAOS Takes 10.6% Of Biotech Capital; Novogen Appoints Chiltern Phase II GDC-0084 Glioma Trial CRO; P&G Olay Launches OBJ Magnemasks Technology In China
 
Aug 21, 2017
Monash Biomedicine Discovery Institute Joins MRCF; ITL Revenue Up 12% To $35m, Profit Up 897% To $3.4m; Teva Launches Generic Of Acrux, Lilly Axiron; Botanix Ready For Phase Ib BTX1503 Acne Trial; Resapp Receives $516k Federal R&D Tax Incentive; Impedimed Submits FDA Sozo Heart Failure Application; Medibio Starts FDA-Directed Cardiac Rhythm Depression Trial; Nuheara Welcomes US OTC Hearing Aid Act; Resonance Begins Testing Artificial Intelligence Iron Test; Cellmid Claims 98% Évolis Hair Growth Success; Optiscan Requests ‘Capital Raising’ Trading Halt; Noxopharm Requests ‘Capital Raising’ Trading Halt; Anatara, Zoetis Negotiate Detach For Animal Diarrhoea; Neurotech Takes Promosalute Italian Deal To 50% Cash Up-Front; FMR Takes 5% Of Resmed, Adds To Biotech Investments; Thorney Takes 6% Of Micro-X; Prima Appoints Grant Chamberlain Director; Bionomics, Merck Sharp Dohme Neuroscience Symposium 
 
Aug 18, 2017
Dr Boreham’s Crucible: Suda; Cyclopharm, HMRI Evaluate Technegas Respiratory Diagnoses; Pro Medicus Revenue Up 15% To $32m, Profit Up 46% To $9m; Medical Developments Revenue Up 20% To $19m, Profit $1.8m; Redhill To Market Parapro’s Esomeprazole (Nexium); PBAC Backs Funding Pharmaxis Bronchitol With Pulmozyme; Cann Pleads Schultz To ASX 15.5% Query; RHS Appoints Alwin Hui Chief Commercial Officer
 
Aug 17, 2017
4-Year Data Backs Prota, MCRI Peanut Immunotherapy; Cochlear Revenue Up 7% To $1,240m, Profit Up 18% To $224m; Allegra To Develop Kangaroo For Tendon, Ligament Repair; Micro-X Takes Over Xinray’s Carbon X-Ray Tube Production; Anatara Requests ‘Zoetis Licence’ Trading Halt; Botanix Requests ‘Acne Trial Ethics Approval’ Trading Halt
 
Aug 16, 2017
CSL Record Revenue Up 13% To $9b, Profit Up 8% To $1.2b; Prima Earns $1.3m French R&D Rebate; Cancer Genetics Buys Vivopharm For $15m Cash, Scrip; EPAT Journal Article Backs Application For Pain Recognition; Optiscan Aims At China, $1m North American Revenue; US Extends Proteomics Patent To All Kidney Disease; Actinogen Enrols 1st UK Patient In Xanamem Alzheimer’s Trial; Bionomics Revenue Up 30% To $28m, Loss Down 56% To $7m; Trent Barry, Traoj Take 7.7% Of Sienna; Oventus CEO Neil Anderson Family Increase, Diluted To 6%; Jarrod White Replaces Hydroponics Co Sec Henry Kinstlinger
 
Aug 15, 2017
More Data Backs Opthea OPT-302 With Lucentis For Wet AMD; Westmead Okays Clarity Sartate For Neuroblastoma Trial; Imagion Hires Starfish To Develop Magsense Imaging; Actinogen Loses Founding Director Dr Anton Uvarov
 
Aug 14, 2017
US FDA Clears Impedimed Sozo For Lymphoedema; Novogen: Review Savings, R&D Focus, Nasdaq Compliance; Epat Pleads Schultz, Olds To ASX 44% Query; Medibio 14m Performance Rights, Options; 50% Fees Hike AGM; Race To Issue 2m Placement Options; CM Capital (Talu) Diluted To 10.4% Of Osprey; GI Dynamics: Dr Gerald Holtmann, Dr Thomas Rösch Advisors
 
Aug 11, 2017
Dr Boreham’s Crucible: Phosphagenics; Pharmaxis Revenue Down 5% To $18m, Loss Up 11% To $18m; Oneventures, Jim Scopa Emerging Companies Investment Tour; Adherium Releases 35.5m Escrow Shares
 
Aug 10, 2017
Phosphagenics Sells Bioelixia For $200k, Royalty; ICU Medical To Buy Medical Australia For $12m; Airxpanders H1 Revenue Up 341% To $1m, Loss Up 73% To $19m; Life Sciences Queensland Appoints Prof Peter Andrews Chair
 
Aug 9, 2017
Resapp Falls 82% On Respiratory Diagnosis Fail; Paradigm Doses 1st Patient In PPS Ross River Virus Trial; Immuron Ready For IMM-529 Clostridium Difficile Israel Trial; Starpharma, MIPS $300k Federal Dendrimer Grant; Uscom Develops Diagnostic Wireless Options; Simavita Developing Alertplus Incontinence Warning System; Auscann Medical Marijuana Manufacture, Supply Licence; Creso: Dr Stu Fillman Medical Manager, Canada CEO Wanted; Lagoda, Fatima Dickey, Richard Bayles Take 11% Of Clinuvel; Investors Mutual Takes 7% Of Mayne Pharma
 
Aug 8, 2017
Westmead Trials CAR-T-Cells For Leukaemia, Lymphoma; Mayne Expects Revenue, Profit Up; CEO Scott Richards To US; Atcor Raises $825k; Benitec Combines Gene Silencing, Replacement For OPMD; LBT, Central Adelaide Trial Woundvue For Foot Ulcers; Impedimed Enrols 1st Sozo Heart Failure Patient; Bard1 Original Study Shows Lung Cancer Test 86% Accurate; Unisuper Takes 5% Of Viralytics, Again; Prolog Reduces To 6.7% Of Airxpanders; Michael Sorensen, VIG Take 18% Of Bioxyne
 
Aug 7, 2017
Starpharma: ‘Vivagel Beats Placebo For BV Recurrence’; Correction: Airxpanders; Airxpanders Up To $25m Oxford Finance Loan, $567k Options; Adalta Receives $1.8m Federal R&D Tax Incentive; Universal Bio H1 Revenue Up 37% To $14m, Loss To $2.5m Profit; Australian Patent For Bard1 Lung, Colorectal Tests; Creso, Virbac Marijuana Deal For Cats, Dogs; Auscann Requests ‘Update’ Trading Halt; Universal Biosensors CEO Rick Legleiter Starts On $450k - Founding Directors Andrew Denver, Denis Hanley Go
 
Aug 4, 2017
Dr Boreham’s Crucible: Airxpanders; Osprey Raises $22m, 1-For-10 Rights Offer For $10m More; Boston Scientific Passes On Reva Distribution Rights; Bard 1 Share Plan Raises $416k Of Hoped-For $1m, Total $1.5m; ACCC Reviews Cryosite Asset Sale, Licence With Cell Care; Atcor Requests Capital Raising Trading Halt
 
Aug 3, 2017
Sienna Falls 30% On $5m Telomerase Cancer Test IPO; CSL Takes $444m, 80% Stake In China’s Wuhan Ruide For Plasma; Neiman Marcus To Sell Cellmid Evolis Hair Growth Products; Unilife Extinguished; Paradigm To Release 34m Escrow Shares; Consonance Takes 5% Of Sirtex; Immuron Loses CEO Thomas Liquard, Dr Jerry Kanellos Interim; Brain Appoints Matthew Mund COO, Marcel Legrand Revenue
 
Aug 2, 2017
EQT Buys Certara For $1b; Asia-Pacific, Melbourne Expansion; Resmed Revenue Up 12% To $2.6b, Profit Down 3% To $430m; Medibio Mach-3 Cardiac Rhythm Depression Test ‘82% Accurate’; Safety Board Backs Redhill Phase III RHB-104 Crohn’s Trial; Medical Developments, Walmart Sam’s Club Spacer Deal; Resapp Takes ‘Trial Update’ Halt To Suspension; Osprey Requests Capital Raising Trading Halt; Quest Takes 6.4% Of Viralytics; Cormorant Reduces To 6.2% In Viralytics, Takes $1.7m Profit; Atcor Duncan Ross To Sales, Founder Michael O’Rourke Goes; Bioscience Managers Appoints Elizabeth Klein For UK
 
Aug 1, 2017
July BDI-40 Down 4%, ASX200 Flat, Big Caps Down 8% - Acrux Up 39%; Compumedics Down 29%; Burnet Wins $16k Discovery Award For $13m Longitude Prize; Genetic Technologies Brevagenplus Awareness Discount; Cellmid Renews China Cosmetic Hair Growth Import Permits; Naos Takes 9.3% Of Biotech Capital; Dimerix Chair Dr James William Non-Executive, 37m CEO Options; Glenn McInally Replaces Anteo CFO Peter Harding-Smith
 
Jul 31, 2017
Haemalogix Buys Rights To Multiple Myeloma Agent; Sienna IPO Raises $4.6m To List On Thursday; William Roberts, Maurice Blackburn Sirtex Class Actions; Clinuvel Sales Up 391% To $18m; Rhinomed Sales Up 140% To $2m; China Evaluates Ellex Itrack For Glaucoma; Suda Wins ISO 9001:2015 For Quality Management; Nuheara Has One Quarter Cash, $9m Placement; Resapp Requests ‘Trial Update’ Trading Halt; Atcor Signs 2-Year New York University Sphygmocor Deal; Oncosil CE Mark Trial ‘Much Slower Than Planned’; Recce: ‘IV Drip Preferred Recce 327 Antibiotic Route’; Zelda, Complutense Cannabinoid Breast Cancer Research; Cochlear 2-Year CEO Chris Smith Goes, Dig Howitt Starts On $1.6m; Alcidion Appoints Geoff Rohrsheim, Rebecca Wilson Directors
 
Jul 28, 2017
Dr Boreham’s Crucible: Proteomics; Ellex Profit Warning; Clarification: Memphasys; Simavita Has One Quarter Cash; Finance Available; Biotech Daily Appendix 4C Quarterly Reports Policy
 
Jul 27, 2017
WEHI $405m+ Canada Deal For Venetoclax For Cancer; G Medical $84m Smartphone Vital Signs China Deal; FDA Clears Cogstate Cognigram; Biotron Phase II BIT225 Combination HIV Trial Recruited; Antisense Responds To FDA ATL1102 For MS ‘Modifications’; Memphasys Settles With Pulau Manukan, Labuan, Prime; Creso To Buy Mernova Marijuana Facility For $10m; IQ3 Revenue Up 191.5% To $5m; Cormorant Increases, Diluted In Viralytics, $2.6m Profit
 
Jul 26, 2017
Acrux Lilly Axiron Sales Fall 10% To $180m, Q4 Up 19%; Admedus Sales Revenue Up 56% To $22m, Financial Year Change; Regeneus Progenza Licence Takes Revenue To $10m; GI Dynamics Hires Proven Process Endobarrier Manufacturer; Cogstate Requests ‘Cognigram FDA Submission’ Trading Halt; Creso Pharma Requests ‘Canada Acquisition’ Halt; Blackrock Takes 7% Of Cochlear; JCP Increases To 8.4% Of Nanosonics; FIL Takes 8% Of Factor Therapeutics; Bluechiip Appoints Andrew Cox Director
 
Jul 25, 2017
STC Takes $160k Victoria Medtech’s Got Talent National; ITL Unnamed US Blood Bank Samplok Contract Extended; Uscom Sales Up 20% To $3.5m; Epat Pays Nviso $393k, 31m Shares For Pain Test Software; Memphasys Requests Litigation Trading Halt; Esense To Develop Cannabis With Oregon’s Wild Rogue; Correction: Epat; G Medical Requests China Call Centre, Distribution Halt; Director Michael Stork Diluted To 12% In Patrys; Ellex CEO Tom Spurling To US, Dr Meera Verma To Executive; Oncosil Loses Co Sec Peter Casey, CFO Tom Milicevic Co Sec; Kevin Hart Replaces Phylogica Co Sec Graeme Boden
 
Jul 24, 2017
Victoria Marks 4,000th, 1,000th Child Cochlear Ear Implant; TBG HLA Diagnostic Wins CE Mark Taiwan Approval; Adalta, La Trobe Uni $427k Federal Fellowship; Epat Responds To Pain Software ASX Aware Query; Bionomics Included In US OTCQX Index; Phylogica Pleads Schultz To ASX 29% Query; Novita Completes Newly Acquisition; Biotech Capital Name Change To BTC Health
 
Jul 21, 2017
Dr Boreham’s Crucible: Compumedics; Boston Trial Backs Ellex Reflex For Eye Floaters; Innate MIS416 Analysis No Help, New Indication Or Technology; Canada Patent For Imugene HER-Vaxx Cancer Vaccine; Lanstead Takes 8% Of Neuren; Race CEO Peter Molloy, Chair Dr Bill Garner Increase, Diluted; Nasdaq 2nd Genetic Technologies Non-Compliance Letter; Medibio Unmarketable Parcel Facility
 
Jul 20, 2017
Nuheara Raises $9m; Optiscan Ships Evaluation Microscopes To Carl Zeiss; Neuren FDA Meeting For Trofinetide Phase III Rett Plans; Invitrocue, Singapore Genome Institute Joint Cancer Lab; Recce Producing 1 Litre A Day Of Recce 327 Antibiotic; Race: Review Of Bisantrene Published; LBT: Bob Finder Goes, Kate Costello Chair, Glenn Haifer NED; Bard1 Appoints Prof Samuel Janes Advisor
 
Jul 19, 2017
Uniquest, Preveceutical Diabetes, Obesity Gene Therapy; FDA Clears Dorsavi Vimove2 For Lower Back Activity; CE Mark, TGA Approval For Epat Pain Recognition Diagnostic; Rhinomed Receives Walgreens US Mute Orders; Cann, 19.9% Owner Aurora Agree Marijuana Info Exchange; Laurence Grimes Cox, LGC Take 5% Of Bluechiip; Medibio Appoints Dr Adam Darkins Director, Deputy Chairman
 
Jul 18, 2017
Prana, Takeda Work On PBT434 For Gut Neuro-Degeneration; Redhill Completes Bekinda RHB-102 Irritable Bowel Trial; Adalta AD-114 Safety Trials Completed, Material Delay; Prima Discloses Novartis $1.3m Milestone; Pharmaxis Grants CEO Gary Phillips 770k ‘Performance’ Rights; Nuheara Requests Capital Raising Trading Halt; Capital Group Takes 6% Of Viralytics; Jim Craig, Bellwether Take 6% Of Bluechiip; ITL: ‘National Diabetes Week Raised Myhealthtest Awareness’
 
Jul 17, 2017
Novartis Pays Prima ‘Undisclosed Significant’ Milestone; Race Raises $2.5m; Universal Bio: Siemens Revenue Up; J&J Down, Despite Sales Up; Pharmaust’s Epichem $3m Revenue, Accreditation, Expansion; Hamacher Adds Rhinomed Mute To Pharmacy Layout Plan; Impedimed Files US Sozo Application For Lymphoedema; Proctor & Gamble Launches OBJ SK-II Magnetic Booster; Uscom Appoints Pacific Medical BP+ Se Asia Distributor; Optiscan Appoints Dr Philip Currie Director
 
Jul 14, 2017
Dr Boreham’s Crucible: Universal Biosensors; Proteomics, Biosanapharma Test Asthma Bio-Similar; IDT Loses Dr Paul Macleman, Gone A-Droving Down The Bass; Reva Board, Executive Changes; 10 Staff Go
 
Jul 13, 2017
Cochlear To Build $50m China Manufacturing Plant; Victoria Government: ‘State Biotech Generates $13b A Year’; Brazil’s Pró-Sangue Buys ITL’s Samplok System; TGA Approves Uscom Spirosonic Lung Function Monitors; Biotron Has Two Quarters Cash; Anteo, Diasource Revise Merger Price, Again; Medlab, Heritage Collaborate On Food Additives; Race Requests ‘Capital Raising’ Trading Halt; Prudential (M&G) Reduces To 12% Of Mesoblast 
 
Jul 12, 2017
Dimerix: ‘DMX-200 Safety, Meaningful Kidney Disease Efficacy’; Bard1 Places $1.1m, Plan For $1m More; US Patent For Patrys 3E10 Cancer Treatment; Atcor Signs 3 Trial Contracts Worth $800k; US FDA Approves Oventus O2vent W; Novita Raising $3.5m, To Buy Newly For $1m Scrip; Target To Sell Nuheara Iqbuds; Crystal Amber Takes 46% Of GI Dynamics
 
Jul 11, 2017
Psivida Licences Durasert For Posterior Uveitis To Alimera; Cogstate Expects Revenue Up 27% To $35m, $1m Loss; Eurostars Grants Uscom Further $330k For Spacer Project; Sydney Uni Diabetes Program Adopts ITL Myhealthtest; Brookestone To Sell Nuheara Iqbuds In All US Shops; Marijuana Licence For Auscann Partner Tasmanian Alkaloids; Hydroponics Cannabis Licence; Mesoblast: 6m Osiris Crohn’s Shares; 7m Executive Options; Dimerix Requests ‘DMX-200 Kidney Trial Results’ Trading Halt; Innate Pleads Schultz To ASX 42% Query; Macquarie Group Below 5% Of Impedimed
 
Jul 10, 2017
Correction: CSL; Paradigm Begins Phase II PPS For Ross River Virus Trial; Bioverativ: ‘CSL Idelvion For Haemophilia Infringes Patents’; Prima Phase I Trial Of IMP321 Routes For Solid Tumors; Novita Requests ‘Book-Build, Acquisition’ Trading Halt; Immuron Claims IMM-124E Safe For Nash, Efficacy Uncertain; Race Joint Venture With Targimmune For Cancer; Neurotech Ships Mente Autism Devices To Turkey; US Patent For Regeneus Sygenus Stem Cells For Acne; RHS PG-Seq For Embryo Screening; Illimuna Benefit; Mach7 CEO Michael Jackman To Start On $460k, $39k Bonus
 
Jul 7, 2017
Dr Boreham’s Crucible: CSL; LBT Share Plan Raises $500k Of Hoped-For $3m; Ellex Blames Foreign Exchange For 1.6% Revenue Fall; Compumedics ‘Restructure’ 12% Revenue Warning; Admedus Takes Cardiocel 3D To US Expanded Access Program; Race Requests ‘Joint Venture’ Trading Halt; Hydroponics ‘Cannabis Licence’ Trading Halt; Advisor Dr Stephen Addis Below 5% In Medibio
 
Jul 6, 2017
Six Australians Win $855k Howard Hughes Scholarships; Prima Raises $6.6m On Nasdaq; Bluechiip Raises $3.4m; USPTO Allows Opthea OPT-302 Trap Molecule Patent; Acrux: Perrigo, Eli Lilly Generic Axiron; Royalties; Taiwan Approves Rhinomed Mute, Turbine; Volpara Pleads Schultz To ASX 35% Query; Allan Gray Increases, Diluted To 13% In Factor Therapeutics; FIL Takes 6.3% Of Factor Therapeutics; Barings Acceptance Takes 17% Of Cyclopharm; Chemical Trustee Reduces, Diluted To 13% Of Cyclopharm; OBJ Appoints Becca’s Steven Schapera Director 
 
Jul 5, 2017
Teva To Pay Suda $2.7m For Zolpimist Insomnia Spray; Cynata: FDA CYP-001 GvHD Pre-IND Meeting ‘Very Positive’; Bard1 Raises $1.1m, Plan For $1m More; Slater And Gordon $25k Medical Research Grants; Rhinomed Unmarketable Parcels Facility; CVC, Stinoc Take 13.8% In Cyclopharm; TDM Takes 14% Of Somnomed
 
 
Jul 3, 2017
10-Year BDI-40 Up 80%, ASX200 Down 9%, Big Caps Up 270% - Sirtex Up 336%; Mesoblast 311%, Starpharma 302%; Pharmaxis Down 87%, Acrux 86%; YTD: BDIi-40 Up 3%, ASX200 9%, Big Caps 23%, NBI 21%; June BDI-40 Up 3%, ASX200 Flat, Big Caps Up 7%, NBI 9%; Osprey Launches Dyetect For Non-Kidney-Failure Patients; Invitrocue Raises $685k For Garvan Cancer Drug Testing; Prana Prepares For Phase I PBT434 For Parkinson’s; Botanix ‘Topical Cannabidiol BTX1503 Safe For Acne Trial’; Cellmid: ‘Midkine Crucial For Melanoma Metastasis’ In Mice; Bard1 Requests ‘Capital Raising’ Trading Halt; Novita Readies Tali Train For Attention Deficit Trial; Pengana (Hunter Hall) Reduces To 12% In Avita; Thorney Takes 15.5% Of Oventus; Psivida Appoints Kristine Peterson Director
 
Jun 30, 2017
Dr Boreham’s Crucible: Starpharma; Prima To Raise $6.5m In US; Up To 22% Oppose Psivida Doubling Shares On Issue To 120m; MGC’s Brett Mitchell, Rachel Kerr Exercise Options; Botanix Requests ‘Trial Results’ Trading Halt; Innate Directors Dump Shares On Drug Fail; Macquarie Group Takes 5.5% Of Impedimed; Resapp To Release 101m Escrow Shares; Prescient Executive Director Paul Hopper To Non-Executive
 
Jun 29, 2017
Neuren Raises $11.5m For Phase III Rett Preparations; Impedimed 1st Sozo Sales; Clarity Raises $4m For ‘Theranostics’; Dorsavi Vimove Measures Movement In Pfizer-Backed Study; Invitrocue To Raise $685k; Clarification: ITL, Myhealthtest; Correction: CSIRO, Data61; MMJ: Marijuana Licence Renewed, Applies For Sales; Esense, 374 Collaborate On Cannabis Terpenes; Memphasys Awaits New Spermsep, Renamed Felix; Prime Changes; Crystal Amber Takes 45% Of GI Dynamics; Robert Lederer Takes 5% Of Anatara; Resonance Loses Dr Jason Loveridge To Germany’s 4SC
 
Jun 28, 2017
Minister Craig Laundy Launches CSIRO Data61: ‘Shift Happens’; Ondek Raises $3.6m; Victoria-Jiangsu Fund $400k For Burnet Lab, China’s Boint; Sirtex Cuts 15% Staff, Loses CMO Dr David Cade, Restructure; Cyclopharm Raises $7m; Reva: 1st Fantom Commercial Sale; ITL, Myhealthtest Win $2.6m CRC Grant; Optiscan Appoints Scintica North America Distributor; Best Buys Extends Nuheara Iqbuds Distribution; Neuren Pleads Schultz To ASX 38% Query; Paradigm M-D Paul Rennie, Kzee, Ear, Take 22%
 
Jun 27, 2017
Innate Tumbles 93% On MIS416 Fail For Multiple Sclerosis; WEHI: Inhibit MK2 To Improve Smac Mimetics For Cancer; Gordagen, Dr Ric Degaris Legal Dispute; Winding Up Claim; Pharmaust Hires BRI To Fix Monepantel (PPL-1) Taste; Neuren Requests Capital Raising Trading Halt; Anteo Pleads Schultz, Funding To ASX 32% Fall Query; Creso EGM For 6m Directors ‘Performance’ Shares; Michael Sorensen, VIG Increase, Diluted To 17% Of Bioxyne; Bio-Melbourne ‘US Regulatory Landscape’ Briefing
 
Jun 26, 2017
Australian Ethical Backs Antisense ATL1102 Trial For DMD; Psivida Applies For EU Durasert Uveitis Approval; Viralytics: ‘Raised Trail Backs Cavatak For Bladder Cancer’; Flinders Uni, SAHMRI Research Glucose, GLP-1, Diabetes; Mach7 Signs $1.8m Radiology Associates Contract; FDA Approves Micro-X Nano-X-Ray; Medibio: Research Supports Heart Rate For PTSD Diagnoses; Neurotech Renews Ese Pazarlama Mente Autism Contract; JM Financial Takes 7% Of Mach7; Phylogica CEO Stephanie Unwin $500k, CSO Dr Hayes $550k
 
Jun 23, 2017
Dr Boreham’s Crucible: Adalta; FDA Approves CSL Haegarda For Hereditary Angioedema; LBT Completes APAS CE Mark Self-Certification; Biotron ‘Oversubscribed’ Rights Offer Raises $1.6m; Cryosite Sells Cord Blood Business For Trials, Storage Focus; Innate Requests MS Trial Results Trading Halt; Nuheara Appoints Maxiim, Dixons For UK Iqbuds
 
Jun 22, 2017
Resapp Australian Trial Delivers 70-97% Accuracy; Imagion Falls 20% On $12m Nano-Magnetic Cancer Test IPO; Oventus Raises $6.5m; Expects $2.5m More; Resonance Bone Marrow R2-MRI In EU, Australia, NZ; Recce Builds Automated Antibiotic Production Facility; Actinogen Enrols US Patients In Xanamem Alzheimer’s Trial; FIL Takes 9% Of Resapp; Crystal Amber Takes 44% Of GI Dynamics; Bank Of New York Mellon Takes 5% Of Cochlear, Again
 
Jun 21, 2017
St Vincent’s Trials LBT APAS Independence; CE Mark For Impedimed’s Sozo; Thalassaemia Federation Backs Resonance Liver Iron Test; AGC Pays Regeneus $1.3m Progenza Milestone; Bluechiip Ships First Validation Stock To Labcon; US Patent; Cynata Files Stem Cells For Cancer Australian Patent; FDA Clears Innate MS416 Trial IND Application; Goldman Sachs Invests $5m In Reva Notes; Immuron Anastasiou, Pattison, Biddicks Diluted In Nasdaq IPO
 
Jun 20, 2017
Compumedics Signs $5m Barrow Meg Neuro-Imaging Contract; G Medical Receives $7m For China Mobile Health JV; All Change At Phylogica; $5m Raised; Genetic Signatures Australia, Euro Test Approval; US Patent; Avita China Study: ‘Recell Improves Donor Site Healing 31%’; Oventus Signs Modern Dental For Sales; Funds Trading Halt; Paradigm To Try PPS For Heart Failure; Suda To Buy Anagrelide From Aluztra For Cancer; BVF, Mark Lampert Take 10% Of Bionomics; Hunter Hall, Pengana Below 5% In Mach7; GI Dynamics: Dr Francesco Rubino, Dr Philip Schauer Advisors; Osprey Appoints Medtronic’s Sandra Lesenfants Director
 
Jun 19, 2017
Medlab Ready For 2 Medical Marijuana Trials; Reva Completes $45m Raising; US Patent For Cynata Stem Cells; Resapp: ‘Smartcough-C Trial Recruited, Results In July’; MGC: Mikro+Polo For Slovenia, Croatia, Bosnia Cannabis Sales; Prescient PTX-100 Targets New Cancer Pathway In Mice; Neurotech Signs Attieh For Saudi Arabia Mente Autism Sales; Esense Signs Beyond Brands For Terpene Marketing, Sales; Ron Shamgar, The Boat Fund Below 5% Of ITL; Noxopharm NOX66 ‘1,000 x More Effective’ For Brain Cancer
 
Jun 16, 2017
Dr Boreham’s Crucible: Genetic Technologies; Nanosonics Signs Sakura Seiki For Japan Trophon EPR Sales; Paradigm: ‘Formulation Failed PPS For Hay Fever’, Falls 51%; Redhill RHB-102 Phase III Gastro Win, Starts 2nd Phase III RHB-105; Gordagen Option On Monash Uni Drug Delivery System; GI Dynamics $6.6m Crystal Amber Note; $13m More Later; Recce Takes $6m Lind Equity Draw-Down Facility; Antisense: ATL1102 Reduces Ms ‘Black Holes’; JCP Increases To 7.3% Of Nanosonics; Clarification: Novogen; Sirtex Promotes New CEO Andrew McLean To Director
 
Jun 15, 2017
US Approves Mayne Doxycycline Hyclate; Canada Accepts Medical Developments Penthrox File, $250k; Biotron Okay To Double BIT225 Dose In HIV Trial; Atomo Raises $1.4m; Proteomics Tells ASX: ‘Results Withheld For Conference’; Zelda, Knop Partner For Medical Marijuana Manufacture; Auscann Gives M-D Elaine Darby 55% Pay Rise To $310k; Paradigm Requests ‘Rhinitis Trial Status’ Trading Halt; Michael Powell, Jolimont Take 7% Of Simavita; Robert Hutchison, Mary-Ann Mckenzie Take 6% Of Simavita; Cryosite Appoints CFO Mark Byrne Interim CEO; Auscann: Dr Danial Schecter CMA, David Pryce Alt-Director; Bio-Melbourne Breakfasts On China
 
Jun 14, 2017
Starpharma Sells Agricultural Business To Agrium For $35m; Auscann Welcomes Greens Marijuana Ban Disallowance; Psivida 2nd Phase III Trial Backs Durasert For Posterior Uveitis; Dorsavi Signs Kieser For Vimove2 For Back Pain; Redhill To Promote Donnatal, Enteragam In The US; Resonance A.I. For Low-Cost Liver Iron Test; WEHI, Peter Mac Lung Cancer Biomarker Directs Treatment; Impedimed: Macquarie Starts Sozo Lymphoedema Trial; ITL Expects Revenue Up 12.5% To $35m; CCS Appoints Parent LBT As APAS Distributor; Michael Abolakian, Hishenk Take 5% Of Novogen; Bioxyne CEO Nam Hoat Chua Takes 15%; Naos Takes 8% Of Biotech Capital; Lisa Dea Replaces MMJ CFO Kwong Choo
 
Jun 13, 2017
WEHI, Peter Mac Combo For BRCA1 Breast Cancer In Mice; Pharmaxis Hits US Bronchitol CF Endpoint, Misses Others; CSL Takes $466m, 80% Stake In China’s Wuhan Ruide For Plasma; Proteomics Validation Study: ‘Promarkerd 86% Accurate’; Garvan’s Genome One Joins Sanford For Personalized Medicine; GI Dynamics Endobarrier: ‘Weight, HbA1C Down 6 Months Later’; Patrys Licences Yale Nanoparticle, 3E10 Link; Esense, Healthy Chocolate Florida Terpenes For Food; BVF Partners, Mark Lampert Sell 12.5m Viralytics Shares To 8%; IDT Loses Founder Dr Graeme Blackman, Advisor Role; Bioxyne Appoints Nam Hoat Chua CEO, Max Parkin Director; Medadvisor Appoints Dr David Chatterton CTO
 
Jun 9, 2017
Dr Boreham’s Crucible: Ellex Medical Lasers; Immuron Cuts US IPO To $8m, Price; Correction: Botanix; GI Dynamics Corrects Dr Stuge In-The-Money Options Vote; Airxpanders Aeroform Breast System At 100+ US Sites; Benitec Receives $636k Extra Federal R&D Tax Incentive; Allan Gray Takes 5% Of Sirtex; Proteomics Requests ‘Promarkerd Study’ Trading Halt; Creso To Release 1.4m Escrow Shares; CEO Dr Regina Groves Replaces Reva Director Anne Keating; David St Denis Replaces Admedus COO Dr Julian Chick; Arik Anderson Replaces Adherium CEO Garth Sutherland; Biotron Appoints Lynx China Adviser
 
Jun 8, 2017
Sienna $6m IPO For Cancer Diagnostics; Melbourne Uni Opens Graeme Clark Institute; MTP Connect, QUT Launch Bridge Program; Botanix BTX1701 Acne Pilot Study ‘Safe, Removes Oiliness’; Medibio: ‘Study Backs Heart Rate Algorithm Depression Test’; Non-Cancer Euro Patent For Pharmaust Monepantel; Immuron Requests ‘Capital Transaction’ Trading Halt; BVF, Mark Lampert Take 9% Of Bionomics; Novogen Loses Chair John O’Connor, Ian Phillips; Cuts Costs
 
Jun 7, 2017
Anaesthesia: RCT Data Fabrication, Non-Random Sampling; Biotech Daily Editorial: Trial Transparency; Imagion $12m IPO For Nano-Magnetic Cancer Test; Atcor Signs Nephrology Associates For Sphygmocor; Oventus: ‘Pilot Trial Mouth Guard Equals CPAP’; Links, Lotsa, Laurence Freedman Below 5% In Bionomics; Pharmaxis Appoints Dr Kathleen Metters Director
 
Jun 6, 2017
MRCF, Uniseed $21m For QUE For Hot Flushes, Dr Rob Crombie CEO; China Extends Ellex Itrack Glaucoma Treatment; Starpharma Dep-Irinotecan Beats Irinotecan In Mice; GI Dynamics: ‘Endobarrier Re-Use Safety, Efficacy’; Japan Patent For Pharmaust Monepantel; Living Cell: ‘Parkinson’s Patients Improving At 130 Weeks’; Anatara Receives $840k Federal R&D Tax Incentive; Medibio Trades On US OTC Market
 
Jun 5, 2017
Monash, Janssen Collaborate On Rheumatoid Arthritis; Melbourne Uni: ‘Stop ’Flu Before Reaching Lungs’; Prima: ‘IMP321 Immune Response For Breast Cancer’; Cyclopharm Underwritten $7m Rights Offer; RHS Raises $1.5m; Sirtex: ‘Sirvenib Shows SIR-Sphere Promise For Asian Patients’; Neurotech Mente Autism Listed On ARTG; Medical Developments, CSIRO Work On Drug Manufacture; Noxopharm Moves To Phase Ib NOX66, Carboplatin Cancer Trial; MGC Partner Ljubljana Uni Wins Cannabis Licence; Benitec Files $27m US Shelf Registration; Airxpanders Releases 35.5m Escrow CDIs, 9m Options; Medibio Appoints Olympian Michael Phelps Director; LBT Appoints Matthew Michalewicz Director; Prana Appoints Dr David Stamler CMO For Huntington’s; Burnet Nanjing Biopoint Liver Test Wins China Gong
 
Jun 2, 2017
Dr Boreham’s Crucible: Analytica; MRCF $6m For Oncores Breast Cancer Surgery Imaging; Starpharma Receives $2.6m Astrazeneca Milestone; P&G Pays OBJ 1st Sales Royalty, Licence $296k; NZ Ambulance Backs Medical Developments Penthrox; Polynovo’s Prof John Greenwood Burn Care Lecture; Mach7 Sells 3D, Breakeven 2018, CEO Search, Mike Lampron COO; Immuron Sponsors Spain Meeting, Travelan Revenue Up; Zelda: ‘In-Vitro Studies Back Marijuana For Cancer’; Reproductive Health Takes Funding Halt To Suspension; Bioxyne Unmarketable Parcel Facility; Director Dr Michael Perry Replaces Avita CEO Adam Kelliher; Correction: Perron Institute (WANRI); GI Dynamics Loses 13-Year Director Mike Carusi; Sue MacLeman Wins Bio-Melbourne Women Leadership Award
 
Jun 1, 2017
May BDI-40 Down 13.5%, ASX200 Down 3%, Big Caps Down 1% - Psivida Up 30%, Cyclopharm 22%; Mesoblast Down 33%, Atcor 31%; Victoria: Cann Marijuana Permit Launches New Industry; Bluechiip 1-For-3 Rights Offer For $2.5m; Applications Open For $2.5m CSL Centenary Fellowships; Cyclopharm: China Trial Results Back US, Newcastle Trials; UK Joins Actinogen Xanamem For Alzheimer’s Trial; Immuron: Nasdaq Hold For Results, $1.5m Grandbridge Loan; Uscom Partners For Barcelona Lung Health Care Project; Creso, Cannapharm Marijuana For Asia Pacific, Latin America; Reva AGM Votes 22% Against Chairman Brian Dovey; Nasdaq Issues Novogen 3rd $US1 Compliance Warning; MGC Requests ‘European Operations’ Trading Halt; Prima Appoints IMP321 Advisory Board; Perron Institute (WANRI) Appoints Prof Alan Robson Chair
 
May 31, 2017
Protagonist, J&J $1.3b PTG-200 Crohn’s Disease Deal; Medadvisor Signs Sigma’s Discount Drug Stores; CSIRO Software For Early Cancer Detection; Kenya Approves Atomo HIV Self-Test; Phosphagenics Loses 3rd Director Dr Cauwenbergh Pre-AGM; Phosphagenics 28% 1st Strike AGM; US, EU Patents For Neuren Trofinetide For Autism Disorders; Nuheara, Widex Deal For Bloom Hearing Iqbuds Sales; Reproductive Health Requests Capital Raising Trading Halt; Cameron Jones Replaces Adalta Co Sec Ian Hobson 
 
May 30, 2017
IP Group $200m For Australia, NZ Commercialization; Orthocell: ‘Ortho-ACI 1st Cartilage Cell Therapy On ARTG’; Ellex To Pay $3m For Itrack Royalties; Cann Expects August Marijuana Harvest; Resapp: ‘Trial Results In July’; Nuheara Ships $1.8m Iqbuds; Oventus Signs Hong Kong Modern Dental Manufacturing; Respiri Claims Draft China Partnership Deal; Acorn Takes 8.6% Of Factor Therapeutics; Immuron Requests ‘Nasdaq Listing’ Trading Halt’
 
May 29, 2017
Death Halts Prescient PTX-200 Trials; Sirtex Injunction Dismissed, $30m Buy-Back Starts June 7; Oneventures $10m For MCRI, Prota Peanut Allergy Work; Phosphagenics Files Up-To $404m Claim Against Mylan; Bioxyne Rights Issue Raises $2.5m, Total $3.07m; Volpara Contracts Up, Current Revenue Down 22% To $2m; Medadvisor Partners With Ihealth For Mobile Products; Noxopharm NOX66, Lupsma Radiotherapy For Prostate Cancer; Michael Powell, Jolimont Take 5.5% Of Simavita; Sarah Prince Replaces Simavita Joint Co Sec Nathan Bartrop
 
May 26, 2017
Dr Boreham’s Crucible: Cochlear; Reproductive Health Science AGM Changes Name To RHS; Washington H Soul Pattinson, Hunter Hall Down To 13% Of Avita; Jason Peterson, Celtic Diluted Below 5% Of Auscann
 
May 25, 2017
Monash Research Leads To ACS Warning On Assay Hit Pains; Melbourne Uni: ‘Cannabidiol Works For Paediatric Epilepsy’; Hydroponics, Phoenix Alliance To Import Cannabis Products; Biotron 1-For-4 Rights Offer To Raise $1.6m; Simavita Rights Raise $848k Of Hoped-For $1.4m; Total $2.35m; Neurotech Ships 1st Mente Autism To Greece; Suda UK Meeting On Zolpimist For Insomnia; Investors Mutual Takes 6% Of Mayne Pharma
 
May 24, 2017
Sirtex CEO Andrew Mclean Starts On $825k, $500k ‘Transition Fee’; GI Dynamics Meta-Analysis: Weight Loss, HbA1c Down; Japan Patent For Regeneus Progenza Stem Cells; Noxopharm NOX66 Rare Cancers Compassionate Use, Trial; Aqsitania Uses Uscom Tspiro For Lung Transplant Monitoring; Steve Lydeamore To Replace Bionomics CFO Melanie Young; Brain Appoints Emil Vasilev Finance, Operations Director
 
May 23, 2017
Minderoo $75m For Eliminate Cancer Initiative; MRCF, Uniseed $6.3m For Innavac; LBT Share Plan For $3m; Up To 80% Of GI Dynamics Oppose Directors Options; Airxpanders 32% Oppose Board Options, 10% Placement Fails; Avita Directors ‘Confident In Recell’, Shares In Lieu Of Pay; Hydroponics ‘Strategic Alliance’ Trading Halt; Quest Reduces To 5% Of Viralytics; Analytica Appoints 13% Dr Peter Corr Director, 10m Options; Gordagen Appoints Craig Newton COO; Brain Resource Appoints Louis Gagnon CEO
 
May 22, 2017
Regeneus Claims Knee Osteoarthritis Safety, Efficacy; Paradigm Ready For Phase II PPS Ross River Virus Trial; Hydroponics $8m IPO, 12th For Medical Marijuana, Equipment; Victoria $450k For Health Accelerator, Applications Open; Invitrocue, Mundipharma Take Assays To Skin, Wound Healing; G Medical China Mobile Health Joint Venture; Neurotech Signs VDT For Mente Autism Germany, Switzerland; BNP, Unisuper, Quest Below 5% In Viralytics; Factor Therapeutics CEO Dr Rosalind Wilson Starts On $275k; Federal Government Entrepreneurs’ Seminar
 
May 19, 2017
Dr Boreham’s Crucible: Medical Developments; Auscann Raises $12m For Medical Marijuana; Memphasys, Hydrix Develop Sperm Harvest Cartridges; Botanix Completes $7.4m Placement; TBD China HLA Plant Wins Accreditation; Pharmaust PPL-1 Reduces Lymphoma Tumors 11% In 3 Dogs; Recce Pre-Clinical Data Backs Recce 327 Antibiotic; Nuheara EGM To Vote On 20m Fosters, Hunter Shares; Rod Gibson Companies Take 14% Of Reproductive Health; Cryosite Loses CEO Andrew Shine, Job Open
 
May 18, 2017
Sirtex 1103-Patient Meta Analysis Yields Mixed Results; Biotech Daily Comment; Victoria Partners With Shanghai Institute Of Medical Quality; Osprey: Correction; Pro Medicus Launches Visage 7 Open Archive In North America; EU Suspends GI Dynamics Endobarrier CE Mark; Avita Recell US Trials Meet Burns Endpoints, Non-Inferiority; Nashville Study Backs Impedimed L-Dex For Lymphoedema; Eli Lilly Picks Cogstate As Alzheimer’s Trials Preferred Provider; Atcor Revenue Warning, Review; Wollongong Uni Grad Cert In Regulatory Science; G Medical Requests Deal, Distribution Trading Halt; Volpara CEO Dr Ralph Highnam Increases, Diluted To 12.5%; Crystal Amber Takes 42% Of GI Dynamics; Sirtex US CEO Kevin Richardson Out; Tom Payne In For US Sales; Stemcell Wants $25m For Israel Deal, Marijuana, Dragon’s Blood
 
May 17, 2017
Reva Posts Positive 12-Month Fantom Stent Data; Cardiologist Hitinder Gurm: ‘Osprey Divert Reduces Dye 40%’; Paradigm PPS Equals Hay Fever Steroids Without Side-Effects; China Orders $3m Compumedics Sleep, Neuro Systems; Sirtex Requests ‘Meta-Study, Sirvenib Results Trading Halt’; Auscann, Tasmanian Alkaloids $15m Joint Marijuana Opiate Halt; Pharmaust Patent For Monepantel Non-Cancer Use; Medibio, Vital Conversations 2nd ‘Mental Health Check-In’; Respiri Swaps Leon L’Huillier Options, Company Secretaries; Regal Funds Increase, Diluted To 10% Of Oncosil
 
May 16, 2017
Actinogen Treats 1st Xanamem Alzheimer’s Patient; Aravax Starts Phase I PVX108 For Peanut Allergy Trial; Cynata Treats 1st CYP-001 Stem Cell GvHD Patient; FIL, Associates Take 5% Of Factor Therapeutics; Living Cell, Auckland Uni Neuro-Degeneration Collaboration; Immuron, US Defense Collaborate On Resistant Shigella; Anteo Appoints Alan Studley Director
 
May 15, 2017
Pharmaxis: ‘$41m Boehringer Ingelheim PXS-4728A Milestones’; Cynata Requests Phase I GvHD Trading Halt; MMJ Starts Marijuana Trial For MS; Bard1: ‘Lung Cancer Test Needs More Work’; Dorsavi Launches Smaller Faster Vimove2, Myvimove Program; Glaxosmithkline $80k Research Award Opens; TDM Takes 12% Of Somnomed
 
May 12, 2017
Dr Boreham’s Crucible: GI Dynamics; Polynovo, Beta Trial BTM Pig Islets For Type 1 Diabetes; Euro Patent For Prescient PTX-200 For Cancer; Oncosil Ex-Director Martin Rogers Exercises 19m Options; Neurotech Confirms FDA Meeting For Mente Autism; Blackrock Takes 6% Of Cochlear; Peter Reilly, Chevron Take 9.5% Of Simavita
 
May 11, 2017
Cochlear Buys Sycle Audiology Software For $106m; Avita Challenges Renovacare Cell Spray US Patent; Dorsavi Signs Snowy Hydro For Visafe Assessments; Queensland $300k For Paradigm PPS Ross River Virus Trial; Australian Patent For Analytica’s Pericoach; Invitrocue Tells ASX It Hopes To Place $700k; Creso Signs Leafcann To Supply Cannabis, Hemp Products; Australian Ethical Takes 7% Of Ellex; MGC Appoints Founder, Director, CTO Roby Zomer CEO; Oncosil Recruits Second Pancreatic Cancer Patient
 
May 10, 2017
Budget 2017: 1st MRFF $66m Trickles In, Steady As She Goes; Biotech Daily Editorial Comment; G Medical IPO Raises $12m For Electronic Health; Monash Licences Immuno-Oncology Program To Corvus; Avita: ‘FDA Has No Questions On BARDA Recell Application’; Immuron Trial Supplies Of Imm-529 For Clostridium Difficile; Medibio, Mayo Mental Health Development Agreement; IDT Wins Victoria Manufacturing Gong; IM Raises $498k To Become Babylon Operations Mining Services
 
May 9, 2017
Psivida Presents 12-Month Medidur/Durasert Uveitis Data; Resapp Collaborates With Médecins San Frontières; Proteomics: ‘World’s Most Accredited Protein Testing Lab’; Ani Launches IDT’s 1st Acquired Generic Pindolol; Cyclopharm Faces 19% Dissent Over Buy-Back; Immuron Hopes To Raise $12m For Nasdaq IPO; Admedus Tells ASX: ‘FDA Cardiocel 3D Grant Not Material’; MMJ Imports Medical Marijuana Capsules; Lucerne Services Takes 6% Of Visioneering 
 
May 8, 2017
Universal Biosensors, Siemens US Blood Analyzer Sales; Botanix Begins Phase Ia Cannabidiol BTX-1503 For Acne Study; Simavita Completes $1.5m Placement; Chiesi To Distribute Pharmaxis Bronchitol For CF In Italy; University Of Kansas Joins Prescient Ptx-200 AML Trial; Resapp Requests ‘Humanitarian Partnership’ Trading Halt; Adalta: AD-114 Scalable, Potential For Wet AMD; Rhinomed Signs Amcal, Guardian For Mute Nasal Plugs; GI Dynamics: Ricardo Cohen, Christopher Thompson Advisers
 
May 5, 2017
Dr Boreham’s Crucible: Oncosil Medical; Just 1 Of 10 Federal ARC Linkage Grants For Biotech; Oventus Files FDA 510k For O2vent W; China Patent For Pharmaust Monepantel (PPL-1) For Cancer; Reva 630k Directors Options, 360k ‘Restricted Shares’ AGM; Airxpanders 1.35m Directors Options AGM; Biotech Capital Licences Chlorasolv From RLS Global; Auscann Wins Marijuana Growing Licence; Nuheara Share Plan Raises $247.5k Of Hoped-For $2.6m; Authentics, Biddicks, Conquest Take 10% Of Immuron; Elizabeth Hammack To Replace Airxpanders Tadmor Shalon; Creso Director Dr Simon Buckingham Moves To Consultant
 
May 4, 2017
Admedus CPR-1 For HSV-2 ‘Safe, Interesting Trends’; Cann Opens Up 117% To Grow Marijuana; Auscann Requests ‘Update’ Trading Halt; China Issues Dorsavi ‘Body Orientation’ Patent; Mayne Tells ASX: Buried Sales Warning ‘Not Material’; Investors Mutual Takes 5% Of Mayne Pharma; Analytica Pericoach Pelvic Floor Exercise Program; IQ3 To Release 80m Escrow Shares
 
May 3, 2017
Ascend Claims 89% ASN-002 NBCC Complete Responses; Simavita Placement, Rights Issue For $2.9m; Applications Open For $8m MTP Connect Project Fund; GI Dynamics Hopes To List On London’s Aim; GI Dynamics 3.9m More Directors Options ‘In The Money’ AGM; Oventus: ‘Trial Shows O2 Vent Improves Snoring; 2 New Trials’; Challenger Below 5% Of Mayne Pharma; Washington H Soul Pattinson, Hunter Hall Has 14% Of Avita; Rhinomed 10-For-1 Consolidation Underway; Oncosil: Dr Chris Roberts Chair, Dr Roger Aston Director; Visioneering Appoints Tom Dooley Director
 
May 2, 2017
Victoria Budget: $34m For Research, WEHI Drug Discovery; Admedus Produces Cardiocel 3D Cardiac Patch; ‘Irrational’ Nice Decision Delays Clinuvel Scenesse 16 Months; Biotron: ‘Nature Article Backs Macrophage Approach’; USPTO Reviews Acrux Competitor Antifungal Patent; ISO Accreditation For ITL’s Myhealthtest; Creso Partner Health House Imports 1st Medical Marijuana; MGC, RMIT Collaborate On Marijuana Genetics, Cultivation; Pancann To Back MMJ Marijuana Growing Expansion; Noxopharm: ‘6 New Cancer Trials In 6 Months’; Biocurate Appoints Dr Glenn Begley CEO
 
May 1, 2017
April BDI-40 Up 3.5%, ASX200 Up 1%, Big Caps Up 4% - Opthea Up 49%, Actinogen 45%, Mesoblast 38%; Cellmid Down 22.5%; Living Cell Completes NTCell Parkinson’s Treatment; Orthocell Ready For Ortho-ATI Rotator Cuff Trial; Analytica Releases Pericoach Version 3; MGC Signs Euro Cannabis Cosmetics Deals; Trading Halt; Oventus Ready For O2vent Pap Hybrid Apnoea Trial; US Orphan Status For Prescient PTX-200 For AML; Lifespot Medical Marijuana Vaporizer Joint Venture; Stemcell Pleads Schultz To ASX 83% Query; Simavita Less Than One Quarter Cash; Raising Trading Halt; Baillie Gifford Reduces To 9% Of Cochlear; Crystal Amber Takes 41% Of GI Dynamics; Dimerix Appoints Hatchtech CEO Hugh Alsop Director; Uscom Appoints Damien Linnett For Sales, Marketing
 
Apr 28, 2017
Dr Boreham’s Crucible: Pharmaxis; Resmed Q3 Revenue Up 13% To $688m; Resapp Licences UQ Paediatric Pneumonia Software; Opthea Completes $45m Capital Raise; Esense Ships Cannabis Terpene To Allor Vaporizers; Biotech Daily Appendix 4C Quarterly Reports Policy; GI Dynamics Has Almost Two Quarters Cash; Medlab Has Almost Two Quarters Cash; Invitrocue Has Less Than Two Quarters Cash; Neuren ‘Will Reduce Cash Burn, Consider Funding’; Phosphagenics AGM For 22m CEO, Directors Options; Stephen Coupe Below 5% Of Nuheara
 
Apr 27, 2017
Cann Group IPO Raises $13.5m For Medical Marijuana; Medical Developments Asthma Spacers In 10k US Outlets; OBJ Signs New Procter & Gamble Technology Deal; Universal Biosensors Revenue Up, ‘2017 Cash Flow Positive’; FDA Clears IDT Pindolol For US Launch; Hunter Hall Reduces To 16.5% Of Avita; FIL Takes 9% Of Impedimed; JK, Kim Hogan Take 6.5% In Actinogen; Raymond Ting Replaces Cellmid Co Sec Aliceson Rourke 
 
Apr 26, 2017
Uniquest, Preveceutical Cannabinoid Nasal Gel ‘To The Brain’; Reva Treats 1st Patient In Fantom ‘Complex Case’ Trial; Oncosil Implants 1st Brachysil Pancreatic Cancer Patient; Redhill Enrols Last Patient In Phase II RHB-102 IBS Trial; Monash Shows G-Coupled Protein Structure; Acrux, Eli Lilly Q3 Axiron Sales Down 26% To $36m; Analytica: US Guidelines Back Pericoach For Incontinence; J&J $285k Singapore Quickfire Obesity Challenge; MMJ: ‘Harvest One TSX-V Listing For Recreational Marijuana’; Mach7 Has One Quarter Cash, ‘More Coming’; Brain Resource Licences Mybrainsolutions To Teva For Israel; Neurotech: Bonvie Distributes Mente Autism In Greece, Cyprus; Washington H Soul Pattinson, Hunter Hall Below 5% In Sirtex; ARC Appoints Prof Sue Thomas CEO 
 
 
Apr 21, 2017
Dr Boreham’s Crucible: Osprey Medical; Anteo Meets Planet Innovation Nplex Diagnostic Milestone; Uniquest, Preveceutical To Develop Scorpion Venom Peptides; Sirtex Requests ‘Sarah Study Results Trading Halt’; Neurotech To Release 699k Escrow Shares; Dr Greg Collier Replaces Phosphagenics Chair Peter Lankau
 
Apr 20, 2017
Astrazeneca $2.7m For Starpharma Cancer Drug Milestone; Innate Completes MS Trial, Awaiting Results; Specialised Thera Abraxane For Oncosil Pancreatic Trial; Recce Calls For Australian Investment In New Antibiotics; Esense Ships Cannabis Terpene Samples To Potential Partners; Medibio CFO Brian Mower Starts On $351k; Innate Grants CEO Simon Wilkinson 500k Options; OBJ Requests ‘2nd Technology Licence’ Trading Halt
 
Apr 19, 2017
Royal Society Backs March For Science; Research Australia: ‘Does Scrapping The 457 Visa Affect You?’; TGA Approves CSL Afstyla For Haemophilia A; Patrys Selects PAB-DX1 For Cancers; Uscom Posts Maiden Cash Flow Positive Quarter; ITL Signs NZ Blood Service For Samplok Sampling Kit; Two US Patents For Redhill’s Bekinda (RHB-102) For Gastro; Victoria To Export 4-D Scanners; Bioxyne To Raise $3m For NZ Asia Sales, Nam Hoat Chua CEO; MD Anderson Approves Oncosil Pancreatic Cancer Trial; Prima 3rd Tactimel Melanoma Trial Cohort Approved; Cynata Ready For FDA Pre-IND Meeting For Stem Cell Development; Resapp Extends Smartcough-C Study To 1500 Patients; Zelda Expands Medical Marijuana Trials To Autism; Benjamin Karasik Takes 10% Of Esense; Nitzan Orgal Takes 6% Of Esense; Sienna Promotes COO Matthew Hoskin To CEO; Bio-Melbourne Connecting Women Lunch Tickets Selling Fast
 
Apr 18, 2017
Ausbiotech: Industry Opposes $2m R&D Tax Incentive Cap; Cho Group Takes 15% Of Invion For $657k, 2 Board Seats; Biotech Well-Represented In Australia-Japan Trade Mission; Immuron IMM-124E For Colitis Passes 1st Preclinical Hurdle; Resonance ‘Ferriscan Not Confounded By Liver Fat’; Anteo, Diasource Agree To $6m Earn-Out; BVF, Mark Lampert Increase, Diluted To 17% Of Opthea; BPH EGM, Spill Directors Ineligible; Rejects $263k Claims; Phylogica Loses Jeremy Curnock Cook, Dr Hayes, Dr Kendall In
 
Apr 13, 2017
Dr Boreham’s Crucible: LBT Innovations; Visioneering IPO Raises $33m For US Contact Lenses; Prima Receives $492k Federal R&D Tax Incentive; Unilife Suspended For US Chapter 11 Bankruptcy Relief; Reproductive Health: ‘Ghent Backs Doplify Test’, Jumps 260%; Bioxyne Requests ‘Capital Raising’ Trading Halt; Polynovo To Release 4.2m Voluntary Escrow Shares; Mohd Razali Abdul Rahman Takes 8% Of Creso
 
Apr 12, 2017
Onji: Inhibiting HCK Reduces Gastric Cancer In Mice; Medical Developments Signs Penthrox Russia Distributor; Ansell Launches Starpharma Vivagel Condom In Canada; CSL: ‘We Will Defend CSL830 Against Shire Patent Claim’; Allegra Rights Issue Raises $1.2m; IDT Manufacturing 2nd Batch Of Temozolomide; Anteo Terminates $9m Bergen Draw-Down Equity Facility; Cynata Applies For Stem Cell For Cancer Patent; Clinuvel, German Insurers Agree Uniform Price; Respiri Class IIa CE Mark For Airsonea At-Home
 
Apr 11, 2017
Cynata Trials Stem Cells For Respiratory Distress In Sheep; Hayward Injunction Delays Sirtex $30m Buy-Back, Again; Medadvisor Earns $1.55m In Q3; Creso $1m Share Plan 4 Times Oversubscribed; Total $9m; Biotron Initiates Chiang Mai 2nd Site For BIT225 HIV Trial; Anteo Files 2nd Battery Patent; Epat Demonstrates Apple-Compatible Pain Application; Yarra Funds Back Above 5% Of Mayne Pharma; Webinvest, Otto Buttula Reduce To 6% Of Oncosil
 
Apr 10, 2017
Bluechiip Wins 1st Major US Contract; US Wallmart, Kmart To Sell Medical Developments’ Spacers; Mesoblast Phase III Heart Trial Passes Futility Analysis; Orthocell Pleads Schultz To ASX 28% Query, Closes Up 37.5%; Novogen Prepares GDC-0084 Glioblastoma Multiforme Trial; Medicines Australia ‘Bridge Program’ Takes Research To Market; Auscann Marijuana Crop Yields 300kg Dried Buds; MGC Starts Slovenia Cannabinoid Extraction Operations; Medibio Joint Venture For Paediatric Mental Health; Noxopharm Starts Idronoxil-C Patent Process; Sirtex Appoints Ex-Cochlear CFO Neville Mitchell Director; Impedimed Appoints Judith Downes Director; IQ’s Farmaforce Appoints Harry Simeonidis General-Manager
 
Apr 7, 2017
Dr Boreham’s Crucible: Opthea; Suda Raises $1.5m; Factor Therapeutics Recruiting 168-Patient Leg Ulcer Trial; FDA Expands Avita Compassionate Use To 68 Patients; Mach7 Unmarketable Facility Sells 309k Shares, 1,370 Parcels; Hemideina Wins STC $40k For Internal Hearing Device; MTP Connect Launches ‘And Health’ For Digital Health; Immuron Appoints Prof Ravi Savarirayan Director
 
Apr 6, 2017
Paradigm PPS For Hay Fever ‘To Earn $1b/pa’; 4 Phase II Trials; Prescient PTX-200, Paclitaxel Safe For Breast Cancer; Immuron Completes IMM-124 Nash Enrolment; Mesoblast Receives $3.7m Federal R&D Tax Incentive; Imugene Options Raise $3m, 10m Options For Dr Axel Hoos; Redhill Licences Enteragam For Diarrhoea; Novogen Kills ATM-3507, Ansina; Other Programs Continue; Anteo Secures $1m Investor, CEO, Director Loans; Memphasys Completes $130k Gel Sale To Dycent, Clarifications; Tumbling 10c Aviragen (Biota) 1m Executive Options; Rhinomed Signs GNC For US Mute Sales; Och-Ziff Increases, Diluted To 17% Of Brain Resource
 
Apr 5, 2017
Opthea Placement, Insto Rights Raise $42m, Retail For $3m More; US Orphan Status For Redhill’s Yeliva For Bile Duct Cancer; IM Medical To Raise $500k To Become Babylon Pump & Power; Viralytics Presents 22 Mitci Patient, 10 Storm B Patient Data; Tumbling 10c Aviragen (Biota) Review Leads To ‘Considering Options’; Unilife Has 3 Days Cash; Staff To Go, Facilities To Close; Bard1, Respiratory Institute Evaluate Cancer Vaccine; Volpara Launches Enterprise 2.0 Software; Botanix Raises $7.4m For Cannabis-Based Dermatology; MGC Completes European Cannabinoid Extraction Facility; MMJ First Marijuana Harvest Nets 60kg Dried Buds; Memphasys $500k Platinum Loan For Sperm Separation; Allan Gray Reduces To 8% Of Pharmaxis; Suda Requests Capital Raising Trading Halt; Zelda To Release 10m Escrow Shares; Prof Chris Porter Replaces MIPS Director Prof Bill Charman
 
Apr 4, 2017
Reva Fantom Bio-Resorbable Stent Wins CE Mark; CSIRO Backs MTP Connect ‘$18b, 28k Jobs, 10 Year Plan’; Bionic Vision Raises $23.5m For Bionic Eye; Invitrocue Validating 10-Day, Patient-Specific Cancer Test; FDA Approves Airxpanders Enhanced CO2 Film; Viralytics Cavatak, Keytruda Melanoma Results Expands Trial; Mesoblast, Harvard HLHS Stem Cell Trial; Oncosil: ‘UK Ethics Approval For Pancreatic Cancer Trial’; Neuren Receives $982k Federal R&D Tax Incentive; Lifespot Bodytel To Monitor Medical Marijuana; OBJ Multiple Unnamed Partner Licencing Deals Underway; Prescient Requests Breast Cancer Trial Results Trading Halt; Botanix Takes Capital Raising Trading Halt To Suspension; BVF Partners, Mark Lampert Take 13% Of Pharmaxis; Australian Ethical Takes 10% Of Pharmaxis; Creso Appoints David Russell COO
 
Apr 3, 2017
March Bdi-40 Up 10%, Asx200 Up 3%, Big Caps Up 5%- Mesoblast Up 46%, Prana 40%, Viralytics 32%; IDT Down 17%, Ellex 14%; Opthea Claims Opt-302 + Lucentis Wet AMD Success; $45m Raising; Mouse Data Backs Benitec ddRNAi BB-301 For OPMD; Bionomics: ‘BNC, Checkpoint Inhibitor For Cancer In Mice’; Uscom Consortium EU $2m For Better Spacers; Nominations Close For $750k Science Prizes April 12; Suda Files Artimist Application To TGA; Hunter Hall Reduces To 5.5% Of Sirtex; M&G Group Takes 13% Of Mesoblast; Thorney Takes 5.8% Of Mesoblast; Allan Gray Reduces, Again, To 15% Of Pharmaxis; Alvin Blumenthal, Suburban Below 5% Of Creso; Avita Releases 3.5m Escrow CEO Loan Shares; Universal Biosensors To Release 26k Escrow Shares; Creso To Release 4m Escrow Shares; Phylogica Loses Co Sec Natasha Forde, Graeme Boden Stays
 
Mar 31, 2017
Dr Boreham’s Crucible: Innate Immunotherapeutics; Mesoblast Heart Failure Trial Interim Analysis; Apceth Drops Cancer, Retains Cynata Stem Cell Option; Genetic Signatures Launches Easyscreen STI Detection Kit; Genetic Technologies Cuts Brevagen Test Cost 87.5%; Botanix Requests ‘Capital Raising’ Trading Halt; Australian Ethical Takes 9% Of Pharmaxis; Dr Dax Marcus Calder Takes 9.5% Of Patrys; Creso Tells ASX: ‘$9m Raise Could Push Price, Rules Obeyed’; Proteomics To Release 29m Shares From ASX Escrow
 
Mar 30, 2017
Starpharma Vivagel Bacterial Vaginosis Results By July; Prana: ‘Animal Studies Back PBT434 For Parkinson’s Disease’; Zelda Raises $6m For Medical Marijuana Trials; Brain Raises $1m, Share Plan; Opthea Requests ‘Trial Results, Capital Raising’ Trading Halt; Imugene Investors Underwrite $1.35m Expiring Options; Botanix Ready For Cannabidiol BTX-1503 For Acne Trials; GI Dynamics Hopes For US Endobarrier Trial This Year; Neurotech Starts FDA Mente Autism Talks; Uscom: ‘Papers Back Monitor For Pre-Eclampsia’
 
Mar 29, 2017
Victoria Genomics Project For Superbugs; Melbourne Uni: Mouse Neural Cells Hope For Gut Disorders; WEHI: Malaria Parasites ‘Walk Through Cell Walls’; Mesoblast Above $1b, Again, $1.8b To Go; Nuheara Raises $4.4m, Plan For $2.6m More; Neurotech Completes US Mente Autism Trial Enrolment; Australia Approves MMJ Cannabis Import; Pfizer To Evaluate Suda Oromist Oro-Mucosal Spray; OBJ, Unnamed Company Bodyguard Collaboration; Pippa Mann Continues As Genetic Technologies Ambassador; Rhinomed Placement, 60m Director Options, Consolidation EGM; W Whitney George Takes 18% Of Rhinomed; Volpara To Release 12m Escrow Shares; Brain Takes Capital Raising Trading Halt To Suspension; David Heaney Replaces Cyclopharm Chair Vanda Gould, Tom McDonald Director
 
Mar 28, 2017
TGA Approves LBT Plate Assessment For Register; Oncosil Recruits 1st Pancreatic Cancer Patient; ITL Claims February ‘Record Revenue, Profit Month’; Novogen Receives $4.4m Federal R&D Tax Incentive; Singapore Patent For Orthocell Celgro Collagen Scaffold; China Patent For Regeneus Stem Cell Acne Treatment; Mach7 To Release 44.2m Escrow, 24m Performance Shares; Prescient Pleads Schultz To ASX 9% Query; FIL Takes 8% Of Resapp; Zelda Requests ‘Capital Raising’ Trading Halt; Unilife Loses V-P, CCO Michael Ratigan
 
Mar 27, 2017
Mesoblast Raises $52.5m For Phase III Programs, Manufacture; Creso Placement Raises $8m, Plan For $1m More; Correction: Bionomics; Federal $50k For Noxopharm, MIPS Pharmacodynamics Studies; Race Signs South Korea Distribution; Recce 327 ‘Safe, Well-Tolerated In Dogs’; Zelda, Cannpal Deal On Medical Marijuana For Pets; Medlab Prepares For Phase II Nrgbiotic Depression Trial; Simavita Reduces Costs, Develops Corporate Strategy; Novita Pleads Schultz To ASX 41% Query; Brain Requests Capital Raising Trading Halt; MMJ Requests ‘Cannabidiol Capsule Import’ Trading Halt; Nuheara Requests Capital Raising Trading Halt
 
Mar 24, 2017
Dr Boreham’s Crucible: Bionomics; Germany Extends Reva Stent Trial To ‘More Complex’ Cases; Benitec Receives $5.6m Federal R&D Tax Incentive; US, Australia Approve Botanix Cannabidiol Export, Import; Peter Hall Ceases Hunter Hall-Linked 9.5% Mach7 Holding; Graham Durbin Super ‘Reduces To 8.3% Of Genera’, Holds 11.6% 
 
Mar 23, 2017
Biotron: ‘Positive Phase II HIV Results Will Lead To Licence’; Paradigm Completes PPS For Hay Fever Treatment; Bard1 Claims 92% Accuracy For Ovarian Cancer Test; Zelda To Trial Cannabis For Insomnia, Eczema In Chile; US Patent For Bard1 Lung, Colorectal Cancer Technology; Creso Pharma Requests Capital Raising Trading Halt; Hunter Hall’s Associates Cease Linked Avita Holding
 
Mar 22, 2017
Neuren Claims Statistical Efficacy For Trofinetide For Rett; Osprey Expects To Break Even In 2019; Uscom Begins China BP+, Spirosonic Regulatory Process; Paradigm Receives $1.3m Federal R&D Tax Incentive; Creso Appoints Sin Solution Latin America Distributor
 
Mar 21, 2017
MIPS: ‘Inhaled Oxytocin Equals IM For Post-Birth Bleeding’; Dimerix Receives $422k Federal R&D Tax Incentive; Medical Developments Opens Manufacturing Facility; Proteomics To Advance Promarkerd Kidney Test In Asia; Adalta Expands Alfred AD-114 For IPF Collaboration; Zelda Pays Caziwell $300k Now To Save $200k Later; Nicholas McDonald Reduces To 5% In Biotech Capital
 
Mar 20, 2017
Mercy Implements Pro Medicus Visage 7 Imaging; Opthea Meets Euro Regulators For Opt-302 Wet-AMD Trial; Uscom Receives $496k Federal R&D Tax Incentive; Neuren Requests Trofinetide Rett Trial Results Halt; Creso Requests ‘Sales, Distribution Update’ Halt; Impedimed Appoints Amit Patel, Don Williams Directors; Medibio Appoints Dr Greg Moon CMO, Dr Yashar Behzadi CPO
 
Mar 17, 2017
Dr Boreham’s Crucible: Mayne Pharma Group; MGC Raises $10m; Innate Raises $2m; CVC, Stinoc Down To 12.8% In Cyclopharm
 
Mar 16, 2017
Visioneering ASX IPO Raises $33.3m For Contact Lenses; Three More US Patents For Prescient PTX-200 For Cancer; Race: ‘French Bisantrene Sales For AML, US IND In 2017’; Noxopharm, Uni Of NSW Collaborate On CNS Protection; Avita Receives $975k Federal R&D Tax Incentive; Innate Requests Capital Raising Trading Halt; Creso: Czech OK Dicbdium Cannabidiol ‘For Health, Disease’; Mach7 M-D Albert Liong Retires
 
Mar 15, 2017
Mesoblast: ‘Stem Cells Aid Lower Back Pain For 36-Months’; Rhinomed Raises $2.2m At 16% Premium; Reva Expects CE Mark, Cash Soon; Sales By July; Prima Recruits 2nd Cohort In IMP321 Melanoma Trial; Rhinomed $280k R&D Tax Incentive; 1-For-10 Consolidation; Genetic Signatures To Release 18.7m Escrow Shares; MGC Requests Capital Raising Halt; Admedus Ex-Chair, Now CEO, Wayne Paterson Starts On $787k; Bio-Melbourne Network Breakfasts On Europe
 
Mar 14, 2017
Pro Medicus, Primary Health Care Sign $15m Visage Deal; Packer & Co Reduces, Takes Profit To 4.96% Of Opthea; Yarra Funds Reduces To 4.85% Of Mayne Pharma; WEHI Mapping Mefloquine For Malaria Leads To Better Drugs; Zelda Reduces 744 Unmarketable Parcels, 1.1m Shares; Admedus: John Seaberg Chair; Wayne Paterson CEO, Director; Biotech Capital Appoints Dr Ric Degaris For Clinical Services
 
Mar 13, 2017
Pharmaxis: Synairgen Pre-Clinical Data For IPF Drug; MMJ Jumps 58% On German O-T-C Medical Marijuana Approval; TBG, Medigen Develop Anti-Thyroid Drug Test; Benitec Issues Nant 29m Shares, Total $5.45m, Nant 28.6%; Botanix Pleads Schultz To ASX 50% Query; Sirtex Delays $30m Share Buy Back, Again; Rhinomed Requests Capital Raising Trading Halt; Australian Ethical Takes 7.6% Of Pharmaxis; GI Dynamics: Manoel Galvao Neto, David Cummings Advisors
 
Mar 10, 2017
Dr Boreham’s Crucible: Neuren Pharmaceuticals; S&P Dow Jones Promotes 6 Biotechs, Demotes 5; Analytica Raises $300k; Nuheara Receives $412k Federal R&D Tax Incentive; Yarra Funds Takes 5% Of Mayne Pharma; Hunter Hall Reduces To 16.5% Of Avita; MM Asset Management Below 5% In MMJ Phytotech; Novogen: David Brown, Andrew Heaton, Cristyn Humphreys Go
 
Mar 9, 2017
US Approves Osprey Dyevert Plus; Phosphagenics, Integrated Animal Health ‘Cease All Licences’; Mayne Buys Transdermal Fentanyl Rights From Par Pharma; Allegra Share Plan To Raise $1.2m; Opthea: ‘FDA Clear Path For OPT-302 For Wet AMD’; MMJ To Grow Marijuana On 5Ha Of Cowichan Tribes Land; Anglo Australian Christian Fund Takes 19% Of Cyclopharm; Windarri, Herz Increase, Diluted To 8% Of Biotech Capital; Crystal Amber Takes 40% Of GI Dynamics; Macquarie Group Playing With MMJ To 5%; Mayne Appoints Nick Freeman CFO, Co Sec
 
Mar 8, 2017
MCRI: ‘Fast, Accurate Test For Bone Marrow Transplant’; Redhill: Concordia Wins $3m ‘Generic’ Donnatal Damages; TGA Approves Actinogen Xanamem For Alzheimer’s Trial; Biotech Capital Share Plan Raises $595k, Total Raised $2.4m; Prescient Completes 1st PTX-200 For AML Combination Cohort; Rhinomed Adds Two US Chains, Expands Symbion Mute Sales; Nuheara Signs Amazon, Brookstone For Iqbud Distribution; MGC Issues 10m Longevity ‘Performance’ Rights; FIL Takes 8% Of Cogstate; Noxopharm To Release 4.3m Shares, 3.3m Options From Escrow; Pharmaust Appoints Dr Richard Mollard CSO, Starts On $183k; Bio-Melbourne 5th Annual ‘Devices + Diagnostics Lab’
 
Mar 7, 2017
Metabloq, Centenary Drug To ‘Block Cancer Metabolism’; Burnet Re-Engineers Hepatitis C Protein For Vaccine; GBS: ‘Otsuka $329m+ Deal For Neurovance For ADHD’; Anteo, Cook Develop Coatings For Implantable Devices; Paradigm Phase II PPS Trial For Ross River Virus; Avita Completes Pivotal US Burns Trial Treatment; Mesoblast: FDA Fast-Track For Msc-100-Iv For Paediatric GvHD; Impedimed Sozo Passes Tests, 1st Installed At Scripps Health; Psivida Feasibility Study With Unnamed Company; Innate Names MIS416 For MS Mechanism-Of-Action Abstracts; GBS Reduces, Diluted To 17% Of Airxpanders; Creso, Domaco Cannibinoids For Human, Pet Food Additives; GI Dynamics: Prof Carel Le Roux, Prof Jan Greve Advisers
 
Mar 6, 2017
Uniseed Raises $20m ‘For Lower Risk, Later Stage Investments’; Pharmaust Shortfall Raises $534k, Total$3.2m; US Patent For Uscom BP+; Medadvisor 500k Customers, 5m CEO Robert Read Rights Vest; Medlab Contracts Zenith For Statin Spray; Unisuper Takes 5% Of Viralytics; Washington H Soul Pattinson, Hunter Hall Take 6% Of Sirtex; Washington H Soul Pattinson, Hunter Hall Take 17% Of Avita
 
Mar 3, 2017
Dr Boreham’s Crucible: Volpara Health Technologies; Phosphagenics $20m+ Mylan TPM-Daptomycin Dispute; Compumedics Wins $2.3m China Contract; Volpara Sales Up 37.6% To $3.2m; Oventus To Release 9m Escrow Shares; US Orphan Designation For Engeneic Nano-Cells; Japan Patent For Suda Sildenafil Oral Spray; Noxopharm: NOX66 With Radiotherapy For ‘Abscopal Effect’; Creso Pharma Requests ‘Swiss Food, Pharma Deal’ Halt; Esense Appoints Shaul Schneider For Business Development 
 
Mar 2, 2017
Victoria: Applications Open For $100k, $500k Grants; Legal Action Delays Sirtex Share Buy-Back; Cynata, Monash Collaborate On Stem Cells For Asthma; Cellmid Paper Describes FGF5 Inhibitor For Hair Loss; Platinum Road $2m Cellmid R&D Tax Incentive Loan; Prime Co-Investor Crescendas Lends Memphasys $250k; Neurotech Appoints Dengg Medizintechnik For Austria Sales; JCP Reduces To 5.8% Of Nanosonics; Craig Hadfield Replaces Volpara CFO, Co Sec Brian Leighs
 
Mar 1, 2017
February BDI-40 Down 2%, ASX200 Up 2%, Big Caps Up 5% - Benitec Up 65%; Compumedics Down 33%; Aviragen (Biota) Going; Victoria Imports Canadian Medical Cannabis; Medical Aust H1 Revenue Down 17% To $7m, Loss To $252k Profit; IQ3 H1 Revenue Up 116% To $2.6m, Loss To $166k Profit; Pharmaust H1 Revenue Up 13% To $1.6m, Loss Down 57% To $414k; TBG H1 Revenue Down 58% To $1.4m, Loss Down 79% To $2.6m; Resonance H1 Revenue Down 2% To $1.3m, Loss To $35k Profit; Phosphagenics Receives $2.3m Federal R&D Tax Incentive; US Patent For Prima IMP321 Cancer Immunotherapy; Actinogen Appoints Dr Geoff Brooke Chairman; Pharmaust Appoints Dr Richard Hopkins CEO, Starts On $183k; IDT Appoints Mary Sontrop Director; Creso Appoints Prof Felix Gutzwiller Advisor
 
Feb 28, 2017
WEHI: ‘Genetic Evidence For Incurable Mactel Blindness’; TGA Approves CSL’s Zemaira For Alpha-1 Antitrypsin Deficiency; Mayne To Market Mithra’s Myring Contraceptive; Compumedics H1 Revenue Down 7% To $16m, Profit Down 88% To $226k; Cellmid H1 Revenue Up 56% To $2.2m, Loss Down 13% To $1.5m; Medlab H1 Revenue Up 83% To $2m, Loss Down 1% To $1.8m; Genentech Takes Phylogica H1 Revenue To $3m, Loss Down 39%; Phosphagenics Revenue Down 27.5% To $1.6m, Loss Down 14% To $17m; Adherium H1 Revenue $1.4m, Loss $1.6m; GI Dynamics Revenue Down 59% To $709k, Loss Down 63% To $17m; Saudi Arabia Approves Admedus Cardiocel Heart Patch; Innate Phase IIb Trial Of MIS416 For MS On-Schedule; MMJ Distributor Hl Pharma Applies For Cannabis Import Licence; Macquarie Group Below 5% Of MMJ; Allan Gray Below 5% Of Acrux; Oncosil Appoints Dr Martin Cross Director; Dr Paul Wotton Replaces Cynata Chair Dr Stewart Washer
 
Feb 27, 2017
Guidelines Back Nanosonics Trophon Decontamination; Orthocell: ‘2-Year Data Backs Ortho-ATI For Gluteal Tendinopathy’; Ellex H1 Revenue Down 2% To $34m, Profit Down 14% To $1m; Universal Biosensors Revenue Up 12% To $19m, Loss To $1m Profit; Mesoblast H1 Revenue Down 92% To $1m, Loss Up 12% To $52m; Mach7 H1 Revenue Up 1594% To $5m, Loss Up 205% To $4m; Suda H1 Revenue 26% To $3.6m, Loss Down 49% To $917k; OBJ H1 Revenue Up 3% To $1.4m, Loss Up 107% To $2.5m; Anteo H1 Revenue Up 2063% To $12m, Loss Down 0.3% To $3m; Genetic Signatures Revenue Up 18% To $1m, Loss Down 17% To $1.3m; Bioxyne H1 Revenue Down 25% To $916k, Profit To $72k Loss; Starpharma H1 Revenue Down 85% To $576k, Loss Down 10% To $9m; Correction: Atcor; Clarification: Cyclopharm; Australia Accepts Imugene HER-Vaxx Patent Application; Botanix Files 5 Permetrex Patent Applications; CVC Below 5% Of Bionomics; Robinwood Takes 44% Of Allegra; ITL Rebrands As ITL Health Group; Biotech Capital Appoints Dr Rocco Iannello Business Development
 
Feb 24, 2017
Dr Boreham’s Crucible: Mesoblast; Airxpanders Completes $45m Placement; Mayne H1 Revenue Up 132% To $295m, Profit Up 298% To $71m; Clinuvel H1 Revenue Up 395% To $7m, Loss To $2.5m Profit; Admedus H1 Revenue Up 86% To $12m, Loss Down 50% To $6.4m; Impedimed H1 Revenue Up 12% To $3m, Loss Up 23% To $14m; Atcor H1 Revenue Up 9% To $1.8m, Loss Down 19% To $1.9m; Probiotec H1 Revenue Down 4.4% To $29m, Profit Up 81% To $545k; Creso’s Health House Approved For Marijuana Imports; Recce: ‘Images Show Recce 327 Kills E Coli In 3 Hours’; Japan, Euro Patents For Antisense ATL1103; Euro Patent For BPH’s Cortical Dynamics Brain Monitor; Naos Takes 7% Of Biotech Capital; Links, Lotsa, Laurence Freedman Reduce Again To 6.45% In Bionomics; Private Portfolio Managers Take 5.5% Of Bionomics; Ausbil Dexia Takes 7% Of Bionomics
 
Feb 23, 2017
Pharmaxis Completes US Bronchitol Cystic Fibrosis Treatment; Polynovo BTM Treats 1st US Trauma Patient; UK Network Rail Adopts Dorsavi Visafe; Atcor 3-Year Sphygmocor Deal With Emory University, Healthcare; Harvest One Raises $32.5m For MMJ’s United Greeneries, Satipharm; Chair Alison Coutts Lends Memphasys $300k, $200k Line-Of-Credit; Allegra H1 Revenue Up 7.5% To $2.6m, Loss To $179k Profit; $1m Rights; Somnomed H1 Revenue Up 27% To $21m, Profit Up 199% To $178.5k; Rhinomed H1 Revenue Up 133% To $1.2m, Loss Down 51% To $1.4m; Cogstate H1 Revenue Up 43% To $19m, Profit Down 62% To $1m; Recce Drops Cancer; Focus On Drug-Resistant Bacteria, Viruses; Invitrocue, Garvan Work On Personalized Cancer Drug Screening; Antisense ATL1103 To Be Named Atesidorsen; Esense Terpene Profiles ‘30% Higher Counts’; FIL Takes 7% Of Resapp; Biotech Capital Appoints Oskar Hakansson For In-Licencing; Adherium Appoints Erin Wansbrough For Business Development 
 
Feb 22, 2017
Sirtex New R&D Axed, H1 Revenue Up 0.2%, Profit Down 26%; Federal Government Approves Medical Marijuana Imports; Medlab Welcomes Cannabis Import Announcement; Auscann, Creso, MGC Joint Welcome For Medical Marijuana; Cyclopharm Revenue Up 14% To $14m, Profit Down 81% To $891k; Cryosite H1 Revenue Up 4.5% To $5.2m, Profit Up 23% To $253k; Regeneus H1 Revenue Up 830% To $8m, Loss To $4m Profit; Orthocell ‘Early Data Shows Celgro Safe, Tolerable’; Breastfeeding Association Backs Medical Australia Pumps; Japan Grants Analytica Pericoach Patent; Prolog Diluted To 8% In Airxpanders; Compumedics Appoints Rob Ferguson US General-Manager
 
Feb 21, 2017
Takeover Panel Reasons For Innate Chris Collins Decision; Analytica: ‘Pericoach Improves Sex, Pelvic Floor Strength’; Cann Claims First Australian Medicinal Marijuana Licence; CMax Sale Takes IDT H1 Revenue Up To $5m, Loss To $12m Profit; Polynovo H1 Revenue Up 328% To $2m, Loss Down 14% To $2m; Bioxyne Appoints Quality Brands China Distributor; Nuheara Best Buy US Launch, Google Play Download; Adalta Inaugural Investor Fibrosis R&D Day; Hong Kong’s Senrigan Takes 14.5% Of Reva; Yodambao Increases, Diluted To 5% Of Dimerix
 
Feb 20, 2017
Bionomics Trials Bnc105, Keytruda For Advanced Melanoma; Immuron Completes IMM-124E Nash Recruitment; Esense Lab Lists On ASX For Plant Terpenes; G Medical IPO Hopes To Raise Up To $12m For Electronic Health; Nanosonics H1 Revenue Up 127% To $37m, Loss To $22m Profit; Acrux H1 Revenue Down 20% To $14m, Profit Down 35% To $6m; Medical Dev H1 Revenue Up 34% To $8m, Profit Up 74% To $410k; Medadvisor H1 Revenue Up 128% To $1.5m, Loss Up 85% To $2m; Takeovers Panel Rejects James Wheeldon Innate Application; Fujifilm Takes 10% Of Cynata; The Boat Fund Takes 5% Of ITL; Peter Meurs Increases, Diluted To 17% Of Dimerix; MGC Releases 210m Escrow Shares; Simon Robertson Replaces Botanix Co Sec Brett Tucker 
 
Feb 17, 2017
Dr Boreham’s Crucible: Resapp; Victoria Provides $32m For Cancer Trials, Research; Pro Medicus H1 Revenue Up 6% To $15m, Profit Up 63% To $5m; ITL H1 Revenue Up 11% To $17.5m, Profit Up 103% To $2m; Bionomics H1 Revenue Down 30% To $7m, Loss Even At $10m; Pharmaxis H1 Revenue Down 26% To $7m, Loss Down 1% To $11m; Polynovo Wins First South African BTM Order; France Pays $17k Per Sirtex Treatment; Vespro Protocol; Memphasys, Prime Dispute GF100 Blood Separator; Lloyds & Cassanove Sells Cyclopharm 18% To Neighbor Church; Simon Buckingham Replaces Admedus Director Michael Bennett; Bio-Melbourne ‘New Kids On The Stock’ Exchange Briefing
 
Feb 16, 2017
Mesoblast 39-Week ‘Durable’ RA Response To Stem Cells; Melbourne, QIMR, Garvan Gene-Map Pancreatic Tumors; GI Dynamics: ‘Endobarrier Safe, Reduces Adolescent BMI 10%’; Dorsavi H1 Revenue Up 46% To $2m, Loss Down 59% To $1.3m; Suda Receives $856k Federal R&D Tax Incentive; Atcor Sphygmocor Identifies Heart Failure Treatment; Mayne Launches Mikart’s Generic Bupap In US; Antisense Plans Two ATL1102 MS Trials This Year; Medibio Appoints Jack Cosentino CEO, M-D; Starts On $389k; Race: ‘FDA Defines NDA Pathway For Bisantrene For AML’
 
Feb 15, 2017
Federal $4.5m For Type 1 Diabetes Research; Federal Government Medical Cannabis Advisory Council; CSL Record H1 Revenue Up 17% To $4.8b, Profit Up 12% To $1b; Memphasys (Nusep), Prime Set Aside $4m Claim; Innate’s Chris Collins Referred To Takeovers Panel; Packer & Co Reduces, Takes Profit To 7% Of Opthea; YZJ, SMK Reduce To 6.5% Of Medical Australia; Race Requests FDA Pre-IND Meeting Trading Halt; Probiotec Appoints Greg Lan Director; Ausbiotech March Asian Investment Series
 
Feb 14, 2017
Cochlear H1 Revenue Up 9% To $609m, Profit Up 18% To $111m; Redhill Completes RHB-102 Gut Infection Trial Treatment; Aviragen (Biota) Vapendavir Fails Phase IIb HRV Trial; WEHI: ‘Stem Cell Hormone-Response Link To Breast Cancer’; Atcor Receives $472k Federal R&D Tax Incentive; Correction: Mesoblast; Biotech Capital Raises $1.8m, Share Plan For More; MGC Ready For Slovenia Medicinal Cannabis Epilepsy Trial; Creso To Launch Marijuana Food Additive In 2017; Cochlear Appoints Ray Jarman Company Secretary; Factor Appoints John Michailidis Director; Botanix Appoints Dr Michael Thurn COO
 
Feb 13, 2017
Mesoblast MPCs Reduce Rheumatoid Arthritis In Sheep; Correction: Viralytics; Biotron Starts BIT225 HIV Trial; $1.6m R&D Tax Incentive; Prima Earns $860k French R&D Tax Payment; Viralytics Receives $4.3m Federal R&D Tax Incentive; Sirtex Tells Investor Todd Hayward: ‘See You In Court’; MMJ Starts Cannabinoid PTL101 For Paediatric Epilepsy Trial; UK Approves Oncosil Pancreatic Cancer Trial; Imugene: Reformulated Her-Vaxx ‘Significant Improvement’; Uscom H1 Revenue Up 29% To $2m, Loss Up 1% To $846k; Mach7 To ‘Break-Even’; Unmarketable Parcel Facility; Factor Therapeutics Offers Unmarketable Parcel Facility; Crystal Amber Takes Hunter Hall GI Dynamics Shares To 39%; Mesoblast To Release 1.3m Escrow Shares; Biotech Capital Requests ‘Capital Raising’ Trading Halt
 
Feb 10, 2017
Dr Boreham’s Crucible: Viralytics; CSL Collaboration Stops Diabetic Kidney Disease In Mice; UK Approves Actinogen Xanamem For Alzheimer’s Trial; Allegra: ‘Evaluations Support Sr-Ht-Gahnite Bone Substitute’; Hunter Hall Dumps 17% Of GI Dynamics; Macquarie Group Takes 5% Of MMJ Phytotech; Unilife H1 Revenue Down 47% To $5m, Loss Down 35% To $44m; MGC Requests ‘Slovenian Marijuana Epilepsy Trial’ Halt; Brent Cubis To Replace Cochlear CFO Neville Mitchell 
 
Feb 9, 2017
Novogen Wins $3m CRC Grant; Psivida $26m FBR ‘At Market’ Facility; Oncosil Expects Delayed Brachysil CE Mark ‘This Year’; Final Actinogen Xanamem Alzheimer’s Trial Results Published; BPH Rejects ‘Invalid’ Board Spill Motion; SG Hiscock Takes 8% Of Resonance; FIL Takes 10% Of Medibio; Creso To Release 5.7m Escrow Shares; Respiri Hires Stewart Corporate For Partner Negotiations; Ashley Morris Replaces Scigen CEO Dr James Kim, $250k Start
 
Feb 8, 2017
Living Cell High-Dose NTCell For Parkinson’s Approved; Oventus CRC Project Wins $3m; Quality System Approved; Medical Developments Penthrox In France, Belgium; $2.6m; Orthocell Files FDA Celgro Dental Application; Proteomics: ‘Article Backs Promarkerd Kidney Disease Test’; Bard1 Lung Cancer Test Feasibility Study; Pfizer Termination Takes Psivida H1 Revenue Up 520% To $8m; Nuheara Ready For Iqbud Concentration, Hearing Trials; Lang Walker Group Takes 19.99% Of Medical Australia; MM Asset Management Takes 5% Of MMJ Phytotech; Michael Aarons Below 5% In Recce; Antisense Trades 3.8m Unmarketable Shares
 
Feb 7, 2017
Applications Open For 3 Victoria $800k Research Fellowships; Medical Developments Penthrox Roll-Out, More Indications; Cellmid Hair Growth Patent; Mach7 To Release 6m ASX Escrow Shares; Zelda Issues 8m Advisory Board Options; Actinogen Issues 5m Employee Options; MGC Takes 80% Of Panax, 20% Option; Oventus Appoints Steven Wick North America BDM
 
Feb 6, 2017
Cyclopharm Expects Record Revenue Up 14% To $14m; Cynata 60-Mouse Study Backs CYP-001 For GvHD; Biotron Mouse Data: ‘BIT225 Reduces HIV Load Faster’; Immuron Starts Paediatric IMM-124E Fatty Liver Disease Trial; Grand Challenges Canada $1.3m Loan For Atomo; Bioxyne ‘Resets’ 6m Dr Peter French Options To 3m; Neurotech Hires Emergo For Mente Autism US Regulation
 
Feb 3, 2017
Dr Boreham’s Crucible: Medical Marijuana; Benitec Jumps 178% On BB-201 Back-Of-Eye Vector For AMD; Allan Gray Takes 15% Of Impedimed; Allan Gray Reduces To 6% Of Acrux; Australian Ethical Takes 6% Of Pharmaxis; Merck Pays Bionomics $13m BNC375 Milestone; Botanix Expands Permetrex Licence To All Topical Drugs; Medadvisor Integrates Healthnotes, Ozdocsonline; Sirtex Interim CEO Nigel Lange Starts On $740k
 
Feb 2, 2017
Cynata Rat Study Backs Cymerus For Heart Attack; Monash Approves Oncosil Pancreatic Cancer Trial; TBG Receives $1m Federal R&D Tax Incentive; Allan Gray Reduces To 7% Of Acrux; Creso, Health House Deal To Import Canadian Cannabis Oil
 
Feb 1, 2017
BDI-40 Down 12%, ASX200 Up 3%, Big Caps Up 12% - Mesoblast Up 40%; Living Cell 37%; Sirtex Down 48%, Impedimed 39%; Oventus O2vent T Recall; Zhuhai Blue China Collaboration; Acrux, Eli Lilly Axiron 2016 Sales Down 6% To $192m, ‘No Generic’; Shareholder Claim Foreshadows Sirtex Legal Action; Canada, Europe Approve Nuheara Iqbuds; GI Dynamics Wins German Endobarrier Reimbursement; Adalta Releases 27m Escrow Shares; Noxopharm, Hong Kong Uni Research NOX66 For Brain Cancer; Respiri Completes Core Technology, Again; Charles Broderick, Uji Take 5% Of MMJ Phytotech; Medibio Appoints Andrew Maxwell Director
 
Jan 31, 2017
Eye Co To Trial Fludrocortisone Acetate For Retinopathy; Admedus H1 Revenue Up 85% To $12m; Clinuvel H1 Customer Receipts Up 533% To $10m; Impedimed H1 Customer Receipts $3m; Innate Falls, Bounces As Director Backs Trump’s Muslim Ban; Sirtex Requests ‘Sales Growth Legal Action’ Trading Halt; Phosphagenics, Terumo Sign TPM-Oxymorphone Patch Deal; Analytica $1.4m Conditional Placements; Euro Patent For Orthocell ‘Cell Factory’; Japan Patent For Dimerix DMX-200 For Kidney Disease; US Patent For Cellmid Midkine Alopecia Treatment; Georgia Approves Noxopharm NOX66 Cancer Trial; Reva Has One Quarter Cash; EU Sales, Finance, US IPO; Rhinomed Has Less Than One Quarter Cash; $2m Chair Loan; Creso Pharma Requests ‘Hemp Deal’ Trading Halt; Naos Takes 5% Of Biotech Capital; Mesoblast’s Dr Eric Rose Wins Thoracic Surgeons Gong
 
Jan 30, 2017
Benitec, Nant Seal BB-401, BB-501 Head, Neck Cancer Deal; Zoetis Pays Anatara Second Detach Option Fee; Dutch Study Backs Volpara Breast Density Test; Neuren Completes Paediatric Rett Trial, March Results; Anteo’s Diasource Revenue Up 15.5% To $23m; Harvest One Raises $25m For MMJ Cannabis Subsidiaries; Medibio Negotiates $3.3m Patents Convertible Note; Pharmaust Receives $406k Federal R&D Tax Incentive; IQ3 Has Less Than One Quarter Cash; Invitrocue Has Less Than Two Quarters Cash; Brain Less Than 2 Quarters Cash, Expects R&D Tax, Revenue; Phylogica Pleads Schultz To ASX 41% Query
 
Jan 27, 2017
Airxpanders To Raise $45m; Prof Alan Mackay-Sim Australian Of The Year 2017; Innate Pleads Schultz To ASX 120% Query, No Trumps; Suda Takes HC Berlin Pharma Settlement Halt To Suspension; Narelle, Andrew Fay Take 11% Of Medical Australia; Cogstate Appoints Jane McAloon Director
 
Jan 25, 2017
Dimerix Placement To Raise $2m; Medibio, Emory Expand Heart Rate Test To PTSD; Anteo $2m EU Grant For Vitamin D Test; Atcor Sphygmocor Shows BP-Cognition Relationship; Paradigm Recruits Phase IIa PPS Hay-Fever Trial; MGC To Trial Skincare Cannibinoids On Slovenian Volunteers; Bank Of New York Mellon Takes 5% Of Cochlear; Airxpanders Takes Capital Raising Halt To Suspension; Japan Patent For OBJ Magnetic Microarray Technology; Sirtex Appoints Rueben Teo Asia-Pacific CEO
 
Jan 24, 2017
Resmed H1 Revenue Up 15% To $1.3b, Profit Down 14% To $202m; Universal Bio Receipts Up 28% To $22m, Loss To $1m Profit; Oventus Pilot Study Backs O2vent T For CPAP; Australian Ethical Takes More Profit Below 5% Of Innate; Hockings Take 31% Of Phylogica; Suda Requests HC Berlin Pharma Settlement Trading Halt
 
Biotech Daily: Welcome To 2017 Editorial; Dr Boreham’s Crucible: Sirtex Medical; Japan’s AGC Pays Regeneus $7m Progenza Fee; Cynata Raises $6m; Atcor Sphygmocor Measures Novartis Drug End-Point; Cogstate Claims Record H1 Revenue Up 43% To $18.5m; SA Government Sells Reproductive Health Shares; Federal Government Hosts China Export Seminars; Airxpanders Requests Capital Raising Halt; Dimerix Requests Capital Raising Halt; Recce Loses Director Dominic Barnes 
 
MGC Issues 26m ‘Performance Shares’; Proteomics Plan Raises $575k, Takes Total To $2m - Dr Richard Lipscombe, William Parker, John Dunlop Increase, Diluted; Ibsen, Ezahc, Narula Take 11% Of Optiscan; Mach7 Approves 10-To-1 Consolidation; Redhill Raises $53m; Perpetual Reduces To 7% Of Sirtex; Regeneus $23m Asahi Glass Licence Of Progenza In Japan; Robert Peters Takes 7% Of Optiscan; DSMB Approves Prima IMP321 For Melanoma Dose Increase; Pharmaust Rights Shortfall Placement Raises $1.6m, Total $2.7m; Innate Pleads Schultz To ASX 48% Query; Optiscan CFO Michael Corry Resigns As Joint Co Sec; Prima Develops IMP761 For Autoimmune Diseases; US FDA Approves Actinogen Phase II Xanamem Alzheimer’s Trial; Uscom Manufactures 1000th Uscom 1a Monitor; Chair Prof Robert Phillips Increases To 19% Of Uscom; Dr Oern Stuge Replaces GI Dynamics Chairman Jack Meyer; Prima, Cytlimic Collaborate On IMP321, Cancer Peptide Combination; BV Health, NRF, Sagamore Take 10% Of Mach7; FIL Takes 9% Of Medibio; Europe Approves CSL’s Afstyla For Haemophilia A; Mallinckrodt Pays Mesoblast $30m For Two Drug Option; Sirtex Unaudited H1 Dose Sales Up 5.6%; Adalta ‘AD-114 Reduces Lung And Liver Fibrosis In Mice’; Europe Approves 3 MGC Cannabinoid Cosmetics; Prana Pleads Schultz To ASX 30% Query; Former Chair Martin Rogers Below 5% In Actinogen; Orthocell Receives $1.95m Federal R&D Tax Incentive; Perpetual Below 5% Of Sirtex; Creso To Release 6.4m Escrow Shares; Rod Gibson, Rosherville Take 13% Of Reproductive Health; CSL To Market Zambon, Newron Xadago For Parkinson’s Disease; TGA Approves WEHI Venetoclax For Leukaemia; Resapp, Massachusetts General Extend Collaboration; Medadvisor Buys Ozdocsonline For $150k; Oventus Quality Management Wins ISO 13485:20121; Adherium Appoints Scott Fleming For Euro Business Development; Redhill Begins 2nd Phase III RHB-105 For Helicobacter PK Study; USPTO Accepts Living Cell NTCell Patent Application; Mayne US Launch Of Fabior For Acne, Sorilux For Psoriasis; Redhill RHB-104 Wins US QIDP For Non-TB Mycobacteria Infections; Starpharma Vivagel Wins US QIDP Status For Bacterial Vaginosis; MTP Connect ‘$18b Sector Value Increase, 28k Jobs In 10 Years’; Prima Doses 1st Patient In 2nd IMP321, Keytruda Cohort Trial; Orthocell, J&J Work On Ortho-ATI For Tendons, Ligaments; Bergen Below 5% Of Anteo; Adherium: ‘UK Nice Backs Smartinhaler For Asthma Medication’; US FCC Approves Nuhear Iqbuds; Analytica ‘Pericoach Helps 70% Of Severe Incontinence Patients’; Mayne US Launch Of 100mg Amiodarone For Arrhythmia; Sirtex Sacks CEO Gilman Wong Over Share-Dealing; Biotron Has Less Than Two Quarters Cash; Mayne Promotes, Appoints Executives; Memphasys Manukan Preference B Shares Injunction Discharged; David Franks Replaces Phillip Hains As Noxopharm Co Sec; Uniquest: ‘J&J, Arthritis QLD Back Dendright DEN-181 For RA’; EU Orphan Status For Benitec BB-301 For OPMD; Airxpanders 1st US Paid Aeroform Breast Expansion Procedure; Impedimed Loses Director Elizabeth Gaines To Fortescue As CFO; GI Dynamics Plan Raises $294k Of Hoped-For $988k, Total $1.8m; Mach7 Completes 10-For-1 Stock Consolidation; Thorney Takes 5.6% Of Anatara; FIL Takes 7% Of Cogstate; Greg Hunt Takes Health, Arthur Sinodinos Innovation; Prima Meets Nasdaq $US1 Rule; Cellmid Wins Federal $100k For Midkine Kidney Trials In Rodents; Yarra Funds Takes 6.6% Of Sirtex; Regal Funds Reduces To 5% Of Adherium; Dorsavi ‘Vimove Better Than Guideline Care For Back Pain’; US Orphan Status For AD-114 For Idiopathic Pulmonary Fibrosis; Creso Claims 1st EU Approval For Cannabinoid Animal Feed Additive; Recce Says Mouse Trial News May Have Led To ASX 131% Query; Oventus Wins O2vent T 1st US Sale; Harvest One To Raise $C15m For MMJ Cannabis Subsidiaries; Telix Partners With Therapeia GMBH For ACD-101 For Glioblastoma; Clarity Appoints Dr Colin Biggin Head Of Quality; Allan Gray Reduces To 13% Of Acrux; CSL Upgrades 2017 NPAT; Uscom: ‘BP+ Predicts Ethnicity, Smoking, Drinking, Obese Heart Risk’; Justyn Stedwell Replaces Allegra Co Sec Richard Ulrick; Cynata: ‘$60m Partnership With Fujifilm For CYP-001 For GVHD; Australian Ethical Takes More Profit To 5% Of Innate; Immuron Studies To Back IMM-124E For Nash; Prima Doses 1st Breast Cancer Patient In Part 2 Of IMP321 Trial; Cogstate Appoints Dr Richard Mohs Director; Dorsavi Share Plan Raises $1m; Regal Funds Reduce Below 5% Of Adherium; Paradigm To Release 9.7m Escrow Shares
 
 
Dec 23, 2016
Mallinckrodt Buys $30m Stake In Mesoblast For 2 Licences; Prana Xmas Present: ‘More PBT2 Work For Huntington’s; Benitec Signs Nantworks Head, Neck Cancer Sub-Licence; Perpetual Reduces To 8% Of Sirtex; ITL Chairman Bill Mobbs Reduces To 37% To ‘Share The Value’
 
Dec 22, 2016
2016 – Biotech Daily’s Year In Review: Money, Malcolm & Medical Marijuana; US FDA Okays Airxpanders Breast Tissue Expansion Aeroform; Living Cell Treats 2nd NTCell For Parkinson’s Cohort; Prima IMP321 ‘Safe, Well-Tolerated’; Device Technologies Orders 1st Polynovo BTM For NZ; Neurotech Mente Autism Italian Shipment A ‘Major Milestone’; MMJ Starts Cannabis Cultivation, Aims At 60 Tonnes A Year; Starpharma Receives $3.5m Federal R&D Tax Incentive; Analytica Receives $1m Federal R&D Tax Incentive; Immuron Files US IPO Registration Statement; Brendan Moran Takes 5% Of LBT; Regal Funds Takes 10% Of IDT Australia; Hunter Hall Takes 18.5% Of GI Dynamics; David Sietsma Takes 10% Of Phylogica; Ex-Acuvax CEO Dr William Ardrey Wins Fraud Retrial
 
Dec 21, 2016
Clinical Genomics, CSIRO US Bowel Cancer Test Launch; Benitec BB-102, BB-103, Combination Reduce Hepatitis B In Mice; US Pilot Study Backs Medibio Heart Test For Depression; Optiscan Raises $1.9m; Redhill Resumes Capital Raising; Apple Approves Nuheara Iqbuds Application; Up To 30% Of Atcor AGM Oppose Share Issue
 
Dec 20, 2016
Redhill Doses 1st Yeliva Multiple Myeloma Patient; Zelda, Curtin Uni Trial Marijuana For Pancreatic Cancer; Factor Recruits 1st US VF-001 Venous Leg Ulcer Patient; UK OK For Prima Aipac Imp321, Paclitaxel Breast Cancer Trial; Recce: ‘Efficacy Correlation’ For Recce 327 For ’Flu In Mice; Volpara Rights Issue Raises $3.7m, Total Raised $10.7m; Antisense Options Raise $73k; Noxopharm Hits $50m For 2 Days, Converts 10m Shares; CEO Dr Graham Kelly, Family Take 37% Of Noxopharm; Neurotech Appoints Scientific Advisory Board; MTP Connect, Advanced Manufacture Growth Centre Partner
 
Dec 19, 2016
Universal Bio Buys Canada Lab For Xprecia Test Strips; Genentech $2.75m For Phylogica Licence For Antibiotics; Global Kinetics, Umotif Partner For Parkinson’s Trials; Imugene Files 4 Immuno-Oncology Patent Applications; Russia Grants Proteomics Promerkerd Diabetes Test Patent; Dorsavi Signs $100k+ Baggage Handling Heathrow Contract; Simavita Receives $1.7m Federal R&D Tax Incentive; Sirtex CEO Gilman Wong Steps Aside For Share Deal Inquiry; Optiscan Requests Fundraising Trading Halt; Up To 37% Of Psivida Oppose Pay, Directors; Prima Changes ADR Ratio To Meet Nasdaq $US1 Bid Rule; Gavin Smith Replaces Polynovo CFO Andrea Goldie For Leave
 
Dec 16, 2016
Multiple US States File Anti-Trust Suit Against Mayne, Others; Imugene Tells ASX: ‘Baker IDI Deal Not Material, No Leaks’; Memphasys Cancels $1m Convertible Notes, Looks At Options; Biotech Capital $132k For Dr Richard Treagus’ Pharmaconnect; Up To 46% Of Unilife AGM Opposes All Directors; Australian Super Below 5% Of Orthocell; Crystal Amber Takes 23% Of GI Dynamics; Medicines Australia Appoints Dr Anna Lavelle Director; Optiscan Appoints Justin Mouchacca Joint Co Sec; Tim Slate Replaces Zelda Co Sec Neville Basset 
 
Dec 15, 2016
TGA Approves Sienna's Adjunct Bladder Cancer Test; Ellex Trains Chinese Surgeons In Itrack For Glaucoma; Resonance: ‘Independent Data Backs Ferriscan’; DSMB Okays Redhill Phase III RHB-104 (Myoconda) Crohn’s Trial; I’rom Pays IDT $10m For 61% Of Adelaide CMax; Sirtex Tells ASX Aware Query: ‘We Complied With The Rules’; Proteomics: ‘Promarkerd Predicts Diabetic Kidney Disease’; Royal Adelaide Approves Cynata CYP-001 Phase I GvHD Trial; MMJ Welcomes Canada Recreational Marijuana Review; Oventus Signs Unnamed Dental Group For Snoring, Apnoea; Phosphagenics Chicken Feed Study Backs TPM For Growth; Respiri Develops Sonosentry Night Asthma Monitor; Bio-Melbourne ‘2017 Trends’ February Briefing
 
Dec 14, 2016
Sirtex Sir-Spheres US Cancer Network Confidence Upgrade; GI Dynamics Raises $1.5m, Plan For $988k More; Prescient Doses 1st PTX-200 AML Patient; Takeda Uses Dimerix Receptor-Hit For Orphan Receptors; Up To 17% Of Benitec AGM Oppose Director Dr John Chiplin; Bio-Melbourne, Dr Thomas Lönngren Workshop Brexit, Trump
 
Dec 13, 2016
Federal $500m Biomedical Translation Fund; Imugene Licences Baker IDI Arginine Modulators For Cancer; Redhill Phase IIa RHB-104 ‘Clinical Efficacy Signals’ For MS; IQ Opens $100m Life Science Fund; Dorsavi Raises $7m, Share Plan For $1m More; Orthocell Raises $4m; CSL Sells Seqirus Warehousing, Logistics To Toll Group; Imugene Pleads Schultz To ASX 50% Query; Hunter Hall Takes 6.7% Of Sirtex; Pokies Bruce Mathieson Increases, Diluted To 6% Of Mayne; UK Approves Cynata CYP-001 Phase I GvHD Trial; Cochlear Appoints Prof Bruce Robinson Director; Alchemia Appoints Darren Book Director; Patrys Appoints Dr Pamela Klein, Dr Allen Ebens Advisors
 
Dec 12, 2016
Sienna Registers CE-Marked IVD Product In EU; Zelda Prepares Medical Marijuana Sleep Trial; Phosphagenics, Tesa Labtec TPM-Oxymorphone Patches; Memphasys Raising Up To $1m For Working Capital, Litigation; Cellmid Expects Rising Pacific Edge CXBladder Test Royalties; GI Dynamics Requests Capital Raising Trading Halt; Bionomics Issues ‘Less Dilutive’ Warrants Over 16m Shares; Race Appoints Prof Martin Tallman For AML Advisory Board
 
 
Dec 8, 2016
NFMRI $50k For Prof Mark Kendall, Prof Michelle McIntosh; Medadvisor Signs Pfizer For Drug Adherence; Taiwan: ‘Medical Developments Penthrox For Pain, Surgery’; Polynovo Signs Surgical Innovations For BTM In South Africa; Creso Delivers 700kg Hemp Seeds For Protein Bars; Avexa Changes Name, Code To Novita Healthcare, NHL; Prescient Restarts PTX-200 Ovarian Cancer Trial; Pharmaust Rights Offer Raises $1m Of Hoped For $4.6m; MMJ Sells Subsidiaries To 70% Subsidiary Harvest One; Up To 45% Oppose Mach7 Founder, Director Dr Nigel Finch; Bergen Reduces To 6% Of Anteo; Grandlodge, Peter Anastasiou Have 13% Of Immuron; FIL Takes 8% Of Medibio; Acrux Loses Director Bruce Parncutt 
 
Dec 7, 2016
Uniquest, Canada Deal For Post-Chemo White Blood Cells; Orthocell Placement Raises $4m; Botanix: Permetrex Transdermal ‘Safe, Low Irritant’; Germany’s BOC To Distribute Rhinomed Plugs In Australia, NZ; MGC Hires Inhemp For Cannabis Cosmetics Sales, Marketing; Auckland’s Milford Substantial In Living Cell, Again
 
Dec 5, 2016
NHMRC $483m For 601 Grants; Federal ‘$200m, 10-Year CSIRO Innovation Fund’; Diabetes Australia Provides $3.2m For Research; Melbourne Uni, CSL Therapeutic Dental Vaccine Works In Mice; Biomérieux Canada To Distribute ITL Safety Subculture Unit; Auscann Cannabis For Zelda, Telethon Brain Cancer Tests; Orthocell Requests Capital Raising Trading Halt
 
Dec 2, 2016
Genetic Technologies Placement Raises $8.1m; LBT Raises $7m; Proteomics Raises $1.44m, Plan For $480k More; MGC 1st Czech Order For $65k Of Cannabis Skincare Cosmetics; FIL Takes 6% Of Somnomed; Bio-Melbourne Appoints Lusia Guthrie Interim CEO; Justyn Stedwell Replaces TBG Co Sec Blair Lucas; Nuheara Appoints CFO Jean-Marie Rudd Joint Co Sec

 

 

 
Dec 1, 2016
November BDI-40 Down 5%, ASX200 Up 2%, Big Caps Down 2% - Neuren Up 51%; Actinogen 30%; Impedimed Down 25%; CSL Takes 3 MABs To Phase I, R&D Spend Constant At $810m; Ellex Placement Raises $10m; Dorsavi Launches Myvisafe Manual Handling Analysis Tool; Chair David Breeze Replaces Deborah Ambrosini As BPH Co Sec
 
Nov 30, 2016
Zelda THC Beats Pure THC, Equals Lapatanib For Cancer In Mice; Profs James McCluskey, Jamie Rossjohn Share $50k Victoria Prize; Living Cell Raises $6.3m; ITL, Myhealthtest, Canberra Uni Federal $50k For New Tests; Genetic Technologies Colorectal Test, Nasdaq Push Price 110%; Nuheara Iqud Production A ‘Significant Milestone’; Ellex Requests Placement Trading Halt; LBT Requests Capital Raising Trading Halt; Proteomics Requests Capital Raising Trading Halt; Up To 10% Of Starpharma Oppose CEO ‘Performance’ Rights; Victoria Science, Medical Research, Technology Panel; Bio-Melbourne Breakfasts On Regenerative Medicine; Anteo Appoints Dr John Hurrell Chairman; Actinogen Loses Chairman Martin Rogers
 
Nov 29, 2016
Genetic Technologies, Melbourne Uni Colorectal Cancer Test; Medical Developments 22 Country Penthrox Application; Cynata Lodges ‘IPSC Assay’ Patent Application; Medadvisor, Asthma Australia Partnership; Antisense 1-For-5 Bonus, New Option Offer; Immuron Receives $1.6m Federal R&D Tax Incentive; Cellmid Receives $831k Federal R&D Tax Incentive; Hyperion Takes 6% Of Cochlear; Up To 45% Of Probiotec Oppose Director Graham Morton; Wayne Stringer Group Down To 19% Of Probiotec; Avexa Loses Singapore Director Allan Tan
 
Nov 28, 2016
Sirtex STC314 For Sepsis Leads 4 New R&D Programs; Hungary $3m For Uscom Lung Cancer Test Consortium; Starpharma Appoints Koushan For Vivagel Condoms In Iran; Oncosil Names Hospitals For Pancreatic Cancer Trial; Mizuno Uses Dorsavi’s Vimove To Select Running Shoes; P&G Licences OBJ Wave II Magnetic Cosmetics Applicator; Canada Permits MMJ 1kg Marijuana Seeds, Recreational Use; Memphasys Remuneration Faces 17.6% Opposition; Probiotec Bets On Chair Geoffrey Pearce For AGM Spill; Jason Peterson, Celtic Take 12% Of Zelda- Chair Harry Karelis, Gemelli 7%, Aunt Zelda, Mara Gordon 12%; Living Cell Takes Capital Raising Halt To Suspension; Phylogica Loses Director, Former Chairman Dr Doug Wilson
 
Nov 25, 2016
Zelda Lodges Medical Marijuana Patents; Prima AGM Faces 32.5% Dissent; Bioxyne AGM Passes Remaining Resolutions; Alchemia Loses Director Nathan Drona Ahead Of Today’s AGM; Imugene Pleads Schultz To ASX 33% Query, Again
 
Nov 24, 2016
Medibio Licences Medtronic Zephyr Biopatch; Living Cell Requests ‘Capital Raising’ Trading Halt; Bioxyne Removes 6m Dr Peter French Options From AGM; Recce 1st AGM 82% Remuneration 1st Strike; Invitrocue Appoints Dr Ramanuj Dasgupta Scientific Director; Cogstate Appoints George Hunnewell Coo, Frank Cheng
 
Nov 23, 2016
Benitec: ‘Phase II EGDR-AS Head Neck Cancer Trial In 2018’; US FDA Approves Cyclopharm Phase III Technegas Trial; Optiscan Launches Viewnvivo Pre-Clinical Endo-Microscope; MSD: ‘Industry Bridge Initiative To Develop Skills’; Wuxi To Manufacture Prima IMP321; Noxopharm: ‘NOX66 Delivers Idronoxil To Rat Brains’; Universal Biosensors Expects 2016 Federal R&D Tax Incentive; GI Dynamics German Endobarrier Reimbursement Progress; Up To 22% Oppose Factor Placement Capacity; Up To 13% Of Viralytics Oppose 666k Director Options; BV Health, NRF, Sagamore Increase, Diluted To 8% Of Mach7; Merchant Takes 7.5% Of Zelda
 
Nov 22, 2016
Volpara Placement Raises $7m, Rights Offer For $3.7m More; Zelda Opens Up 15% For Medical Marijuana, Closes Down 8%; Mayne Launches IDT’s Temozolomide In The US; Anatara: ‘Pig Detach In 2017; Prof Tracey Brown Human Health’; Hunter Hall Takes 9.5% Of Mach7; Factor Therapeutics, Monash Uni Wound Collaboration; Sweden Approvals Paradigm PPS Hay Fever Trial; Biotron Remuneration Report Faces 18% Dissent; Viralytics Appoints 4-Professor Clinical Advisory Board; WEHI’s Prof Jane Visvader, Prof Geoff Lindeman Win Ramaciotti; Recce Loses Director Bernadette Murdoch Ahead Of AGM
 
Nov 21, 2016
UAE Approves Admedus Cardiocel Heart Patch; Bluechiip Wins 2nd Federal $50k Grant For Over-Temp Chip; Opthea Completes Opt-302 Phase IIa Wet AMD Trial Enrolment; Genera Receives $722k Federal R&D Tax Incentive; Ex-Advisor Transocean Claims 50m Memphasys Options, Fees; Imugene COO Leslie Chong Promoted To CEO; Bioxyne Loses Director George Cameron-Dow; Biotech Capital Partners With Dr John Chiplin; Factor Appoints Prof William Marston, Prof Mark Sleeman
 
Nov 18, 2016
Adherium Study: ‘Smartinhaler Improves Asthma Outcomes’; Cochlear Complex US Court Of Appeal Patent Decision; Medibio Expects To Raise $13.5m; Up To 40% Of Polynovo Oppose 33% Directors Fee Pool Hike; Volpara Requests ‘Capital Raising’ Trading Halt; Zelda Relists Nov 22 For Marijuana For Insomnia, Acne, Cancer; BVF Partners, Mark Lampert Reduce To 13.6% In Viralytics
 
Nov 17, 2016
WEHI, Melbourne Uni Organoids Bank For Pancreatic Cancer; Impedimed Sozo For Heart Failure Available In 2017; Volpara, Microsoft Collaborate On Breast Imaging Analytics; Suda: ‘Hydrotropes Enhance Viagra Permeation In Rabbits’; Creso To Market Cannimed’s Medical Cannabis In Europe; Mach7 To Release 1.5m Escrow Shares; Up To 20% Oppose LBT Placement Capacity; Novogen 16% Oppose Remuneration Report; Anthony Barton, Associates Take 5% Of Phylogica; Monash’s Prof Christopoulos, Prof Sexton Win $80k GSK Prize; Prof Ian Gust Wins Top Research Australia Gong; Noxopharm Appoints Three Trial Advisors, Consultants
 
Nov 16, 2016
CSL: ‘CSL112 Safe, Removes Cholesterol Post-Cardiac Arrest’; Mach7 Raises $9m; Zelda Backdoor IPO Raises $4m; Atcor Raises $1.9m For Sales, Working Capital; Texas Children’s Okays Resapp Kids Respiratory Trial; Phosphagenics Recovers OTC Licence, Bioelixia Sale; Medibio Requests ‘Major Capital Raising’ Trading Halt; Phoria, Skinview Win $25k MCRI Bytes4health Prizes; Crystal Amber Takes 17.5% Of GI Dynamics; Resonance Appoints Dr Travis Baroni Director
 
Nov 15, 2016
FDA Approves Sienna’s 1st Telomerase In-Vitro Diagnostic; Simavita Launches Assessplus For Home Care; RMIT Nebulizer Wins $663k Johnson & Johnson Quickfire Challenge; Pharmaxis, Woolcock Work On Orbital Inhaler For CF; Proteomics, Linear Partner For Diagnostics, Clinical Trials; TBG To Distribute Omixon’s Holotype HLA Typing In Asia-Pacific; Cynata Receives $1.75m Federal R&D Tax Incentive; Antisense Receives $396k Federal R&D Tax Incentive; Anteo AGM Survives Remuneration Report, Up To 34% Dissent; Up To 25% Oppose Anatara Placement Capacity; Perpetual Takes 9% Of Sirtex; DRH, David Hannon Reduce To 10% Of Noxopharm; Stephen Coupe Takes 5.5% Of Nuheara; Adalta Appoints Dr Robert Peach A Non-Executive Director 
 
Nov 14, 2016
Monash Biomedicine Discovery Institute Opens; EMA Committee Backs CSL Afstyla For Haemophilia A; Correction: Universal Biosensors; Mesoblast MSC-100- IV For GvHD Passes ‘Futility Test’; Neuren Recruits Rett Trial, Lang Walker Funding EGM; Early Capra Trial Data Backs Viralytics Cavatak For Tumors; Medical Developments Appoints McKesson US Distributor; Volpara Test In Breast Cancer Risk Tool, H1 Revenue Up 5% To $1.2m; Up To 23% Dissent Against Impedimed AGM Resolutions; Atcor Requests Capital Raising Trading Halt; Mach7 Requests Capital Raising Trading Halt; ITL To Release 6.7m Escrow Shares; Anteo Loses Chairman Mark Bouris Before AGM; Impedimed Euro Bio-Impedance Heart Failure Advisory Board
 
Nov 11, 2016
Anteo Joins DMTC For NPlex Medical Countermeasure Tests; Living Cell 2nd Parkinson’s NTCell Cohort Approved; Mass General Okays Resapp Pivotal Kids Respiratory Trial; Redhill FDA Meeting For 2nd RHB-105 Phase III Helicobacter Trial; Botanix Prepares Human Cannabidiol BTX-1503 For Acne Trial; USPTO Issues 3rd LBT APAS Patent; Monash Antibodies For Proteomics Promarkerd Kidney Test; CE Mark For Neurotech’s EEG Mente Autism; Prime Demands Memphasys $5m Payment
 
Nov 10, 2016
Ellex: ‘79% Increased US Itrack Reimbursement’; Research Backs Resonance R2-MRI For Sickle Cell Disease; Atomo, Ng Biotech Develop Rapid P-O-C Pregnancy Blood Test; TGA Approves Medlab Cannabis Import Licence; Phosphagenics Extends Terumo’s Opioid Patch Licence; Antisense 27% Remuneration 1st Strike; Up To 14% Dissent At Admedus AGM; Epiaxis Wins Johnson & Johnson Innovation Start-Up Slam
 
Nov 9, 2016
Suda, Eddingpharm Potential $34m Zolpimist Insomnia Deal; Bluechiip Sells Tracking Kits To China, Eastern Europe; UK NHS Approves Mach7 Imaging Products; GI Dynamics German Registry Backs Safety, Efficacy; SG Hiscock Takes 6% Of Resonance; Clinuvel Rolling US Scenesse For EPP NDA In 2017; Avita Adds 2 Sites To Regenercell Diabetic Foot Ulcer Trial; Dr Charles Day Innovation And Science CEO; CRC Advisors

Nov 8, 2016
WEHI Links Myc Protein To T-Cell Division And Apoptosis; Crossbeta Licences Adalta Shark Antibodies For Alzheimer’s; Adalta, XL-Protein Develop Long-Acting AD-114 For Fibrosis; Pharmaust Rights Offer To Raise $4.6m; Optiscan Receives $726k Federal R&D Tax Incentive; Australian Super Takes 5% Of Osprey; FIL Takes 5.5% Of Cogstate; Australian Ethical Below 5% Of IDT; Wayne Stringer Group Takes 23.5% Of Probiotec; Psivida Appoints Deb Jorn Head Of Corporate, Commercial 
 
Nov 7, 2016
Innate: ‘Most MS Patients Want MIS416 Open Access Treatment’; ITL Sells 1m Donorcare Needle Guard 2 In 1st Month; FDA Removes Factor Therapeutics VF-001 Hold, Trial OK; Sirtex CEO Gilman Wong: ‘I Sold Shares To Pay Tax On Rights’; Imugene Starts HER-Vaxx Asia Gastric Cancer Trial; Medlab Prepares Nanabis Cannabis Cancer Pain Trial; MGC Starts Euro Cannabidiol Skin Treatment Registration; Creso, Greveling, A&H Marijuana Deal For Pet Health; Platinum Takes 9% Of Imugene; Dimerix Appoints G-M Kathy Harrison CEO
 
Nov 4, 2016
Malta’s Neurotech $7m IPO For Brain Disorder Products; ASIC Stops TW Holdings, Auscann Prospectus; Mayne ‘Cooperating With US Justice On Doryx Investigation’; Meeting Paper Backs Atcor Sphygmocor For Heart Failure; Allan Gray Reduces To 13% Of Acrux; Otto Buttula, Webinvest Diluted Below 5% Of Imugene; Dimerix Loses Director Dr Elizabeth Jazwinska Ahead Of AGM; Data61 Connects Melbourne Medtech Students, Jobs; Bionomics, MSD Neuroscience Symposium
 
Nov 3, 2016
‘Market Conditions’ (Trump?) Halts Redhill $13m Raising; Volpara: ‘FDA Mammography Rules Back Our Enterprise’; Acrux Challenges Kaken Onychomycosis Patent; Prana Prioritizes Europe On US FDA Data Request; Cellmid US Launch Of Évolis Hair-Loss Products Next Week; Mayne US Launch Of Extended-Release Morphine Sulphate; MMJ Gets Better Subsidiary Offer From Harvest One; Resapp 26% Remuneration 1st Strike, 27% Director Options; Bard1 Appoints Dr Leearne Hinch CEO; Cryosite Appoints Nicola Swift Director
 
Nov 2, 2016
IDT Ships 1st New Drug Temozolomide To US Distributor Mayne; Osprey Launches Dyevert Plus, Available In 2017; Redhill $13m ADS Capital Raising; Acrux Files ACR-065 For Onychomycosis Patent; Suda Applies For Oral Mucosal Drug Delivery Patent; Bioxyne Launches Progastrim For Gut, Protract For Eczema; Medibio Depression Study Claims 86% Accuracy; Recce: ‘Recce 327 Safe In Mice, Does Not Inhibit Cancer’; Novogen’s GDC-0084 Triggers 16m Dr Kelly, Triaxial Shares; Nuheara Appoints Wynit For US, Canada Iqbuds Distribution; Prescient Receives $645k Federal R&D Tax Incentive; Imugene Remuneration 1st Strike With 37% Against; Bank Of America Below 5% In Suda, Again
 
Nov 1, 2016
October BDI-40 Down 0.5%, ASX200 Down 2%, Big Caps Down 7% - Genetic Signatures, Compumedics Up 42%; Prana Down 34%; Federal $417m For 989 ARC Grants; Reva Hails Fantom II Stent Trial Safety Data; Cellmid Raises $3m For Evolis Hair Loss US Launch; MMJ Requests ‘Changed Transaction’ Trading Halt; Probiotec Directors Removal AGM; Correction: Prescient; Medadvisor To Release 2.8m Escrow Shares; Memphasys Director Andrew Goodall Takes 39%; Unilife Appoints Rosemary Crane, Duane Desisto Directors
 
Oct 31, 2016
Novogen $8.7m For Genentech’s GDC-0084, Glioblast Pty Ltd; CE Mark For New Uscom Spirosonic Devices; Orthocell Rat Study Validates ‘Cell Factory’ For Repair; Prana Receives $4.8m Federal R&D Tax Incentive; Medadvisor Completes $5.5m Healthnotes Acquisition; Clinuvel Pleads Schultz To ASX 27% Query; Q1 Income Up 364%; Pharmaust Has One Quarter Cash, $2.1m More Coming; Platinum Takes 6% Of Imugene; Creso Appoints Medic Hemp-Based Cbdium Czech Distributor; Immuron Up To 50m Share Nasdaq IPO AGM; Memphasys AGM For 24m Chair, 7m Advice Options; Prescient AGM For 8m CEO Shares, 764k Director Options; Imugene Loses Director Dr Anton Uvarov; Proteomics, Orthocell Win WA Export Gongs
 
Oct 28, 2016
Medical Developments, CSIRO Undisclosed Drugs Deal; IDT Sells CMax Trials Business To Japan’s I’rom For $14m; Burnet Program-Led Strategic Blueprint; Neuren Options Raise $930k; Anteo, Ellume Collaborate On Point-Of-Care Diagnostics; Oventus Snoring, Sleep Apnoea Devices At 1300smiles; US Patent For Starpharma Priostar Glyphosate; Immuron Recruits 101 Of 120 IMM-124E Fatty Liver Patients; Atcor 24% Oppose Director David Brookes; OBJ 34% Oppose 10% Placement Facility; Dorsavi 900k CEO Performance Rights AGM; Cellmid Takes Capital Raising Trading Halt To Suspension; Dr David Thurin, Dalit, Diluted Below 5% Of Benitec; Dorsavi’s Visafe Wins Two London Gongs
 
Oct 27, 2016
Federal Government $190m For 320 NHMRC Grants; Gates Foundation $3.6m For Atomo HIV Test; Uscom Monitor ‘Guides Paediatric Septic Shock Treatment’; Dorsavi US Low Back Pain Registry For Treatment, Payment; Nuheara Raises $5m For Iqbuds; Streuli To Distribute Creso Marijuana Gum In Switzerland; Mayne US Launch Of Generic Entocort EC For Crohn’s Disease; Vittoria To Distribute Rhinomed Mute, Turbine Plugs In US; Adherium Faces 14% Dissent To 2.6m Director Loan Shares; Paul Ruggiero, ‘Like-Minded Investors’ Below 5% Of Cellmid; Pharmaxis AGM For 827k More CEO ‘Performance Rights’; Avita $366k Directors Shares In Lieu Of Pay AGM; IDT Requests ‘Corporate Transaction’ Trading Halt; Patrys Pleads Schultz To ASX 33% Query
 
Oct 26, 2016
Victoria: ‘Monash, CSIRO Win Regenerative Medicine Centre’; P&G Licences OBJ Wave II Magnetic Cosmetics Applicator; Nanosonics Q1 Record Sales Up 174% To $18m; Acrux Lilly Q3 Axiron Sales Fall 6% To $51m; Impedimed Q1 Revenue Up 13% To $1.7m, Lymphoedema Up 100%; Cogstate Signs Clinical Ink For Tablet-Based CNS Trials; Cellmid Requests Capital Raising Trading Halt; Creso Pharma Requests ‘European Update’ Trading Halt; Tbilisi Centres Approve Noxopharm NOX66 Cancer Trials; Japan Accepts OBJ Skincare Patent; MGC 4m Director Dr Ross Walker Shares AGM; Bluechiip 3m CEO Rights, 1.6m Shares In Lieu AGM; Starpharma 1.1m More CEO ‘Performance Rights’ AGM; Optiscan AGM For 19.5m Director, 5m Underwriter Options; Chairman Robert Finder Takes 6% Of LBT; Merchant Reduces To 11% Of Polynovo; Rod Gibson Companies Take 11% Of Reproductive Health; Alvin Blumenthal, Suburban Take 11% Of Creso, Maybe 
 
Oct 25, 2016
J&J’s Dr Jeanne Bolger: ‘No Limit To Our Investment’; Prof Ian Gust: ‘CSL - Outstanding Leadership, Laser Focus’; Race Appoints Irisys For Bisantrene Manufacture; Creso IPO Raises $5m For Marijuana Food Additives; Nuheara Requests Capital Raising Trading Halt; Sirtex 14.25% Dissent Against CEO Performance Rights; ASX Approves Unilife Return To Trading; Analytica 60m Director Options AGM; Bioxyne 9.75m Director Options AGM; Patrys 15m CEO Options AGM; Sirtex Promotes Nigel Lange To Coo; Andrew Wilks, Protagonist, Resapp Win Ausbiotech, J&J Gongs
 
Oct 24, 2016
Victoria Premier Daniel Andrews Opens Ausbiotech Conference - Monash Medicines Manufacturing Innovation Centre, Appoints Amanda Caples Lead Scientist, Dr Gareth Goodier Parkville Chair; CSL’s Paul Perreault: ‘Innovate, Focus On Patients, Or Leave’; Innovation & Science Australia’s Bill Ferris On R&D Review; Federal $7.4m For 14 MTP Connect Projects; Benitec $5m+ Nant Cancer ddRNAi Collaboration; Amplia Licences (Alchemia) CTX Focal Adhesion Kinase Drugs; ITL To Launch Donorcare Needle Guard 2; Invitrocue, Genome Institute Colorectal Cancer Collaboration; TGA Cancels GI Dynamics Endobarrier Listing, Trial Continues; Australian Ethical Takes Profit To 7% Of Innate; Graham Durbin Superannuation Takes 11.6% Of Genera; Rhinomed Loses CFO, COO Justine Heath; Race Appoints Prof Douglas Smith Consultant Advisor; Analytica’s Chelsea Cornelius Wins MTAA Gong
 
Oct 21, 2016
Cleveland Okays Resapp US Paediatric Respiratory Trial; Imugene Raises $3.2m; Viralytics AGM For 666k Director Options; Factor Therapeutics 1m Dr Robert Ryan Options AGM; Genera 1m CEO Richard Hannebery ‘Rights’, 250k Option AGM; Botanix 16m Director Options AGM; Respiri 10m Director Options AGM; Directors Go; Deutsche Bank Takes 14% Of Genetic Signatures; Brendan Moran Takes Profit To Below 5% Of LBT
 
Oct 20, 2016
WEHI, Servier, Vernalis S63845 Blocks Cancer In Mice; Proteomics To Develop Promarker Giardia Test; Avita Appoints South Africa, Benelux Distributors; Simavita Assessplus For Home Incontinence Assessment; Japan Patent For Redhill RHB-104 (Myoconda) For MS; US Patent For Adherium Smartinhaler Optical Dose Counter; Medadvisor Joins Bupa-Healthscope Adherence Program; Australian Ethical Takes 5.7% Of Cyclopharm; Facing Spill, Probiotec Appoints Graham Morton Director; Frost & Sullivan Gongs For Atcor, Mesoblast
 
Oct 19, 2016
Admedus HSV-2 Vaccine Safe, Cuts Viral Shedding, Not Sores; WEHI Imaging Shows Leukaemia Cells Avoiding Chemo; Medadvisor Raises $8m; FDA Expands Avita Recell Compassionate Wound Treatment; Prof Richard Shine Wins 2016 Prime Ministers Science Prize; Imugene Requests Capital Raising Trading Halt; Prescient Pleads Schultz To ASX 30% Query; Optiscan Pleads Schultz To ASX 27% Query; Paradice Investments Takes 5% Of Impedimed; Regeneus Just Avoids Remuneration 1st Strike; Phylogica AGM For 30m Director Options; Bio-Melbourne Breakfast Kicks Off Innovation Week
 
Oct 18, 2016
Phosphagenics – Back From The Brink; Paradigm Placement Raises $6m, Share Plan For $1m More; Allegra $755k Robinwood Related-Party Placement; Mayo, Atlantic Health Study Impedimed Sozo Feasibility; Genetic Signatures: ‘Easyscreen STI Validated’; Orthocell Begins Celgro Scaffold Nerve Repair Study; Clinuvel: UK Nice Recommends STA Review; Cochlear Director Donal O’Dwyer Faces 22% AGM Dissent; Up To 17% Dissent At IDT AGM, Geoff Lord Goes; Living Cell 2nd Strike Board Spill AGM; Blackrock Takes 5% In CSL, Again; LBT’s Lusia Guthrie Takes Profit On 1.75m Shares To Below 5%; Chris Retzos, Associates Take 5% Of Immuron; Benitec Gains, Loses Co Sec Sakura Holloway
 
Oct 17, 2016
Admedus Jumps 68% On FDA Adapt Vascucel Clearance; ITL Samplok Global Distribution Agreement With Biomérieux; Cynata Stem Cells Normalize Asthma Model In Mice; Opthea Receives $2.6m Federal R&D Tax Incentive; Bioxyne 60-Patient PCC Probiotic Gut Health Trial; Cogstate Has Less Than Two Quarters Cash; Dorsavi Earns $1m For Second Quarter In A Row; Regeneus Delay In Signing Japan Partner; LBT AGM For 1.5m CEO Options; Up To 17% Dissent Against Cogstate Directors Options, Fees; Medadvisor Requests ‘Capital Raising’ Trading Halt
 
Oct 14, 2016
CSL Raises $727m To Buy $500m Shares, Working Capital; Sienna Earns ISO 13485, $638k R&D Tax Incentive; MMJ Raises $4m, Releases 17.5m Escrow Shares; FDA Wants More Data For Adalta AD-114 Fibrosis Orphan Status; Medibio Receives $3m Federal R&D Tax Incentive; Anatara Receives $420k Federal R&D Tax Incentive; Paradigm Requests Capital Raising Trading Halt; Pharmaust Treats 2nd Dog In Phase II Monepantel Cancer Trial; Blackrock Takes 5% Of Cochlear, Again; JK, Hogan, Below 5% In Actinogen; Ibsen, Ezahc, Narula Increase, Diluted To 5.7% Of Optiscan; Memphasys Director Andrew Goodall Takes 39%; Cynata 800k Directors Options AGM; Proteomics Appoints Ex-Novo Nordisk Roger Moore Director; Brain Founder Dan Segal Retires 
 
Oct 13, 2016
Cyclopharm Completes Stage 1 Of Technegas FDA Process; Starpharma Phase III Vivagel BV Trials Enrolled; Resonance Measures Liver, Pancreatic Fat In Diabetes Study; FDA Sets November 7 For Clinuvel Pre-NDA Meeting; Creso Pharma $5m IPO For Marijuana Food Additives; USPTO Grants OBJ Skincare, Oral Care Patents; Innovation And Science Australia Bill Passes Parliament; Impedimed 2nd Strike, 635k ‘Performance’ Rights, 1.2m Options AGM; Memphasys Receives $497k Federal R&D Tax Incentive; Allan Gray Increases, Diluted To 13% Of Impedimed; Vintage Quits Probiotec
 
Oct 12, 2016
Medadvisor ‘Tap To Refill’ Processes 2m Scripts Worth $80m; Nuheara Sells-Out $1m Of Iqbuds; CSL Remuneration 1st Strike, 34% Oppose Directors Fee Hike; Resapp Wins Slattery IT, Tech23 Gong; Admedus Appoints Maja Mcguire Co Sec
 
Oct 11, 2016
Viralytics: ‘Cavatak With Keytruda Safe, Well-Tolerated’; Antisense Higher Dose ATL1103 Normalizes Acromegaly SIGF-I; Prof Geoff Faulkner, Prof Steven Lane Win $1.25m CSL Grants; Sirtex Trials Sir-Spheres For Bile Duct Liver Cancer; MMJ Raises $4m; Immuron IMM-124W For Nash ‘75% Randomized’; Antisense Share Cancel, Options AGM; Matthews, Acorn, Diluted To 15% Of Reproductive Health; Medadvisor Appoints Simon Chamberlain Product, Strategy; All Change At QRX
 
Oct 10, 2016
FDA Approves LBT, Hettich Auto Plate Assessment System; Sirtex Sir-Spheres Safe For Kidney Cancer; FDA 510k Leads To Polynovo BTM New Zealand Launch; Uscom Budapest 12-Month Revenue Up 48% To $739k; ITL Samplok In Biomérieux UK Tender; Factor Therapeutics IND For US Phase II VF-001 Wound Trial; Cellmid $1m Q1 Record Evolis Hair Loss Sales; Medibio: ‘$11m From Federal Tax Incentive, Grants, Options’; Volpara Website, Social Media To Explain Breast Density; Australian Ethical Takes More Ellex Profit To 6.4%; Regal Funds Below 5% Of Impedimed, Again; Former Polynovo Director David Kenley Below 5%; Whitney George Takes 7% Of Rhinomed; Tim Bateman Replaces Acrux CFO, Co Sec Sharon Papworth; John Osborne Replaces Avexa Co Sec Lee Mitchell
 
Oct 7, 2016
Redhill Expands Phase III RHB-104 (Myoconda) Trial, Early Stop; Two Sirtex Liver Cancer Studies Combine For Meta-Analysis; Medadvisor, Osteoporosis Australia Partner For Adherence; Admedus $159,693 Director ‘In Lieu’ Shares AGM; MMJ Requests ‘Capital Raising’ Trading Halt; Medical Developments Chair David Williams 146k DRP Shares; Tisia, Henderson Below 5% Of Actinogen
 
Oct 6, 2016
Victoria Secures 5 US Companies For Clinical Trials; Redhill Ready For Phase II Yeliva For Liver Cancer Study; Sienna US, UK Distributors, Expects Revenue Increase; Mesoblast MPC Kidney Failure Efficacy, Safety Published; Reproductive Health Rights Issue Raises $488k, $502k To Go; Anatara To Release 12.7m Escrow Shares; Nanosonics 56k Rights, 279k Options; Double NED Pay AGM
 
Oct 5, 2016
Ausbiotech October International Biofest; FDA Okays Universal Biosensors, Siemens Coagulation Test; Living Cell Doses 1st Phase IIb NTCell For Parkinson’s Cohort; Psivida Begins 2nd Phase III Medidur Uveitis Trial; FDA Approves Avita Recell ‘Continued Access’; Cellmid: ‘Anti-Midkine Antibodies Help THC For Glioblastoma’; Mach7 Signs Microsoft For Cloud Imaging, Goshen Hospital; Race Appoints Sai Life Sciences To Manufacture Bisantrene; Allan Gray Takes More Profit To Below 5% Of Nanosonics; Peter Corr, Inov8 Take 12% Of Analytica; Actinogen Chair Martin Rogers Retires, Pending Share Plan
 
Oct 4, 2016
Bioscience Managers $50m ‘Significant Investor Visa’ Fund; Dimerix: ‘Early Data Backs DMX-200 For Kidney Disease’; Volpara’s 1st Sale To Perth’s Women’s And Breast Imaging; Immuron $992k Rights Shortfall, Over-Subs Takes Total To $6m; Viralytics Cavatak For Pancreatic Cancer, Trials Data; Anatara Files Detach For Piglets Application, Humans Next; Resapp AGM For 27m Director, Scientist, Advisor Options; Peter Harding-Smith Anteo CFO, Richard Martin Director; Race Appoints Prof Roland Walter Consultant 
 
Oct 3, 2016
September BDI-40 Up 2%, ASX200 Up 0.1%, Big Caps Down 1%  - Bionomics Up 92%, Osprey 42%; Benitec Down 26%, Actinogen 22%; Ausbiotech: ‘R&D Review Risks Competitive Advantage’; Resapp: ‘More Positive Respiratory Disease Analysis Data’; Polynovo To Market BTM Wound Treatment Directly In The US; ASX Removes Medivac From Official List; Genera: ‘US, UK Sample Data Backs Paptype HPV Test’; Genetic Technologies Promotes Brevagenplus 
 
Sept 30, 2016
Sunshine Heart Drops Aorta Cuff For Fluid Overload Filter; ITL $500k Macquarie Invasive BP Monitoring Contract; Johnson & Johnson $98k For Best Biological Technology; Rhinomed Trial: ‘No Turbine Benefit For Healthy Cyclists’; Genetic Signatures Share Plan $1m Takes Total To $15m; Universal Biosensors Earns $9.4m Federal R&D Tax Incentive; Allan Gray Reduces To 17% Of Pharmaxis; Australian Ethical Increases, Diluted To 6% Of IDT; Australian Ethical Below 5% Of Atcor; Pulitano Family Takes 9% Of Bluechiip; Unilife Requests Accounts Suspension; Memphasys Dr Robert Gilmour Goes, Stephanie Georgiou Co Sec 
 
Sep 29, 2016
Bio-Melbourne: ‘R&D Tax Review - A Handbrake On Innovation’; Biotech Daily: $2m Cap Will Hit The Best Companies; BDO: ‘Review Will Adversely Impact Innovation’; Oneventures $15m For Murdoch Children’s Peanut Allergy; Actinogen: ‘FDA Could Delay Xanamem Alzheimer’s Trial’; Avita Appoints Teb Sanaat Lotus Iran Distributor; Australian Ethical Reduces To 5.6% Of Atcor; Resapp Requests ‘Study Results’ Trading Halt; Cochlear CFO Neville Mitchell To Retire; Factor Therapeutics: Melanie Farris Co Sec, Saskia Jo Finance 
 
Sep 28, 2016
Federal ‘Consultation’ On R&D Tax Incentive Review; Qbiotics Raises $16.5m For EBC-46 Cancer Drug, Wound Healing; Peter Doherty Developing Potential Malaria Vaccine; Dorsavi Wins $350k Victoria Manufacturing Grant; MMJ Spins-Out United Greeneries, Satipharm For $39m; OBJ AGM For 10m Directors ‘Performance’ Rights; Foundation For Medical Research October Conference; Marie McDonald Nanosonics Director, Dr Ron Weinberger; Psivida Appoints Prof Jay Duker Director
 
Sep 26, 2016
FDA Approval For Oventus O2vent-T, October Launch; Prescient Doses 1st Florida Breast Cancer Patient; Airxpanders: ‘Aeroform Halves Breast Expansion Time’; ASX Terminates Brand TV Medivac Takeover; Oncosil Receives $2.3m Federal R&D Tax Incentive; Unilife Running Out Of Time For ASX, Nasdaq; Sunshine Heart Below Nasdaq $US1 Bid Rule; Australian Executor Trustees Below 5% In Bluechiip; MMJ Requests ‘Corporate Transaction’ Trading Halt; Adherium 2.6m Directors Shares, 43% Fees Hike AGM; Admedus Appoints, Promotes Sales, Marketing Staff
 
Sep 23, 2016
Vale Athina Tsagarakis (18 July 1967 – 22 Sep 2016); Compumedics Raises $6.5m; Bard1 Adds Ovarian Cancer Test To Development Pipeline; Probiotec Wayne Stringer: ‘Remove Directors Johnston, Kuo’; FDA Clears Global Kinetics Wrist Parkinson’s Kinetigraph; Resonance Develops Bone Marrow Iron MRI Test; Phosphagenics Pleads Schultz To ASX 31% Query; Avita Euro Burns Meeting Recell Symposium
 
Sep 22, 2016
Victoria Signs Nanjing Translational Medicine Deal; Bluechiip Rights Issue Raises $1.5m; Redhill Rizaport For Migraine South Korea Licence; European Adhesion Patent For Cellmid Midkine Antibodies; Imugene Receives $1.3m Federal R&D Tax Incentive
 
Sep 21, 2016
Bionomics: ‘BNC210 Outperforms Lorazepam For Anxiety’; Volpara Expects FDA Mandate For Breast Density; Compumedics Requests ‘Capital Raising’ Trading Halt; Proteomics Receives $573k Federal R&D Tax Incentive; FDA Approves Somnomed Alpha; Sirtex AGM For 63k CEO ‘Rights’, 40% Directors Fees Hike; Psivida 500k Shares, 850k Options For New CEO Nancy Lurker; Orbimed Below 5% In Viralytics; Mayne Pharma Appoints Nancy Dolan Director; MGC, Sydney Uni 2nd Medical Cannabis ‘White Paper’
 
Sep 20, 2016
CSIRO $52m Over 5 Years For ‘Future Science Platforms’; Federal Government $23m For Incubator Support; ITL Wins $900k Barwon Health Supply Contract; CE Mark Approval For Speedx Resistanceplus MG; Allegra Expands Sr-Ht-Gahnite Bone Substitute To All Uses; Memphasys To Raise $940k For Working Capital, Legal Costs; Imugene Her-Vaxx Passes Pre-Clinical Toxicology 
 
Sep 19, 2016
UK Approves Cynata Phase I Cyp-001 For GvHD Trial; Pharmaust Treats 1st Dog In Phase II Monepantel Cancer Trial; Bionomics Requests BNC210 Anxiety Disorder Trial Halt; Asia Union Decreases To 50% Of Genetic Signatures; Crystal Amber Takes 16% Of GI Dynamics; Ausbiotech Hosts Adelaide Broker Meets Biotech
 
Sep 16, 2016
Nanosonics Breaks The $1b Barrier; Benitec ddRNAi TT-034 ‘No Efficacy For Hepatitis C’; Paradigm Rhinosul PPS Effective For Hay Fever In Guinea Pigs; Memphasys Requests Capital Raising Trading Halt; Pharmaust’s Epichem Certified To International Standards; Kneehab, Jax Win J&J Health Technology Challenge; WEHI’s Emma Nolan Wins $5k Prize For Breast Cancer; Nancy Lurker Replaces Psivida CEO Dr Paul Ashton
 
Sep 15, 2016
Resapp: ‘Unnamed Organization Tests Respiratory Diagnostic’; Study Backs Analytica Pericoach For MS Faecal Incontinence; Aviragen (Biota) Revenue Down 62% To $13m, Loss Up 33% To $34m; Bluechiip, Planet Innovation Tracking Device Agreements; Australian Ethical Reduces To 10% Of Innate; Innate Director Christopher Collins Holds 17%; Allan Gray Increases To 13% Of Starpharma; Dorsavi CTO Daniel Ronchi Below 5%
 
Sep 14, 2016
Oncosil: ‘US Trial, CE Mark, Dr Chris Roberts For Chairman’; TGA Cancels GI Dynamics Endobarrier Approval; Uniquest’s Inflazome Raises $22m; Medibio, Monash Sleep And Mental Health Collaboration; Study: ‘Impedimed L-Dex Cuts Breast Cancer Lymphoedema’; Factor Appoints Dr Robert Ryan Director; Bio-Melbourne Breakfasts On India; Actinogen: ‘Understanding Alzheimer’s Symposium’
 
Sep 13, 2016
Ausbiotech Calls On Government, ALP To Keep 45% Tax Incentive; Biotech Daily: ‘Penny-Pinching Cut A Disgrace’; Melbourne Uni: ‘Peptide Polymers Kill Resistant Bacteria’; Redhill, Standford Uni Yeliva Head, Neck Cancer Mouse Study; WEHI: ‘Cone Snail Venom Insulin Could Aid Human Insulin’; Canada Approves Starpharma Vivagel Dual Protect Condom; TGA Device Branch: ‘Cancel GI Dynamics Endobarrier’; Psivida Revenue Down 94% To $2m, Profit To $29m Loss; Regal Funds Re-Takes 5% Of Impedimed; SG Hiscock Takes 5% Of Resonance; Ausbiotech, Johnson & Johnson Awards Open 
 
Sep 12, 2016
Medical Developments: Purdue $3m For Penthrox In Canada; Regeneus Receives $3m Federal R&D Tax Incentive; Adalta Hires Fujifilm For AD-114 Manufacture; US FDA Approves Novogen Cantrixil Ovarian Cancer Trial; Memphasys (Nusep) Continuing Prime, Manukan Legal Action; Invion Receives $619k Federal R&D Tax Incentive; Kinetic Takes 7% Of Osprey; Michael Sorensen, ‘Custodian Nominee’ Take 19.9% Of Bioxyne; MMJ To Release 8,755,000 Escrow Shares; Oncosil To Lose Director Martin Rogers; Phylogica Prof Paul Watt From CSO To Director, Advisor
 
Sep 9, 2016
Redhill Yeliva Multiple Myeloma Trial; More Indications; UAE Approves Medical Developments Penthrox Pain-Killer; Factor Closer To Venous Leg Ulcer Trial Start; Anteo Receives $2m Federal R&D Tax Incentive; Admedus, Dr Lane, Dr Woollard Settle Cardiocel Fight; CSL $6.6m CEO ‘Rights’, Directors 33% Fee Hike AGM; Brandon, MRCF, Australian Super Take 24% Of Osprey; Prof Marshall’s Ondek Quits Bioxyne, Takes $159k Profit; FIL Takes 6% Of Resapp; Novogen Appoints Kate Hill Interim Co Sec, Lionel Mateo Goes
 
Sep 8, 2016
New Jersey’s Certara Acquires Melbourne’s D3 Medicine; Anatara Piglet Safety Study Readies Detach Application; Optiscan Rights Issue Raises $550k, Total $2.2m; Bio-Melbourne September Bio-Briefing Takes A Risk
 
Sep 7, 2016
Paradigm, Griffith Collaborate On PPS For Alphavirus; Speedx Wins Federal $1m For Antibiotic Resistance Tests; Osprey $1m Share Plan Takes Total To $29m; Resonance Extends Unnamed Company Phase III Trial Contract; Bio-Melbourne ‘Advances In Cancer’ Bio-Breakfast
 
Sep 6, 2016
WEHI Studies Coeliac Disease Gluten-Free Failure, Oats Safety; Medical Developments: BL&H For South Korea Penthrox; Ellex To Launch ‘Eye One’ Portable Eye Examination System; Invitrocue To Supply Non-Animal Chemical Testing Plates; Novogen Issues Dr Leong 2m Options, Advisers 400k Shares; Proteomics, UWA Search For Mesothelioma Biomarkers; Mach7 Imaging Platform At Qatar’s Sidra Medical Centre; IDT Wins $266k Victoria Future Industries Lab Upgrade Grant; Ross Himstedt Takes 5% Of Invion
 
Sep 5, 2016
ITL $1m Queensland Metro South I-V Contract; Cynata, Fujifilm Stem Cell Term Sheet; Regience KK Terminated; Reproductive Health Raises $525k, Rights Offer For $990k More; Actinogen $2.8m Federal R&D Tax Incentive; Race: Carthagenetics Bisantrene ‘Named Patients’ Program; Novogen Director Prof Peter Gunning To Join Advisory Board
 
Sep 2, 2016
Ausbiotech, Greens Oppose ‘Omnibus’ R&D Cut, Labor Review; MRFF; Mygolgi Wins Bio-Melbourne, Victoria Advamed Scholarship; Genetic Signatures Placement Raises $14m, Share Plan; Mach7 Revenue Up 1192% To $2m, Loss Up 111% To $14.6m; Proctor & Gamble Launches OBJ Olay Eye Wand In China; MGC, Epilepsy Action Australia Partner For Trials; Cynata Requests Trading Halt; Bluechiip Files Australian Patent For Over-Temperature Chip; Peter Corr, Inov8 Take 11% Of Analytica; Bioxyne: Guy Robertson CFO, COO, Co Sec; Dr Peter French; Avexa Appoints Mark Simari Director; Thomas Lynch Replaces Adherium Chair Dr Doug Wilson; Oneventures Hires Dr Graeme Wald For Life Sciences; Mesoblast Appoints Bill Burns Vice-Chair For Deals; Bio-Melbourne ‘Advances In Cancer’ Bio-Breakfast
 
Sep 1, 2016
August BDI-40 At Record $8.3b, ASX200 Down 2%, Big Caps Down 6%; Admedus $8.3m Rights Issue Raises $5.7m; Total Raised $18.3m; Admedus Revenue Up 40% To $14m, Loss Down 5% To $24m; Anteo Revenue Up 472% To $14m, Loss Up 36% To $6m; Avita Revenue (Discontinued) Up 19% To $3.5m, Loss Up 23% To $9m; Medical Australia Revenue Down 5% To $14m, Loss Up 2131% To $5m; Unilife Revenue Down 25% To $13m, Loss Down 12.5% To $79m; Suda Revenue Up 3% To $6m, Loss Down 34% To $3.2m; TBG (Progen) Revenue Up 306% To $3.3m, Loss Up 566% To $12m; Pharmaust Revenue Up 14% To $2.7m, Loss Up 104% To $4m; IQ3 Revenue Up 130% To $2m, Loss Up 4% To $2m; Bluechiip Developer Kit Deal With Unnamed US Company; Nearly 50% Opposition To Innate 4.85m Director Options
 
Aug 31, 2016
Benitec: Cash To 2018, Hep B Drug Renamed BB-101, Pipeline; Imugene Her-Vaxx Stocks Delivered For Gastric Cancer Trial; ITL Wins Austin Health Supply Extension; Adalta, Alfred Hospital, La Trobe Uni $50k Federal Grant; Medadvisor To Acquire Healthnotes For $5.5m; Biomérieux Takes LBT Revenue Up 226% To $8m, Profit Up 1014% To $4m; Cellmid Revenue Up 55% To $5m, Loss Up 5% To $3.5m; Adherium Revenue Down 10% To 2.6m, Loss Up 528% To $8m; Medlab Revenue Up 107% To $2.6m, Loss Up 38% To $7m; Bioxyne Revenue Up 23% To $2m, Profit Up 11% To $224k; European Patent For Redhill RHB-104 (Myoconda) For MS; Phosphagenics To Begin TPM Chicken Feed Life-Cycle Study; Genetic Signatures Requests Capital Raising Trading Halt; Global Kinetics Appoints Timothy Still CEO; Alan Fisher Replaces Bionomics Director Trevor Tappenden; Allan Gray Reduces To 14% Of Acrux
 
Aug 30, 2016
CSL Files FDA CSL830 For Hereditary Angioedema Application; Immuron, US Navy Campylobacter, Etec Collaboration; Medlab Takes Nrgbiotic For Depression To Phase IIa Trial; Atcor Revenue Down 19% To $5.6m, Loss Up 130% To $5m; Allegra Revenue Down 32% To $5m, Loss Up 138% To $2m; Genetic Signatures Revenue Up 64% To $3m, Loss Up 14% To $3m; Anatara Posts 1st Revenue Of $2.8m, Loss Down 60% To $724k; Resonance Revenue Down 3% To $2.6m, Profit To $382k Loss; Alchemia Revenue Up 112% To $25m, Loss To $21m; Psivida Adds 13 Patents, Applications This Year; Tiga Takes 5% Of Anatara; Memphasys Appoints John Pereira Director
 
Aug 29, 2016
Ellex Revenue Up 16% To $73m, Profit Up 80% To $3m; Starpharma Revenue Up 166% To $4.5m, Loss Up 20% To $23m; Genetic Technologies Revenue Down 59% To $1m, Loss Down 4%; Phosphagenics H1 Revenue Up 34% To $1.3m, Loss Down 37%; Correction: Anteo; Medadvisor Requests ‘Material Acquisition’ Trading Halt; MGC EGM For 170m Placement, 32.5m Director Shares; Medivac To Become Brand TV Media; MTP Appoints Dr Martinez-Coll, Dr Tewari, Dr Thomson; Novogen Hires Dr Gordon Hirsch, Dr Peng Leong, David Cain; Ausbil Dexia Increases, Diluted To 6% Of Bionomics
 
Aug 26, 2016
Mayne Revenue Up 89% To $267m, Profit Up 381% To $37m; Compumedics Revenue Up 12% To $37.5m, Profit Up 66% To $3m; Dorsavi Revenue Up 75% To $3m, Loss Down 35% To $5m; Antisense Revenue Down 71% To $1m, Profit To $2.5m Loss; Medadvisor Revenue Down 13% To $1.4m, Loss Up 462% To $3m; Ellex Wins $2.5m Federal Government Manufacturing Grant; Avexa Underwritten Rights Issue Raises $2.2m; Goodbye Tyrian Diagnostics (Proteomics); Medadvisor, Diabetes Australia Product Order Tool; Allan Gray Reduces To 15% Of Acrux; Somnomed Chair Dr Peter Neustadt Below 5%, TDM Takes 10%; Mark Ziirsen To Replace Admedus CFO Stephen Mann; Anteo Loses Sam Andersen, Shane Hartwig; Richard Martin Co Sec
 
Aug 25, 2016
Mesoblast Revenue Up 115% To $56m, Loss Down 96% To $5m; Clinuvel Revenue Up 97% To $6m, Loss Down 70% To $3m; Acrux Revenue Up, Profit Up, Patent Fight Stops Dividend; Probiotec Revenue Down 0.3% To $66m, Loss To $4m Profit; Neuren To Expand Rett Trial, Lang Walker Funding EGM; Adalta Receives $738k Federal R&D Tax Refund; Admedus November Launch Of Vascucel For Vessel Repair; Euro Patent For Prima’s IMP731; US Patent For Mach7 Mobile Medical Image Capture; Tony Grist, Denlin, Oaktone Below 5% In Actinogen; Adam Blumenthal, Anglo Menda Take 8% Of Noxopharm; IQ Group Appoints Jimena Hurtado Research, Lei Xu Asia Pacific 
 
Aug 24, 2016
Sirtex Revenue Up 36% To $178m, Profit Up 69% To $40m, Dividend; Impedimed Revenue Up 21% To $6m, Loss Up 76% To $26m; Medtronic Takes Heartware For $1.45b; Drs Mal, Stewart Washer -The A To Z Of Medical Marijuana; Acrux, Lilly To Appeal US Patent Decision; Proteomics To Develop Endometriosis Diagnostic; Cryosite Revenue Up 3% To $10m, Profit Down 33% To $302k; IDT Revenue Up 8% To $17m, Loss Up 34% To $4m; Regeneus Revenue Down 9% To $1.9m, Loss Down 46% To $3m; Rhinomed Revenue Up 134% To $1m, Loss Up 13% To $6m; Gordagen $1.3m R&D Tax Incentive Settles Metamor Loan
 
Acrux Falls 45% On Axiron Patent Ruling; ITL Revenue Up 10% To $31m, Profit Down 84% To $344k; OBJ Revenue Up 0.5% To $1.5m, Loss Up 51% To $3.6m; Invitrocue, Qiagen Partner For Biomarkers, Translation; Admedus 8-Year Data: No Calcification, No Repeat Procedures; MGC Ready For Cannabinoid Patch Human Safety Trial; Living Cell: Diatranz Otsuka Closing Invercargill Pig Facility; Yuuwa Has 54% Of Adalta, Platinum 8%, Citycastle 5%; Escrow; Crystal Amber Takes 14.5% Of GI Dynamics; DRH, David Hannon Take 11% Of Noxopharm; Gerardo Incollingo Replaces IQ3 Co Sec Kelvin Boateng 
 
Aug 22, 2016
Pro Medicus: ‘The Roll-Out Has Just Begun’; Adalta Opens Up 24% For AD-114 For Fibrotic Diseases; Optiscan ‘Carl Zeiss Endorses Two Microscope Prototypes’; Polynovo Revenue Up 2366% To $3.5m, Loss Up 130% To $3m; Thailand Approves Imugene Her-Vaxx Gastric Cancer Trial; Noxopharm To Trial NOX66 For Cancer Radio-Resistance; Aphria To Supply Cannabis For Medlab Cancer Pain Trial; TBG (Progen) Sells PG500 To Zucero For $6m; Biotron Finds Additional Anti-Zika Compounds; Chair Prof Robert Phillips Increases, Diluted To 17% Of Uscom; Bergen Takes 7.3% Of Anteo; Race Appoints Gordon Beck V-P Europe Named Patient Sales; Nuheara Appoints Jean-Marie Rudd CFO
 
Aug 19, 2016
WEHI, Olivia Newton-John Map Cancer-Linked DCLK1 Protein; Pro Medicus Revenue Up 57% To $28m, Profit Up 98% To $6m; Cyclopharm H1 Revenue Up 27% To $6.5m, Profit Up 59% To $284k; Pharmaxis Revenue Down 68% To $19m, Profit To $16.5m Loss; Federal Government Innovation, Science Grants; Paradigm PPS Passes Toxicology, Phase I Safety For Hay Fever; Kinetic Increases, Diluted To 6% Of Osprey; Race Appoints Dr Rudolf Steiner Europe Advisor; Resapp Wins Talent Unleashed Gong
 
Aug 18, 2016
Medical Developments Revenue Up 33% To $15m, Profit $1.6m; Somnomed Revenue Up 28% To $44m, Profit Down 72% To $165k; Proteomics Licences Promarkerd Kidney Test To Omics; Resapp Test ‘Can Show Asthma, Wheeze Severity’; Mach7 Up To $5.5m Maine Health Imaging Licence; Dorsavi Develops Viperform-Ami To Prevent Sports Injuries; Oncosil Calibrates Brachysil For Pancreatic Cancer; Optiscan Rights Issue Raises $552k Of Underwritten $1.4m; US NIH Grant For Immuron IMM-124E Child Fatty Liver Trial; Mayne Buys GSK Acne, Psoriasis Products For $65m; Admedus Rights Issue Opens; Reproductive Health $278k Federal R&D Tax Incentive; YZJ, SMK ‘Transfers’ 5% Of Medical Australia
 
Aug 17, 2016
CSL Profit Down 10% To $1.6bn, Record Revenue Up 9% To $8bn; Cogstate Revenue Up 69% To $27m, Loss To Profit Of $2.6m; Nanosonics Maiden $122k Profit On Sales Up 93% To $43m; Uscom Revenue Up 44% To $2.9m, Loss Up 58% To $1.9m; Reva Awaiting Trial Results, Sales Ready, Cash To April 2017; US Grants Mesoblast 2 Rheumatoid Arthritis Patents; Reproductive Health Launches Doplify For Gene Testing; Medibio, University Of Sydney Cardiac Stress Test Trial; Crystal Amber Takes 13% Of GI Dynamics; Medlab CEO Sean Hall Increases, Diluted To 31.5%; Living Cell Pleads Schultz To ASX 25% Query; Actinogen Unmarketable Parcel Facility; Dr Tadataka Yamada Replaces CSL Director John Akehurst
 
Aug 16, 2016
$1m Of $60k Cass Foundation Grants Open; Victoria Grows Paediatric Epilepsy Marijuana, Advisors; Adherium Provides Smartinhalers To Astrazeneca; Megan Boston Replaces Benitec Director Iain Ross; Bio-Melbourne Workshops Medtronic, IBM Diabetes Data
 
Aug 15, 2016
Qbiotics EBC-46 For Solid Tumors ‘Well-Tolerated, Efficacy’; Medlab $4.4m Of Underwritten $5.4m For Cannabis Pain Trial; Bluechiip Rights Offer For $1.5m; MMJ Prepares Phase II Israel Cannabidiol PTL101 Epilepsy Trial; Recce Finds Maximum 280mg/kg Recce-327 Dose For Mice; Medadvisor, Glaucoma Australia Unite For Drug Adherence; CVC Withdraws Bionomics Board Spill Notice; Dimerix Pleads Schultz, Old News, Meetings To ASX 114% Query; Botanix Welcomes US DEA Cannabis Restrictions; MMJ Appoints Catherine Harvey COO; Phylogica Appoints Dr Rohan Hockings Alternate Director; Race Joint Co Sec Damon Sweeny Resigns
 
Aug 12, 2016
Protagonist Raises $117m, Lists On Nasdaq For Peptide Drugs; Adalta IPO Raises $10m For Fibrotic Diseases; WEHI Shows Role Of MLKL, RIPK3 Proteins In Mouse Necroptosis; Medical Developments Receives 1st French Penthrox Order; CM Capital (Talu) Diluted To 18% Of Osprey; Adherium Releases 25m Voluntary Escrow Shares
 
Aug 11, 2016
Resonance Hepafat-Scan ‘Accurate, Repeatable, Equals Biopsy’; Belgium $1.4m For Clarity’s Plateview Plaque Rupture Test; Impedimed’s Sozo Body Composition Test Ready For Pre-Order; Atomo Raises $4.5m For Diagnostic Platform; Novogen Files FDA Cantrixil For Ovarian Cancer IND; Taipei Hospital Okays Imugene HER-Vaxx Gastric Cancer Trial; Bluechiip Requests Capital Raising Trading Halt; MGC Sells Erin Mining Data For $500k; CEO Dr Philippe Wolgen Takes 5% Of Clinuvel; CEO Dr Graham Kelly, Family Take 32% Of Noxopharm; DRH, David Hannon Take 10% Of Noxopharm; Adam Blumenthal, Anglo Menda Take 7% Of Noxopharm; Nanosonics Appoints Dr Steven Farrugia For Design, Development; MMJ Loses Director Ross McKay
 
Aug 10, 2016
Cellmid: ‘Midkine Improves Osteoporosis In Mice’; Psivida Study: ‘Smaller Insert Needle Superior’; Impedimed, Scripps Sozo Heart Failure Device Study; Biodiem Raises $1m; Noxopharm To Begin NOX66 Cancer Trials In Tbilisi; Pharmaust Investigator Monepantel Dog Cancer Trials; Prana Pleads Schultz To ASX 45% Query, ASX Misses 16%; Benitec Greg West CEO, Dr Cliff Holloway, Bryan Dulhunty; Oventus Appoints Scientific Advisory Committee; Nuheara Appoints Bruce Borenstein Head Of Sales; Prima Below $US1 Nasdaq Compliance, Again
 
Aug 9, 2016
Mesoblast Phase II Rheumatoid Arthritis Safety, Efficacy; Cochlear Record Revenue Up 22% To $1,131m, Profit Up 30%; Mach7 Appoints Soliton UK Distributor; Dorsavi Vimove For Adolescent Idiopathic Scoliosis; Medical Developments FDA Penthrox Trial, US Spacer Deal; Bionomics Revenue Up 31% To $22m, Graeme Kaufman Goes; Noxopharm $6m IPO, Opens Down 10%; Impedimed: ‘FDA Guides On Digital Health, Low Risk Devices’; Gary Goetzke Replaces Impedimed’s Dr Michael Panaccio; David Adams Executive; Race Appoints Dr Daniel Levy, Dr Kalidas Kale Consultants
 
Aug 8, 2016
WEHI Targets MCL-1 For Multiple Myeloma; Federal $1m Collaboration Grants Open; ITL Contract Extended With Biomérieux; OBJ ‘Defining Moment’, Signs P&G Master Licence; Medibio Claims 83% Heart Rate Depression Test Accuracy; Immuron Appoints Medique For US Travelan Distribution; Adherium Opens San Mateo Office
 
Aug 5, 2016
WEHI Launches Haemopaedia Mouse Blood Type Database; One Funds Increases, Diluted To 8% Of Avita; Regeneus Pleads Schultz To ASX 29% Query; Medibio Requests ‘Data Validation Results’ Trading Halt; TBG Delists From The US OTC Market
 
Aug 4, 2016
Federal Government $500m Biomedical Translation Fund; Osprey Raises $28m, Plan For $1m More; USPTO Allows 2 Patents For Prescient PTX-200; Mach7 Appoints Alphatron Distributor For Benelux; Psivida Appoints Dr Dario Paggiarino Chief Medical Officer; Adherium Appoints Ross Bradding, Julia Chambers; Bio-Melbourne August, September Briefings, Breakfast
 
Aug 3, 2016
Anteo Launches Zika, Vitamin D Tests; Three Coupling Kits; Clinuvel Completes FDA Scenesse Vitiligo Safety Study; Mach7: ‘$1m Client Is Virginia Commonwealth Uni Health’; Reva Submits Fantom Stent CE Mark Application; MMJ, Cowichan Land Lease For 26t Marijuana Per Year; China Grants Analytica Pericoach Patent; Pharmaust, Uni Of NSW Swap Monepantel, Mucin Rights; Mayne Completes Teva Asset Acquisition; Orthocell To Release 27m Escrow Shares, 4m Options; Factor Therapeutics Appoints Medical Advisory Board; Optiscan Appoints Andrew Froude For Preclinical Products
 
Aug 2, 2016
Psivida, NY Hospital For Special Surgery Osteoarthritis Trial; FDA Approves 300-Patient Oncosil Pancreatic Cancer Trial; Redhill Completes Phase IIa RHB-104 For MS Follow-Up; Mach7 Signs $1m 5-Year US Medical Centre Imaging Deal; Osprey Requests Capital Raising Trading Halt; Melroses Convert 5m Recce Performance Shares, Take 38.5%
 
Aug 1, 2016
July BDI-40 Up 15%, ASX Up 6%, Big Caps Up 6%, NBI Up 14% - Osprey Up 62%, Antisense Up 60%, Impedimed 41%, Uscom 37%; Cynata Applies For Phase I UK CYP-001 GvHD Trial; FDA ‘Clear Path’ For Dimerix DMX-200 For Kidney Disease; Unilife ‘No Material Shortall Shortfall, Staff Changes, Cuts’; Mesoblast 2-Year Back Pain Data Backs Lower Dose MPCs; Dorsavi Revenue Up 122% To $3m, $1m In Q4; Euro Patent For Regeneus Fat Stem Cells For Acne; Bluechiip Sells 1st Sample Tracking Starter Kit To China; Innate Placement, 4.85m Director Options AGM; Medlab Welcomes NSW Cannabis Law Change, Trial Ready; Rhinomed Appoints McKesson Mute Wholesale Distributor; Adherium CEO Garth Sutherland Increases, Diluted To 7%
 
Jul 29, 2016
International Stem Cell Implants 1st Parkinson’s Patient; US NIH Cedars-Sinai $797k For 4DX Pre-Clinical Lung Scanner; Admedus Raises $10m, Rights Issue For $8m More; Heartware H1 Revenue Down 14% To $165m, Loss Down 33%; Resmed Revenue Up 10% To $2.4b, Profit Down 0.1% To $469m; Medical Aust Revenue Down 5% To $14m, Human Health Up 8%; Osprey Pleads Schultz To ASX 28% Query; Mayne Wins $26m From Forest; FDA Approves Analytica Pericoach Sexual Health Claim; Phosphagenics Details Terumo Licence, R&D Deal; Agenix Votes To Become CCP For Refrigerator Control; Reproductive Health Has Less Than Two Quarters Cash; Botanix US Partner Manufactures Synthetic Cannabidiol; Quest Takes 7.5% Of Viralytics
 
Jul 28, 2016
Psivida: ‘Medidur Stops Posterior Uveitis Return, P < 0.00000001’; Actinogen: ‘AIBL Study Backs Xanamem Mode Of Action’; Ellex Unaudited Revenue Up 16% To $73m, Pre-Tax Profit $4m; Bioxyne Probiotic Sales Up 31% To $2m; Impedimed Expands Mayo BIS Trial Agreement To Development; Astrazeneca Expands Starpharma DEP Program; Dimerix Begins DMX-250 For Nash Program; Invitrocue, University Of Singapore Hepatitis B Collaboration; Regal Funds Reduces, Diluted To 6% Of Adherium; Cochlear Appoints Five Senior Executives; Recce Produces 9L Recce-327, Sydney HQ, Lab
 
Jul 27, 2016
Burnet, Germany’s Artes Combine For Hep C Vaccine; Antisense Interim Data: ‘ATL1103 Acromegaly Safety, Efficacy’; Model Backs Prana PBT2 For Alzheimer’s, Huntington’s; Compumedics $3m China Contract, ‘Number 3 Worldwide’; Acrux, Lilly Axiron Sales Fall 4% To $199m; Avexa $2.2m Rights Issue For Tali - Mark Simari Replaces Benjamin Yeo, Allan Tan To Retire; Analytica Raises $500k From 12% Inov8; Admedus Requests Capital Raising Trading Halt; Allan Gray Takes More Profit To 5.5% Of Nanosonics; JCP Reduces, Takes Profit To 8.4% Of Nanosonics; Anteo Appoints Tamara Mills COO
 
Jul 26, 2016
Opthea Phase I OPT-302 AMD ‘Safety, Activity’; Cellmid Sales Revenue Up 147% To $4m; Race Hires Camargo For Bisantrene US Regulatory Pathway; Oventus Starts Titratable O2vent-T Trial; Pharmaxis CEO Gary Phillips Earns 827k Performance Shares; Stephen Tindall, K One W One Diluted To 6.6% Of Adherium; Nuheara To Launch Iqbuds In Las Vegas In January 2017; Tyrian, Contagno Asset Management Back-Door AGM 
 
Jul 25, 2016
MTP Connect 10-Year Competitiveness, Productivity Plan; Correction: Factor Therapeutics; Polynovo To Trial Matrix Insulin For Type 1 Diabetes; TBG, Progen Complete PG545 Dose Escalation Trial; Optiscan $1.4m Rights Offer; WPP’s Ikon Sues Cellmid’s Advangen For $939k; Race Hires Crystal Pharmatech For Bisantrene Formulation; Simavita To Delist From Toronto Stock Exchange; Respiri Airsonea 85% Accuracy ‘Impressive, A Major Milestone’; SRV Below 5% Of Dimerix; Botanix Offers Unmarketable Parcels Facility; Avexa Requests ‘Entitlement Offer’ Trading Halt
 
Jul 22, 2016
Factor Therapeutics: ‘US Phase II VF-001 Venous Ulcer Trial’; Applications Open For $25k Slater & Gordon Research Grants; US Patent For Redhill (Giaconda) RHB-105; Anatara Earns $2.3m Revenue; Optiscan $600,000 Loan Conversion, Total Raised $2.8m; Rhinomed Signs Unnamed US Pharmacy Chain For Mute Trial; BT Investment Increases, Diluted To 5% Of Mayne; Founder Dr Chris Hart Takes 36% Of Oventus; Paradigm To Release 19.5m ASX Escrow Shares; Resapp Wins Asia-Pacific Talent Unleashed Gong; Buchan Appoints Analyst Elyse Shapiro Senior Consultant
 
Jul 21, 2016
Nanosonics Sales Up 93% To $43m, Record Q4 Sales; Starpharma Signs Sky And Land For China Manufacture, Sale; Universal Biosensors ‘Cash-Flow Positive This Year’, Buy-Out; Cyclopharm H1 Sales Up 21% To $6m; Uscom Sales Up 94% To $2.6m; Genetic Signatures Sales Up 75% To $1.8m; Somnomed Revenue Up 28% To $44m; Australian Ethical Takes 11% Of Innate; Tiga Takes 7% Of Oventus, CEO Neil Anderson Takes 8%; Regal Funds Increases, Diluted To 9% Of Prescient; Correction: Cogstate Revenue Up 70% To $27m; CSIRO Appoints Dr Rob Grenfell Health, Biosecurity Director; RACI Dines On Defence’s Dr Felicia Pradera Zombie Apocalypse
 
Jul 20, 2016
Chief Scientist: ‘Research Infrastructure Consultations’; Mass General For Resapp US Paediatric Respiratory Trial; Mayne Retail Offer Raises $254m, Total Raised $888m; US Patent For Actinogen’s Xanamem For Alzheimer’s; Immuron Partners For Colostrum IMM-124E For Autism Studies; Impedimed Hires Redox For Electronic Health Records; Recce: ‘Testing Shows Recce-327 Non-Carcinogenic’; Fidelity $8m Placement Takes It To 10% Of Adherium; Innate Places $1.2m, Total Raised $6.6m; Cogstate Revenue Up 70% To $14m; Admedus Sales Up 40% To $14m; IQ3 Corp’s IQ Capital Wins US Investment Banking Licence; Benitec Pleads Schultz To ASX 40% Query; Cellmid Appoints Colour Collective US Distributor; Australian Ethical Takes More Ellex Profit To 7.7%; FIL Takes 5% Of Resapp, 5% Of Somnomed; Botanix Hires Mark Davis, Steve Newhard For BTX1503 For Acne
 
Jul 19, 2016
Oventus Opens Up 20%, Closes Up 40%; Mobius Takes 5% Of Oventus; 2nd US Patent For Uscom BP+; TBG China Plant Earns First HLA-Typing Revenue; Medivac Deed Of Company Arrangement Approved; Phylogica Loses Co-Founder, CEO Dr Richard Hopkins; Somnomed Derek Smith CEO Starts On $598k
 
Jul 18, 2016
Greg Hunt Innovation Minister, Susan Ley Retains Health; Impedimed, Vanderbilt Partner For BIS Cardiac Test; Psivida To Close UK Research Saving $1.2m A Year; FDA Accepts Clinuvel Scenesse Data Package For EPP; Medlab To Raise $5m For Cannabis Pain Trial; Immuron To Repay $1m Sea Otter Note; Compumedics Expects $37m Revenue, Low Cost Manufacturing; Paul Ruggiero, ‘Like-Minded Investors’ Take 16% Of Cellmid; Victoria, Bio-Melbourne US Trade Mission; MTP Connect 10-Year Plan Roadshow 
 
Jul 15, 2016
Psivida: ‘Medidur Prevents Uveitis Return, Improves Acuity’; COO Glenn Cross To Replace Ausbiotech CEO Dr Anna Lavelle; Pharmaxis US Bronchitol Cystic Fibrosis Trial Recruited; US Patent For Analytica Autostart Burette; Botanix Opens Up 35%, Closes Up 50%; Inverarey Sells, Buys Down To 6% Of Immuron
 
Jul 14, 2016
NHMRC Top Awards For Menzies School Of Health Research; Volpara Launches Software, Hires Sales Staff; Redhill, US NIAID Collaboration On Ebola; Universal Biosensors Record H1, Q2 Sales - Cash Flow Positive; Cyclopharm Appoints Dr Michael Guo Clinical Program Head
 
Jul 13, 2016
US, NZ Patents For Antisense ATL1103 For Acromegaly; Race Opens Up 42.5%; Race CEO Peter Molloy Takes 7.6%, Chair Dr Bill Garner 28.5%; Recce Adds Viruses To Bacteria, Cancer For Recce-327; UK Okays Aviragen BTA585 RSV Trial, US Clinical Hold; Simavita Appoints Nathan Bartrop Joint Co Sec; MGC Appoints Prof Uri Kramer Consultant, Australian Trials
 
Jul 12, 2016
Victoria $20m Health, Medical Research Plan; Orthocell Ready For Ortho-ATI Tennis Elbow Trial; Prima, German Collaboration On IMP321 For Solid Tumors; Prescient Shortfall Shares Raise $1.3m, Total $10.4m; Impedimed US L-Dex 2017 Reimbursement $168 Per Test; US Approves Over-The-Counter Analytica Pericoach; Invitrocue Developing Pancreatic Toxicity Assay; Bluechiip Has One Quarter Cash; Respiri (Isonea) Pleads Schultz To ASX 83% Query; Tony Walker Takes 16% Of Bard1; Avexa Loses Director Bruce Hewett To The UK’s Clinigen
 
Jul 11, 2016
Sirtex Dose Sales Up 16% To More Than $200m; Avita Raises $9m; Race Raises $4m For Bisantrene Cancer Drug; Hong Kong Approves Imugene HER-Vaxx Gastric Cancer Trial; US Patent For Uscom BP+; Admedus: ‘32% Staff Cut, $12m Cost Cut, Break Even July 2018’; Juniper Produces Pharmaust Monepantel (PPL-1) For Trials
 
Jul 8, 2016
Innate Oversubscribed Rights Issue Raises $3m, Total $5.5m; BPH Raises $627k; US Blood Bank Extends ITL Samplok Contract; Reva Directors, Investors Take Visium’s 1.4%
 
Jul 7, 2016
J&J Opens Applications For $665k Quickfire Challenge; WEHI Cancer DNA Test To Reduce Colorectal Chemotherapy; Adalta IPO To Raise $10m For AD-114 For Fibrosis; Biopharmaceuticals Australia $250k ZZ Manufacturing Grant; Atcor Adds Unnamed 35m Lives Insurer For US Cover; Osprey Claims Record June Quarter Sales; Unnamed IVF Company Adopts Bluechiip Tracking Technology; Resapp ‘Schultz’ To ASX 35% Fall Query; Uniquest Below 5%; Singapore Grants Nusep’s Prime Biologics Albumin GMP
 
Jul 6, 2016
Psivida Wet AMD Rabbit Study Takes Durasert TKI To Clinic; Aviragen (Biota), Georgia State University Deal For RSV; Clinuvel Wins US Scenesse For EPP Fast-Track Status; Dorsavi Signs $250k US Contracts; Redhill Signs Grupo Juste In Spain For Rizaport For Migraine; Goodbye Nusep, Hello Memphasys; Otto Buttula, Webinvest Above 5% Of Imugene, Again; Nanosonics Appoints Ex-GE Steven Sargent Director
 
Jul 5, 2016
Immuron Rights Offer Raises $5.3m; MMJ: Recreational Marijuana Task Force ‘A Value-Driver’; Chris Retzos Increases, Diluted To 8% Of Prescient; Paul Ruggiero, ‘Like-Minded Investors’ Take 11% Of Cellmid
 
Jul 4, 2016
Pro Medicus Signs $18m Imaging Deal With Mayo Clinic; Biotech Capital Invests $100k In Accounts Subsidiary Bio101; CE Mark For Speedx HSV-1, HSV-2, VZV Diagnostic; Nusep Name Change To Memphasys; Regal Funds Takes 9% Of IDT Australia; Haakmans, Dussman Increase, Diluted To 31% Of Simavita; Paul Ruggiero, ‘Like-Minded Investors’ Take 10.3% Of Cellmid; Bionomics Loses 9-Month Director Dr Alan Dunton; MMJ Appoints Richard Jarvis CFO
 
Jul 1, 2016
10-Year BDI-40 Up 163%, ASX Up 3%, Big Caps Up 308%, NBI Up 262% - Year-To-June 30: BDI-40 Up 8%, ASX200 Down 4%; Big Caps Up 27%; WEHI: ‘Protein Hope For Malaria Vaccine’; Mesoblast $120m Kentgrove Facility, October Heart Results; Oventus Raises $12m, To List On July 14; Medadvisor, Bristol-Myers Squibb Education Collaboration; Regal Funds Takes 5% Of Impedimed; Brain Loses Founding Director Nestor Hinzack
 
Jun 30, 2016
Federal Election 2016: Promises, Evidence And Credibility; Mayne Raises $634m Of $888m Target, Retail Offer Opens July 5; IDT Raises $6m For Generics Manufacture; Bionomics Begins Phase II BNC210 PTSD Study; Canada Licences MMJ Marijuana Plant, Performance Shares; Cynata Considering Regience $400k Offer; Allegra Borrows $1m From 35% Robinwood; Oncosil Hopes For CE, FDA Approvals ‘In The Near Term’; Acrux ‘Seven Projects By July 2017’, Patent Hearing; Resapp Negotiating Paediatric Study With 2 US Hospitals; Phosphagenics: ‘TPM No Benefit In Older Piglets’; Paul Ruggiero, ‘Like-Minded Investors’ Take 10% Of Cellmid; Ward Ferry Takes 6% Of Simavita; Universal Biosensors Appoints Craig Coleman Director
 
Jun 29, 2016
TBG Takes 51% Of RBC For $4.7m; Simavita Raises $7.4m; Unnamed Company Extends Atcor Trial Contract $600k; Prescient Offer Raises $2m Of $3.4m; Placing Shortfall; Avita Hires IMS For Burns Centre Savings Study; Medadvisor: ‘180k Users, 1.6k Pharmacies, $1m Scripts A Week’; Agenix EGM To Become CCP For Refrigerator Control; Paul Ruggiero, ‘Like-Minded Investors’ Take 7% Of Cellmid; Cellmid Posts Midkine Symposium Interviews; Alchemia Loses Founder Dr Tracie Ramsdale; Proteomics Loses Founder Dr Bill Parker, James Moses; 2016 Research Australia, $80k GSK Awards
 
Jun 28, 2016
Heartware Jumps 93% On $1.5b Medtronic Offer; Mayne To Buy 42 Teva Drugs For $881m; WEHI Maps Plasmodium Vivax Malaria Genome; Europe Grants Antisense ATL1103 Acromegaly Orphan Status; Optiscan To Place $750k, Rights Offer For $1.4m; Nuheara IQbuds Win WA ‘Most Disruptive Technology’ Gong; Avita Data Published In Regenerative Medicine; IDT Requests Capital Raising Trading Halt; MMJ Requests ‘Canada Marijuana Licence’ Trading Halt; Australian Ethical Takes 13% Of Prescient; Crystal Amber Takes 12% Of GI Dynamics; Bio-Melbourne, Royal Society Partnering Breakfast
 
Jun 27, 2016
Botanix $3.5m Takes Bone To Cannabinoid Dermatology; Barda Awards Avita Further $11m For Recell; Clarity, Queensland Uni, Phebra Share $2.5m CRCP Grant; Pharmaust Prepares For Monepantel (PPL-1) Dog Cancer Trial; Cyclopharm $336k For Canada Association Support; MGC Receives $45k For Cannabis Cosmetics; Regal Funds Takes 10% Of Prescient; Dimerix To Release 247m Escrow Shares; Anatara Loses CEO Paul Schober, Gains Mike West, Kylie Davis; Somnomed Appoints Jim Evanger US Subsidiary CEO; MGC Loses Director Nick Castleden
 
Jun 24, 2016
UCLA Backs Genetic Signatures Enteric Pathogen Test; Bionomics Completes Phase II BNC210 Anxiety Trial Enrolment; Cellmid: ‘Midkine Antibodies Aid Bone Healing In Mice’; Medibio: ‘Algorithm Distinguishes Five Sleep Stages’; Contagno Back-Door Into Tyrian For Asset Management; Gameday + Mt Magnet South = Impression Mouth Guards
 
Jun 23, 2016
Redhill RHB-104 Potential Efficacy For Crohn’s Disease; Merck Inc Pays Bionomics $978k Licence Fee Share; Global Kinetics, US Parkinson’s Foundation Movement Trial; Bioxyne Contracts Datapharm For Probiotics Trial; Living Cell Berlin Poster May Have Pushed Price 40%; GI Dynamics Presents Final Endobarrier Trial Data; ‘Power, Water Shortages’ End Anatara Pig Diarrhoea Trial; Up To 11% Of Simavita Votes Oppose 100% Directors Pool Hike; Viburnum, Wyllie Funds Take 13.6% Of Universal Biosensors; BPH Pleads ‘Investor Relations Specialist’ To ASX 117% Query
 
Jun 22, 2016
Clinuvel Begins Commercial Roll-Out Of Scenesse For EPP; Prima: Phase IIb 6-Patient Data – ‘IMP321 Safe, Well-Tolerated’; WEHI Breast Cancer Prevention Trial 25% Enrolled; Australian Patent For Neuren’s Autism Spectrum Trofinetide; Prana Analysis Indicates PBT2 Huntington’s Efficacy; Bio-Melbourne ‘Lessons From Theranos’ Briefing 
 
Jun 21, 2016
WEHI: ‘Denosumab Stops Breast Cancer In Mice’, Human Trial; France Approves Medical Developments Penthrox; Resapp Interim Adult Data Shows Algorithm Accuracy; Immuron, Walter Reed Shigella Collaboration; Cynata Phase I GvHD Application Delayed Until July; US Patent For Orthocell Tenocytes, Collagen Scaffold; Cyclopharm $1.3m China Deal, H1 Revenue Expected Up 21%; India Approves Genera RTI-Plex Diagnostic; Recce: ‘327 Antibiotic Preclinical Studies By March 2017’; ITL Failed Malaysia Air-Conditioning Profit Warning; Up To 18% Oppose Universal Biosensors Directors, Pay; Bard1 Director Dr Irmgard Irminger-Finger Takes 19.6%; Genetic Technologies: Prof Susan Gross Medical Director
 
Jun 20, 2016
Oventus O2vent: ‘A Disruptive Technology’; Bard1 Opens Down 20%, Lung Cancer Blood Test; Resapp Requests ‘Study Results’ Trading Halt; Avita Appoints Troy Barring COO, Ross Saunders Sales
 
Jun 17, 2016
J&J, Queensland Innovation Office; $300k Quick Fire Awards; Genetic Signatures Launches Analyte Specific Reagents In US; China Patent For Orthocell Celgro Collagen Platform; Antisense Plans Phase IIb MS Trial, Freemind For Funding; Avexa Signs 3 More Clinics For Tali Trial; 2nd Trial Planned; Benitec Receives $3.6m Federal R&D Tax Incentive; Respiri (Isonea) Raises $4.3m; Medical Australia Completes Medivet Sale For $207k; Australian Patent For BPH, Cortical Dynamics Bar Monitor; BVF Partners, Mark Lampert Reduce To 13.6% In Viralytics
 
Jun 16, 2016
Uscom Signs $65m 5-Year China Deal; QBid Places First Immuron Travelan, Protectyn Orders; Orthocell: ‘Early Celgro Shoulder Safety, Tolerability’; Victoria $365k For $2.5m Medical Developments Plant; Prescient Ready For PTX-200 Combination AML Trial; Pharmaust’s Epichem Wins $250k Leishmaniasis Grant; Anatara Detach Pig Trials, Latrobe ANA0019 For Humans Study; Avita 2-For-9 Rights Issue For $11.5m; Oventus $12m IPO Opens; Alchemia Still Selling Hyact, Panther Gone, Suspension Lifted; GSK Extends Medadvisor Respiratory Drug Messages; Bionomics Appoints David Wilson, Peter Turner Directors
 
Jun 15, 2016
China Approves All Ellex YAG Laser Treatments; Anteo, Atomo Partner For Point-Of-Care Cardiac Arrest Test; UWA Study Backs OBJ Micro-Array For Disinfection; Resonance 2-Year Unnamed Company Collaboration; Phylogica: ‘Study Backs Phylomer Antisense Delivery’; Alchemia Suspended For ‘Insufficient Operations’; Sample Issue Delays Factor Therapeutics US VF001 Wound Trial; Cellmid Launches Evolis Professional Hair Products; MGC Plants Slovenia Marijuana Test Crop; Bioxyne Director Options, Dr Peter French Starts On $120k; Kinetic Takes 5% Of Impedimed; Otto Buttula, Webinvest Below 5% Of Imugene; Mach7 Loses Ken Poutakidis, Gains Alister Wayne Spittle
 
Jun 14, 2016
Teva Returns Mesoblast Cardiac Drug, Draw-Down Facility; Medical Developments Unnamed Canadian Penthrox Deal; Proteomics China Partner $1.3m For Promarkerd Test, Patent; Avita Requests ‘Capital Raising’ Trading Halt; Astrazeneca To Use Adherium Smartinhaler In US COPD Trial; Bone Backs $3m Botanix Backdoor For Cannabidiol Dermatology; Uscom Appoints Pozitronics Vietnam Distributor; Immuron Travelan Listed In Magellan’s Travel Catalog; Australian Patent For Novogen ATM-3500 Compounds; Prana Pleads Schultz To ASX 38% Query; Regal Funds Takes 7% Of Airxpanders; FIL Increases To 8% Of Starpharma; Anteo CEO Dr Jef Vangenechten Starts On $534k; MMJ Appoints Stanislav Sologubov, John Hollister Executives; Gongs For WEHI’s Prof Doug Hilton, Dimerix Prof Kevin Pfleger
 
Jun 10, 2016
Innate Placement Raises $2.4m, Rights Offer For $3m More; Rhinomed Cops 2nd ASIC $33k Non-Disclosure Fine; Mesoblast Extends ‘Corporate Developments’ Suspension; Rhinomed Sleep Apnoea Trial ‘Non-Significant’; Medtronic Below 5% In Reva; LBT CEO Lusia Guthrie Appointed Clever Culture Chair; Michael Corry To Replace Optiscan CFO Co Sec Bruce Andrew 
 
Jun 9, 2016
Paradigm Ready For Phase I PPS For Hay Fever Trial; Nuheara Iqbuds Pre-Order Hits $1m; BPH, Cortical Dynamics Appoints Distributor; Respiri (Isonea) Aims At Polluted China, India Markets; TDM Takes 6% Of Somnomed; Cynata Appoints Dr Paul Wotton Director; New Scigen Director Dr Marek Dziki Appointed Chairman
 
Jun 8, 2016
Allegra Back With Bioresorbable Sr-Ht-Gahnite Ceramic Bone; Airxpanders Raises $20m, Appoints Scott Murcray CFO, COO; Uscom Placement Raises $2m; Compumedics $700k China Order; Appoints Steve Otto For Sales; Oventus Lodges $12m IPO Prospectus; Actinogen: ‘FDA Enhances Phase II Xanamem Alzheimer’s Trial’; Nuheara Signs Flextronics For Iqbud Manufacture; Geneva Uni Lets Eurogold Complete Bard1 Acquisition; Bio-Melbourne: ‘Bio-Tech Hype - Lessons From Theranos’; Cryosite Appoints Andrew Shine CEO; Trevor Doolan Replaces ITL CFO David Holden
 
Jun 7, 2016
Living Cell 81-Week Data: ‘NTCell Efficacy For Parkinson’s’; Sirtex Recruits Trial Of Sir-Spheres Against Sorafenib; FDA Okays Mayne’s Generic Dofetilide For Heart Rhythm; Resapp Enrols 322 Perth Patients, Brisbane Site Opens; Avita Appoints Mintcare For Malaysia Distribution; Bluechiip Supplies Two Sample Kits To Potential Partners; Admedus Undertakes Review And Restructure; Prima Regains Nasdaq $Us1 Compliance; Suda: ‘On-Multi-Track Despite Share Price’; Scigen Appoints Dr Marek Dziki Director
 
Jun 6, 2016
Dimerix Doses 11th Of 30 DMX-200 Kidney Disease Patients; Airxpanders Requests ‘Capital Raising’ Trading Halt; Toronto’s Sprott, W Whitney George Take 5% Of Rhinomed; Somnomed Chairman Dr Peter Neustadt Holds 7%; Ravindran Krishnan Takes 6.5% Of Mach7; Nuheara Chair Grant Mooney Goes, Justin Miller Interim; Halt; Scigen Chair Dr Slawomir Ziegert Goes, Dr James Kim CEO
 
Jun 3, 2016
Bluechiip Moves Focus From Bio-Banks To Suppliers; Mesoblast Takes ‘Asset Development’ Halt To Suspension; Suda Rejects $6m HC Berlin Pharma Claim; Queensland Lists Analytica, Medical Australia Infusion System; Prescient Files $3.4m Rights Issue Replacement Prospectus; Resapp To Release 55m Escrow Shares 
 
Jun 2, 2016
Victoria $10m For $80m Monash, Melbourne Bio-Research; Clinuvel Nasdaq’s ‘1st International Designation ADR Biotech’; Pharmaust Preparing For US IPO, Listing; Dr Stephanie Simonds Wins $16k Victoria Premier’s Gong
 
Jun 1, 2016
May BDI-40 Up 3%, ASX200 Up 2%, Big Caps Up 10% - Cellmid Up 32%, Psivida 26%; Anteo Down 27%, Avita 22%; Mesoblast Requests ‘Asset Development’ Trading Halt; Somnomed Retail Offer Raises $6.5m, Total $10.5m; Sirtex Downgrades Sales Growth From 20% To 15-17%; BPH To Raise Up To $300k; ‘ASICc Comments’ Delay Prescient Rights Issue; Phosphagenics TPM Dairy Cattle Feed Trial; Arrow To Promote Medadvisor Drug Adherence Platform; Acrux Appoints Dr Geoff Brooke, Dr Simon Green Directors; Bio-Melbourne, CSIRO Geelong ‘Bio-Containment’ Briefing
 
May 31, 2016
Nanosonics: ‘Trophon Meets Scotland NHS Guidelines’; Allan Gray Takes More Profit To 6.5% Of Nanosonics; BARDA $3.4m For Polynovo Next Step In BTM For Burns Trial; Avita Starts Regenercell Diabetic Foot Ulcer Trial; Immuron Rights Offer For $6m; Tasmania Uni Licences Emtin For Alzheimer’s To Alzhyme; Federal $1.4m Grant For Atomo Dengue, Chikungunya Test; Volpara Revenue Up 31% To $2.3m, Loss Up 95% To $4.2m
 
May 30, 2016
Ellex Interim Review Shows 2RT Safe, Possible Efficacy; UK Guidelines Recommend Resonance Ferriscan; Impedimed, Mayo Clinic 5-Year Indications Trial Deal; TBG Supplies HLA Typing Kits To MD Anderson Cancer Centre; Prima Files US Sec ‘Shelf Registration’ To Raise Up To $84m; Novartis, Medadvisor 12-Month Engagement Trial; Medibio Claims Pilot Study ‘Success’; Imugene Files HER-Vaxx Gastric Cancer Trial Ethics Requests; Canada Approves MGC Cannabis-Based Cosmetics; Hunter Hall Below 5% Of Medical Developments; Polynovo Requests ‘Non-Clinical Trial Funding’ Trading Halt; Biomedvic, Ausbiotech Host Innovation Connect
 
May 27, 2016
Aviragen (Biota): Cardiac Issue Halts BTA585 RSV Trial; Eurogold Raises $3m For Bard1 Lung Cancer Test; WEHI ‘Cell Death Trigger Could Lead To New Drugs’; OBJ, Proctor & Gamble Sign New 5-Year Deal; Simavita $1m Funding, Exit TSX, 100% Directors Pool Hike EGM; Fil Takes 8% Of Impedimed; Hunter Hall Takes 17% Of GI Dynamics; Crystal Amber Takes 10% Of GI Dynamics; Immuron Requests ‘Rights Issue Capital Raising Trading Halt’; Admedus Appoints 6% Holder Mathew Ratty Director; Recce Appoints Bernadette Murdoch Director
 
May 26, 2016
FDA Approves CSL Afstyla For Haemophilia A; GI Dynamics Scott Schorer: Endobarrier Restart Or New Trial; Clover, Premneo DHA Fails Phase III BPD Trial; Brian McNamee; TBG Wins $60k China Grant For HLA Typing Kit; Up To 18% Of Reva Oppose 50% Directors Pool Hike; M&G Quits GI Dynamics, Takes $45m Loss; Paul Hopper, Associates Increase, Diluted To 8% Of Prescient; Airxpanders To Release 99m Escrow CDIs
 
La Trobe Uni $5m Strategic Innovation Fund; Admedus To Supply Royal Adelaide Hospital Infusion Pumps; Starpharma DEP-Cabazitaxel Eliminates Neutropenia In Rats; Victoria Backs Delegates To San Francisco Bio 2016; Invitrocue: ‘3-D Scaffolds Enhance Stem Cell Liver Cells’; Medical Developments US, Portugal Spacer Distributors; MGC: ‘FDA Okays CBD Cosmetics, $1.85m California Distributor’; Immuron Phase II IMM-124E Nash Trial 50% Enrolled; Multiple Doses Of Recce 327 Antibiotic Safe In Mice; Benitec Focus On Science, Hep B, AMD Vector, US Director; Rhinomed Recruits Inpeap Sleep Apnoea Trial Recruitment 
 
May 24, 2016
Innate 11-Months For MIS416 Results, Finding MS Endpoints; Reva To Launch Fantom Stent By July 2017, Cash-Tight; WEHI, QIMR To ‘Switch On’ Natural Killer Cells For Cancer; Clarity Raises $2m For Sartate Neuroendocrine Tumor Trial; FDA Approves CSL Flucelvax Quadrivalent ’Flu Vaccine; GSK $80k Research Excellence Nominations Open; D3 Appoints Dr Sanela Bilic, Dr Tiffany Lin To Clinical Team; Brett Crowley Replaces Uscom Co Sec Catherine Officer 
 
May 23, 2016
ALP: ‘R&D To 3% Of GDP, IIF Reinstated, Investment Programs’; Biotron: ‘2 Compounds Active Against Zika Virus’; US Approval, Patent For Mayne’s Doryx MPC; MGC Requests ‘Cosmetics Approval, Distribution’ Trading Halt; Factor Therapeutics 3m Dr Chris Behrenbruch Options EGM; Admedus To Lose CEO Lee Rodne, Review; Starpharma’s Dr Jackie Fairley Wins Bio-Melbourne Gong
 
May 20, 2016
Greens Science, Research, Innovation Policy- 4% Of GDP; Osprey Dyevert Trial Shows 47% Cardiac Dye Reduction; MGC ‘Oversubscribed Priority Offer’ Raises $2.5m, Total $7.5m; Rhinomed Share Plan Raises $167k, Total $4.7m; Analytica: ‘Case Studies Back Pericoach Pelvic Floor System’; Mesoblast Receives $6m Federal R&D Tax Refund; TGA Questions GI Dynamics Endobarrier Compliance; Medlab Pleads Schultz To ASX 50% Query; Invitrocue Appoints Scientific Advisory Board
 
May 19, 2016
WEHI Necroptosis Combination Kills AML In Mice; Applications Open For $316k Victoria Prizes, Fellowships; Bluechiip Raises $180k; Respiri In Underwritten 1-For-2 Rights Offer For $4.3m; Phosphagenics Escapes 2nd Strike; Gains, Loses Directors; Japan Patent For LBT APAS; QRX 18% Against Remuneration; Merchant Takes 12.5% Of Polynovo; Bluechiip Appoints Hugh Douglas For North America 
 
May 18, 2016
Reva Fantom Safe, ‘Low Late Lumen Loss’; Polynovo BTM Closes Skin Over Burnt Skull Bone; Prescient Placement Raises $7m, Rights Issue For $3.4m More; Clinuvel Scenesse Restricted Euro Approval, No Free Use; Phosphagenics, Themis Expand TPM-Diclofenac Licence; UBS AG Reduces To 6% Of GI Dynamics; Respiri (Isonea) Takes Capital Raising Halt To Suspension; Oncosil Appoints Michael Warrener For Sales, Marketing; TBG Chairman Jitto Arulampalam Returns To Executive
 
May 17, 2016
WEHI Cancer Drug Action Insight To Resistance; Phosphagenics TPM-Oxycodone Mystery Japan Option; Nusep Sues Prime For GF100 Blood Separation Unit; Clarification: Nusep; Regeneus, Adelaide Uni, Macquarie Uni $340k ARC Pain Grant; Medical Australia To Distribute Ardo Breast Pumps; CCP To Backdoor Into Agenix For Refrigerator Control
 
May 16, 2016
Starpharma Condoms For Rio Olympics; Regeneus Progenza Stem Cell Osteoarthritis Trial Enrolled; Nusep: Prime Shareholder Convertible Loan For $5m; Opthea (Circadian) Companies Reduce To 6% Of Antisense; Polynovo To Release 32m Escrow Shares; Prescient Requests Capital Raising Trading Halt; Respiri (Isonea) Requests Capital Raising Trading Halt; Sirtex Appoints Kevin Richardson Americas CEO; Recce Appoints Dr Dominic Barnes Director
 
May 13, 2016
Prima Licences CVac To Cashless Sydys For $400m, 10%; Invitrocue To Grow Tumor Cells For Drug Testing; Credit Suisse, JP Morgan Chase Below 5% In Mesoblast; Hyperion Takes 5% Of Cochlear; Optiscan Appoints Archie Fraser CEO On $137k
 
May 12, 2016
Federal Government Call For Submissions On $20b MRFF; Europe Confirms CSL’s Idelvion For Haemophilia B; Antisense FDA Orphan Status For ATL1103 For Acromegaly; Scott Schorer To ‘Reboot’ GI Dynamics; Credit Suisse, JP Morgan Chase Mesoblast Substantial Notices
 
Draximage Deal Off, Cyclopharm Funds US Technegas Trial; Cellmid Symposium Leads To ‘Adaptive Pathway’; Medical Developments: ‘FDA Workload Delays Penthrox’; Cyclopharm Avoids 2nd Strike, 6% Oppose Chair Vanda Gould; Dicks Sporting Goods To Trial Rhinomed Turbine Plugs; Europe Approves MGC Cannabinoid Cosmetics; M&G Reduces To 10% Of GI Dynamics, Takes $3m-$6m Loss; Volpara Directors Hold 36%; United Overseas Venture Takes 5% Of Mach7 
 
May 10, 2016
Mesoblast Q3 Revenue Down 2%, Celgene Option Expiry; Aviragen Q1 Biota Royalties Revenue Down 10% To $7m; Up To 15% Of Unilife Votes Oppose 10-To-1 Consolidation; Qbid To Distribute Immuron Travelan, Protectyn In China; GI Dynamics Cuts Costs, Staff By Further 30%; UBS AG Buys, Sells, Borrows, Returns 7% Of Impedimed; GI Dynamics Appoints Brian Callahan Chief Compliance Officer; Adherium Appoints Mark Licciardo Joint Company Secretary
 
May 9, 2016
Avita: ‘Renovacell, Needling Restore Scar Pigment’; Roadshow; Cynata: ‘$40m Apceth Cymerus Licence Option’; Antisense Doses 3 Of 4 Acromegaly Patients, Extends Trial; Osprey Data Analysis: ‘Avert Reduces Dye, Kidney Injury’; Unilife Discovers Previous Chairman, CEO ‘Violations’; GI Dynamics Endobarrier With Liraglutide Best For HbA1C; Canopy Takes 15% Of Auscann En Route To TW Backdoor; Prana Receives $6.5m Federal R&D Tax Incentive; LBT Appoints Brent Barnes CEO Replacing Lusia Guthrie 
 
May 6, 2016
Federal Government $163m For 258 Arc Projects; Dimerix Shares $499k ARC Grant With Perkins Institute, UWA; OBJ Delivers 200k Skin Care Devices To Proctor & Gamble; Avita Recell ‘Reduces Long-Term Scarring And Itching’; Ellex: ‘Data Backs Ab Interno Canaloplasty For Glaucoma’; Waisman Manufactures Cynata CYP-001 For GvHD Trial; Mach7 Signs $650k Deal With Unnamed US Radiology Group; Acorn Takes 7.5% Of Factor Therapeutics (Tissue Therapies); Narelle, Andrew Fay Take 10% Of Medical Australia; Simavita Loses Director Craig Holland
 
May 5, 2016
Redhill Roadshow To Deepen Australian Connection; Eliminate Dengue: ‘Wolbachia Reduces Zika’; Starpharma: ‘Vivagel Active Against Zika Virus’; Somnomed Raises $4m, $6.5m To Go; Heartware Q1 Revenue Down 21% To $74m; Gordagen: US Study ‘Ne1-Elite Muscle Recovery Efficacy’; Opthea Doses First Phase IIa Opt-302 AMD Patient; Goodbye Tissue Therapies, Welcome Factor Therapeutics; Lang Walker Group Takes 17% Of Medical Australia; Pt Dwi Satrya Utama Takes 5% Of Mach7; GI Dynamics Appoints Jim Murphy CFO
 
May 4, 2016
Early Investor Tax Break, Venture Capital Pass Senate; Avcal Details Early Stage Investor, Venture Capital Changes; Research Australia: Budget Cuts To ARC, CRCs, MRFF; Comment: Biotech Daily, ALP Opposition, Melbourne University; MGC Raises $5m, Rights Offer For More; St Vincent’s Approves Orthocell Celgro Hip Trial; Airxpanders 1m Directors Options, Election AGM - Greg Lichtwardt, Zita Peach In; Albert Cha, Brigitte Smith Out; Pharmaxis Sells 1,103 Unmarketable Parcels; Genetic Technologies Rings The Nasdaq Bell, Again
 
No Obvious Changes To Biotech, Innovation; 45% R&D Tax Incentive – Apparently Unchanged; NHMRC, ARC Grants – Undisclosed; Small To Medium Business Tax Cuts; Potential Cuts To Entrepreneurs, CRC Programs 
 
May 3, 2016
Avexa’s Tali ‘Effective For Attention Training In Children’; Somnomed Underwritten Rights Issue To Raise $10.5m; Europe Grants Psivida’s Medidur Orphan Status; Polynovo Principal Investigators Meet For US BTM Burn Study; Founder Harry Rosen Below 5% Of Phosphagenics; Biotech Daily Policy On Mega-Day-Traders; IDT Opens New Adelaide CMax Trials Facility; Novogen To Close Yale Joint Venture Cantx; Recce Prepares Recce-327 Antibiotic For FDA Trial Process; A-Bio Demands Nusep Pay $4.6m, Prime Negotiations Continue; Daniel Moore Replaces GI Dynamics Chairman Jack Meyer; Optiscan Board: Alan Hoffman, Peter Francis, Dr Ian Griffiths
 
May 2, 2016
April BDI-40 Up 1%, ASX200 Up 3%, Big Caps Up 2.5% - Tissue Therapies Up 57%, Prana 32%; Neuren Down 28%, Airxpanders 22%; MCRI, Curve Offer Two $25k Bytes-4-Health Start Up Grants, Places; Mach7 Raises $2.5m; Japan Patent For Prima’s Lag-3; Japan Patent For Cynata Mesenchymal Stem Cells; Orthocell Receives $1.5m Federal R&D Tax Incentive; Neuren Has Two Quarters Cash, $3m More Coming; Goldman Sachs Borrows, Buys To 5% Of Sirtex; Peter Corr, Inov8 Take 9% Of Analytica; MGC Requests ‘Capital Raising’ Trading Halt; ASX Query; Prof Philip Cohen For St Vincent’s Prof Pehr Edman Lecture
 
Apr 29, 2016
Canada Approves Sirtex Sir-Spheres For Liver Cancer; Phosphagenics Up 170% On 4-Product Unnamed Japan Deal; Strongbridge Pays Antisense $1m For ATL1103; Optiscan Raises $600k; Jet.Com To Sell Rhinomed Anti-Snoring Mute Plugs In The US; Admedus Revenue Up, Two Quarters Cash; Staff, Pay Cuts; Innate Less Than Two Quarters Cash, $1.5 R&D Credit Coming; Invion Has Less Than Two Quarters Cash, Costs Down; Tissue Therapies EGM Backs Factor Name, Capital Raising; Analytica Chairman Dr Michael Monsour Takes 23%; Medadvisor Appoints Carlo Campiciano Co Sec
 
Apr 28, 2016
MGC To Buy Prague’s Panax For Up To $2m Cash, Scrip; Dimerix FDA DMX-200 Meeting Triggers 75m  Share Conversion; Heartware Completes ‘Lateral’ Minimally Invasive Enrolment; Immuron Appoints McKesson For Nth America Travelan Sales; Biotech Daily Appendix 4C Quarterly Reports Policy; Medlab Has Two Quarters Cash, $900k R&D Incentive Coming; Mach7 Requests ‘Capital Raising’ Trading Halt; Inaugural NHMRC Dementia Forum In Brisbane
 
Apr 27, 2016
Victoria Budget 2016: Some Benefits, ‘No Cuts’ To Biotech; Volpara Opens At 50c, Climbs 7% To 53.5c, Closes At 50c; Pro Medicus $7m Franciscan Health System Contract; Acrux, Eli Lilly Axiron Sales Down 3% To $48.5m; All Change At Simavita, $3m Raised, $3.4m To Go; Resmed Q3 Revenue Up 7% To $595m, Profit Down 3% To $116m; Dorsavi Q3 Revenue Up 33% To $657k; Bioxyne Q3 Probiotics Revenue Up 132% To $647k; Anteo Pleads Schultz To ASX 31% Query; OBJ, Procter & Gamble Extend Collaboration 5 Years; Ex-Acuvax Dr William Ardrey Appeals 4 Years Gaol
 
Apr 26, 2016
Neuren: ‘Trofinetide Safe, No Efficacy For TBI’, Down 43%; Aviragen (Biota) Trades Inavir Royalty For $26m; Nusep Takes Prime Transaction Trading Halt To Suspension
 
Apr 22, 2016
Tissue Therapies Underwritten Rights Issue Raises $5.3m; Neuren Requests ‘Brain Injury Trial Results’ Trading Halt; MGC Requests ‘Cannabis Plant Acquisition’ Trading Halt; Brain Receives $639k Federal R&D Tax Refund; Adherium Loses Co Sec, Commercial Head Bronwyn Le Grice
 
Apr 21, 2016
Opthea OPT-302 ‘Safe’ For Wet AMD Alone, In Combination; Avita: Regenercell, Renovacell Wound Healing ‘Significant’; Imugene Files For Hong Kong Her-Vaxx Gastric Cancer Trial; Orthocell ‘Cell Factory’ For Bone Regeneration Published; Living Cell NZ Placement Raises $432k, Total $3.7m; Resonance Sells 5m Unmarketable Parcel Shares For $75k; Rhinomed Signs Performance Bike, Inbox Fitness For US Sales; Nusep Requests ‘Transaction’ Trading Halt; Prima Pleads Schultz To ASX 23% Query; Reproductive Health 5.75m Director Options AGM; Jenny Swain, Rob Truscott Replace Allegra’s Chris Calamos; Reproductive Health Director Fabian Dwyer Resigns
 
Apr 20, 2016
Nanosonics Record Q3 $12m Revenue, 10m $28m Notes Converted; Resapp Raises $12.5m; Somnomed Q3 Revenue Up 32% To $11m; MMJ Signs Partners To Import, Promote Medical Marijuana; Analytica Share Plan Raises $568k, Total $2.3m; Biotron Receives $1.5m Federal R&D Tax Refund; Reva $1.3m Directors Stock, 50% Directors Fees Hike AGM; Pro Medicus Appoint Starfish Anthony Glenning Director
 
Apr 19, 2016
TGA Okays Dimerix DMX-200 Special Access For Kidney Disease; Redhill Takes RHB-105 To 2nd Phase III Helicobacter Trial; Viralytics Updates Three Cavatak Trials; Medibio Takes Heartlink’s IP For $1.2m In Scrip; Immuron Appoints Allocation To Sell Travelan In The US; MGC Pleads Schultz, Cannabis Cosmetics, Law To ASX 50% Query; M&G Reduces To 11% Of GI Dynamics, Takes $3m-$6m Loss; Mesoblast To Release 15m Escrow Shares; Simavita Takes Capital Raising, Board Halt To Suspension; Cogstate Appoints Abby Moore Acting Co-Sec
 
Apr 18, 2016
Volpara IPO Raises $10m For Breast Imaging; Nuheara Crowd-Sources $500k In 2 Weeks For Iqbuds; Cochlear Chairman Rick Holliday-Smith To Chair Qbiotics; Bio-Melbourne 3D Printing Briefing; Resapp Requests ‘Capital Raising’ Trading Halt; Simavita Requests ‘Capital Raising, Board Change’ Halt
 
Apr 15, 2016
Unilife ‘Cambridge Withdraws Legal Action’; Phosphagenics David Segal, Potential 2nd Strike AGM; Rhinomed EGM For 10m Director Ron Dewhurst Options; Correction: Uniseed; Australian Ethical Takes More Ellex Profit To 9%
 
Apr 14, 2016
Sirtex Completes Resirt Kidney Cancer Trial Enrolment; Compumedics $2m US, Sydney Sleep, Neuro Diagnostic Deals; Uniseed Provides $1.95m Of $4m For Perkii Live Probiotics; Universal Biosensors Q1 Service Fees Up 68% To $5m; Immuron Signs CVS For Travelan US Distribution; Proteomics Expands In India, Hires Sreeja Sony For Sales; Bionomics Working Group For Board Renewal; Allan Gray Takes Profit To 7% Of Nanosonics
 
Apr 13, 2016
ITIF: ‘Australia 52nd For Biopharma Innovation Policies’; Victoria Legalizes Medicinal Cannabis; Innate Completes Phase IIb MIS416 For MS Enrolment; FDA Approves IDT Generic Temozolomide For Brain Cancer; Biota ‘Transformation’ Name Change To Aviragen; Rotary Bowel Cancer Programs Adopt Clinical Genomics Test; Anteo Files Two More Battery Patents; MGC Sells First Cannabidiol-Based Cosmetics On-Line; 3D Director Frank Pertile Diluted To 4.75% Of Mach7; Michael Catanzariti, Ty Webb Diluted To 4.99% Of Mach7; Optiscan Loses 2nd Chairman Patrick O’Connor
 
Apr 12, 2016
Biota Starts Phase IIa BTA585 RSV Trial; Uscom Posts $1m Record Q3 Total Revenue; Nusep Sells Gells To Dycent Shanghai For $170k; Canada 2nd Patent For Suda Anti-Emetic SUD-002; JCP Takes 9% Of Nanosonics; Charles Goode Companies Take 100-268% Profit On Cogstate; Pulitano Family Takes 6% Of Bluechiip; MMJ To Release 17.5m Voluntary Escrow Shares; Dr Robert Gilmour Replaces Nusep Director Mark Gell; Imugene Appoints Dr Yelena Janjigian Advisor
 
Apr 11, 2016
Cryosite Steps-Up To Save 2,000 Stemlife Cord Blood Materials; Prana Regains Nasdaq Compliance; Links, Lotsa, Laurence Freedman Reduce To 8% In Bionomics; Lagoda, Fatima Dickey, Richard Bayles Take 10% Of Clinuvel; Nusep Director Andrew Goodall Buys 207m Shares To 36%; Recce ‘Update’ Loses Directors Ian Brown, Prof Dongke Zhang; Stephen Roberts Replaces Cryosite Chairman Andrew Kroger; Stephanie Unwin Replaces Phylogica Chair Bruce Mcharrie; CFO Melanie Leydin Replaces Alchemia Co Sec Steve Denaro
 
Apr 8, 2016
Nominations For $750k Prime Minister’s Science Prizes; Admedus Extends Coroneo Distribution To Australia, NZ; Orthocell ‘Deal Ready, Positioned For Growth’ Roadshow; Cyclopharm Potential 2nd Strike Board Spill AGM; Cellmid Establishes Midkine Lyramid, Kinera Subsidiaries; 3D Completes Mach7 Merger, Name Change, ASX Code Coming; Oncosil Reschedules 24m Loan Shares EGM; Flindersfertility Backs Reproductive Health On Facebook; Otsuka Diluted To 5% In Living Cell; Bio-Melbourne Breakfasts On Scale-Up At CSIRO Clayton
 
Apr 7, 2016
Neuren Starts 2nd Phase II Trofinetide Rett Syndrome Trial; Ellex Raises $5m; Cynata: ‘CYP-001 Stem Cells Prolong GVHD Survival In Mice’; US Allows 3rd LBT Apas Patent; M&G Reduces To 12% Of GI Dynamics, Takes $2.5m-$5m Loss; Auckland’s Milford Diluted Below 5% Of Living Cell; Sabby Reduces To 5% Of Benitec 
 
Apr 6, 2016
Oventus $20m IPO, FDA Approves Anti-Snoring Mouth Guard; Ellex Requests Placement Trading Halt; Recce Registers Trade Mark; Reminder: RACI April Dinner - Opthea’s Dr Megan Baldwin
 
Apr 5, 2016
Federal Government Appoints $20b MRFF Advisers; Nusep Shortfall Raises $1.8m, Total Raised $2.85m; Monash IVF Validates Nusep Spermsep; IQ3 $US25m Joint Venture For Oncology Compound, Biomarker; Reproductive Health Releases 4m Escrow Shares; Windarri, Herz Family Take 9% Of Biotech Capital
 
Apr 4, 2016
Mercy Health Signs $21m, 7-Year Pro Medicus Visage 7 Deal; Bionomics Starts Phase I BNC101 Cancer Stem Cell Trial; Starpharma: ‘DEP-Cabazitaxel Breast Cancer Efficacy In Mice’; Medical Developments Appoints Middle East Distributor; Biotech Capital Acquires Biointelect For 10m Shares; Invion: ‘FDA Backs INV102 Phase III Smoking Cessation Plans’; Living Cell Share Plan Raises $483k, Total $3.3m; Simavita, Pointclickcare To Integrate Systems; Adherium Europe Office, Appoints John Tarplee; Cellmid 4th Midkine Symposium In Budapest
 
Apr 1, 2016
March BDI-40 Up 4%, ASX200 Up 4%, Big Caps Down 2% - Mesoblast Up 34%, Osprey 29%; Antisense Down 30%, Prana 28%; UK Allows Sirtex SIR-Spheres Monotherapy Alternative; Mesoblast Stem Cell Trial ‘Improves Knee Pain, Function’; Universal Biosensors Review FDA Tax Halt, Coagulation Test; Anatara Earns Milestone For Zoetis Detach Shipment; Biodiem China Licencee Starts LAIV Phase I Safety Study; Medibio ‘Pleased’ With FDA Depression Test Meeting; Nusep Adviser Prof John Aitken Wins $2k Carl Hartman Gong
 
Mar 31, 2016
Redhill: ‘Phase III RHB-105 (Giaconda Heliconda) Success’; Perkins Institute Develops Blood Vessel Repair Drug; Rhinomed Raises $4m, Share Plan; Thai Study: ‘Uscom Reduces Paediatric Mortality’; Resapp: ‘Increased Data Sets Improve Diagnoses’; Journal Article Backs Patrys Cancer Drug Acquisition; 3D EGM Votes To Become Mach7, Board Changes; Bioxyne Back To The Probiomics Probiotic Future; Regal Funds Takes 7% Of Adherium
 
Mar 30, 2016
Opthea Expects OPT-302 For Wet AMD Safety Results In April; MMJ Prepares Lucky Lake For 10-Fold Marijuana Production; IDT Sub-Contracts Canada’s Wellspring For Manufacture; Brian Dovey Replaces Reva Chairman Robert Stockman
 
Mar 29, 2016
Volpara $10m IPO For Breast Imaging Software; MGC, Sydney Uni ‘White Paper’ On Medical Cannabis; Patrys Licences Yale Nuclei-Penetrating Anti-DNA Antibodies; Rhinomed: US Distribution, Trial Delay, Funds Trading Halt; Clarity Appoints Ex-Cochlear CEO Dr Chris Roberts Director; Phosphagenics Receives $2.4m Federal R&D Tax Refund
 
Mar 24, 2016
Living Cell Begins 18-Patient Phase IIb NTCell Parkinson’s Trial; US Grants Mesoblast ‘Key’ Rheumatic Patent; Clinuvel ‘Confident’ After Nice Workshop For UK Benefits; Eurogold $3m Prospectus For Bard1 AG Cancer Blood Test; Tissue Therapies ‘Factor Therapeutics’ Name Change Egm; Mgc Signs $477k Czech Cannabis Cosmetics Distribution; Caldera: Robert Mitchell CEO For Prostate Cancer Tests; RACI Dines On Opthea’s Dr Megan Baldwin
 
Mar 23, 2016
Oneventures $20m For Clinical Genomics Test, Dr Paul Kelly; TBG: 2 Tests On The Market, 20 More In 2 Years; MRCF $4m For CSIRO Partner Mecrx; 3D Partner 333D To Raise Up To $5m For Oz Brewing Backdoor; Pharmaxis, Synairgen: ‘In-Vitro LOXL2 Success For IPF’; Proteomics To Screen Venoms For Analgesics, Antibiotics; Proteomics Releases 829k Escrow Shares; GI Dynamics Appoints Scott Schorer CEO, Starting On $524k; Uscom Appoints Ex-J&J Chao Xian David He Director; Adherium: Opens US Office Appoints James Hattersley; Resapp Loses Director Adam Sierakowski; Medadvisor Appoints Nick England Advisor
 
Mar 22, 2016
NHMRC $3.3m For Windfarm Health Impacts - AMA Position, Biotech Daily Comment; Actinogen Applies For Phase II Xanamem For Alzheimer’s Trial; Biopharmaceuticals Australia: $250k Paranta Grant ‘Pivotal’; Impedimed Share Plan Raises $74k Of Hoped-For $7.5m; Oncosil Postpones Loan Share EGM
 
Mar 21, 2016
Victoria Invests $25m In Genomic Sequencing; Oneblood Adopts ITL Samplok Blood Sampling Kit; Bone $3m Botanix Backdoor For Cannabidiol For Acne; Avexa Plan Raises $384k For Tali; Total Raised $874k; Bluechiip Technology In Autism Biobank; Arrow To Promote Medadvisor Compliance Platform; Australian Ethical Reduces To 3.4% Of Avita; Medibio To Release 24m Escrow Shares; Dorsavi Loses Chief Marketing Officer Dave Wildermuth
 
Mar 18, 2016
Biota Sells Antibiotic Assets To Spero; Tissue Therapies $15m ‘Key To Turnaround’; Clarity Wins $1m Federal Commercialization Grant; Cogstate Wins $2.6m Depression Extension Study Contract; Analytica $1.8m Placements Share Plan; Medadvisor Begins Trial Of GP Link To Monitor Medication Use; Novogen: 42% Dissent Against Iain Ross, 31% Oppose CEO Options; FIL Takes 9.6% Of Clinuvel; Viburnum, Wyllie Funds Take 12% Of Universal Biosensors; Sirtex Loses Americas Head Mike Mangano
 
Mar 17, 2016
Victoria Pledges $1.2b For Sunrise, Regional Industries; CSIRO, ARMI Improve Bone Marrow Stem Cell Harvesting; WEHI: ‘T-Cell Release Discovery Could Improve Treatments’; Tissue Therapies Hopes To Raise $15m; Netherlands Reimburses Sirtex Sir-Spheres Treatment; Biotron: ‘BIT225 Combination Better Than Interferon, Ribavirin’; Mesoblast Licences Stem Cell Technology For Diabetes; Israel’s Adama Licences Starpharma Priostar 2,4-D Herbicide; Novogen Receives $2.8m Federal R&D Tax Refund; Pro Medicus To Buy-Back 10m Shares; Bluechiip Loses Director Matt Morgan
 
Mar 16, 2016
GI Dynamics To Apply To FDA For New Endobarrier Trial; CVC: ‘Remove Bionomics Graeme Kaufman, Trevor Tappenden’; Nusep Raises $1.1m, $1.8m Shortfall To Be Placed; Prima IMP321, Adjuvant For Melanoma ‘Induces T-Cell Response’; Psivida Medidur Data Shows Small Increase In IOP; ITL Myhealthtest Joins HCF Catalyst Incubator; 3D, Mach 7 Distribution Deal With South Africa’s Intrihealth; Tissue Therapies ‘Capital Raising’ Trading Halt; M-D Paul Rennie, Kzee, Ear Takes 25% Of Paradigm; Dr Jef Vangenechten To Replace Anteo CEO Dr Geoff Cumming; Arthur Charlaftis, Kos Sclavos, Mike Da Gama Join Medadvisor
 
Mar 15, 2016
GI Dynamics Endobarrier Fails Safety, Efficacy; Clinuvel Raises $8m, Prepares European Scenesse Centres; Medical Developments, CSIRO Complete New Technology; Canada Approves Adherium’s Smartturbo, Smarttouch; International Stem Cell To Raise $8m; Viralytics Canon Trial: ‘Cavatak Safe, Anti-Cancer Activity’; OBJ Pleads Schultz To ASX 18% Query; Avita Enrols Renovacell Re-Pigmentation Study; Lagoda, Fatima Dickey, Richard Bayles Take 10% Of Clinuvel; Deutsche Bank ‘Returns’ Below 5% Of Genetic Technologies; Heartware Appoints Chadwick Cornell Director; Unilife Chair Alan Shortall Goes With $2m, Ramin Mojdeh Goes
 
Mar 14, 2016
UK NHS 2-Year Uscom BP+ Supply Contract; Recce-327 Antibiotic Active Against 7 Cancers In-Vitro; Atcor Receives $462k Federal R&D Tax Refund; Resapp To Take ‘De Novo’ FDA Route, Pivotal Trial; Australian Ethical Takes More Ellex Profit To 10%; JCP Takes 8% Of Nanosonics; GI Dynamics Requests Endo Trial Trading Halt
 
Mar 11, 2016
Avita Signs Sinopharm For China Distribution; S&P Indices: 5 Biotechs Promoted, 5 Demoted; Listen And Learn Joins Avexa Tali Evaluation; Medibio Acquires US, Canada University Data Sets; Novogen Withdraws 61% Directors Pool Hike Resolution; Clinuvel Requests Capital Raising Trading Halt; Resapp Pleads Schultz, News, FDA Meeting To ASX 44% Query; Genetic Signatures 18.4m Escrow Shares To Be Released
 
Mar 10, 2016
OBJ: ‘Ready To Promote Awareness To The Market’; Gordagen Winds Up 20% Investor Felda For $652k Debt; China Patent For Invion INV102 For Smoking Cessation; Prana 6-For-1 ADS Ratio Change, Consolidation; Analytica Ends Salesforce4hire Agreement, Cuts Spending; Raphael Lamm, Shomron Takes 11% Of Alchemia; Deutsche Bank Sells, Returns To 5% Of Genetic Technologies; Bio-Melbourne ‘Wireless And Wearable Technology’ Lab
 
Mar 9, 2016
Strongbridge ‘Cash Position’ Returns Antisense ATL1103; Avita Claims Regenercell Efficacy For Venous Leg Ulcers; Federal Government To Transfer Synchrotron To ANSTO; IDT Extends Thiotepa Contract $13m, 4 Years; Siemens Pays Universal Biosensors Milestones For Lower Strip Prices; US Patent For Atcor Sphygmocor Blood Pressure Test; Tissue Therapies Creates US Subsidiary Factor Therapeutics; Haakmans, Dussman Increase, Diluted To 37% Of Simavita; Regeneus Pleads Schultz, ‘Media’ To ASX 70% Query; Tom Bloomfield Replaces Prima Co Sec Deanne Miller On Leave
 
Mar 8, 2016
International Stem Cell Ready For Phase I Parkinson’s Trial; Melbourne Uni $36m Bio21 Expansion For CSL Hub; Sirtex Soramic Trial Recruits 420 Patient Liver Cancer Trial; Benitec BB-HB-331 Reduces Hep B 98.5% In Mice; Pharmaust Plans 3 Phase II Monepantel (PPL-1) Cancer Trials; Imugene HER-Vaxx Product Ready For Gastric Cancer Trial; ITL Pilots Myhealthtest Sales Through Act Pharmacies; 3D Medical Signs 5-Year Mach7 Licence With Penn State; Bluechiip Shortfall Raises $125k, Total $815k; Apple Watch, Fitbit Pass Medibio, Swinburne Stress Test; Raphael Lamm, Shomron Take 7.45% Of Alchemia
 
Mar 7, 2016
FDA Approves CSL’s Idelvion Factor IX For Haemophilia B; Resapp, Uniquest Collaboration Trials Pneumonia Diagnostic; Clarification: Baxalta; FDA Allows Avita Recell Compassionate Use For 36 Patients; Antisense Requests ‘ATL1103 Program’ Trading Halt; Potential Partner Prompts 2nd Proteomics Promarkerd Study; Prima Below $US1 Nasdaq Non-Compliance; EGM Loss Triggers Bionomics ‘Shareholder Consultation’; Alchemia Appoints Kentgrove Founder David Lamm Director; Ausbiotech Reminder Call For Asia Investment Presenters
 
Mar 4, 2016
Admedus Claims Preliminary HSV-2 Vaccine Safety, Efficacy; China Approves Clinical Genomics Bowel Cancer Test; Starpharma Signs Aspen For Vivagel BV For Australia, NZ; Compumedics ‘Does Not Know’ AFR China Bribe Company; TBG (Progen) Sells Pharmasynth To Luina For $2.2m; WEHI: ‘Cancers Dependent On MCL-1’; Probiotec Signs New Contracts Worth $10m A Year; MGC, Sipnose Collaborate For Intra-Nasal Cannabinoid; BPH Re-Appoints Gregory Gilbert Director; Kentgrove Takes 19.9% Of Alchemia; Orthocell Appoints Prof Rocky Tuan To Advisory Board
 
Mar 3, 2016
Baxalta: Haemophilia, Immunology, Oncology; 64% Of Bionomics EGM Stops Sabby, CVI, Empery BVF Warrants; FDA Approves Atcor, Suntech ‘Oscar2 With Sphygmocor Inside’; Anteo Takes Up To $9m Bergen Draw-Down Equity Facility; Cynata, Regience Stem Cell LOI To Preliminary Agreement; MMJ Phytotech Extends Medical Cannabis Gelpell Licence; Graham Durbin Superannuation Takes 10.6% Of Genera; Sunshine Heart Chairman John Erb Appointed CEO
 
Mar 2, 2016
Wuxi’s IMP321 Dosed In Prima European Breast Cancer Trial; Avita Launches Regenercell, Renovacell In Europe; Resapp: ‘Diagnostic Finds Disease Missed By Auscultation’; Southern Orthopaedics Joins Paradigm Bone Bruising Trial; Bio-Melbourne ‘Wireless And Wearable Technology’ Lab; Universal Biosensors Appoints David Hoey Director; Brain Appoints Dr Stephen Koslow, Matt Morgan Directors; Medical Developments David Williams Sells 1m More Shares
 
Mar 1, 2016
February BDI-40 Down 4%, ASX200 Down 2.5%, Big Caps Flat - Mesoblast Up 26%, Clinuvel 26%; Benitec Down 56%, IDT 29%; Benitec: ‘No Hep C Data Until Year-End, Big Pharma Likes Hep B’; MMJ Phytotech Raises $5m; Volpara $20m IPO For Breast Imaging For Early Cancer Detection; Medivac Administrators Appointed; Oncosil Possible CE Mark Delay, Further FDA Filing; Medical Australie H1 Revenue Up 6% To $8m, Profit To $5m Loss; Termination Takes LBT H1 Revenue Up 169% To $4.3m, Profit Up 270% To $2m; Phosphagenics Revenue Up 8% To $2.7m, Loss Up 125% To $20m; Anteo H1 Revenue Up 16% To $2m, Loss Up 36% To $3m; IQ3 H1 Revenue Up 277% To $1.2m, Loss Up 243% To $813k; Optiscan Extends Suspension For Capital Raise, Accounts; Sandon Capital Quits Alchemia
 
Feb 29, 2016
Pfizer: ‘Queensland Uni 2nd Non-US Innovation Centre’; Euro-Committee Backs CSL Idelvion For Haemophilia B; WEHI: ‘Birinapant, P38 Inhibitors Combine For AML’; Biota Respiratory Syncytial Virus BTA585 ‘Well-Tolerated’; Adherium Supplies 5,700 Smartinhalers For NZ Asthma Study; Atcor Rolls Out Insurance Cover For Sphygmocor Tests; Taiwan Approves ITL Samplok Blood Sampling Kit; Rhinomed Appoints McArthur Medical For Canada; OBJ H1 Revenue Up 29% To $1.4m, Loss Up 47% To $1.2m; Correction: Admedus; Pharmaust H1 Revenue Up 47% To $1.5m, Loss Down 10% To $1m; Regeneus H1 Revenue Down 30% To $881k, Loss Down 46% To $3m; Adherium H1 Revenue Down 34% To $1.6m, Loss Up 481% To $3.7m; Medadvisor H1 Revenue Up 94% To $680k, Loss Up 281% To $1m; Nanosonics Chairman Maurie Stang Sells 2.5m Shares; Australian Ethical Takes 5% Of Pharmaxis; Elizabeth Gaines Replaces Impedimed Director Jim Hazel; Simon Gennari Replaces Alchemia Chairman Ken Poutakidis
 
Feb 26, 2016
Benitec Falls On Closing TT-034 For Hep C Trial; Brisbane Wesley Hospital Joins Resapp 400 Patient Trial; Heartware 2015 Revenue Down 1% To $382m, Loss Up 73% To $73m; Ellex H1 Revenue Up 13% To $35m, Profit Up 43% To $1m; Pharmaxis Revenue Down 25% To $9m, Loss Up 70% To $11m; Admedus H1 Revenue Up 37% To $6.6m, Loss Up 19% To $14m; Avita H1 Revenue Up 49% To $2m, Loss Up 45% To $5m; Mayne H1 Revenue Up 114% To $127m, Profit Up 349% To $18m; Resonance H1 Revenue Up 1% To $1.3m, Profit To $22k Loss; GI Dynamics Revenue Down 54% To $2m, Loss Down 27% To $49m; Genetic Signatures Revenue Up 101% To $890k; Orthocell Sales Revenue Up 17% To $451k; Rhinomed Posts First Significant Revenue Of $522k; Opthea H1 Revenue Up 41% To $515k, Loss Down 43% To $1.7m; MMJ Requests ‘Capital Raising’ Trading Halt
 
Feb 25, 2016
MMJ Welcomes Federal Medical Cannabis Amendment; Alchemia Completes $30.2m Capital Return; Bluechiip Share Plan Raises $240k, Total $690k; Compumedics H1 Revenue Up 11% To $17m, Profit Up 106% To $2m; Acrux H1 Revenue Up 27% To $18m, Profit Up 39% To $10m; Cellmid H1 Revenue Up 103% To $1.4m, Loss Up 72% To $1.7m; Genetic Tech H1 Revenue Down 64% To $517k, Loss Down 37% To $3m; Allegra H1 Revenue Down 27% To $3m, Loss Up 340% To $1m; Probiotec H1 Revenue Up 2% To $30m, $2m Profit; Oncosil 24m Loan Shares EGM; JCP Takes 7% Of Nanosonics
 
Feb 24, 2016
Sirtex H1 Revenue Up 40% To $113m, Profit Up 51% To $27m; Eurogold EGM To Drop Mining For Bard1 Lung Cancer Test; Gordagen, Monash Collaborate On Drug Delivery Concept; Imugene Prepares For Phase Ib HER-Vaxx Gastric Cancer Trial; JCR Launches Mesoblast’s Temcell For GvHD In Japan; Reva Completes Fantom II Trial Recruitment; Cyclopharm Revenue Down 1.5% To $15m, Profit Up 18% To $5m, Dividend; Impedimed H1 Revenue Up 30% To $2.7m, Loss Up 83% To $11m; Cryosite H1 Revenue Up 10.5% To $5m, Profit Up 8% To $358k, Dividend; Dorsavi Signs Physio Corp For Viperform Pilot Program; Optiscan Takes Fundraising Halt To Suspension; FIL Decreases, Diluted To 7% Of Starpharma; Peter Meurs Takes 21% Of Dimerix; Yodambao Takes 6% Of Dimerix; GI Dynamics Loses 2014 CEO Michael Dale; Simon O’loughlin Replaces Tyrian’s Dr Caroline Popper
 
Feb 23, 2016
OBJ Claims Kneeguard Pain, Mobility Trial Success; Unilife Signs $104m Amgen Collaboration; Paradigm Starts Zilosul For Bone Bruising Safety Trial; Nusep, Newcastle, Prof John Aitken Work On Human, Horse IVF; Resmed Buys Brightree Software For $1.1b; Uscom H1 Revenue Up 54% To $1.5m, Loss Up 114% To $837k; Sirtex Sirflox Results Republished In Oncology Journal; David Sietsma Takes 5% Of Anteo; Matthew Callahan, SRV Take 6.4% Of Dimerix
 
Feb 22, 2016
Compumedics Korea Deal Opens $4b Brain Imaging Market; Optiscan Requests Fundraising Trading Halt; Mesoblast Claims GVHD ‘Responses, Extended Survival’; Immuron, Prof Gerhard Rogler To Study IMM-124E For Colitis; ITL Expands Myhealth Test, Tightens Health Care Belt; Pippa Mann Drives Genetic Technologies Brevagenplus Sales; UBS AG Buys, Sells, Borrows, Returns To 5% Of Mayne; Hunter Hall Takes 5% Of Medical Developments; MTP Connect: Sue Macleman, Bronwyn Evans, Ashley Bates; Resapp Appoints Co-Founder Brian Leedman Director
 
Feb 15, 2016
WEHI, QIMR Gene-Map Scabies For Prevention, Treatment; Queensland Grants QIMR $153k For Cytomegalovirus Vaccine; Avexa Completes Tali Acquisition; Nusep Rights Issue For $2.8m; JCP Takes 6% Of Nanosonics; Broadfin Takes 9% Of Biota; Prescient’s Steven Yatomi-Clarke Appointed CEO On $310k; Bioxyne Appoints Dr Peter French Executive Director; Bio-Melbourne Breakfasts On Investment Trends
 
Feb 12, 2016
FDA Further Orphan Status For Clinuvel Scenesse; Viburnum, Wyllie Funds Take 11% Of Universal Biosensors; Victoria Appoints 2nd Innovation Panel – Light On Biotech; Bluechiip Ready For Genea IVF Product Development; Atcor H1 Revenue Down 41% To $1.7m, Profit To $2.3m Loss; Polynovo Expects Increased H1 Loss
 
Feb 11, 2016
Cochlear H1 Revenue Up 27% To $558m, Profit Up 32% To $94m; Australia Welcomes NZ’s $4.5m For Synchrotron; Reva Enrols 200 Trial Patients, Goldman Sachs Exercises $16m; College Of Radiology, Florida Uni To Use Pro Medicus Visage 7; MMJ: ‘Marijuana Capsules Equal Or Better Than Sativex’; Medlab Welcomes Federal Medical Marijuana Bill; Avita Appoints MSM Medical For German-Speaking Countries; Denmark’s Aarhus Municipality Takes Simavita’s SIM System; La Trobe Uni Appoints Dr Dan Grant To Engage Industry 
 
Feb 10, 2016
Nominations Open For $40k Victoria Premier’s Awards; Unilife Extends Amgen Option, Defers Loans, $11m Shares; Unilife H1 Revenue Up 13% To $11m, Loss Up 23% To $51m; Ampliphi: Federal $860k Westmead Bacteriophage Grant; MMJ, Yissum Apply For Marijuana Delivery US Patents; Regal Funds Takes 11% Of Oncosil; Wayne Paterson Admedus Chair; Chris Catlow, Graeme Rowley Go
 
Feb 9, 2016
Impedimed $75m For L-Dex, Heart Test; Plan For $7.5m More; Swinburne Tests Wearable Devices For Medibio Mental Health; Melbourne Uni Trials Brain-Machine ‘Stentrode’ In Sheep; Biota Starts Phase II BTA074 Ano-Genital Warts Trial; Actinogen Receives $1.3m Federal R&D Tax Refund; Admedus Loses Director Peter Turvey; Psivida Loses Director Peter Savas
 
Feb 5, 2016
Atcor $835k Trial Contract, Scot Macdonell V-P Sales; Medical Developments, Avita Complete $2.5m Respiratory Deal; Genetic Technologies, Hendrix Genetics Settle IP Case; US Repurpose Patent For Pharmaust PPL-1; Europe, Australian Patents For Bluechiip Tracking Systems; Impedimed Requests Capital Raising Trading Halt; Suda Receives $669k Federal R&D Tax Refund; Opthea EGM For 7m CEO, Director Options; MMJ Completes Health Canada Marijuana Plant Inspection
 
Feb 4, 2016
South Australia Uni And Sementis, Bharat Work On Zika Vaccine; Eliminate Dengue Zika Mosquito Biological Response; Immuron Receives $1.5m Federal R&D Tax Refund; CVC Takes 5.2% Of Bionomics; Taiwan’s Medigen Takes 52% Of TBG (Progen); Edward Chang, Eternal Materials Take 18.5% Of TBG; TBG Appoints Edward Chang Director; Cellmid Appoints Elizabeth Masamune Director Of Advangen; Medivac: Rodger Johnston M-D, Michael Higginson Co Sec
 
Feb 2, 2016
Starpharma: ‘120-Day Dendrimer Mouse Tumor Success’; Federal Government CRC Funding Round Opens; Recce-327 Antibiotic: ‘Effective In Lower Doses In Mice’; Diasource Chair Rolf Sickman Appointed Anteo Director; Bio-Melbourne Briefing: ‘Innovation And Opportunities’
 
Feb 1, 2016
January BDI-40 Down 5%, ASX200 Down 6%, Big Caps Up 0.2% - Reva Up 33%, Orthocell 32%; Prana Down 26%, Antisense 23%; TBG (Progen) Raises $13m, To Relist On Feb 3; Pharmaust Receives $546k Federal R&D Tax Refund; Nusep Raises $371k, Rights For $2.8m; MMJ Phytotech Has Less Than One Quarter Cash; Invion Loses Chair Brett Heading, Dr Greg Collier Interim; Nusep Loses Michael Graham, Andrew Goodall Quits Prime
 
Jan 28, 2016
Cancer CRC Shares $731m Merck Blood Disorder Licence; Victoria: RMH, WEHI, Peter Mac Leukaemia Trial Backs Venetoclax; Acrux Launches Lenzetto For Menopause In Europe; Avexa Raises $490k, Plan For Tali; Halts ATC For HIV, Coal Mine; US Patent For Prima’s IMP731; Alchemia EGM Approves 9.3c Return Of Capital; Dorsavi $202k London Underground OHS Contract; Cynata: ‘UK Regulator Approves CYP-001 GvHD Trial’; ‘Freeman Road’ Takes 8% Of Resapp
 
Jan 27, 2016
Medical Developments Penthrox Launch, Respiratory FDA OK; Living Cell: ‘NTCell Stops Parkinson’s, Safe At 58 Weeks’; Admedus To Sell Coroneo Products; Recce Claims Antibiotic Kills Tuberculosis, Gonorrhoea; Prima Ready For Tactimel Phase I IMP321 For Melanoma Trial; Polynovo Appoints Leon Hoare Director; Medibio Appoints Dr Franklyn G Prendergast Director; Sienna Appoints Dr John Chiplin Director; WEHI ‘Cures’ AML In Mice; MCRI, Jupiter Collaborate On JOT101 For Friedreich’s Ataxia; Nohla Raises $30m, Appoints Lawrence Gozlan Director; Recce IPO Raises $5m For ‘Superbug’ Antibiotics; Gordagen Collaboration With Japan’s Matsumoto; Anatara, Zoetis Licence Option; Medadvisor, Epilepsy Queensland Collaborations; Clinical Network Services Opens Washington DC Office; Imugene Appoints Stuart Roberts For Corporate Development

 

 
SPECIAL SUMMER CATCH UP EDITION
3D Medical Loses CEO Max Ghobrial, Albert Liong MD Mach7; UBS AG Reduces To 7% Of GI Dynamics; John Leaver Below 5% In Bionomics; Genetic Technologies: ‘Results Support Brevagenplus’; CSL Signs $1.8b Debt Deal; Polynovo Plan Raises $4.4m, Total $12.9m; Psivida’s Medidur Meets Primary Phase III Endpoint; Cogstate Signs $4.6m Alzheimer’s Trial Deal; Immuron Claims 80% C-Difficile Pre-Clinical Efficacy; Rhinomed Receives $436k Federal R&D Tax Incentive; Prima Begins Phase IIb IMP321 Metastatic Breast Cancer Trial; Orthocell EGM; Simavita Loses CFO, Co Sec Tom Howitt; Australian Ethical Reduces To 6% Of Avita; Admedus Raises $7m; Medibio Signs Non-Binding Deal With Medtronic; Medibio Saudi Arabia Stress Deal; Anteo Raises $5m Of $12m For Diasource Acquisition; Quest, BVF Increase In Viralytics; Medical Developments Takes Avita Respiratory Business For $2.6m; Sabby Takes 5% Of Admedus; Psivida To File For EU Approval For Eye Therapy; Brain Resource Share Plan Raises $109.5k; Brain Resource Chair Evian Gordon Diluted To 8%; Cyclopharm Collects $2m Insurance Pay-Out; Neuren Ready For Trofinetide Phase II Rett Trial; Unilife Signs $21m Exclusivity Deal With Amgen; Sunshine Heart Appoints Eric Lovett For Pivotal Study; US Patent For Orthocell Tissue Repair Technology; ASX Queries Phosphagenics 33% Jump; UBS Group Takes 6% Of IDT; Anteo, Diasource Agree New Terms; Phosphagenics Sues Mylan Laboratories; Allan Gray Reduces To 7.5% Of Phosphagenics; Cogstate Loses Director Dr Alan Finkel; Asia Union Below 5% In Cogstate; Prima Tells ASX ‘Reports May Have Pushed Price 13.5%’; Psivida Hopes To Raise $23m; Australian Ethical Reduces To 11% Of Ellex; Mesoblast Phase III Heart Failure Trial Scaled Back; Avita Completes 30-Patient Acute Burns Trial Recruitment; Heartware Appointed Stephen Oesterle Director; Impedimed Creates Chronic Heart Failure Advisory Board; Anteo Completes Diasource Buy-Out; Simavita Plans $5m Placement; Regeneus Says Progenza Stem Cells ‘Safe’; Avita Replaces Prof Fiona Wood, Directors; 3D: ‘US Patent For Merger Partner Mach7’; Canada To Inspect MMJ Cannabis Cultivation; Avita Signs Japan, South Korea Recell Distribution; Psivida Raises $25m; Medibio Receives $1m R&D Tax Incentive; Simavita Receives $1m R&D Tax Incentive; Uscom Study Validates Clinical Use; Deutsche Bank Takes 6% Of Genetic Technologies; Somnomed Claims 30% H1 Sales Jump; Imugene Director Steps Down; 3D Medical Records First Sale Through E-Unity Deal; Medadvisor Appoints Sandra Hook Director; Reva Hires Richard Kimes To Lead Operations; Starpharma Raises $1.9m; Imugene Extends Vienna Immunotherapy Research; Phosphagenics Reports Positive Pig Results; Oncosil Appoints Cochlear’s Dr Chris Roberts Director; Medadvisor Claims 1m Tap-To-Refill Prescriptions; Resapp Options Raise $470k; Ellex To Expand Production Facilities; Resmed Q2 Sales Increase 7% To $454.5 Million; Bernard Stang Reduces To 7% Of Nanosonics; Sabby Takes 9% Of Benitec; Simavita Launches Purchase Plan; Clinuvel Investor Raises Holding To 8%; Viralytics Completes Oversubscribed $4m Share Plan; Prescient Receives $464k Grants
 
 
 
Dec 18, 2015
Osprey Data Analysis Backs Avert Reduced Kidney Damage; 3D: ‘Roche Hails Role In FDA Alectinib Lung Cancer Approval’; Anteo $15m Note To Buy Belgium’s Diasource; Admedus Raises $7m From US Investor; ASIC Fines Living Cell $33k For Alleged Investor News Leak; European Patent For Imugene’s HER-Vaxx; Allan Gray Reduces To 15% Of Starpharma; UBS Reduces To 8% Of GI Dynamics; Medadvisor Appoints Theo Antonopoulos Sales, Marketing
 
Dec 17, 2015
2015 – The Year In Review; Mesoblast: ‘18-Month Runway, Japan Revenue, $2b GvHD Market’; Alchemia EGM For 9.3c Return Of Capital; Phosphagenics Completes TPM-Oxycodone Dosing; Impedimed Starts US L-Dex Commercial Launch; Cynata Signs Stem Cell Deal With Apceth; Agenix Secures $1.6m China Funds; Bluechiip Placement $450k, Share Plan; Tissue Therapies Renames Vitrogro VF-001, Complying With FDA; Dimerix Appoints Dr Liz Jazwinska Director; Imugene Shareholder Otto Buttula Resigns As Director
 
Dec 16, 2015
Pharmaxis: ‘Bronchitol Paediatric Cystic Fibrosis Efficacy’; Benitec’s Loss Of CEO Dr French ‘Looks Like Retaliation’; Biotech Wins 13 Of 50 Federal ARC Future Fellows Grants; Starpharma Signs MOU For Chinese Vivagel Condoms; Atcor Signs A&D For Sphygmocor XCel Japan Distribution; Orthocell Perth Celgro Shoulder Tendon Trial Approved; IDT Share Plan Raises $2m, Total $8m; Adherium Appoints Dr William Hunter Director; Solagran 2015 Revenue Up 21% To $2.5m, Loss Up 64% To $6.4m
 
Dec 15, 2015
International Stem Cell Melbourne Parkinson’s Trial; Australian Patent For Regeneus Cancer Vaccine; European Patent For Paradigm Respiratory Treatment; Bluechiip Requests ‘Capital Raising’ Trading Halt; Simavita Dissent On Director Numbers, Fees; WA Subsidises Analytica Pericoach For Incontinence; Solagran Hopes To Raise $3m, Resume Operations; FIL Takes 8% Of Starpharma; Oncosil Appoints Ex-Sirtex US Charles Rowland US Head
 
Dec 14, 2015
Viralytics Placement Raises $28m, Share Plan For $4m More; FDA Approves Avita Recell ‘Expedited Access Pathway’; Oncosil Files FDA Pancreatic Cancer Ide Application; FDA Orphan Designation For Dimerix DMX-200 For Kidney Disease; Imugene Delayed HER-Vaxx Gastric Cancer Trial Moves To Asia; Minister Pyne, Israel PM Netanyahu Talk Innovation; Resapp 400-Adult Patient Trial Approved; Cogstate $2.4m Phase III Cancer Trial Testing Contract; UBS AG Buys, Sells, Borrows, Returns Below 5% Mayne; Goodbye Progen, Welcome TBG Diagnostics
 
Victoria, Ausbiotech Host ‘International Biofest 2016’; Prima, NEC, Yamaguchi IMP321 Proceeds To Human Trials; Goodbye Circadian, Hello Opthea; Cellmid Receives $1m Federal R&D Tax Refund; IM Medical To Pay $95k Legal Bill; Mark Heaysman Replaces Dorsavi US Head John Kowalczyk 
 
Dec 10, 2015
CSL: ‘From R&D To 20% Of Global Protein Market’; WEHI Toxoplasma Studies ‘Could Lead To Vaccine, Treatments’; Invion Plan, Placement Raise Final Total Of $2.1m; Viralytics $2.9m Federal R&D Tax Refund, Fund Raising Halt; Suda Expands Amherst Zolpimist, Sud-002 Deals; FIL Takes 7% Of Impedimed; Novogen Appoints Dr James Garner CEO, Starts On $400k
 
Dec 9, 2015
Starpharma Raises $32m, Share Plan For $3m More; Avita Recell Study: ‘Reduces Hospital Stay 63%’; Phylogica Phylomer-Omomyc Kills Lymphoma 600% In-Vitro; Invion Plan, Placement Raise $1.3m; Canada Patent For Orthocell Bio-Scaffolds, Tenocyte Combo; Ian Mann Lends Optiscan $300k, Takes Board Seat; Impedimed: ‘US Breast Cancer Survivor Guideline Published’; QRX Administrators Execute Deed Of Company Arrangement; Benitec CEO Dr Peter French ‘Steps Down’; Stephen Roberts Replaces Cryosite Director Christina Boyce; Progen Changes Directors Ahead Of TBG Merger; Goldman Sachs Below 5% Of Nanosonics
 
Dec 8, 2015
National Innovation And Science Agenda Comment - Biotech Daily, Ausbiotech, Medicines Australia; Sydney Uni, CSIRO Join Uniseed $50m Fund; Bionomics Raises $16m For Phase II PTSD Trial; Correction: TDI, Kayban; Antisense ATL1102 Shows Promise In AML Mouse Study; Florida’s Broward Health Adopts 3D’s Mach7 Imaging; Alchemia Receives $6.4m Federal R&D Tax Refund; Innate To Release 29m Escrow Shares; Goldman Sachs Above 5% Of Nanosonics
 
Dec 7, 2015
PM Malcolm Turnbull Launches $1b Innovation, Science Agenda; Bio-Melbourne Welcomes Agenda ‘Inflection Point’; Neuren Trofinetide Shows ‘Beneficial Effects’ For Fragile X; Benitec In-Vitro Data Backs BB-HB-331 For Hepatitis B; Progen Meeting Backs Medigen TBG Backdoor, Suspension; Starpharma Requests Capital Raising Trading Halt; Mach7 Waives $10m Minimum For 3D Merger; Suda Pleads Schultz To ASX 17% Query; Up To 37% Of Psivida Oppose 500k Director Options; Goldman Sachs Below 5% Of Nanosonics; UBS AG Buys, Sells, Borrows, Returns To 5% Mayne
 
Dec 4, 2015
Cytomatrix Creates $100m Nohla For Cord-Blood Stem Cells; S&P Dow Jones Promote Sirtex To Asx100; Bionomics Requests ‘US Placement’ Trading Halt; Michael Catanzariti Increases, Diluted To 10.4% Of 3D; Resapp Releases 9m Escrow Shares 19m Options; Phosphagenics Anna Legg Replaces Co Sec Mourice Garbutt; Goldman Sachs Above 5% Of Nanosonics
 
Dec 3, 2015
FDA Requests Clinuvel Scenesse Vitiligo Pre-Clinical Trial; Progen Meets $10m Minimum For Medigen TBG Acquisition; Paradigm Treats 1st Zilosul Special Access Patient; Neuren Requests Trofinetide Fragile X Results Trading Halt; Health Canada Approves Rhinomed’s Turbine, Mute; Bluechiip, Genea Fertility Tracking Licence; Cynata, Regience Consider Japan, Asia Partnership; Chris Retzos, Associates Take 9% Of Prescient; Phosphagenics Begins Second TPM Pig Study
 
Dec 2, 2015
Astrazeneca Picks 2nd Starpharma DEP Cancer Molecule; CSIRO, Kayban, Boron Develop Flax Seed Anti-Microbial; Medadvisor IPO Raises $5m For Drug Compliance App; Circadian Receives $3m Federal R&D Tax Refund; Living Cell Resumes NTCell Manufacture; Goldman Sachs Above, Below 5% Of Nanosonics, Yet Again
 
Dec 1, 2015
Mesoblast Drags November BDI-40 Down 3%, ASX200 Down 1% - Genetic Technologies Up 100%, Compumedics 54%; Atcor Down 44%; Compumedics $250k California Hospital Diagnostic Contract; Correction: Dateline; European Cellmid Midkine T-Cell Patent; 3D’s Mach7 Yuma, Arizona Contract; Antisense Receives $706k Federal R&D Tax Refund; ITL Takes Myhealthtest, Bill Mobbs Increases, Dilutes To 42%; Nusep Loses 2nd Strike Vote, Wins Spill Vote, Name Change; Circadian: Kempler, Sistenich In; Fisher, McMeckan, Howard Out; Merchant Reduces To 13% Of Polynovo; Ron Dewhurst Replaces Rhinomed Chairman Martin Rogers; Sunshine Heart Loses 6-Year CEO Dave Rosa
 
Nov 30, 2015
Anteo Diasource $12m Rights Issue, $15m Convertible Note; Euro Patent For Neuren’s NNZ-2591 For Parkinson’s, Autism; 3D To Distribute Client Outlook’s Eunity Imaging Products; Circadian New Directors Trading Halt, Name Change AGM; Optiscan 41% Oppose CFO, Director Bruce Andrew; Prescient Appoints Prof Jeffrey Lancet Advisor
 
Nov 27, 2015
Clarification: Tissue Therapies, The ASX And Chi-X Trading; Oncosil Receives $1.5m Federal R&D Tax Refund; Stirling To Back-Door MX360 For Non-Biotech Web-Trading; M&G Group Increase, Diluted To 10.3% Of Mesoblast; Viburnum, Wyllie Funds Take 9.4% Of Universal Biosensors; Medibio ‘Surprised’ By Rush For Corporate Stress Test Pilot
 
Nov 26, 2015
Japan To Pay Up To $234k Per Mesoblast Temcell GvHD Course; Avexa AGM Votes To Acquire Tali Health; Pharmaust Hires Genscript For Pre-Phase II PPL-1 Optimization; Regeneus 45-Dog KVax Vaccine Trial For Canine Lymphoma; Progen Receives $1m Federal R&D Tax Refund; Prima Receives $420k Federal R&D Tax Refund; Sun AGM Changes Name To Dimerix; Oncosil Withdraws 10% Placement Resolution, Others Passed; Novoskin, Novowound Acquisitions Delay Polynovo AGM; Cell Care Reduces To 20% Of Cryosite; Greenlight Reduces To 5.6% Of GI Dynamics; Prescient Appoints Prof Farhad Ravandi Leukaemia Advisor
 
Nov 25, 2015
Adelaide Uni Trials Ampliphi Bacteriophage For Golden Staph; Sementis To Raise $2m For Chikungunya, Allergy Vaccines; Polynovo Raises $8.5m, Plan, To Take Novoskin, Novowound; Prescient Places $1m, Total Raised $2m; Gordagen Up To $3m Loan, Chairman Fred Nadjarian Retires; Uscom Rebadges Thor Devices ‘Spirosonic’; Isonea Starts Airsonea Chicago Trial; Hong Kong, Australia Patents For Orthocell ATI, Celgro; CBA, Related Parties Below 5% Of Sirtex, Yet Again; Talu Below 5% Of Universal Biosensors; Chairman Andrew Kroger Takes 28% Of Cryosite; Paul Hopper, Associates Increase, Diluted To 12% Of Prescient; Bio-Melbourne Innovation Week Breakfast With The Minister
 
Nov 24, 2015
Capital Radiology Becomes 1st 3D Medical Mach7 Customer; D3, Medicines Development Moxidectin For River Blindness; Prescient Share Plan Raises $927k; Regeneus Licences Macquarie Stem Cell Selection System; Medibio, Johns Hopkins Heart Rate Depression Trial Approved; Japan Patent For Cellmid Midkine For Hair Loss; Avita Appoints Medical Z, Ideal Medical French, UK Distributors; Novogen Hires Novotech As CRO For Cantrixil Cancer Trial; Prime Convertible Loan Reduces Nusep To 55%; Correction: Paradigm; Up To 17% Dissent Against Clinuvel 37.5% Directors Pool Hike; Pharmaust Appoints Florida’s Redchip For Investor Relations; NY Empery Takes % Of Orthocell; JK, Kim Hogan Take 6% Of Oncosil; David Franklyn Replaces Sun’s Howard Digby, Dr Anton Uvarov; Buchan Hosts Sydney Women’s Health Event
 
Nov 23, 2015
 
Nov 20, 2015
 
Nov 19, 2015
 
Nov 18, 2015
 
Nov 17, 2015
 
Nov 16, 2015
 
Nov 13, 2015
Airxpanders Changes FDA Process To De Novo, 30-Day Delay; Medical Australia: ‘No Deal Yet For Medivet Business’; Nusep $200k Former M-D Prakash Patel Settlement; Living Cell 40% Remuneration 1st Strike, 3m Options Withdrawn; Up To 34% Of Biota Oppose Director Russell Plum, Again; Prana AGM 17% Remuneration Report Dissent; Simavita Directors Pool Increase AGM; Bionomics, Merck Neuroscience Symposium On Monday
 
Nov 12, 2015
NZ Approves 18-Patient Living Cell IIb NTCell Parkinson’s Trial; TGA Approves BPH, Cortical Dynamics’ Anaesthesia Monitor; Starpharma Receives $3.4m Federal R&D Tax Refund; 3D Medical Share Plan For $5m; Benitec 39% Oppose 7m Director Options, 18% Remuneration; Up To 43% Of Novogen Oppose Directors; Prof Perry Bartlett Wins AIPS $50k CSL Florey Medal; Prof John Greenwood South Australian Of The Year; Novogen Applies For Australian Super-Benzopyran Patent; Wisconsin’s Medico-Mart To Distribute Immuron’s Travelan; Bank Of America ‘Returns’, Sells To Below 5% In Suda
 
Nov 11, 2015
Bioxyne: ‘Mariposa Licences HI164OV To China’s Shanxi Kangbao’; QRX Creditors Meeting; Novogen: ‘Mouse Trials Back Anisina For Neuroblastoma’; Australian Patent For Regeneus Stem Cells For Inflammation; Phosphagenics Receives $2.6m Federal R&D Tax Refund; Progen Lodges Medigen TBG Prospectus; Queensland, J&J Innovation $300k Quick Fire Challenge
 
Nov 10, 2015
Resapp ‘Accurately Differentiates Respiratory Illnesses’; Orthocell First Celgro Dental Scaffolds ‘Safe, Effective’; Dr Asselin-Labat, Dr Gebhardt Win $2.45m Viertel Prizes; Invion Share Plan; Alchemia AGM Backs Fondaparinux Sale; Oncosil AGM To Increase Director Fee Pool 150% To $500k; Goldman Sachs Below 5% Of Nanosonics
 
Nov 9, 2015
Federal Government $630m For 800 NHMRC Grants; EMA Expands Admedus Cardiocel To Whole Valve Replacement; Armaron Bio Phase II Trial Of NP202 For Cardiac Recovery; Neuren Raises $6.3m For Paediatric Rett Syndrome Trial; Ireland Okays Medical Developments Penthrox, $900k Orders; Viralytics Storm Trial: ‘Cavatak Hits Tumor, Well Tolerated’; Journal Article Backs Uscom Over Catheter For Children; Immuron, One Way Liver Work On Nash Diagnostic; Antisense Appoints Resmed’s Dr Gary Pace Director; Oncosil To Release 7.5m Escrow Shares; Prana Below $US1 Nasdaq Non-Compliance; Allan Gray Reduces To 10% Of Phosphagenics; Goldman Sachs Above 5% Of Nanosonics, Yet Again
 
Nov 6, 2015
Biotech Daily 10th Birthday; Viralytics, Merck Cavatak, Keytruda Cancer Collaboration; Psivida Expands To Osteoarthritis Pain; Unilife Wearable Injector Deal With Medimmune; Genetic Signatures, UCLA Collaborate On Molecular Testing; Medibio, Vital Conversations 1st Stress Test Customer; Resapp Requests ‘Study Results’ Trading Halt; Actinogen To Release 125m Corticrine Escrow Shares; Goldman Sachs Below 5% Of Nanosonics
 
Nov 5, 2015
Genetic Technologies Pleads Schultz To ASX 58% Query - Posts Breast Cancer Guidelines News To Nasdaq, Not ASX; Invion: ‘High Court Dismisses CBio Executive Appeal’; WEHI: ‘Mass Drug Administration For Relapsing Malaria’; Regeneus Cryoshot Efficacy For Horse Joints; Sirtex Loses Asia Pacific Head Dr Burwood Chew; Phylogica: ‘Phylomer-Omomyc Effect In Mouse Breast Cancer’; Cynata Hires US CRO For Stem Cell Study; Immuron Signs Travelcare For US Distribution; Australian Ethical Reduces To 7% Of IDT; JP Morgan, Credit Suisse 35% Mesoblast ‘Lock-Up’ Notices; Australian Ethical Takes 7% Of Atcor; Goldman Sachs Above 5% Of Nanosonics, Yet Again
 
Nov 4, 2015
Admedus Launches Cardiocel In Malaysia; Antisense, Strongbridge ATL1103 Reduces Acromegaly GHBP; Bionomics: ‘BNC105, TH302 Renal, Breast Cancer Synergy In-Vivo’; Proteomics Signs China Promarkerd Kidney Test Deal; Uscom Establishes London Office; Ellex’s ABIC For Glaucoma At US Ophthalmology Meeting; Europe Grants Bluechiip Patent; MMJ Canada Marijuana Plant Ready For Inspection; Gordagen Appoints NE1-Heart US Distributor; Allegra ‘Outsources’ Active Knee Manufacture To Signature; Lagoda, Fatima Dickey, Richard Bayles Take 7% Of Clinuvel
 
Nov 3, 2015
Mesoblast US Sec Form, Implies $98m Nasdaq IPO; Somnomed Buys Canada’s Strong Dental For $743k; Impedimed, Harvard Cardiac Bio-Impedance Spectroscopy; Biota Appoints Mark Colonnese CFO
 
Nov 2, 2015
 
Oct 30, 2015
OBJ: ‘Magnetic Microarray Doubles Disinfectant Kill Power’; Nanosonics Q1 Trophon Sales Up 56% To $6.5m; Heartware Q3 Revenue Down 5% To $92m; Mesoblast Two Week ‘Capital Raising’ Suspension; Prima Places $2m; Circadian Name Change To Opthea AGM; Nusep Name Change To Memphasys, Spill, Directors Stock AGM; CFO Aliceson Rourke Replaces Cellmid Co Sec Lucy Rowe; Biotech Daily Review Of Appendix 4C Filings
 
Oct 29, 2015
Neuren Completes Trofinetide Brain Injury Trial Enrolment; Prescient Share Plan To Raise $1m; ITL’s Myhealthtest Joins NRMA Jumpstart Program; Impedimed 25% Remuneration 1st Strike; Compumedics Unusual 28% Remuneration 1st Strike; Resapp AGM For 5m Founding Scientist Options; Private Portfolio Managers Take 5% Of Bionomics; Hunter Hall Reduces To 5% Of Sirtex; Australian Ethical Increases To 7% In Avita; Chairman Paul Hopper Diluted Below 5% Of Imugene; Goldman Sachs Below 5% Of Nanosonics, Yet Again; Allegra Loses September CEO Peter Welsh
 
Oct 28, 2015
UK Approves Medical Developments Penthrox, $1m Milestone; 3D Medical Raises $4m For Mach7 Merger, $6m To Go; Imugene Receives $756k Federal R&D Tax Refund; Orthocell: ‘Ortho-ATI Improves Tennis Elbow’; US Patent For Mesoblast Cardio-Vascular Stem Cells; Prescient Requests Capital Raising Trading Halt; Challenger, Entities Take 6% Of Sirtex; Tim Robertson, Farjoy Take 9% Of Medlab; Goldman Sachs Above 5% Of Nanosonics, Yet Again; Pharmaust Backs 20:1 Consolidation, Loses Prof David Morris; Andrea Goldie Replaces Polynovo CFO Co Sec Chris Mews
 
Oct 27, 2015
Monash Chancellor Dr Alan Finkel Appointed Chief Scientist; Living Cell: ‘NTCell Stops Parkinson’s Disease’; MMJ Phytotech Starts Israel Marijuana Trial For MS; Belgium OK For Prima Phase IIb IMP321 Breast Cancer Trial; Regeneus Treats 1st RGSH4K Tumor Vaccine Patient; US, Australian Patents For Proteomics Kidney Test; Cellmid Q1 Évolis Hair Loss Products Earn $1m; Sirtex Dissent Against CEO Performance Rights; Tissue Therapies 1.6m 100% Premium Options-For-Pay AGM; Genetic Technologies 14m CEO Eutillio Buccilli Options AGM; Genera 2m CEO Richard Hannebery ‘Rights’ AGM; Isonea 2m Director Options, Name Change AGM; Goldman Sachs Below 5% Of Nanosonics
 
Oct 26, 2015
3D To ‘Merge’ With Mach7, Raise $10m, Change Name; Medlab To Begin Nano-Statin, Insulin Trials; Impedimed Buys US Intersection Medical For Heart Failure; Sun Adds 4th Site To DMX-200 Kidney Trial; Resmed Posts $567m Q1 Revenue, Dividend; Uscom Posts Record Q1 $611k Cash Receipts; Passport Health To Sell Immuron’s Travelan; Imugene Loyalty Options; Psivida AGM For 500k More Director Stock Options; MMJ Votes To Increase Directors Pool 150% To $500k; Somnomed AGM For 250k Chairman Dr Peter Neustadt Options; Tissue Therapies To Lose Director Dr Mel Bridges
 
Oct 23, 2015
WEHI, Baker, Garvan Find Obesity Sensor Protein; ANU, Garvan, Genentech Find Gene To Fight Sepsis; Eli Lilly Returns VEGFR-3 To Circadian; Acrux, Eli Lilly Q3 Axiron Sales Up 14% To $57m; MMJ Raises $2m, Piper Alderman For Australian Regulation; 3D, Hephaestus Dental Prosthetic Design Collaboration; Mayne AGM For $3m CEO Loan Shares, Pay Pool Rise 71% To $1.2m; Analytica AGM For 14m Director Options; CVC, Stinoc Down To 14.5% In Cyclopharm, Unnamed Institution; AMP Below 5% Of Medical Developments; Hunter Hall Takes 16% Of GI Dynamics; Asia Union Reduces To 7% In Cogstate; Goldman Sachs Above 5% Of Nanosonics, Yet Again; Stirling Loses M-D Peter Boonen, Gains Co Sec Elizabeth Hunt; Genera HPV Advisory Board Appointments
 
Oct 22, 2015
Benitec TT-034 For Hep C Reaches Liver, No Adverse Events; Walter Reed Treats First Avita Recell Trauma Patient; Phosphagenics Hires Tesa Labtec For TPM-Oxymorphone Patch; Somnomed Sells 250k Anti-Snoring Mouthguards, Compliance; Simavita Signs 2,500 North American Incontinence Beds; Sun Name Change To Dimerix AGM; Grandlodge, Peter Anastasiou Take 14% Of Immuron; Hunter Hall Takes 15% Of Avita; Oncosil Appoints Tom Milicevic CFO, Co Sec
 
Oct 21, 2015
Journal Article Backs Avita Recell For Facial Defect Repair; Pharmaust Final Phase I/II PPL-1 Solid Tumor Data; Up To 26% Of LBT AGM Oppose Director Kate Costello; Biotron AGM For 5m CEO Replacement Options; MMJ Requests ‘Capital Raising’ Trading Halt; Goldman Sachs Below 5% Of Nanosonics
 
Oct 20, 2015
Polynovo Completes 5-Patient Novosorb Proof-Of-Concept; Avita Raises $10m; Airxpanders: ‘Aeroform Cuts Breast Expansion Time 50%’; Novogen ‘Retracts’ Cantrixil Ovarian Cancer Announcement; Walk The Synchrotron With Bio-Melbourne; Allan Gray Further Reduces To 11.4% Of Alchemia; Goldman Sachs Above 5% Of Nanosonics, Yet Again
 
Oct 19, 2015
Osprey Tumbles 72% On Avert Nephropathy Failure; Novogen: ‘Cantrixil, Platinum Stops Ovarian Cancer’ In Mice; St Vincent’s Institute Hosts Transplant Meeting; WEHI’s Dr Ewa Michalak Wins NBCF $680k; Koma To Distribute Anteo Mix&Go In South Korea; Unilife Borrows $14m More, Cuts Staff, Executive Pay; Viralytics AGM For 5.7m More Director Options; Benitec Appoints Hepatology Advisory Board; Proteomics Appoints James Moses Director, WA Export Gong
 
Oct 16, 2015
Reva Claims ‘Excellent Acute Outcomes, Safety’; Melbourne Uni’s Prof John Hopper Wins $50k Victoria Prize; Mesoblast, Celgene Extend GVHD Option Another 6 Months; Bio-Melbourne, STC Take Victoria To US Advamed; Progen To Back-Door Medigen’s TBG For Immune Matching Kits; Avita Requests ‘Equity Placement’ Trading Halt; Starpharma 1.1m More CEO ‘Performance Rights’ AGM; Pharmaxis AGM For 1.6m CEO ‘Performance Rights’; Bionomics AGM To Elect Dr Alan Dunton, Issue 560k Options; Goldman Sachs Below 5% Of Nanosonics
 
Oct 15, 2015
Cochlear, GN Resound ‘Smart Hearing Alliance’; Orthocell ACI Study: ‘Knee, Ankle Cartilage Utility’; Universal Bio Strip Sales Beat 500m Units, PT-INR Test Delay; Proteomics Loyalty Options Raise $126k; CSL 11% Oppose CEO ‘Performance’ Stock, Again; $1b Buy-Back; JCP Takes 5% Of Nanosonics; Goldman Sachs Above 5% Of Nanosonics, Yet Again; Antisense Appoints William Goolsbee Director; Prescient Loses M-D Dr Robert Crombie
 
Oct 14, 2015
Ramaciotti $1.4m For Biomedical Research; Cynata, Massachusetts General Cancer Collaboration; Heartware Falls 20% On CE MVAD Halt; Queensland Funds Hospitals $469k For Simavita Rehabilitation; Cyclopharm Declares 0.5¢ Maiden Interim Dividend; US Patent For Starpharma Vivagel For Bacterial Vaginosis; US Allows LBT APAS Method, Software Patent; Benitec AGM For 2.6m Director Options; Admedus Director In Lieu Shares, 10-To-1 Consolidation AGM; Atcor 3m Director Options, Elect Randall King Nelson AGM; Bio-Melbourne Tours Trajan Scientific
 
Oct 13, 2015
Dr Chris Nave Tells WEHI Meeting: ‘Biotech Curve Is Up, Steep’; Taiwan Waterpark Disaster Reports Positive Avita Recell Use; Regeneus Receives $3.4m Federal R&D Tax Refund; Rett Foundation Commits $1.4m To Neuren Trials; Prima Raises $1.6m From Netherlands Nyenburgh; Somnomed Q1 Sales Up 30% To $9.6m; Cellmid AGM For 8m Director Options; Living Cell AGM For 3m Director Options; MMJ Hires Gaelan Bloomfield PR, Implies Victoria Licence Bid
 
Oct 12, 2015
Clover Licences Omega Oil To Premneo, Dr Brian Mcnamee; Cyclopharm Ultralute Boosts Mo-99 By 50%; FDA Approves Osprey Dyevert Automatic Dye Modulation; WEHI Images Trib1 For Blood Cancer Drugs; Antisense Manufactures MS Early Access ATL1102, Study; Medibio Canada Study Compares Mental, Sleep Disorders; Uspto Allows Neuren Trofinetide (NNZ-2566) Rett Patent; Avexa To Acquire Tali For Development Disabilities, To Raise $4m; Oncosil Expects BSI Fast-Track Review In November; Phosphagenics Cuts Staff, Early Stage Programs; LBT To Lose Founding CEO Lusia Guthrie; Tissue Therapies Appoints Prof Christian Behrenbruch Director; Nusep Director Andrew Goodall Reduces To 36%
 
Oct 9, 2015
Recce IPO To Raise $5m For Superbug Antibiotics; CSL Borrows $707m At 1.43%; Prima Receives $475k Final Saxony Bank Cvac Grant; Invion $2.4m Federal R&D Tax Refund, Pays Metamor Loan; Nusep Repays $250k Singapore Loan; CBA, Related Parties Buy, Borrow To 5% Of Sirtex, Again; IDT CEO Loan Shares AGM; David Lamont Replaces Promoted CSL CFO Gordon Naylor; Bruce McHarrie Replaces Phylogica Chairman Dr Doug Wilson; Bio-Melbourne Takes A Walk On The Synchrotron Wild Side
 
Oct 8, 2015
Merck Invests $13m In Bionomics, Extends Pain Collaboration; Lonza To Manufacture Benitec Drugs; Ellex Increases Sales, Reduces Costs, Forex Benefit; US Patent For Suda Oral Spray Sildenafil (Viagra); Nanosonics AGM For 278k, $364k Executive ‘Performance Rights’; Oncosil Appoints Executives David James, Dr Greg Rogers; IDT Appoints Ex-Hospira Hugh Burrill Director
 
Oct 7, 2015
High Court Rules Isolated BRCA Gene Not Patentable; Medicines Australia Concern Over IP Impact; CEO Dr Anna Lavelle Opens Ausbiotech Conference; Victoria To Build On Success; Prof Alan Trounson: ‘Australia Lags On Stem Cells’; Prof Maree Smith, Ellume, Spinifex Win J&J Innovation Gongs; LBT APAS Trial ‘Far Exceeds Expectations’; CE Mark For Avita Regenercell, Renovacell; Australian Ethical Reduces, Diluted To 10% In Avita; NY Lagoda, Fatima Dickey, Richard Bayles Take 6% Of Clinuvel; WEHI, MRCF Catalyzing Commercialization Symposium; Actinogen Alzheimer’s Investor Symposium
 
Oct 6, 2015
‘Call Us’ Victoria Minister Tells Ausbiotech; US Funding; Victoria To Legalize Medical Marijuana In 2017, Trials; Burnet, Innoviron Create Preclinical CRO 360-Biolabs; Admedus Releases Sheep Tri-Leaflet Valve Results; Heartware Replies To Investor Valtech Complaint; Hong Kong’s Senrigan Takes 15% Of Reva; Kevin Fischer Replaces Genetic Technologies CFO Brian Manuel; Bio-Melbourne Quality-Briefing Tours Trajan Scientific
 
Oct 5, 2015
Invion Claims INV102 Success For Smoking Cessation; FDA Doubles Avita Recell Compassionate Use Ide; Clinuvel, FDA Talk Scenesse For EPP; Ascend Treats First ASN-002 BCC Patient; Unilife AGM For $99m Shares; Prescient AGM For 700k Director Options, 25m Shares; Ron Dewhurst, Kroy Wen Take 8% Of Rhinomed; Goldman Sachs Below 5% Of Nanosonics, Yet Again
 
Oct 2, 2015
Resonance, Pfizer Study Machine Classified Fibrosis; Ausbiotech Invest, Conference Starts On Tuesday; Goldman Sachs Takes 5% Of Nanosonics, Yet Again; ASIC Extends QRX Reporting, AGM Up To 2 Years
 
Oct 1, 2015
September BDI-40 Down 1%, ASX200 Down 4%, Big Caps Down 2% - Oncosil Up 48%, IDT 38%, Medical Developments 38%, Biotron Down 36%, Tissue Therapies 24%, Benitec 22%; Ellex Reduces Glaucoma Surgery To 5-Min Procedure; Correction: Analytica; Adherium: ‘Three UK Studies Back Smartinhaler’; Paranta Raises $7m For PB01 For Cystic Fibrosis; Reva Enrols First 110-Patient Fantom II Cohort; Patrys Shuts German Plant, COO Roger McPherson Goes; Genetic Signatures Director Patrick Noland Resigns For US
 
 
Sep 29, 2015
Polynovo Wins Up To $38m BARDA Burns Trials Contract; Cogstate $4.5m Alzheimer’s Contract Extension; Actinogen: ‘Xanamem For Alzheimer’s Delivered To Brain’; Psivida: ‘FDA Will Accept Six Month Medidur Data For Uveitis’; Neuren Completes Fragile X Trial Patient Visits; Patrys PAT-SC1 Deal, PAT-SM6 On Hold, Car T-Cell Closed; Dorsavi $9m UK Yourphysioplan Vimove Deal; Pharmaust’s Epichem Moves Into New Lab; Hunter Hall Reduces To 6% Of Sirtex; CBA, Related Parties Sell, Return Below 5% Of Sirtex; Bionomics Appoints Dr Alan Dunton Director; Allegra Shrinks, Loses CEO Tom Milicevic
 
Sep 28, 2015
Viralytics: ‘5 Of 12 PFS In Cavatak Melanoma Extension Trial’; Viralytics Begins Cavatak Keytruda Melanoma Trial; Mundipharma Pays Medical Developments $10m; GI Dynamics: ‘German Diabetes Society Backs Endobarrier’; Phosphagenics Begins TPM Piglet Nutrition Trial; Analytica Hires Salesforce4hire For US Sales, 52m Options; Sirtex AGM For $1.5m, 46k CEO ‘Performance Rights’; UBS AG Takes 9% Of GI Dynamics At ½¢ A Share; Probiotec Sells Protein Plant To Beston Pure Dairies For $7m; Polynovo Requests ‘Trial Funding Contract’ Trading Halt; Actinogen Requests ‘CSF Study Results’ Trading Halt; Resapp Requests ‘Study Results’ Trading Halt
 
Sep 25, 2015
Alchemia Sells Last Asset Fondaparinux To Dr Reddy’s For $24m; Optiscan: ‘Extended Carl Zeiss Deal Worth $3m’; Correction: Clinuvel; Unilife, Novartis Expand Injectable Drug Delivery Deal; Queensland, J&J Innovation $300k Quick Fire Challenge; Innate Adds 9 Patients To MIS416 Compassionate Use Program; Medibio Signs Vital Conversations For Cardiac Stress Test; Capital Group Below 5% Of GI Dynamics
 
Sep 24, 2015
Starpharma Vivagel CE ‘Device’ Mark For Bacterial Vaginosis; Pro Medicus Signs $11m Imaging Deal With Allegheny; OBJ Placement Raises $6.25m, Share Plan For $1.75m More; China Approves Biodiem, BCHT LAIV ’Flu Vaccine Trial; IDT, Mayne Finalize 2014 Temozolomide Distribution; NY Lagoda, Fatima Dickey, Richard Bayles Take 5% Of Clinuvel; Poipu 19.5%, Torney 12%, Carrara 19.5% In Stirling
 
Sep 23, 2015
Admedus Starts Aortic Valve Repair Trial; WEHI, ACRF Cancer Lab Opens; Singapore Approves Medical Developments Penthrox; Optiscan Takes Collaboration Halt To Suspension; Pharmaust AGM Votes On 20-1 Consolidation, Dr Best Options; Biota Loses Dr Jim Fox, Gains Armando Anido, Dr Michael Dunne; Solagran Loses Ace Aim, Salim Group Director Andi Solaiman
 
Sep 22, 2015
Pharmaxis, Boehringer PXS4728A Meets Phase I Endpoints; TGA Approves BPH Cortical Brain Anaesthesia Monitor; OBJ Requests ‘Capital Raising’ Trading Halt; Sirtex Appoints Ex-Avcal Dr Katherine Woodthorpe Director; Genetic Signatures Appoints Patrick Noland US Head; Bio-Melbourne Orphan Drug, Device Regulation Workshop
 
Sep 21, 2015
PM Turnbull Puts Innovation, Chris Pyne Centre Of Agenda; Biotech Daily Editorial; Compumedics $1m, 3-Year Shanghai Sleep Contract; EMA Study Takes Clinuvel Closer To European Roll-Out; Optiscan Requests ‘Collaboration Negotiation’ Trading Halt; Dorsavi Rights Offer Raises $2m, $1m Underwritten Shortfall; Innate Placement To Raise $3.4m; CVC Diluted To 18% Of Cyclopharm
 
Sep 18, 2015
Japan Confirms Mesoblast Temcell, JR-031 For GVHD; Rhinomed Places $2.5m; Stirling DOCA, Peter Dykes, Peter Torney, Timothy Shaw; Innate Requests Capital Raising Trading Halt; Cogstate 1.1m CEO Brad O’Connor, 300k Director Options; Patrys Pleads June News To ASX 30% Query
 
Sep 17, 2015
China Pollution Cardio-Respiratory Opportunity For Uscom; ANU Reduces Below 5% Of Bionomics; Webinvest, Otto Buttula Take 7% Of Oncosil; Susan Whiting Diluted Below 5% Of Biotech Capital; Proteomics Releases 1.5m Escrow Shares; Optiscan Loses July Director George Cameron-Dow; Tissue Therapies Loses Director Iain Ross; Bio-Melbourne Brainstorms ‘Health Hackathons’
 
Sep 16, 2015
Bionomics BNC210 Safe, Nicotine Response; Orthocell Adds Detail To Bone Cell Factory Study; Bluechiip Expects $50k Matched Federal Grant; Rhinomed Requests Capital Raising Trading Halt; Benitec Adds Texas Methodist Institute To TT-034 Hep C Trial; Anatara: ‘Detach Reduces Pig Scour’, Dr Holyoake Advisor; MRCF-Funded Auspherix Expands Domainex Collaboration; Gordagen Appoints Natural Alternatives US Manufacturer; Viralytics 9m Options For M-D Dr McColl, CSO Dr Shafren
 
Sep 15, 2015
Orthocell Study Backs Cell Factory For Bone Healing; Ausbiotech Wants PM Malcolm Turnbull To Speed Tax Reform; Correction: Federal Biotech Grants; Imugene AGM For Directors, COO Stock, Increase Pool To $400k; Nicholas McDonald Diluted To 7.6% In Biotech Capital; Genetic Signatures Appoints Dr Tony Radford Director
 
Sep 14, 2015
Hatchtech, Dr Reddy’s Up To $279m Xeglyze (Deovo) Deal; Medical Developments, Mundipharma Up To $77m Euro Deal; Cyclopharm Draximage $6m US Technegas Trial Deal; Compumedics $2m South Korea Neuroscan Distribution Deal; Ellex Cites 2 Case Studies Of 2RT For AMD; Sun Enrols 1st Dmx-200 Kidney Disease Patient; Biotech Takes 3 Of 24 Federal Grants Worth $2.4m Of $14.6m; Proteomics ‘Loyalty Options’ To Raise $126k; Rhinomed, Sleepgp Partner For Snoring, Sleep, Mute Plugs
 
Sep 11, 2015
Federal Government Backs CSIRO, Anatomics 3-D Sternum, Ribs; Sunshine Heart C-Pulse Pulmonary Hypertension Sheep Study; CBA, Colonial, Citicorp Below 5% In Pro Medicus; Sabby Takes 7.5% Of Benitec
 
Sep 10, 2015
Psivida Licence - Revenue Up 665% To $38m, Loss To $9m Profit; Immuron Lists On US OTCQB; Challenger, Entities Take 5% Of Sirtex; BVF Partners, Mark Lampert Take 13% Of Pharmaxis; Nusep Appoints Andrew Goodall To Prime Board; Bio-Melbourne Workshops Orphan Drug, Device Regulation
 
Sep 9, 2015
Gordagen Phase I Melt3 Tablet Safety, Bioavailability; Antisense Doses 300mg Acromegaly Patients; Oncosil Brachytherapy CE Mark Review; Nusep Raises $267k, Director Andrew Goodall Diluted To 38%; Australian Ethical Takes 5% Of Somnomed; IQ3 Appoints David Batista For US Investment Banking
 
Sep 8, 2015
Burnet: ‘Promising HIV Drugs Less Effective In Brain’; Imugene To Place $3m, Options; Clarity Licences Fusion Cathepsin S Antibody For Cancers; Medavisor $5m For Backdoor Listing For Adherence App; Compumedics $600k Perth Children’s Neurology Contract; Ausbiotech Octoberfest Focus On Regenerative Medicine; OBJ Expands Proctor & Gamble Work To Shaving Products; RACI Symposium, Dinner With Dr Nick Ede: ‘Whatever It Takes’; QRX Creditors Meeting Delayed, Again, To December; Director Peter Jones, Stuart Andrew 14% In Biotech Capital
 
Sep 7, 2015
Starpharma, Astrazeneca Dep Deal $180m-Plus Potential; 3D Quality Audit, Printer Commissioned, 333D Agreement; Imugene Requests Capital Raising Trading Halt; Acrux, Gedeon Richter Lenzetto Euro Approval, $3m Payment; Invion Cancels Shareholder Entitlement Issue; BVF Partners, Mark Lampert Take 18% Of Circadian; Treagus Family Increase, Diluted To 17% Of Biotech Capital
 
Sep 4, 2015
Victoria Awards $26m Infrastructure Support Grants; Japan To Approve Mesoblast, JCR JR-031 For GVHD; Optiscan, Mr Solutions Launch Celllive Imaging System; Starfish Diluted To 44% Of Dorsavi; Regeneus To Release 48m Escrow Shares; MMJ To Release 7.2m Escrow Shares
 
Sep 3, 2015
NHMRC Grants $5.8m To 11 EU, California Collaborations; Independent Roche Registry Data Backs Sirtex Sir-Spheres; Admedus Releases Smaller Cardiocel Scaffold; Cortendo Prospectus Cites Antisense ATL1103 Milestones; Resapp Appoints Experien, Blue Curve For FDA Applications; Auckland Trust, Lang Walker Take 13% Of Biotech Capital; Unilife Hires Morgan Stanley For Strategic Review; Prima Pleads Schultz To ASX 28% Query; Cryosite Loses January CEO Joseph Saad; Ampliphi Appoints Dr Alexander Gaidamaka Chemistry Head
 
Sep 2, 2015
Heartware Buys Israel’s Valtech For $1.2bn; WEHI: ‘Childhood Coeliac Same As Adults’, Treatment Options; Medibio Expects To Raise $3m; ITL Accelerates $2.45m Myhealthtest Acquisition; Bluechiip Adds Kit, Reader, Button To Cryo-Tags; Unilife Revenue Down 10% To $19m, Loss Up 57% To $129m; Progen Revenue Down 40% To $3.4m, Loss Up 159% To $4.7m; Regeneus Revenue Down 2% To $2m, Loss Down 12% To $6.6m; Avita Recell Patent Validated In 11 European Countries; Innate Appoints Receptos Founder Dr Robert Peach Director
 
Sep 1, 2015
August BDI-40 Down 4%, ASX200 Down 9%, Big Caps Down 4.5% - Reva Up 58%, Genetic Technologies Down 28%; Airxpanders Files Aeroform 510(K) Submission To FDA; Uscom Completes Thor Acquisition; Biotech Capital Lang Walker $1m, Bruce Hancox, Jon Pilcher; Invion Raises $1m From Unnamed US Investor; Resapp 1st Patient Enrolled At Princess Margaret Hospital; Suda Revenue Down 35% To $5.7m, Loss Up 64% To $3.4m; Bioxyne Revenue Down 50% To $1.6m, Profit Down 83% To $201k; Phosphagenics H1 Revenue Up 113% To $978k, Loss Up 399%; Antisense ATL1103 Partner Cortendo Files For Nasdaq Listing; Immuron Applies For US OTCQB, Full US Listing; Canada’s Investors Group Takes 7% Of Adherium; Prescient CSO Prof Said Sebti Wins Nature Translation Gong
 
Aug 31, 2015
Bionomics To Start US BNC101 Colon, Pancreatic Cancer Trials; MMJ, Satispharm Sell 1st Marijuana Capsules, Available On-Line; US Disaster Preparedness Agencies Interest In Avita Recell; Medical Australia Revenue Up 25% To $15m, Profit To $217k Loss; Clinuvel Revenue Up 29% To $3.3m, Loss Up 89% To $10.4m; Cellmid Revenue Down 16% To $3m, Loss Up 126% To $3.3m; Immuron Revenue Up 7% To $1.1m, Loss Up 36% To $3.4m; IQ3 Revenue Up 2013% To $922k, Loss Up 96% To $1.9m; IM Medical Surprised By $270k Legal Bill; Novogen Advisory Committee Sets Pipeline Priorities; Adherium Founder, CEO Garth Sutherland Takes 8%; Medibio Requests ‘Capital Raising’ Trading Halt; Chris Smith Takes Cochlear’s Wheel, Goodbye Dr Chris Roberts
 
Aug 28, 2015
Living Cell Wins $2m NZ Grant For NTCell For Parkinson’s; Rhinomed Mute, Turbine Production Up To 4m Packs A Year; Mayne Revenue Down 1.3%, Profit Down 64%, $91m US Plant; Alchemia Revenue Down 25% To $12m, Loss Up 128% To $16m; Admedus Revenue Up 29% To $10m, Loss Up 282% To $25m; Allegra Revenue Down 8% To $7m, Loss Up 1262% To $855k; Genetic Technologies Revenue Down 44% To $3m, Loss Down 13%; Avita Sales Up, Revenue Down 9% To $3m, Loss Up 38% To $7m; Avita Takes ‘Equity Placement’ Trading Halt To Suspension; Pharmaust Revenue Up 21% To $2.4m, Loss Up 46% To $2m; Invion Requests Capital Raising Trading Halt; One Funds (Bioscience Managers) Takes 17% Of Adherium; Brian Mayo-Smith, K One W One Take 8% Of Adherium; Och-Ziff Lightens To 18.7% Of Brain Resource; Reproductive Health Embryocellect For IVF Training Course; Bio-Melbourne Tours The Red Cross Blood Bank
 
Aug 27, 2015
Race To Raise Up To $10m For ‘Lost’ Bisantrene For AML; Admedus HSV-2 Trial Safe, Proceeds, Takes 72% Of Coridon; Clinuvel, FDA To Discuss Scenesse For EPP Pathway; Biomérieux Pays LBT $8m To Part Company On Plate Streaking; Adherium IPO Raises $35m For Smartinhaler, Astrazeneca Takes 6%; Ellex Revenue Up 15% To $63m, Profit Up 113% To $1.7m; Cryosite Revenue Up To $10m, Profit Down 10% To $455k, Dividend; Resonance Revenue Up 16% To $2.7m, Loss To $463k Profit; LBT Revenue Down 41% To $2.4m, Profit Up 66% To $549k; Anteo Revenue Down 7% To $2.4m, Loss Up 69% To $4.2m; Genetic Signatures Revenue Up 57% To $2m, Loss Up 54% To $2.7m; Brain Resource Revenue Up 6% To $2.7m, Loss Up 30% To $2.6m; OBJ Revenue Up 59% To $1.5m, Loss Up 4% To $2.3m; Clarification: Cyclopharm H1 $179k Profit; Medibio Wins 1st Corporate Stress Contract; Cellmid To Launch Évolis Hair Growth Campaign; Hunter Hall Reduces 1% In Sirtex To 7.4%; MMJ Requests ‘Cannabidiol Update’ Trading Halt; Imugene M-D Charles Walker Steps Down, Leslie Chong COO; Immuron Appoints Peter Anastasiou Vice Executive Chairman
 
Aug 26, 2015
Anteo Buys Belgium’s Diasource For Up To $34m Cash, Scrip; Dorsavi Placement Raises $4m, 1-For-10 Offer For $3m More; Tissue Therapies, QUT Continue Vitrogro R&D; Compumedics Revenue Up 9% To $33.5m, Profit Up 117% To $2m; Cyclopharm H1 Revenue Down 23% To $5m, $132k Loss, Maiden Dividend; Impedimed Revenue Up 38% To $5m, Loss Down 6% To $8m; Uscom Revenue Up 48% To $2m, Loss Down 20% To $1.2m; Dorsavi Revenue Up 141% To $2m, Loss Up 126% To $8m; CBA, Related Parties Sell, Return To 5% Of Sirtex; Prescient ‘Encouraged’ By Early PTX-200 For Cancer Data; US Patent For Paradigm’s PPS For Bone Bruising; Suda Takes 100% Control Of Artimist; Avita Requests ‘Equity Placement’ Trading Halt; Unilife Appoints Harry Hamill, Mary Wold; Jim Bosnjak Goes
 
Aug 25, 2015
3D Medical, Intelerad Partner For Direct Imaging; Final Results Back Airxpanders Aeroform Device; Progen Revenue Up 64% To $6m, Loss Down 14% To $2m; Ra Capital Below 5% Of Benitec; Profs Mcarthur, Roberts, Emery Join Victoria Cancer Centre; Immuron Appoints Ex-Alchemia Thomas Liquard CEO; Dibbs Barker Appoints Dr Andrew Rankine For Biotech IP; Medibio Requests ‘Stress Product Agreement’ Trading Halt
 
Aug 24, 2015
Nusep, Melbourne Uni Work On Hydrogel Membranes; Antisense Cortendo Revenue Up To $707k Maiden Profit; Uscom Share Plan Raises $195k, Total $2.1m; Israel Approves MMJ Marijuana Capsule Trial; 3D Medical Pleads Schultz To Asx 35% Fall Query; Dorsavi Requests Capital Raising Halt; MJGD, BSMI; Irwin, BIOA Trusts Each Take 8% Of Paradigm; Bill Paspaliaris, Peter Milonas Each Take 6% Of Paradigm; IWES, Ex-CEO Boaz Wachtel Take 5% Of MMJ Phytotech; Pharmaust To Lose Director Prof David Morris; Genetic Signatures Appoints Mark Langan, Anna Sandham 
 
Aug 21, 2015
Biota Starts Phase I BTA585 For RSV Studies; Rhinomed Signs Boots Exclusive UK Mute Distributor; Dorsavi 3-Year Compliance Deal With Designinc Architects; Pro Medicus Revenue Up 22% To $18m, Profit Up 113% To $3m; Medical Developments Revenue Up 24% To $12m, Profit Up 75% To $1.5m; Atcor Revenue Up 8% To $5.5m, Loss Down 18% To $2m; Starpharma Revenue Up 35% To $1.7m, Loss Up 30% To $19m; GI Dynamics Cuts Costs, Staff By 46%; Medibio Completes Corporate Stress Test Development; Australian Ethical Reduces To 9% Of IDT; Oceania, Hosken Slip Below 5% Of Atcor; M-D Paul Rennie, Kzee, Ear Take 24% Of Paradigm; Prescient To Issue 700k Chairman, Director Options; Reva Appoints Medtronic’s Regina Groves CEO, Starts On $540k; Immuron Hires Red Chip For US Investor Relations
 
 
Aug 19, 2015
Benitec Raises $19m Of Hoped For $95m, 22.5% Discount; Editorial: Another Band Fails To Make It Big In The USA; ITL Revenue Up 10% To $28m, Profit Up 5% To $2m; Pharmaxis Revenue Up 465% To $59m, Turnaround $18m Profit; Circadian Revenue Up 7% To $939k, Loss Up 33% To $5m; Living Cell Revenue Down 87% To $1m, Loss Up 4% To $7m; Cogstate Revenue Up 41% To $16m, Loss Up 30% To $5m; Paradigm Opens Up 14.3%; IQ3 US Subsidiary To Operate Investment Bank; Rhinomed Requests ‘Global Distribution’ Trading Halt
 
Aug 18, 2015
Dorsavi Signs US Football Team, Colleges For Viperform; IDT Revenue Up 18% To $16m, Loss Down 55% To $3m; Living Cell Resumes NTCell Manufacture; Gordagen Receives $1.1m Federal R&D Tax Incentive; Benitec Requests ‘Capital Raising’ Trading Halt; Saskia Jo Replaces Tissue Therapies Co Sec Drummond McKenzie
 
Aug 17, 2015
Mesoblast: ‘Faster Phase III Heart Trial’, Revenue Down, Loss Up; Invion: High Dose INV103 (Cpn10, XToll) Potential For Lupus; Paradigm IPO Raises $8m For Bone Bruising, Respiratory; Dorsavi Signs 4th Crown Contract, Largest To Date; Avita, Huddersfield Uni Study Recell Mechanism Of Action; Bioxyne Expects $200k NPAT; Airxpanders Releases 845k Escrow US Shares (2.5m CDIs); UBS AG Trades, Returns Acrux Shares Below 5%; Hockings Take 28% Of Phylogica; Sietsma Increase, Maintain 9% Of Phylogica 
 
Aug 14, 2015
Austin’s Dr Peter De Cruz Wins $16k Victoria Premier Award; Prima Earns Undisclosed Historical Novartis Royalty; Polynovo: ‘Metabolic, AOD9604 Sale Reduces Loss’; W.H.O. Confirms Trofinetide As INN For Neuren NNZ-2566; Cogstate Claims 2 More Trial Contracts Worth $3m; GI Dynamics H1 Revenue Down 47% To $1m, Loss Down 6% To $28m
 
Aug 13, 2015
Sirtex Record Revenue Up 36% To $178m, Profit Up 69% To $40m; Neuren EU Orphan Status For Trofinetide For Rett, Fragile X; Acrux Revenue, Profit Down, 12 Generics Pipeline; Reva Fantom II Trial On-Track, Funds Secure; Genetic Signatures Signs Poland, Ireland Distributors; Gordagen Hires Ascendiant As US Bank, Advisor; Perpetual Below 5% Of Pro Medicus, Again; OBJ Grants Advisors Prof Wright, Dr Benson 2m Shares; Dr Thomas Lönngren Talks EU Regulation At Bio-Melbourne
 
Aug 12, 2015
Victoria Releases Research, Biotech Discussion Papers; CSL Record Profit Up 34% To $1.9bn, Revenue Up 29% To $7.7bn; Phylogica Rights Issue Raises $10m; $20bn MRFF Passes Senate, Commercialization Ignored; IDT Earns $1.4m Upfront From US Distributor Ani; Cellmid Appoints New York’s EAS Advisors For US Expansion; Perth’s Princess Margaret Hospital Joins Resapp Trial; Isonea Airsonea Wheeze Monitor US Trial; UBS AG Buys, Sells, Borrows, Returns Acrux Shares To 6.4%; Actinogen Xanamem Phase I Triggers 3m Dr Loveridge Shares; Mark Studd Replaces Nusep Co Sec Elissa Hansen
 
Aug 11, 2015
Cochlear Posts $926m Record Revenue, Profit Up 33% To $146m; Analytica Raises Further $65k; Heartware Completes Endurance 2 Destination Enrolment; Actinogen Xanamem Phase I Triggers 5m Martin Rogers Shares; CB Co, Curran Super Fund Reduces, Diluted To 8.6% Of Atcor; Rod Gibson, Rosherville Take 6% Of Reproductive Health; Clinical Genomics: Howard Chandler ‘Emeritus Scientist’; Universal Biosensors Loses Director Chris Smith To Cochlear; Pork CRC To Assist Anatara Detach Pig Diarrhoea Trials
 
Aug 10, 2015
Antisense: Cortendo US IPO Details ATL1103, COR-004 Program; Benitec $95m Nasdaq Listing Delayed, Continuing; Bionomics Revenue Down 40% To $17m, Profit To $17m Loss; Nusep Begins Spermsep IVF Trial, Share Plan; Regeneus Begins Progenza Stem Cell Knee Trial; Medivac $200k Loan To Relist, Board Changes, Review; Mayne Launches 50mg Doryx For Acne As US Schools Return; Pratt’s Thorney (Tiga) Diluted Below 5% Of Mayne; Analytica Appoints EMA, CBio Dr Thomas Lönngren Director; Bio-Melbourne JP Morgan Conference Briefing
 
Aug 7, 2015
Clarity, Melbourne Uni $365k ARC Imaging Grant; Genera 6,000 Patient Data ‘Consistent’ With 2011 Study; FIL Takes 6% Of Impedimed; Hunter Hall Takes 14.7% Of GI Dynamics; UBS AG Buys, Sells, Borrows, Returns Acrux Shares To 7.5%
 
Aug 6, 2015
US Grants Genetic Technologies Brevagenplus Patents; Novogen Lodges 2 Anti-Tropomyosin Australian Patents; Analytica Rights Issue Raises $2.8m Of Hoped-For $3.8m; Suda ‘Delighted’ By FDA Response To SUD-001 Migraine Program; Isonea Airsonea ‘Major Advance’ To Work With Breathing; Federal Government Appoints David Thodey CSIRO Chair; Polynovo CEO Paul Brennan 12.6m Long-Term Options; Immuron To Issue 6m Director Options ‘In Lieu Of Cash’; Anatara Chair Mel Bridges, Parma Increase, Diluted To 12.5%; Stirling Products (DOCA) Restructure EGM
 
 
Aug 4, 2015
Mayne $4m Federal-South Australia Manufacturing Grant; Traveler’s Supply To Buy 50,000 Packs Of Immuron Travelan; Correction: MMJ Phytotech; Merchant Reduces To 15% Of Polynovo; CSL Closes Above $100 A Share, Again
 
Aug 3, 2015
August BDI-40 Up 6%, ASX200 4%, Big Caps 10% - Tissue Therapies Up 80%, Universal Biosensors 35%, GI Dynamics Down 72%, Analytica 20%; Sunshine Heart Transcutaneous Energy Trial In 2016; Heartware H1 Revenue Up 5% To $197m, Loss Up 277% To $57m; Alchemia Hyact Buyer Panther Behind Schedule; CSL, Novartis Close Seqirus ’Flu Vaccine Deal; MMJ Phytotech M-D Andreas Gedeon Starts On $345k; CSL Call For MRFF Translation Component; Bio-Melbourne; Medibio One Quarter Cash: ‘Burn Reduced, $1m R&D Tax Credit’; Bionomics Appoints Tony Colasin Chief Business Officer
 
Jul 31, 2015
GI Dynamics: ‘US Protocol Might Cause Hepatic Abscesses’; Victoria Appoints Philip Dalidakis Minister For Innovation; CSL, Novartis Closing Seqirus ’Flu Vaccine Deal; African Patent For Suda’s Artimist For Malaria; Resmed Revenue Up 8% To $2b, Profit Up 2% To $483m; Rhinomed Has One Quarter Cash, Expecting Sales Growth; Invion Has Less Than One Quarter Cash, Considering Options; Up To 45% Of Prima Votes Oppose Ridgeback Shares; Brendan Moran Takes 6.5% Of LBT; Bio-Melbourne: ‘Check Registration For Epilepsy Breakfast’
 
Jul 30, 2015
GI Dynamics Terminates US Endobarrier Trial; Sydney Uni To Test Cynata Stem Cells For Cardiac In-Vivo; Ellex Expects Record Revenue Of $62.5m; Cellmid Raises $4m For Advangen Hair Growth Sales; Unilife $96m Facilities, Imperium Insulin Patch Pump Launch; Novogen Reviews Programs; Simavita New Business Model, Canada Distributors; Analytica: ‘Online Article Inaccurate’; Ellerston (Packer Family) Below 5% Of Acrux; Retrophin Below 5% Of Clinuvel; Kevin Wyld, Avanteos Reduces To 5% Of LBT; Regeneus Has Less Than Two Quarters Cash, $3m R&D Credit; Bluechiip Has One Quarter Cash, $500k R&D Tax Credit
 
Jul 28, 2015
WEHI Partnering WEHI-842 To Block Malaria Conductor Protein CSL Takes rVIII-Single-Chain (CSL627) For Haemophilia A To FDA; Phytotech Raises $5m, Completes MMJ Merger, Name Change; Tissue Therapies Changes Vitrogro From Device To Drug; Anatara Plan Raises $2m, Takes Total To $9m; Atcor: ‘AHA Backs Sphygmocor’; Correction: Nusep; Cogstate Signs $1.6m Alzheimer’s Disease Trial Contract; UBS AG Buys, Sells, Borrows, Returns Sirtex Shares To 5%; Cellmid Requests Capital Raising Trading Halt; Immuron Appoints Dr Jerry Kanellos COO, CSO
 
Jul 27, 2015
Victoria Awards 8 Veski $450k Three-Year Grants; Federal Government Opens ANSTO Electron Microscope; Invion, Hovione Partner On Inhaled INV104 For Asthma; Nusep Advances Sperm Separation, Resolving ‘Legacy’ Issues; Prima Plan Raises $10m; OKS AGX Allows Agenix To Keep Thromboview; US Patent For Suda’s Sud-002 For Nausea And Vomiting; Orthocell Pleads Schultz, Climbs 17% On Lengthy ASX Query; Resonance CSO Prof Tim St Pierre Wins Western E&Y Gong
 
Sunshine Heart Resumes C-Pulse Pivotal Trial; Compumedics Expects Revenue Up 10%, Profit Up 100%; Acrux, Lilly Axiron Sales Fall 14% To $211m; ‘Freeman Road’ Takes 5% Of Resapp; Phytotech Requests ‘MMJ Merger Update’ Trading Halt; ‘Legal Reasons’ Close Dr Christian Behrenbruch’s Long Tail 
 
Jul 23, 2015
Universal Biosensors H1 Revenue Up 160% To $7.5m, Loss Down; Journal Publishes Mesoblast Diabetes Trial Results; Reproductive Health Raises $1.3m; Optiscan Raises $690k, Total $1.2m; IM Medical Raises $287k, $345k Underwritten Shortfall To Go; Hunter Hall Reduces 1% In Sirtex To 8.4%; Sigma-Aldrich To Distribute Anteo’s Mix&Go; Pharmaust Closes ‘Successful’ PPL-1 For Cancer Trial; Avita $20m EGM For New Direction In US; Nusep Wants Buyers For Its 68% Of Singapore Prime; Cogstate Launches Precision Recruitment 2.1 For Trials
 
Jul 22, 2015
Interim Iain Ross Replaces Novogen CEO Dr Graham Kelly; FDA Approves Genetic Signatures Easyscreen Sample Kit; Atcor Rights Issue Raises $3.2m, Total $5.2m; Correction: Optiscan; Uniquest Takes 7.5% Of Resapp; Allan Gray Reduces, Again, To 15.5% Of Impedimed; Pharmaust Requests ‘Trial Results’ Trading Halt; Tissue Therapies CFO, Co Sec Drummond McKenzie Retires
 
Jul 21, 2015
Heartware Starts European Miniature Cardiac Pump Trial; WEHI Links Inflammation, Arthritis, Heart Valve Disease; Patrick O’Connor Replaces Optiscan Chair Angus Holt, George Cameron-Dow Director; Barclays ‘Returns’ Genetic Technologies Shares Below 5%; Reproductive Health Requests Capital Raising Trading Halt; Cellmid Appoints Pharmaventures Dr Fintan Walton Director; Bio-Melbourne August Breakfast On Epilepsy; Innovationcafe: Productivity, Commercialization, Culture 
 
Jul 20, 2015
Uscom To Raise $1.95m For Thor Devices Acquisition; Verva Sells IP To Reverx, Unnamed US Company, Liquidation; Wearable Thermometer Wins 1 Of 13 Federal Grants; US Guidelines For Lymphoedema ‘Will Benefit Impedimed’; Optiscan Requests ‘Board Changes’ Trading Halt; Hunter Hall Takes 13.5% Of GI Dynamics
 
Jul 17, 2015
Genera India Distributor, Completes 2013 Paptype Trial; Phylogica, UQ $670k ARC Linkage Grant; Uscom Takes Capital Raising Halt To Suspension; Tim Robertson, Farjoy Takes 6% Of Medlab, CEO Sean Hall Takes 34%, Chair Michael Hall Takes 7%; Director Drew Townsend Takes 10%
 
Jul 16, 2015
Osprey Completes Avert Expanded Claims Trial Enrolment; Study Backs Orthocell ‘Cell Factory’ For Cartilage Repair; US Orphan Drug Designation For Novogen’s Anisina; Pharmaust Treats 2 Dogs With PPL-1, Carboplatin; Dorsavi Sales Revenue Up 157% To $1.4m; Barclays ‘Returns’ 1% Of Genetic Technologies To 5%; Gordagen Appoints Dr Rocco Iannello, Prof David Prior 
 
Jul 15, 2015
Mesoblast: ‘High Dose MPCs May Have Heart Failure Efficacy’; Biotron Share Plan Raises $2m, Total $4m; Cynata Raising $5m; Resapp Diagnostics Opens On The ASX; Medlab Opens On The ASX; Clinical Genomics Signs Philippines, NZ Distributors; Medibio Lodges US Patent Application; Uscom Requests Capital Raising, Transaction Trading Halt; Dorsavi Loses CFO Jerome Whelan
 
Psivida: 'Medidur Significant Benefit For Uveitis'; Novogen: Anisina Boosts Chemo For Neuroblastoma In Mice; ITL: Myhealthtest, Hba1c Test Launched For Diabetes Week; Ellex, Melbourne Uni $355k 2RT Immune System ARC Grant; Tissue Therapies Acquires Vitrogro IP From QUT; Cogstate: ‘Trials Contracts Push Revenue Up 62%’; Unnamed US University Studies Antisense ATL1102 For Cancer; Proctor & Gamble Fund 6th OBJ Work Plan; Reproductive Health Distributes In China, Hong Kong, Macau; Genetic Technologies Plans US Brevagenplus Trials 
 
Jul 13, 2015
WEHI: ‘Molecular Switch Creates Long-Term Immunity’; Universal Biosensors Strip Fees Up 137%; Phytotech’s MMJ To Distribute AI Fame Products; Medlab IPO Raises $6m For Food Additives, Gut Health; Prima Tells ASX 44% Up, 32% Down Query: ‘Share Plan Not News’; Invion Pleads Schultz, News To ASX 63% Query; OBJ: Proctor & Gamble Sale To Coty ‘No Known Impact’; Acrux Appoints Felicia Colagrande, Charles O’Sullivan 
 
Jul 10, 2015
ASX Queries Repeat Optiscan Chair Angus Holt Notices; Optiscan Rights Issue Raises $426k, $264k To Go; Biodiem $242k ARC Linkage Grant; Alchemia: Ken Poutakidis Chair, Nathan Drona Audit; Wishny Sritharan Krishnarajah Diluted Below 5% In Sun 
 
Jul 9, 2015
Benitec Buys-Out Biomics Stake In Hepbarna For Hep B; Clarification: Australian Ethical, Atcor; Dorsavi Signs North American Sports Teams For Viperform; Anteo, IMRA Mix&Go, Gold Diagnostics Proof-Of-Concept; Nusep: ‘ASIC Concludes Investigation, Takes No Action’; Universal Biosensors Receives $8.2m Federal R&D Tax Refund; Orthocell $430k ARC Grant For Laboratory Tendons; Cellmid Forecasts $2m 2014-’15 Revenue; Jason Peterson, Celtic, Associates Diluted Below 5% In Sun; Alchemia Chairman Tim Hughes Goes; Genetic Technologies Appoints Brian Manuel Joint Co Sec
 
Jul 8, 2015
Australian Ethical Launches Biotech, IT, Renewables Fund; Slater And Gordon $25k OH&S Research Grants Open; Senate Inquiry Into Medical Research Future Fund; Admedus Cardiocel Patient 7-Years Calcification-Free; Prima 5c Share Plan To Raise Up To $10m; Analytica $3.7m 1-For-2 Rights Issue; OBJ: ‘P&G SK-II Eye Wand Launches Exceed Expectations’; Compumedics: ‘German Trade Mission Helps $5m In Deals’; Immuron Loses April CEO Dr Leearne Hinch; ITL Pleads Profit Warning, Journal Article To ASX 44% Query; Phosphagenics Loses Founder, CEO Harry Rosen; Andrew Carter Replaces Bio-Melbourne’s Andrew Macdonald; Bio-Melbourne ‘Massive Health Data’ Briefing
 
Jul 7, 2015
Avita Donates Recell, Staff To Taiwan Burns Victims; Acrux, Lilly Sue Lupin Over Axiron Patents; Prima: ‘EMA Endorses IMP321 Phase IIb Breast Cancer Trial’; Sandon Withdraws Alchemia Board Spill EGM; Uscom Signs 8 Distribution Agreements; Peter Meurs Takes 19.96% Of Sun; Raff Group Transfers 7.6% Of Genera; Cellmid Appoints Dr Bryce Vissel Advisory Board Chair
 
Jul 6, 2015
Vale Alastair Lucas; Avita: ‘Recell Repigments Vitiligo And Piebaldism 78%’; DSMC Tells Biotron: ‘Focus On BIT225 Combination, Genotype 3’; Simavita Signs Paul Hartmann For Australian Distribution; Phytotech Applies For Israel Marijuana Trials For MS; Analytica Trading Halt, Pleads Funding To ASX 80% Query; Orthocell Pleads Schultz To ASX 15% Query; RA Capital ‘Trims’ To 9% Of Benitec; Matthew Callahan, SRV Take 6% Of Sun; Rhinomed Appoints Chris Froome Turbine ‘Ambassador’; Uscom Appoints Stephen Wilson US Business Development
 
Jul 3, 2015
Vast Buys Alchemia Vast Platform, $100k Upfront, Royalties; Anatara Places $4.4m, $2.6m 2nd Tranche, Share Plan; Benitec Continues ddRNAi For OPMD; ITL Profit Warning; ‘Tax’ Reduces Chair Angus Holt, Gralaw To 6% Of Optiscan; Goodbye Narhex, Welcome Resapp; All Change At Sun For Dimerix

 

 
Jul 2, 2015
Clinuvel: ‘Scenesse Dramatically Changes Lives’; FDA Allows Polynovo BTM Wound New Data Extension; Phylogica $10m Underwritten 1-For-1 Rights Issue; Imugene Hires Simbec-Orion For HER-Vaxx Gut Cancer Trial; Analytica Appoints Current Technology US Distributor; Immuron Phase II IMM-124E Nash Trial 27.5% Enrolled; Mediobio Applies For US Patent For Heart Stress Test; Orbimed Drops Unilife $26m Debt Hurdle; Phytotech, MMJ Merger Unconditional; FIL Takes 6% Of Starpharma

Jul 1, 2015
9-Year BDI-40 Up 155%, ASX200 Up 8%, Big Caps Up 221%, 12-Month BDI-40 Up 17%, ASX200 1.2%, Big Caps 28%, Impedimed Up 477%, Pharmaxis 245%; Alchemia Down 94%, Tissue Therapies 87%; Circadian Starts US Phase I OPT-302 Wet AMD Trial; Sirtex Releases More Sirflox Sub-Group Analyses; Alchemia To Sell Hyact, Oncology To Panther For Up To $21m; Prana PBT2 Extension Study Dose Safe After 2 Years; BVF Partners, Mark Lampert Take 12% Of Pharmaxis; Anatara Requests Capital Raising Trading Halt; OBJ Pleads Schultz To ASX 19% Query; Novogen Appoints Ian Phillips Interim Chairman; Bio-Melbourne ‘Think Global’ Bio-Breakfast
 
Jun 30, 2015
Ausbiotech Launches Medtech Directory In China; Clarification: Spinifex, Uniseed; Sun EGM Votes To Acquire Dimerix, Raise Funds Unopposed; Nusep $221k Loan, Prime Update, Chair Alison Coutts On $269k; Prima 580m Warrants,123m Shares, 20m CEO Rights, Notes EGM; UBS AG Buys, Sells, Borrows IDT Shares To 6%
 
Jun 29, 2015
Novartis Buys Spinifex For $916m; Medical Developments $71.5m+ Europe Sales Deal; US Patent For Cellmid Midkine C-Domain; Prescient Notifies FDA Of PTX-200 IND Transfer; Invion Completes INV102 For Smoking Cessation Dosing; Actinogen Chairman Martin Rogers Executive On $80k; Imugene Proposes 5m Options For Director Dr Axel Hoos; Tissue Therapies Loses CSO Prof Zee Upton
 
Jun 26, 2015
Resonance Liver, Cardiac Iron Measurement Trial Contract; OBJ Files Australian Emulsion Destabilizing Patent; Living Cell Transfers Diabecell R&D To US, Reduces NZ Staff; Alchemia Appoints Spill Contender Ken Poutakidis Director; Allan Gray Increases, Diluted To 17.5% Of Alchemia; Paul Hopper, Associates Take 16% Of Prescient
 
Jun 25, 2015
US Class Action Filed Against QRX, Ex-CEO Dr John Holaday; Benitec Doses 1st ‘Potentially Therapeutic’ TT-034 Hep C Patient; Prof Christian Behrenbruch And ‘The Long Tail’; Patrys PAT-Sc1 Gastric Cancer China Licence; 3D Signs 25 Titanium Jaw Joints Deal; Mayne Borrows $171m To Pay $US45m Debt, Expansion; Analytica UK, US Pericoach For Incontinence Launches; BVF Partners, Mark Lampert Take 18% Of Circadian; Australian Ethical Takes 6% Of Atcor; Medical Developments Requests ‘Euro Licence’ Trading Halt; Suda Appoints Dr Pullman, Dr Ralph, Prof Chung Advisers
 
Jun 24, 2015
Novogen Anisina (ATM-3507) Kills Melanoma In Mice; Anaheim California Police Assess Dorsavi Visafe; Beston Buys Probiotic Dairy Protein Plant For $7m; Pharmaust Receives $329k Federal R&D Tax Refund; Vivo, GBS, Prolog, Anonymous Substantial In Airxpanders; Quest, Troy Cairns Take 5% Of Viralytics; 3D Releases 114m Escrow Shares; Proteomics Releases 175k Escrow Shares
 
Jun 23, 2015
Cellmid Cannabinoid, Midkine Collaboration For Brain Cancer; Benitec Hopes To Raise Up To $91m, List On Nasdaq; Medical Australia For Human Health - Medivet, Jeremy Delk Go; Airxpanders Lists On ASX; Prescient Issues 4.5m PTX-100 Milestone Shares; QRX Creditors Meeting Delayed To September
 
Jun 22, 2015
3D Medical Printed Titanium Jaw Joint Implanted; Benitec, Reneuron Join Stem Cells, ddRNAi, Bob Atwill V-P; Cytomatrix Hires Michael Sistenich Corporate Development; Bio-Melbourne ‘Massive Health Data’ Briefing
 
Jun 19, 2015
NSW $25m For Paediatric Research, Clinical Trials Centre; GI Dynamics Sacks Chief Medical Officer Dr David Maggs; Prana Receives $7m Federal R&D Tax Refund; Dorsavi: ‘US CPT Code 97750 Covers Vimove, Vipermove’; Benitec Changes ADR Ratio To 20-To-1; Ausbiotech June Bio-Beers & Bubbles 
 
Jun 18, 2015
Paradigm $8m IPO For PPS For Bone Bruising, Hay Fever; Biotron To Place $2m, Share Plan For $2m More; CSL Pays $44m Upfront For Biocryst’s Rapivab ’Flu Drug; Singapore Approves Admedus Cardiocel Repair Scaffold; Sandon Calls For Alchemia Board Spill; Anatara Begins 2nd Pivotal Detach Trial For Piglet Diarrhoea; BVF Partners, Mark Lampert Take 9.5% Of Pharmaxis; Uscom Releases 1.2m Escrow Shares
 
Jun 17, 2015
WEHI Gene Discovery Hope For Muscular Dystrophy; CSL To Present Raft Of Data On Haematology Portfolio; Atcor Raises $2.2m, 1-For-10 Rights Issue For $3.2m More; Pharmaust Takes PPL-1 Dog Cancer Trial To Combination Dose; USPTO Allows Avita Composition Of Matter Patent; Medibio ‘Validates Heart Rate Stress Test’; Chairman David Williams Buys 2m Polynovo Shares; Bio-Melbourne ‘Think Global’ Bio-Breakfast; RACI Dinner - Dr Paul Macleman: Lifecycle Of A Molecule
 
Jun 16, 2015
Engeneic: ‘Complete Response For Mesothelioma Patient’; Dimerix Investors Agree To Sun Back-Door Listing; Biotron Requests ‘Capital Raising’ Trading Halt; Unilife Alan Shortall Wins Ernst & Young Philadelphia Gong
 
Jun 15, 2015
Queensland Uni, Janssen Cilag Work On Inflammatory Disease; Living Cell: ‘4-Patient Parkinson’s Study Safety, Efficacy’; Compumedics $7.5m, 3-Year China Sleep Diagnostics Deal; Resonance, CSIRO Partner On MRI Product Pipeline; US Approves Circadian Phase I OPT-302 For Wet AMD Trial; Atcor Requests Capital Raising Trading Halt; Bionomics Files BNC105 Combination Patent; Cellmid: ‘High Dose Midkine Safe In Rats, Monkeys’; Rhinomed Ready For Monash Inpeap Sleep Apnoea Trial; Alfred Joins Polynovo Novosorb CE Mark Deep Burns Trial; Optiscan To Raise $2m; Australian Ethical Below 5% In Pharmaxis; Genetic Technologies Appoints Brian Manuel CFO
 
Jun 12, 2015
CBio Three Lose $1.3m Appeal, Invion Starts Bankruptcy Trial; Narhex Raises $4m To Become Resapp Diagnostics; Living Cell Requests ‘Clinical Trial Results’ Trading Halt; BVF Partners, Mark Lampert Take 8.5% Of Pharmaxis; Barclays Bank ‘Returns’ 1% Of Genetic Technologies To 6%; Genetic Technologies Appoints CEO Eutillio Buccilli Director; Bio-Melbourne ‘Commercializing Tropical Medicine’ Briefing
 
Jun 11, 2015
Actinogen Ready For Last Stage Of Phase I Xanamem Trial; Prima Receives $320k French Tax Credit; Patrys PAT-SM6 Manufacture Further Delays Cancer Trial; Asia Union Decreases To 6% Of Tissue Therapies; Immuron Appoints Dr Dan Ruben Peres Innovation Head
 
Jun 10, 2015
Resonance Study Backs MRI Test For Liver Fibrosis; WEHI: ‘Dendritic Cell Control Aids Immune System’; Airxpanders IPO Raises $36.5m For Breast Implant Device; Rhinomed Disputes, Won’t Challenge ASIC $33k Fine; Alchemia Winding Up To Pay Fondaparinux Dividends; FIL Takes 5% Of Starpharma; FDA Re-Activates Prescient PTX-100 IND; Anatara $61k Federal R&D Tax Incentive, Pig Trials Continue; Optiscan Takes Fundraising Trading Halt To Suspension; IDT Appoints Alan Fisher Director
 
Jun 9, 2015
Mesoblast Claims MPC Kidney Failure Efficacy, Safety; Proteomics: ‘1st Diabetic Kidney Disease Test’, Jumps 278%; Viralytics: ‘Early Cavatak Effect In Bladder Cancer Trial’; Heartware Issues ‘Urgent Correction’ For Pump Use; 3D, Genesis Care Collaborate On Personalized Radiation; Australian Patent For Sun, Dimerix DMX-200 For Kidney Disease; LBT Begins US Apas Trial; GI Dynamics 19% Oppose Directors Stock; BVF Partners, Mark Lampert Take 6.4% Of Pharmaxis; Phosphagenics Appoints Dr Steve Meller To Partner TPM
 
Jun 5, 2015
CSIRO Seashells For Drugs, Vaccine Delivery; Mesoblast Receives $6m Federal R&D Tax Refund; Federal Government: ‘New Chief Scientist Wanted’; Admedus HSV-2 Phase II Trial ‘On-Track’; Novogen: ‘TRXE-009 Crosses Blood-Brain Barrier In Mice’; Clinuvel Begins EU Training For Scenesse Prescriptions; Nusep Directors To Take $215k Convertible Notes; BVF Partners, Mark Lampert Take 5% Of Pharmaxis; Bergen Sells 64m Prima Shares To 2%; Optiscan Requests Fundraising Trading Halt; Imugene Appoints Prof Ursula Wiedermann CSO 
 
Jun 4, 2015
Biota Takes Anaconda For AP611074 For Ano-Genital Warts; 3D Signs Mach7 Telstra Health Deal; Analytica Claims Pericoach ‘Encouraging Early Sales’; Prima Recompiles With Nasdaq Minimum Price Rule; Oncosil Appoints Dr Ashish Soman Chief Medical Officer
 
Jun 3, 2015
Biotech Wins 6 Of 18 Federal Commercialisation Grants; Auspherix Raises $12m For Anti-Bacterials; Simavita, Matrixcare To Develop US Incontinence Records; Bergen Sells 100m Prima Shares To 6%; JP Morgan Chase Borrows, Lends, Returns To 9% Of Prima Then Ceases Substantial; Australian Ethical Below 5% In Alchemia; Novogen Appoints Bryce Carmine, Ian Phillips Directors
 
Jun 2, 2015
Viralytics: ‘Complete Response In 8 Cavatak Patients’; Circadian, Eli Lilly: ‘IMC-3C5 Safe, Potential Cancer Efficacy’; Novogen Rights Issue Raises $18m, Takes Total To $33m; Clinical Trial Backs Dorsavi Vimove System For Low Back Pain; Dorsavi Signs UK Physiotherapy Plan; IQ3 To Raise $100m For Related Fund; Simavita Signs Bunzl For Australian SIM Distribution; Flindersfertility Adopts Reproductive Health Embryocellect; Cellmid, Taiwan’s Maywufa Hair Growth Contract; Cortendo Takes 8.5% Of Antisense; Brain Resource Nasdaq Listing, Name Change; Correction: Agenix 
 
Jun 1, 2015
Solid Gains Push BDI-40 Up 13%; ASX200 Down 1%, Big Caps Up 0.3% - Prima Up 488%, Pharmaxis 56%; Analytica Down 47%; Sirtex: ‘SIR-Spheres With Chemo Reduces Liver Tumors’; Tissue Therapies: ‘Up To 2 Years To EU Vitrogro Approval’; EMA Orphan Status For Prana’s PBT2 For Huntington’s; Genetic Technologies: ‘NEJM Backs Tests Like Brevagenplus’; US FDA Expands Dorsavi Vimove Label; Sun EGM For Dimerix Backdoor Listing For Kidney Disease; Sandon Capital Takes 13% Of Alchemia; IM Medical To Raise Up To $750k; Craig Chapman, Adam Gallagher Replace Agenix Nick Weston
 
May 29, 2015
Ex-Avantogen, Acuvax Dr William Ardrey 4-Years Gaol; Alchemia Tumbles 58% On Fondaparinux 47% Sales Fall; Gordagen Phase I Sub-Lingual Vitamin E Tocotrienols Trial; Novogen Applies For US Anti-Tropomyosin Patent; Sirtex Requests ‘More Major Study Results’ Trading Halt; Reva AGM 18% Dissent On One Resolution; Wayne Holman, Ridgeback Take 6% Of Prima; Rod Gibson, Rosherville Take 5.5% Of Reproductive Health; Ray Ridge Replaces Reproductive CFO, Co Sec Donald Stephens; Impedimed Inventor Prof Leigh Ward Wins Clunies Ross Award; Victoria, STC Medtech’s Got Talent Selects Five Finalists
 
May 28, 2015
Federal Government Introduces 1.5% R&D Tax Incentive Cut - Ausbiotech ‘Bitterly Disappointed’, Asks Senate To Block; Orthocell Receives $1m Federal R&D Tax Refund; Biodiem’s Opal To Raise Up To $4m; Dorsavi Signs 2 US Basketball Teams For Viperform; Atcor: ‘US Guidance Backs Central BP Waveform’; Medibio, Preventice Remote ECG, Distribution Agreement; QRX Pleads Schultz To ASX 81% Query, Administration; Allan Gray Down To 8.6% Of Nanosonics, Chairman Stang 9%; Perpetual Below 5% Of Pro Medicus; Bergen Takes 12% Of Prima; Bio-Melbourne Breakfasts On Cell Therapies; Dr Nigel Finch Replaces 3D Chair Matthew Morgan
 
May 27, 2015
Federal $20bn MRFF Legislation Introduced; Reva Confident Of Fantom, CE Mark Trial, US IPO; FDA Approves Sunshine Heart Pivotal C-Pulse Trial Restart; Antisense ATL1102 EU Early Access For Multiple Sclerosis; Resonance Hepafat-Scan Trial, Sander Bangma Appointed G-M; Bank Of America Sells, Borrows, Diluted, Increases In Suda; Applications Open For NSW Medical Device Program; IQ3 To Raise Up To $3m For IQX; Narhex Votes To Become Resapp Health
 
 
 
May 18, 2015
Pharmaxis $750m+ Boehringer Deal For PXS4728A For Nash; Brandon, MRCF, Uniseed $6.5m For Occurx For Ocular Fibrosis; Admedus To Launch Cardiocel Repair Patch; Nanosonics Kills HPV On Trans-Vaginal Ultrasound Probes; Mayne Completes Hedgepath Suba-Itraconazole Licence; Benitec Hep C ddRNAi US Patent Granted, Euro Patent Allowed; Biotech Advisory IQ3 Opens Up 17%, Closes Up 67%, Raises $4m; CBA, Related Parties Buy, Borrow 6% Of Sirtex; Bluechiip Pleads Schultz To ASX 33% Query; Bionomics: Dr Jens Mikkelsen CSO, Jack Moschakis Legal, Co Sec
 
 
May 15, 2015
Cortendo ‘Up To $131m’ Deal For Antisense ATL1103; Resmed To Sell Rhinomed Mute Anti-Snoring Nasal Plugs In UK; Novogen: ‘Oral Anisina (ATM-3507) Kills Cancer In Mice, No Tox’; Burnet Opens Nanjing Biopoint Diagnostics Laboratory; Reva Adds Australia To Fantom II Coronary Stent Trial; Cellmid $1m Loan; Biodiem Expects $40k For 1st Flu Vaccine Royalties; Reproductive Health Works With France’s Innopsys
 
May 14, 2015
Melbourne Uni Hope For Single Lifetime ’Flu Vaccination; Ridgeback Invests $15m In Prima, $5m Share Plan; Sirtex: ‘Abstract Backs Sir-Spheres Liver Tumor Reduction’; Resmed Falls 19% On Sleep Apnoea Device-Related Deaths; Phosphagenics ‘More Work Needed For Oxymorphone Patch’; ITL’s Myhealthtest Wins $1m Federal Commercialisation Grant; Siemens Launches Universal Biosensors Xprecia Analyzer; Reva Begins Search For Regulatory, Commercial CEO; Antisense Requests ‘ATL1103 Licencing’ Trading Halt; Rhinomed Requests ‘Mute Euro Sales’ Trading Halt; Edinburgh Uni Diluted To 8% Of Actinogen; David Dolby, Dagmar Dolby Trust Diluted To 18.5% Of Cogstate
 
May 13, 2015
WEHI, Research Australia Welcome MRFF; Grant Thornton: ‘Budget Overlooks Biotech, R&D Sly Cut’; Ausbiotech: ‘Budget Underwhelming, Few Bright Spots’; Bio-Melbourne Calls For Translation Element To MRFF; Dimerix Backdoor Into Sun For Kidney Disease, Raise $1.6m; Psivida Signs 2 Evaluation Deals With Unnamed Company; Tissue Therapies New EU Clinical, Pre-Clinical Vitrogro Trials; Avita Granted US Recell Methods Patent; Amp Takes 5% Of Medical Developments
 
May 12, 2015
Mesoblast ‘RA Stem Cells Cardio-Vascular Impact’; Actinogen Xanamem Safe To 35mg; Cogstate Appoints Dr Alan Finkel, $2m, Myer Diluted; Bone Quits Biotech For Takor Geospatial Imaging; Medical Developments Negotiating Global Distribution Deals; Medical Developments David Williams Sells 7m Shares To 40.5%; Medlab IPO For Up To $9m For Food Additives, Medical Cannabis; Phosphagenics Loses Lawrence Gozlan, Peter Lankau Chair
 
May 11, 2015
Applications Open For $316k Victoria Prizes; Acuvax Ex-CEO Dr William Ardrey Guilty On 18 Fraud Charges; Prima, NEC, Yamaguchi IMP321 Collaboration For Liver Cancer; Medibio Begins Pivotal 80-Patient Heart-Rate Depression Trial; Cynata Pleads Schultz, Roadshow To ASX 22% Query; Reproductive IVF Contracts, Appoints Ray Ridge CFO, Co Sec; Sun Requests ‘Acquisition, Capital Raising Trading Halt’; Pharmaust Claims 2nd Biomarker Backing For PPL-1 For Cancer; Narhex Hopes To Raise Up To $4m For Resapp; Allan Gray Reduces To 15% Of Starpharma; Impedimed Appoints CEO Richard Carreon M-D
 
May 8, 2015
Chiesi Adds EU To Pharmaxis Bronchitol Distribution; Polynovo Ready For Novosorb CE Mark Deep Burns Trial; Novogen: ‘TRXE-009 Kills DIPG Brain Cancer Cells In-Vitro’; Bone Requests ‘Acquisition’ Trading Halt; Medical Developments Global Penthrox Plans; Martin Rogers, Dr Jason Loveridge Diluted In Actinogen
 
May 7, 2015
Compumedics Wins $1m US Hospital EEG Contract; Dorsavi Signs Caterpillar As 1st US Health, Safety Contract; Polynovo Closes AOD9604 Sale To Lateral; Phytotech Extends Yissum Licence To Nano-Cannabis; Myhealthtest Takes Chairman Bill Mobbs To 44% Of ITL; 3D Medical Appoints Dr Nigel Finch Director; Bionics Institute Hosts Prof Mark Dodgson On Innovation
 
May 6, 2015
EU Approves Medical Developments Penthrox, $850k Milestone; Ausbiotech China Medical Technologies Guide; Ellex Challenges Ophthalmic Laser Market Leader; GI Dynamics To Restart US Trial By July, Restrictor Unveiled; Anteo Releases Mix&Go 200nm Magnetic Particles Coupling Kit
 
May 5, 2015
Victoria Budget: Biotech Shares $200m Future Fund, More; Drawbridge: ‘Editorials Back Rationale For Phaxan’; Clinuvel Adds VLRX001 For Vitiligo To Pipeline; Nominations Open For GSK $80k Research Award; Ampliphi Appoints Scott Salka CEO
 
May 4, 2015
CE Mark For Atcor, Suntech Oscar 2 With Sphygmocor; Starpharma, Astrazeneca Extend Dendrimer-Oncology Work; Benitec Files US Sec Draft Registration Statement; Heartware Q1 Revenue Up 5% To $89m; Medical Developments 9 Months Sales Revenue Up 24% To $8m; Rhinomed Sales ‘Recover’, Signs Sigma For Distribution; Mayne Takes Control Of Oxycodone, Methamphetamine, Doryx; Innate Joins US Consortium For MS Trial Assessment; Acorn Below 5% Of Starpharma; Genetic Technologies Repairs Nasdaq Deficiencies; Oncosil Loses Lawrence Gozlan
 
May 1, 2015
April BDI-40 Up 4%, ASX200 Down 2%, Big Caps Down 5%; - Compumedics Up 73%, Antisense 53%; Biotron, Prima Down 24%; Pharmaust: ‘PPL-1 Reduces Biomarker P70S6K In 1st Dog, Too’; Progen To Buy Medigen’s TBG For Diagnostics, Keep PI-88; Invion Founder Dr William Garner Increases, Diluted To 4.5%; GI Dynamics 2m CEO, Directors Shares, Options AGM; Reva 1.6m Directors Shares, 1.3m Directors Options AGM
 
Apr 30, 2015
Starpharma: ‘Trial Patients Tolerate High Dose Dep-Docetaxel’; Polynovo Sells AOD9604 For $1.5m To David Kenley, Lateral; ‘CNS Drugs Back In Favor’ Buchan Brain Medicine Lunch Told; Sydney Uni, Balnaves $650k For 28 Early Career Researchers; Uniquest, Astrazeneca Open Innovation Collaboration; Uscom Receives $313k Federal R&D Tax Refund; Analytica Has Less Than Two Quarters Cash
 
Apr 29, 2015
Benitec Doses 5th TT-034 Hepatitis C Patient; ITL To Buy Related-Party Myhealthtest For Self Testing; Novogen Placement Raises $15m; Biotech Daily Appendix 4C Quarterly Reports Policy; Cellmid Has Less Than Two Quarters Cash; Prescient Has Less Than Two Quarters Cash; Tony Grist, Denlin, Oaktone Increase, Diluted In Actinogen; Brett Heading Replaces Invion Chairman Dr Ralph Craven; Thomas Fontaine Replaces BPH Director Hock Goh 
 
Apr 28, 2015
GBS Investee Celladon Falls 81% On Mydicar Heart Failure; Nanosonics $9.3m Q3 Receipts Take 4C Positive, Again; EMA Backs Orphan Status For Prana’s PBT2 For Huntington’s; Kansas University Cancer Center Joins Impedimed L-Dex Trial; Proteomics Wins Middle East Generics Testing Contract; Minderoo (Metal) Group Reduces To 8% Of Admedus; JK, Hogan, Tisia, Henderson Increase, Diluted In Actinogen; Prescient Appoints Dr Terrence Chew CMO; Novogen Re-Complies With Nasdaq Equity Value Rules 
 
Apr 27, 2015
CE Mark For Avita’s Expanded Recell Burns Treatment; Cogstate Claims $6m In Test Contracts, ‘Best Year For Sales’; Oncosil Awarded ISO Certification; St Vincent’s 2015 Forum: ‘Medicine Beyond Pills & Potions’
 
Apr 24, 2015
Actinogen Raises $10m, $1m Plan; Xanamem Ethics Approval; Suda: ‘2 Articles Back Sublingual Artimist For Malaria’; Resmed Q3 Revenue Up 6% To $543m; Acrux, Eli Lilly Axiron Sales Slip 1%, Forex Pushes Royalty Up; Anatara To Release 8m Escrow Shares; Narhex Becomes Resapp EGM
 
Apr 23, 2015
Melbourne University: ‘Cancer Drug For Malaria Resistance’; Proteomics A2 Milk Contract; IQ3 IPO To Raise $4m For Biotech Advisory; Reva Enrols European Patients In Fantom II Stent Trial; Tissue Therapies, EMA To Discuss Further Vitrogro Trials; One Funds (Ex-Octa Phillip) Takes 10% Of Avita; CSL CFO Gordon Naylor To Lead Influenza Vaccine Business
 
Apr 22, 2015
Uscom: ‘Monitor Detects Pre-Eclampsia At 5 Weeks’; Invion Rights Issue Raises $5.4m, Takes Total To $6.3m; Regeneus Phase I Progenza Osteoarthritis Ethics Approval; Actinogen Requests Alzheimer’s Trial Capital Raising Halt; US Orphan Status For Novogen Cantrixil For Ovarian Cancer; Admedus Appoints Genpharm For Mid-East, North Africa Sales; Nusep Settles $132k Lawler Partners Auditor Debt; Hunter Hall Takes 12% Of GI Dynamics; Australian Ethical Takes Profit On Pharmaxis To 6%; Director John Dunlop Takes 10.5% Of Proteomics; Suda Appoints Anthony Fox, Roger Cady Migraine Advisers
 
Apr 21, 2015
CSIRO, Berghofer, ANU Malaria Breath Test; WEHI: ‘Combination Therapy Could Cure Hepatitis B’; Viralytics: ‘Melanoma Extension Trial Immune Activity’; Prescient PTX-100 Reduces Multiple Myeloma Tumors In Mice; Pro Medicus $9.5m US Imaging Deal; Compumedics $2.2m China Neuro-Monitoring Contract; Imugene Files Her-Vaxx Reformulation Patent; Cochlear US Patent Case Goes To Appeal Court; Medibio To Pay $3m For US, Canada Patents; Proteomics To Release 75k Escrow Shares; Novogen $15m Placement, $15m Rights Issue; Biotron Receives $1.7m Federal R&D Tax Refund; Anteo Branches Into Battery Technology
 
Apr 20, 2015
Brandon Capital Raises $200m For MRCF; Victoria Joins NSW Medicinal Cannabis Trials; Bionomics Begins Phase II BNC210 Anxiety Trial; Immuron Claims 1st US Travelan Sales; Imugene Improved Her-Vaxx Raises Antibodies 10-Fold In Mice; Genetic Technologies Adds Two US Brevagen Test Centres; Simavita Incontinence System Reduces Infections, Falls, Costs; Directors Dr Lipscombe, Dr Parker Take 44% Of Proteomics 
 
Apr 17, 2015
Heartware Pump ‘Not Inferior’ For Destination Therapy; Sunshine Heart: ‘Minor Changes’ To Restart Pivotal Trial; Admedus Rights Issue $16.1m Takes Total To $28.1m; Phosphagenics Begins Phase II TPM-Oxycodone Patch Trial; Proteomics Raises $3m, Opens Up 17.5%; Benitec Licences Asklepios Adeno-Associated Virus; Thorney Takes 5.8% Of Mesoblast; Novogen, Feinstein Collaborate On Brain Cancer
 
Apr 16, 2015
Clarity Licences Baker IDI Plaque Detection Technology; Impedimed Q3 Lymphoedema Test Revenue Up 104% To $700k; Actinogen Ready For Final Xanamem Dose-Escalation Cohort; Analytica Begins 100-Patient Pericoach Incontinence Trial; Euro Patent For Antisense ATL1103 For IGF-1 Reduction; Avita Share Plan Raises $1m Of Hoped-For $6m; Mladen Marusic Below 5% Of Patrys; GI Dynamics Completes US 10-For-1 Consolidation; Buchan’s April Three Tickers On Neuroscience; Two Weeks To Ausbiotech Medical Technologies Conference
 
Apr 15, 2015
Cellmid Trial: ‘Évolis One Reduces Hair Loss’; Poland Approves Psivida Iluvien; Bluechiip Raises $1m; Pharmaust Takes PPL-1 To Higher Dose, Capsule Formulation; New Jersey’s Sabby Ceases Substantial In Viralytics; Solagran Claims US Patent For Ropren, Prenols
 
Apr 14, 2015
WEHI Discovers ‘Architects’ For Body Blueprint; Actinogen Advisers Detail Xanamem Alzheimer’s Trial; Euro Patent For Compumedics Stroke, TBI Diagnostic; Anteo, UQ Pre-Clinical Imaging Partnership; Avita Appoints Adam Kelliher CEO, Starts On $434k; Medibio Appoints Mayo’s Prof Franklyn Prendergast Adviser; UK Barclays Bank Takes 7% Of Genetic Technologies
 
Apr 13, 2015
Celgene Takes 4.5% Of Mesoblast, Option On GVHD Indications; Editorial: Reporting Goldman Sachs Substantials; IDT Manufactures 1st Of 23 US Generics, FDA Confirms Transfer; Universal Biosensors J&J Service Fees Up 142%; Bluechiip Requests ‘Capital Raising’ Trading Halt; European Patent For Actinogen’s Xanamem; Pharmaust Approved For 7-Day Dog PPL-1 Cancer Treatment; Nusep’s Alison Coutts Temporary Resignation From Prime; Phosphagenics: Dr Murdoch, Dr Collier, Mr Lankau Directors
 
Apr 10, 2015
Canada Approves Heartware Pump For Bridge-To-Transplant; Genetic Signatures Installs 1st Easyscreen Respiratory Tests; Admedus Ready For Phase II HSV-2 Vaccine Trial; Cancer Therapeutics CRC Wins $5.4m Wellcome Grant; Marquette Lends Nusep $239k; Bone Pleads Schultz To ASX 40% Query 
 
Apr 9, 2015
Novogen Anisina (ATM-3507) Kills Mutated Melanoma In-Vitro; Phytotech Regulator Asks Target If Ready For Inspection; Unilife Appoints Dr Richard Beckman Chef Medical Officer; Bio-Melbourne Breakfasts On USPTO’s Teresa Stanek Rea
 
Mesoblast Expands US Phase III Back Pain Trial To Europe; Dorsavi Wins Repeat Visafe OHS Orders; CE Mark For Genera’s Paptype, RTI-Plex; Adelaide’s Lyell McEwin Hospital Joins Pharmaust PPL-1 Trial; Patrys Appoints Dr James Campbell CEO, Starts On $300k; Former Medibio Chairman Vince Fayad Resigns; Ausbiotech Victoria Biobeers & Bubbles 
 
Apr 7, 2015
WEHI: ‘Low MCL-1 Levels Compromise Blood Production’; Pharmaxis PXS4728A ‘Safe, Orally Bio-Available’; South Australia Uni: ‘Edaravone Aids Alzheimer’s In Mice’; Benitec TT-034 ‘Expressing shRNA In Dosed Patients Livers’; Admedus Expands Adapt Tissue To Brain, Spine Dura Mater; Regeneus Scales-Up Progenza For Osteoarthritis Trial; Phylogica Takes 7.5% Of UK Phoremost In Phylomer Deal; Goldman Sachs Below 5% Of Nanosonics, Again; Tissue Therapies Loses CEO Dr Steven Mercer, Chairman Goes; Phytotech Requests ‘MMJ Merger Update’ Trading Halt; Applications Closing For STC $140k Medtech Entrepreneurs
 
Apr 2, 2015
Cytomatrix Raises $6m; Medibio Raises $2.6m, Takes Invatec, Chris Indermaur Chairman; Immuron Appoints Dr Leearne Hinch CEO; QRX Pleads Schultz To ASX 100% Query; Novogen Hires New York’s PCG For US Investor Awareness
 
Apr 1, 2015
Sirtex Helps Drag March BDI-40 Down 19%, ASX200 Down 1%; - Atcor Up 72%, IDT 58%; Tissue Therapies Down 53%, GI Dynamics 50%; Simavita Raises $8.3m; Cochlear Wins 3 Of 4 Infringement Appeals, To Fight On; US FDA Approves Prescient PTX-200 For Cancer IND Transfer; GI Dynamics US 10-For-1 Consolidation; Anteo Extends Research Agreement With Unnamed Company; Brandon, MRCF Increase, Diluted To 16% Of Osprey; Signostics Appoints Kevin Goodwin CEO 
 
Mar 31, 2015
Dr Bill Ketelbey Paints The Actinogen Renaissance; Genetic Signatures Opens Up 20% At 48c; Rhinomed Signs Ebos Symbion For Mute Distribution; ITL Expands Malaysian Manufacturing Facility; Pharmaust Granted Japan PPL-1 Collaboration Patent; Uscom: ‘AMA CPT Category 1 Code Applies To BP+’; Genetic Technologies Pleads Nasdaq, Again, To ASX 52% Query; Minderoo (Metal) Group Further Diluted To 11% Of Admedus; Goldman Sachs Buys, ‘Borrows’ Takes 5% Of Nanosonics, Again; CM Capital Increases, Diluted To 8.6% Of Osprey; Cellmid Appoints Lucy Rowe Company Secretary
 
Mar 30, 2015
Phylogica: ‘Phylomer-Omomyc Fusion Kills Cancer’; Tumor Vaccine Potential For Innate’s MS Drug MIS416; Novogen Cantrixil Pre-Clinical Ovarian Stem Cell Cancer Data; Compumedics Wins $375k China Brain Injury Test Deal; Genetic Signatures Lists On ASX Tomorrow; Nusep IVF Collaboration With Newcastle University; Simavita Requests ASX, TSX Compliance, Placement Halt; Rhinomed Requests Mute Distributor Trading Halt
 
Mar 27, 2015
Psivida Completes Medidur Posterior Uveitis Trial Enrolment; Dorsavi Posts First UK Vimove Sales; Mesoblast Allowed Japan Ischemia Stem Cell Patent; Suda Raises $5.3m; Victoria, Osaka To Collaborate On Medical Research; UBS AG Buys, Sells, Borrows, Returns Sirtex Shares Below 5%; Invion Founder Dr William Garner Down To 6%; Perpetual Reduces To 7% Of Pro Medicus; Phylogica Appoints Natasha Forde Joint Company Secretary
 
Mar 26, 2015
Europe Calls For More Tissue Therapies Vitrogro Data; LBT Granted First US Patent For APAS Plate Analysis; Invion, Patrys And Commsec Iress Data; Goldman Sachs Below 5% Of Nanosonics; NAB Below 5% In Sirtex; Academy Of Health And Medical Sciences Launched; Suda Requests Capital Raising Trading Halt; Reva Appoints Scott Huennekens Director
 
Mar 25, 2015
NHMRC $123.5m For 113 Projects ; Phosphagenics 2nd Vitamin E Licence For Animal Products; Anteo Trials Mix&Go On Cook Medical Devices; Capital Group Takes 8% Of Mesoblast
 
Mar 24, 2015
Actinogen Increases Phase I Xanamem For Alzheimer’s Dose; Pharmaust: ‘PPL-1 Reduces P70S6K In All 6 Cancer Patients’; Correction: Invion; Phytotech To Acquire Canada’s MMJ For Up To $21m Scrip; Narhex Target Resapp Optimization Study; Coeliac Charities Donate $40k To WEHI
 
Mar 23, 2015
Osprey Placement Raises $16m; Invion: ‘FDA Approves INV102 Trial Strategy’; Starpharma Dendrimer-Docetaxel Trial ‘50% Recruited’; BPH EGM For Director Shares, Options
 
Mar 20, 2015
Biota, GSK Lose US Relenza Pending Patent Appeal; Clinuvel Scenesse Approval ‘A Breakthrough For Alpha-MSH’; Genetic Signatures IPO Raises $7.5m; Invion Raises $895k, Rights Issue For $4.1m, Closes Lind Deal; Allan Gray Increases, Diluted To 18% Of Pharmaxis; Goldman Sachs Buys, ‘Borrows’ Takes 5% Of Nanosonics; UBS AG Buys, Sells, Borrows, Returns Sirtex Shares To 5%; NAB Buys, Borrows, Returns Sirtex Shares To 5%; YZJ, SMK Reduce, Diluted To 14% Of Medical Australia; Medibio Completes 1-For-100 Consolidation; Phytotech Requests ‘Material Acquisition’ Trading Halt
 
Mar 19, 2015
WEHI-345 Slows Inflammation, Multiple Sclerosis Potential; US Approval For Analytica’s Pericoach; STC Offers $140k For 5 Medtech Entrepreneurs With Talent; Japan Fast Track Investment Incentives For Mesoblast; Hunter Hall Buys 1.3m Sirtex Shares To 9.4%; Hunter Hall Takes 11% Of GI Dynamics; Reproductive Health Releases 17m Escrow Shares; Osprey Takes Capital Raising Halt To Suspension; Dr Bronwyn Evans Appointed To Federal Growth Centre 
 
Mar 18, 2015
Biotech Daily Editorial: Sirtex Not All Doom And Gloom; Admedus Places $12m, Rights Issue For $16m More; Nanosonics Share Plan Raises $3m; Novogen ‘Anisina (ATM-3507) Kills Cancer Cytoskeleton In Mice’; Simavita Continues Incontinence Monitor Roll-Out; Solagran US Patent For ‘Processing Vegetable Raw Materials’
 
Mar 17, 2015
Sirtex Tumbles 62% On Sirflox Cancer Trial Fail; NHMRC $25m Grant For Genomics Research; Osprey Requests Capital Raising Trading Halt; Pharmaust Completes Low-Dose Cohort; Actinogen Appoints Profs Ritchie, Masters, Cummings Advisors; Pro Medicus Completes Buy-Back, To Buy-Back Further 10% eases, Diluted To 17.7% Of Impedimed
 
Mar 16, 2015
Oncosil Expands Indications To Liver Cancer; Reva Implants First Two Fantom Stent Trial Patients; Genetic Signatures Launches Respiratory Test Kit; Pharmaust Raises $3m; Sirtex Requests Major Study Results Trading Halt; Admedus Requests Capital Raising Trading Halt; Invion Takes Capital Raising Halt To Suspension; NSW ‘Will Boost Medical Research 18% - If Re-Elected’; Hyperion Reduces Below 5% Of Cochlear; CB Co, Curran Super Fund Reduces To 11% Of Atcor; Dr Christopher Harvey Replaces Progen Director Heng Tang 
 
Mar 13, 2015
WEHI Edits Genomes To Kill Cancer For Its 100th Birthday; Universal Biosensors New Features For Siemens Test; BPH Energy: Papers Back Molecular Discovery HLSR; Agenix, Oks Resolve 2008 Thromboview Investment Case; Hunter Hall Takes 9.6% Of GI Dynamics; Asia Union Decreases, Diluted To 7% Of Tissue Therapies; Pratt’s Thorney (Tiga) Increases, Diluted To 5% Of Mayne; Simavita Proposes Warren Bingham For Director
 
Mar 12, 2015
Pharmaxis Jumps 101% On $40m Boehringer PXS4728A Licence; Admedus Wins First Cardiocel Orders From Hong Kong; Minister Tells Bio-Melbourne: ‘Victoria Committed To Biotech’; S&P ASX Indices: 5 Biotechs Up, 5 Down; Avita Raises $5m, Share Plan For Up To $6m; Invion Requests Capital Raising Trading Halt; Pharmaust Requests Capital Raising Trading Halt; Actinogen Pleads ‘Road-Show’ To ASX 49% Query; Phosphagenics Pleads Schultz, S&P Index To 31% Fall Query; RACI Dines On Fibrotech’s Prof Spencer Williams; Judith Smith Replaces Universal Biosensors’ Andrew Jane
 
Mar 11, 2015
UK Fund’s $13m For Medicines Development River Blindness; Benitec Doses 4th TT-034 Hepatitis C Patient; Ampliphi Raises $17m For Bacteriophage Antibacterial; Genera Tests On Register, CE Mark News ‘Next Week’; 3D Sells Mach7 Products To Telstra Health, Gains Data Service; Allan Gray Reduces To 9.6% Of Nanosonics; Allan Gray Increases, Diluted To 17.7% Of Impedimed
 
Mar 10, 2015
Atcor Jumps 116% On AMA ‘Sphygmocor’ CPT Category 1 Code; Federal Science Minister Opens Flinders Tonsley Campus; Anteo Appoints Veritas Japan Mix&Go Distributor; BPH Share Plan Raises $204k; Avita Requests ‘Equity Placement’ Trading Halt; Medical Developments Pleads Schultz, News To ASX 8% Query; Allan Gray Reduces To 17% Of Acrux; Allan Gray Reduces To 12% Of QRX
 
Mar 9, 2015
Deaths Take Sunshine Heart To ‘Temporary Enrolment Pause’; Genetic Technologies Raises $18.6m; Mayo Clinic Joins Impedimed L-Dex Study; Orthocell Ready For Pilot Dental Bone Repair Trial; Regeneus Applies For Human Progenza Osteoarthritis Trial; Correction: Sirtex
 
Mar 6, 2015
Dr Megan Baldwin Sharpens Circadian Focus; Liver Infections Halt GI Dynamics US Trial; TGA Approves Genera Diagnostics For Register; WEHI Identifies Human Antigen R Role For Antibodies, Immunity; Nanosonics Dr Ron Weinberger Wins ‘Innovation Hero’ Gong; Genetic Technologies Requests Capital Raising Trading Halt; Hunter Hall Forced To Sell More Sirtex To 7%; Breaks $2b; Starfish Ventures Increases, Diluted To 8.6% Of Impedimed; Medibio EGM Backs Invatec Heart-Depression Test Acquisition
 
Mar 5, 2015
Nanosonics Places $25m, Plan For $3m More; Tissue Therapies Offer Raises $3.7m, Places $570k, Total $8.27m; Sirtex Completes French Trial Recruitment; MD Anderson Joins Impedimed Post-Approval L-Dex Study; Living Cell Changes Diabecell Trial Focus To US; Pharmaust 2nd Cancer Patient Tolerates PPL-1, Stable Disease; Antisense Ready For High-Dose ATL1103 Acromegaly Trial; GI Dynamics Requests ‘Business’ Trading Halt; Chairman Andrew Kroger Takes 25.6% Of Cryosite; CEO Wayne Stringer Takes 18% Of Probiotec
 
Mar 4, 2015
Federal R&D Tax Credit Stands At 45%, $100m Cap; Comment; Acrux: ‘FDA Tightens Testosterone Labelling’; Biota Begins 150-Patient Vapendavir Asthma HRV (Cold) Trial; NSW Grants $14.2m For Cancer Research; Novogen: ‘TRXE-009 Can Kill Brain Cancer Cells’; Narhex Ready For Respiratory ’Phone Diagnostic Trial; Rhinomed Appoints Christian Johnson For US Sales; Bio-Melbourne Launches Women In Leadership Awards
 
Mar 3, 2015
WEHI Finds MLC-1 Protein Key For Milk Production; Pro Medicus Rolling Out High-Speed 2-D, 3-D Imaging; Benitec Prepares For Patients 4, 5 In TT-034 Hepatitis C Trial; Benitec Receives $2m Federal R&D Tax Refund; Graham Durbin Superannuation Takes 9% Of Genera; Nanosonics Requests ‘Material Fundraising’ Trading Halt; Phylogica Pleads Schultz To ASX 31% Fall Query; Victoria Innovation Minister To Open Bio-Melbourne Program
 
Mar 2, 2015
February BDI-40 Up 10%, ASX200 Up 6% - Cynata Up 254%, Genetic Tech 200%; Correction: Viralytics; Biota $22m For France’s Anaconda For Wart, HPV Anti-Viral; Neuren Tumbles 44% On FDA Breakthrough Refusal; Europe Upholds Amended CSIRO, Benitec Patent; Phytotech To Fund Canigma Vaporizer, Ross Smith Device Query; Genera Notes Raise $615k; Heartware 2014 Revenue Up 34% To $356m, Loss Down 67% To $25m; Admedus H1 Revenue Up 17% To $5m, Loss Up 1,333% To $11m; Off-Shore Processing Hits Suda H1 Revenue 52% To $3m, Loss Up; Avita H1 Revenue Down 23% To $1.4m, Loss Up 6% To $3.4m; Genetic Tech H1 Revenue Down 38% To $1m, Loss Down 5% To $5m; Circadian H1 Revenue Down 8% To $366k, Loss Up 90% To $3m; Brain: ‘Journal Article Backs Depression Treatment Test’; Bionomics To List On US OTC-QX
 
Feb 27, 2015
Prima Cans 10-Year CVac For Ovarian Cancer, Immutep Focus; Bionomics; ‘New Biomarkers Benefit Bnc105 For Kidney Cancer’; Ellex H1 Revenue Up 19% To $31m, Profit Up 108% To $815k; Pharmaxis Revenue Up 133% To $13m, Loss Down 68% To $7m; Medical Aust H1 Revenue Up 44% To $8m, Loss To $420k Profit; LBT H1 Revenue Down 32% To $1.6m, Profit Down 34% To $511k; GI Dynamics Revenue Up 25% To $4m, Loss Up 36% To $62m; Progen H1 Revenue Up 88% To $2.5m, Loss Up 4% To $2m; Pharmaust H1 Revenue Down 8% To $1m, Loss Up 68% To $1m; Simavita Revenue Up 238% To $581k, Loss Down 23% To $4m; Dorsavi H1 Revenue Up 113% To $825k, Loss Up 270% To $4m; Probiotec H1 Revenue Down 2% To $31m, Profit To $26m Loss
 
Feb 26, 2015
Prime Minister Adds ‘Commercial Application Of Science’ Prize; Mayne H1 Revenue Down 15% To $60m, Profit Down 53% To $4m; Alchemia H1 Revenue Up 36% To $7m, Loss Up 188% To $16m; Acrux H1 Revenue Down 67%, Profit Down 72%, Ross Barrow Goes; Resonance H1 Revenue Up 21% To $1m, Return To Profit $448k; Phosphagenics Revenue Up 85% To $2.5m, Loss Down 29% To $7m; OBJ H1 Revenue Up 49% To $1m, Loss Down 12% To $809k; Biotron Pleads Schultz Again, Old News To ASX 23% Query; Capitol Health Takes 6% Of 3D Medical (Safety Medical); Genetic Technologies Appoints CFO Eutillio Buccilli CEO
 
Feb 25, 2015
Reva Details Fantom Stent, European Registration Trial; Tissue Therapies Files EMA 180-Day Review Answers; Phosphagenics To Sell Bioelixia Cosmetics Division; Oncosil Reworks EU, US Pancreatic Cancer Trial Design; Compumedics H1 Revenue Up 8% To $16m, Profit Up 125% To $904k; Impedimed H1 Revenue Up 28% To $2m, Loss Up 71% To $6m; Clinuvel H1 Revenue Up 32% To $1m, Loss Up 129% To $7m; Cryosite H1 Revenue Up 10.5% To $5m, Profit Up 8% To $358k; Allegra H1 Revenue Up 1% To $4m, Loss Up 194% To $262k; Brain H1 Revenue Down 7% To $1m, Loss Up 39% To $1m; Pfizer Drops Case Against Mayne Pharma’s Generic Tikosyn
 
Feb 24, 2015
Actinogen Recruits Subjects For Xanamem Alzheimer’s Trial; Phylogica Euro Patent For Screening, Drug Resistance; Anteo Files Sample Pre-Treatment Bioseparations Patent; NSW Promises $20m For Paediatric Research - If Re-Elected; Pharmaust 5th Patient Biomarker Changes In PPL-1 Cancer Trial; Uscom H1 Revenue Up 147% To $1m, Loss Down 40% To $391k; Cellmid H1 Revenue Down 55% To $685k, Profit To $1m Loss; Mayne Completes Doryx Acquisition; Correction: Atcor; Living Cell Founder Prof Bob Elliott Steps Down As Executive; Anatara: Dr Paul Schober CEO, Damian Wilson, Paul Grujic
 
Feb 23, 2015
Two US Patents For Prescient PTX-200 For Ovarian Cancer; Bionomics H1 Revenue Up 43% To $7m, Loss Down 17% To $5.7m; Atcor H1 Revenue Up 7% To $3m, Turns $1m Loss To $41k Profit; Narhex Executes UQ Respiratory App Deal; Imugene Pleads Schultz To ASX 33% Query; Healthlinx EGM Backs Move To Manalto For Social Media; Regeneus Appoints Greencross’ Dr Glen Richards Director; Phytotech Founder Ross Smith Goes, Rights Hurdles Met
 
Feb 20, 2015
NSW Awards $2.7m Genomics Collaborative Grants; Federal Government Intellectual Property Paper; Medical Dev H1 Revenue Up 21% To $5.5m, Profit Up 72% To $731k; Sunshine Heart Takes $13m Loan, Security Agreement
 
Feb 19, 2015
WANRI: ‘Peptides Limit Stroke Brain Damage’; Cynata Up 146% Percent On Large Scale, Low Cost Stem Cells; Cyclopharm Revenue Up 26% To $15m, Loss To $4m Profit; Regeneus H1 Revenue Up 46% To $1.1m, Loss Down 10% To $6m; Universal Bio Revenue Down 37% To $9.5m, Loss Down 20% To $9m; Alchemia Fondaparinux Q2 Profit Share Down 32% To $1.9m; CBA Borrows, Lends, Buys, Sells Down To 6.5% Of CSL; RA Capital Reduces To 10% Of Benitec
 
Feb 18, 2015
Sirtex H1 Revenue Up 37% To $81m, Profit Up 58% To $18m; Osprey Marks First Sales Of $10k; Nanosonics H1 Revenue Up 50% To $16m, Loss To $1m Profit; Immuron H1 Revenue Up 39% To $529k, Loss Down 9% To $1.3m; Cogstate H1 Revenue Up 44% To $8m, Loss Up 1% To $2.7m; Psivida, Alimera Iluvien Available In The US Next Week; Europe Grants 3rd Patent For Patrys PAT-SM6; Anatara: ‘Detach Reduces Pig Mortality, Morbidity’; Imugene Receives $231k Federal R&D Tax Refund
 
Feb 17, 2015
Immuron Appoints Beijing’s Linker For China Sales; Progen Receives $854k Federal R&D Tax Refund; IDT H1 Revenue $6m, Loss Up 42% To $3m; ITL H1 Revenue Up 9% To $14m, Profit Up 34% To $1.6m; Anteo H1 Revenue Flat At $1.8m, Loss Up 265% To $2.3m; Nanosonics Pleads Schultz, Sales To ASX 26% Query; Cynata Requests Manufacturing Trading Halt; Clifford Eu Increases, Diluted To 9% Of Nusep
 
Feb 16, 2015
Mesoblast 160-Patient Data Backs MSC-100-IV For GVHD; FDA Orphan Drug Status For Neuren’s Trofinetide (NNZ-2566); Cynata Hires US CRO For Stem Cell Study; Actinogen Ready For Xanamem Alzheimer’s Phase I Trials; Reproductive Health Appoints Israel, South Africa Distributors; Safety Medical Returns As 3D Medical On Wednesday
 
Feb 13, 2015
FDA Limits Prana PBT2 Huntington’s Dose; Brain Wins Up To $1.9m Boeing Contract; Federal Government, Australian Museum Eureka Prizes Open; Compumedics Pleads Schultz To ASX 30% Query; United Super, CBus Below 5% Of Acrux; Craig Chapman, Nampac Increase, Diluted To 18.35% Of Agenix; Polynovo CEO Paul Brennan Starts On $270k, Ivy Cheng; Ausbiotech Bio-Beers & Bubbles Across Australia
 
Feb 12, 2015
Mesoblast H1 Revenue Up 24% To $26m, Loss Up 65% To $51m; Mayne Raises $72m, $43m To Go; Genetic Technologies Pleads Nasdaq, News To ASX 52% Query; Cynata Hires New York’s PCG Advisory Group
 
Feb 11, 2015
Federal Government Caps R&D Tax Incentive At $100m; Ausbiotech Concern Over R&D Tax Changes; CSL Record H1 Revenue Up 6% To $3.5b, Profit Up 7% To $891m; Novogen Lodges First Super-Benzopyran Patent; Correction: Otifex; Optiscan Pleads Schultz To ASX 31% Query; Spinifex Appoints Dr Peter Spargo, Dr Chris Richardson; Safety Medical: Matthew Morgan, Frank Pertile Directors
 
Feb 10, 2015
Federal Parliament Passes IP Amendment Bill; Vaxxas Raises $25m; Cochlear Record H1 Revenue, Profit Up; Mesoblast US Disc Repair, Reconstitution Patent; US Patent For Drawbridge Phaxan Anaesthetic, Sedative; Otifex: ‘Betahistine For Glue Ear Safe, Tolerated’; Unilife H1 Revenue Up 0.3% To $9m, Loss Up 44% To $54m; Correction: Prescient; Mayne To Raise $115m For Doryx, Drugs, US Division; BPH Share Plan For Up To $200k; Cytomatrix: Prof Alan Trounson, Prof Miles Prince Advisors
 
Feb 9, 2015
Melbourne Uni Sequences Roundworm Genetic Code; Pharmaust Finds Biomarker Changes In PPL-1 Cancer Trial; Prescient Licences P27 Biomarker For GGTI-2418, PTX-100; Orthocell Treats First Asian Ortho-ATI Tendon Patients; Safety Medical Becomes 3D Medical; UBS AG Buys, Sells, Borrows, Returns Acrux Shares To 8%; Hunter Hall Sells 3m Alchemia Shares To 8%
 
 
Feb 5, 2015
Ellex 2RT Laser For AMD Earns US Journal Cover; Unilife Raises $57m In The US; Simavita Receives $1.4m Federal R&D Tax Refund; Genetic Technologies Funding EGM
 
Feb 4, 2015
Cynata, UWA Collaborate On Stem Cells For Lung Fibrosis; Patrys: ‘PAT-SM6 Safe, Tolerable For Multiple Myeloma’; Tissue Therapies Places $4m, Rights Issue For $3.7m More; Genetic Technologies Meets 1st Nasdaq Rule, Extension; Hunter Hall Takes More Profit To 8% In Sirtex; Sienna Appoints Dr Cliff Holloway Interim CEO
 
Feb 3, 2015
Melbourne, Monash, Harvard Find Skin Immune Cells; Immuron Enrols First Phase II IMM-124E Nash Patients; Impedimed Adds 2 US Clinics To L-Dex Pilot Program; Phytotech Claims Cannabis Program Starts, Ross Smith; Acrux 10% Resistance To CEO Michael Kotsanis 4m Options; Melanie Leydin Replaces Prescient Co Sec Sean Henbury
 
Feb 2, 2015
January BDI-40 Down 1%, ASX200 Up 3%, Big Caps Up 4% - Genetic Technologies Up 69%, Neuren 46%; Alchemia, Pharmaxis Down 21%; Invion Completes INV102 Smoking Cessation Trial Enrolment; Acrux, Eli Lilly Axiron Sales Recovering From Cardiac Scare; Tissue Therapies ‘Capital Raising’ Trading Halt; Bionomics Restarts BNC210 Anxiety Program; Unilife To Raise $53m; Universal Biosensors Retains $US10m Loan Option; Medibio Has Less Than One Quarter Cash; $2.5m Placement Vote; Bank Of America, Merrill Lynch Buy, Borrow 6% Of IDT; Imugene Promotes CEO Charles Walker To M-D; Clinical Genomics: Warren Bingham, Michele Houldsworth; Phytotech To Lose Founder Ross Smith; Erlyn Dale To Co Sec; BPH Appoints Bruce Whan Director, Deborah Ambrosini Co Sec
 
Jan 30, 2015
Nanosonics H1 Revenue Up 48% To $14m; Australian Patent For Suda’s Sildenafil Oral Spray; LBT Has Cash, Despite December Burn; Ron Dewhurst, Kroy Wen (Back) Take 7% Of Rhinomed; Unilife Requests US Placement Trading Halt; Ausbiotech’s April Medical Technologies Conference
 
Jan 29, 2015
WEHI ‘Obese Fat Tissue Inflammation Key To Type 2 Diabetes’; Alchemia Review: Dividends, Program Sales, Trial Review; Ellex Expects H1 Revenue Up 19% To $31m, Profit Up 199%; Uscom H1 Revenue Up 121% To $722k; Genetic Technologies: ‘6 New US Centres Offer Brevagenplus’; Simavita Signs Abena For Denmark, 1st Orders Received; US Patent For Orthocell Celgro Scaffold; Nasdaq Accepts Novogen Compliance Plan, Extends Time; Resonance Loses M-D Liza Dunne; Reva Appoints Dr Ross Breckenridge Director; Phytotech Appoints Dr Daphna Heffetz Israel CEO
 
Jan 28, 2015
Avita Begins Pivotal 30-Patient US Recell Burns Trial; Progen: ‘Medigen Brings Forward PI-88 Liver Cancer Results’; US Patent For Circadian’s VEGFR-3; Neuren NNZ-2566 To Be Renamed ‘Trofinetide’; Rhinomed Next Generation Turbine Ready For Shipping; Genetic Technologies: Vale Director David Carter; Phytotech Appoints Dr Benad Goldwasser Director; Acuvax Ex-CEO Dr William Ardrey Fraud Trial Begins
 
Jan 27, 2015
Prima’s Immutep Earns ‘$1m-Plus’ GSK Milestone; Finland, Luxembourg Approve Psivida’s Iluvien; Biotech Wins 4 Of 10 Federal ‘Research Connections’ Grants; Viralytics Begins Cavatak Bladder Cancer Trial; Brain Resource Preparing FDA Depression Test Application; China Re-Registers Uscom 1A Monitor; Ausbiotech: Queensland LNP Promises $90m Fund If Re-Elected
 
Jan 23, 2015
Resmed Posts Record, $1bn H1 Revenue, Profit; Circadian Receives $2.2m Federal R&D Tax Refund; Universal Biosensors: Lifescan New Onetouch Verio Meter; Phytotech Jumps 119% On Hopes For Medical Marijuana; Isonea Loses 4th CEO In 12 Months, Trials Planned; Reproductive Health India Distributor, Indonesia Deal; Healthlinx EGM To Become Manalto For Software
 
Jan 22, 2015
Phytotech Opens Up 60% For Medical Marijuana; Genetic Technologies Takes Kentgrove $24m Equity Facility; Atcor Receives $461k Federal R&D Tax Refund; Sienna To Lose Founding CEO Dr Kerry Hegarty; CEO Alan Shortall Takes 9% Of Unilife, Frontier Takes 7%; Chris Ntoumenopoulos Replaces Narhex’s Cyril D’silva; Murdoch Children’s A Finalist For Ozapp Prize
 
Jan 21, 2015
Pharmaxis Begins Phase I PXS4728A Inflammatory Disease Trials; Unilife $6m Abbvie Syringe Deal; US Patent For Cellmid Midkine For Heart Failure; EMA Delays Tissue Therapies Vitrogro Application, Again; Baillie Gifford Increase To 13.4% Of Cochlear; UBS AG Buys, Sells, Borrows, Returns Acrux Shares To 8%; Clinuvel Appoints Willem Blijdorp Director
 
Jan 20, 2015
WANRI: ‘Helicobacter Pylori May Protect Females Against MS’; Nicholas McDonald Takes 9% Of Biotech Capital; Pharmaust’s 1st Cancer Patient Reaches 28 Days, 2 Drop Out; J&J Service Fees To Universal Biosensors Up 89% To $6.45m; Prima Receives $777k Federal R&D Tax Refund; Prima Appoints Stuart Roberts Investor Relations Head; Cryosite Appoints Joseph Saad CEO, Starts On $250k
 
Jan 19, 2015
Invion: INV102 ‘Clinically Relevant’ Interim Smoking Results; Medical Developments: ‘Penthrox European Sales By May’; Medical Australia, Kentucky Dog Cancer Vaccine Partnership; Medlab Begins Probiotics Depression Trial

 

 
Canada Patent For Prima’s MHC Class II Ligands; Rhinomed Receives $570k Federal R&D Tax Refund; Anteo, IMRA Collaborate; Antisense Ethics Approval For 600mg Acromegaly Dose; Compumedics ANZ $1m Export Facility; Phylogica, Roche Genentech Antibiotics Collaboration; EU Ratifies EMA Clinuvel Scenesse Approval; Belgravia, Blackmans Diluted Below 5% In IDT; IM Medical To Be Syncom Data Centre Services; Reproductive Health Appoints Turkey Distributor; Chiesi Backs Pharmaxis Bronchitol Trial, Novaquest Settled; Australian Ethical Takes 13% Of IDT; Nasdaq Sends Prima Price Non-Compliance Notice; Nusep Director Andrew Goodall Takes 39%, Ti Rakau 13%; Neuren Applies For Breakthrough, Orphan For NNZ-2566 For Rett; Imugene Finalizes Her-Vaxx Trial Protocol, Hires WIL Research; Genetic Technologies Raises $258k Of Hoped For $3m; IDT Raises $17m; I’Rom Increases, Diluted To 9% Of IDT; Avexa Plan Raises $796k; Neuren Tells ASX: ‘News, FDA Applications Pushed Price 54%’; John Manusu, Ying Ming Chiu Diluted Below 5% Of Nusep; Admedus Claims ‘Excellent’ Cardiocel Results; Simavita Available In Canada, H1 Revenue $458k; Cynata Raises $2.9m; Immuron, Immune Biologics Partner For Alcohol Toxicity; Nusep Swaps $89k Loan From John Manusu To Mark Gell; Benitec Doses 3rd TT-034 Hepatitis C Patient; Actinogen Tells ASX: ‘Appointing Dr Bill Ketelbey Pushed Price 57%’; Simavita Appoints Michael Brown Chairman; Medivac Director Robert Crossman Resigns; Melbourne Uni: Prof Graeme Clark Shares $US500k Cochlear Prize; Biotron Tells ASX: ‘Trial News, Presentation Pushed Price 26%’; Leanne Ralph Replaces Impedimed Co Sec Stephen Denaro; Sirtex Completes Foxfire Global Trial Recruitment; Federal Government $46m NHMRC-ARC Dementia Fellowships Open; Sienna Antibody Test Deal With Bostwick; Clinical Network Services US Office; Safety Medical Raises $4m To Acquire 3D Medical; Hunter Hall Eases 1% In Alchemia; Unilife Tells ASX: ‘JP Morgan 10% May Have Pushed Price 6.5%’; Healthlinx AGM Backs Sale Of Ovplex For $60k (Plus GST); Australian Patent For Cellmid Hair Growth Midkine; Biomérieux To Terminate LBT Previ Isola Deal; Monash University, Janssen-Cilag Work On Autoimmune Diseases; Monash Licences MIPS Technology To Capsugel; WEHI: ‘MCL-1 Removal Kills Resistant Lymphoma Cells’; David Hastings Replaces Unilife CFO Dennis Pyers; Bone Pleads Schultz To ASX 80% Query; Phosphagenics Appoints Dr Ross Murdoch CEO; Heartware Begins HVAD Less Invasive Study; Optiscan Pleads Schultz To ASX 50% Query; Mesoblast Begins Phase III Back Pain Stem Cell Trial; Immuron Starts US NIH-Funded Trial Of IMM-124E For Ash; Psivida’s Iluvien For DME On Sale In Portugal; MRCF $2m To Solvanix For Garvan Antibody Stabilizer; China Patent For Orthocell Celgro Scaffold; FDA Approves Signostics Signosrt Bladder Scanner; Novogen Compounds ‘Promote Brain Cell Growth’, Note Cancelled
 
2014: BDI-40 Down 4%; ASX200 Up 1%, Big Caps Up 25%; Impedimed Up 457%, Clinuvel Up 397%, Sirtex Up 144%, QRX Down 98%, Alchemia Down 84%
 
Dec 19, 2014
Victoria To Legalize Medical Cannabis; WEHI Discovers How Apoptosis Hides From Immune System; Genera Notes Raises $2m, $500k More By March; Australian Patent For Regeneus Stem Cell Freezing, Thawing; Progen Phase I PG545 Solid Tumor Trial Up To 4th Cohort; Novogen Raises Further $1.75m, Total Raised $7.75m; Anteo Mix&Go Activation Kit For Multiplex Microspheres; Anatara Starts Detach Pig Diarrhoea Trial; Nusep AGM Fight, Remuneration 1st Strike, Most Votes Pass
 
Dec 18, 2014
2014 - The Year In Review; Nanosonics Expands To Former Cochlear Site In Lane Cove; Genetic Technologies: ‘Study Backs 77-SNP Brevagenplus’; IDT Completes 23 US Generic Drugs Acquisition; Proteomics Extends IPO For China Partner Talks; Nusep Receives $822k Federal R&D Tax Refund; FIL Takes 5% Of Impedimed; Immuron To Lose Interim CEO Amos Meltzer; Nusep, ASIC Undertaking; AGM Resolutions Concerns; Virax Prescient Code Change; Actinogen Loses Director Dr Brendan De Kauwe; Clarity Appoints Prof Dale Bailey Adviser
 
Dec 17, 2014
Siemens Launches Universal Biosensors Coagulation Test; Novogen To Raise $4m - Shares Run Up To 27c, Down To 10.5c; Prima Completes $31m Immutep Acquisition; Acorn Reduces To 6% Of Starpharma; Grist, Hogan, Henderson Diluted Below 5% In Imugene; Chairman Paul Hopper Increases, Diluted To 5% Of Imugene; Medical Developments Appoints Philip Powell Director; Uscom Appoints Denise Pater Distribution, Sales Manager
 
Dec 16, 2014
Melbourne Uni Antibody Discovery For All-Dengue Vaccine; FDA Approves Osprey Avert Plus; Novogen: ‘TRXE-009 Active Against Melanoma In Mice’; Europe Upholds Mesoblast Osiris Stem Cell Patent Claims; OBJ Cartilage Treatment Option With P&G; Ausindustry Ok For Oncosil Offshore R&D, Expects $7m; OBJ, P&G Launch SK-II Magnetic Eye Care In Hong Kong, Taiwan; Up To 18% Oppose 375k Psivida Director Options; Benitec Appoints Dr Claudia Kloth Head Of Manufacturing
 
Dec 15, 2014;
Vale WEHI’s Prof Don Metcalf; WEHI Trials Tetralogic’s Birinapant For Hep B Cure; Living Cell Implants Fourth NTCell For Parkinson’s; Long Term Study Backs Clinuvel Scenesse For EPP; Prima Cleared For Pivotal CVac Pancreatic Cancer Trial; Cellmid Raises $1.3m, Japan Midkine Antibody Granted; Kinetic Takes 7% Of Osprey; Actinogen Appoints Pfizer’s Dr Bill Ketelbey CEO; Bluechiip Appoints Michael Ohanessian Director; Avexa Hails Coal Contract To Fund Pivotal ATC For HIV Trial; Prof Don Metcalf (26.2.1929-15.12.2014)
 
Dec 12, 2014
NSW $7m Medical Devices Fund Applications Open; Innate Adds 7 NZ Compassionate Use MIS416 Patients; Prana Pleads Schultz To ASX 29% Query; Genera Takes Capital Raising Halt To Suspension; WEHI’s Jane Visvander Wins Royal Society Of Victoria Medal; Unilife Hires Intel’s Kevin Sellers, Promotes Stephen Allan
 
Dec 11, 2014
Acrux, Eli Lilly Sue Amneal Over Axiron Patents; Prescient (Virax) Takes Aktivate; Paul Hopper On $180k; WEHI’s Prof Guillaume Lessene Wins $50k NFMRI Medal; Cellmid Requests Capital Raising Trading Halt
 
Dec 10, 2014
WEHI Welcomes Research Fund Changes; Biotech Daily, Less So; Benitec: Researchers Find Chemo-Resistance Mechanism; NSW Awards $448k, ATP, California Medical Device Program; Impedimed Underwritten Rights Issue Raises $33m; Cogstate: ‘H2 Will Be Better Than H1, 2015’; Genera Requests Capital Raising Trading Halt
 
Dec 9, 2014
Antisense ATL1103 Acromegaly Trial, ATL1102 MS Access, Partners; CE Mark For Universal Biosensors Siemens Coagulation Test; Gi Dynamics ‘Separates’ CFO Bob Crane, Cuts 10% Staff; Imugene $834k Plan, $500k Placement Take Total To $3.6m; Bone Rejects BN006 For Rheumatoid Arthritis; Alchemia Appoints Consultants For Vast ‘Transaction’; Cochlear Appoints Glen Boreham, Alison Deans Directors
 
Dec 8, 2014
Orthocell, Bonesupport Partner Celgro, Cerament; Phosphagenics Ready For Phase II Topical Oxycodone Patch; Rhinomed Mute Plugs Approved, On-Sale; Healthlinx To Sell Ovplex IP For $60k ‘Plus GST’; Prescient (Virax) Completes Consolidation, Code Change; Goodbye Bioprospect, Hello Medibio; Imugene Releases 300m Escrow Shares; Edinburgh Uni Takes 11% Of Actinogen, Dr Jason Loveridge 6%; Mladen Marusic Takes 5% Of Patrys; Bluechiip M-D Andrew McLellan Starts On $275k
 
Dec 5, 2014
Monash-Led Study Shows Obesity-Leptin-Hypertension Link; Starpharma Condom Delayed Up To 6 Months In Japan; Correction: Living Cell; Prima Upgrades Patient Cell Collection Systems; Mesoblast To Release 2.9m Escrow Shares; Retrophin Reduces To 7% Of (Former) Target Clinuvel; Bank Of America, Merrill Lynch ‘Borrow’ Up To 8% Of Suda; Chairman Martin Rogers Takes 8% Of Actinogen
 
Dec 4, 2014
Meta, Melbourne Uni, GSK, CSL, Hospira Savings Collaboration; Living Cell Plan Raises $1m, Total Raised $4m; Reva Begins Fantom Trial; Viralytics Cavatak, Ipilimumab Clear For Melanoma Trial; Novogen Receives $1.5m Federal R&D Tax Refund; Oceania, Hosken Take 5% Of Atcor; WEHI’s Prof Alan Cowman Wins Thai Malaria Medal
 
Dec 3, 2014
CSL: ‘R&D Spend Expected To Increase To Build Pipeline’; WEHI: Apoptosis, Necroptosis Link To Skin Disease; Biotron Recruits 60-Patient Thai Hep C Trial; Unilife, Unnamed Company 10-Year Eye Injection Agreement; Genetic Technologies Share Plan For Up To $3m; OBJ Cosmetics Dermaportation Licence To NY’s Coty; Cogstate Offloads Axon Sports; Circadian Appoints Opt-302 Ophthalmic Disease Advisors
 
Dec 2, 2014
Sienna At Bio21: ‘From Incubation To Graduation’; Monash Licences Use Of Fenretinide For Dengue To 60P; Netherlands Approves Psivida’s Iluvien; Rhinomed Claims 75% Mute Success For Snoring; Viralytics Receives $2.5m Federal R&D Tax Refund; Nusep Sells Minomic For $378k; Virax Becomes Prescient, Code Change Coming; Scintilla, Techinvest Take 6% Of Agenix; OBJ Requests ‘Product Agreement’ Trading Halt; Medical Australia Appoints COO Darryl Ellis CEO
 
Dec 1, 2014
November BDI-40 Up 3.5%, ASX200 Down 4%, Big Caps Up 4% - Circadian Up 167%, Optiscan Up 83%, Patrys Down 25%; Europe Clears GI Dynamics Endobarrier For Sales; Imugene Her-Vaxx Response In Mice; Pharmaust Treats 1st PPL-1 Canine Cancer Cohort; Virax: All Change For Prescient Therapeutics, Consolidation; Actinogen Takes Corticrine For Alzheimer’s, Board Changes; Calzada Becomes Polynovo, Code Change; Westpac, Associates Take 7% Of Mayne Pharma; Isonea Swaps Ross Blair-Holt For Bruce Mathieson – AGM; Genetic Technologies Loses Prof Ian McKenzie, Dr Mervyn Cass
 
Nov 28, 2014
Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol; Victorian Clinical Genetics Services Non-Invasive Prenatal Test; New Zealand Approves Starpharma Ansell Vivagel Condom; Atcor Raises $1m; Imugene: ‘Linguet For Sale - Speed Preferred’; Analytica Narrowly Wins Remuneration Vote; Advanced Surgical Becomes Allegra Orthopaedics; BVF Partners, Mark Lampert Take 13.6% In Viralytics; Bone Loses Founder Dr Roger New, Phillip Wingate Appointed
 
Nov 27, 2014
Labor Policy: ‘Innovation Key To Jobs, Growth’; NHMRC Backs Alltrials Campaign; Alchemia Fondaparinux Q1 Profit Share Down 18% To $2m; Australian Hospitals Ready For Immuron IMM-124E Nash Trial; Viralytics Up To 21% Oppose Remuneration, Director Options; Invion Receives $790k Federal R&D Tax Refund; Genetic Technologies Takes Last Ironridge Note; Atcor Requests Capital Raising Trading Halt; Medibio (Bioprospect) ‘Material Contract’ Suspension
 
Nov 26, 2014
LBT Prepares For US FDA Pivotal APAS Trial; NRMA Trials Brain Resource Technology; Mesoblast AGM Faces 11% Director Options Dissent; Up To 13% Dissent To Uscom Chairman Dr Rob Phillips Rights; Baker Bros Takes 9% Of Circadian; Safety Medical’s 3D Medical Appoints Max Ghobrial CEO; Tony Hartnell Replaces Advanced Surgical’s John O’Meara
 
Nov 25, 2014
Dimerix Shelves IPO, Prepares To Treat 1st Kidney Patient; Benitec Lodges Appeal To European Patent Decision; Mesoblast Welcomes Japan Stem Cell Act; Phylogica Wins European Phylomer Library Patent; Safety Medical $5m For 3D Medical Imaging Back-Door Listing; BVF Partners, Mark Lampert Take 13% Of Circadian; Packer & Co Increases, Diluted To 9% Of Circadian; Orthocell 36% Oppose Director Matthew Callahan Options; Up To 12% Dissent At Avexa AGM; Investors Underwrite Cynata’s Expiring Options; Bioprospect To Become Medibio, ‘Material Agreement’ Trading Halt; Genetic Technologies Loses CEO Alison Mew; Probiotec To Lose Founding CEO Wayne Stringer
 
Nov 24, 2014
Victoria State Election And State Biotechnology Policies; Genetic Technologies Dr Mervyn Jacobson Awaits Sentence; Acrux: ‘EMA Finds No Cardiac Risk From Testosterone Therapy’; Admedus Takes HPV Vaccine To Phase I Trial; Pharmaust Treats 2nd PPL-1 Cancer Patient; Clinical Genomics Wants Bowel Cancer Test Partners; Regeneus Streamlines, Reduces Costs, Headcount; Analytica Pericoach Available; Jonathan Lim Partly Underwrites Avexa Share Plan To $250k; Oncosil CEO Daniel Kenny Takes Dr Neil Frazer’s 12m Shares; Bank Of America, Merrill Lynch Reduce To 5% Of Suda
 
Nov 21, 2014
Dorsavi Earns First US Revenue; Calzada: ‘Metabolic, AOD9604 For Sale - Speed Preferred’; Up To 29% Of Starpharma Oppose CEO Rights; Up To 16% Dissent Against Invion Dr Mitchell Glass Options; Novogen Identifies Lead Anti-Cancer Candidate As ATM-3507; Medical Australia To Release 18.3m Escrow Shares
 
Nov 20, 2014
Genetic Signatures $15m IPO Opens; Immuron Completes 40-To-1 Consolidation; Nusep AGM For 3.6m Chair Options, Raft Of 28 Resolutions; Hartnell Family, Robinwood Take 35% Of Advanced Surgical; Novogen Loses Chair Iain Ross To ‘Conflict Of Interest’; CFO Daniel Hill Replaces LBT Co Sec Jamie Dreckow
 
Nov 19, 2014
Genetic Technologies Dr Mervyn Jacobson - Gaol Likely; Queensland Welcomes Stafford Fox $2.5m For Brain Institute; Bone Terminates Founder Proxima Deal – Reviewing Options; WEHI Shows Oats To Coeliac Link; Genetic Technologies Sells ‘Heritage’ Business For $2m; CLJE Takes 7% Of Advanced Surgical
 
Nov 18, 2014
Melbourne Uni Team Finds Genetic Cause For Rare Epilepsy; ASX Aggregator ‘Misinterprets’ Antisense Substantial; Ellex: Research Backs 2RT Laser Treatment For AMD; Ireland Becomes 13th Country To Approve Psivida’s Iluvien ; Pharmaust Joint PPL-1 IP With Unnamed Japanese Company; Prana PBT2 Huntington’s Results In Lancet, FDA Meeting; Pfizer Sues Mayne Over Dofetilide Anti-Arrhythmic Drug; Up To 16% Dissent Against Circadian Director Stock Plan; Up To 31% Oppose Living Cell Placement; Up To 23% Of Unilife Oppose Director Shares
 
Nov 17, 2014
Invion On-Track With 4 Programs; Women In Science Parkville Precinct For Gender Balance; Cellmid Licences Midkine To Zoetis For Pets; Starpharma Pleads Super-Schultz To ASX 25% Fall Query; Up To 17.5% Oppose 3m Calzada Director Options; Bioprospect Hires Michael Player For Depression Heart Test; Generation, Associates Below 5% Of Cochlear; Circadian Companies Increase, Diluted To 9% In Antisense
 
Nov 14, 2014
Proteomics IPO To Raise Up To $6m; GSK Invests $31m In Boronia Blow-Fill-Seal Manufacturing; ACRF Grants $9m To Four Institutions; UK Approves Viralytics Phase I Cavatak Bladder Cancer Trial; Carl Zeiss Pays Optiscan $258k For Endo-Microscope Sheath; Regeneus Australian Patent For Fat Stem Cells For Acne; Flextronics To Expand Unilife Production; Up To 15% Oppose Immuron Placement Capacity, Again; Up To 20% Of Prima Oppose 24m Director ‘Performance Rights’; NZ Pie Funds Take 7% Of Medical Australia; Simavita Appoints Craig Holland Director
 
Nov 13, 2014
Benitec Doses 2nd TT-034 Hep C Patient; 4D, Touchlight Deals; Impedimed $33m Underwritten 3-For-13 Rights Issue; UK Nice Sends Avita Recell Back To Large Area Wound XP Future; Osprey Avert Sales Underway, Trials On Track; Belgium Approves Psivida’s Iluvien For DME; Mesoblast Phase II Back Pain Data Presented; China Allows Starpharma Dendrimer Agro-Chemical Patent; Imugene Places $2.25m, Share Plan For More; 37% Of Biota Oppose Directors Russell Plum, Dr Jim Fox, Pay; Analytica Pericoach Launch Delay; Calzada Appoints Paul Brennan CEO; Lang Walker Takes 16% Of Medical Australia, NZ Windfall 14%; Correction: Agenix 
 
Nov 12, 2014
Neuren: ‘NNZ-2566 Phase II Safety, Efficacy For Rett Syndrome’; WEHI, Peter Mac, Garvan Block Neochromosomes; Melbourne Uni Shows Genetic Resistance To Typhoid; Admedus Regen Investors Legal Action; Novogen Raises $1.8m Of Hoped For $3m-$20m; Nasdaq Letter; Bionomics Survives 21.5% Remuneration Dissent; Up To 45% Of Patrys Oppose Chairman John Read; Patrys Appoints Dr James Campbell Director; Sienna Appoints Tony Di Pietro CFO; Agenix Loses Director Anthony Lee
 
Nov 11, 2014
Bionomics Takes-Back BNC210 From Ironwood; Rhinomed Turbine Wins CE Mark; Innate Doses 4 MS Patients, Appoints Dr Claudia Mansell; Avita Receives $1.4m Federal R&D Tax Refund; Benitec Pleads Schultz To ASX 40% Query, ASX Misses 35%; Up To 9% Oppose Anteo Placement Capacity, Options; Impedimed Requests Capital Raising Trading Halt; Alchemia’s Dr Tracie Ramsdale Replaces CEO Thomas Liquard; Daniel Kenny To Replace Oncosil CEO Dr Neil Frazer
 
Nov 10, 2014
Pharmaust Cleared To Restart Adelaide PPL-1 Cancer Trial; Invion Takes $17m Lind Equity Draw-Down Facility; Medical Australia Raises $2m; Correction: Biotech Daily Editorial; Bluechiip Cryo-Storage Agreement With Italy’s Siad Group; Neuren Requests NNZ-2566 Rett Trial Results Trading Halt; MC Management Takes 6% Of Admedus; Up To 15% Dissent At Alchemia AGM; Cynata To Release 10m ASX Escrow Shares; All Change At Regeneus
 
Nov 7, 2014
Biotech Daily Ninth Birthday Editorial; Gaol For Phosphagenics Three - Ogru, Gianello, Jiang; Novogen: ‘Cantrixil Effective For Ovarian Cancer In Mice’; Viralytics Cavatak, Checkpoint Inhibitor Efficacy In Mice; 6 Months Delay For Patrys PAT-SM6 Combination Cancer Trial; Up To 17% Of Nanosonics Oppose Director Dr David Fisher; Nasdaq: Genetic Technologies 45 Days For $US2.5m Equity Plan
 
Nov 6, 2014
Prima CVac 2nd Remission Overall Survival; Orthocell Claims To Grow Human Tendons; Miele Expands Nanosonics Trophon European Distribution; European Patents For Actinogen, Corticrine 11 Beta-HSD1; IP Australia Accepts Cynata Cymerus Manufacturing Patent; Circadian Completes $3.4m Rights Issue; Antisense Plan Raises $267k Of Hoped For $1.5m, $2m Total; Correction: Imugene; Resonance, UWA Win 2014 WA Innovator Gong For Hepafat-Scan; Prof David Craik Wins $80k GSK Award For Cyclotides
 
Nov 5, 2014
Genetic Technologies Dr Mervyn Jacobson ‘Guilty’; Phosphagenics $6m Theft Sentencing Adjourned; Federal Government: $354m For 941 ARC Grants; Imugene Placement For $2.25m, Share Plan, Her-Vaxx Trial; Bioprospect, UNSW Heart Rate For Depression Diagnosis Trial; Biotron Rights Issue Raises $4m; Phylogica Expects $1.9m Federal R&D Tax Refund; Veritas Takes 6.6% Of Cochlear; Dorsavi Appoints Dave Wildermuth Chief Marketing Officer
 
Nov 4, 2014
Nusep, Prime Separate; Partners With Minitüb For Animal IVF; EMA Delays Tissue Therapies Vitrogro For Christmas Holidays; Reproductive Health Buys Back Unmarketable Parcels; Hunter Hall Takes More Profit To 10% In Sirtex; Kathryn Andrews, Phillip Hains Replace Prana Richard Revelins
 
Nov 3, 2014
October BDI-40 Down 6%, ASX200 Up 4%, Big Caps Up 6% - Medical Developments Up 23%, Alchemia Down 86%, Benitec Down 43%; Federal Government Commercialization Advice, $1m Grants; Impedimed Jumps 94% On $129 L-Dex Reimbursement; Singapore Approves Early Access For Admedus Cardiocel; IDT To Buy 23 Generic Drugs, $15m Placement, $3m Share Plan; Cytomatrix, Heiq J-V For 3-D Stem Cells; Living Cell Completes NTCell Parkinson’s Recruitment; Benitec Licences ddRNAi To Circuit Therapeutics For Pain; Novogen ASX Placement Trading Halt; Imugene Requests Capital Raising Trading Halt; Tissue Therapies Appoints Timothy Hughes Director; Alchemia Drops 3m Director Options, Pay Rise Resolutions
 
Oct 31, 2014
Victoria Backs Brandon MRCF $200m Biotech Translation Fund; WEHI Apoptosis Research Leads To New Disease Targets; Starpharma Share Plan $3.5m Takes Total Raised To $21.5m; Analytica Rights Raise $2.56m Taking Total To $3.4m; Advanced Surgical Wins $1.6m NSW Medical Device Fund Grant; Heartware Q3 Revenue Up 25% To $78m; Bluechiip Appoints Glory Biotech South Korea Distributor; Hockings Take 25.5% Of Phylogica
 
Oct 30, 2014
J&J Opens Asia Pacific Innovation Centres For Collaboration; Pharmaxis Starts 3rd Phase III Bronchitol Cystic Fibrosis Trial; German Eye Advocacy Group Backs Ellex Canaloplasty; Analytica Ready For 100-Patient Pericoach Incontinence Trial; Mesoblast To Release 70k Escrow Shares; Virax 40m M-D Options, Prescient Name Change AGM; Isonea AGM For 11m Director Options; Bioxyne AGM For 2.6m Director Options; IDT Takes Acquisition, Capital Raising Halt To Suspension; Advanced Surgical Requests ‘Significant Funding’ Trading Halt; Julie Phillips Elected Ausbiotech Chair, New Directors; Resonance CSO Prof Timothy St Pierre Resigns As Director
 
Oct 29, 2014
Genetic Technologies Dr Mervyn Jacobson Awaits Verdict; Melbourne Uni Blood Test For Alzheimer’s Disease; Prof Sam Berkovic, Prof Ingrid Scheffer Share $300k PM Prize; Starpharma $4.2m R&D Tax Refund, Ansell Condoms In Shops; Rhinomed Plan For $1.6m Raises $586k, Total Raised $5m; ASIC: ‘Mariposa Fined $4k On Accounts’; Clinical Genomics Appoints Biochain China Distributor; Wales NHS Guidelines Positive For Nanosonics Trophon; Ausbiotech Calls For Investment Conference Registration; Patrys CFO Roger McPherson Acting CEO; Ausbiotech: Dr Chris Nave, Uscom, Atomo Win J&J Awards
 
Oct 28, 2014
Monash Becomes Pfizer’s 1st Non-US Innovation Centre; Psivida Receives $28m Iluvien Milestone; Up To 24% Of Sirtex Oppose 60% Directors Pool Increase; GI Dynamics Applies To Trade On Nasdaq; Baillieu Holst Re-Initiates Bioprospect Research Coverage; OBJ AGM For 45m Directors’ Performance Rights; Probiotec 2nd Strike Board Spill AGM; IDT Requests Acquisition, Capital Raising Halt
 
 
Oct 24, 2014
FDA Clears Antisense Path For ATL1102 For Multiple Sclerosis; Resmed Q1 Revenue Up 6% To $434m, Profit Up 3%; Acrux Axiron Q3 Sales Down 11% To $41m; Brandon’s MRCF $1m To Auspherix For Anti-Bacterials; Advanced Surgical Raises $1m, Name Change AGM; Analytica Receives $989k Federal R&D Tax Refund; Clinuvel Requests European Regulatory Trading Halt; Mesoblast AGM For 240k, $385k Director Options; Viralytics AGM For 1.2m Director Options; Suda AGM For 2.75m Joseph Ohayon ‘Performance Rights’; Sietsma Takes 9% Of Phylogica; Pharmaust Re-Appoints, Re-Elects Dr Wayne Best Director; Solagran Appoints Dr Ian Nisbet Director
 
Oct 23, 2014
Bio-Melbourne: ‘Nimble Network To Fight Infectious Disease’; Calzada Files For Novosorb FDA Approval, BARDA Funding; GI Dynamics 10-For-1 US Consolidation EGM; Dr John Chiplin Replaces Cynata Director Howard Digby; Imugene Director Dr Nick Ede Steps Down To Executive; Acuvax 6-Day Director Nigel Lee Steps Down To Advisor; Alchemia’s Prof Tracey Brown Wins Telstra Gong
 
Oct 22, 2014
Genetic Signatures Up To $15m For Molecular Diagnostics; Novogen: ‘TRX-E-009-1 Kills Paediatric Cancer In-Vitro’; Pharmaust Treats 2 Dogs In Ppl-1 Canine Cancer Trial; BPH Energy Has Less Than One Quarter Cash; Orthocell AGM For 2.1m Director Options; Phylogica AGM For 6.5m CEO Options, Directors’ Fees
 
Oct 21, 2014
Hatchtech Phase II Trial Kills 100% Of Head Lice Eggs; Pharmaust’s First Cancer Patient Dies, PPL-1 Trial Delay; Clinical Genomics, CSIRO Bowel Cancer Blood Test Agreement; Circadian 1.5m CEO Dr Megan Baldwin Options, Plans AGM; Bluechiip Loses 2nd CEO Dr Jason Chaffey, Japan Contract; Dr Tracey Mynott, Myeng Take 15% Of Anatara; Ausbiotech’s Dr Anna Lavelle Elected ATSE Fellowship 
 
Oct 20, 2014
Antisense ‘Higher, Longer ATL1103 Dose For Acromegaly’; Starpharma Dep-Docetaxel Longer Duration, Fewer Spikes; Sirtex Completes ‘Toxicity-Free’ Kidney Cancer Dosing; Canada Approves Admedus Cardiocel; LBT Wins $250k South Australia Grant For Woundvue; Avita 2nd Strike Board Spill AGM; Dr Mel Bridges, Parma Take 5% Of Anatara
 
Oct 17, 2014
Virax To Buy TCN-P Cancer Drug For $343k, $2.3m Shares; Federal Government: $580m NHMRC Grants; Calzada Name-Change To Polynovo, 3m Director Options AGM; Actinogen Cortricine Acquisition AGM; Hunter Hall Takes More Profit To 11% In Sirtex; Nusep Appoints Mark Gell Director; Acuvax Appoints Nigel Lee For Activistic Funds Collection
 
Oct 16, 2014
Anatara Lists To Develop Pineapple Stems For Diarrhoea; Federal Government $17.9m For CSIRO-Monash Group; Nanosonics Q1 Revenue Up 19% To $6m, Cash Flow Positive; Universal Biosensors Record Q1 Strip Fees Of $1.6m; Novogen To Raise $10m Through ASX Bookbuild; Dorsavi OH&S Service Wins New Contracts; Starpharma 1.5m CEO Rights, 22% Directors Fees AGM
 
Oct 15, 2014
Federal Action Plan: TGA To Accept ‘Trusted’ Regulation; Comment: Cochlear, Medicines Australia, Biotech Daily - Ausbiotech Welcomes Tax, Regulatory Changes; Biotron 2-For-9 Rights Issue For $4m; Immuron Ready For Two Phase II IMM-124E Fatty Liver Trials; CSL 11% Oppose CEO Paul Perreault $3m ‘Performance’ Stock; Auspherix, Domainex Work On Antibiotic-Resistant Infections; Antisense Receives $1.14m Federal R&D Tax Refund; Virax Requests ‘Material Transaction’ Trading Halt; Hunter Hall Takes 8% Of GI Dynamics; UBS AG ‘Returns’ 2.6m Acrux Shares To 8%
 
Oct 14, 2014
Bionomics: ‘Pre-Clinical Bnc105 Combination Tumor Efficacy’; Reproductive’s Embryocellect IVF Test Ready For Launch; Australian Patent For Prima, Immutep LAG-3 Technology; Admedus 180% Directors Fees AGM; Immuron 40-To-1 Consolidation AGM; Federal Government ‘Action Plan For Australia's Future’; Bone Aggregates Unmarketable Parcel Shares; Analytica Around Australia Pericoach Tour
 
Oct 13, 2014
Dr Richard Treagus Revives Biotech Capital For Biotech; Medical Australia 1-For-10 Rights Issue For $6m; Biotron Capital Raising Trading Halt; Analytica, Sportsmed Work On Pelvic Floor, Data Collection; UBS AG Takes 9.6% Of Acrux; AMP Reduces To 5% In Acrux; Prima AGM For 24m Director Rights, Placement, Bergen Shares
 
Oct 10, 2014
Biotron Jumps 90% On BIT225 ‘Undetectable’ Hepatitis C Levels; Alchemia Phase III Ha-Irinotecan Cancer Trial Locked; Living Cell Partner Otsuka Lends Joint Venture Up To $38m; Admedus Appoints John Seaberg, Wayne Paterson Directors
 
Oct 9, 2014
Ex-Phosphagenics Dr Esra Ogru ‘Guilty’, ‘Why?’, Expect Gaol; Sirtex Completes Sirflox, Results In June 2015; Regeneus Rebuts ABC-TV 7.30 Stem Cells Report; J&J Pays $US1.75b For D3 Investment Alios; Analytica Wins CE Mark For Pericoach; Victoria Launches Heart Hospital, Medical Technology, Vision; Australian Patent For OBJ’s Magnetic Cleaning Technology; Dr Larry Marshall Replaces CSIRO CEO Dr Megan Clark
 
Oct 8, 2014
CSL $210m Broadmeadows Expansion For $683m PA Output; Living Cell Placement Raises $3m, Share Plan; Acuvax Completes Activistic Acquisition; US Patent For Imugene’s Her-Vaxx; Clarification: Regeneus; Nusep Banks $1.2m Andrew Goodall Note, Loan, Prime Debt; Rhinomed Appoints Two South-East Asia Distributors; Benitec Appoints Georgina Kilfoil For TT-034 Hep C Enrolment
 
Oct 7, 2014
WEHI Molecule Prevents Inflammatory Cell Death; Phosphagenics: ‘Phase II Acne Trial Endpoint Not Significant’; Regeneus Falls 57%, Requests ABC-TV 7.30 Report Trading Halt; GI Dynamics EU Endobarrier Shipments Halted, Systems Review; Atcor Sphygmocor For US Obesity Cholesterol Trial; Unilife Signs Sanofi 15-Year Wearable Injector Deal; Anteo AGM For 17m Director Options; Tissue Therapies 9% Oppose Placement; Progen 2nd Strike Board Spill AGM
 
Oct 6, 2014
$9.5m Circadian In $17.4m Placement, Rights Issue; GI Dynamics EU Endobarrier Shipments Halted, Systems Review; Unilife Draws Down Early Orbimed $11.5m; Acorn Reduces, Diluted To 8% Of Starpharma; Safety Medical Proceeds With Backdoor 3-D Printing; Bioprospect $3.5m Commitments For Heart-Mental Illness Test
 
Oct 3, 2014
WEHI, France’s Servier Collaborate On Blood Cancers; Analytica $850k Placement, $3.17m Rights Issue; Correction: Prima; Victoria Sends 23 Organizations To Chicago Advamed Meeting; Unilife AGM For 4m CEO Alan Shortall Shares; Schroder, Associates Reduce To 5% Of Cochlear
 
Oct 2, 2014
Bergen Helps Prima Acquire Immutep For $32m Cash, Scrip; T-Cell Response Takes Admedus HSV-2 Vaccine To Phase II; Ansell Ready To Market Starpharma Vivagel Condom; Reva Says Fantom Stent Will Be Superior To Competitors; Genera, Beckman Coulter Agreement, Richard Hannebery CEO; Bio-Melbourne Devices, Diagnostics Partnering Forum; Narhex From HIV, Coal, Gold, Diamonds To Respiratory ‘Apps’; Biota’s Dr Joseph Patti Starts On $571k, Russell Plumb On $286k; Pharmaust PPL-1 Dog Cancer Trial Begins; Healthlinx Acquires Manalto Social Media Business; Circadian Requests ‘Funding Event’ Trading Halt; Bioprospect Requests ‘Capital Raising’ Trading Halt
 
Oct 1, 2014
September BDI-40 Down 4%, ASX200 Down 6%, Big Caps Down 0.75% - Living Cell Up 32%, Clinuvel Up 31%, Biotron Down 26%; European Guidelines Recommend Sirtex Sir-Spheres; WEHI: ‘JAK Inhibitors Can Treat 80% Of Bowel Cancers’; Mesoblast Partner JCR Files For JR-031 GVHD Japan Approval; Novogen Takes FDA Advice On Cantrixil For Ovarian Cancer; Genetic Technologies Launches Brevagenplus In The US; Allan Gray Takes 16% Of Starpharma; Analytica Takes Capital Raising Trading Halt To Suspension
 
Sep 30, 2014
Ascend $11m IPO For Skin, Breast Cancer; EMA Finds More Tissue Therapies Vitrogro Questions; SA Uni, Sementis Work On Virus, Allergy, Cancer Vaccines; Proctor & Gamble Launch 1st OBJ Magnetic Cosmetic; Viralytics Cavatak Combination Mouse Efficacy; Correction: Bionomics; Patrys Anti-Cancer Compound PAT-LM1 Australian Patent; Up To 27% Oppose Genetic Technologies Ironridge Notes; MC Management Takes 5% Of Admedus; Bio-Melbourne Breakfasts On Infection Readiness
 
Sep 29, 2014
FDA Psivida Iluvien Approval Triggers $29m Payment; Bionomics BNC105 Combination Cancer Biomarkers ; Viralytics Claims Cavatak Phase II Melanoma Efficacy; Advanced Surgical 23-For-50 Rights Issue For $1m; Dimerix Ready For Phase II DMX200 Kidney Disease Trial; Living Cell, Auckland Uni Neuro-Degeneration Collaboration; Bluechiip Plan Raises $763k, Takes Total To $1.863m; MR Marketing Optiscan-Based Cell-Live Imaging; Calzada, TGA Rule Change Impact On AOD9604; IM Medical Delay In Becoming Data Centre; Biota’s Patti, Plum, Fox Shuffle Jobs, Richard Hill Retires; Bone’s Oral Parathyroid Hormone Not Found In Blood Tests; Analytica Requests Capital Raising Trading Halt; OBJ Requests ‘Product Launch’ Trading Halt
 
Sep 26, 2014
Clinuvel Expects European Scenesse Result Next Month; Reva Notes, Options To Raise $55m; Psivida Sales Of Iluvien For DME In France In Doubt; Antisense: ‘Patersons Underwrites $1m Of $1.5m Plan’ ; Rhinomed Appoints Interfusion Turbine Colombia Distributor; QRX 2nd  Strike Board Spill AGM; Sirtex AGM For 73k, $1.6m CEO Rights, Directors Pay Up 60%
 
Sep 25, 2014
Antisense Places $1m, Plan For $1.5m More; Regeneus Receives $3.7m Federal R&D Tax Refund; Jason Peterson, Professional Payment Take 14% Of Sun Bio; Deloitte, Bio-Pharmaceuticals Australia Roadshow
 
Sep 24, 2014
Neuren Expects November Rett Syndrome Results; Sirtex Declares 14c Fully-Franked Final Dividend; Invion, 3m Complete Inhaled INV102 Feasibility Studies; Ibsen, Narula Take 7% Of Optiscan; Patrys To Lose M-D Dr Marie Roskrow; Greg Tunny Replaces Isonea CEO Stephen Tunnell, Update; Genetic Tech: David Carter, Dr Lindsay Wakefield Directors; Sharon Papworth Replaces Acrux CFO, Co Sec Tony Di Pietro
 
Bionomics Acquires Distressed Prestwick For $391k; Invion: ‘Interim Data Shows INV102 Safe For Asthma’; Optiscan Raises $750k; Antisense Requests Capital Raising Trading Halt; US Patent For Circadian, Vegenics VEGFR-3 Trap Molecules; Living Cell Appoints Three Professors For NTCell Advice; Virax Appoints Prof Douglas Joshua To Advisory Board; Regeneus Opens Singapore Clinic, Appoints Dr Patrick Goh 
 
Sep 22, 2014
Starpharma Placement Raises $18m, Share Plan For $5m More; Primary Pays $2m For Genetic Technologies Heritage Business; Benitec, CSIRO Appeal Euro Decision On Graham Patent; Clinuvel Presents Scenesse To Europe’s CHMP Tomorrow; Progen Progresses To 3rd PG545 Solid Tumor Cohort; Advanced Surgical To Distribute Small Bones Products; Bluechiip Claims More Sales, Micronic Project On-Track; Optiscan Requests Fundraising Trading Halt
 
Sep 19, 2014
LBT Starts Automated Plate Assessment Clinical Trials; Clinuvel Singapore J-V For Paediatric Scenesse, CUV9900
 
Sep 18, 2014
Acrux Falls As Much As 31% On FDA Testosterone Meeting; Osprey Launches Avert Plus ‘Smart’ Syringe Monitor System; Cynata Licences Stem Cells From Cellular Dynamics; GI Dynamics: ‘Endobarrier Reduces Heart Risk’; Starpharma Requests Capital Raising Trading Halt; Suda Wins ISO 9001:2008 Certification; Rhinomed Appoints Trisports Japan Turbine Distributor; Bioxyne Appoints Ian Brown Probiotics Consultant ; Mark Peatey Replaces ITL Director Sanjay Sehgal
 
WEHI Trials Denosumab For BRCA Mutation Breast Cancer; Federal Minister Ian Macfarlane Backs Eye Research, Hospira; Universal Biosensors Blood Coagulation Test Delayed; Nanosonics Trophon ‘3-Fold More Effective Than Wipes’; Healthlinx Appoints Timothy Chapman Director; Medicines Australia Appoints Liberal Staffer Tim James CEO; Asia Union Increases, Diluted To 8% Of Tissue Therapies
 
David Miles Leads Review Of Cooperative Research Centres; W.H.O. Funds Vaxxas Polio Nanopatch Trials; FDA Agrees Faster Avita Recell Burns Trial; FDA To Respond To Antisense ATL1102 For MS; Euro Patent; Australian Patent For Orthocell Ortho-ATI; Medline Wins $277k Lorien Contract For Simavita System; Biota: ‘Loss Of Barda Contract Delays Annual Report’; Clinuvel Pleads Retrophin Bid To ASX 31.7% Query; Mining Invest, Elias Leo Khouri Below 5% Of Bioprospect
 
Genetic Technologies $2m Notes, Restructure, Name Change; Compumedics, Beijing Bestmed Sign 3-Year $5.6m Contract; Imugene Her-Vaxx Ready For Clinical Trial Production; Resonance $650k Shortfall Takes Total Raised To $1.9m; Bernard Stang Lightens To 9% Of Nanosonics; Cogstate Loses Rodolfo Chapa; Quixote Shares To Dolby, Myer; Avita Requests ‘Regulatory Update’ Trading Halt
 
WEHI Discovers Cartilage Role In Rheumatoid Arthritis; Prime Minister Abbott Opens Doherty Institute; October For Alchemia Phase III HA-irinotecan Cancer Results; Retrophin Takes 8% Of Target Clinuvel In Tiny Trades; CSL $3m CEO Options, Rights; 20% Directors Fees Hike AGM; Cochlear $1.6m Dr Chris Roberts Stock, $500k Prof Byrne AGM; CB Co, Curran Super Fund Reduces To 13% Of Atcor; Simavita Loses Chairman Peter Cook; Actinogen Appoints Vincent Ruffles Clinical Research Head
 
Ausbiotech Gold Coast Octoberfest Registration Opens; Medical Developments Appoints Galen UK Distributor; Cogstate Recruitment Contract For Alzheimer’s Trial; Regeneus Launches KVax Dog Cancer Vaccine; Sun Adds Asthma Genetics To Drug Testing; Bluechiip Ex-M-D, Brett Schwarz Below 5%; GI Dynamics Appoints Daniel Moore Director; Michael Graham Replaces Nusep Director Prakash Patel; Psivida Elects Dr James Barry Director; Genetic Technologies Takes Fund Raising Halt To Suspension
 
Burnet Chair Alastair Lucas Stands Down; Victoria Opens Applications For Four $150k Fellowships; Hunter Hall Takes 10% Of Alchemia; BVF Partners, Mark Lampert Take 12.5% In Viralytics; Mining Invest, Elias Leo Khouri Down To 9% Of Bioprospect; Calzada Loses Director Dr Roger Aston To Oncosil
 
Virax To Reactivate GGTI-2418 FDA IND For Breast Cancer; Avexa Manufactures Special Access ATC For HIV; Regeneus Plan Raises $3m, Takes Total To $6m; Pharmaust Begins PPL-1 Dog Cancer Trial; Isonea Pleads Schultz To 31% Fall Query, Cashed-Up; Genetic Technologies Requests Capital Raising Trading Halt; Ron Dewhurst, Kroy Wen (Back) Take 6% Of Rhinomed; Oncosil Changes: Roger Aston, Neil Frazer, Martin Rogers
 
Genetic Technologies Dr Mervyn Jacobson Pleads ‘Not Guilty’; Olivia Newton-John Institute Opens, Victoria Grants $4.5m; US Army Approves Neuren Phase II Concussion Trial; Invion 30mg INV103 Ineffective For Mild Lupus, Stronger Dose; Bluechiip Placement Raises $1.1m, Share Plan For More; Pharmaxis: ‘Bronchitol Benefit For High Risk Bronchiectasis’; Imugene Appoints Vienna University For Her-Vaxx Pre-Clinical; Viralytics Appoints Peter Turvey, Malcolm McColl Directors - Replacing Dr Phillip Altman And Peter Molloy; Impedimed Appoints Dr Frank Vicini Chief Medical Officer; Bioprospect Heart Rate Depression Test, Dr James Campbell 
 
Federal Court Backs Myriad, Genetic Technologies BRCA Case; FDA Orphan Status For Prana PBT2 For Huntington’s Disease; Correction: Reproductive Health; Bionomics Receives $7.5m Federal R&D Tax Refund; Westpac, Associates Take 6% Of Mayne Pharma
 
Sep 4, 2014
Genera HPV, Respiratory Tests To TGA; STI Tests, More To Come; Reproductive Health: ‘Sales This Year, Profit In 2017’; Ascend Plans Basal Cell, Breast Cancer Trials For 2015; Tissue Therapies Pleads Schultz To ASX 21% Query; Sweden Approves Psivida’s Iluvien For DME; Uscom: ‘Four Studies Support Broad Monitor Applications’; Resonance Joins US Liver Disease Forum; Constables Below 5% Of Antisense; Bioprospect Requests ‘Restructure’ Trading Halt 
 
Sep 3, 2014
Antisense ATL1103 Phase II ‘Success’ For Acromegaly; WEHI Shows Antibiotic Emetine Blocks Malaria Proteins; Impedimed Jumps 49% On CPT Category 1 Reimbursement Code; Cynata Begins Euro Process, Listed Option Trading; Orthocell To File For Japan, EU Approval In 2015; Atcor Wins French Trial For Sphygmocor; Nasdaq Non-Compliance Letter For Genetic Technologies 
 
Sep 2, 2014
Hatchtech Trials Prove One-Shot Head Lice, Egg Treatment; ARC $546k Grant For Phylogica, UQ Phylomer Tumor Project; Nanosonics Pleads Revenue, Meetings To ASX 11% Query; Immuron Reduces Hadasit Royalty ; CEO Harry Rosen Diluted To 5% Of Phosphagenics

 

 
Sep 1, 2014
August BDI-40 Up 11%, ASX200 Down 0.1%, Big Caps Up 9% - Bionomics Up 31%, Tissue Therapies Up 28%, Compumedics Down 25%; Rhinomed Placement Raises $3.4m, Share Plan For $1.6m More; Universal Biosensors Receives $8m Federal R&D Tax Refund; Suda Revenue Up 115% To $9m, Loss Up 23% To $2m; Cyclopharm H1 Revenue Up 37% To $6.6m, Loss To $923k Profit; Advanced Surgical Revenue Up 11% To $8m, Loss Down 89%; Cellmid Revenue Up 267% To $3m, Loss Down 3.5% To $1.5m; Immuron Revenue Up 597% To $1m, Loss Down 28% To $2.5m; Nusep Revenue Down 7% To $851k, Loss Up 109% To $4m; Genera Revenue Up 208% To $207k, Loss Up 9% To $2.5m; Perpetual Sells 15m Resmed Shares, Down To 5%; Antisense Requests ATL1103 Acromegaly Results Trading Halt; Mesoblast Appoints Charlie Harrison Co Sec; Kevin Baum Replaces Acuvax Director Alex Bajada
 
Aug 29, 2014
Ex-Phosphagenics CEO Dr Esra Ogru Bail Extended; Benitec TT034 Hepatitis C Trial: ‘More Delays, More Trial Sites’; Ellex Revenue Up 27% To $54m, Loss To Profit Of $788k; Atcor Revenue Down 44% To $5m, Profit Turns To $2m Loss; Alchemia Fondaparinux Sales Up 2% To $10m; Alchemia Revenue Down 35% To $16m, Loss Down 45% To $7m; Genetic Technologies Revenue Down 34% To $5m, Loss Up 9%; Medical Australia Revenue Up 30% To $12m, Loss To $105k Profit; LBT Revenue Down 11% To $4m, Profit Down 38% To $331k; Avita Sales Down, Revenue Down 19% To $3m, Loss Down To $5m; Phylogica Revenue Up 5% To $826k, Loss Down 5% To $3m; Circadian Revenue Down 24% To $878k, Loss Down 16% To $4m; Dorsavi Revenue Up 42% To $2.6m, Loss Up 14% To $2.5m; Unilife Revenue Up 436% To $16m, Loss Down 8% To $62m; Michael Dale To Replace GI Dynamics CEO Stuart Randle
 
Aug 28, 2014
Victoria To Allow Medical Cannabis Trials; Federal Government, ARC Open Monash Bio-Nano Centre; Japan Allows Phylogica Peptide Phylomer Patent; Pharmaxis Anti-Inflammatory PXS4728A ‘In The Clinic In 2015’; Pharmaxis Revenue Up 56% To $5m, Loss Up 19% To $52m; Admedus Revenue Up 7% To $8m, Loss Up 239% To $8m; Resonance Revenue Up 35% To $2m, Loss Down 65% To $72k; Pharmaust Revenue Up 17% To $2m, Loss Up 156% To $1.3m; Cryosite Revenue Up 4% To $26m, Profit Down 18% To $2m; Bluechiip Pleads Schultz To ASX 191% Query; Unilife Pleads Schultz To ASX 20% Query; Rhinomed Requests Capital Raising Trading Halt; LBT Appoints Daniel Hill CFO
 
Aug 27, 2014
Actinogen To Acquire Scotland’s Corticrine For Alzheimer’s; AFL Approves Regeneus Hiqcell For Injuries; Imugene Appoints Ex-Alchemia’s Charles Walker CEO; Unnamed Company To Study Anteo Mix&Go For Diagnostic; Optiscan Completes Microscope Sterility Sheath Tests; Och-Ziff Takes 19.7% Of Brain Resource; Compumedics Revenue Up 14% To $31m, Loss To $909k Profit; Mayne Pharma Revenue Up 72% To $143m, Loss To $21m Profit; Impedimed Revenue Up 22% To $3.6m, Loss Down 6% To $8m; Rhinomed 1st Sales, Revenue Down 3% To $291k, Loss Down 82%; Phosphagenics H1 Revenue Down 23% To $712k, Loss Down 54%; Pharmaust Releases 330m Escrow Shares; Medical Australia Chairman Gary Lewis To Retire
 
Aug 26, 2014
St Vincent’s Isolate Diabetes-Causing Immune Cells; Actinogen Requests Acquisition, Capital Raising Halt; Mesoblast Revenue Down 10% To $26m, Loss Up 31% To $81m; Anteo Revenue Up 43% To $2.6m, Loss Up 14% To $2.5m; Progen Revenue Up 64% To $6m, Loss Down 14% To $2m; US Court Rules For Genetic Technologies Against GSK ; ANSTO Settles With Cyclopharm For $2.65m; Harding Loevner Below 5% In Cochlear; IM Medical Drops White Data For ADX; Reproductive Health Appoints Sue MacLeman Director; Mayne Appoints Prof Bruce Robinson Director
 
Aug 25, 2014
Orthocell: ‘Ortho-ATI Durability For Tennis Elbow’; Ming Hao Zheng, Ying Fan Take 9%, Jia Xun Xu 6% Of Orthocell; Acuvax Raises $800k For Activistic Collection, Back To ASX; TGA Lists Uscom BP+ On Register; Patrys Plans Combination PAT-SM6 Multiple Myeloma Trial ; Anteo Mix&Go Patent, Provisional Patent Applications; Mayne Appoints Dr Ilana Stancovski CSO; Regeneus Revenue Up 18% To $2m, Loss Up 45% To $7.5m; Paul Hodgkinson Replaces Mesoblast CFO Jenni Pilcher; Alchemia Appoints Jenni Pilcher CFO; LBT Appoints Dr Patti Doherty For US Trials
 
Aug 22, 2014
Ex-Phosphagenics Dr Esra Ogru Pleads Guilty To Deception; Brain Revenue Down 26% To $3m, Loss Up 12% To $2m; Correction: Nanosonics - Revenue Up 46% To $26m, Loss Down 55% To $3m; Hunter Hall Takes Profit, Reduces To 12% In Sirtex; Suda Hopes For Artimist Partner, Who Inclusion; Probiotec Revenue Up 1% To $68m, Profit Up 51% To $1m; Medical Developments Signs PSUK As Distributor; FDA Clears Isonea Sonosentry1 As O-T-C Detector, Patent; IM Medical Requests Acquisition, Capital Raising Halt
 
 
Aug 20, 2014
CDPP Details Ogru, Gianello, Jiang Phosphagenics Invoices; Sirtex Revenue Up 31% To $131m, Profit Up 31% To $24m; South Africa Approval For Acrux Estramist For Menopause; IDT Revenue Flat At $13m, Loss Up 24% To $7m; Cogstate Revenue Down 1.2% To $12m, Loss Up 99% To $4m; Brain Adds 5 US Addiction Centres
 
Aug 19, 2014
Bionomics $3m Maiden Profit On Revenue Up 133% To $28m; Regeneus Register Shows 2-Year Hiqcell Joint Benefit; Innate Ready To Start Phase IIb MIS416 MS Trial; Medline’s First US Commercial Order Of Simavita Diagnostic; Antisense Hires Destum For Partnering, Licencing Deals; Analytica Appoints US Clinical Advisory Board
 
Aug 18, 2014
Living Cell Implants 2nd NTCell Parkinson’s Patient; Regeneus Placement Raises $3m, Share Plan For $3m More; Genera, Incelldx ‘Strategic Alliance’; Phylogica, Genentech Undisclosed Drug Discovery Project; Reva Raising $25m For 2014 Fantom Stent Trial; Uscom Revenue Up 67% To $1m, Loss Up 11% To $1.5m; Benitec Pleads Schultz To ASX 13% Query, ASX Misses 13%; Anteo Appoints Josh Soldo Scientific Affairs V-P
 
Aug 15, 2014
WEHI Identifies MCL1 To Control Killer Cells ; GI Dynamics H1 Revenue Up 149% To $1.7m, Loss Up 20% To $24m; Living Cell Revenue Up 0.5% To $8m, Loss Up 128% To $7m; Perpetual Sells 15m Resmed Shares, Down To 6%; Sirtex Breaks $20, Perpetual Takes Profit, Below 5% ; Cellmid Issues 600k More Shares To Brynne Edelsten
 
Aug 14, 2014
QRX Ends Dual Opioid Moxduo Program, $3m For Alternatives; Admedus WA Facility Ships 1st Cardiocel To The US; Genetic Technologies, Histogenetics Settle Patent Case ; Cogstate $800k Cognition Contract With Unnamed Company; Itl Revenue Up 4% To $26m, Profit Down 18% To $2m; Executive Chairman Bill Mobbs Takes 39% Of ITL; Australian Super Takes 6% Of Orthocell
 
Aug 13, 2014
CSL Record Profit Up 8% To $1.4bn, Revenue Up 8% To $6bn
 
Aug 12, 2014
Neuren Prepares For US IND For NNZ-2591; FSHD $300k Takes Novogen To Neuro-Muscular Indications; Orthocell Opens On ASX, China Royalty, Substantials; Brendan Moran Takes 6% Of LBT; Correction: Nanosonics
 
Aug 11, 2014
Phosphagenics Dr Esra Ogru Deception Conspiracy Trial; Orthocell Raises $8m To List On ASX Tomorrow; Agenix Sells AGX-1009 For Hep B To China’s Cinkate For $2m; Phosphagenics TPM-Oxymorphone Pharmaco-Kinetic Study; Allan Gray Takes 12% Of Nanosonics
 
Aug 8, 2014
Clinuvel Rebuffs Retrophin $95m Offer: ‘Not Enough’; NHMRC Details Federal Government $200m For Dementia; Hunter Hall Takes 6% Of GI Dynamics; Suda Loses Director Ken Robson
 
Aug 7, 2014
US NIH Funds Mesoblast End-Stage Heart Failure Trial; Japan Approves Nanosonics Trophon EPR; Pharmaust Treats First Ppl-1 Cancer Patient; Bluechiip, St Micro Move To High Volume Tag Production; Calzada Expects Loss Up 67%, Hunting Key Staff; Damien, Justin Haakman, Dussman Take 43% Of Simavita
 
Aug 6, 2014
Paladin Launches Immuron’s Travelan In Canada; Life Sciences QLD, Translational Research Conference; Regeneus Requests $6m Capital Raising Trading Halt
 
Aug 5, 2014
Cochlear Revenue Up 7% To $805m, Profit Down 17% To $109.5m; Cogstate $7m Rater-Training Contract; Ellex Expects $54m Full Year Revenue, Loss To $1m Profit; O’Brien Institute ‘Frontiers In Human Engineering Symposium’; Phosphagenics Over-Subscribed Share Plan Raises $3m; Probiotec Chairman Maurice Van Ryn Resigns; Dr Katrin Leadley Replaces Heatware CMO Dr David Hathaway 
 
Aug 4, 2014
Biota’s LANI ’Flu Drug ‘No Significant Benefit Over Placebo’; New Indications For Osprey Avert Dye Reduction System ; Bio-Melbourne Hosts Dr Thomas Lönngren On EU Regulation; Pharmaxis Sues Financier Novaquest; Unilife ‘Completes’ Equity Draw-Down Facility ; Bennelong ‘Revises’ Resmed Substantial Calculation To 2.7%; Medical Australia Appoints Dr Amy Crouch Vet Manager
 
 
Jul 31, 2014
US Safe Status For Calzada’s Troublesome AOD9604; Biotech Daily Appendix 4C Quarterly Reports Policy; Unilife Has One Quarter Cash; Genera Has Almost Two Quarters Cash - Sales, Merger; Genetic Technologies Has One Quarter Cash, ‘Transactions’
 
Jul 30, 2014
BRIL Group: ‘Set Aside 25% Of MRFF For Commercialization’; GI Dynamics Enrols 1st Patients In French Endobarrier Trial; Medical Australia Q4 Cash Flow Positive; Progen: ‘Medigen PI-88 Trial Goes On Despite Interim Results’; Hunter Hall Takes 9% Of Alchemia
 
Jul 29, 2014
Burnet, Germany’s Artes Collaborate On Malaria Vaccine; Nanosonics 12-Month Sales Up 44% To $21.5m; Mayne To Distribute IDT’s Generic Temozolomide In The US; Norway Approves, Portugal Pays For Psivida Iluvien For DME; Antisense Completes Phase II ATL1103 Acromegaly Dosing; US Patent For Imugene’s Her-Vaxx
 
Jul 28, 2014
Retrophin Offers $92-95m For $71m Clinuvel; Progen Falls 76% As PI-88 Fails To Meet Liver Cancer Endpoints; Tissue Therapies Files EU Answers - Response Within 90 Days; Cynata Contracts Uni Of Wisconsin For Stem Cell Shelf Life; Changes Delay Phosphagenics Opioid Trials; Prana Deregisters $22m Shares; Vale Clinuvel Director Jack Wood; Medical Development Director Maurice Van Ryn Resigns
 
Jul 25, 2014
Acrux Axiron H2 Sales Up 3% To $92m; LBT Plan Raises $517k, Total $2m; Novogen Hires Regis, Pharmaceutics Int For Cantrixil; Reva Director James Schiro Resigns For Health Reasons; Acrux Appoints Michael Kotsanis CEO, M-D
 
Jul 24, 2014
Patrys PAT-SM6 Multiple Myeloma Study, CSIRO Cell Lines; Admedus Has 66% Of Vaccine Company (Formerly Coridon); Universal Bio H1 Revenue Down 75% To $3m, Loss Down 9.5%
 
Jul 23, 2014
Biotron ‘BIT225 Reduces Immune Impairment, Cognition Potential’; Antisense Closes ATL1102 Stem Cell Mobilization Program; Macquarie University Joins Impedimed L-Dex Lymphoedema Trial; Dorsavi Hails First US Viperform Diagnostic Sale; Clinical Genomics Colovantage Bowel Cancer Test Trial; Fisher Funds Below 5% In Nanosonics; Prima CEO Marc Voigt Starts On $278k
 
Jul 22, 2014
Vale Avexa Advisor Prof Joep Lange, Killed On Flight MH17; Oversubscribed Orthocell Ipo Raises $8m; Safety Medical Plan Underwritten To $400k For 3-D Printing; Clarification: Bluechiip; Fisher Funds Reduce To 5% In Nanosonics; Bank Of America, Merrill Lynch Take 8% Of Suda
 
Jul 21, 2014
TGA Approves Starpharma, Ansell Vivagel-Coated Condom; Benitec 1st Hep C Patient Safety, Month Delay To 2nd Patient; CE Mark Approval For Calzada, Polynovo Novopore; GI Dynamics US Sec Reporting Ahead Of Nasdaq Co-Listing; Drawbridge Australia, UK Divisional Anaesthetic Patents; European Patent For Progen PG500 Series; Bluechiip Claims More Sales, US Patent; George Cameron-Dow Replaces Bioxyne’s Jeremy Curnock Cook; Fleming Takes 19.9% Of Bioxyne, Phillip Ceases; Virax Appoints Prof Joseph Sparano To Advisory Board
 
Jul 18, 2014
Prana Sub-Analysis ‘Understands’ Alzheimer’s Placebo Effect; Reminder: Bio-Melbourne Fibrotech $3m To $81m+ Briefing
 
Jul 17, 2014
Burnet, Deakin Block Malaria Proteins; FDA Approves Rhinomed Turbine Sports Nasal Plugs; US Army $3m For Delayed Neuren Brain Injury Trial; Dorsavi Viperform Adopted By Brazil’s São Paulo Soccer Club
 
Jul 16, 2014
NSW, ATP, California Medical Device Post-Doc Program; Imugene Hires Mymetics To Manufacture Her-Vaxx; UK Patent For Cellmid Midkine Hair Growth; Extended US Patent For Prima’s CVac; Oncosil Manufacturing Process Re-Validated
 
Jul 15, 2014
Cellmid Hails US FGF5 Hair Growth Study; FDA Approval For Dorsavi’s Vimove Spinal Diagnostic; Optiscan Raises $634k, Zeiss $260k Neurosurgery Milestone; Ethics Approval For Oncosil Pancreatic Cancer Trial; Calzada Executive Search, Laurent Fossaert To Go; Bluechiip Tracking Installed At Shanghai Outdo; Rhinomed Pleads Schultz, Publication To ASX 87% Query; Hunter Hall Takes More Profit, Reduces To 14% Of Sirtex; Suda, Bergen End Draw-Down Equity Facility
 
Jul 14, 2014
FDA Spa For Starpharma Phase III Vivagel Vaginosis Trial; Probiotec Milk Proteins Eczema Trial; Cynata Contracts Wuxi For Pre-Clinical Stem Cell Studies; Universal Biosensors Strip Fees Up 56%, Total Revenue Down; Generation, Associates Take 6% Of Cochlear; Optiscan Requests Fundraising Trading Halt
 
Jul 11, 2014
Phosphagenics Raises $16.3m, Plan For $3m More; QRX FDA End-Of-Review Meeting, Hunting For A 3rd Director; Resonance Ends Vueklar Acquisition, Focus On Hepafat-Scan; Benitec Expects 1st TT-034 Hepatitis Trial Data Next Week; Correction: Bio-Melbourne Network, Uniseed
 
Jul 10, 2014
Federal Government $35m For Type 1 Juvenile Diabetes; Neuren Ready For US Army Phase II NNZ-2566 Concussion Trial; Rhinomed Has One Quarter Cash; Burn Down, Sales Up, Loan; Novogen $20m Capital Raising EGM; Bioprospect Appoints Stephen Pearce Adviser; To Raise $2m; Scigen Sells Design Rights To Bioton SA For $12m; Bennelong Takes 5% Of Resmed; Prima Euro-Head Marc Voigt Replaces CEO Matthew Lehman; Bio-Melbourne Fibrotech $3m To $81m+ Briefing
 
Jul 9, 2014
All Change At QRX: Treagus, Hancox Replace Farrell, Pace, Campbell, Quinn; Progen, Medigen PI-88 Interim Analysis This Month; Rhinomed, Fitness First Partner On Turbine Nasal Plugs; Phosphagenics Requests ‘Funding Event’ Trading Halt; Perpetual Takes Profit, Again, Down To 5.6% Of Sirtex 
 
Jul 8, 2014
Novaquest Tries To Avoid Pharmaxis $US20m, Trial Threat; Regeneus Licences Human Cancer Vaccine; Ellex Wins First European 2RT Laser Sales For AMD; Living Cell CEO Dr Ken Taylor Starts On $280k; Dorsavi NZ Vimove Approval, Sunderland FC UK Buys Viperform; Pharmaxis LOXL2, SSAO Programs Licence Progress; Acrux Pleads Schultz To ASX 13% Query; OBJ Pleads Schultz To ASX 14% Query
 
Jul 7, 2014
Travelan Earns $1m For Immuron; LBT APAS Study Shows Accuracy For Reading Agar Plates; Antisense ATL1103 Canada Patent, Acromegaly Trial Progress; Medical Australia Settles US Patent Case; Imugene To Lose Dr Nick Ede, Appoints Otto Buttula Director
 
Jul 4, 2014
Sirtex Breaks $1b Barrier; Brain Resource Raises $7m, Share Plan For ‘About $1.5m’ More; Dorsavi Buys Workplace Compliance For $120k, Mark Heaysman; Rhinomed Pleads Schultz, ‘Overselling’ To ASX 52% Query; Genetic Technologies Tests 4k Brevagen Samples In 2013-’14; Pharmaxis Requests ‘Financier Communication’ Trading Halt; Bio-Melbourne Appoints Dr Krystal Evans CEO; Kris Knauer, Pitt St, Greenfields, Moneybung Bioprospect 10%
 
Jul 3, 2014
Sirtex Q4 Dose Sales Up 27% To About 2,214 Doses, $33m; Revenue Up, Compumedics Expects Return To Profit; CBio Executives Appeal Invion $1.3m Court Order; Atcor Sales Fall Takes Profit To Loss
 
Jul 2, 2014
WEHI-916 Blocks Malaria Gatekeeper Enzyme; Bone Starts Oral Capthymone Osteoporosis Trial; D3, Viroclinics Alliance For Virology Development; Compumedics Signs $4m Asia Sleep Diagnostic Contracts; GI Dynamics Slow Sales, Loses Mark Twyman; Calzada Backs Chairman David Williams 10m Options; Benitec Unmarketable Parcel Facility; Acuvax Activistic Funds Collection Placement EGM; Constables Reduce To 5% Of Antisense; Brain Requests Capital Raising Trading Halt; Kris Knauer Replaces Bioprospect Director Peter May
 
Jul 1, 2014
June BDI-40 Up 0.4%, YTD Up 0.3%; 8-Years Up 130%, ASX200 6% - YTD: Benitec Up 780%, Anteo Up 291%, Acrux Down 72%; Psivida Adds 10 More EU Countries To Iluvien Approval; Simavita Claims First US Sales; Regal Underwrites $1.4m In Expiring Suda Options; Lou Panaccio Starts As Avita Chairman, Dalton Gooding Goes; Bluechiip: Dr Jason Chaffey M-D; Joe Baini, Ron Finkel To Go
 
Jun 30, 2014
Australia No 4 In Biotech Innovation – Scientific American - John Brumby, Michelle Gallaher Comment; Genera To Merge With Larger Diagnostics Business; Regeneus Begins US KVax Dog Cancer Vaccine Market Trial; Scigen Sells India Plant To Anglo Gulf For $7m
 
Jun 27, 2014
QRX Director Attacks EGM Board Spill Statement; Bio-Melbourne Age-Related Macular Degeneration Breakfast 
 
Jun 26, 2014
Monash Uni, Pfizer Centre For Victoria Commercialization; Neuren Completes NNZ-2566 Rett Syndrome Enrolment; Benitec: DSMB Approves Calimmune 2nd ddRNAi HIV Cohort; Impedimed Begins L-Dex Post-Approval Trial; South African Approval For Medical Developments Penthrox; Admedus Expects Revenue Up 22% To $9m
 
Jun 25, 2014
Avexa Reasserts Its Apricitabine (ATC) Program For HIV; US Trials Network Continues Mesoblast Cardiac Research; Itl Profit Warning; Mayne Completes Hedgepath Suba-iraconzaole Licence; Victoria: Bill Clinton, Bob Geldof For AIDS 2014 In Melbourne
 
Jun 24, 2014
Bionomics, Merck $537m Deal For BNC375 Cognition Drug; Siemens Orders 1st Universal Biosensors PT-INR Test Strips; Italian Approval For Psivida, Alimera Iluvien; Anatara Develops Incitive’s Pineapple Stems For Diarrhoea; Cogstate Signs $2m In Contracts; Acuvax Drops Cancer For Activistic Funds Collection; RA Capital Takes Small Profit To 11% Of Benitec; Queensland, Canada Industry Organizations Collaborate; Brain Resource Loses Director Russell Jamison
 
Jun 23, 2014
Living Cell Resumes Phase I/II NTCell Parkinson’s Trial; Uscom Manufactures 1st BP+ Units In Sydney; Pharmaust Screens Cancer Patients In Phase I/II PPL-1 Trial; Simavita Completes $3m Part 1 Of Capital Raising; Circadian Wins $245k 1st Queensland Biopharmaceuticals Grant; Acuvax To Raise $600,000; Court Orders CBio Officers To Pay Invion $1.3m; Isonea Close To US Approval For Sonosentry (Wheezeometer); Virax Appoints Ground Zero For GGTI-2418 US IND; Bionomics Requests ‘Commercial Transaction’ Trading Halt; Steven Kritzler Below 5% In Nanosonics; Safety Medical Swaps Brazilian Gold Mine For 3D Printing; Neuren Appoints Dr Clive Blower To Product Development
 
Jun 20, 2014
Victoria $17.5m Cancer Research Grants; NSW $50k Supports 7 Delegates To Bio 2014; Cyclopharm Cyclotron Collateral Water Damage; Quest Close To Filing Lung Cancer Test With Cellmid Midkine; Innate Phase IIb MIS416 Trial For MS Delayed 8 Weeks; Bone Back To Pre-Clinical Studies For BN006 For Arthritis; KFT For GJK Takes 10% Of Universal Biosensors; CBA Takes 7% Of CSL; Benitec Loses Director Dr Mel Bridges
 
Jun 19, 2014
Patient Data Backs Pharmaxis Bronchital CF Trials; Alchemia Starts Phase I Colorectal Cancer Trial; Simavita Requests $10m Capital Raising Trading Halt; Rodon To Manufacture Cellmid’s CAB102 For Cancers; Nusep Completes $6m 1st Tranche In Prime; Hunter Hall Takes 5% Of GI Dynamics; Isonea Appoints David Ashmore Director
 
Jun 18, 2014
Victoria $6m For Four Projects; Medical Technology Plan; Novogen Proves Concept Of TRX-1 For Ovarian Cancer; LBT Placement Raises $1.5m, Share Plan For $1.5m More; Compassionate Use MS Patients ‘Benefit From Innate MIS416’; Atcor, Suntech Launch 24-Hr Oscar 2 BP Monitor; US Grants Patrys 3rd PAT-SM6 Patent; China Patent For Drawbridge Phaxan; Bioprospect Cardiac Mental Illness Test In The Cloud
 
Jun 17, 2014
WEHI Gene Switch Reverses Leukaemia; FDA Clears Osprey 2nd Generation Avert Dye Reduction System; Atomo Point-Of-Care Diagnostic Wins New York Award; Resonance Raises $1.3m Of Hoped-For $5.1m; Sunshine Heart Appoints Brian Brown Head Of Operations
 
Jun 16, 2014
GI Dynamics Endobarrier: ‘Acute Drop In Glucose, Weight’; Mesoblast Receives $5m Federal R&D Tax Refund; Genera: ‘Canada Roche Approval Backs Paptype’; Uscom Appoints Unetixs Vascular Uscom 1a US Distributor; LBT Requests Capital Raising Trading Halt; Invion Grants CEO Dr Greg Collier 10% Pay Rise To $330k
 
Jun 13, 2014
Asurequality In-Vitro Diagnostics ISO Approval; Suda Appoints Torreya For Artimist Deal; Actinogen: ‘Actinomycetes Isolates Stop Cancer Stem Cells’; Cryosite Profit Warning; Healthlinx Raises $200k For Video-Gaming; Robert Thomas Replaces Starpharma Chair Peter Bartles; Medicines Australia’s Dr Brendan Shaw Off To Geneva
 
Jun 12, 2014
Orthocell Ortho-ATI Tendon Pain Pilot Trial: ‘Safety, Efficacy’; Maison De Beauté Takes Le Métier Phosphagenics Range; Cogstate Signs First Precision Recruitment Client; Up To 34% Of Universal Biosensors Oppose AGM Votes; Genera Pleads Reports To ASX 47.5% Query, 120% To Go
 
Jun 11, 2014
Ex-Phosphagenics Dr Robert Gianello, Dr Woei-Jia Jiang Plead Guilty; Hettich Pays LBT $1m Milestone; Avita 10-Patient Trial: ‘Recell Works For Depigmentation’; Cynata Partners With Grey For Nebulized Stem Cells; Hunter Hall Below 5% In Viralytics; BVF Partners, Mark Lampert Take 8% In Viralytics; Mining Invest, Elias Leo Khouri Diluted To 23% Of Bioprospect; KFT For GJK Takes 5% Of Universal Biosensors; Medical Developments Appoints Mark Edwards Co Sec
 
Jun 10, 2014
Invion Details INV102 (Nadolol) Clinical Program; Dr Stephen Woodford Takes 13% Of Uscom
 
Jun 6, 2014
Walker Group Details QRX ‘Failures’ For Board Spill; Admedus Share Plan Raises $10.1m, Total Raised $18.4m; Cogstate Revenue, Profit Warning, To Sell Axon Sports; Benitec Receives $776k Federal R&D Tax Refund; S&P ASX200: Mayne Pharma In, Acrux Out; Mesoblast Pleads Schultz To ASX 14% Fall Query; Biotron Pleads Schultz To ASX 24% Query
 
Jun 5, 2014
Orthocell $8m IPO For Stem Cell Tendon, Soft Tissue Injuries; Calzada, Polynovo Treat 1st Novosorb Major Burns Patient; Alchemia HA-irinotecan Trial Results Delayed 3 Months; FDA Warning Letter For Heartware’s Miami Lakes Plant; Starpharma Docetaxel Trial Underway, Phase III Vaginosis; Compumedics US Supply Agreement With Medassets; Nusep Changes Singapore Scrip To Debt
 
Jun 4, 2014
Dimerix IPO To Raise $9m For Dmx200 For Kidney Disease; US Patent For Neuren NNZ-2591; Court Orders CBio Officers To Pay Invion $1m; BPH, Molecular Discovery Suspend Early Programs; Agenix Completes Tyrian Licence; Analytica Chairman Dr Michael Monsour Buys 17m Shares; Spinifex Appoints Dr Ronald Marcus Chief Medical Officer
 
Jun 3, 2014
Biota Sacks More Staff, To Close Australian Operations; Biotech Daily Comment; NSW $19m For 3 Cancer Research Translation Centres; Viralytics: ‘19 Of 51 Melanoma Patients Reach 6-Month PFS’; Bluechiip Raises $500k; Resonance To Buy Scotland’s Vueklar For MRI Products; QRX Board Spill EGM; AMP Reduces To 6% In Acrux; Australian Ethical Below 5% In Universal Biosensors; Hunter Hall Takes Profit, Reduces To 16% Of Sirtex; Hunter Hall Takes 8% Of Alchemia
 
Jun 2, 2014
May BDI-40 Up 1%, ASX200 Up 0.1%, Big Caps Up 2% - Prima Up 57%, Analytica Up 42%, Universal Bio Down 42%; Cochlear’s Recalled CI-512 Returns As ‘Thinnest Implant’; Atcor Wins 1st China Sphygmocor Order; Phase I Data Backs Circadian VGX-100 For Solid Tumors; Antisense Takes $1m Macquarie Bridging Loan; Cogstate, Merck Canada Change Cognigram Conditions; Allan Gray Takes 14.5% Of Starpharma; Benitec O-T-C Trades Approved In US 
 
May 30, 2014
Alchemia Fondaparinux March Profit Share $2.4m; Benitec Appoints Bank Of New York Mellon For ADR Program; Virax Completes GGTI-2418 Pathway, Paul Hopper Deal; Resonance Requests Transaction Trading Halt; Balam, Leon Semenko Below 5% Of Rhinomed
 
May 29, 2014
Benitec Treats First Hepatitis C Patient; Analytica Starts Pericoach Production; FDA Registers Sienna SCD-7 Telomerase Cancer Diagnostic; TGA Approves Resonance Hepafat-Scan For Register; Orthocell Hopes To Raise $8m In IPO; Medical Developments Closer To UK Penthrox Approval; Smartstent Wins 1st Victoria Medtech’s Got Talent; Biodiem, Griffith University Collaborate On BDM-I; Calzada EGM For 10m Chairman David Williams Options; Fisher Funds Below 5% In Universal Biosensors; Ex-CEO Gary Davey Reduces, Diluted To 7.4% Of UScom; Genetic Technologies Appoints Eutillio Buccilli CFO
 
May 28, 2014
Patrys PAT-SM6 Combination For Multiple Myeloma Patient; Prana Pleads Schultz, Olds To ASX 33% Query; Mesoblast Accelerates Lonza Singapore Cell Manufacture; Medical Developments Sales, Profit Warning; Fisher Funds Sell 2m Universal Biosensors Shares To 5%; Spinifex Appoints Four Advisors; Federal Government Appoints Penny Dobson To ANSTO
 
May 27, 2014
Novogen Super-Benzopyran For Prostate Cancer; Queensland Supports UQ Skin Cancer Laser Detection; Imugene Appoints Bachem To Manufacture Her-Vaxx Peptide; Immuron: 6% Oppose Grandlodge Shares; Hunter Hall Takes 5% Of Viralytics; Isonea Pleads Options To ASX 35% Query
 
May 26, 2014
FDA Requires QRX Moxduo ‘Superiority’; Clinical Genomics Ready For Colovantage Plasma Roll-Out; US Patent For Prima’s Cvac For Ovarian, Pancreatic Cancer; Phosphagenics: 7% Oppose Remuneration, Directors Options; Veritas Takes 6% Of Cochlear; Medicines Australia To Lose Chief Executive Dr Brendan Shaw; Acuvax Appoints Alex Bajada Director
 
Queensland Uni, Organovo Print Kidney Tissue; Thai Coup ‘No Impact On Biotron Trial’; Euro Patent Office Upholds Challenge To Benitec; Agenix Releases 11.5m Escrow Shares; Sietsma Takes 7% Of Phylogica 
 
May 22, 2014
FDA Orphan Status For Clinuvel’s Scenesse For Hailey-Hailey; Up To 10% Of GI Dynamics Oppose CEO Stuart Randle Stock; Minderoo (Metal) Group Reduces, Diluted To 13% Of Admedus
 
May 21, 2014
Phosphagenics Oxycodone Patch Relieves Pain In Horses; Immuron Appoints DB Pharm South Korea Distributor; ATP Innovations Wins Two Incubator Gongs
 
May 20, 2014
Compumedics Sells $295k Doppler Box X To Brazil; Resonance Ferriscan Deal With Florida Hospital; Analytica Completes $3m Raising; Correction: Agenix; QRX Slides Criticize Moxduo Trial Design; Fisher Funds Reduce To 6% Of Universal Biosensors; FIL Takes 7% Of Clinuvel; Sietsma Takes 6% Of Phylogica; Avita Appoints Lou Panaccio Chairman
 
May 19, 2014
Bionomics: ‘BNC105P Safe With Gemcitabine, Carboplatin’; Clinuvel On Scenesse Delay, Orphan Status For Hailey-Hailey; US Institute Backs Nanosonics Trophon EPR Probe-Cleaner; Genera Notes Raise $345k, $500k Placement, Q-Sand Spin-Out; Royal Adelaide Approves Pharmaust PPL-1 Cancer Trial; Agenix To Sell China AGX-1009 Hep B Project To US Cinkate; Bluechiip $12k Sales, $97k Federal Export Grant; Uscom Appoints UK, Ireland Distributors For BP+; Acorn Reduces To 9% Of Starpharma; Circadian Appoints Michael Tonroe CFO, Co Sec
 
May 16, 2014
Phosphagenics Ex-CEO Dr Esra Ogru Charged With Theft; Ex-Actinogen David Zohar 5 Months Gaol For Misleading ASX; GIDynamics: ‘6 Endobarrier Patients Cease Insulin, 5 Reduce’; Janssen Ends Phylogica Endosomal Escape Trap Deal; Phylogica, Phosphagenics NY’s Metier Tribeca Partner Broke; Simavita Pleads Schultz, Shaw Report To ASX 25% Query; Genetic Technologies Reduces Dr Mervyn Jacobson To 5%; Perpetual Takes Profit, Again, Down To 7% Of Sirtex; Nestor Below 5% In Genera
 
May 15, 2014
Prima: ‘Final Data Shows CVac Ovarian Cancer Benefit’; Progen Treats First Three PG545 Solid Tumor Patients; Ellex 24 Month Data Backs 2RT For AMD; Viralytics Poster Backs Cavatak For Melanoma; Avita: ‘Recell Superior For Hypo-Pigmented Scars’; Uscom Raises $1.4m; Otsuka Drops Living Cell NTCell, $2m Option; Genera Pleads Schultz To ASX 34% Query; Walker Group Calls For QRX Board Spill; CDPP Drops Charges, Vanda Gould Cyclopharm Chairman; Virax Appoints Dr Rob Crombie M-D, Starts On $300k
 
May 14, 2014
Federal Budget: $20b Fund, R&D Tax Credit, IIF, NHMRC, ARC, CRC; Response: Biotech Daily: ‘What Is There Not To Like?’; WEHI’s Prof Doug Hilton: ‘Fund Is A Game-Changer’; Bernard O’Shea: ‘Mind The Commercialization Gap’; Bio-Melbourne: ‘Fund Offers Nothing For Local Biotechs’; Avcal Questions Commercialization; CRC Has Concerns; Medicines Australia Welcomes Fund, Co-Payments; Regeneus Study: ‘Stem Cells Reduce Neuropathic Pain’; Clinuvel Raises $7.2m; Psivida Hopes For Single Phase III Medidur Uveitis Trial; Calzada Appoints Max Johnston, Philip Powell Directors; Progen Heng Tang To Pharmasynth, Jitto Arulampalam Exec
 
 
WEHI: ‘RIPK1 Links Cell Death, Inflammatory Disease’; Circadian’s Opthea, FDA Meet On OPT-302 For Wet AMD, 2015 Trial; Admedus Raises $8m, Share Plan For More; Xeraya, JP Asia Invest $14m In Nusep’s Prime Biologics; Bone CEO Peter Young Goes, Osteoporosis Trial Approved; LBT Presents APAS Auto-Plate Assessment; Virax Falls On 1-For-5 Share News; Universal Biosensors Slides 39% On Slide; Clinuvel Requests Capital Raising Trading Halt; M&G Buys 8m GI Dynamics Shares, Diluted To 13%; Correction 
 
May 9, 2014
BARDA Terminates $US231m Biota Contract; WEHI: SOCS4 A Key To Influenza Response; US Fast Track Status For Prima’s CVac For Ovarian Cancer; Bluechiip China Deal; Suda 40% EGM Resistance, 2 Resolutions Withdrawn; United Super, CBus Take 5% Of Acrux; Polaris, Domain Reduces, Diluted To 4.6% Of GI Dynamics; J&J Reduces, Diluted To 6% Of GI Dynamics; ATV, Medtronic, Greenlight Diluted In GI Dynamics; Unilife Appoints John Ryan General Counsel, Co Sec; Rhinomed Appoints Baden Cooke European Brand Ambassador
 
May 8, 2014
Federal $169m For ANSTO Nuclear Medicine Plant; Progen Expects Interim PI-88 Liver Cancer Results This Month; Orthocell Buys Uni Of WA Stem Cell IP; Veritas Takes 5% Of Cochlear; Franklin Resources, Affiliates Below 5% In Cochlear; Admedus Requests Capital Raising Trading Halt; Clarification: Analytica
 
Admedus First US Cardiocel Tissue Sale; CSIRO, Deakin Uni New Bio-Secure Anti-Viral Facility; Cellmid Prepares CAB102 For Human Cancer Trials; Analytica Expects US, Australian Pericoach Reimbursement; Nominations Open For $80k GSK Research Excellence Award; Nusep Requests Capital Raising Trading Halt; University Of Queensland Hosts July Nano-Bio Conference 
 
May 6, 2014
FDA Allows Teva (Chemgenex) Synribo For Home Use; GI Dynamics, GSK: ‘Bile Acid Endobarrier Method Of Action’; Clinuvel Starts Singapore Phase II Scenesse For Vitiligo Trial; Circadian: ‘OPT-302 Inhibits Wet AMD In Mice’; Psivida’s Tethadur Sustained Delivery Of Antibodies; Prima Provides Ovarian, Pancreatic Cancer Timelines; Antisense Aims For New ATL1102 MS Trial In 2015
 
May 5, 2014
Hearing CRC: ‘Hearing Aids May Delay Dementia’; Immuron Clears Paladin $1.5m Debt; Novogen Forms Children’s Oncology Drug Alliance; Clinical Genomics Blood Test For Bowel Cancer; Bellberry $400k For 5 James Cook University Researchers; Virax Licence Option For P27 Cancer Biomarker Test; Webinvest Takes 7% Of Imugene
 
Friday May 2, 2014
Federal Audit Commission Hits CRCs, IIF, R&D Tax Incentive - Biotech Daily Comment; Shire Buys MRCF-Backed Fibrotech For $81m, Milestones; GI Dynamics Expects Placement To Raise $34m; Clarity Raises $1.1m For Personalized Medicine Imaging; Novogen, Genea Work On Stem Cells For Degeneration; Allan Gray Takes 18.55% Of Acrux; Hunter Hall Takes 7% Of Alchemia; Heartware Warns On Battery Life, Q1 Revenue Up 35% To $72m;QRX COO Dr Edward Rudnic Replaces CEO Dr John Holaday
 
May 1, 2014
April BDI-40 Down 17%, ASX200 Up 2% - QRX Down 88%, Prana Down 80%, Acrux Down 40%, OBJ Up 75%; Barda Explains Biota Stop-Work Order; Medicines Australia: ‘Commission Of Audit Flawed On PBS’; Admedus Cardiocel Patient Reaches Six-Years With No Issues; Suda’s Westcoast Expands To East Coast; AMP Reduces To 7.4% In Acrux; Virax Requests ‘Material Transaction’ Trading Halt
 
Apr 30, 2014
Biota Falls 34% On Barda ’Flu Drug ‘Stop-Work’; Victoria’s $18m To Promote Health, Medical Research Plan; US Patent For Mireven’s Micro-RNA Technology; Cellmid Midkine Symposium Presents New Findings; Biodiem, UWS Collaborate On BDM-I For MRSA; GI Dynamics Surprise Capital Raising Trading Halt; Impedimed Plan Raises $2.35m, Takes Total Raised To $11m; Progen’s Pharmasynth Wins Medigen PI-88 Contract; Neuren AGM Modest Dissent Against 3.3m CFO, COO Free Rights; Acuvax Has No Cash
 
 
Apr 28, 2014
Acrux Falls 37% On Axiron Q1 Sales Down 27% On Q4; US Patent For Progen 500 Series Anti-Cancer Compounds; Prima Re-Starts Euro CAN-004 CVac Ovarian Cancer Trial; OBJ, Proctor & Gamble Deal On Unnamed ‘Products’; Nusep Loses Director Dr Stephen Van Der Mye; Claire Newstead-Sinclair Returns As Cogstate Co Sec
 
Apr 24, 2014
TRI: ‘Blocking E-Selectin Protects HSC From Chemotherapy’; Virax Looks For Co-X-Gene Opportunities; Analytica Sets Rights Issue Dates
 
Apr 23, 2014
FDA Committee 3rd Strike For QRX Moxduo, Falls 85%; Phosphagenics Enrols Phase II TPM-Tretinion Trial; Bluechiip Share Plan For Up To $1.75m; Biodiem Closes Rights Issue With $815k; Unilife Reports ‘Blogging Short-Sellers’ To US SEC; Imugene Appoints Dr Neil Segal To Advisory Board; Actinogen Appoints Dr Brendan De Kauwe Executive Chairman; Circadian CEO Dr Megan Baldwin Starts On $300k; LSQ Strategic Risk And Crisis Communications Workshop; OBJ Requests ‘Material Agreement’ Trading Halt
 
Apr 22, 2014
Analytica $1.8m Placement, Rights Offer For $1.2m More; QRX Requests Moxduo FDA Advisory Committee Trading Halt; Allan Gray Takes 17% Of Acrux; Bio-Melbourne Breakfasts On Mice, Zebrafish, Models; Cellmid Releases 38m Advangen Escrow Shares
 
Apr 17, 2014
Queensland $990k For MRCF, Q-Sera Snake Venom Coagulant; Pharmaxis Sales Up 42%, LOXL2 Term Sheet, US Aridol Sales; Phosphagenics AGM For 3m Director Options, Fees Up 33%; RA Capital Takes 12% Of Benitec; Mass Mutual Reduces Below 5% In Novogen; Genetic Technologies Backs Dr Mervyn Jacobson Share Plan; Simavita CFO, Co Sec Tom Howitt Resigns As Director
 
Apr 16, 2014
Orthocell IPO For Tendon, Cartilage, Soft Tissue Repair; Drawbridge Phase I Phaxan Anaesthetic Safe, Effective; Queensland Scientists Stop Dengue With Wolbachia; Avexa, PX Biosolutions Win Victoria Technology Vouchers; US Patent For Atcor Cardiac Output Method; Analytica Requests Capital Raising Trading Halt
 
Apr 15, 2014
NSW $65k Grants For San Diego Bio 2014 Close In 14 Days; Medicines Australia Calls For Federal Research ‘Certainty’; Bluechiip To Supply Tracking Cryopin To Synchrotron; Cellmid, Biotecnol Collaborate On Midkine Tribodies; Psivida, Alimera September FDA Iluvien PDUFA Date; Royal Adelaide Approves Pharmaust PPL-1 Cancer Trial; Benitec Completes $31.5m Placement; Innate Ready To Start MIS416 MS Trial In June; Bioniche Sells Animal Health Business
 
Apr 14, 2014
Burnet, Guominxinhe $5m For Point-Of-Care Diagnostics; Viralytics Cavatak, Docetaxel NSCLC Synergy In-Vitro, In Mice; Bioprospect To Acquire Cardiac Test For Mental Illness
 
Apr 11, 2014
Spinifex Raises $48m For EMA401 Pain Drug, US Office, Directors; Bluechiip Books First Commercial Sales; Rhinomed Drops Options On 40% EGM Dissent; LBT Pleads Schultz To ASX 27% Query; Osprey AGM For 1.3m Director, CEO Options; Suda EGM For 32.5m Director Options; Osprey Releases 2m Escrow Shares
 
Apr 10, 2014
Osprey Diabetic Limb Pilot Study Safety, Efficacy; FDA Compassionate Use For Avita’s Recell Wound Treatment; Biodiem Expects To Raise $1.3m; Resonance Placement, Entitlement Offer For $5.1m; Westpac, Associates Take 5% Of Mayne Pharma; Bioprospect Requests Acquisition Trading Halt 
 
Compumedics, US Health Trust Purchasing Agreement; Pharmaust Licences Uni Of NSW PPL-1 Cancer Drug Patent 
 
Apr 8, 2014
WEHI: ‘Thrombopoietin Acts On Platelet Progenitors’; Viralytics Cavatak Active At Non-Injected Sites, PD-1 Potential; Resonance Requests Capital Raising Trading Halt; Avita Develops Non-Refrigerated Recell Treatment; Regeneus To Harvest Human Fat For Allogeneic Stem Cells; Mesoblast Pleads ‘Nasdaq Fall, Shorts’ To ASX 16% Fall Query; Virax Pathway Acquisition, 490m Shares EGM
 
 
Apr 4, 2014
Bone To Restart Oral Capthymone For Osteoporosis Trial; Hennessy To Manufacture Regeneus KVax Dog Cancer Vaccine; Biotron Receives $1.7m Federal R&D Tax Refund; Perpetual Takes Profit, Again, Down To 8% Of Sirtex; Allan Gray Takes 15.6% Of Acrux; ASX Releases 15m Bioxyne Shares From Escrow
 
Apr 3, 2014
Correction: Editorial; Reva Aims For First-In-Man Fantom Stent Trial This Year; 3-Month Sirtex Dose Sales Up 18%, 39th Consecutive Quarter; Mayo Study Backs Atcor Sphygmocor For Heart Failure; Reva AGM For 75k Director Options; Solagran Appoints Lodge For Resurrection
 
Apr 2, 2014
Editorial: Trials, Tribulations And Transparency; Patrys Grows Human IgM Antibody In Plants; Advanced Surgical Licences Sr-HT-Gahnite For Bone Grafts; GI Dynamics Responds To TGA Advertising Complaint; Suda Appoints 4 Experts For Artimist Expansion Trial
 
Apr 1, 2014
March BDI-40 Down 5%, ASX200 Down 0.2%, Big Caps Down 3% - Viralytics Up 66%, Anteo Up 56%, Reva Down 54%; Prana Falls As PBT2 Fails To Reduce Alzheimer’s Plaques; Antisense Completes ATL1102 MS Toxicology Study; Living Cell’s Dr Andrea Grant, 55 Staff To JV, Dr Ken Taylor CEO
 
Mar 31, 2014
Analytica Finalizing Pericoach Incontinence Training Tool; Prana Requests Phase II Alzheimer’s Results Trading Halt; IM Medical Closer To White Data Merger
 
Mar 28, 2014
Impedimed Raises $8.8m, Plan For $3m More; Miele To Distribute Nanosonics Trophon In Germany; Cyclopharm Says Unfair ANSTO Competition Closes Cyclotron; Invion Rights Raise $889k Of Hoped-For $2m, Total $5.9m So Far; Alimera Refiles Psivida Iluvien NDA To FDA; Reva To Lose 40 Staff, Raise Up To $27m; Invion Founder Dr William Garner Reduces To 11.24%; Avexa Halts Share Facility; ATC, Alabama Coal Mine Update
 
Mar 27, 2014
Patrys PAT-SM6 Multiple Myeloma Results Back Combination; Reva Dumps Rezolve For Fantom, Cuts Staff; Biogrid, Genomics Health Alliance Pilot Project; Preliminary Dutch Coverage For GI Dynamics Endobarrier; Neuren AGM For 30m CFO, COO Loan Shares, 3.3m Free Rights
 
Mar 26, 2014
Regeneus Register Shows Hiqcell Joint Benefit; Invion Founder, Ex-CEO Dr William Garner Reduces To 11.63%; Impedimed Requests Capital Raising Trading Halt; Prima Adds 3 Experts To Board For CVac Ovarian Cancer Trial
 
Mar 25, 2014
Sirtex, Guerbet Collaborate On Liver Cancer Trials; Innate Ready For Phase IIb MIS416 Multiple Sclerosis Trial; Pharmaust Lodges Ethics Application For PPL-1 Cancer Trial; Virax Raising $3m For Pathway GGTI-2418; Perpetual Buys 15m Resmed Shares, Up To 7%; Buchan Appoints Rebecca Wilson CEO
 
Mar 24, 2014
Patrys Prepares For PAT-LM1 Lymphoma Trial; FDA Sets April 22 For QRX Hearing; Dimerix Raises $1.5m For DMX200 For Proteinuria; Israel Issues Patent For Imugene’s Her-Vaxx; Genetic Technologies, Promega Settle; Cogstate Tests To Be Used In A4 Alzheimer’s Study; Bluechiip, Micronic Co-Development Agreement; Bone, William Harvey Work On BN006 For Rheumatoid Arthritis; Mass Mutual Reduces, Diluted To 6% In Novogen; Bio-Melbourne Breakfasts On RNAi
 
Mar 21, 2014
FDA Approves Cochlear Nucleus Hybrid; Ascend Drug ‘Effective For Cutaneous B-Cell Lymphoma’; Simavita Launches In The US, Prepares For Europe; Virax Requests Capital Raising Trading Halt; Antisense Completes Phase II ATL1103 Acromegaly Recruitment; Oncosil Director Lawrence Gozlan, 11m Loan Shares EGM
 
Mar 20, 2014
Bioprospect Technical Reports Back Depression Heart Test; Biodiem Receives $359k Federal R&D Tax Refund
 
Mar 19, 2014
Bionomics Falls On BNC105p Renal Cell Carcinoma Data; Nominations Open For $500k Prime Minister’s Science Prizes; Avexa Pleads Schultz To ASX 73% Query; Dennis Pyers Replaces Unilife CFO Richard Wieland, Job Offer
 
 
Mar 17, 2014
UK Early Access To Medicines Scheme Starts In April; Bionomics BNC105 Renal Cell Cancer Trial Trading Halt; Bio-21 Cluster Expands To Biomedical Research Victoria; Victoria $250k Vouchers For Sienna, Blamey & Saunders, NPlex; Virax Acquires Pathway For GGTI-2418, Paul Hopper Director; Oncosil Ethics Application Starts Pancreatic Cancer Trial; Imugene Appoints Ground Zero For Her-Vaxx FDA Application; Invion Withdraws Bankruptcy In Ex-CBio Executives Case; Progen Pleads ‘Awareness’ To ASX 25% Query; OBJ Pleads Schultz To ASX 36% Query; Benitec Appoints Prof Craig Lewis NSCLC Chief Medical Adviser; Rhinomed Loses Director Simon Isaacs AKA ‘Lord Reading’
 
Mar 14, 2014
Japan Approves Starpharma Vivagel Condom Coating; Psivida Places $8m With RA Capital; Virax Requests Transaction Trading Halt; Orbimed Provides Unilife $66.5m Debt Financing; Cormorant, BVF, Abingworth, Sabby Substantial In Viralytics
 
Mar 13, 2014
Viralytics Completes $27m Fund-Raising; RA Capital Takes 7% Of Benitec, Trial Delay; Genetic Technologies Founder Mervyn Jacobson Shares EGM; Calzada Appoints David Williams Chairman; Bionomics, CEO Dr Deborah Rathjen Win Singapore Gongs
 
Mar 12, 2014
Victoria Opens $1m Round 2 Of Massachusetts Partnership; Victoria Launches Medtech Boardroom Stimulator; US Court Allows Genetic Technologies To Sue Agilent; Correction: S&P Indices, Prana In ASX 300; Analytica Appoints Bryan Dulhunty CFO
 
Mar 11, 2014
Compumedics Books $2m China Orders; Starpharma Receives $4.7m Federal R&D Tax Refund; Biotron Adds Phase II Thai Hep C Trial Sites; Brain Licences Mybrainsolutions To Bosch, Welltok; CSIRO Diluted Below 5% In Benitec; Mesoblast Appoints Jonathan Symonds Strategy Support
 
Mar 10, 2014
Uscom Appoints Avalon Medical Norway, Sweden Distributor; Innate Pleads Morgans Report To ASX 43% Query; Anteo Pleads Schultz, All Ords To ASX 55% Query; Former Chairman John Manusu Takes 6% Of Nusep; Blackrock Below 5% Of Cochlear, Again; CB Co, Curran Super Fund Takes 14% Of Atcor; Rhinomed 40m Directors’ Options EGM
 
Mar 7, 2014
Genetic Technologies Brevagen Breast Cancer Test Value; S&P ASX 300 Promotes Bionomics, Demotes Prima; AMA Refuses Resonance Ferriscan Insurance Code Change; Isonea Claims ‘Electronic Stethoscope’ On Journal Article; Acrux Pleads Schultz To ASX 10% Fall Query; Blackrock Takes 5% Of Cochlear, Again; Dr David Thurin, Dalit Increase, Diluted At 6% Of Benitec; Medivac Appoints Peter Elliott, Adds Property To Portfolio
 
 
Mar 5, 2014
Cynata, U Of Massachusetts Amherst MSC Proof-Of-Concept; Alchemia Licences Two CRC FAKs From UK Cancer Research; Grandlodge, Anastasiou Increase, Diluted To 13% Of Immuron; Novogen Appoints Prof Peter Gunning, Iain Ross, David Gryska; Bio-Melbourne, Meta, Swinburne Medical Tech Breakfast
 
Mar 4, 2014
Leukaemia Foundation Provides $13m For Research Grants; US, Canada Patents For Fibrotech; Small Technologies Cluster Tapping-In Grants; Calzada Pleads FDA, David Williamson To ASX 37.5% Query
February BDI-40 Down 1%, ASX200 Up 4%, Big Caps Up 0.5% - Benitec Up 128%; Correction: Victoria Government; Optiscan 2nd Generation Endomicroscope In Sydney Gut Trial; WEHI Joins Asia Pacific Malaria Elimination Network; GI Dynamics Revenue Up 238% To $2.5m, Loss Up 33% To $40m; Phosphagenics Revenue Down 19% To $2m, Loss Up 21% To $13m; Avita H1 Revenue Down 3% To $2m, Loss Down 16% To $3m; Optiscan H1 Revenue Down 96% To $41k, Profit To $1m Loss; Pharmaust H1 Revenue Up 11% To $1m, Loss Up 98% To $640k; OBJ H1 Revenue Up 587% To $728k, Loss Down 9% To $918; Uscom Appoints SMT Medical German Distributor; Nusep, Prime Borrow $1.4m; Invion Releases 77m Escrow Shares; Cynata Director Howard Digby Goes Non-Executive; Queensland Offers $4.25m In Research Partnership Grants; Phosphagenics Spill: Lawrence Gozlan, Nathan Drona, Dr Cauwenbergh; Bio-Melbourne Hosts Animal V Human Health Debate
 
 
Feb 17, 2014
Pharmaust, NSW Uni Patent For PPL-1 Chemo Enhancer; Prana Requests Phase II Huntington’s Results Trading Halt; Cellmid Issues 600,000 Shares To Brynne Edelsten; Nab, Westpac, Bt Below 5% In Acrux; Clarification: Medical Australia, Bruce Hancox, Windfall
 
Feb 14, 2014
Hearing CRC Develops Super-Directional Hearing Aid; Full FDA Approval For Chemgenex, Teva Synribo (Omapro); Report Pushes Genetic Technologies Up 65% On Nasdaq; Rhinomed Breatheassist For Migraine Drug Delivery; Ex-CEO Dr Phillip Comans, Wigram Take 10% Of Bioxyne; Bio-Melbourne Hosts ‘Devices And Diagnostics Lab’
 
Feb 13, 2014
Actinogen Back To Antibiotic Future; Progen: ‘PG545 Almost Doubles Median Survival In Mice’; US Patent Allowed For Biotron BIT225; Onq To Distribute Bluechiip In Australia, New Zealand; Mayne $18m Placement At 79.5c; Allan Gray Takes 14.5% Of Acrux; Universal Bio Revenue Down 49% To $15m, Loss Up 27% To $12m; Suda Hires Kad Consultants For FDA Advice; Oncosil Appoints Natalie Ruffles Clinical Research V-P ; Medical Australia: Darryl Ellis COO, Bruce Hancox Director
 
Feb 12, 2014
Mayne Buys 4 Forest Labs Brands For $13m; $18m Placement; CSL Record H1 Revenue Up 5% To $3b, Profit Up 3% To $714m; USPTO Backs Genetic Technologies Non-Coding Patent, Again; Cogstate Wins Unnamed Company $1.6m Paediatric Trial Deal; ITL H1 Revenue Down 2% To $13m, Profit Down 17% To $1m; Analytica Promotes COO Geoff Daly To CEO, Starts On $210k; Pete Meyers Replaces Prima Director Dr Richard Hammel; Rhinomed Appoints Brent Scrimshaw, Dr Eric Knight Directors
 
Feb 11, 2014
Burnet’s Prof Sharon Lewin To Head Doherty Institute ; WEHI Links Gene Splicing And Developmental Diseases ; Melbourne Genomics Health Alliance Launched; NHS Scotland Reimburses Psivida’s Iluvien For DME; Bluechiip Signs Biospensa As Malaysia Distributor; Cochlear H1 Revenue, Unit Sales, Profit Down; Biota H1 Revenue Up 161% To $34m, Loss Up 54% To $4.5m; Unilife H1 Revenue Up 386% To $7.5m, Loss Up 1.4% To $31m; YZI Trading Takes 25% Of Medical Australia ; Reva Appoints David Eisler General Counsel V-P; Santo Costa To Replace Alchemia Chairman Nathan Drona; Alison Coutts Replaces Nusep’s Prakash Patel, Co Sec Change
 
Feb 10, 2014
FDA Clears Admedus Cardiocel For US Market; Cynata Hires Waisman For Stem Cell Manufacture; Clinuvel Starts Phase II Scenesse Hailey-Hailey Disease Trial; Uscom Wins 4-Star Central Blood Pressure Rating; Psivida H1 Revenue Up 4.5% To $1.3m, Loss Up 39% To $8m; US Patent For Cellmid For Preventing Surgical Adhesions
 
Feb 7, 2014
Nature Paper Backs Benitec TT-034 For Hepatitis C; Allan Gray Takes 13% Of Acrux; Virax Hopes For Transgene Co-X-Gene Licence Royalty; US Athletes Survey Shows Interest In Rhinomed Turbo; Phylogica Pleads Schultz To ASX 42% Query; Mass Mutual Ceases 15.5% In Tyrian; Bio-Melbourne Breakfasts With Avcal’s Yasser El-Ansary
 
Feb 6, 2014
Approvals For Prima Phase II CVac Cancer Trial Changes; Viralytics Issues First $6m Of $27m Raising; Mayne Expects H1 Revenue Up 159% To $71m, Loss To Profit; Bluechiip, Onq Integrate Tracking, It Systems; Living Cell Appoints Dr Ken Taylor NTCell Program Director
 
Feb 5, 2014
Acrux Tells ASX: ‘Report Cut Price 10%’, $US50m 2015 Milestone; US Patent For Viralytics Cavatak; Lancet Paper Backs Spinifex EMA401 For Neuralgia; All Change At Isonea, Pokies Bruce Mathieson Aboard; Hanrine, Gina Rinehart Invest $1.4m In Oril, Take 27%; Perpetual Reduces To 11% Of Sirtex; Healthlinx Completes 500-For-1 Consolidation
 
Feb 4, 2014
WEHI: ‘JAK Inhibitors Potential For Stomach, Bowel Cancer; Genetic Technologies Dr Mervyn Jacobson Court Dates; Gordagen Raises $6m For Vitamin E Tocotrienols; GI Dynamics 2013 Revenue Up 229% To $2.6m, Expansion, Trials; Acrux Falls On FDA Testosterone Investigation; College Group Becomes Instinctif Partners; TGA Special Approval For Calzada, Polynovo Novosorb; CE Mark Approval For Uscom BP+; UK Minister David Willetts Research Funding Meeting
 
Feb 3, 2014
January BDI-40 Up 6%, ASX200 Down 3%, Big Caps Up 1%  - Prana Up 50%, Benitec Up 39%, Ellex Up 34%, Atcor Down 19%; Admedus, Coridon: ‘Interim Phase I HSV-2 Vaccine Safe, Efficacy’; WEHI: ‘B-Cell Elimination Could Lead To Lymphoma Test’; Bionomics BNC105 Ovarian Cancer Phase I Identifies Dose; Capital Group Takes 7% Of Mesoblast; German Insurance Code For GI Dynamics Endobarrier; Victoria Premier’s Award For Health And Medical Research; Prana Pleads Schultz, Presentations To ASX 19% Query; Isonea Requests More Board Changes Trading Halt; Novogen Appoints Dr Justine Stehn, Prof Peter Gunning; Bluechiip Appoints Ex-QBF Matthew Morgan Director
 
Jan 31, 2014
Celladon Lists On Nasdaq For Mydicar Heart Treatment; Acrux, Eli Lilly Axiron Sales Up 142% To $203m, $28m ‘Dividend’; Healthlinx Ends Administration, Trent Telford Takes 10%; Progen Receives $974k Federal R&D Tax Refund; Rhinomed Launches Turbine At Bike Races, Facebook; Medivac Hopes For Funds, To Rebadge As Woolwich Capital
 
Jan 30, 2014
Mesoblast: ‘Stem Cells Effective For Low Back Pain’; Canada Approves Atcor’s Sphygmocor XCel; Viralytcs $23m Placement, $4m Rights Issue; Patrys Shortfall Raises $925k, Total $7.7m; EU Regulator Delays Clinuvel Scenesse Review To Mid-2014; Progen Pleads Medigen PI-88 Progress To ASX 17% Query; Landon Clay, East Hill Take 11% Of Biota; Medigard Has One Quarter Cash; Eyeon, Spacetime, Stephen Copulos Take 7% Of Healthlinx; Queensland MM, Bryan Frost Take 10% Of Healthlinx
 
Jan 29, 2014
ASX, Biotech Up: Clinuvel Up 13%, Living Cell Down 8%; Immuron Details Phase IIb IMM-124E Nash Trial; Grandlodge, Anastasiou Reduce To 15% Of Immuron; David Plush, Texas Woods Below 5% In Immuron; FDA Okays Invion Re-Start Of INV102 Smoking Cessation Trial; Bone Raises $4m, Rob Towner Chairman, Leon Ivory Goes ; Uscom, Deltex Doppler Monitor Distribution Collaboration; FIL (Formerly Fidelity) Reduces Below 5% In Acrux; Allan Gray Takes 11% Of Acrux; Cellmid Signs Huana Likang As China Distributor; Nusep Appoints Andrew Goodall To Prime Board
 
Jan 28, 2014
IDT Option On Perrigo’s HRT FDA Application; Neuren On-Track For Four NNZ-2566 Phase II Trials; Goodbye Bioniche; Australian Custom Pharmaceuticals, Calzada AOD9604 Licence; Bioprospect Raises $1m For Invatec Depression Diagnostic; Viralytics Requests Capital Raising Trading Halt; Bluechiip CEO Brett Schwarz, Sales Head Brett Roberts Go; Allan Gray Takes 13% Of Starpharma; Gleneagles Takes 27%, LSAF 7%, Chifley 7% Of Healthlinx
 
Jan 24, 2014
Resmed Record H1 Revenue, Profit; Cochlear To Appeal ‘$151m’ US Jury Patent Trial Verdict; Plaintiff Withdraws From Unilife US Lawsuit; Starpharma Pleads Schultz To ASX 16% Fall Query; Phylogica Appoints Investor Dr Bernard Hockings Director
 
Jan 23, 2014
Patrys Completes Phase I/IIa PAT-SM6 Multiple Myeloma Dosing; Starpharma To Begin Phase I Dendrimer-Docetaxel Trial; Woolcock Institute: ‘LF-15 For Steroid-Resistant Asthma’; Persistency Reduces Below 5% Of Living Cell
 
Jan 22, 2014
10-Year Study Backs Patrys PAT-SC1 For Gastric Cancer; Immuron’s Underwritten $10m 11-For-6 Rights Offer; Antisense ATL1102 Stem Cell Mobilization Trial Approved; Ontex Distributes Suda’s Westcoast Incontinence Products; Lonza To Manufacture Regeneus’ Cryoshot Canine Stem Cells; Melbourne Uni, Sanofi Pasteur Undisclosed Alliance; Bioprospect Back-To-Biotech EGM; Isonea Wins Las Vegas Consumer Electronics Show Gong
 
Special Summer Catch Up Edition
Mesoblast Pays Osiris $15m Milestone For Prochymal; Japan Approves Biota, Daiichi Sankyo Inavir For ’Flu Prevention; Antisense: ‘Higher Dose ATL1103 Reduces Acromegaly Marker’; Calzada, Polynovo Begin Novosorb Serious Burns Trial; Cogstate Phase II/III Alzheimer’s Trial Tender, $8m Raising; Cryosite Profit Down To $1m; Avexa Raises $1m Of Hoped-For $3.3m; Bioxyne EGM Closes Failed Vitality Deal; Leaf Joins Actinogen For Production Efficiency, Funds Trials; Admedus Expects $690k R&D Tax Rebate; Malaysia’s Xeraya Invests $14m In Nusep’s Prime; Progen Completes Phase III Liver Cancer Enrolment; Osprey: ‘40% Dye Reduction’ In Avert Pilot Trial; Phylogica Raises $5.2m; Admedus Acquires WA Manufacturing Facility; Psivida To Raise $US19m; Benitic TT-034 FDA Application Delayed One Week; Ellex Buys Iscience For Canaloplasty; Isonea’s Stewart Washer Out, Tim Oldham In, Ross Haghighat Up; Oncosil Re-Approves Loans To Dr Neil Frazer And Martin Rogers; Osprey Enrols First Patient In Avert Device Trial; Bioniche Appoints Donald Olds COO; Genetic Technologies CEO Alison Mew Extends Leave; Isonea Launches Asthmasense Prime In Las Vegas; Resmed Details Peter Farrell’s Non-Executive Role; Capital Group Takes 5.6% Of Mesoblast; Sirtex Sir-Spheres December Quarter Sales Up 19%; Genetic Technologies Claims 23% Increase In Brevagen Tests; Viralytics Completes Phase II Melanoma Treatment; Atcor H1 Sales Down 50%, $1m Loss; European Patent For Bone’s Lexicon; Psivida Ships First Orders Of Iluven To NHS Hospitals; Analytica Appoints Carl Stubbings Director; Biota Raises $31m; Heartware 2013 Revenue Up 87% To $237m; FDA Approves Benitec Hepatitis C Trial; Reva Completes CE Mark Approval Study Enrolment; Starpharma Expects $4.7m R&D Tax Incentive; Atcor’s Sphygmocor Approved In China; Circadian, Opthea Licence OPT-302 (VEX-300) To Selexis; Patrys Raises A Further $1.3m; Stirling (DOCA) To Re-List; Suda Hemostyp Launched In Australia; Agenix Granted Canada Thromboview Patent; Cynata Appoints Dr Kilian Kelly VP Product Development; Prima Amended Phase II Approved In Belgium; Australian Leaders Below 5% In Atcor
 
Jan 2, 2014
Special Edition; 2013: BDI-40 Up 18%; ASX200 Up 15%, Big Caps Up 18%; Admedus Up 926%, Prana 346%, Neuren 320%; Pharmaxis Down 92%, Prima 57%
 
Dec 20, 2013
Resonance Jumps 183% On FDA Hepafat-Scan Approval; Novogen, Cornell Collaborate On Glioblastoma Multiforme; Ellex Raises $3m For US Glaucoma Business; Athyrium Lends Universal Biosensors Up To $28m; Actinogen Acquires Laboratory Space At Murdoch University; FDA Requests Halts Invion Smoking Cessation Trial; Imugene Backs Biolife, Chair Change, Webinvest 6%; Antisense Requests Xmas Eve ATL1103 Results Trading Halt; Genetic Technologies Dr Mervyn Jacobson Down To 19%; IM Medical Drops Biotech For White Data; Nusep’s Dr Stephen Van Der Mye Appointed Interim Co Sec 
 
Dec 19, 2013
2013 - The Year In Review; Pulled Rat Study Halts Living Cell NTcell Parkinson’s Trial; Relabeling Eases Psivida Iluvien FDA Path; Imugene Secures Patents For HER-Vaxx Delivery; Federal Grant For Starpharma MIPS Lung Cancer Research; Pharmaust Prepares For Canine Cancer Trial; Allan Gray Takes 16% Of Tissue Therapies; Suda Appoints Michael Stewart Chairman, Stephen Carter CEO; Rhinomed Appoints Dr Mitch Anderson Sports Advisor
 
Dec 18, 2013
Innate IPO Raises $10m, Hopes To Trade On Monday; Simavita Quick IPO For $1m To List On ASX; Cellmid: ‘574-Patient Study Backs Midkine Disease Biomarker’; Benitec Tribetarna Increases NSCLC Survival In Mice; Bionomics Receives $7m Federal R&D Tax Refund; Progen Expects $614k Federal R&D Tax Refund; Genetic Technologies’ Dr Mervyn Jacobson Drops To 6%; Correction: Medical Australia; Bone Receives Cornerstone $200k Bridge Loan; Ellex Requests Acquisition, Capital Raising Trading Halt; Isonea Pleads Schultz, Lost CEO To ASX 19% Fall Query
 
 
Dec 16, 2013
Patrys Raises $5.5m; Anteo Raises $5.5m; OBJ: ‘GSK Phase II Analgesia Trial’; Drawbridge Begins Phase I Phaxan Anaesthetic Trial; Alchemia Appoints Thomas Liquard Chief Operating Officer; Actinogen Appoints Dr Anton Uvarov Director; Tisia, Henderson Take 10% Of Actinogen
 
Dec 13, 2013
OBJ: ‘Bodyguard Lubricen Improves Knee Function’; Oversubscribed $2.5m QRX Plan Raises $4.1m, Total $11.6m; Allan Gray Takes 10% Of Acrux; NAB Ceases, Again; Windfall (NZ) Trust Takes 10% Of Medical Australia; Lang Walker Companies Take 11% Of Medical Australia; Bone Renewal EGM; Actinogen Raises $1.5m; OBJ Hires Dr Steve Meller For Deal Negotiations; BPH Director Greg Gilbert Resigns
 
Dec 12, 2013
FDA Agrees Hatchtech Phase III Trials; Euro, Japan Patents; Admedus Buys Genzyme Fully-Equipped Plant For Cardiocel; Meta-Analysis Backs Atcor Sphygmocor For Cardiovascular; Antisense Completes Toxicology Dosing; Avexa Hires Nextpharma For ATC Capsules; Tissue Therapies $7m Rights Issue Takes Total To $10m; Simavita Backdoors Into Genetic Technologies GTech; Wilson HTM Reduces To 5.3% Of Universal Biosensors; Genetic Technologies Appoints Dr Paul Kasian Director; Phosphagenics TPM Cow Supplements ‘Reduce Anti-Biotic Use’
 
Dec 11, 2013
Most Patients Enrol In Prana PBT2 Alzheimer’s Extension Trial; Correction: Antisense; Cellmid Raises $2m; FDA Sets May 2014 QRX PDUFA Date; Avexa: ‘Alabama Coal Revenue For ATC By October 2014’; Avita Loses Chair Dalton Gooding, CEO Dr Bill Dolphin
 
Dec 10, 2013
Scotland Approves Pharmaxis Bronchitol; Medical Australia Raises $4m For Medivet Acquisition; Healthlinx DOCA, 13.8b Share, 500-To-1 Consolidation AGM; Starpharma Loses Co Sec Ben Rogers, Nigel Baade Appointed
 
Dec 9, 2013
Benitec Files US IND For ‘Single-Shot’ TT-034 For Hepatitis C; Prana Completes Phase II PBT2 ‘Imagine’ Alzheimer’s Dosing; Well-Funded Suda Pauses Bergen Draw-Down Equity Facility; Medical Developments H1 Profit Fall; GSK Ends Contract; Allan Gray Takes 9% Of Acrux; Hunter Hall Reduces To 4% Of Biota; Persistency Reduces To 6% Of Living Cell; Cellmid Requests Capital Raising Trading Halt; Avita Requests ‘Company Changes’ Trading Halt
 
Dec 6, 2013
FDA Approves Tissue Therapies Vitrogro Trial; Biota Doses BARDA Phase II Northern Hemisphere ’Flu Patients; Victoria Israel $500k For Collaboration Grants; Victoria, STC $100k For 5 Medical Technologies; Genetic Technologies Brevagen ‘Cost-Effective’; Novogen Co Sec Andrew Bursill Resigns
 
Dec 5, 2013
CSL Meets 2012 R&D Targets, $531m Budget, Protein Focus; CSL Licences CSL362 For AML To Janssen Biotech; Biotron: ‘BIT225 Reduces Reservoir Cell HIV’; Virax Reviews Assets, Opportunities; FMR Ceases, Fidelity Holds 5% Of Acrux; Acuvax Ex-CEO Dr William Ardrey Fraud Trial Reset
 
Dec 4, 2013
Mesoblast Stem Cells ‘Safe, Some Efficacy’ In Type 2 Diabetes; Bluechiip Adds 10 Trial Sites, Talks To Asian Distributors; Living Cell Tells ASX: ‘Saturday News Published On Monday’
 
Dec 3, 2013
NSW Cancer Centre Files For Stage Two; UKTo Fund Psivida, Alimera Iluvien For DME; Simavita IPO Raises $14m For Incontinence; GI Dynamics: ‘Meta-Analysis Shows Efficacy’; Progen, Beta Deal On Heparanase; MRCF $1m For Auspherix To Develop Antibiotics; Unilife To Supply Injectible Delivery For Novartis Drugs; Cogstate, Axon, GSK Partner For Elite Performance; Bioprospect Requests ‘Biotech’ Trading Halt; Circadian Loses Robert Klupacs, Appoints Dr Russell Howard
 
Dec 2, 2013
November BDI-40 Down 1%, ASX200 Down 2%; Big Caps Down 0.6%  - Anteo Up 146%, Patrys Up 80%, Impedimed Up 52%; Heartware Pays $33m For Circulite, Synergy Platform; Bioxyne Sells HI164OVTo Mariposa, Dr Phillip Comans Goes; Bioniche To Delist From ASX In 2014; Resonance Pleads Schultz, AGM ASX 107% Query; Up To 26% Oppose Immuron Placement Capacity, Share Issues; Bioxyne 28% Remuneration 1st Strike; Australian Leaders Reduces To 8% Of Atcor; Alison Coutts Replaces Nusep Chair John Manusu
 
Nov 29, 2013
Ascend, 3m Collaboration For Solid Tumors; Antisense Applies For ATL1102 Stem Cell Mobilization Trial; Cynata Jumps 36% On Open; Patrys Multiple Myeloma Patients Tolerate PAT-SM6; Circadian: 23% Oppose Remuneration, Don Clarke Goes; 36% Oppose Genetic Technologies EGM Note, Options - Prof Ian McKenzie, Grahame Leonard Appointed Directors; Steven Kritzler Reduces To 5% Of Nanosonics; Progen: Jitto Arulampalam Chair, Dr Hongjen Chang Director
 
Nov 28, 2013
Safety Board Approves Alchemia Phase III Ha-Irinotecan Trial; Alchemia Fondaparinux Profit Share Up Despite Sales Fall; Neuren $2m Share Plan Takes Raising To $23.5m; Institut Curie To Use Impedimed L-Dex In Cancer Trial; Eli Lilly Launches Acrux’s Axiron In Brazil; Cynata Returns To ASX From Eco Quest Tomorrow; OBJ Files 3rd Magnetic Transdermal Patent Application; Perth’s Cornerstone Hopes To Save Bone; Progen Loses Remuneration Vote - 71% Against; Pharmaxis AGM Faces 16% Dissent Against Remuneration; Up To 19% Oppose Avexa Remuneration Report; Quixote, Myer Family, Asia Union, Diluted In Cogstate; Genetic Technologies Director Benjamin Silluzio Withdraws; Adrian Bowers Replaces Resonance Co Sec Naomi Haydari
 
Nov 27, 2013
Victoria Awards $635k Technology Vouchers; Analytica 2014 Launch For Pericoach Anti-Incontinence Tool; Cynata Readies For Commercial Stem Cell Manufacture; Antisense ATL1103 Acromegaly Trial On-Track; Circadian Completes Phase Ib Enrolment, Safety Review; QRX, Teva Deal For Moxduo In Israel; Viralytics Appoints Prof Keith Flaherty To Scientific Board; Progen Loses Chairman Stuart James
 
Nov 26, 2013
QRX Resubmits Moxduo FDA Application, Again; Dagmar Dolby Takes 8% Of Cogstate; Novogen Files US Anti-Tropomyosin Drug Patent Family; Bank Of America, Merrill Lynch Take 5.5% Of Suda; Mayne AGM 8% Oppose Executive Option Change; IM Medical Pleads Technology News To ASX 200% Query; Actinogen To Lose Executive Director David Zohar; Solagran Appoints Dr Darren Schliebs CEO
 
Nov 25, 2013
Mesoblast, Regeneus Welcome Japan Phase II Approval Law; Living Cell Earns $2m On NTCell Parkinson’s Implant Approval; Novogen, Cantx Trilexium ‘Destroys Ovarian Cancer Spheres’; 32% Of Starpharma AGM Opposed Withdrawn Constitution; Avita 75% Remuneration 1st Strike; Up To 29% Of Unilife Oppose Director Shares; Allied Health Formally Renamed Admedus; Bioxyne Placement, Options EGM
 
Nov 22, 2013
Biota Closes Antibiotic Programs; Acrux Takes Hexima Drugs For Transdermal Route; Editorial: Proxy Advisors And AGMs; Up To 28% Of Acrux Oppose Chairman Ross Dobinson Options; Up To 35% Of Cellmid Oppose CEO Maria Halasz Loan Shares; Starpharma Blames ‘Proxy Advisors’ For Constitution Vote
 
Nov 21, 2013
CSL Heart Therapy CSL112 ‘Reverses Cholesterol Transport’; Antisense $550k 1-For-3 ‘Loyalty’ Options, Consolidation; Thai Green Light For Biotron BIT225 Hepatitis C Trial; Unilife, Hikma Deal $40m Upfront, Milestones; Editorial: Reporting UBS AG In Biotechnology Companies; UBS AG Ceases Substantial In Cochlear, Neuren; Allied Health Becomes Admedus, 8% Oppose Directors’ Stock
 
Nov 20, 2013
Biota Begins Two Phase I LANI Trials For Influenza NDA; Rhinomed Launches Turbine Nasal Plugs; Up To 26% Of Resmed Oppose Incentive Plan, Executive Pay; Clarity Appoints Inteq’s Dr Alan Taylor Executive Chair; IDT Loses Director Dr Roger Aston; Ausmedtech, Burnet ‘Diagnostics For Emerging Markets’ 
 
Nov 19, 2013
WEHI Celebrates 10 Years Of Drug Discovery; Mesoblast Stem Cells Benefit Heart Pump Patients; Innate To Raise Up To $12m For MIS416 For Multiple Sclerosis; Cogstate Loss Warning, Cuts Staff, $7.55m Raising; Correction: Cynata (Eco Quest); NSW Uni Assigns Pitney Patents To Pharmaust; Allan Gray Takes 8% Of Acrux, 13% Of QRX
 
Nov 18, 2013
IDT Files First FDA ANDA For Generic Temozolomide For Cancer; Prana: ‘Most Alzheimer’s Trial Patients In Extension Study’; FDA Approves Medical Developments’ Space Chambers; US Patent For Patrys PAT-SM6; ASX Reinstates Virax From Tomorrow; Eco Quest, Consegna Become Cynata, Rhinomed; Cellmid To Pay Brynne Edelsten Up To 1.4m Shares For Hair; Cogstate Requests Capital Raising, Guidance Trading Halt; Osprey Appoints Avert Cardiac Dye Study Investigators
 
Nov 15, 2013
Calzada Loses Chair David Franklyn At AGM, Dr Roger Aston In; Prima Loses Reviver Martin Rogers; Circadian Expects $2.5m Federal R&D Tax Refund; Consegna Becomes Rhinomed On Monday; UBS AG Reduces To 5% Of Neuren
 
Nov 14, 2013
Mesoblast: ‘Prochymal Benefit For Paediatric Acute GVHD’; Regeneus Developing Canine Cancer Vaccine, Human Potential; Resonance, Alliance To Provide European Imaging; Novogen, Genea Collaborate On Degenerate Diseases; Correction: Reva; Avexa Plan To Raise Up To $3m, Small Parcel Facility; Eco Quest Completes 1-For-20 Consolidation; Talu Takes CM Capital’s 10% Of Universal Biosensors; Hockings Take 19.99% Of Phylogica; Capital Concerns, Logue Family Below 5% Of Immuron, Again; Genetic Technologies Director Tommaso Bonvino To Retire
 
Nov 13, 2013
QRX Raises $7.5m, 34% Oppose Remuneration; NSW $250k To Cardiovascular Research Network; Virax Released From Administration; Suda Raises $5.6m; Canada Approves Immuron OTC Travelan; Patrys Rights Issue To Raise $12.5m; Impedimed: AMA Raises BIS Lymphoedema Test To CPT Code 1; Acrux, Eli Lilly Sue Actavis Over Axiron Patents; Reva Rezolve2 Sales Delay, Finance, New Products Pipeline; Isonea To Lose CEO Michael Thomas In 2014; Thai Quoc Tang Gaol For Tissue Therapies Share Trading; Consegna AGM Votes To Become Rhinomed
 
Nov 12, 2013
Heartware September Quarter Revenue Up 140% To $59m; Unilife, Medimmune Deal On Wearable Injectors; Ellex Claims Sales Improvement; Suda Restructures Protopharma Artimist Deal; Uscom Appoints Medsource As Southern US Distributor; Up To 24% Of Suda AGM Oppose Placement Capacity; Atcor Pleads Schultz To ASX 33% Query
 
Nov 11, 2013
Clinuvel US Phase III EPP Trial Misses Primary Endpoint; FDA Further Delays Invion Phase II INV102 Smoking Cessation Trial; Mesoblast Stem Cells Improve Stroke Recovery In Rats; FDA Committee Backs Cochlear Hybrid Hearing Implant; Patrys PAT-SM6, Carfilzomib Trial For Multiple Myeloma; Antisense Receives $974k Federal R&D Tax Refund; QRX $5m Placement, $3m Share Plan; Phylogica Underwritten $6m Rights Issue, Notes; Suda Deal, Capital Raising Halt; Hires Torreya For Deals; Jason Peterson, Celtic Capital Cease Consegna Substantial; Robert Thomas Replacing Starpharma Chair Peter Bartles; Impedimed Appoints David Adams Second US Director
 
Nov 8, 2013
Immuron IMM-124E ‘Alleviates Liver Fibrosis In Mice’; Federal Government $522m For 1,177 ARC Research Projects; Allied Ships 1st European Cardiocel Order; Viralytics Prepares For New Cavatak Melanoma Trial; FDA Clears Immuron Phase II IMM-124E ASH Trial; Anteo, BBI Solutions To Investigate Mix&Go For Diagnostics; Patrys 2nd US Patent For PAT-LM1; Osprey Completes $14m Placement; Biodiem Departs The ASX; Biotron AGM Rolls Director Bruce Hundertmark; Up To 11% Of Alchemia AGM Oppose Director Options; Up To 24% Of Nanosonics Oppose Chairman Maurie Stang; ‘Third Party’ Agrees To Pay Back Phosphagenics Theft
 
Nov 7, 2013
Prima Trial Changes, Drops Licence, Israel-Palestine Deal; Novogen, Yale Joint Venture Cantx For Ovarian Cancer; Centenary Institute, Mirrx Collaborate On Mirna Blockmir; J&J’s Lifescan Ends Universal Biosensors Test Strips; Biotech Daily Is Eight, Today; Unilife CEO Alan Shortall Rebutts US Legal Action; Unilife Pleads Schultz, US Law Suit To ASX 16% Fall Query; Anteo’s CEO Dr Geoff Cumming Starts On $400k; Phylogica Requests Capital Raising Trading Halt
 
Nov 6, 2013
FDA Orphan Designation For Patrys PAT-SM6 For Cancer; Resmed Swaps $US400m Credit Facility For Up To $US1bn; Biota Incentive Plan 259% Rise AGM, Law Firm ‘Investigates’; Unilife Requests US Lawsuit Trading Halt; Ausimed To Support Early-Stage Australia-Israel Research; Imugene Appoints Dr Axel Hoos Director, Steve Harris Goes
 
Nov 5, 2013
Imugene Completes First $850k Tranche Of $2.5m Placement; Bioniche Appoints Dr Michael Berendt CEO
 
Nov 4, 2013
Clinuvel Phase II Scenesse Trial For Darker Skin Vitiligo; Tissue Therapies $3m Placement, $5.3m Rights Offer; Eco Quest Raises $5m, To Become Cynata; Minderoo (Metal) Group Reduces To 16% Of Allied Health; Anteo Agm: 25% Oppose Placement Capacity
 
Nov 1, 2013
Adjusted 7-Year BDI-40 Up 160.7%, ASX200 6.9%; October BDI-40 Up 2.5%, ASX200 Up 4%; Big Caps Up 5% - Allied Health Up 102%, Benitec 65%, Phosphagenics 61%; MRCF $2m For Protego Sternum Protector; Allan Gray Takes 6.75% Of Acrux; Living Cell: ‘Diabecell Reduces Hypoglycaemic Events’; Alchemia: ‘Dr Reddy’s Stronger In North America’; Perpetual Takes 12% Of Sirtex; Franklin Resources, Affiliates Take 5% Of Cochlear; Australian Ethical Takes 10% Of Ellex; Dr Bernard Hockings Reduces To 5.8% Of Phylogica; Ausbiotech Elects Directors Julie Phillips, Dr Andrea Douglas
 
Oct 31, 2013
FDA Approves Teva, Mesoblast Phase III Cardiac Trial; Prana PBT2 Reverses Memory Loss In Old Normal Mice; Reva Implants 87th Rezolve2 Stent Live To Conference; Hatchtech Raises $13m, Dr Richard Treagus Director; Agenix To Sell AGX-1009 For Hep B To China For $2m; UBS AG Takes 6% Of Neuren; Dr Esra Ogru, Phosphagenics Deed; Robert Gianello To Court; Tissue Therapies Has One Quarter Cash; Raising Trading Halt; Unilife Has One Quarter Cash; CEO Dr Neil Frazer Takes 8% Of Oncosil; Ian Frazer, Allied, Nanosonics Win Ausbiotech Janssen Gongs
 
Oct 30, 2013
Ausbiotech Brisbane Conference Opens; FDA Orphan Status For Neuren NNZ-2566 Fragile X Trial; WEHI’s Prof Terry Speed Wins $300k PM’s Science Prize; Regeneus Hiqcell Arthritis Treatment In Melbourne; Pharmaxis Opts For Novaquest’s $42m; Impedimed Appoints Investigators For Pivotal Trial; DSM To Manufacture Circadian, Opthea OPT-302 (VGX-300); Immuron AGM For 18m Director, CFO Shares, 55m Options; Proctor & Gamble Promotes Isonea Airsonea To Women; Cellmid To Release 10m Advangen Escrow Shares; Novogen Appoints Lionel Mateo Joint Co Sec; Biodiem Has One Quarter Cash, Delisting
 
Oct 29, 2013
TGA Approves Progen Phase I PG545 Solid Tumor Trial; No Adverse Cardiac Events In Reva 30-Day Rezolve2 Follow-Up; Eco Quest Cynata AGM Suspension; Alchemia HA-Irinotecan For Lung Cancer ‘Good Early Data’; US Patent For Drawbridge Phaxan Anaesthetic; Xeraya $13m For Nusep’s Prime, Alison Coutts Takes Chair; Sirtex Small Dissent Against CEO Performance Rights; Alchemia Receives $9m Federal R&D Tax Refund; Psivida AGM For 370k Director, CEO Options; Domain Reduces To 5.6% Of GI Dynamics; Ausbiotech, Koreabio Collaboration
 
Oct 28, 2013
Vale Lou Reed 1942-2013; Ausbiotech Investor Conference; CEO Dr Anna Lavelle Back; Clinuvel Scenesse Efficacy In Two Hailey-Hailey Patients; Invion Pays Accolade $500k For Zafirlukast For Asthma; Allied Pleads Schultz To ASX 60% Query; Mesoblast Partner JCR Files For First Japan MSC Approval; Atcor $625k German Trial Contract; Prof Ruth Bishop Wins $50k AIPS, CSL Florey Medal
 
Oct 25, 2013
Biotron BIT-225 Reduces G-3 Hep C In HIV Co-Infected Patients; Japan Approves Cyclopharm Technegasplus For Clinical Use; Tissue Therapies Files For Pivotal US Vitrogro Trial; Atcor Sphygmocor Mexico Approval Not Complete; Virax Raising $2.5m, Preparing To Resurface On ASX; Minderoo (Metal) Group Takes 18% Of Allied Health; Watermark, Australian Leaders, Braitling Below 5% Of Mayne; Kinetic Takes 6% Of Osprey; Belgravia, Geoffrey Lord Increases, Diluted To 9% Of IDT
 
Oct 24, 2013
Mesoblast, Intrexon, Ziopharm Unite For New Cancer Drugs; Starpharma: ‘Dendrimer-Docetaxel Stops Neutropenia In Rats’; Phosphagenics: ‘Opioid Patch Beats High Dose Tablet’; Federal Government Recommits To Research Funding; Acrux Axiron Sales Down, $26m Milestone; Schroder, Associates Take 7% Of Cochlear; Inverarey Takes 7% Of Immuron; OBJ Pleads Schultz To ASX 23.5% Query; WEHI ‘It’s A Hit - Decade Of Drug Discovery’ Symposium; Bio-Melbourne, Infection Network Breakfast On Superbugs
 
Oct 23, 2013
Federal Government: $559m NHMRC Grants; Imugene To Buy Biolife HER-Vaxx For 300m Shares, Raises $2.5m; Allied Oversubscribed Rights Offer Raises $10.4m; Viralytics Receives $1.9m Federal R&D Tax Refund; USPTO Allows Immuron Cow Colostrum Patent; Up To 38% Of Genetic Technologies Oppose EGM Votes; Australian Ethical Takes 7% Of Pharmaxis; Benitec Releases 2m Escrow Shares, Issues 1m Tacere Shares; Nanosonics CEO Michael Kavanagh Starts On $410k; Cyclopharm Chairman Vanda Gould Steps Aside; Andrew Manhire Replaces Medical Dev Co Sec Wendy Gouveia
 
Neuren Places $21.5m, Share Plan For $3m More; Walter And Eliza Hall Trust Funds WEHI Equipment; Osprey Begins 20-Patient Diabetic Limb Recovery Trial; Allan Gray Returns To Substantial In Acrux; Westpac, BT Take 6%; NAB, Associates ‘Lend’ Below 5% Of Acrux; Correction: IDT; I’rom Increases, Diluted To 16.5% Of IDT; Invion Pleads Schultz To ASX 47% Query; Virax Appoints Sean Henbury Co Sec; Happy 10th Birthday To Pharmaust’s Epichem; Ausbiotech Readies For Melbourne, Brisbane Conferences
 
FDA Rejects Psivida's Iluvien For DME, Again - New Trial; FDA Approves Iroko, Iceutica Perth-Invented Nano-Diclofenac; Novogen Draws Down Further Hudson Bay $1m; Anteo To Trial Mix&Go Magnetic Beads, Plates; Pharmaxis AGM For 2m CEO ‘Performance Rights’; Allied Health AGM For 7m Director Options, Name Change; Cellmid AGM For 12m CEO Loan Shares; IDT Dr Graeme Blackman Increases, Diluted To 9%; Hunter Hall Down To 18% Of Sirtex; Imugene Requests Acquisition, Capital Raising Trading Halt
 
Avita Investigator Recell Trial ‘Excellent’ Repigmentation; US ‘Fast-Track’ For Neuren Fragile X Trial, Trading Halt; Cellmid, Pacific Edge Cxbladder Test Signs US Deal; Japan Patent For Cellmid’s Midkine; US Patent For Oncosil Pancreatic Cancer Treatment; Psivida Requests FDA PDUFA Iluvien DME Review Trading Halt; Federal Government Boosts Suda Westcoast Record Revenue; Starpharma AGM For 950k CEO ‘Performance Rights’; Patrys Loses Director Dr Alan Robertson; Canary Networks Biotechnology Sydney, Melbourne Shows
 
Pharmaxis Prepares For US Bronchitol CF Trial In 2014; IDT Completes $3.1m Placement; Allied Phase I Herpes Vaccine Trial ‘Safe So Far’; Circadian Phase Ia VGX-100 Solid Tumor Trial Enrolled; Antisense Expects Early Look At ALT1103 Acromegaly Data; Benitec Pleads Schultz, Roadshows To ASX 45% Query; Cyclopharm Chairman Vanda Gould Charged On Tax Schemes
 
Ramaciotti Foundations $2.2m For Biomedical Research; Osprey Raises $14m; CSL AGM: 20% Oppose CEO Paul Perreault ‘Performance Rights’; US, Australian Patents For BPH, Cortical Dynamics Monitor; Isonea, Uhealth Sales, Distribution Collaboration; Pharmaxis Q1 Bronchitol Sales Up 179%; Novogen Up 36% On Deal Speculation
 
Oct 15, 2013
Medical Developments Files European Penthrox Application; Eco Quest $6m Share Plan Opens; Uscom: ‘China’s Pioneer Commits To 5-Year, $7m Distribution’; QRX Licences South Africa Moxduo IR To Aspen; Innate Completes Move From NZ To Sydney For MS Drug; Benitec AGM For 67% Increase In Directors Fee Pool; Genetic Techno Tom Howitt Acting CEO, Alison Mew On Leave
 
Starpharma Dendrimer-Oxaliplatin Cuts Neurotoxicity In Mice; Ellex: ‘Study Backs 2RT For Early AMD’; Osprey Requests Capital Raising Trading Halt; European Patent For Consegna’s Breatheassist; Limberg Takes 6% Of Regeneus; Invion Executive Dr James Campbell Returns To Non-Executive
 
Mesoblast Buys ‘Competitor’ Osiris For Up To $106m; Melbourne Uni, Procypra Collaborate On Parkinson’s
 
 
Burnet’s Hepseevax Raising $1.5m For Delta 3 For Hep C; University Of Queensland, Leo Collaborate On Skin Cancer; Cogstate, Merck: ‘Cognigram Measures Cognitive Decline’; Kaiser Permanente Expands Impedimed L-Dex U400 Roll-Out; QRX Closer To Resubmitting Moxduo Application To FDA; Novogen Acquires Genscreen’s Anti-Tropomyosins For Cancer; Universal Biosensors J&J Verio Back, Siemens Test Delayed; Biodiem AGM Votes To Delist From ASX; Neuren Pleads Schultz, Good News To ASX 39% Query; Alchemia AGM For 3m Director, CEO, Ex-CEO Options; Australian Leaders Reduced, Diluted To 9% Of Atcor 
 
Prof Alan Cowman, Prof Lloyd Hollenberg Win Victoria Prizes; Regeneus: ‘Hiqcell Effective, Safe For Osteoarthritis’; TGA Allows 8 More Surgeons To Use Allied’s Cardiocel Patch; Clinical Genomics Buys Enterix For Blood Bowel Cancer Test; US Politics Could Delay Benitec On-Track Hepatitis C Trial; Broad Euro Patent For Cellmid’s Midkine; Bionomics $17m Off-Shore R&D Eligible For 45% Rebate; Bioniche Urocidin Canada Filing Delayed 6 Months; Agenix Quits China, Thromboview China Patent; Nusep Receives $1.65m R&D Tax Refund; David Adams To Replace Impedimed Director Dr Mel Bridges
 
Acrux Axiron First Euro Approval, Products In Development; Ausbiotech: Melbourne 2016 International Bio Symposium; CSL Settles US Anti-Trust Suit For $68m
 
3-Month Sirtex Dose Sales Up 4%; Cellmid Receives $712k R&D Tax Refund; Healthlinx Raises $70k; CEO Alan Shortall Takes 6.7% Of Unilife
 
Cellmid Anti-Midkine Efficacy Against Tumors In Mice; ATP, Ignition Labs Launch 4 Startups With $25k Each, Mentors; Genetic Technologies Underwritten Plan Raises $1.4m Of $3m; Anteo AGM For 9m Director Options; NAB, Associates Take 5% Of Acrux; Australian Ethical Takes 6% Of Universal Biosensors; Australian Ethical Takes 9% Of Ellex; Ascend Appoints Dr Peter Smith Chair, Mark Ewing Director
 
Oct 2, 2013
US Patent For Phylogica Synthetic Phylomer Libraries; Isonea AGM For 1m 14c Director Options; Atcor’s Sphygmocor XCel Equals Tonometry For Stiffness; Acrux Appoints Dr Tim Oldham Director; Federal Parliamentary Friends Of Women In Science Meetings
 
Sep 27, 2013
Bionomics: ‘BNC375 100-Fold Therapeutic Window, Safety’; IDT Rights Issue Raises $2m; $4m To Go; Bioniche Raises $10m; Antisense Consolidation; $570k 1-For-3 ‘Loyalty’ Options; Euro Patent For Imugene’s Linguet; Medical Developments Appoints Leon Hoare Director
 
Sep 26, 2013
Menzies Research: ‘Less Drugs With Atcor Sphygmocor’; US Approves Ellex SLT For Government Contracts; Genetic Technologies’ Immunaid To Raise Up To $10m; Psivida Revenue Down 39% To $2m, Loss Down 52% To $13m; Generation, Unnamed Associates Take 5% Of Cochlear
 
Sep 25, 2013         
‘No Calcification’ In Allied 5-Year Cardiocel Follow-Up; Victoria’s Technology Voucher Program Opens; Sunshine Heart Raises $49m; Australian Antisense ATL1102 Multiple Sclerosis Patent; Denlin, Tony Grist Diluted Below 5% In Oncosil
 
 
 
Sep 20, 2013
Living Cell Implants First-In-Human Pig NTCell For Parkinson’s; Sunshine Heart To Raise $42m; Suda Appoints Ex-Phylogica Nick Woolf Chief Business Officer; Impedimed Board Loses Greg Brown; Morten Vigeland CFO; Cellmid To Supply Hair Lotion To Japan’s Natural Garden; Schroder, Associates Take 5% Of Cochlear; Jason Peterson. Celtic Take 5% Of Imugene; Eco Quest Requests Cynata Acquisition Trading Halt
 
Sep 19, 2013
Prima Suspends Phase II/III CVac Cancer Study For Endpoint; Mesoblast: ‘Stem Cells Equal Graft For Lumbar Spinal Fusion’; Ellex Placement Raises $3.3m; Phosphagenics Begins Phase I TPM-Oxymorphone Dosing; Regeneus Opens Up 14%; Bioniche Raises Raising To $9m; Virax Placements To Raise Up To $2.5m; Consegna Name Change To Rhinomed, Sells Imugene Shares; Biota Revenue Up 65% To $35m, Loss Down 55% To $9m; Sunshine Heart Capital Raising; Pharmaxis Loses Dr John Villiger, Richard Van Den Broek
 
Sep 18, 2013
Viralytics Cavatak Meets Melanoma Endpoint Ahead Of Plan; Calzada Files Novosorb FDA Wound Dressing Application; Uscom Raises $1m; Osprey Cincor Dye Trial Continues, ‘Avert’ The Priority; Imugene Discontinues Linguet Ibuprofen; Bio-Melbourne Breakfasts On Emerging Technology Jobs
 
Sep 17, 2013
Osprey Focus On Heart Dye Reduction Over Capture; Genetic Technologies Settles Genelex Non-Coding DNA Case; Medivac Sells Metamizer; Eco Quest Pleads Schultz, Cynata To ASX 28% Query; Ender 1, SNP, Apercen, Polansky Take 6% Of Clinuvel; Ellex Requests Capital Raising Trading Halt
 
Sep 16, 2013
Ian Macfarlane For Industry, Peter Dutton Health; Biodiem BDM-I Active Against Cryptococcus, Fungi; Living Cell NTCell Improves Parkinson’s In Monkeys; Suda $1.9m Secured Convertible Notes; Starpharma Priostar Evaluation With Gowan; Bluechiip Offers Blue-Diligence Advice; Pharmaust Share Plan Raises $185k; Biota Loses Director, Ex-CEO Peter Cook; Cyclopharm Regains Director Henry Townsing
 
Sep 13, 2013
Sunshine Heart Pivotal Trial Enrols 1st Of 388 Patients; Prana PBT2 Huntington’s Results Delay, Alzheimer’s Extended; Oncosil $7.8m Placement, Plan For $2.5m More, Director, Co Sec; Actinogen Closes Laboratory, Loses Staff; Cochlear 2nd Strike Spill, $1.4m CEO Options AGM; CSL AGM For 25,000 CEO Paul Perreault ‘Rights’, Dr McNamee $5m; Benitec Lung Cancer Candidate Wins Uni Of NSW Gong
 
Sep 12, 2013
Victoria Awards Three $150k Veski Fellowships; EU Orphan Status For Patrys PAT-SM6 For Multiple Myeloma; 17 Of 25 GI Dynamic Endobarrier Trial Sites Recruiting; Oncosil Requests Capital Raising Trading Halt; Bioniche Settles Dispute With Dissenting Shareholders
 
Sep 11, 2013
Starpharma: Dendrimer-Oxaliplatin Superior, Less Toxic In Mice; Regeneus IPO Raises $10.5m, ASX Listing Next Week; Mayne Licences Suba-Itraconazole To Hedgepath For Cancer; UK Approves Viralytics Phase I/II Cavatak Cancer Trial; QRX Licences Moxduo To Aspen For Australasia; Correction: Unilife; Calzada Pleads Schultz To ASX 10.5% Fall Query; Chairman Andrew Kroger Takes 25% Of Cryosite
 
Sep 10, 2013
Unilife Long Term Syringe Deal With Sanofi; Heartware Leaves The Building; Synthesis Opens Cambridge Chemistry Facility; Genetic Technologies Completes $5m Ironridge Notes Document; Celtic, Denlin, Tisia, Henderson, JK Have 25% Of Eco Quest; Mark Pryn Replaces Circadian CFO, Co Sec Steven Zammit
 
Sep 9, 2013
UK Diabetologists Funds GI Dynamics Endobarrier Trial; FDA Approves Neuren Phase II NNZ-2566 Fragile X Trial; BSI Submits Tissue Therapies Vitrogro Dossier To EMA; S&P ASX300 Promotes Mayne, Demotes Pharmaxis
 
Sep 6, 2013
‘Coalition Decides ARC Grants’ - Shadow Treasurer Joe Hockey; FDA Sets October Date For QRX On Moxduo; Stefan Cross To Replace Mayne USA President Phil Hodges; Michael Quinert Replaces Healthlinx Malcolm Lucas-Smith
 
Sep 5, 2013
Innate $12m For Phase IIb Progressive Multiple Sclerosis Trial; John Leaver Increases, Diluted At 6% Of Bionomics
 
Sep 4, 2013
Ellex Recruits 50 Patients, Adds 2 Sites To 2RT AMD Trial; Parkinson’s UK Grants $260k For Prana PBT434 Study; Mexico Approves Atcor’s Sphygmocor XCel; NSW $3.25m For Chronic Disease; Isonea: Airsonea CE Mark Documents Filed; Cellmid Revenue Up 344% To $761k, Loss Down 22% To $1.5m; Ausbiotech Brisbane Conference: ‘Bio-Economy In Transition’; Australian Museum Eureka Prizes Tonight
 
Sep 3, 2013
Election Editorial: No One Offering A $1bn Phase III Trials Fund; Allied Treats 1st HSV-2 Patients, Call For Volunteers; Virax Votes For Resuscitation; Genetic Technologies, Genesis Settle Patent Case; Phosphagenics Opioid Posters At Las Vegas Pain Conference; Immuron Loses Director Dr Elane Zelcer; Prana’s PBT2 Wins Elsevier Neuroscience Gong; Uniquest’s Dendright Appoints Helen Roberts CEO
 
 
Aug 30, 2013
Biotron Targets HIV, Hep C Co-Infection; New York Clears Genetic Technologies Brevagen For US; Biodiem To Delist In November; South Korea Approves Nanosonics Trophon; Viralytics Pleads Schultz To ASX 19% Query; Atcor Revenue Up 41% To $9m, $2.7m Maiden Profit; Ellex Revenue Down 10% To $43m, Profit Turns To $816k Loss; Alchemia Revenue Up 3,247% To $24m, Loss Down 68% To $5m; Compumedics Revenue Down 3% To $27m, Loss Down 46% To $1.5m; Allied Health Revenue Up 15% To $7m, Loss Down 81% To $2m; Avita Revenue Down 22% To $4m, Loss Up 5% To $8m; Mass Mutual Reduces To 7% In Novogen; Genetic Technologies Revenue Up 31% To $8m, Loss Up 76% To $9m; Resonance Revenue Down 4% To $1.7m, Loss Down 36% To $173k; Unilife Pleads Schultz To ASX 30% Query
 
Aug 29, 2013
Hearing CRC Remote Cochlear Implant Mapping Module; Living Cell Direction Change, Phase IIb Trial Questions; IDT Placement, Rights Issue To Raise $6m; Mesoblast Revenue Down 9% To $35m, Loss Down 13% To $62m; Reimbursement Delays Pharmaxis French Bronchitol Launch; Cryosite Revenue Up 9% To $9m, Profit Up 22% To $1m, Dividend; IDT Revenue Up 7% To $11m, Loss Up 191% To $5m; Prima Files US Sec ‘Shelf Registration’ To Raise Up To $67m; Cambridge’s Dr Greg Winter In Bio-Melbourne Blockbuster; Bone Pays ASX Fees, Returns To Listing
 
Aug 28, 2013
WEHI Test For Coeliac Disease Shows Greater Prevalence; More Data Delays QRX 6 Months, 2014 Launch Hopes; FDA Approves 286-Patient Heartware Destination Trial Extension; Cyclopharm H1 Revenue Up 15% To $5m, Loss Down 23% To $986k; Circadian Revenue Down 22% To $1m, Loss Up 2% To $5m; Impedimed Revenue Down 8% To $3m, Loss Down 31% To $8.5m; Brain Revenue Down 34% To $4m, Profit Turns To $1.5m Loss; Progen Revenue Up 24% To $3.5m, Loss Down 39% To $2m; Eco Quest 100m Director’s Options EGM; Wilson HTM Reduces To 5.3% Of Universal Biosensors; Michael Kavanagh Replaces Nanosonics CEO Ron Weinberger; Sunshine Heart Appoints Dr Patrick Verta Chief Medical Officer
 
Aug 27, 2013
Agenix, Arrayjet Collaborate For Micro-Array Diagnostiq; Living Cell: Independent Audit Of Argentine Diabetes Trial; Acrux Revenue Up 56% To $17m, Profit Down 6% To $7m, Dividend; Mayne Pharma Revenue Up 60% To $84m, Profit To $3m Loss; Eco Quest Share Plan Raises $458k; Genetic Technologies Placement Raises $3m; Allan Gray Reduces (Just) Below 5% Of Acrux; IDT Requests Capital Raising Trading Halt; Chris Smith Replaces Universal Bio’s Dr Elizabeth Wilson; L'Oéal: Kathryn Holt, Misty Jenkins, Joanne Whittaker
 
Aug 26, 2013
CE Mark First Approval For Allied Health Cardiocel; Nusep Share Plan Raises $1.2m; Anteo Files 2 Australian Mix&Go Patent Applications; QRX Requests ‘FDA Review’ Trading Halt; Benitec Promotes CEO Dr Peter French To M-D; Prana Pleads Schultz To ASX 14% Query
 
Aug 23, 2013
FDA Approves Osprey Avert Cardiac Dye Reduction System; Nanosonics, Toshiba Sell 6 Trophons To UK Hospital; US Patent Expands Biodiem BDM-I Anti-Microbial Claims; Medical Developments Revenue Up 4% To $12m, Profit Down 15%; Nusep Expects $1.6m R&D Tax Refund; La Jolla Cove Deal Sends Bone Into Suspension; Nicholas Falzon Replaces Oncosil Co Sec Jillian McGregor
 
Aug 22, 2013
Coalition: ‘Faster Trials, Drug Approvals; $35m For Diabetes’; Labor’s Peter Beattie: ‘I Will Champion Biotechnology’; LBT Revenue Up 333% To $4.4m, One-Off Turnaround $531k Profit; OBJ Raises $1.85m; Probiotec Revenue Up 5% To $70m, Profit Down 52% To $597k; Genetic Technologies Signs Interwest For Brevagen Tests; Graeme Kaufman Replaces IDT Chairman Dr Graeme Blackman; Progen PG545 Toxicology Study, Dr Keith Dredge Returns; ASX To Release 6,535,910 GI Dynamics CDIs From Escrow
 
Aug 21, 2013
Coalition R&D Credit ‘Review’; $100m Transition, Export Funds; Sirtex $3m For ANU Professorial Chair; Avita Dutch Recell Vitiligo Trial Recruits All 10 Patients; Cogstate Revenue Up 4% To $12.6m, Profit To Loss; Pharmaust Share Plan For $1m; Consegna Share Plan For $1m; Dr Dax Marcus Calder Takes 6.4% Of Patrys; Bone Requests ‘La Jolla Cove Status’ Trading Halt; Merchant Reduces, Diluted To 16% Of Calzada; Isonea’s Asthmasense Wins Frost And Sullivan Gong
 
Aug 20, 2013
Greens $2bn Science Funding To Take R&D To 3% Of GDP; Labor Promises $250m Medical Research Innovation Fund; Bluechiip Placement Raises $2.55m; GE $4m Nanosonics US Sales Staff, EU Greens ‘Game-Changer’; Generic Fondaparinux Earns Alchemia $9.6m In 12 Months; Allied Pleads Schultz, RBS Morgans To ASX 30% Query; Anteo Revenue Up 22% To $1.8m, Loss Down 8% To $2.2m; OBJ Requests Capital Raising Trading Halt
 
Aug 19, 2013
Bone: ‘La Jolla Cove Still Delaying Payments’; John Richards Replaces Biota’s Jefferey Errington, Bonuses; Acorn Takes Profit, Reduces To 12% Of Starpharma; Och-Ziff Takes 10% Of Brain Resource; Consegna Requests Capital Raising Trading Halt
 
Aug 16, 2013
Tissue Therapies Rebutts Student Claims; Oncosil Pleads Schultz, News To ASX 48% Query; Webinvest Takes 5% Of Oncosil; Medivac Rodger Johnson M-D, Metamizer Deals, $800k Notes; Bluechiip Takes Capital Raising Trading Halt To Suspension
 
Aug 15, 2013
Sirtex Revenue Up 16% To $100m, Profit Up 7% To $18m, Dividend; South Korea Approves Prima CVac Ovarian Cancer Trial; Brain Resource Raises $2m; Suda’s Westcoast Wins Government Preferred Status; Pharmaxis Revenue Up 41% To $11.6m, Loss Up 13% To $43.5m; ITL Revenue Down 12% To $25m, Profit Up 86% To $2.5m, Dividend; Eco Quest Pleads Schultz, Cynata, Directors To ASX 40% Query; Dr Roger Aston, Prof David Morris Substantial In Pharmaust
 
Aug 14, 2013
CSL Record Profit Up 19% To $1,338m, Revenue Up 7% To $5,642m, Marie Mcdonald Replaces Director Ian Renard; Suda Completes Novadel Acquisition; Nanosonics Revenue Up 35% To $17.6m, Loss Up 23% To $5.8m; Labor Names Medical Technology ‘1st Innovation Partnership’; Biota Clears Way For Up To $82m Capital Raising; Biotron BIT Capsule Increases Bioavailability 1.6-Fold; Ellex Profit Warning; Correction: Sunshine Heart; Clarification: GI Dynamics; Greenlight Takes 7% Of GI Dynamics; Jason Peterson, Celtic Capital Below 5% Of Imugene; Bluechiip Requests Capital Raising Trading Halt
 
Aug 13, 2013
Patrys: ‘2 Of 6 Phase I Multiple Myeloma Patients Respond’; WEHI, CSL, Ludwig ‘Interleukin-11 A Potential Cancer Target’; Medical Developments Positive Cardiac Safety Trial; Sunshine Heart Hires Minnetronix For C-Pulse Power System; Regeneus IPO Opened Today; Hunter Hall Has 18% Of Sirtex; Medtronic, J&J, Polaris, Domain, Advanced Diluted In GI Dynamics; ANU Reduces To 5% Of Bionomics; Chairman William Mobbs Takes 35% Of ITL
 
Aug 12, 2013
Uniquest’s Dendright Signs Collaboration With Janssen ; Reva Resolve2 Stent Implant Live To Conference; Perpetual Takes 2m Of Dr Bruce Gray’s 7m Sirtex Shares; Sirtex Directors’ Rights Plan; Pharmaust Raises $2.5m, Founder Bryan Mclarty Resigns
 
Aug 9, 2013
Mayne Signs Two Subacap Distributors For Europe; Heartware H1 Revenue Up 81% To $110m, Loss Down 38% To $28m; Genesis Directors: Phi San Lam, Frankie Chen, Sharon Kwan
 
Aug 8, 2013
Benitec, NSW Uni Beta III Tubulin Gene For Lung Cancer Licence; Regeneus $12m Fat Stem Cells For Musculoskeletal IPO; Imugene Up 60% On Linguet Vitamin D ‘Meltlet’, Partner Talks; Bluechiip Stem Cell, Blood Bag Cryo-Preservation Cassette ; Advanced Surgical Orthofix Distribution Deal, Spinal Sale; Oncosil Hires Emergo For Regulatory Pathways; Bioniche $8m Placement At 30.7 Cents
 
Aug 7, 2013
Sirtex Founder Dr Bruce Gray Sells $87m More Shares; Patrys Last Group Dosed In PAT-SM6 Multiple Myeloma Trial; South Korea Approves Atcor Sphygmocor Xcel; European Patent For Viralytics Picornaviruses For Cancer; Japan Grants Imugene Linguet Buccal Delivery Patent; Bioniche Requests Up To $8m Capital Raising Trading Halt; Novogen Appoints Prof Paul De Souza Medical Board Chairman; Acuvax Ex-CEO Dr William Ardrey Fraud Trial Set
 
Cochlear Revenue Down 3% To $753m, Profit Up 133% To $133m, CEO Dr Chris Roberts: Australian Regulation Concern; Medicines Australia: More Drugs Exported Than Cars, Alcohol; Benetic Licences ddRNAi To Regen For Cancer Vaccines; TGA Approves Isonea Airsonea Wheeze Monitor; Malaysia’s RC Precision To Make Bluechiip Equipment; M&G Group Buys 2m More GI Dynamics Shares; Asia Union Decreases, Diluted To 10% In Tissue Therapies 
 
Aug 5, 2013
Neuren Responds To Phase II Rett Trial Petition; Ex-Ceo Dr Esra Ogru Pays Phosphagenics $570k ‘Restitution’; Europe Begins Tissue Therapies Review In September; Allan Gray Reduces To 5% Of Acrux; Annmac Increases, Diluted To 10% In Agenix; Pharmaust EGM Backs Peloton Pitney Backdoor Listing; Viralytics Trades On US OTC Market; OBJ Pleads Schultz To ASX 54% Query
 
 
 
Jul 31, 2013
Bionomics ‘Up To $190m’ Merck Licence For Pain Compound; Biotron Enrols All 12 Phase II Hep C/HIV Patients; EGM To Revive Virax, Elect Dr Wayne Millen Director; Benitec Share Plan $2.8m Takes Total To $10.7m; Davies Collison Cave US Intellectual Property Seminar
 
Jul 30, 2013
Biota CEO Russell Plumb Faces Few Australian Investors; CSIRO Decodes Barrier Reef Coral For Sunscreen; Victoria Appoints Leonie Walsh Lead Scientist; Suda Final Report: ‘Artimist Superior To Quinine For Malaria’; Genetic Technologies’ Gtech Buys Incontinence Test Simavita; Genetic Technologies Requests Capital Raising Trading Halt; Consegna Hires Chinamed For Breatheassist Turbine; Metal Group Takes 17% Of Allied Health; Victoria-India Scholarships ‘Bring Best And Brightest’
 
Jul 29, 2013
Neuren NNZ-2591 Efficacy For Fragile X In Mice; Prana Doses 1st PBT2 Alzheimer’s Imaging Extension Patient; Calzada: No Secret Trials, AOD9604 Prescribed Legally; Tissue Therapies EU Vitrogro ‘Device’, 6 Months To Sales; Canadian Allowance For Bone Axcess II Oral Peptide Patent; Bionomics Begins BNC101 Safety Analysis; Cellmid, UK’s Abcodia Midkine For Colorectal Cancer Test; Compumedics $324k Qatar Order For Long-Term EEG System; Hunter Hall Reduces To 7% Of Biota 
 
Jul 26, 2013
CSIRO, Duke, Singapore $20m Pandemic Partnership; Regeneus Up To $12m IPO For Fat Stem Cells Technology; Calzada, Polynovo Treat Last Free-Flap Novosorb Patient; Phosphagenics: ‘TPM Patch Delivers Oxycodone Over 72 Hours’; Neuren Pleads Schultz To ASX 42% Query; MJGD, BSMI Trust Take 6.5% Of Benitec; Irwin, Bioa Trust Take 6.5% Of Benitec
 
Jul 25, 2013
Acrux Axiron H1 Sales Up 148% To $91m, On-Track For $25m; UK Nice Approves Sirtex Sir-Spheres; Psivida: ‘French Reimbursement For Iluvien’; Phylogica, Cubist Collaborate On Antimicrobial Phylomers; Biota To Meet Australian Investors; Dr David Thurin, Dalit Take 6% Of Benitec
 
Phosphagenics: $5.7m Theft, Dr Esra Ogru Dismissed, 5 Others; Brain Describes New US FDA ‘De Novo’ Pathway; Patrys Treats 3rd PAT-SM6 Multiple Myeloma Cohort; Benitec Completes $7.9m Placement; Court Rejects Dissidents’ Bioniche EGM; Two Australian Patents For BPH, Molecular Discovery HLS5; Ausbiotech Melbourne, Brisbane October Bio-Fests 
 
Jul 23, 2013
Prana Completes Phase II PBT2 Huntington’s Trial; Calzada Share Plan Raises $2.6m, Total Raised $3.85m; Nusep To Sell 10% Of Prime, Share Plan For $1.9m; Pharmaust Completes Pitney, 3 Cancer Platform Acquisition; Resonance Ferriscan Test For Phase II Iron Overload Trial; Oncosil, Eckert & Ziegler Manufacturing Agreement; Novadel Approves Sale To Suda; Craig Chapman, Nampac Take 18.5% Of Agenix; Brain Files Depression Test With FDA
 
Jul 22, 2013
Biodiem, Canberra Uni Use Hep D To Fight Liver Disease; Phosphagenics CEO Dr Esra Ogru Resigns As Director; Atcor Expects Maiden Full-Year $2.8m Profit; QRX, Aesica Collaborate On ‘Stealth Beadlet’ Deterrent; Invion Begins Phase II Trial Of INV102 For Smoking Cessation; Progen: ‘Medigen Expects Enrolment By End-Of-Year’; Psivida Underwritten Offer To Raise Up To $12m; AMP Takes 7.7% Of Acrux; Constables Take 6% Of Antisense; Cellmid Releases 7.5m Escrow Shares; Suda Requests Acquisition Trading Halt; Bio-Melbourne, Small Technologies Cluster US Tour 
 
Jul 19, 2013
NSW $10m For 5 Medical Device Companies; ATP, Ignition Labs: UK, Griffith Hack, BA On-Board; Viralytics Phase II Interim Melanoma Safety Efficacy; Bluechiip Signs Mitegen For Global Cryopin Tracking; ITC Stops Taiwan’s Apex, Drive Importing Resmed Copies; Benitec 25-To-1 Consolidation, ASX Code Change; Psivida Requests Capital Raising Trading Halt; Phylogica’s Dr Richard Hopkins, Dr Paul Watt Swap Jobs; Catherine Officer Replaces Uscom Co Sec Sarah Prince
 
Jul 18, 2013
Pharmaxis 143% Revenue Growth ‘Disappointing’, PBS Rules; Fujikura Pays Cellmid $440k For Midkine Test Licence Option; FDA Approves Ellex 2RT For Macular Oedema, AMD Next Focus; Invion Starts Phase II INV103 (XToll) Lupus Trial; Mesoblast Earns $4.3m R&D Tax Refund; Phosphagenics Inquiry Continues; Lindsay Carthew Takes 12% Of Agenix; Catherine Officer Replaces Viralytics Co Sec Sarah Prince; Bio-Melbourne Breakfasts On Alzheimer’s
 
Jul 17, 2013
Biota Begins Phase II 'Flu Trial, Board Changes, Price Falls; Genera Placement, Notes Raise $500k, Trials And Tribulations; Calzada, Polynovo US Novosorb Trial For Hernia Repair; Skolkovo Takes Bone BNC006 For Rheumatoid Arthritis; Benitec AGM Votes For Placement, 25-To-1 Consolidation; Starpharma Hires Dr Tony Eglezos For Business Develoment; Sophie Karzis Replaces Medivac Co Sec Malcolm Lucas-Smith; Ying Ming Chiu Takes 5% Of Nusep
 
Jul 16, 2013
Compumedics $285k French Grant, Appoints German Sales Rep; Medical Australia Votes For Medivet Merger, Consolidation; OBJ, GSK Study Electromagnetic Toothbrush; EU Approves Bioniche Folltropin Cow Stimulant; Cellmid Appoints Jillian McGregor Joint Co Sec
 
Jul 15, 2013
GBS Declines ‘Insufficient’ $30m Federal Investment Fund; Euro Methods Patent For Atcor’s Sphygmocor; WEHI Uncovers Immune Response Cell Mechanism; Cogstate Says Test Helps Diagnose Alzheimer’s; Invion Placement, Directors’ Shares EGM; Imugene Releases 100m Escrow Shares; Alchemia Loses Chairman Mel Bridges, Gains Timothy Hughes; Progen Appoints Heng Hsin Tang M-D, Director Change
 
Jul 12, 2013
Melbourne Uni Thin Film Coatings For Drug Delivery; US Patents For Neuren NNZ-2566, NNZ-2591; Psivida Interim Data Backs Micro-Insert For Uveitis; Eco Quest Moves To Take 100% Of Cynata For Stem Cells; Phosphagenics Ready For TPM-Tretinoin Acne Trial; Hunter Hall Lightens, Again, To 19% Of Sirtex; Perpetual Reduces To 8% Of Sirtex; Greenlight Takes 5% Of GI Dynamics; Oncosil Pleads Schultz, Dr Neil Frazer To ASX 67% Query; Scott Ward Replaces Impedimed Director Martin Kriewaldt
 
Jul 11, 2013
Off-US-Patent Allows Ellex To Expand SLT For Glaucoma; M&G Group Takes 15% Of GI Dynamics; Griffith Uni Soluble BDM-I Expands Biodiem Targets; Starpharma, MIPS $548k ARC Grant; Prima Pleads Schultz To ASX 55% Query
 
Jul 10, 2013
Benitec ddRNAi Licencee Calimmune HIV Clinical Trial; Patrys Macquarie $428k ARC Grant For Cancer Diagnostic; US Patent For Genetic Technologies’ Immunaid; ITL Buys Malaysian Device Factory; Genera Takes Capital Raising Trading Halt To Suspension
 
Jul 9, 2013
ARC $47m For 17 Laureate Fellowships ; ARC $10m For Monash, Melbourne Bionic Eyes; WEHI BH3 Mimetics Study Shows Breast Cancer Effect In Mice; Calzada’s Polynovo 40/60 Novoplastiq JV For Facial Surgery; Mayne Launches US Doryx Authorized Generic; Progen: ‘US Study Backs PG545 For Pancreatic Cancer’; Nusep Converts $1.7m Debt To 7c, 40% Premium Notes; Antisense Pleads Schultz, ‘Chat Rooms’ To ASX 27% Query; Canada Health, Bioniche Talk Urocidin Filings; Allan Gray Takes 12% Of QRX
 
Jul 8, 2013
Resonance, Novartis Study Backs Ferriscan Monitor; Allied Health Cardiocel Special Adult Approval; Isonea Raises $13.5m; Pokies Bruce Mathieson Takes 19%; Bioniche Completes $8m Palladin Finance; David Plush, Texas Woods 14% Of Immuron; Director Related; Genera Requests Capital Raising Trading Halt
 
Jul 5, 2013
Pharmaxis Wins $776k ARC Grants For 2 Firbrosis Projects; Pharmaust 950m Share EGM For Pitney Acquisition; Consegna Pleads Schultz To ASX 70% Query; Alchemia Loses Director Nerolie Withnall
 
Jun 21, 2013
Federal Government $130m Industry Collaboration Fund Opens; Uniquest Appoints Dr Dean Moss CEO; Management Changes; LBT Requests ‘Joint Venture’ Trading Halt
 
Jun 20, 2013
Prana’s PBT434 Modifies Parkinson’s Disease In Mice; Pharmaxis Starts European Paediatric Bronchitol CF Trial; CSIRO Sponsors Deadly Award For Indigenous Scientists; Avexa Signs Deal With Link For Apricitabine; Allan Gray Takes 12.4% Of Starpharma; McRae Technology Reduces Below 5% In Allied Health
 
Jun 19, 2013
Federal Opposition Restates Promise To Protect Research; Medicines Australia Welcomes Opposition Promises; Allied Health, Coridon Ready For Phase I HSV-2 Trial; France Funds GI Dynamics Endobarrier Value Study; Fedmed Signs As Genetic Technologies’ 7th US Provider Network; Prana Funds Huntington’s Patient Self-Report Test; Sunshine Heart C-Pulse Hits 25 Patient-Years; Anteo, Unnamed Company Mix&Go Feasibility Study; Isonea Appoints Hong Kong’s Refined For Airsonea Scale-Up; Impedimed Pleads Schultz To ASX 28% Query
Mayne Subacap US Trials, EU Approval, TGA Application; Unilife ‘Imminent’ Contract Delayed; UK Nice Recommends Psivida’s Iluvien For DME Sub-Group; US Grants Circadian VEGFR-3 Diagnostic Patent; Alchemia Pleads Schultz To ASX 14% Fall Query; Allied Health Loses Cardiocel Ceo Bob Atwill
 
Jun 11, 2013
QBiotics Raising $10m For Rainforest Cancer, Wound Drug; Invion Placement Raises $2m; Patrys PAT-SM6 For Melanoma Data Published; Compumedics $500k Funding ; Singapore Grants Nusep Plasma Import Licence; Bionomics Completes Phase II BNC105 Kidney Enrolment; 71% Of Doctors In Isonea Survey Back Airsonea
 
Jun 7, 2013
FDA Approves Impedimed L-Dex U400 As Lymphoedema Tool; Pharmaxis CEO Gary Phillips Starts On $388k; Calzada Requests Capital Raising Trading Halt; Universal Biosensors Wins Victoria Manufacturing Award; Cochlear, Sunshine Heart Win Australian Design Awards
 
Jun 6, 2013
Benitec Placement Raises $7m, Share Plan For $3m More; Cyclopharm, Macquarie Imaging’s Non-Destructive Analysis; New Zealand Patent For Patrys’ PAT-LM1; Medical Australia To Buy Medivet For $10m; Invion Requests Capital Raising Trading Halt; Paladin Labs Throws Bioniche A Urocidin Cash, Debt Lifeline; Hunter Hall Lightens, Again, To 21% Of Sirtex; Baillie Gifford Reduces To 11.4% Of Cochlear; McRae Reduces To 6% Of Allied Health; Octa Phillip Takes 9% Of Avita; Hadasit Increases, Diluted To 6% Of Immuron; Medigard Loses Director Peter Clark, Gains Robert Krakowiak; Bioxyne Loses Joint Company Secretary Laura Raymer
 
Jun 5, 2013
FDA Fast-Tracks Neuren’s NNZ-2566 For Rett Syndrome; Japanese Composition Patent For Mesoblast Stem Cells; Benitec Takes Capital Raising Trading Halt To Suspension; Consegna Claims Qualitative Breatheassist Success; Sirtex Calls For Shareholder Input On Pay Increases; Ausbiotech, Beacon Asia Biotech Invest Conference
 
Jun 4, 2013
Circadian Phase I VGX-100 Trial Treats 34 Solid Tumor Patients ; Antisense Begins ATL1102 MS Tox Study; Publication ; Viralytics Enrols 35th Phase II Cavatak Melanoma Patient; ATP Innovations’ Ignition Labs Has $125k For 5 Start-Ups; Signostics Appoints Thermo Fisher Distributor; Imugene Plan Raises $183k; Receives $181k R&D Tax Payment; Immuron, Takeda Terminate Travelan Licence; Healthlinx Administrators, Creditors Meeting; Bio-Melbourne ‘Innovation Precincts’ Bio-Breakfast
 
Jun 3, 2013
May BDI-40 Up 6%, ASX200 Down 5%; Big Caps Down 1.6% - Neuren Up 79%, Psivida Up 68%, Medical Developments Down 23%; Victoria’s Premier’s Award For Melbourne Uni’s Dr Aung Ko Win; Cochlear Nucleus 6 Launch, Profit Warning; FDA Halts Pharmaxis Aridol Imports; Bionomics Phase I Renal, Ovarian Cancer Progress; Allied Expects $1.9m Commercialisation Australia Grant; Beijing Bestmed Invests $500k In Compumedics; Bank Of New York Mellon Sells 5% Of Cochlear; Benitec Plans Euro Lung Cancer Trial, Funding Trading Halt; Asia Fund $17m For Nusep Plant, Loses Co Sec Tom Rowe; Cryosite Appoints Christina Boyce Director; Goodbye Neurodiscovery, Hello Oncosil Medical
 
May 31, 2013
FDA ‘Breakthrough Designation’ Explained; Suda Expects Artimist Licencing Talks By October; Biotron Earns $892k Federal R&D Tax Refund; Correction: Reva
 
May 30, 2013
Uscom To Buy NZ’s Pulsecor For $2.5m In Scrip; ABS Novacell Proposes Nusep Fractionation India Franchise; Psivida Claims New ‘Big Pharma’ Evaluation Agreement; Bioniche Rejects 2nd Meeting Requisition; Reva AGM Dissent On Auditors
 
May 29, 2013
Bone Claims La Jolla Cove Funding ‘In Arrears’; Novogen Share Plan Raises $790k, $3.3m Total; Hunter Hall Lightens To 22% Of Sirtex; ITL Chairman William Mobbs Decreases, Concentrates To 33%; Medigen Takes 19.7% Of Progen, Taiwan’s Well Hallmark 9%
 
May 28, 2013
Pharmaxis To Halt Early Programs; Cut 48 Jobs, Burn Rate; Australian Patent For Acuvax, Biolife Her-Vaxx; Phosphagenics Earns $3.2m Federal R&D Tax Refund; Cellmid Completes Advangen Acquisition; Immuron Appoints 17% Stephen Anastasiou Director
 
May 27, 2013
Acrux, Eli Lilly Challenge Israel’s Perrigo On Axiron Patents; Datapharm: Complete NSW Trial Insurance Survey
 
May 24, 2013
Cochlear Unveils Nucleus 6 Processor; Japan Grants 2 More Patents To BPH’s Cortical Dynamics; Acrux CFO Jon Pilcher Joins Neuren; Acrux Promotes Clive Blower, Tony Di Pietro; Immuron’s Nina Webster Rejoins Acrux; Cogstate Appoints Mark Edwards Company Secretary; Bluechiip Releases 24.7m Escrow Shares; Medigen Takes 19.6% Of Progen
 
May 23, 2013
Medical Developments Profit Warning, Major CSIRO Milestone; Consegna Option Rights Issue Raises $130k; $252k To Come; Datapharm: ‘Dai-Sys To Compete With Foreign Contractors’; Bioxyne, Vitality Deal Falls; Cogstate Tests In Major Alzheimer’s Study; Nusep Lodges Dengue Fever Test, Treatment Patents; Imugene Linguet Delivery Starts With Vitamin D; Annmac, Carthew, Chapman, Nampac Substantial In Agenix; Bioniche Concerned Investors Question Core Business Sale
 
May 22, 2013
Alchemia Fondaparinux Sales Fall 28%, Merck Serono Deal; Reva 1st Generation Stent ‘Comparable To Competitors’; Siemens Unveils Universal Biosensors Coagulation Test; Pharmaxis Appoints Pharmaswiss East Europe Distributor; Anteo, Gennova Sales Deal For Europe, Latin America; Benitec Pleads Schultz To ASX 14% Query; Biodiem Japan BDM-I Patent For Malaria, Trichomoniasis; Allan Gray Takes 11% Of Starpharma; Heartware Directors’ Stock 28% Dissent, Elected Unopposed; IDT Loses Blackman, Blackman, Burnet For Kaufman, Shigeno
 
May 21, 2013
FDA Clears Pharmaxis Bronchitol For CF Path; Former CBio Executive Repays Invion ‘Termination Pay’; Agenix Appoints Craig Chapman Director
 
May 20, 2013
WEHI: ‘Immune Protein CD52 Can Stop Type 1 Diabetes’; Neuren Up 45% On AGM; Genetic Technologies Signs Multiplan For Brevagen Tests; Progen Raises Underwritten $5.2m; Acorn Below 5% In Pharmaxis; Bioniche Says William Wells Holds 5.6%
 
May 17, 2013
FDA Sets July Advisory Committee Meeting For QRX Moxduo; Invion Share Plan Raises $1.1m; Agenix $1m Rights Issue Shortfall, New Director; Ellex Appoints Dr Meera Verma, Rahmon Coupe Directors
 
May 16, 2013
WEHI Study Finds Malaria Parasites ‘Talk’ To Each Other; Bionomics, CRC ‘Ctx-0357927 Inhibits Melanoma Tumors In Mice’; Australia Allows Bone Lexcicon Patent; Angelina Jolie Pumps Genetic Technologies 33%; Up To 15% Of EGM Votes Oppose Prima Shortfall Shares; Cellestis Four Win ATSE Clunies Ross Awards
 
May 15, 2013
Federal Budget: Innovation Untouched; NHMRC, ARC Funding Up; Comment: Biotech Daily, GBS, Norton Rose, Medicines Australia, Ausbiotech, Bio-Melbourne Network; Victoria Opens Ausmedtech With $1m Grants; Mesoblast Stem Cells Effective For AMI In Sheep; Prima Raises $5m Of Hoped For $15m; Neuren Pleads Schultz To ASX 66% Query; Isonea Pleads Schultz, Presentations To ASX 27% Query; Bioniche Shareholder Group 2nd Meeting Requisition; Mesoblast Chief Executive Prof Silviu Itescu Diluted To 22%; Scott Ward Replaces Impedimed Director Martin Kriewaldt, To Lose Dr Mel Bridges In November; St Vincent’s Forum ‘Unleashing Innovation’ Reminder
 
May 2, 2013
Cyclopharm’s Technegas ‘Could Help Detect, Manage COPD’; Psivida, Alimera New US PDUFA Date For Iluvien For DME; St Vincent’s Institute Research Forum ‘Unleashing Innovation’; OBJ Prepares For Transdermal Internet Cosmetic Crème Trial; Mass Mutual Reduces To 8% In Novogen; Craig Hitchins Replaces Medivac Director John Evans
 
April BDI-40 Down 3.7%, ASX200 Up 4.5%; Big Caps Up 5%; CSL Resumes Influenza Vaccine Production For Australia; CSIRO Trial Developing Alzheimer’s Blood Test; US Patent For Alchemia’s Vast Platform; Antisense ATL1102 Multiple Sclerosis Toxicology Study; Immuron Rights Issue Raises $284k Of Underwritten $1.9m; Nusep Raises $350k To Raise $15m For $50m Prime Facility; Imugene Share Plan For Up To $600k; Uscom Appoints Grupo Sim Mexico Distributor; M&G Group Takes 13% Of Starpharma; Acuvax Has One Quarter Cash, $5m Placement; Clinuvel Requests Capital Raising Trading Halt; Tom Milicevic Appointed Advanced Surgical CEO; GI Dynamics Appoints Dr David Maggs Chief Medical Officer
 
WEHI, QIMR Broad Malaria Vaccine To Begin Trials In 2014; Suda Sub-Lingual Artimist ‘Superior To IV Quinine For Malaria’; Pharmaust To Acquire Pitney For 3 Cancer Platforms; US Sales Take Heartware Q1 Revenue Up 87% To $47.5m; Psivida, Alimera Iluvien Available To UK Private DME Patients; Genetic Technologies Licence For Genetics & IVF Institute; China Patent For Imugene’s Linguet; Correction: Phosphagenics, Calzada & AOD9604; Biotech Daily Appendix 4C Quarterly Reports Policy; Medical Australia Has One Quarter Cash; Genetic Technologies Less Than Six Months Cash, Revenue; Healthlinx Requests Funding Suspension; Northcape Below 5% In Pharmaxis; Wilson HTM Reduces 1% In Universal Biosensors
 
Biotechs Win $889k Of $10m Commercialisation Grants; Genetic Technologies Licence To Preventiongenetics; Suda Requests Phase III Results Trading Halt; Pharmaust Requests Acquisition Trading Halt; Goodbye Sunshine Heart; Bioniche Receives Shareholder EGM Request; Viralytics Chairman Paul Hopper Resumes Non-Executive Role
 
Acrux, Eli Lilly Axiron Q1 Sales Up 55% On Q4, 128% On Q1, 2012; CSIRO Licences Raft Polymerization Technology To Mirus Bio; Resmed Record Q3 Revenue, Profit; OBJ: ‘Novus Cites Boston Bombing For Underwriting Balk’; GI Dynamics Enrolling US Endobarrier Trial Patients; Calzada, Metabolic ‘Clarify’ AOD9604 Sports Claims; Johnson & Johnson Reduces 1.8% In GI Dynamics
 
Pharmaxis Falls 52% On Failed Bronchiectasis Trial; Patrys Moves To 3rd Multiple Myeloma Dose; Euro Patent For Phylogica’s AP-1 Phylomers; Bioniche Investor Concern; Consegna Expects $510k Federal R&D Tax Refund; Invion IND For INV103 (CPN10) For Lupus; Prima Appoints Prof Kohrt, Dr Klein Clinical Advisors
 
Alchemia Signs ‘Up To $240m’ Astrazeneca Collaboration; Lonza To Manufacture Bionomics BNC101; Neuren Doses 1st Phase II Rett Patient; Phase I Fragile X Trial; OBJ Raises $860k Of $3.5m, Novus Balks At ‘Fully Underwritten’; Allan Gray Takes 6% Of Acrux 
 
‘WEHI-539 Shuts Down Cancer Protein Bcl-Xl’; Pharmaxis Phase III Bronchiectasis Results Trading Halt; Mesoblast Phase II Stem Cell Disc Repair ‘Positive Trend’; Patrys PAT-SM6 Binds To GRP78, LDL; Medical Australia: $1m PA Manufacture, Supply Contracts; Neuren AGM For 50m Chairman Dr Richard Treagus Shares; LSQ Appoints Prof Uwe Heinrich, Stephen Burrill Ambassadors
 
Atcor: South African Study Backs Sphygmocor; Psivida: ‘Alimera Prices Iluvien At $8-10k Per Treatment’; USPTO Grants Merial 2nd Genetic Technologies Patent Exam; Neurodiscovery Director’s Shares, Options, Name Change EGM; WEHI Appoints Christopher Thomas Board President; Novogen Loses Director Josiah Austin; CFO’s Hains, Vaughan Replace Immuron’s Graeme Stevens
 
Cyclopharm Ultralute Extends Nuclear Imaging Life 50%; Japan Methods Of Use Patent For Prima’s CVac; Novogen Share Plan For Up To $2.5m; Consegna Option Rights Issue To Raise $382k; IOOF Below 5% In Mayne Pharma; Denlin, Tisia, Henderson, JK Take 19% Of Neurodiscovery; Bio-Melbourne Briefing On More Efficient Drug Development
 
Biota Cuts 30% Staff, Closes Programs, Moves Office; Calzada, Polynovo Trial: Novosorb ‘Beats Gold Standard’; Nanosonics Signs Toshiba To Distribute Trophon EPR In UK; Consolidated Consegna Returns To CGP Code; Ampliphi (Special Phage Services) Collaborates With Intrexon; US China Patents For Starpharma Drug Delivery; Sunshine Heart Placement Raises $13.5m; CDPP V JM Goes To Canberra High Court Full Bench; Genetic Technologies Pleads Schultz, Old News To ASX; Baillie Gifford Takes 12.7% Of Cochlear; Mesoblast Appoints Prof Eric Rose Director
 
UCSD Joins Benitec Phase I/II TT-034 Hepatitis C Study; Genetic Technologies Jumps On March Study Results; IDT Revises Guidance From Positive To Flat; Progen Underwritten Rights Offer For $5.2m; Suda Artimist Manufacturing Scale-Up Completed; Neurodiscovery Acquires Enigma, Name Change To Oncosil; University Of Sydney Hosts 1st Tedmed Conference
 
LBT, Hettich JV For Automated Plate Assessment; US Orphan Status For Benitec, Genable GT308 RP Program; Phosphagenics, Themis Sell TPM-Diclofenac To Novartis; Two Biotechs Awarded $250k Victorian Technology Vouchers; Bank Of New York Mellon Takes 5% Of Cochlear; Graham Edwards, Montoya Take 6% Of Pharmaxis; Cyclopharm AGM To Vote On 1.7m M-D Shares
 
Sirtex Completes 1st Line Sirflox Recruitment; FDA Approves Mayne’s 200mg Delayed-Release Doryx; Sunshine Heart Raises $12m; Alchemia Plan 3-Fold Over-Subscribed, Raises $2.75m; Novogen Placement Raises $2.5m; Regeneus, Cryosite Develop Storage Procedure; Isonea Launches Asthamsense Cloud Smart-Phone Application; Prana Chair Geoff Kempler, Baywick Diluted Below 5%; Vatican Gong For Mesoblast’s Prof Silviu Itescu
 
Immunexpress Joins Dutch Consortium For Sepsis Detection; MEI (Novogen) Me-344 Active Against Ovarian Cancer In Mice; Novogen Requests Capital Raising Trading Halt; Pharmaxis Q3 Sales Even; Sunshine Heart To Raise Up To $71m; Eco Quest’s Cynata Licences Its Stem Cell Technology; Benitec Appoints Ex-Cephalon CEO Kevin Buchi Director
 
Antisense Begins Phase II ATL1103 For Acromegaly Dosing; Patrys Completes 2nd PAT-SM6 Multiple Myeloma Cohort; Correction: Bone; Japan Patent For Avita’s Recell; Pharmaxis Hires United Medical For Bronchitol In Brazil; Phylogica Contracts New York’s Griffin For Potential Deals; Burnet Virology, Immunology Merge For Vaccine Development
 
LSQ Welcomes Federal Government McKeon Review; Novogen Isolates Most Potent Form Of CS-6; Bone BN006 Phase I RA Trial Equals Adalimulab At Half-Dose; Viralytics: ‘Dose-Ranging Patients Tolerate IV Cavatak’; Nanosonics Trophon EPR Increases Probe Coverage; Prima Plan Price Change From 10c To 95% Of 10-Day VWAP; Platypus Capital Below 5% In Sirtex; Perpetual Takes 8% Of Sirtex
 
Allied Hails Increased Pre-Authorization Use Of Cardiocel; Bionomics Underwritten Rights Issue Raises $12.15m Of $16.4m; Resonance Expects FDA Hepafat-Scan Approval Within 6 Weeks; Suda Buys Novadel Novamist Spray For $400k, Stock; M&G Group Takes 12% Of Starpharma; Cellmid Loses Joint Company Secretary Andrew Bald
 
Phosphagenics Ready For Phase I TPM-Oxycodone Trial; Sirtex 6% Q3 Dose Sales Growth; Correction: Starpharma; Psivida Evaluation Agreement With Unnamed Company; EMA Continues Lengthy Review Of Clinuvel’s Scenesse
 
Starpharma To Take Vivagel To Phase III Vaginosis Trial; Benitec Tribetarna Improves Lung Cancer Treatment In Mice; Alchemia Sells Fondaparinux In India, Patent Extensions; Prana Receives $2.5m Federal R&D Tax Refund; Australian Ethical Reduces Below 5% In Neuren; ASX Releases 8m Bioxyne Escrow Shares; David Zohar Reduces, Diluted To 21% Of Actinogen; Ellex R&D Manager Malcolm Plunkett Resigns As Director
 
Starpharma Vaginosis Trial ‘Not Significant’; Adverse Events; Resonance Wins $200k EU Trial Contract; IDT Appoints Dr Paul Macleman CEO On $300k; Novogen: ‘CS-6 Kills Ovarian Cancer Stem Cells In-Vitro’; Advanced Surgical Raises $252k Of Hoped-For $1.5m; Consegna Shares, Options Consolidation Code Change; Data Boards Back Prana Huntington’s, Alzheimer’s Trials; Jason Peterson, Associates Take 9% Of Consegna; Neurodiscovery Appoints Martin Rogers Director On $80k; Victoria Presents Voucher Winners At STC Networking Event
 
March BDI-40 Down 1%, ASX200 Down 2.7%, Big Caps Down 1.2% - Psivida Up 21%, Pharmaxis Down 40%; Reva Starts Rezolve2 Coronary Stent Trial; Allied Lodges US FDA Cardiocel 510k Application; Phosphagenics Extends Nippon Zoki TPM Collaboration; Starpharma Bacterial Vaginosis Trial Results Trading Halt; Endo Returns Urocidin Sponsorship To Bioniche; Prima Share Plan, Options Rights Offer For Up To $20m; Resmed Takes Apex, Medical Depot To ITC, US Federal Court; Sunshine Heart Loses Director Donal O’Dwyer In Move To US
 
Federal Government $100m For Innovation Investment Fund; Agenix Tells Ausbiotech Summit: ‘Paving The Way In China’; Benitec Raises A Further $180k, Total $980k ; Immuron 3-For-2 Rights Issue For $1.9m; Prana Requests Capital Raising Trading Halt
 
John Brumby Tells Ausbiotech Summit: ‘Partner With China’; Universal Bio: J&J Lifescan’s 2nd Glucose Meter Recall; Cellmid Licencees Progress Lung, Bladder Cancer Tests; Suda Malaria Trial Locked, Artimist Test Units Manufactured
 
Mar 20, 2013
Patrys: ‘PAT-SM6 Enhances Chemo-Combinations In-Vitro’; Allan Gray Resumes Buying In Acrux To 5%; $5m Euro Grant For Prima CVac Development; Consegna Reduces Consolidation From 25 To 5-To-One; NZBio Votes Living Cell ‘Company Of The Year’
 
Mar 19, 2013
FDA Refuses Pharmaxis Bronchitol Application; Heartware Raises $143m; Biotron Phase I/II Trial: ‘Bit225 Kills HIV In Reservoir Cells’; Genetic Technologies Begins Euro Patent Assertion Program; Antisense To Pay Up To $300k For China Toxicology Study; Resonance Wins European Trial Contract; Isonea Takes Asthma Monitor To Cloud Computing
 
Mar 18, 2013
European Bureaucracy Entangles Tissue Therapies, Again; Regeneus Expands To Queensland; Thorney Increases, Diluted To 5.6% In Mesoblast; Investors Mutual Takes Profit On Mayne Pharma; Armada Associates Take 5.2% Of Alchemia; Bioxyne Releases 8m Escrow Shares; Impedimed Loses Peggy Brooker, Promotes Morten Vigeland; Ondek Appoints Dr Jenny Harry Chief Executive Officer; Healthlinx, La Jolla Cove Part Company
 
Mar 15, 2013
Buchan Calls For Motor Neurone Disease Research Funding; USPTO Backs Genetic Technologies Non-Coding DNA Patent; Nusep Sells Proteoiq Tool To California’s Premier Biosoft; FDA Nasal Calcitonin Concerns Good For Bone Oral Delivery; Correction: Monash Vision Group; Perpetual Takes 7% Of Resmed
 
Mar 14, 2013
Monash Hopes For 1st-In-Human Bionic Eye In 2014; Mesoblast Completes $170m Placement; Tissue Therapies Regulatory Trading Halt; FDA Sets August PDUFA Date For QRX Moxduo ; Consegna Pleads Schultz To ASX 200% Query; Sunshine Heart Appoints Jon Salveson Director
 
Mar 13, 2013
Hugh Alsop Replaces Hatchtech CEO Dr Ross Macdonald; Starpharma, Makhteshim Agan Agri-Collaboration; Cellmid Raises $2m; Consegna Options Rights Issue For $420k; Heartware Sets Price To Raise $125m; Tang Wen Sen Diluted Below 5% Of Agenix
 
Mar 12, 2013
Pharmaxis’ Dr Alan Robertson Goes, Gary Phillips New CEO; Heartware To Raise About $125m; Medical Australia UK 5-Year Deal; Consegna 25:1 Consolidation
 
Mar 11, 2013
Alchemia Placement Raises $10m, Share Plan For $2m More; Cellmid Pleads Schultz, Again, To ASX 69% Query, Trading Halt
 
Mar 8, 2013
Pharmaxis Completes Bronchiectasis Trial, Results By July; Circadian Licences VEGF To Santa Crux For Reagents; CSL CEO Paul Perreault Starts On $1.7m A Year; Federal Minister Greg Combet Opens $25m Phebra Facility; FDA Approves Wireless Version Of Universal Biosensors Meter; FDA Rejects Isonea Sonosentry, Airsonea On-Track; Prana Reports PBT2-Tau Mouse Data; Suda Appoints Ken Robson Director; Bioniche Spins Human Health Into Bioniche Therapeutics
 
Mar 7, 2013
Patrys PAT-SM6 Safe, Signs Of Efficacy In Multiple Myeloma ; Prana Tells ASX PBT2-Tau Conference Announcement ‘Material’; Allan Gray Takes 12% Of Tissue Therapies; Graham Durbin Takes 7% Of Genera; Alchemia Requests Capital Raising Trading Halt; Biological Repositories Society’s First Sydney Meeting
 
Mar 6, 2013
Mesoblast Raises $170m For Spine Trial, Inflammatory Disease; Allied Claims 4 Years Without Calcification For Cardiocel; Cogstate, Merck Launch Cognigram In Canada; US Patent For Alchemia Hyact Platform; GI Dynamics Signs CMS As Brazil Distributor; Prana PBT434 Targets Parkinson’s Alpha-Synuclein Protein; Novogen, Ingham Combine For Super-Benzopyrans For Cancer
 
Mar 5, 2013
‘Coalition Will Protect R&D’ MP O’Dwyer Tells Bio-Melbourne; Benitec Raises $800k; Japanese Patent For Imugene’s Linguet; Appeal Lodged Against Genetic Technologies Patent Finding; Charles Goode Companies Take 6% Of Cogstate; Resmed CEO Michael Farrell Starts On $732k
Alchemia Phase III Ha-Irinotecan Recruitment Closed; Eli Lilly, Acrux PBS Listing For Axiron; Prima Starts Phase II/III CVac Ovarian Cancer Trial In Europe; QRX Resubmits FDA Moxduo NDA; Bionomics Requests Capital Raising Trading Halt; Heartware Revenue Up 34% To $US111m, Loss Up 59% To $US88m; Ellex H1 Revenue Down 16% To $22m, Profit Down 78% To $144k; Optiscan H1 Revenue Up 223% To $936k, Turnaround Profit $136k; Impedimed Revenue Down 7% To $1.4m, Loss Down 13% To $5m; Avita H1 Revenue Down 34% To $2.4m, Loss Up 78% To $4m; Uscom H1 Revenue Down 28% To $363k, Loss Down 41% To $671k; GI Dynamics Revenue Up 185% To $668k, Loss Up 2% To $27m; Progen H1 Revenue Up 222% To $1m, Loss Down 30% To $4m; Clinuvel Passes EMA Manufacturing Audit; OBJ Rights Issue For $3.5m ; Bluechiip Appoints Eric Hall North America Product Manager
 
Feb 22, 2013
Optiscan Down 9%; Medical Developments H1 Revenue Up 25% To $6m, Profit Up 25%; Genetic Technologies H1 Revenue Down 8% To $2m, Loss Up 12%; Allied Health H1 Revenue Up 13% To $4m, Loss Up 9% To $2m; Agenix Raises $419k Of Hoped For $1.2m, Shortfall; Immuron CEO Joe Baini Resigns; Circadian Appoints Steven Zammit CFO, Co Sec
 
Feb 21, 2013
Atcor H1 Revenue Up 43% To $5.4m, Turnaround Profit $2.3m; Phylogica Revenue Down 90% To $134k, Loss Down 19% To $1m; China Grants Divisional Patent For Biodiem’s BDM-I; Hartnell Family, Robinwood Take 15% Of Advanced Surgical; Mick Farrell Succeeds Resmed CEO Dr Peter Farrell
 
Feb 20, 2013
Phosphagenics Topical Opioid For Local Pain; Bioxyne Raises $508k; Dr Collier, Dr Campbell To Join Executive; Phosphagenics Revenue Down 16% To $2.7m, Profit To Loss; Cogstate H1 Revenue Down 12% To $6m, Profit To Loss; Neurodiscovery Acquisition; Placement, Options EGM; Tissue Therapies Requests Capital Raising Trading Halt; Medicines Australia Chairman Mark Masterson Resigns; Circadian Loses CFO, Co Sec Susan Madden
 
Feb 19, 2013
Novogen CS-6 ‘Kills Ovarian Cancer Stem Cells In-Vitro’; Polyactiva Raises $9.2m For Drug-Polymer Drug Delivery; Anteo Partners With One World Lab For Mix&Go Sales; Advanced Surgical Places $594k, Rights Issue For $1.5m More; Circadian H1 Revenue Down 22% To $600k, Loss Up 125% To $4m; Pharmaust H1 Revenue Up 32% To $1m, Loss Down 52% To $324k; Allied Health Tells ASX Price Query ‘News Not Material’; GI Dynamics Releases 48.6m Escrow CDIs; Fisher Funds Take 6% Of Nanosonics; Director, CSO Dr Andrew Heaton Takes 6.5% Of Novogen; Jarrod White Replaces Bioxyne CFO, Co Sec Ashok Jaraith
 
Feb 18, 2013
Federal Government Innovation Policy; Medicines Australia Welcomes Trials Reform, Precincts; GBS Venture Partners ‘Thrilled’ By Funding Re-Investment; Ausbiotech, Bio-Melbourne Welcome Initiatives; Acrux H1 Revenue Up 9% To $5m, Profit Down 58% To $2m; Bioxyne Proceeds With Vitality Acquisition; Calzada, Polynovo Revise BARDA Application; Trial Progress; Alchemia Q2 Fondaparinux Royalty Up 90% To $3m; Acuvax Biolife Acquisition, Name Change EGM; Perpetual Takes 6% Of Resmed; Social Investments Reduces To 5% Of Neurodiscovery; Alchemia Promotes CFO Charles Walker To CEO
 
Feb 15, 2013
Federal Court Dismisses Genetic Technologies Patent Case; Greens, Coalition, Independents Win Non-Binding R&D Vote; Pharmaxis H1 Revenue Up 77% To $6m, Loss Up 6% To $21m; Cellmid H1 Revenue Up 263% To $258k, Loss Down 41%; Consegna Raises $633k; Bio-Melbourne Goes Mobile For Devices, Diagnostics Lab; Mass Mutual Reduces To 9% In Novogen; Tom Rowe Replaces Nusep Company Secretary Swapna Keskar
 
Feb 14, 2013
US Army Tests Biodiem BDM-I For Plague, Anthrax; Uniquest, UTS, MRCF Create Helmedix For Immune Diseases; Chief Scientist Recommends Innovation Council; Sirtex H1 Revenue Up 25% To $46m, Profit Up 34% To $8m; Universal Biosensors Revenue Up 102% To $30m, Loss Down 38%; Nanosonics H1 Revenue Down 13% To $4m, Loss Up 97% To $6m; Starpharma H1 Revenue Up 24% To $1.3m, Loss Down 61% To $1.8m; Psivida H1 Revenue Down 50% To $1m, Loss Up 74% To $5m; Impedimed Signs 3m For Australia, New Zealand Sales; Allan Gray Below 5% In Acrux; Constables Take 5% Of Antisense
 
Feb 13, 2013
FDA Allows Minimal Trial Data For ‘Breakthrough Therapies’; FDA Approves Mesoblast Singapore Stem Cell Plant; CSL Record H1 Revenue Up 6% To $2.5b, Profit Up 24% To $608m; Biota H1 Revenue Up 90% To $11m, Loss Down 79% To $2.3m; Allied Earns ISO Certificate For Cardiocel Management System; Avita Passes ISO Audit; CSL CEO-Elect Paul Perreault Appointed Executive Director
 
Feb 12, 2013
Mireven: ‘miRNA-7-5p Effective For Melanoma In-Vitro’; Capital Group Clients Below 5% Of Cochlear; USPTO Allows Acrux Transdermal Testosterone Patent; US Patent For Antisense ATL1102 For Multiple Sclerosis, Study; Acuvax Signs Biolife Deal For Back To Cancer Future; China Partner Pays Biodiem $98k; Agenix Hopes To Licence, Partner All Three Technologies; Bioxyne Appoints Jarrod White Company Secretary
 
Feb 11, 2013
Bionomics Names LGR5 As BNC101 Cancer Stem Cell Target; Cellmid Midkine Diagnostic Licence Option To Japan’s Fujikura; Heartware Warns Users To Check Driveline Connector; Nexgenia Uses CSIRO's RAFT For Polymer-Based Diagnostics; Phosphagenics Oxycodone Patch Returns To Clinical Trials; US Insurer To Reimburse Resonance’s Ferriscan; Avexa Sells All Allied Health Shares; Steve Harris Replaces Imugene Chairman Fabio Pannuti
 
Feb 8, 2013
Biodiem, QIMR: BDM-I Kills Schistosoma Japonicum In-Vitro; EMBL Australia, SAHMRI Call For 3 Leaders For Research Group; Ellerston (Packer Family) Takes 10% Of Acrux; Resonance Appoints Dr Jason Loveridge Director
 
Feb 7, 2013
Greens, Libs Move For Science, Research Budget Protection; US, China Patents For Mesoblast Composition-Of-Matter; Reva 6-Month Follow-Up: ‘No Further Major Events’; Neurodiscovery $1.5m, Dr Aston Chair, Phase III Brachysil; Bioniche Hunts For New Partners For Urocidin; Prima Earns $1.4m Federal R&D Tax Refund; Circadian $1.3m Federal R&D Tax Refund; Sunshine Heart CEO David Rosa $322k Base Salary; Insurer Joins Invion (CBio) Action Against Former Executives
 
Feb 6, 2013
Allied, CSIRO Study: Cardiocell Promotes Stem Cell Growth; Eco Quest, Cynata Prove Stem Cell Ischemic Limb Concept; Mayne Plan Raises $5.1m; Victoria Premier’s Award Nominations Open ; Capital Group Clients Reduce To 6% Of Cochlear; Lind Fund Takes 5.5% Of Consegna; Medicines Australia: Drug Exports Beat Cars, Wine; Avita Appoints Novartis V-P Director; Universal Biosensors Director Dr Colin Adam To Retire
 
Feb 5, 2013
Red Cross, CSL, Bio-Melbourne: ‘Artificial Blood Not Imminent’; WEHI: MCL-1 Survival Essential For Treatment; Cochlear Record H1 Revenue, Unit Sales; Bio-Link To Market Phylogica’s Anti-Inflammatory Phylomers; Prima CEO Matthew Lehman: ‘Manufacture Is Key’, Pilot Trials; Metal Group, Avexa, McRae Diluted In Allied Health; Calzada, Metabolic AOD9604 Helps Osteoarthritis In Rabbits; Novogen Files Super-Benzopyrans Patent Application; US Patent For Ampliphi Bacteriophage Therapy; Sunshine Heart To Delist On May 6; Uniquest Promotes Dr Dean Moss To Acting CEO
 
Feb 4, 2013
WEHI, Synchrotron Capture Cell Death; Alchemia Completes Phase III Ha-Irinotecan Recruitment; Bionomics BNC375 Enhances Rodent Episodic, Working Memory; Calzada, Polynovo Recruit 20-Patient Novosorb Wound Trial; Circadian Nears Completion Of Phase I VGX-100 Tumor Trial; Graham Edwards, Montoya Take 5.5% Of Pharmaxis
 
January BDI-40 Up 6%, ASX200 Up 5%, Big Caps Up 2% - GI Dynamics Up 41%, Pharmaxis Down 46%; Biodiem Renews US Institute BDM-I Pre-Clinical Research; Imugene Has Less Than One Quarter Cash; Cogentum Michael Johnson Replaces Consega’s Fabio Pannuti; Gude Buer Replaces Genesis Exec Director Catherine Yan 
 
FDA Committee Blocks Pharmaxis, Comment, $38m Facility; Janssen Extends Phylogica Collaboration; Neuren Appoints Dr Richard Treagus Executive Chairman; Atcor H1 Sales Up 43% To $5.4m, Turn-Around Profit; Ellex H1 Profit Warning ; Baycrest $3m Agenix Facility; Progen Earns $723k Federal R&D Tax Refund; Biotech Daily Appendix 4C Quarterly Reports Policy; Benitec, Medical Aust, Bioprospect, Bioxyne Cash-Strapped; Consegna Board, Management Trading Halt
 
Jan 30, 2013
Mesoblast Ready For Phase II Rheumatoid Arthritis Trials; Acrux Jumps 8% On 2012 Axiron Sales Up 208% To $71m; Antisense: FDA Approves Isis, Genzyme Kynamro; Regeneus, Kolling: ‘Fat Stem Cells Help Dog Cancer Vaccine’; Sunshine Heart Hopes To Depart ASX By July; Warren Watson Replaces Sunshine Heart’s Dr William Peters; Calzada Earns $789k Federal R&D Tax Refund; EMA Discusses Delayed Tissue Therapies Vitrogro 
 
FDA Concerns On Pharmaxis Trial Design; Trading Halt; Tissue Therapies Has One Quarter Cash; Considering Options; Alchemia Loses CEO Dr Pete Smith; Uniquest Loses M-D David Henderson; Medical Developments CEO John Sharman Earns Bonus
 
FDA Clears Resonance Ferriscan As Exjade Companion Test; Antisense Ready For UK ATL1103 Acromegaly Phase II Trial; Resmed Record Quarter, H1 Revenue, Profit; Genetic Technologies Earns $4m In Q2; BPH, Melbourne Uni Brain Monitor Linkage Grant
 
WEHI Links Immune Cell Death Defects To Autoimmune Disease; Pharmaxis Q4 Revenue, Sales Double; Psivida’s Alimera Hopes For Iluvien DME Patient Access Scheme; Nusep Sells Software Business To California’s Premier; Prima CEO Matthew Lehman’s Investor Roadshow; Viralytics CEO Dr Malcolm Mccoll Starts On $357k
 
Cellmid Anti-Midkine Antibodies Reduce Kidney Damage In Mice; Allied Share Plan’s $2.9m Takes Raising To $4.6m; Bio-Melbourne, Red Cross, CSL Breakfast On Artificial Blood; Reva Releases 23m Escrow Shares
 
Bathurst Study: ‘Uscom Saves Sepsis Lives, Hospital Costs’; Consegna Files Breatheassist BO2LT Patent Application; Osprey To Release 50k Escrow CDIs 
 
Jan 21, 2013
Medical Developments Phase III: Penthrox Efficacy, Safety; Bioxyne Reviews HI-164OV Database; Euro-Patent For Cellmid Midkine Vascular Occlusive Disease; Agenix 1-For-1 Rights Issue To Raise $1m; Cogstate H1 Revenue Down To $9m, Loss Down To $500k; Bone Claims Early BN006 Success In Rheumatoid Arthritis; Dr Malcolm McColl Starts As Viralytics CEO Today; Correction: Patrys

 

Resonance Liver Fibrosis Trial: Not Competitive; Correction: Bluechiip; Endo Returns Urocidin Rights To Bioniche; Prima Director Martin Rogers Sells 10.5m Shares; Neuren To Begin Phase II Trial Of NNZ-2566 In Rett Syndrome; Consegna Raises $357k, Appoints Phillip Hains Joint Co Sec; Bruce Gray Sells $7m Sirtex Shares; Agenix Says Fortrend Reneged On Facility, Fund Raising; Medical Developments Signs Spacer Deal With Glaxosmithkline; Progen PG545 Licence With Medigen; Healthlinx Agreement With Mane Expires; Malcolm Lucas-Smith Replaces Healthlinx Director John Evans; Invion Begins Phase II Asthma Trial; Nusep Receives $227k Share Payment; Sienna Appoints Dr David Earp Director; Clinical Network Services Buys NZ Partner Beltas; Maria Maileli Replaces Ellex Co Sec Guiseppe Canala; Consegna To Issue 48m Placement Shares; Proxima Takes 33% Of Bone; Heartware 2012 Q4 Revenue Up 40% To $32m; Sunshine Heart Begins Pivotal US C-Pulse Trial; Nusep’s Singapore Facility Produces GMP-Quality Albumin; Raff Group Takes 7% Of Genera; Citigroup Takes 7% Of Patrys; Sirtex Sir-Spheres 2102 Q4 Sales Up 25%; Neuren Appoints Dr Nancy Jones Head Clinical Development; Clifford Eu Takes 10% Of Nusep; Allied’s Adapt Tissue Superior Or Equal To Synthetic Implant; WEHI Discovers How Insulin Attaches To Receptor; GI Dynamics, Gore Settle Patent Litigation; Bone Completes Phase II BN006 Rheumatoid Arthritis Phase II Treatment; Nusep Completes Singapore-Based Prime Facility Lease; Mesoblast Phase II Results Take Lumbar Spine Fusion To Phase III; Sirtex Founder Dr Bruce Gray Sells $9.6m Shares; Patrys Phase I/IIa Multiple Myeloma Trial Doses 2nd Group; Bluechiip Signs 1st North America Distributor; Oxford’s Isis Appoints Helen Ujvary Australia Representative; US Registers 25 Genea Stem Cell Lines; Progen Expects $723k R&D Tax Refund; Victoria $300k For Infection, Immunity Alliance; Bionomics Expects $4.2m R&D Tax Refund; Cell Care Takes 23% Of Cryosite; QRX’s Moxduo Expected To Launch In Q3, 2103; Aspire $US25m Sunshine Heart Stock Purchase Facility; Phosphagenics Begins Phase I Oxymorphone Patch Trial; Spain Approves Psivida, Alimera Iluvien; Japan Patent For BPH, Diagnostic Array Respiratory Pathogen Test
 
Dec 21, 2012
Alchemia Falls 36% On Audeo Oncology Demerger Failure; Bionomics: Ironwood Begins Phase I BNC210, IW-2134 Anxiety Trial; Viralytics Share Plan Raises $3.5m; Bluechiip Plan Raises $587k, Total $2.1m; NHMRC $200k For Allied, Coridon HPV Vaccine; Genetic Technologies Sues Prevention Genetics, Genelex; Suda To Aquire Novamist Sublingual Platform; Agenix Requests Capital Raising Trading Halt; Cathrx Has Left The Building; Eco Quest To Acquire 29% Of Cynata
 
Dec 20, 2012
Biotech Daily: The Year In Review; Acuvax Dr Roger Aston, Paul Hopper Back To Cancer Future; Invion, Numoda $2m Draw-Down Equity Clinical Trial Facility; Benitec Appoints Synteract For Hepatitis C Clinical Trials; UBS AG Below 5% Of Acrux; Imugene Appoints Phillip Hains Co-Company Secretary
 
Dec 19, 2012
Clinuvel Claims Scenesse Phase II Vitiligo Success; Prana Completes Phase IIa PBT2 Huntington’s Recruitment; Hunter Hall Takes More Profit From Sirtex; Allan Gray Takes 5% Of Acrux; UBS AG Takes 5% Of Acrux; Acuvax Requests Acquisition Trading Halt; Calama Takes 7% Of Tyrian
 
Federal Government $128m NHMRC Grants; Sirtex Joins S&P ASX200; Nusep Earns $1.5m Federal R&D Tax Refund; Atcor Expects $697k Federal R&D Tax Payment; UQ, Emory Collaborate For Que Oncology; Genera Raises $800k; Melanie Leydin Replaces CFO Tony Panther; Bank Of East Asia, David Li Take 28% Of Biodiem; Medivac Loses Director Paul McPherson 
 
Dec 17, 2012
Living Cell Deal With Otsuka For NTCell For Neurology; Allied Placement Raises $1.7m, Share Plan; Invion Meets FDA For INV103 For Lupus; Immuron Mouse Studies Back IMM-529 For Clostridium Difficile; European Committee Rebuffs Antisense Partner Isis, Genzyme; Universal Biosensors Plan Raises $1.2m, Total Raised $13.2m; Consegna Placement Raises $500k, Share Plan For $250k More; Fortrend Takes 9% Of Agenix; Chairman Andrew Kroger Takes 23% Of Cryosite; Alchemia Takes Nasdaq Listing, IPO To Suspension; Starpharma Appoints Eve Williamson V-P Business Development; WEHI’s Prof Peter Colman Wins Inaugural Bragg Medal
 
Dec 14, 2012
Bionomics Names Alpha-7 BNC375 For Alzheimer’s Disease; Biotron Completes Phase I/II HIV Treatment; Mayne Buys GSK’s Kapanol Opioid For $14m, Placement, Plan; Dr Phillip Comans Replaces Bioxyne CEO David Radford; Avexa AGM Defeats Director, 47% Shun Alabama Coal Mine; Commonwealth Director Of Public Prosecutions V JM; IDT Loses M-D Dr Robyn Elliott
 
Dec 13, 2012
Mesoblast Cells ‘Safe, Effective For Cord Blood Expansion’; Gilead Pays $362m For YM’s $14m Cytopia CYT387; Hatchtech Raises $6m For Phase III Deovo Lice, Eggs Trial; Viralytics US Phase II Melanoma Trial: ‘Interim Efficacy’; Prana: ‘PBT2 Inhibits Huntington’s Symptoms In Mice’; Alchemia Requests Audeo IPO, Capital Raising Trading Halt; Allied Health Requests Capital Raising Trading Halt
 
Dec 12, 2012
Teva Backs Mesoblast Phase III Cardiac Trial; Harding Loevner Takes 6% Of Cochlear; Correction: Agenix; Biodiem India Partner Prepares For Export; Prana 24% AGM Dissent Against Director Options; Consegna Takes Capital Raising Halt To Suspension; Novogen Appoints Andrew Bursill Company Secretary
 
Dec 11, 2012
Spinifex Starts Phase II EMA401 Chemo Neuropathy Trial; Thromboview Platform Returns As Agenix Lead Product; Cyclopharm Rights Issue Raises $2.1m; Bearish M&G Group Takes 11% Of Starpharma; Circadian Creates Internal VEGF Subsidiaries
 
Patrys Doses 1st Three PAT-SM6 Multiple Myeloma Patients; Viralytics Plans UK Cavatak IV Cancer Trial; Avexa Signs Potential ATC Distributors; Allan Gray (Orbis) Takes 10% Of Nanosonics; European Patent For OBJ’s Dermaportation Technology; Avexa Reduces To 10% Of Allied Health; Consegna Requests Capital Raising Trading Halt; Genetic Technologies: Alison Mew CEO, Ben Silluzio Director; Ex-CEO Dr Paul Tan Replaces Living Cell CSO Prof Bob Elliott 
 
Dec 7, 2012
Novogen Back To Cancer Future With CEO Prof Graham Kelly; WEHI Immune ‘Kill Switch’ NLRP1 Could Be Chemotherapy Target; Proctor & Gamble, OBJ Magnetic Transdermal Trials; Bioniche Director Nick Photiades Retires
 
Dec 6, 2012
CSL: All Programs On-Track, Hiring R&D Staff; Melbourne Uni, Bio Farma Adjuvant Vaccine Collaborations; Starpharma Dendrimer-Docetaxel 4 Tumor Superiority In Mice; Roche’s 454 Settles Genetic Technologies Patent Case; Allan Gray Takes 11% Of QRX; Genesis 6-Day Director Houwen (Tina) Tan Resigns; Isonea Asthma ’Phone Update
 
Dec 4, 2012
Osprey Begins Catheter-Based Limb Recovery Trial; Benitec, Uniqure Cross-Licence ddRNAi, AAV5 Delivery; Australian Ethical Takes 5% Of Universal Biosensors; Correction: GI Dynamics; Eastland Promotes CEO, CFO, Looks For New Projects
 
Dec 3, 2012
November BDI-40 Down 5%, ASX200 Flat, Big Caps Up 7%, Patrys Up 27%, Genetic Technologies Down 38%; Psivida: UK Nice Refuses Iluvien Rebate, Appeal Available; Benitec Compound Silences 90% OPMD Gene Expression; Phosphagenics Broadens Opioid Patch To Platform; M&G Group Takes 13% Of GI Dynamics; Alchemia Expects $9m Offshore R&D Tax Refund; Bone Capthymone Dose Trial; David Kenley Takes 6% Of Calzada
 
Nov 28, 2012
Editorial: Mervyn, Mervyn, Mervyn !; Starpharma Vivagel Fails Phase III; FDA NDA On Hold; Allied’s Cardiocel Sheep Trial Grows New Tissue; Bioxyne To Let Shareholders Decide HI-1640V’s Fate; Genetic Technologies Appoints Dr Mal Brandon Chairman; Consegna Loses Director Brendan Fleiter, Belt-Tightening; Healthlinx 27% AGM Dissent Against Director Nick Gatsios; Nusep Loses 3 Directors Ahead Of 2nd Strike AGM; GI Dynamics Releases 90.5m Escrow Shares
 
Nov 27, 2012
Genetic Technologies Loses Chairman, CEO, Directors, Staff; Genetic Technologies’ Dr Mervyn Jacobson High Court Trial; CSL 20% Profit Upgrade; Prana Completes Alzheimer’s Imaging Trial Recruitment; Biotron Begins 3-Month BIT225 Toxicology Studies; Antisense Earns $670k R&D Tax Rebate; $830k More To Come; Bluechiip Tagging Methods, Apparatus European Patent
 
Nov 26, 2012
WEHI: Immune Gene ARIH2 Could Control Chronic Infections; Universal Biosensors Placement Raises $12m, Share Plan; OBJ Faces 22% Against Remuneration; Cathrx To Delist On New Year’s Eve
 
Nov 22, 2012
Minister Asher Awards $50k Victoria Prizes, $18k Fellowships; Living Cell Phase I/IIa Diabecell Efficacy, Phase IIb Trial Begins; Neuren Phase I Shows Oral NNZ-2566 Safe, Rett Syndrome IND; Alchemia Earns $1.4m From Fondaparinux, Sales Up 30%; Phylogica Upgrades Phylomer Library ‘47-Fold’; Universal Biosensors Requests Capital Raising Trading Halt; Viralytics 36.5% AGM Dissent At Directors Fees Pool Hike; Starpharma Expects $6m R&D Tax Payment; Agenix EGM To Licence Tyrian Assets, Issue Fortrend Shares; Alchemia To Lose Chairman Dr Mel Bridges In 2013; Small Technologies Cluster BBQ On Victoria’s Impact
 
Nov 21, 2012
FDA Approves Heartware Pump For Bridge-To-Transplant; Unconditional FDA Approval For Sunshine Heart C-Pulse Trial; WEHI’s $185m Research Facility; Bluechiip Placement Raises $1.5m, Share Plan; Japanese Patent For Biodiem’s Anti-Microbial BDM-I; Biota Clears Overhang, 2013 BARDA Phase II Milestone; Hunter Hall Reduces To 26% In Sirtex; Viralytics Takes Capital Raising Halt To Suspension
 
Nov 20, 2012
Avita Prepares For 2013 Recell Venous Leg Ulcer Trial; Sirtex To Establish German Manufacturing Facility; US FDA Approves Atcor Sphygmocor Xcel; Baillie Gifford Takes 12% Of Cochlear; US FDA Approves Mesoblast Manufacturing Process; Novogen, MEI Pharma Me-344 ‘A Most Licensable Product’; Sunshine Heart Requests Regulatory Trading Halt; IDT Loses 2nd Strike Vote, Wins Spill Vote; Circadian Faces 22% Against Remuneration; Bioxyne Savings: CEO David Radford 0.6-Time, Director Shares
 
Nov 19, 2012
Cyclopharm Enrols 1st Technegas Phase III Trial Patient; BPH: Cortical’s 2nd Chinese Brain Monitor Patent; Teva: ‘Working With Mesoblast On Phase III Cardiac Trial’; Viralytics Requests Capital Raising Trading Halt; Correction: Novogen; Bioprospect Loses Peter May, Charles Pellegrino
 
Nov 16, 2012
Benitec Expects US Hep C ddRNAi Monotherapy Trial In 2013; Biotron Presents Phase IIa ‘100% Hep C Cure’ Data; NZ Ethics Approval For Living Cell Parkinson’s Trial; IOOF Takes 6% Of Mayne Pharma; Agenix Completes 1-For-25 Consolidation; Novogen Distributes MEI Shares; Prima Faces 21% Against Remuneration, 24% Incentives; Bluechiip Takes Capital Raising Halt To Suspension; Living Cell Appoints CEO Dr Andrea Grant M-D
 
Nov 15, 2012
Allied, Coridon DNA Vaccine Protects Mice From HPV Tumors; Prana Phase IIa PBT2 Huntington’s Disease Trial On-Track; Clarification: Bionomics AGM Dissent; Mesoblast Talks Teva, Pleads Trading To ASX 21% Fall Query; Mayne Completes Metrics Acquisition; Circadian Licences VEGF To Bio-Rad For Research Products; Biota Appoints Russell Plumb CEO, Dr Joseph Patti Strategy; Investors Mutual Takes 6.5% Of Mayne Pharma; Melanie Leydin Replaces Biodiem Co Sec Richard Wadley; Nusep’s Prof John Aitken Wins NSW Scientist Of The Year
 
Nov 14, 2012
Prima: ‘Further Interim Data Backs CVac For Ovarian Cancer’; Bionomics 47% Dissent At Directors Fees, 1m Options; Reva On-Track For 2014 Sales, Funds Secure; Avexa Coal Mining AGM; Cathrx Votes To Delist; Bluechiip Capital Raising Trading Halt; Viralytics Appoints Dr Malcolm McColl CEO
 
Nov 13, 2012
Benitec, CCIA Mouse Study Delivers ddRNAi To Lung Tumors; Bluechiip, Italy’s H&S Develop Bio-Bank Software; ASX Suspends Broke Genesis, Directors Resign; Viralytics Receives $1.5m R&D Tax Payment; Bruce Mathieson Increases To 9% Of Mayne; Sanofi Appoints Laurence McAllister M-D Australia, NZ; Sunshine Heart, CM Capital Lose Dr Mark Harvey; CM Capital’s Andy Jane Replaces Osprey Director Dr Harvey; Calzada To Lose Director Dr John Chiplin; St Vincent’s Asian Biotech Century Forum
 
Nov 12, 2012
NSW $20m For Children’s Medical Research; Victoria’s 1st Voucher Applications Close November 28; Viralytics Phase I Cavatak Safe, Anti-Tumor Activity; TGA Accreditation For Nusep Manufacturing; Alchemia’s Audeo Files Estimated US Share Price; Biota Opens Down 7% On Nasdaq; Novogen To Acquire Triaxial Pharmaceuticals; Australian Ethical Increases To 13.5% In Avita; Bioniche 48% AGM Dissent On Employee Share, Option Plans; Genesis ‘Lack Of Funds’ Trading Halt
 
Nov 9, 2012
Eli Lilly Axiron Sales Fall Hits Acrux Price; Biota Takes 10.5k Investors To Nasdaq; Biotron Begins Phase II BIT225 Trial For HIV With Hepatitis C; BPH’s Cortical Dynamics Brain Response Trial Closes; Cyclopharm Fighting Fund, US Trial 1-For-4 Rights Issue; Australian Ethical Reduces To 6% In Neuren; Mayne Pharma 17% AGM Dissent Against Chair Roger Corbett; Prana AGM For 9m Directors Options; WEHI’s Prof Jerry Adams Wins AAS Macfarlane Burnet Medal; Pharmaust Loses Mining Director Greg Cunnold
 
Nov 8, 2012
DSMB Backs Alchemia Ha-Irinotecan Colorectal Cancer Trial; CSIRO Soldier Beetle Gene For Antibiotic, Anti-Cancer Drugs; Bionomics’ Ironwood IND For Anti-Anxiety IW-2143 (BNC210); Circadian VGX-100 Combo Inhibits Colorectal Cancer In Mice; Griffith University To Expand Biodiem BDM-I Delivery Variants; Bio-Melbourne Breakfasts On Paediatric Market; Significant Dissent At Invion (CBio) AGM; Small Dissent At Uscom AGM; Durbin Super Takes 6% Of Genera; MEI Pharma Consolidation Changes Novogen Distribution; Medical Dev’s John Sharman Earns 2nd Tranche Shares
 
Nov 7, 2012
Biotech Daily’s 7th Birthday; Senz Begins Phase I/II Trial Of Val-1000 For Acute Leukaemias; Allied Wins $2m Arcomed Infusion Contract; Novogen’s MEI Data Shows High MDS Response Rates; Medical Developments To Supply Asthma Spacer To Canada; Patrys Enrols 1st Multiple Myeloma Trial Patient; Ellex To Launch New Eye Products At Chicago Congress; Biota Earns $4.2m R&D Tax Credit; Bruce Mathieson Increases To 8% Of Mayne; Resonance Ferriscan Closer To Reimbursement; QRX Faces 20% Opposition On Remuneration, Director Options
 
Nov 6, 2012
CSL112 ‘May Reduce Recurrent Cardiac Risk’; Endo Ends Phase IIIBioniche Urocidin Bladder Cancer Trial; Novogen’s MEI Pharma Raises $26m; Cyclopharm Requests Entitlement Offer Trading Halt; Dr Bernard Hockings Takes 7% Of Phylogica
 
Nov 5, 2012
Avexa Invests $10m In Alabama Coal Mine ‘For ATC’ - History; Quest Licences Clinical Genomics Biomarkers; $1m Gates Funds For MIPS Inhaled Oxytocin; Medical Developments Appoints J&J’s Max Johnston Director
 
Nov 2, 2012
Queensland Uni To Produce Cheap Vaccines Quickly; Ausbiotech Closes With Investment Summit; Patersons Cuts Biodiem $2.55m Rights Issue Underwriting; Healthlinx Final Ovplex Data ‘Validates Test’; M&G Group Takes 12% Of GI Dynamics; Euco Takes 5% Of Nusep; Avexa Requests Investment Trading Halt; OBJ Pleads Schultz To ASX 33% Query; Antisense Director Prof George Werther Retires
 
Nov 1, 2012
October BDI-40 Down 3%, ASX200 Up 3%, Big Caps Up 3%, Viralytics Up 70%, Neuren Up 56%, Prima Down 33%; Patrys Expands PAT-SM6 Multiple Myeloma Trial To Melbourne; Ellex To Supply Signostics Ultrasound Sub-Assembly; Mayne Licences Intas Injectables, Retail Offer Raises $25m; No GSK Biota Relenza Sales, No Royalty; Inavir Earns $26k; Consegna Passes On Aspen Medisys; Consegna Has Less Than One Quarter Cash, $6m Facility; Pharmaust Has One Quarter Cash, $1m Raising; Andrew Baker, Starpharma, Vaxxas Ausbiotech Janssen Gongs; Connor O’Meara Wins $7k Ausbiotech-Glaxosmithkline Award; Ausbiotech Elects Michelle Burke Director
 
Oct 31, 2012
Victoria Opens Ausbiotech Conference With $1.9m Programs; Osprey Device Reduces Kidney-Toxic Cardiac Dye; Octa Phillip Fund Has $55m To Invest; Medical Developments Asthma Spacer Supply Deal; Phosphagenics Expands TPM Horse Supplements; Baillie Gifford Takes 9.6% Of Cochlear; Cryosite Easily Wins 2nd Strike Vote; Nusep 2nd Strike Board Spill, Directors’ Shares AGM; Paul Hopper Replaces Imugene’s Dr Warwick Lamb
 
Oct 30, 2012
EMA Delays Tissue Therapies Vitrogro Up To 210 Days; Octa Phillip-Bioxyne Board Spill Fails; Bye-Bye Biota, Hello Nasdaq; Full US Approval For GI Dynamics Endobarrier Trial; Phosphagenics TPM Injectable Antibiotic Deal To India’s Agila; Alchemia Has One Quarter Cash, $60m IPO, $2m Tax Credit, Sales; Isonea Raises $4m; Nusep Places $1m; John Leaver Takes 6% Of Bionomics; Landon Clay, East Hill Take 13% Of Biota; CB Co, Curran Super Fund Takes 13% Of Atcor; Consegna 77m Shares, 80m Options, 1m Notes AGM; Bone $1,671,987 Directors, Others Shares As Fees AGM; Prof Maree Smith, Dr Jim Aylward Win LSQ Gongs
 
Oct 29, 2012
Ausbiotech October Conference Opens This Week; Lymphology Assoc Backs Impedimed’s L-Dex Lymphoedema Test; Starpharma Improves Docetaxel Tumor Delivery In Mice; Ellex, Healthlinx Face 2nd Strike AGM Spill Votes; Medivac’s Republica Backdoor Listing AGM; Eastland Name Change To Suda AGM; Actinogen Has Less Than One Quarter Cash, Fundraising; Agenix 1-For-25 Consolidation Timetable
 
Oct 26, 2012
Mireven Claims Preclinical Mir-7 Head, Neck Cancer Success; Nice Result: Pharmaxis UK Bronchitol Reimbursement; Court Approves Biota Merger, Nabi Consolidates Shares; Paranta Contracts DSM For Follistatin Manufacture; Melbourne Uni, Janssen-Cilag Work On Respiratory Drug; Resmed Q1 Revenue Up 8% To $329m, Profit Up 41%; Biotron Prepares For 2nd Strike Board Spill AGM; Biotech Daily Appendix 4c Quarterly Reports Policy; Psivida AGM For 314k CEO, Director Options; Prima Appoints Marc Voigt CFO, Deanne Miller Counsel
 
Oct 25, 2012
Neopec: Breast Regrowth In 1-Of-5 Pilot Trial Patients; Agenix Licences Tyrian’s Technology For $500k Shares; Allan Gray (Orbis) Takes 9% Of Nanosonics; Bioxyne Reminder For Spill Meeting, Dr Doug Wilson Resigns; Neuren Pleads Schultz To ASX 54% Query; Phylogica Has One Quarter Cash, $2m Tax Credit, $1.6m Raising; Patrys PAT-SM6 Multiple Myeloma Poster Wins German 1st Prize; Eco Quest AGM For 10m Director Options
 
Oct 24, 2012
Reva: ‘Two Major Stent Events, 80% At 4-Months Follow-Up’; Cellmid Underwritten Options Raise $545k; Avexa Reduces To 11% Of Allied Health; Probiotec AGM For 2.1m Director Options, 40% Fees Rise; Pfizer’s Mendel Grobler Wins Medicines Aust Pat Clear Gong; Sunshine Heart C-Pulse Wins Frost & Sullivan Award 
 
Oct 23, 2012
Shareholders Approve Biota, Nabi Merger For US Listing, $26m; Sirtex Sir-Spheres ‘Extend Survival 5 Months’; Resonance Ferriscan Liver Iron Test For 2 Clinical Trials ; Avexa, Valevia Show AVX13616 In-Vitro Anti-Bacterial Activity; GI Dynamics Study Backs Endobarrier Re-Implantation ; Uscom ‘More Accurate Than Blood Pressure In Pregnancy’; Sirtex Avoids Spill By 0.015% Or 8,000 Votes; CBio Ex-Executives Countersue Invion
 
Oct 22, 2012
Federal ARC, CRC Grants ‘Protected’, Escape ‘Review’; Biota Investors Diluted 25% For US Listing, $26m; Universal Biosensors Quarter Strip Fees Up 291% To $555k; Viralytics Doses 13 Of 63 Phase II Cavatak Melanoma Patients; China Allows Benitec RNAi Hepatitis C Patent ; Starpharma AGM For 960k CEO ‘Performance Rights’; Allied Health AGM For $115k Directors’ Shares In Lieu Of Pay; Circadian AGM For 88k M-D ‘Performance’ Shares; Medical Developments Appoints Wendy Gouveia Co Sec
 
Oct 19, 2012
NHMRC Grants Unfrozen, Down 3% To $652m For 1,141 Grants ; Bluechiip Partners With Swiss Lugano For Automation; Antisense Rebounds On Isis Reflected FDA Glory; Viralytics AGM For 43% Directors Pay Pool Rise, Options; Investors Mutual Take 8% Of Mayne Pharma; Watermark (Australian Leaders) Take 9% Of Mayne Pharma; Octa Phillip Directors Jeremy Curnock Cook, Matt McNamara Replace Avita’s Dr Paul Watt
 
Special Authorization For 1st Allied Infant Cardiocel Implant; Starpharma Vivagel Bacterial Vaginosis Trials Recruited; Ramaciotti Foundations $1.6m For Biomedical Research; Bioniche Immunocidin ‘Alternative To Chemotherapy In Dogs’; Federal Court Approves Alchemia-Audeo Demerger; FDA Indications Call Could Boost Resonance Ferriscan; Genetic Technologies, One Lambda Patent Agreement; US Patent For Calzada Polynovo Novosorb; Phylogica AGM For Notes, 6m Executive Bonus Options
 
Progen’s PI-88 Fails Phase II Melanoma Combination Trial; Antisense ‘Reflected Glory’ Price Fall Query, Trading Halt; ATO Provides Alchemia Demerger Tax Relief; Heartware Quits Early Stage Trial; CSL To Buy-Back $900m More Shares; Cathrx Signs Manufacture, Supply Deal With GMMI; Ex-CEO Dr Roger Aston Below 5% In Mayne Pharma; Pokies Bruce Mathieson Increases, Reduced To 6% Of Mayne; Australian Ethical Below 5% Of Universal Biosensors; Isonea AGM For 1m New Directors’ Options; LBT AGM For 500k Director Dr Caroline Popper Options; Alistair Jobling Replaces Acuvax Director Keong Chan
 
Calzada, Polynovo Novosorb Human Proof-Of-Concept; Cochlear Remuneration 1st Strike With 31% Against; Two Strikes Policy – Biotech Daily Editorial; Psivida Developing Tethadur Biosilicon Protein Eye Treatment; Biotron Claims ‘100% BIT225 48-Week Efficacy’; Bionomics Details Alpha-7 Compounds For Alzheimer’s Disease; Cogstate Test ‘Useful In Detecting Alzheimer’s’; Phase IIa Observations Back Clinuvel Scenesse For Vitiligo; Phylogica Notes To Raise $1.6m; Avita Plan Raises $4.2m, Total $10.5m; Nabil Luyer Takes 10.5% Of Healthlinx; Prima AGM For 1.2m New Directors’ Options, Rights
 
Prima Phase II ‘Positive Trend’ For CVac For Ovarian Cancer; Alchemia Votes 99% In Favor Of Demerger; Genetic Technologies Files 4 More US Patent Suits ; Ellerston (Packer Family) Buys $10m More Of Acrux; Bionomics AGM For 1m New Directors’ Options; Nusep To Spin-Out Prime Biologics
 
Cogstate $3.7m Phase III Schizophrenia Trial Contract; Administrators Close Virax For Deed Of Arrangement; Impedimed AGM Votes On $365k CEO Termination Pay; IDT Defers AGM For Missed 25% Spill Motion; Calzada 1.5m Directors’ Options AGM; Spill Motion; Immuron Appoints Daniel Pollock Director; Progen Company Secretary Paul Dixon Resigns; Nanosonics Wins NSW Premier’s Export Gong
 
Benitec Buys-Back US Spin-Out Tacere For $1.5m Scrip; Graeme Kaufman To Replace Bionomics Chair Chris Fullerton; Ellex Looking To Expand Laser Line; Biotron HIV Trial Delayed; Prepares For HIV/Hep C Trial
 
QRX, Paladin Labs Sign Potential $25m Canada Moxduo Licence; Clarification: Nanosonics; Pharmaxis Posts Best 3-Month Sales Of $584k; Alchemia Draft ATO Demerger Class Ruling; Meeting Date; Prana Chair Geoff Kempler, Baywick Increases, Diluted To 5% 
 
Oct 9, 2012
Vaxxas, Merck & Co Nanopatch Vaccine Deal; Mayne, Metrics Acquisition AGM; Nanosonics M-D Rights, Placement, GE Notes AGM; Viralytics Loses Co Sec Tom Rowe; Bio-Melbourne Environment, Social Impact Breakfast
 
Oct 8, 2012
Atcor Wins $3m Pharmaceutical Trial Contract; China Patent For Benitec Hep C RNAi Constructs; Mayne Raises $14.8m For Metrics, $40.2m To Go; Pharmaxis Pleads Schultz To ASX 14% Query, News Reports; ASX Okays Cathrx Request To Delist; Dr Roger Aston Replaces Immuron Chair Prof Colin Chapman
 
Oct 5, 2012
Eco Quest’s $250k For Dr Allen Bollands Cynata Stem Cells; GI Dynamics Holders Extend 90m Share Voluntary Escrow; Alchemia Demerger Meetings Delayed 7 Business Days; Correction: Pharmaust; QRX AGM For 600k Director Options; Invion (CBio) AGM For 25m Director Options; Uscom AGM For 3m Executive Chairman Options
 
Oct 4, 2012
NZ Clears Living Cell Pig-To-Human Brain Cell Transplant; $55m Mayne To Pay $120m For US Generic Company Metrics Inc; 3-Month Sirtex Dose Sales Up 37%, Breaks Through $10; Prima Completes Phase II Ovarian Cancer Trial; Bluechiip Granted US Tagging Methods, Apparatus Patent; Pharmaust To Lose Founder Bryant Mclarty; Acuvax Ex-Ceo Dr William Ardrey Bailed To November
 
Oct 3, 2012
Vale Prof Nancy Millis 1922-2012; Research Review Calls For Up To $3.6b More Per Year; Ausbiotech Tribute To Prof Nancy Millis, Biotech’s 1st Lady; GI Dynamics Endobarrier Non-Obese Insuline Sensitivity Benefit; Benitec Claims Proof-Of-Concept For ddRNAi Pain Compound; Euro Patent For Novogen, MEI Pharma ME-344 For Cancer; Nusep Installs 1st Prime Unit In Singapore; Isonea Applies For US Sonosentry OTC Sales; Consegna Breatheassist Meets Triple A Sales Due Diligence; Baillie Gifford Takes 9.6% Of Cochlear; Thee Woon Goh Takes 12% Of Nusep
 
Oct 2, 2012
FDA Conditional Approval For Sunshine Heart Pivotal Trial; Prana Places $6m For PBT2 Trials; Bone Begins Capthymone For Osteoporosis Trials; Cellmid Earns $748k Federal R&D Tax Credit; Uscom Targets Hypertension; Circadian Director Dr Errol Malta Retires; Imugene Director Roger Steinepreis Resigns
 
Oct 1, 2012
September BDI-40 Up 6%, ASX200 Up 1.6%, Big Caps Up 4%, Patrys Up 70%, Universal Bio Up 54%, Bioniche Down 48%; Florey, Servier Collaborate On Alzheimer’s Disease; Clinuvel Answers EMA Scenesse Questions; Sunshine Heart Requests Regulatory Trading Halt; Prana Requests Capital Raising Trading Halt; China Patent For Bone Axcess IV; Alchemia Appoints 3 Audeo Directors; Probiotec Appoints Robin Tedder Director
 
Sep 28, 2012
Vale Dr Helmer (Hank) Agersborg; US Defence Grants Avita $841k For Slow Recruitment; Clinuvel CSO Dr Helmer Agersborg Dies; Biodiem 1-For-2 Rights Issue For $2.55m; Medivac, Republica Merger; Patrys AGM For 375k CEO Options, Loan Share Plan
 
Sep 27, 2012
CSL, Karolinska: CSL2H10 Blocks Type 2 Diabetes In Rodents; Germany Extends Pharmaxis Patents To 2020; Sirtex Pays Fully-Franked 10c Dividend; Bluechiip Earns $920k R&D Tax Credit; Isonea 3-For-5 Rights Issue For $4m; Progen: Medigen Enrols 1st China PI-88 Liver Cancer Patient; Cathrx To Delist Before Raising $5m; Cryosite Prepares For Cell Care Board Spill AGM; Nusep: Directors Lend $494k, Chase $1.4m Debt; Biodiem Takes Capital Raising Halt To Suspension; All Healthlinx Ovplex Sale EGM Votes Pass - 19% Dissent
 
Sep 26, 2012
Living Cell Diabecell ‘Reduces HbA1c, Diabetes Events’; TGA Special Access For Allied Health’s Heart Patch; US Growth Hormone Receptor Patent For Antisense ATL1103; Boots UK Dumps Phosphagenics’ Anti-Fat Cream; Atcor AGM For 1.4m CEO Options; Isonea Takes Capital Raising Halt To Suspension; Bluechiip Appoints Brett Roberts Commercial Director
 
Sep 25, 2012
Alchemia: 82 Treated Patients - ‘No Unexpected Toxicities’; Allan Gray Takes 10% Of QRX - Buys Low, Sells High; Firebrick Hopes To Cure The Common Cold In 5 Years; Florida Approves Genetic Technologies Brevagen Test; Biodiem Requests Capital Raising Trading Halt; Octa Phillip Letter To Bioxyne Shareholders; Consegna Breatheassist Trials, Patent; Psivida Revenue Down 29% To $3m, Loss Up 179% To $24m; Novogen, Kai Medical Backdoor Listing Fails; Biota Merger Meeting Set For October 23
 
Sep 24, 2012
Vaxine’s $3.4m For Bioxyne’s Probiotec, New Hi-164OV Trial; GSK Competitor Hits Alchemia Fondaparinux 1st Profit; Optiscan Earns $746k Zeiss Neurosurgery Milestones; Uscom ‘Role In Cancer Treatment’; St Vincent’s, Macquarie Adopt GI Dynamics Endobarrier; Isonea Requests Capital Raising Trading Halt; Mayne Reviewing Options, May Or May Not Raise Capital; Burnet’s Prof Gilda Tachedjian Wins Frank Fenner Gong
 
Sep 21, 2012
Research Backs Patrys PAT-SM6 For Tumor Cell Death; Universal Biosensors, Siemens Manufacturing, Supply Deal; Cathrx $2.2m R&D Tax Credit; Progen To Continue Developing PG545 For Cancer; Immuron Names Clostridium Difficile Product ‘IMM-529’; Sirtex Prepares For Founder Dr Bruce Gray Board Spill AGM; Agenix 25-For-1 Consolidation AGM, 10m Chairman Options
 
Sep 20, 2012
German OK For Patrys Phase I/IIa PAT-SM6 Multiple Myeloma Trial; Bioxyne Prepares For Board Spill EGM; Imugene Targets Vitamin D Deficiency, Erectile Dysfunction; China, Japan Patents For Broadvector Hip Failure Repair; Lloyds & Cassanove Takes 13.5% Of Cyclopharm; Medical Developments Loses Dr Anthony Coulepis, Usha Charan
 
Sep 19, 2012
Federal Government Freezes All Grants; Ausbiotech Statement, Biotech Daily Comment; NSW Government Launches $5m Medical Devices Fund; Avexa In-Vitro Success Claimed With HIV Integrase Inhibitors; Sunshine Heart Chair-Elect Jon Erb Starts On $100k, Options; Immuron Clostridium Difficile Candidate ‘100% Mouse Efficacy’; Perpetual Takes More Profits In Sirtex Down To 6.6%; Eastland Preparing Artimist Manufacturing; Cellmid Appoints Martin Rogers Director
 
Sep 18, 2012
Biota Lowers Nabi Takeover Sights From $US54m To $US27m; FMR, Fidelity Hong Kong Takes 5% Of Acrux; Invion (CBio) Earns $2m R&D Tax Credit; Australian Ethical Takes 5% Of Universal Biosensors; ANU Increases, Diluted To 7% Of Bionomics; Bionomics Appoints Graeme Kaufman Director; Bioprospect Loses Director Jacob Khouri
 
Sep 17, 2012
Bionomics Buys Cancer Stem Cells Eclipse For $8-10m Scrip; Reva Hopes To Ride Abbott Polymer Stent ‘Bow Wave’; Australian Ethical Takes 14% In Avita; Dissent At Nabi Could Affect Biota Merger; Regeneus Establishes Patient Database
 
Sep 14, 2012
Victoria Government $5m Innovation Voucher Program; Cellmid Option Rights Issue To Raise $600k; IDT Looking For New Technology; Eastland Completes Artimist Paediatric Malaria Dosing; Ausbiotech Melbourne Bio-Beers & Bubbles
 
Sep 13, 2012
WEHI, Murdoch Create Ian Potter Personal Medicine Centre; Cellmid Says Évolis Hair Growth Products Exceed Forecast; Phylogica $2m R&D Tax Credit, Explains Process; AMP Below 5% In Acrux; M-D Wayne Stringer Takes 15% Of Probiotec; Eastland Pleads Schultz, Again, To ASX 14% Query; Imugene Answers ASX ‘Too Much Money’ Query; Bioniche Revenue Down 8% To $31m, Loss Up 93% To $24m; John Erb Replaces Sunshine Heart Chairman Nick Callinan; Chairman Mel Bridges Quits Leaf Energy; Reva Appoints Dr David Muller Co-Principal Investigator; Mark Ostrowski Replaces Genetic Technologies’ Lewis Stuart
 
Sep 12, 2012
Impedimed CEO Richard Carreon Changes Payer Course; Phylogica Cosmetic Skin Repair Deal With NY’s Le Métier; Immuron Signs Harvest & Health For China Travelan Sales; Data Board Backs Prana Alzheimer’s PBT2 Imaging Trial; Perpetual Below 5% Of Resmed; Perpetual Takes Profits In Sirtex To 8%; Bionomics Appoints 2 Executives, Promotes Dr Sue O’Connor
 
Sep 11, 2012
CSL Potential $1.5b US ’Flu Pandemic Preparedness Contract; Medicines Australia: R&D More Than $1b For 3rd Year; ANU’s Prof Chris Goodnow Wins $80k GSK Research Award; UQ’s Dr Fiona Simpson Wins $25k Cancer Trailblazer Prize; Calzada, Polynovo Treat 1st Novosorb Free-Flap Patient; Pharmaxis AGM For 230k Director ‘Rights’
 
Sep 10, 2012
US Ampliphi To Buy Sydney’s Special Phage; Ausbiotech Prepares For 2012 Melbourne Conference; Pharmaust Drops Mining To Re-Focus On Epichem; AMP Sells 2m More Acrux Shares To 5%; Patrys Plan Raises $850k, Takes Total To $2.85m; Suspended Solagran Loses Finance Director David Croll
 
Sep 7, 2012
Biogrid, Biobank Collaborate For Cancer Research; European Patent For Antisense ATL1101; Biota In Talks For Russell Plumb CEO Job; Sienna Raises $900k
 
Sep 6, 2012
Starpharma, Astrazeneca Oncology Dendrimer Deal; WEHI Awarded $6.25m Apoptosis Cancer Research Grant; Genetic Technologies Licence For Conexio Genomics; Psivida Says UK Funding Body Accepts More Iluvien Data; Bio-Melbourne Neuroscience Breakfast
 
Sep 5, 2012
Victoria’s $8 Million Technology Voucher Program; Avita Placement Raises $6.3m, Share Plan For $3.7m More; Uscom Raises Further $256k, Takes Total To $952,200
 
Sep 4, 2012
Hatchtech FDA Meeting For Phase III Head Lice, Egg Treatment; Isonea Free Spring Trial Of Asthma Application; Frostbland To Distribute Cellmid Évolis Hair Products; CBio Trades As Invion From Tomorrow
 
Sep 3, 2012
August BDI-40 Up 1.2%, ASX200 Up 1.1%, Big Caps Up 6%, CSL Up 50% Ytd, Sunshine Heart Up 56%, Phylogica Down 25%; Optiscan Raises $1m, Bergen Agrees To End Draw-Down Facility; Immuron Sales Up 110%, Revenue Up 56%, Loss Down 12%; Circadian Revenue Down 19% To $1.5m, Loss Down 53% To $5m; Advanced Surgical Revenue Up 18% To $9m, Loss Down 95%; US Patent For Healthlinx Tumor Biomarker AGR2; Allied Health Revenue Down 5% To $6.5m, Loss Up 411% To $10m; Avita Requests Capital Raising Trading Halt; Prima CEO Matthew Lehman Starts On $316k; Prima’s Martin Rogers Joins Consegna’s Changing Board
 
Aug 31, 2012
Sunshine Heart FDA Application For Pivotal C-Pulse Trial; FDA Meeting For Invion (CBio) XToll For Lupus; Phillip Comans Call For Bioxyne Board Spill – Fight Looms; Cyclopharm H1 Revenue Up 14% To $4m, Loss Down 17% To $1.3m; QRX (Licence) Revenue Up 984% To $1.9m, Loss Down 38% To $16m; Avita Revenue Up 13% To $5m, Loss Up 327% To $7.7m; Impedimed Revenue Down 24% To $3.2m, Loss Down 17% To $12m; Biodiem Revenue Up 422% To $1.3m, Loss Down 61% To $1m; Nusep Revenue Up 42% To $2.5m, Loss Down 22% To $5m; Pharmaust Revenue Up 2% To $1.6m, Loss Down 26% To $4m; Pokies Bruce Mathieson Buys 15% Of Isonea; Optiscan Requests Placement Trading Halt
 
Aug 30, 2012
Fox Foundation Pays Prana $199k PBT434 Parkinson’s Milestone; Ellex Revenue Up 10% To $48m, Loss Turns To $1m Profit; Living Cell Revenue Up 115% To $3.8m, Turnaround $6.3m Profit; GI Dynamics H1 Revenue Up 298% To $220k, Loss Flat At $11m; Genetic Technologies Sues Reproductive Genetics Institute; CBio Approves Inverseon Merger Votes To Become Invion; Clarification: CBio; Paradice Falls Below 5% Of Acrux
 
Aug 29, 2012
Sirtex Revenue Up 19% To $87m, Profit Up 49% To $17m; Tissue Therapies Raises $1m From New Unnamed Investor; Probiotec Revenue Down 10% To $66m, Profit Up 112% To $1.2m; CBio Meets Tomorrow For Inverseon Merger To Invion; Scigen H1 Revenue Up 13% To $8m, Turnaround $3.8m Profit; Braitling, Australian Lenders Take 5% Of Mayne Pharma
 
Aug 28, 2012
Spinifex Phase II Trial: ‘EMA401 Reduces Neuralgic Pain’; Genetic Technologies Revenue Down 66%, Profit Turns To Loss; Bluechiip, Gentris Work On Pharmaco-Genomics, Bio-Repository; Regeneus Sets Up Macquarie Uni Clinic Fat Stem Cells Lab; Healthlinx EGM To Sell Ovplex Assets; Medical Australia Revenue Up 5% To $9m, Loss Up 95% To $669k
 
Aug 27, 2012
Nanosonics Revenue Up 295% To $13m, Loss Down 58% To $5m; Brain Resource Revenue Up 6% To $6m, Profit Up 44% To $388k; Virax In Voluntary Administration; MRCF Pays Mireven $500k Milestone For Anti-Cancer Mirna-7; Octa Phillip Calls Bioxyne Chairman, CEO Spill Meeting; Graeme Kaufman Replaces Cellmid Director Robin Beaumont; Chairman William Mobbs Takes 29% Of ITL
 
Aug 24, 2012
Cyclopharm Builds Cyclotron At Mater Brisbane; Alchemia Demerger Meeting In October; Calzada’s Polynovo Develops Synthetic Skin, Slow Trials; Acrux Revenue Down 89% To $11m, Profit Down 87% To $7m; Atcor Revenue Down 14% To $6.4m, Loss Down 36% To $2m; IDT Revenue Down 24% To $10m, Loss Up 678%; ‘Next Year Better’
 
Aug 23, 2012
Mireven, Silence Collaborate On WAIMR’s miRNA For Cancer; US FDA Conditional Approval For GI Dynamics Pivotal Trial; Senz Claims Funding For Val-1000 Leukaemia Trials; Medical Developments Revenue Up 11%, Profit Up 55%, Dividends; Cryosite Revenue Up 20% To $8m, Profit Up 206% To $1m; ITL Revenue Down 25% To $31m, Profit Up 41% To $1.3m
 
Aug 22, 2012
Biota Claims Japan Success On ’Flu Preventative Inavir; Mesoblast Revenue Up 98% To $38m, Profit To Loss, $207m Cash; Start-Up Australia Invests $47.7m, Returns $85.3m; CSL Profit Up 4.5% To $983m On Revenue Up 7% To $4,624m; Biota Revenue Up 53% To $22m, Loss Down 33% To $19m; LBT Revenue Up 38% To $1m, Loss Down 0.5% To $1.2m; Alchemia Revenue Down 45% To $726k – No Fondaparinux Cash; Fisher Funds Takes 6% Of Universal Biosensors; Director Michael Stork Increases, Diluted In Patrys; Dr Dax Marcus Calder Takes 5.3% Of Patrys; Cathrx Director Jeffrey Goodman Resigns
 
Aug 21, 2012
Biodiem Claims Early LAIV Success With Vivalis EB66; Biotech Takes 2 Of 3 L’Oréal Women In Science $25k Fellowships; Cogstate Revenue Up 48%, Return To Profit With $2.45m; Phosphagenics H1 Sales Down 39%, Revenue Up 57%, Loss Up 42%; Mayne Sales Up 10%, Revenue Up 5%, Profit Up 265% To $6m; Phylogica Revenue Down 16% To $2m, Loss Up 8%; GI Dynamics To Release 19m Escrow US Shares (97m CDIs); Dr Bernard Hockings Takes 6.5% Of Phylogica
 
Aug 20, 2012
QRX Says More Existing Moxduo Data Could Convince US FDA; Uscom Raises $696k, Hopes For More; Eastland Completes Artimist Trial Dosing ; Fisher Funds Take 5% Of Nanosonics; Chairman Angus Holt’s Gralaw Doubles To 10% Of Optiscan; Biota East Coast Shareholder Briefings
 
Aug 17, 2012
European Patent For Anteo’s Mix&Go Bio-Glue; Consegna Appoints Chinamed For Breatheassist Manufacture; AMP Reduces To 6.35% Of Acrux; Correction: Bio-Melbourne Briefing
 
Aug 16, 2012
CBio Expects $2.2m R&D Tax Credit, $1.2m Executive Legal Action; Nusep Restructures Board, Management; Sunshine Heart Raises $17m Of $27m, More Expected; Bio-Melbourne Briefing: ‘When To Sell, Licence, Quit’
 
Aug 15, 2012
Reva Stent Trial: No Adverse Events, Pivotal Trial Planning; Immuron Tests IMM-255 Against Swine ’Flu In Ferrets; Bionomics Revenue Up 68% To $7m, Loss Down 67% To $3m; ‘Key US Patent’ For Bionomics BNC105; Up To 17% Of EGM Votes Oppose Patrys Director Shares
 
Aug 14, 2012
Burnet Institute Developing Preventative Hep C Vaccine; Sosei Assigns Neurodiscovery NSL-043 To Beijing Tide; A-Bio Invests $5m In Nusep’s Plasma Plant; Hall Phoenix Diluted Below 5% Of Bone
 
Sunshine Heart Raises $19m Of Hoped For $27m; Benitec, Stanford Research ddRNAi For Neuropathic Pain; Atcor $1m Unnamed Pharma Contract; Isonea Completes 1-For-20 Stock Consolidation; Jason Peterson, Celtic Capital Takes 9% Of Imugene
 
Biota Publishes Scheme Booklet, Experts’ Report; Pharmaxis Revenue Up 85% To $8m, Loss Down 16% To $39m; Sunshine Heart Requests Capital Raising Trading Halt
 
Aug 9, 2012
Novogen’s MEI Buys SBio’s Pracinostat For $US500k Scrip; Psivida Places $5.36m; Japan To Grant Viralytics Cavatak Multiple Myeloma Patent; Biota Nabi, Nasdaq Scheme Meeting Set For September 25; Neuren Appoints Dr Joseph Horrigan Head Of Clinical, Medical; Eastland Pleads Schultz, Patient Enrolment To ASX 41% Query
 
Aug 8, 2012
 CE Mark Approval For Genetic Technologies Brevagen Test; UK Regulatory Delay For Tissue Therapies’ Vitrogro; Heartware H1 Revenue Up 44% To $53m, Loss Up 113% To $39m; Euro Patent For Biodiem’s BDM-I; Isonea Launches New Asthma Smart-Phone Application; Calzada Appoints Prof David McQuillan Director; Ellerston (Packer Family) Takes 7% Of Acrux; Terrapinn Biopharma Conference
 
Aug 7, 2012
 
Aug 6, 2012
 Prof Arun Sanyal NIH Grant Covers Immuron IMM-124E Trial; FDA Conditional Approval For Sunshine Heart’s New Driver; CBio Starts CPN10 (XToll) FDA Process For Lupus; Medical Developments Doses Final Penthrox Euro Patient; Capital Investment Transfers 7% Of Atcor; Cellmid Appoints Andrew Bald Joint Company Secretary
 
 
Aug 2, 2012
 
 Bathurst Uscom Study Reduces Septic Shock Mortality 90%; ‘Drug Exports Bigger Than Cars’ - Medicines Australia; Viralytics US Patent For Killing Cancer Cells Pre-Transplant; Pharmaxis Files Bronchitol Cystic Fibrosis NDA To FDA; Psivida: Alimera Resubmits Rejected Iluvien NDA To US FDA
 

Jul 31, 2012
Psivida Returns To Biosilicon - For Eye Diseases; Biota’s Inavir Q4 Royalty Up 25%, Year-To-Date Up 47.3%; Blackrock Sells Below Substantial In CSL ; Pharmaust $1m Placement; Returns From Mining Foray; Papers Back Uscom For Hypertension In Pregnancy; Sunshine Heart Has Less Than One Quarter Cash; $28m Raising; Atcor Has Less Than Two Quarters Cash; More Coming; Cathrx Has One Quarter Cash; $1m Loan; More Coming; James Rae Replaces Bioniche Chairman Graeme McRae
 
Jul 30, 2012
 
 Benitec, Medistem Article Backs ddRNAi For Transplant; Calzada, Polynovo Broaden Novosorb Trial For Recruitment; Regeneus, Cryosite Collaborate On Frozen Fat Stem Cells; CBio EGM To Become Invion For Anti-Inflammatory Diseases; Isonea EGM Votes Pass Easily - 15% Oppose Pursuit Of Happiness; Nanosonics Appoints Cochlear’s Michael Kavanagh Director
 
Jul 27, 2012
 
 Sunshine Heart To Raise $28m For Pivotal C-Pulse Trial; Universal Biosensors $1.5m Siemens Test Strip Milestone; Germany Approves Psivida’s Iluvien; Correction: Cellmid; Kai Medical Sleep Treatment Backdoors Into Novogen; Uscom Has Less Than Two Quarters Cash, More Coming; Actinogen Has One Quarter Cash, More Coming; Dr Stewart Washer Replaces Isonea Chair Ross Haghighat
 
Jul 26, 2012
 
 California Approves Genetic Technologies’ Brevagen Test; GSK 2011-’12 Biota Relenza Royalty Down 36% To $4.2m; Cellmid Allowed 4th US Midkine Patent
 
Jul 25, 2012
 
 CE Mark For Sunshine Heart C-Pulse Aorta Cuff Pump; US Patent For Hatchtech, Phase II Data Presentations; Actinogen Actinomycetes For Tamiflu’s Shikimic Acid; Sirtex Practitioners Discuss Sir-Sphere Efficacy; Pharmaxis Appoints Dr Simon Buckingham Director; Viralytics Loses M-D Bryan Dulhunty For Commercialisation
 
Jul 24, 2012
 
 Mesoblast Stem Cells Effective In Arthritis Sheep Trial; Sunshine Heart Hails 12-Month Data, 1st 24-Month Patient; US, Canada Approve Bioniche Dog Cancer Drug; Andrew Goodall Increases To 20% Of Nusep; Impedimed’s Greg Brown Joins Genetic Technologies
 
Jul 23, 2012
 
 Ellex Expects Turnaround 2011-’12 Profit; Atcor Applies For US Clearance For Sphygmocor Xcel; Biodiem Rodent Data Backs BDM-E For Retinitis Pigmentosa; EMA Approval Of Uniqure’s Glybera ‘Good For Benitec’; Biotech Daily Appendix 4C Quarterly Reports Policy; Cellmid Has Less Than Two Quarters Cash - More Coming
 
Jul 20, 2012
 
 FDA Approves Phase III Psivida Medidur-Micro Uveitis Trial; Dr Stephen Woodford Takes 5% Of Uscom; Afandin Fails To Fund Antisense ATL1101 For Cancer; CSL Loses Executive Director, 45-Year Veteran Peter Turner; Acuvax Ex-CEO Dr William Ardrey Fraud Case - Bail To October
 
Jul 19, 2012
 
 Biodiem, RMIT Research LAIV For Non-’Flu Vaccines; Genesis, Mariposa Merger Fails; France Approves Psivida’s Iluvien, Alimera To Raise $US40m; IDT Appoints Dr Ashley Bates Business Development Manager; Share Buy-Back Takes Director Sanjay Sehgal To 5% Of ITL
 
Jul 18, 2012
 Antisense, Tianjin JV Takes ATL1102 Back To Clinic For MS; CE Mark For Ellex 2RT Laser Treatment; Biotech Takes 5 Of 6 Victoria Grants - Up To $1.5m Each; Alnylam RNAi Success ‘Good For Benitec’; US Axcess III Patent For Bone; Pharmaxis Bronchitol Sales Begin, R&D Pipeline Detailed; Circadian Companies Increase, Diluted To 11% In Antisense; Robert Towner Takes 6% Of Neurodiscovery
 
 
Jul 13, 2012
Reva Closes Rezolve Pilot Trial – No Major Coronary Events
 
Jul 12, 2012
Resonance Applies For FDA Clearance For Liver Fat Test; Cogstate Expects Up To $12m Revenue, $2.7m Profit; Richard Carreon Starts As Impedimed CEO; Bioxyne Sends Data Pack To Potential Suitors; Citigroup Ceases In Patrys; Consegna Requests Licencing Trading Halt; Genesis Appoints Catherine Yan Director
 
Jul 11, 2012
Regeneus Claims Fat-Stem Cell Efficacy In Mouse Arthritis; Sunshine Up 342% On Nasdaq, 132% On ASX In Three Days; Lang Walker, Companies Take 10% Of QRX; Calama Takes 5% Of Tyrian
 
Benitec ddRNAi Licence To Dublin’s Genable For Eye Disease; Sunshine Heart Pleads ‘Media Reports’ To 200% Price Rise; Eastland Convertible Notes To Raise $760k; Heartware Appoints Peter McAree CFO 
 
Jul 9, 2012
Alchemia Prepares For 3-Way Split, ASX, Nasdaq Listings; Viralytics 1st Phase II Extension Patient Dosed; BPH, Molecular Discovery, Peter Mac P53 Tumor Collaboration; Mylan Sues Mayne Over Doryx; Merial Challenges Genetic Technologies Non-Coding DNA Patent; Antisense Pleads Schultz, Licence Deal To ASX 20% Query; Citigroup Takes 11% Of Patrys; Immuron To Issue 1-For-4 Bonus Options
 
Jul 6, 2012
Foundation $600k For Neuren Rett Syndrome Phase II Trial; Singapore Patent For Healthlinx Ovplex; Atcor EGM For Placement, Directors’ Shares
 
Jul 5, 2012
WEHI Leads SUV39H1 Enzyme Immune Change For Asthma; Cancer Therapeutics CRC 2nd Compound, Screening Platform; Medical Developments, CSIRO Methoxyflurane Production Deal; Perpetual Takes 5% Of Resmed; Japanese Patent For Bone’s Axcess III
 
Jul 4, 2012
Starpharma 2013 Dendrimer-Docetaxel Cancer Trial; Sirtex 12-Month Dose Sales Up 23%, Implied Revenue $86m; Clarification: Osiris Trial Data; Victoria $1m For Osprey, Baker, RMH Diabetic Foot Infections; Late Contract Reduces Atcor Revenue Guidance; Consegna Extends Aspen Evaluation, Canadian Patent
 
Jul 3, 2012
Allied Health, CSIRO Cardiac Stem Cell Collaboration; Pharmaxis Grants CEO Dr Alan Robertson 200k Rights; Consegna Develops Breatheassist Elite Sports; Medical Australia, Analytica Sell Mediflush Tuta Burettes; M&G Group Buys 3m More Starpharma Shares, Again; Osprey Appoints Neville Mitchell, Vic Fabano; Republica Capital Takes 13% Of Medivac
 
Jul 2, 2012
6-Year BDI-40 Up 82%, ASX200 Down 19%, Big Caps Up 66%; 1-Year BDI-40 Down 12.6%, ASX200 Down 11.1% - Neuren Up 189%, Antisense 188%, Avita 69%, Pharmaxis 65%; June BDI-40 Down 8.6%, ASX 200 Up 0.5% - Antisense Up 15%, QRX Down 67%; CBio, Inverseon Merger For Anti-Inflammatory Diseases; Impedimed L-Dex Lymphoedema Prevention Data; Acrux CEO Dr Richard Treagus Retires, Ross Dobinson Exec Chair; Tissue Therapies Expects Delayed CE Mark In July; Bluechiip Appoints Ron Finkel Non-Executive Director
 
 
 
Jun 27, 2012
 
Jun 26, 2012
 
 
Jun 22, 2012
 
 
 
Jun 19, 2012
Peter Mac BRCA Study Changes Ovarian Ca Treatment, Trials; BPH Cortical Dynamics $4m IPO Fails; IM Medical Completes Sale Of Capitol Health Shares
 
Jun 18, 2012
Mesoblast: ‘Unfounded Speculation’ Hit Price 14%; Immuron Raises $1.44m; Imugene 200m Shares, 50m Options Consegna Linguet EGM; Benitec Appoints Carl Stubbings Chief Business Officer
 
Jun 15, 2012
Bionomics, Merck Serono End MS Co-Development; Virax, 4G Deal Collapses; Atcor Raises $1m; Prima CEO-Elect Matthew Lehman Meets Investors, Timelines; Bioxyne Takes HI-164OV Trial Results Halt To Suspension; Queensland Uni’s Prof Mark Kendall Wins $100k Rolex Gong; Bio-Melbourne Breakfasts On The Future Of CRC Program; Safety Medical Goes Gold Mining In Brazil
 
Jun 14, 2012
Resmed Launches Narval Jaw Position Device; Payment Ends Nusep, Nxgen Longer Lasting Listing Litigation; Healthlinx Loses Dr Stewart Washer, Dr John Chiplin; Larry Knopf Replaces Heartware Co Sec David McIntyre; Atcor Takes Capital Raising Trading Halt To Suspension
 
Jun 13, 2012
Governor Chernov To Lead Victoria US Bio Delegation; Bioxyne Requests HI-164OV Phase IIb Results Trading Halt; Challenger, Novaport Below 5% In Medical Developments
 
Jun 12, 2012
Medicines Australia To Forum: ‘Drugs Are Post-Mining Future’; Circadian Placement Raises $1m At 7% Premium; Richard Carreon Replaces Impedimed CEO Greg Brown; Chairman Andrew Kroger Takes 20% Of Cryosite; Atcor Requests Capital Raising Trading Halt
 
Jun 8, 2012
Universal Biosensors Earns Siemens $1.5m Test Milestone; Mesoblast Dental Stem Cells For Neuro Diseases; Uni Of NSW Health Science Alliance; Cyclopharm Completes Share Consolidation, Returns To CYC; Further Data Confirms Pharmaxis Bronchitol CF Efficacy; Health Canada Approves New Sunshine Heart Pump Driver; Prima Closes 2 Projects; Focus On CVac For Ovarian Cancer; Neuren CEO Larry Glass Elected M-D, Dr Graeme Howie Goes
 
Jun 7, 2012
Verva Phase II Trial: VVP808 Reduces Type 2 Diabetes HbA1c; Circadian Takes Capital Raising Trading Halt To Suspension; Avita Appoints Vistek Distributor For Recell China Launch; US Inserter Patent For Psivida; Atcor Supplies Netherlands Young At Heart; Durbin Super Takes 5% Of Genera; Annmac Increases, Diluted To 19% Of Agenix; Safety Medical Requests Acquisition Trading Halt
 
Jun 6, 2012
US 606 Patient Data Shows Sirtex Sir-Spheres Safe, Efficacious; Biodiem Licences ANU Dengue Fever Technology; Portugal Approves Psivida’s Iluvien For DME; Optiscan Scope ‘More Accurate, 100% Sensitive’, 1st Royalty; Salomao & Zoppi Evaluate Genera’s Sirocco, Tests; CBA Reduces To 5.3% Of Resmed; Landon Clay, East Hill Take 12% Of Biota; Heartware Loses Director Christine Bennett; Russia, Japan Grant Bone Axcess Patents; OMI Drops Syringes, Coal, Tin - Goes Graphite Mining
 
Novogen, Marshall Edwards ME-143 ‘Low Toxicity’; Prima To List On Frankfurt Exchange; Allied CE Mark Application For Cardiocel Patch; Phosphagenics: 3m Adhesive Caused Crystallization; German Research Backs Uscom For Ventilation; Harding Loevner Takes 5% Of Cochlear; Circadian Requests Capital Raising Trading Halt; Nusep Appoints Bioexpress US Gel Distributor; Atcor Welcomes Halma Takeover Of Partner Suntech; Challenger, Novaport Reduce 1% In Medical Developments; UK’s College Hill Opens Melbourne Office 
 
 
 
May 31, 2012
Novogen, Marshall Edwards Dose 1st ME-344 Cancer Cohort; Pfizer Pays Phylogica Undisclosed Research Milestone; GI Dynamics, Gore Closer To Patent Ownership Trial; Prima Introduces CEO-Designate Matthew Lehman; Immuron EGM Votes Pass Easily, 6% Oppose Director Shares; Bio-Melbourne ‘Engaging With Japan’ Briefing
 
May 30, 2012
Victoria’s Innovation Minister Opens Monash Imaging Facility; Genzyme Pays Antisense Partner Isis $25m For NDA Filing; Biodiem, Miami University Study BDM-E For Retinitis Pigmentosa; Uscom To Raise $1.5m To $5m For Sales, New Markets; Australian Patent For Progen PG500 Series; Robmar Below 5% In Cryosite; Terry White To Sell Cellmid’s Évolis Hair Growth Products; John O’Connor Replaces Novogen Director Peter Da Scutt 
 
May 29, 2012
Wrong Control Kills Neuren Cancer Trial; Dr Bains Goes; Bioniche Claims Vaccine For E Coli In Beef; CSIRO Granted US, Euro shRNAi Gene Silencing Patents; Nusep Lodges Patent Applications For Waste Blood Process; Impedimed Retail Rights Offer Raises $844k, $8.7m Total; Actinogen Director David Zohar Bailed For Aluminex IPO
 
May 28, 2012
Bioxyne Prepares For Phase IIb Hi-164OV COPD Results; Ausbiotech Appoints CM Capital’s Dr Mark Harvey Director; Cyclopharm 5-To-1 Consolidation, Trading As CYCDA; Consegna 65m Shares, $1.4m EGM For Fees, Acquisitions; Chairman Andrew Kroger Takes 16% Of Cryosite
 
May 25, 2012
TGA Approves Acrux, Eli Lilly Axiron; GSK Opens Combination Melanoma Phase III Trial; Genetic Technologies Up 98% For The Week; Bio-Melbourne Hiraoki Kitano Drug Engineering Breakfast; Australian Ethical Increases To 7% In Neuren; Immuron Appoints Dr Roger Aston, CEO Joe Baini Directors; Iain Ross Replaces Tissue Therapies Director Greg Baynton; Swapna Keskar Replaces Nusep Co Sec Tom Rowe
 
May 24, 2012
Bionomics Starts 134-Patient BNC105 Ovarian Cancer Trial; WEHI Drug Could Prevent Malaria Brain Damage; Heartware BTT Results Published, Europe Label Extended; US LDL Patent For Patrys Pat-Sm6; Study Shows Impedimed Could Save US $1m A Year; Resmed, Biancamed, Omron Sleep Monitor Launched In Japan; Prima COO Matthew Lehman To Replace CEO Martin Rogers; Drill Investments Below 5% Of Immuron; Chairman Andrew Kroger Takes 12% Of Cryosite
 
May 23, 2012
Clinical Genomics, CSIRO, Flinders Uni Bowel Cancer Test; Clinuvel Starts US Scenesse EPP Phase III Trial ; Medical Developments Licences Penthrox To Nippon Zoki ; US Patent For QRX Moxduo Pain Relief; Phosphagenics Turns To Germany’s Labtec For Patch Problem; Genetic Technologies Jumps 66% On Nasdaq; Bioxyne Appoints Torreya Partners Advisers; Ellerston Capital Takes 5% Of Acrux; David Zohar Assoc Reduces, Diluted To 24% Of Actinogen; Mayne Appoints Peter Truelove Sales, Marketing Director; Impedimed L-Dex U400 Wins Biocom Gong
 
May 22, 2012
Monitoring Board Backs Alchemia Phase III Cancer Trial; GSK Australia Reports $54m Profit For 2011; Genetic Technologies: Brevagen Sales Increasing
 
May 21, 2012
Melanoma Institute: GSK’s Dabrafenib Shrinks Brain Tumors Pharmaxis Files Bronchitol  Cystic Fibrosis NDA To FDA; Peter Turvey Replaces Allied Health Director Jet Soedirdja; Victoria Awards Open: 2 Prizes, 12 Fellowships; Boots Launches Phosphagenics’ Anti-Fat Cream In UK; OBJ Claims Procter & Gamble Deal, No Details; Fluorotechnics Votes To Go Mining, Suspended
 
 
May 15, 2012
Verva VVP Paper Shows New Mode Of Diabetes Action; Healthlinx Takes Ovplex Ovarian Cancer Test To India; Novogen’s Marshall Edwards Raises $5.2m; Immunexpress Appoints Robert Lilley Director; Allan Gray (Orbis) Takes 8% Of Nanosonics; Allan Gray Takes Profit, Reduces To 5% Of Acrux; AMP Takes 7.4% Of Acrux; Bio-Melbourne Briefing On Open Innovation Models
 
May 14, 2012
Alchemia’s Fondaparinux Takes 22.5% Of US Market; Despite Results, Transgene TG4001 Proves Virax Co-X-Gene; Immuron Appoints Ziwell For More SE Asia Sales; Japan Grants Agenix Thromboview Patent; Drill Investments Reduces, Diluted To 5.6% Of Immuron; CBio Pleads Schultz To ASX 29% Query
 
May 11, 2012
Heartware Q1 Sales Up 47% To $26.3m; UK NHS Guidelines Include Uscom For Surgical Care; Biota Earns $3.4m Q3 Inavir Royalties, Phase III Trial Enroled; Nanosonics Share Plan For $5m; Allan Gray (Orbis) Takes Profit, Reduces To 6% Of Acrux; AMP Takes 6.3% Of Acrux; Monash, Weizmann Obesity Conference
 
May 10, 2012
Mesoblast Appoints Teva’s Dr Ben-Zion Weiner As Director; Immuron Contracts Integramed For SE Asia Travelan Sales; Avita Starts Recell US Defense Scar Trial; UQ Wins $100,000 Gates Grant For Rotavirus Vaccine
 
May 9, 2012
Federal Budget: NHMRC, ARC Funding Up $85m, PBS Down $164m; Comment: Biotech Daily, Ausbiotech, GBS, Bio-Melbourne; Biodiem, Vivalis Collaborate On Virus Vector; Genetic Technologies Settles Geneseek Patent Suit; Heartware Completes Heart Pump Destination Enrolment; Cathrx To Raise $12m, Delist, Sell Business; Bluechiip Hires Plexus For Matchbox Tag Readers
 
May 8, 2012
UK Approves Psivida, Alimera Iluvien For DME; Biodiem Earns $830k LAIV Licence Fees; Bluechiip Brett Schwarz: ‘Follow Europe, Not US Bio-Banking’; Allan Gray (Orbis) Takes Profit, Reduces To 7% Of Acrux; Paradice Investments Takes 6% Of Acrux; AMP Takes 5% Of Acrux; Phosphagenics Adds David Jones For Cosmetics Sales
 
May 7, 2012
Bioxyne Could Be Sold By Year End; US Patent For Cellmid Anti-Midkine T-Cells; Immuron Contracts NZ’s Synlait For Cow Colostrum; Victoria Budget $60m For Cancer Agency; Probiotec Profit Warning: Drugs Good, Diet Products Not; Medivac’s Sunnywipes Joins WHO Collaboration
 
May 4, 2012
Nanosonics Placement Raises $15.5m, Share Plan; Antisense Raises $5m Of Expected $6.5m; US Patent For Anteo’s Mix&Go Bio-Glue; Jason Peterson, Celtic Capital Below 5% Of Acuvax
 
May 3, 2012
Ventus $40m IPO Opens; Impedimed 1-For-4 Rights Issue Raises $7.8m, $5.9m For Retail; Compumedics Sells $1m Diagnostics To China; US Patent For Biodiem’s BDM-I For Malaria, Trichomoniasis; Capital Concerns, Logue Family Takes 6% Of Immuron; Bone Placement, Stock Issue In Lieu Of Payment EGM; Goldfire Robert Martin, Accord Take 13% Of Acuvax
 
May 2, 2012
Victoria Budgets $35m For Innovation - $26m For Synchrotron; Budget Comment: Biotech Daily, Ausbiotech, Bio-Melbourne; Human Implications From Bioniche Dog Cancer Drugs; Hatchtech Raises $8m, Appoints Dr Ross Macdonald CEO; Osprey Opens - Up 5%; GI Dynamics Trial Data Published In Journal Article; Metal Group Increases To 18% Of Allied Health; ITL Sells ‘Troubled Malaysian Distributor’ For $1.1m; Allan Gray (Orbis) Reduces To 8.5% Of Acrux; Imugene Buys Consegna’s Linguet; Tissue Therapies Pleads Schultz To ASX 22% Query; Nanosonics Requests Capital Raising Trading Halt
 
May 1, 2012
April BDI-40 Flat, ASX200 Up 1.4% - Heartware, Sirtex, Cellmid, Psivida Up, Sunshine Heart Down; Adaptive Sonics Files Patent Infringement Against Cochlear; Atcor Launches Sphygmocor Xcel System; US Court Allows Mayne Pharma Doryx Generics; Living Cell Share Plan Raises $1m; IDT Profit Warning; Ex-Chairman Theodore Onisforou Reduces To 5% Of Cryosite; Impedimed Requests Capital Raising Trading Halt; Pharmaust Has One Quarter Cash; Consegna Has One Quarter Cash, Linguet Sale Trading Halt; Imugene Requests Acquisition Trading Halt; Malcolm McComas Replaces Pharmaxis Chairman Denis Hanley; Bruce Parncutt Replaces Acrux Director Ken Windle
 
Apr 30, 2012
UQ, Axiom Molecular Nuclear Medicine Collaboration; Correction: Avexa ; Prana Doses 1st Phase II Trial Huntington’s Patient; Osprey To List On ASX On May 2; GI Dynamics 19-Patient Re-Implantation Trial; Two UK Dogs Treated With Medical Australia’s Fat Stem Cells; Genera $1m Share Plan; Uscom Less Than Six Months Cash, Sales Up, Costs Cut, Capital; Heartware AGM For 1.5m Director Shares, 245k Options; Cellmid EGM For 136m Shares, $5m Placement, 5m CEO Options; Consegna Appoints Dr Nicholas Ede Technology Officer
 
Cheaper HIV Trial Allows Changed Avexa ATC Strategy; Allied Rights Raise $1.9m; Takes 44.4% Of Coridon; Resmed Record 3rd Quarter Revenue, Profit; Bayer Pays Tyrian $US325k To End Deal, Continues Development; Consegna Acquires Ozpharma’s Linguet; Allan Gray (Orbis) Takes Profit, Reduces To 10% Of Acrux; Select Reduces Below 5% Of Circadian; Bio-Melbourne Bio-Breakfasts On Bio-Banking
 
FDA Panel Votes For Heartware’s Pump; Swiss Insurance For Clinuvel’s Scenesse; Austria First Psivida Iluvien Approval For DME; GSK Q3 Biota Relenza Royalty $1.5m; Cellmid Placement Raises $1.5m; Acrux Small Revenue Forecast Reduction; QRX: Watson Actavis Takeover ‘Good For Moxduo IR’; Nusep ABS Novacell Agreement For Singapore Blood Plant; Australian Patent For Phylogica Phylomer Library Screening; US Patent For Novogen, Marshall Edwards Me-143 For Cancer
 
Genera Unveils Sirocco Automated Diagnostics Platform; Heartware Prepares For FDA Expert Panel Meeting; Starpharma Pleads Schultz To ASX 8% Query; Medical Developments Expects $2.2m Net Profit; Cathrx Has Less Than One Quarter Cash, Funding ‘Soon’; Correction: Cyclopharm; Bio-Melbourne Network Workshops Social Networks; ASIC Prosecutes Actinogen’s David Zohar
 
Starpharma Passes $500m; Biota Buys Nabi For Its $52m Cash, Nasdaq Backdoor Listing; Immuron Placement Raises $1m, Share Plan For $1m More; Agenix Takes Second Fortrend Facility For $1.2m; Cryosite $1m Profit Guidance, Dividend; M-D Fabio Pannuti Takes 8% Of Consegna; Cyclopharm AGM For 6.7m Director Shares; Cellmid Requests Capital Raising Trading Halt
 
Europe Signs-Off Pharmaxis’ Bronchitol For Cystic Fibrosis; Australian Ethical Takes More Than 140% Profit On Avita; Cellmid $330k Share Issue Says Goodbye To La Jolla Cove; CBio Appoints IR Head Melanie Farris Company Secretary; Immuron Takes Capital Raising Trading Halt To Suspension; GSK $80k Research Award Nominations Extended To April 30; Acuvax Ex-CEO Dr William Ardrey Fraud Case - Bail To July
 
Pharmaxis On-Track For Bronchitol; ASM8 Scientific Review; Nasdaq, US OTC Listings Mixed Results For Avita, Prima; Australians Implanted With GI Dynamics’ Endobarrier; Hyperion Takes 7% Of Cochlear; Neuren Pleads Schultz To ASX 35% Query; Cellmid Opens Évolis Hair Product Website; Consegna: Breatheassist Nasal Plugs Regulator-Free
 
Ausbiotech: Industry Upbeat - Despite Economy, Policy; Cellmid Jumps 107% On US Midkine Adhesion Patent; Immuron Requests Capital Raising Trading Halt; Anteo ‘Mix&Go Solves Bio-Glue Damage For Research’
 
Pharmaxis: ‘ASM8 Duration Caused Non-Significant Result’; Living Cell Appoints Dr Barry Snow For Parkinson’s Trial; Osprey Raises $20m, To List On ASX; Allied Signs Nature Tech, VGXI For Phase I HSV2 Trial Material; Consegna To Acquire 100% Of Leading Edge With 252m Shares; Mesoblast Half-Way In Phase II Stem Cell Spinal Trial
 
Apr 16, 2012
Antisense’s Prof Pinchas Cohen: ‘ATL1103 Extends Life’; Ventus $40m IPO For Snoring, Sleep Apnoea Nasal Plugs
 
Apr 13, 2012
Bioniche Calms Investors With Revenue, New Projects; Alchemia Treats 53 Cancer Patients, Awaits Safety Review; Prima To List On Nasdaq Next Week; Genetic Technologies’ Immunaid Raises $1m; Bioxyne Confirms Name Change, Phase IIb COPD Trial On-Track; UBS AG Falls Below 5% Of Pharmaxis; Evado Evaluates UWS Complementary Medicine; Fermiscan Drops Biotech For Resources, Name Change
 
Apr 12, 2012
Canada Approves Acrux, Eli Lilly Axiron; Vivopharm Acquires RMIT Toxicology Testing Business; Consegna To Spin-Out Aspen Medisys; Patrys Executives US Investor Road-Show; Life Sciences Queensland Road-Show
 
Apr 11, 2012
QRX Claims Moxduo CR Phase I Success, Tablets Resist Tamper; Sirtex Claims March Quarter Dose Sales Up 34%; Novogen, Marshall Edwards Ready For ME-344 Tumor Trial; Canadian Patent For Prima’s CVac Ovarian Cancer Vaccine; US Patent For BPH, Molecular Discovery’s Tumor Suppressor; UBS AG Takes 5% Of Pharmaxis; Dr Mervyn Jacobson Reduces To 29% Of Genetic Technologies; Chairman Mel Bridges Buys 500k Genetic Technologies Shares
 
 
 
Mar 30, 2012
Heartware Buys Worldheart For $8m; Nusep Borrows $300k To Expand Consumables Business; Optiscan Takes $2m Bergen Draw-Down Equity Facility; Avita Holds Rome Skin Conference
 
 
 
 
 
 
 
Antisense-China JV For ATL1102 For MS, Cancer, Asthma; Psivida Up 80% On Probable European Iluvien Approval; 2nd US Process Patent For Alchemia’s Fondaparinux; Sirtex H1 Revenue Up 8% To $37m, Profit Up 70% To $6m; Mayne H1 Revenue Flat At $27m, Profit Up 242% To $4m; Cyclopharm Revenue Up 8% To $10m, Profit To $1.7m; Scigen Revenue Up 29% To $US16m, Loss Up 72% To $17m; Resonance H1 Revenue Up 11% To $898k, Loss Down 37% To $241k; Compumedics H1 Revenue Down To $15m, Return To $403k Profit; Biodiem H1 Revenue Up 118% To $550k, Loss Down 49% To $689k; GI Dynamics Claims 1st Endobarrier Revenue
 
Allied’s Coridon Starts Work On Therapeutic HPV Vaccine; Acuvax Ex-Ceo Dr William Ardrey Faces 22 Fraud Charges; Living Cell NTCell Parkinson’s Trial, EU Tissue Patent; IP Sale Gives Living Cell Maiden H1 $8m Profit; Cryosite H1 Revenue Up 17% To $4m, Profit Up 114% To $349k; Ellex Acquires Distributor Subsidiary; La Jolla Cove Reduces To 6% Of Bone
 
Mesoblast H1 Revenue Down 82% To $19m, Loss Up 147% To $44m; Genetic Technologies H1 Revenue Down 74%, Profit To Loss; Phylogica H1 Revenue Down 22% To $1.4m, Loss Up 55%; Brain H1 Revenue Up 9% To $4m, Profit Up 170% To $1.5m; Advanced Surgical H1 Revenue Up 17% To $4m, Loss Down 65%; Dr Daina Vanags Replaces CBio M-D Helen Cameron, Directors; Prima Pleads Schultz, Good News To ASX 21% Query; Challenger, Novaport Reduce 1% In Medical Developments; Solagran, Art Life $94m Russian Joint Venture
 
Tyrian Loses All Key Staff, Review Awaiting Suitor; QRX H1 Revenue Up 242% To $356k, $5.3m To Go, Loss Down 43%; Probiotec H1 Revenue Down 4% To $34.5m, Profit Up 162% To $3m
 
US Patent For Phylogica’s ‘Neuroprotective Peptides’; Ellex H1 Profit Up 26% To $654k On Revenue Up 18% To $26m; Medical Developments H1 Profit Up 44% To $1m, Revenue Up 3%; Lifescan Verio IQ Recall ‘No Impact’ On Universal Biosensors; Uscom H1 Revenue Up 8% To $1m, Loss Up 4.6% To $503k; GI Dynamics Releases 48.6m Escrow Shares; Nextgen Ceases Substantial In Phosphagenics; La Jolla Cove Reduces To 8% Of Bone; Solagran Requests Joint Venture Trading Halt
 
Feb 22, 2012
CSL H1 Revenue Up 6% To $2.3bn, Profit Down 3.4% To $483m; Acrux H1 Revenue Down 95% To $5m, Profit Down 91% To $5m; Acrux To Lose CEO Dr Richard Treagus; Phosphagenics $1m ‘Tax Profit’, Revenue Down 38% To $3m; Novogen To Bid For $3.75m Of Marshall Edwards $7.5m Rights; Impedimed Revenue Down 25% To $1.5m, Loss Down 27% To $6m; Dr Bruce Gray Sirtex Payment Ends UWA Case; M&G Group Buys 1m More Mesoblast Shares; Bioprospect To Raise $3.25m Via Note, Placement, Rights Issue
 
Feb 21, 2012
Sonic Deal Ends Genetic Technologies’ 2nd US Lawsuit; Myriad, Genetic Technologies BRCA Gene Patent Case; LBT H1 Revenue Up 52% To $481k, Loss Down 18% To $653k; Cogstate H1 Revenue Up 75% To $7m, Profit Up 480% To $3.4m; University Of Queensland Master Of Bioinformatics
 
Feb 20, 2012
GI Dynamics To Implant Australian Endobarrier ‘By July’; Universal Biosensors Revenue Down 19% To $15m, Loss Up 122%; Dr Greg Collier, Dr James Campbell Launch Vitality Devices; Avita Appoints Bank Of New York Mellon To List On US OTCQX; ITL H1 Revenue Down 21% To $17m, Profit Up 930% To $1.1m; Orbis Reduces To 16.5% Of Phosphagenics; Cell Signals Reduces, Diluted To 7% Of Cellmid; Nusep Loses Director John O’Connor
 
Feb 17, 2012
WEHI Cell Signal Research For Blood Disorder Treatments; Heartware Revenue Up 50% To $77m, Loss Up 87% To $40m; Patrys Hires Dr Yoshimoto, CSL Options Lapse; Naos Takes 7.6% Of Patrys, Holder Mystery Continues; Reva Enrols 1st European Stent Trial Patient; Living Cell Pleads Schultz To ASX 38.5% Query; Medical Developments Appoints R Cegla German Distributor; Bio-Melbourne Workshops Bio-Animation; Scott Richards Takes The Helm At Mayne Pharma
 
Feb 16, 2012
Queensland Uni, J&J, Janssen Work On Spider Venom For Pain; Nanosonics H1 Revenue Up 166% To $5m, Loss Down 33%; Bionomics Targets Alzheimer’s, Neuro-Degenerative Diseases; Certificate Clears Genetic Technologies Brevagen For US; Advanced Surgical To Distribute Small Bones Products; Broadvector Buys 50% Of Hip Implant Failure Therapy; Citigroup Reduces 1% In Patrys; La Jolla Cove Reduces To 9% Of Bone
 
Feb 15, 2012
Editorial: Patrys, Citi And Hiding Behind Nominee Companies; FDA Sets Anzac Day For Heartware Approval Hearing; Barda Pays Biota $4.3m, H1 Revenue Down 3%, Loss Down 31%; Phosphagenics New Oxycodone Patch: 4.5 Times More Drug; Healthlinx Develops Ovarian Cancer Survival Biomarker; Sunshine Heart To List On Nasdaq; TGA Registers Cellmid Évolis Hair Product; US Patent For Viralytics’ Cavatak; FDS Pays $US2m For Scigen Israel, Hep B Vaccine; Isonea, Qualcomm Wireless Cloud-Based Asthma Monitor
 
Feb 14, 2012
$180k For WEHI Ovarian Cancer Gene Study; Prima Files Registration For Nasdaq Listing; QRX Appoints Dr Edward Rudnic Chief Operating Officer; Fluorotechnics Goes Mining
 
Feb 13, 2012
Biota: Japan Enrols 1st Inavir Phase III Prevention Patient; Biomérieux Guarantees LBT $1.8m Applicator Royalties; Calzada Search For AOD9604 Bone Repair Partners; Lloyds & Cassanove Takes 10.5% Of Cyclopharm; Cellmid Terminates Needed, But Costly, La Jolla Cove Notes; Actinogen Tells ASX: Cutbacks Will Help Survival; Citigroup Ceases Substantial In Patrys; Fermiscan Pleads Schultz To ASX 38% Query
 
Feb 10, 2012
Nominations Open For $90k Victoria Premier’s, Smorgon Award; FDA Approves Mylan Doryx; Mayne Patent Case Continues; GI Dynamics Adds Manchester ‘Centre Of Excellence’; Citigroup Resumes Substantial In Patrys, Reduces To 5%; Fluorotechnics Requests Resources Trading Halt; Mesoblast CFO Jenni Pilcher Appointed Group Co Sec; Bioprospect’s Peter May Re-Replaces M-D Charles Pellegrino
 
Feb 9, 2012
Antisense: Phase II ATL1103 Trial, New Patent, Deal Closer; Biodiem Licences LAIV To Changchun Bcht; Patrys Completes Phase I PAT-SM6 Treatment; Sunshine Heart Raises $2.1m For Nasdaq Listing; Impedimed Increases US Covered Lives, Registers 1st Patient; BPH’s Cortical Earns WA Voucher; Immuron Rebuts Paladin ‘Misinformation’; La Jolla Cove Exits Viralytics, Takes 10% Of Bone; Avita Passes All Quality Audits; OBJ Pleads Schultz To ASX 28% Query
 
Feb 8, 2012
Cancer Foundation Supports 2 New WEHI Labs; Victoria Supports Biota Expansion; GSK Q2 Biota Relenza Royalty $500k; Tissue Therapies: $10m Cash, Awaiting CE Mark, Ready To Sell; Dr Stewart Washer Replaces Two Immuron Directors; ASIC Fines Bioprospect $33k On Mining Disclosure; Solagran: Journal Backs Ropren For Cognition In Rats
 
Feb 7, 2012
Benitec, Medistem ddRNAi-Stem Cells Treats Arthritis In Mice; Cochlear Survives Implant Recall With Record H1 Revenue; Probiomics EGM Backs Hunter Takeover, Name Change; Clinuvel Files Scenesse European Application
 
Feb 6, 2012
Sirtex SIR-Spheres, Sorafenib Phase III Comparison Trial; Alchemia’s Fondaparinux Takes 18% Of US Market; Calzada, Polynovo Wound Treatment Trial Begins; Genetic Technologies Settles Eurofins Case; Bone Up 186% On Euro Patent For Oral Peptide Delivery
 
Feb 3, 2012
Victoria ‘Supports’ GSK $60m Boronia Upgrade; Prima Enrols 1st Phase III Ovarian Cancer Patient; Bionomics Details Phase I Kidney Cancer Trial Data; Baillie Gifford Takes 8% Of Cochlear; Probiomics Extends Hunter Offer Three Weeks
 
Feb 2, 2012
Genetic Technologies Salutes Dr Malcolm Simons; Cathrx Direction Change, Loses CEO, CFO; US Patent For Living Cell’s Auckland Island Pigs; Ellex H1 Revenue Up 15%; Atcor Wins $1.1m Commercialization Australia Grant; Naos Holds 11.5% Of Phylogica; Bio-Melbourne Workshops TGA Biological Regulations; Paige Exley Replaces Nicki Farley As Narhex Co Sec
 
Feb 1, 2012
Quiet January: BDI-40 Falls 1.1%, ASX200 Up 5.1% - Clinuvel, Genetic Tech Up More Than 30%; Bionomics Down 20%; Starpharma Mouse Data Backs Dendrimer Delivery To Tumors; Calzada Ends Talks With Unnamed US Company, Keeps $400k; Citi Ends Prime Broker Substantials In Patrys, Phylogica; Evado Opens Singapore Help Desk; Allied Health Has Less Than One Quarter Cash, $3.5m Facilities; Pharmaust Has One Quarter Cash, ‘Uneven Payments’; Consegna Has Less Than Two Quarters Cash; Tyrian Has One Quarter Cash, Costs Cuts; Avexa Director Jet Soedirdja Resigns
 

 

 

Jan 22, 2012
Summer Catch-Up Edition
Mayne Pharma EGM For 7.5m Options For M-D Scott Richards; Macquarie Uni Hospital Takes 30% Of Cyclopharm Imaging Venture; Patrys Plans Phase II Pat-SM6 Multiple Myeloma Trial; Consegna Raises $613,000; Neoclone To Distribute Tyrian Antibodies; Anthony Barton Ceases In Phylogica; Starpharma, Eli Lilly Continue Drug Delivery Program; John Leaver Takes 5% Of Bionomics; Australian Ethical Increases To 15% In Avita; Select Vaccines Goes Uranium, Coal Mining In Tanzania; CEO Helen Cameron Sells 53% Of Her CBio Shares; Cochlear: ‘Brazing’ The Root Cause Of Implant Failure; Clinuvel: Phase III Scenesse Significant Prophylaxis For EPP; Viralytics Share Plan Raises $4.7m; Isonea Raises Underwritten $3.7m Of Hoped-For $4.3m; Pharmaxis ‘Minor Resubmission’ To Rebate Committee; Ausbil Dexia Takes 7% Of Bionomics; ‘Balam Global’ Takes 6% Of Consegna; Brookside Capital Takes 8.5% Of Reva;
Immusant Raises $20m For Wehi Coeliac Vaccine; Catholic Uni, O’Brien Regenerative Wound Centre; Elastagen Appoints Xavier Yon Director; Actavis Pays $6m Upfront For QRX’s Moxduo In US; Progen Moves Anti-Cancer PG545 From Sub-Cutaneous To IV; CBio Details XToll Timing, CEO Share Trading; US Patent For Novogen, Marshall Edwards Cancer Drugs; Start Up Reduces Below 5% In Bionomics; Landon Clay, East Hill Take 10% Of Biota; FDA Approves Neuren NZ2566 Human Trials; Reva Begins Bioresorbable Stent Trial; Calzada, Polynovo Ready For 2 Novosorb Skin Trials; Acorn Takes 6% Of Pharmaxis; Consegna Closes Aspen Medisys Deal; CBio Loses Directors Dr Terje Kalland, Dr Thomas Lonngren; Barings Acceptance Takes 14% Of Cyclopharm; Balam Global Takes 9% Of Consegna; Living Cell Appoints Dr Andrea Grant CEO; Prima Developing Oral Cancer Vaccine; JCP Ceases In Resmed; Westpac, BT Increase Diluted In QRX; Isonea Raises $4.6m; Novogen $2m For Marshall Edwards, Changes ADR Ratio;
Phylogica, Janssen Collaboration; Isonea Begins Trading On US OTCQX; Alchemia Treats 1st Phase III Hyact Cancer Patient; FDA Approves Phase II Prana PBT2 Huntingdon’s Trial; US Patent For Novogen Marshall Edwards Compounds; Unnamed US Company Pays Calzada, Polynovo $100k; GI Endobarrier Commercially Available In Netherlands; Ironwood, Bionomics BNC210 Deal Starts With $2.9m; Biotron Options Raise $8m; Benitec: Pfizer, Tacere, ‘Extremely Positive’ Hep C Preclinical Results; Circadian Begins Phase I VGX-100 Solid Tumor Trial; Heartware Dualis Collaborate On Wireless Heart Pump; J&J’s Lifescan Launches Universal Biosensors Onetouch In US; FDA Approves Immuron Phase IIb Fatty Liver Trial; Dutchess $5m Funding For Virax; US Phase I Trial Shows Benitec Technology Safe, Immune Response; Balam Takes 13% Of Consegna; Heartware 2011 Revenue Up 50% To $82m;
FDA Signs-Off On Starpharma Phase III Vivagel Vaginosis Trial; Prana Appoints Prof Rudy Tanzi CSO; Bergen Takes 7% Of Isonea; Xenome Appoints Dr Julie Cherrington Chair; Bio-Melbourne Breakfasts On 3-D Tissue-Printing; Mariposa To List Through Genesis; Clinuvel Pleads Good News To ASX 22% Query; Acorn Increases, Diluted To 13% Of Starpharma; Citigroup Increase To 11% In Phylogica; Biotron Pleads Schultz To ASX 36% Query; Bone Pleads Capital Raisings To ASX 175% Query; Paladin, Immuron Complete Draw Down Facility Agreement; Sienna Geron Licence, $260k Grants, Appoints Carl Stubbings; Dr Gregory Winter; Biosceptre Investor Briefing, To Raise $15m; Uniquest, Janssen-Cilag To Develop Rheumatoid Arthritis Treatment; Wehi Shows AML May Be Susceptible To Drugs Targeting Mcl-1; CBio Appoints Gregory Thomas Brown Alternate Director; US Patent For Anteo ‘Use Of Metal Complexes’; Japanese Patent For Prima Cancer Antigen Cripto-1 Antibody; CBio Review Considers All XToll, Arthritis Options; Viralytics: US Trial Supersedes Australian Trial; Citigroup Takes 7% Of Patrys

 
 
Nov 30, 2011
Patrys Raising $3m; Up To 46% Of Sunshine Heart Votes Oppose Director Options; Immuron Survives Remuneration, Scraps 4m Director Options; Viralytics Share Plan Underwritten To $1m; Tissue Therapies Pleads Schultz To ASX 45% Fall Query; Thee Woon Goh Takes 9% Of Nusep; Lang Walker Companies Increase To 6.5% Of QRX; Hunter Hall Reduces 2% In Sirtex; Founder Prof Noam Gavriely Criticizes, Ceases In Isonea
 
Nov 16, 2011
Pharmaxis 1-For-3 Rights Issue To Raise $80m; Starpharma $32m Placement, Share Plan; Cogstate $2.6m Depression Trial Contract; Nusep Settles 2nd US Patent Case; Alchemia EGM On $15m Placement, Orbis Shares; Isonea Takes Capital Raising Halt To Suspension; Founder M-D Nick Gatsios To Resign From Healthlinx In 2012; Research, Activism Gong For WEHI’s Prof Doug Hilton; Bioniche Investigator Dr Alvaro Morales Wins Canada Gong
 
Nov 15, 2011
Mesoblast: Cardiac Stem Cells Show Safety, Efficacy; WEHI’s Prof Strasser Wins $50k Victoria, $100k Smorgon Prizes; Bionomics Details BNC201 Panic Attack Trial Data; Calzada Remuneration Report 1st Strike; Cryosite Pleads Schultz To ASX 38% Query; Consegna Appoints Brendan Fleiter Director
 
Nov 14, 2011
Psivida Falls 49% On FDA Iluvien Rejection; Prana: ‘PBT2 Reverses Loss Of Synaptic Activity’ In Mice; USPTO Allows Cellmid Midkine Cardiac Ischemia Patent; Phosphagenics ‘Over-Subscribed’ Plan Raises $3m; Cathrx Underwritten 1-For-7 Rights Issue Raises $2m; Australian Ethical Sells 2m Tissue Therapies Shares; Antisense Pleads Schultz To ASX 77% Query; Starpharma Requests Capital Raising Trading Halt; Isonea Requests Capital Raising Trading Halt
 
Nov 11, 2011
Broadvector Acquires CSIRO IP, Holding, Raises Funds; Nanosonics Remuneration Report Faces 20% Opposition; Tissue Therapies ‘Robust’ Final Vitrogro Wound Data; Corning To Evaluate Bluechiip Tracking Technology; Small Dissent On Starpharma Rights, Remuneration Approved; Sunshine Heart AGM For 13m Director Options, Incentive Plan; Wilson HTM Ceases Substantial In Nanosonics; Bio-Beers
 
Nov 10, 2011
Stem Cells Australia Opens For Business; Mesoblast Cells Reduce Blood Sugar Levels In Monkeys; St Vincent’s Approves BPH, Cortical Dynamics Trial; Healthlinx Expands Garvan Prostate Cancer Biomarker Trial; Isonea To Issue US Stock Pre-OTCQX Listing; CBio Action Group Founders Disband, Cease Substantial; Chairman Dr Zhukov Pervan Takes 21% Of Actinogen; LBT Director Dr Mike Hirshorn Retires
 
Nov 9, 2011
CSL Raises $1.5b To Retire Debt, Buy Back Shares; PBAC Denies Pharmaxis Bronchitol Subsidy, Again; Actinogen’s Cancer Actinomycetes For Cheap Biofuel, Up 150%; BPH, Cortical Dynamics 3rd NZ Patent For Bar Monitor; Low-Show Votes Oppose Clinuvel Director ‘Rights’
 
Nov 8, 2011
12 Of 15 Sunshine Heart Cardiac Patients Improve; WEHI Malaria Vaccine Wins $1m Gates Foundation Grant; FDA Accepts QRX Application; Likely PDUFA Date Set; US ATCC To Evaluate Bluechiip Tracking Device; US Formulation Patent For Clinuvel Melanin-Activating Drug; Universal Biosensors, Lifescan One Touch Verio In Canada; Trouble At Uscom Mill, AGM Adjourned, Chairman Attack; CBio Directors ‘Review’ Resignation Threat And Stay; Cryosite AGM Defeats Remuneration, Chair Theo Onisforou; Landon Clay, East Hill Take 10% Of Biota; Dr Cherrell Hirst Replaces Mel Bridges As Impedimed Chair; Viralytics Appoints Prof Jeffrey Weisberg To Scientific Board
 
 
Nov 4, 2011
Clinuvel Phase II Scenesse For EPP ‘Improves Quality Of Life’; CBio Action Group Wins Board Spill, Poison Pill Turns Placebo; Cyclopharm 1-For-3.2 Rights Issue To Raise $2.1m; Immuron Raises $533k Of Hoped For $4.4m; Pharmaust Share Plan Raises $281k Of Hoped For $2.5m; Onyx Increases, Diluted To 7% Of Fermiscan
 
Nov 3, 2011
Cochlear’s Dr Chris Roberts: ‘Recall Has Not Cost Patients’; Added Australian Patent Protection For Acrux Axiron; US Patent For OBJ’s Dermaportation Technology; Wilson HTM Reduces 1% In Universal Biosensors; Australian Ethical Takes 92% Profit On 14m Neuren Shares; Australian Ethical Increases To 13.7% In Avita; Alchemia Requests Capital Raising Trading Halt; NAB Extends Cyclopharm Debt Repayment; Probiomics To Raise $200k For Hunter Listing; 21% Of Prima Voters Oppose Remuneration Report; Scigen Tells ASX: Polish Loan, Divesting Israel, China Business
 
 
 
Oct 18, 2011
Genetic Technologies Sells 600 Breast Cancer Tests; CBio Final Clinical Study Report, Novo Nordisk 60-Day Option; Cochlear Recall Costs Up To $150m, Directors Fees Frozen; Biomérieux Pays LBT $274k; $274k More By Year-End; Pharmaust’s Epichem Wins WA Export Gong; Charges Against UBNZ’s May Wong End Genesis Finance Talks; Two Actinogen Directors Take 43% Of Company; Cathrx Has One Quarter Cash, $2m Coming; Benitec Votes On 70m Director Options, Small Name Change
 
Oct 17, 2011
Victoria Unveils $55m Biotech Support Program; NHMRC Grants $674m For 1,140 Projects; Pharmaxis Bronchitol Euro-Review Trading Halt; Clinuvel Hopeful Of European Scenesse Dossier By Year-End; Calzada’s Novoskin Viable In Pig Trial; QRX Focus Expands To Partner Deals, Correction; Patrys To Release IgM Scale-Up Data; Progen: Korea Approves Medigen PI-88 Liver Cancer Trial; Helicon Signs Deal To Acquire Aspen Medisys With Shares; Ithree Joins Medical Research Commercialisation Fund; ITL AGM Proposes Shares In Lieu Of Directors’ Pay
 
Oct 14, 2011
Biotech Specialist Jon Mowles Wants Your Company In Britain; Cathrx 1-For-7 Rights Issue To Raise Up To $2m; Cogstate Signs 2 Contracts Worth $1.6m; Nanosonics Scaling-Up Production, Launch Of N20 Disinfector; Perpetual Takes 9% Of Sirtex; QRX AGM Votes On 250k CEO Options, Elect Director; LBT AGM Votes On 500k Director Options, Elect Directors; Pharmaust’s Dr Martine Keenan Wins UK Chemistry Prize
 
Oct 13, 2011
GBS 1998 IIF $42.5m Investment Beats US Peers; Europe Approves Acrux Recuvyra Pain Relief For Dogs; Avita Launches Recell For Venous Ulcers In Europe; Agenix Signs China Deals For AGX-1009 For Hepatitis B; AMP Reduces Below 5% In Sirtex; CBio Raises $7.3m Of Underwritten $10.8m; CBio Chair Stephen Jones, 2 Directors Lose Executive Roles; Atcor Wins US Medicare Rebate Appeal; JDJ Distributes Charles River CRO Services; Helicon Requests Aspen Medisys Trading Halt
 
Oct 12, 2011
CSIRO’s Ezio Rizzardo, David Solomon Win PM’s Science Prize; CE Mark For Cellmid’s MK Elisa Test; Allied Owns 37% Of Coridon; Bioniche AGM To Elect Directors, Set Pool At $735k; Jasper Hill Falls Below 5% In Select Vaccines; Bluechiip Loses Director Larry Lopez
 
Oct 11, 2011
Allied Jumps 48.5% On 100% HSV-2 DNA Vaccine Efficacy In Mice; Antisense Completes Phase I ATL1103 Dosing; Universal Biosensors $4.5m J&J Blood Glucose Project; Hunter Immunology To Take Probiomics To Bioxyne; Healthlinx Ovplex Trial - ‘More Samples, Better Result’; Ausbiotech Ready For 2011 Conference; Bio-Melbourne Breakfasts On Movember
 
Oct 10, 2011
Healthscope ‘Beta’ Tests Peter Mac, Circadian Cancer Test; Biotron: BIT225 ‘Good Antiviral Activity’ Against Hepatitis C; Atcor Signs Two Contracts Worth $1.9m; FDA Agrees Starpharma Phase III Bacterial Vaginosis Trial; Starpharma AGM Votes On 375k CEO ‘Rights’, Employee Plan; Milstein Gong For WEHI’s Prof Doug Hilton; Nusep Appoints Three Directors; Northcape Takes 6% Of Pharmaxis; Fermiscan EGM Dissent On Director Options, Pay Increase
 
Oct 7, 2011
Patrys CEO Dr Marie Roskrow: ‘$5m Needed, $15m Better’; Viralytics: ‘Cavatak Active Against BRAF-Resistant Cancer’; Inex Distributes Healthlinx Ovplex In Malaysia; Calzada Loses CEO Dr Stewart Washer; Bionomics AGM On 2.6m CEO Options, Director Election; Clinuvel AGM Votes On 230k Director Performance Rights; Biotron Requests Phase IIa Hep C Results Trading Halt; Probiomics Requests Acquisition, Capital Raising Trading Halt
 
Oct 6, 2011
Cellmid Humanizes First Midkine Antibody HU91; Benitec US ddRNAi Hepatitis C Patents Granted, Allowed; Calzada’s Wound Treatment Novosorb Passing Pre-Clinical; Wilson HTM Reduces 1% In Avita; Peter Vaughan Replaces Isonea Co Sec Brad Slade
 
Sep 1, 2011
August Cruels BDI-40 - Down 12.6%, ASX200 Down 2.9%; Bionomics Poster Shows Anti-Anxiety, Anti-Depression Link; Clinuvel Completes Scenesse Pre-Clinical Program; Advanced Surgical Revenue Down 1%, Loss Up 264% To $3m; Cyclopharm Revenue Up 10% To $3.6m, Loss Up 99% To $1.5m; Allied Health Revenue Up 63% To $7m, Loss Up 3236% To $1.4m; Helicon Places $898k; China Patent For Viralytics Anti-Cancer Echovirus Evatak; Imugene Requests Strategic Alliance Halt; CBio Requests Capital Raising Halt; Acrux Loses Founder, Director Prof Barrie Finnin; Sunshine Heart Loses Founder, Director Crispin Marsh
 
Aug 31, 2011
Mayne Revenue Up 36% To $50m, Profit Down 48% To $1.7m; Phylogica Revenue Up 259% To $2.5m, Loss Down 21% To $3.6m; Compumedics Profit Down 80% To $81k, Revenue Down 5% To $31m; Avita Revenue Up 17% To $4.5m, Loss Down 67% To $2m; Resonance Revenue Down 4% To $2m, Loss Up 210% To $317k; Probiotec Revenue Down 2% To $74m, Profit Turns To $10m Loss; Nusep Share Purchase Offer Raises $2m; Isonea Agreement With Unnamed Fortune 500 Company; Virax Has Less Than One Quarter Cash; $2.5m Placement; Cellmid $8m La Jolla Cove Convertible Note EGM; Resmed Appoints Robert Douglas COO, 20m Share Buy-Back; ASX Frees Acrux From Appendix 4C Quarterly Reports; Uscom Loses Director Bruce Rathie
 
Aug 30, 2011
GI Dynamics IPO Raises $80m Of Hoped For $95m; Two Weeks To Nominate For $7k Ausbiotech GSK Student Award; Universal Biosensors, J&J’s Lifescan Amend Licence; Ellex Revenue Down 9% To $43m, Profit Turns To $700k Loss; Optiscan Revenue Down, Cuts Costs, $14k Maiden Profit; Licences, Fees Return Imugene To $416k Profit; Impedimed Revenue Up 10% To $4m, Loss Up 30% To $15m; Probiomics Revenue Up 25% To $940k, Loss Down 99% To $1k; Bioprospect Revenue Up 1162% To $499k, Loss Down 2.5% To $3m; Karmelsonix Becomes Isonea
 
Aug 29, 2011
Victoria $7m Biotech Secondary School At University High; Cathrx Signs 2nd Commercialization Term Sheet; Immuron Readies For Israel Phase I/II IMM255 Influenza Trial; Nanosonics Revenue Up 93% To $3m, Loss Up 37% To $11m; Phosphagenics H1 Sales Up 203%, Loss Up 697%; Medical Developments Revenue Up 23%, Profit Up 98% To $2m, Dividend; Australian Patent For Allied’s Adapt Bovine Patch; Bank Of New York Mellon Quits Cochlear; Orbis Takes 19% Of Impedimed; Australian Leaders Takes 7.7% Of Atcor
 
Federal 45% R&D Tax Credit Awaiting Royal Assent; Atcor Revenue Down 19% To $7.5m, Loss Up 153% To $3m; Avita Appoints Dr Michael Mendicino R&D Manager; ITL $940k Turnaround Profit, Revenue Flat At $41m; Actinogen EGM To Acquire Celgenics; Simon West Reduces, Diluted To 6% Of Phosphagenics
 
Aug 25, 2011
Sirtex Revenue Up 1.2% To $73m, Profit Down 29% To $11.5m; Genetic Technologies Maiden Profit; Revenue Up 111% To $18m; FDA Approves Avita Recell Scar Treatment Trial; QRX Files Moxduo Clinical Data Pack To FDA; Genetic Technologies, Attomol Settle Patent Action; QRX Rights Issue Raises $1.5 Of Hoped For $10m; Immuron Places $517k; Cogstate Claims $1m Depression Trial Contract; CBio, Springtree Terminate Draw Down Equity Loan
 
Aug 24, 2011
Long-Awaited Federal 45% R&D Tax Credit On The Way; Spinifex Raises Further $6.5m For Pain Drug Trials; Viralytics Prepares For FDA-Approved Phase II Melanoma Trial; Bayer To Cancel Tyrian Agreements, Review, Redundancies; Mesoblast Revenue Up 15,708% To $121m, Profit Up 713% To $91m; Cogstate Revenue Down 15% To $8m, Profit Turns To $846k Loss; Quixote Investment Takes 17% Of Cogstate; Spartan Takes 6% Of Acuvax
 
Aug 23, 2011
Dr Georgina Such Wins $20k L’Oréal Prize For Drug Delivery; Acrux Revenue Up 67% To $93.5m, Profit Up 23% To $57m; Cryosite Revenue Up 8.5%, Profit Up 7,149% To $334k; Priceline To Sell Phosphagenics Cosmetics; Helicon Improves Nasal Airflow Device; Robert Martin, Accord Take 13% Of Acuvax; OBJ Says USPTO Has Allowed Drug Delivery Patent; Chemeq, Pallane, Stirling Fail To Pay ASX Listing Fees
 
Aug 22, 2011
Mesoblast Treats 1st Stem Cell Lumbar Disc Patient; Immuron On-Track For FDA Phase IIb IMM-124E Nash Trial; Living Cell Implants 1st Argentinian Diabetes Patients; Patrys Detects PAT-SM6 In Target Tumors; Michael J Fox Grants $200k For Prana Preclinical Work; Victorian Government $50k For GSK, Starpharma Cosmetics; Pharmaxis Files Re-Exam Documents To European Committee; ASX Asks IM Medical EGM Resolution Questions; Cogstate Acquires Axon, Appoints Rudy Chapa US Director
 
Aug 19, 2011
Cathrx Signs European Commercialization Term Sheet; Compumedics Expects Small Profit ; Nominations Open For $50k AIPS, CSL Florey Medal; Baillie Gifford, Associates Take 5% Of Cochlear; Manning & Napier Takes 5% Or 5.5% Of Cochlear; Bone Loses Director Dr Barry Walker; Pharmaust (Going Mining) Adds Geologist Director
 
Aug 18, 2011
Starpharma Swaps Condom Companies; Delay To Market; Little Dissent At Sunshine Heart EGM; Victoria Auditor-General: Biotech Investment Qualified Tick; Brain Profit Down 88% To $269k; Revenue Down 31% To $5.65m; Healthlinx Share Plan Raises $136k
 
Aug 17, 2011
Scale-Up, Deployment Issues Delay Reva Stent Trial 6 Months; Biotech Wins $2.2m Of Commercialisation Australia’s $8m; Patrys Compound Active Against Multiple Myeloma; Psivida, Hospital For Special Surgery Orthopaedics Trial; FDA Allows Novogen, Marshall Edwards Phase I Tumor Trial; Correction: Australian Ethical Takes 8% Of Neuren; Biota Revenue Down 78% To $15m, Profit Turns To $28m Loss; CSL Profit Down 11% To $941m, Revenue Down 7% To $4,322m; IDT Loss Down 20%, Revenue Up 7% To $13m; Immuron 1-For-5 Rights Issue To Raise Up To $4.4m; Hunter Hall Reduces 1.5% In Fluorotechnics; Garvan’s Prof John Shine To Chair CSL; Three IM Medical Resolutions Fall, Dr Williams Prevails
 
Biosceptre Raises $8m For Cancer Product, Targets; Neuren Places $3m Shortfall Shares, Australian Ethical Takes 11%; Start-Up Claims 18% PA Return On Innovation Funds; Leaf Ships 1st Product, Misses $250 Milestone; Viralytics 1-For-10 Consolidation Completed; BPH: Cortical Dynamics IPO Extended
 
 
Pharmaxis Sales Up, Revenue Down 17% To $4.5m, Loss Down 1%; LBT Revenue Down 81% To $740k, Profit Turns To Loss; Correction: Nusep, The Sub-Editor And The Moose; AMP Takes 5% Of Sirtex; Tempo Ceases In Antisense
 
Phenomics Facility Doubles Mouse Library In 6 Months; EGM Fight Looms Between IM Board, Dr Laurie Williams; Nusep Share, Options Offer EGM; Ibsen Takes 5% Of Optiscan; Fermiscan Pleads Schultz To ASX 257% Query
 
Biotech Wins 2 Of 17 ARC Laureate Fellowships; Goodbye Cellestis, Welcome Genetic Technologies, Allied; USPTO Grants Further Imaging Patent To Optiscan; Hunter Hall Buys 2m Biota Shares; Helicon Buys ‘$200m’ Nanotechnology For $3.5m Shares; Up To 33% Of EGM Votes Oppose Karmelsonix Chairman Shares
 
 
WEHI, Abbott, Genentech Phase I ABT-199 Leukaemia Trial; Medical Developments Enrols 1st UK Clinical Trial Patient; USPTO Grants Benitec Further Graham Family ddRNAi Patent; Prana Appoints Lawrence Gozlan Director
 
Prima Wins $5.5m Grant, Cites Dendreon For ASX 37% Fall Query; Resmed 2011 Record Revenue Profit, 66th Consecutive Quarter; Heartware H1 Revenue Up 88% To $38m, Loss Up 8%; Bluechiip Tells ASX: Cash Sufficient, One-Off Costs; Benitec Relocates To Sydney, Greg West Appointed CFO
 
Alchemia ‘Delighted’ By Long-Awaited Fondaparinux Launch; Cellestis Declares 6c Special Dividend; Eastland Option Rights Issue To Raise $491k; Blackrock Returns To Substantial In CSL; Viralytics Deferred Settlement Trading, Code; Leaf Energy’s CEO Ken Richards Starts On $190k
 
Bionomics Ends Mesothelioma Trial; BNC105 ‘Safe’ In Renal Ca; Investors Back Qiagen Cellestis Takeover; FDA Clears Resonance Cardiac Iron Test; Fermiscan Placement To Raise $2m, Changes Directors; Up To 45% Of Votes Oppose Eastland 22.5m Directors Options; New Emerging Fund Takes 5% Of Sunshine Heart; Sunshine Heart Appoints Gregory Waller Director; Dr John Domagala Joins Biota’s Scientific Advisor Board

Aug 2, 2011
Novogen Sells Consumer Health Business For $10m; Bioniche, Plasvacc Deal Falls Through; Bluechiip Gearing-Up For Commercialization; Anteo Appoints Mark Bouris Chairman; Federal Grant Underpins Vaxxas $15m For No Needle Patch; Cellmid Completes Technology Transfer, GMP Production; Up To 30% Of Votes Oppose Viralytics 29m Director Options; Leaf Appoints Ken Richards CEO, Dr Jay Hetzel Director; Orbis Takes Profit On 1.8m More Acrux Shares; Australian Ethical Takes 13% Of Avita; Bone Appoints Founder Dr Roger New Chairman
 
July BDI-40 Up 4.5%, ASX200 Down 4.0% -Year To July 31: BDI-40 Up 74.2%, ASX Down 1.5%; Biodiem Regains ’Flu Vaccine Rights, Expands Licences; CBio Misses Phase IIa XToll Rheumatoid Arthritis Endpoint; Avita Unaudited Revenue Up 19% To $4.5m; Karmelsonix Has One Quarter Cash, Funds Coming; Bionomics BNC105 Cancer Trial Results Trading Halt; M&G Group Takes 9% Of Mesoblast
Genetic Technologies Raises $12m, ASX 23% Query; Immune Systems Raises $2.6m; Biotech Wins $1m Of Commercialisation Australia’s $5m; Victoria’s $1.6m For Medical Research Commercialization Fund; Sirtex Says Dose Sales Up 19% For Year; Novogen Ready To Sell Consumer Products; Mandolin, Robert Towner Diluted In Allied Health; Bio-SA’s 2011 Biosciences Strategy; BPH’s Cortical Dynamics $2m IPO Delayed One Month; Bioprospect Loses Snr Sgt Anthony Langdon, Jumps 37.5%



June 3, 2011

BPH’s Cortical Dynamics $2m Brain Anaesthesia Monitor IPO; Biomd Early Look Shows Adapt Heart Valve Superior; Bionomics Details Kidney Cancer Program; Healthlinx Ovplex Ovarian Cancer Test Australian Patent; Novogen’s Marshall Edwards Appoints Dr Robert Mass CMO

June 2, 2011

US Inc Research Buys Trident Clinical Research; Medical Developments Upgrades Expected Profit To $1.5m; Bioprospect Share Issue, Gasfield Drilling EGM; Stirling Loses Director Gulshan Jugroo

June 1, 2011

Pharmaxis Drags May BDI-40 Down 3.8%; ASX200 Down 2.4% - Benetic Up 158%, Viralytics Up 81%, Genetic Technologies Up 60%; Cephalon Takes Chemgenex; Compulsory Acquisition; Phosphagenics AGM Clear Win, Dissent On Executive Shares; Pharmaust’s Epichem Wins $1.8m Contract Extension; Bone Share Issue EGM; Probiotec Sells Non-Core Assets, Loss-Making Businesses; Norwood Shareholders Back Chinese Coal Mining; Greg, Jo-Anne Beirne Take 9% Of Benitec

May 31, 2011

WEHI ‘Upends Theory Of How Cells Grow And Move’; Dubai Approves Prima’s CVac For Ovarian Cancer; Johns Hopkins Uses Benitec Variant For Prostate Cancer; Genetic Technologies Processes First US Brevagen Sample; Cephalon 0.5% From Chemgenex Compulsory Acquisition; Biomd Takes 87% Of Allied Medical; ASX Queries Pharmaxis Trading Halt, Reply Backs CEO Sales; OMI Director Gary Stewart Replaces Co Sec David Woodford; ARC Linkage Grants In Full

May 30, 2011

Biotech, Biological Science Win $19m ARC Linkage Grants; Centaurus Takes 8% Of Cellestis, Loses Derivatives; Merck Serono Wins Top Employer Gong; Solagran Finds $4.6m Loans, Credit; Stirling Zodiac Immune Network Sublingual TB Agreement

May 27, 2011

Sweden - First European Approval For Acrux’s Ellavie; Cephalon Lifts Chemgenex Option Condition, 2% Shares To Go; BNP Paribas Takes Loss, Reduces To 7% Of Pharmaxis; Nusep Profit Turns To Loss, Additional Directors Sought; UBS Ag Takes 5% Of Probiotec; Acuvax Hopes To Raise $275k

May 26, 2011

Prima Raises $21m; Genetic Technologies Sues GSK, BMS, Pfizer, 7 More; Avita Launches Recell Wound Treatment In Gulf States; Virax Share Issue EGM; Fisher Funds Cease Substantial In Pharmaxis; Biomd Takes 65% Of Allied Medical; Citigroup Takes 10% Of Phylogica; Dr Marie Roskow Replaces Patrys CEO Dan Devine; Benitec Appoints Gregory West Joint Company Secretary

May 25, 2011

Pharmaxis Falls 74% On Euro Trend Vote Against Bronchitol; Marc Sinatra’s Bioguide Brief: ‘Why I Wasn't Holding PXS’; WEHI Wins $2m For Malaria And Immunity Research ; Prima Placement, Share Plan To Raise $38m; Cellmid’s Licencee Claims Lung Cancer Diagnostic Accuracy; Japanese To Grant Benitec RNAi Hepatitis C Patent; Viralytics Presents Cavatak For Tumor Efficacy Data; Tissue Therapies Rights Issue Raises $4m, $5m Placed; Virax $2m 1-For-2 Rights Issue, $1m Placement; Reva Investors Back All Resolutions, Tight Rein On Pay; Helicon Explores Ozpharma’s Sub-Lingual Route

May 24, 2011

Resmed Reorganizes Management For New Indications; Cancer Trials Australia Closes Trial, Translational Lab; Germany, Brazil Approve Reva Rezolve Stent Trial; Cephalon Slowly Increases To 84% Of Chemgenex; US Dental Pulp Fat Composition Patents For Mesoblast; Australian Methods Patent For Clinuvel’s Scenesse; Immuron Appoints Dr Arun Sanyal For IMM-124E Phase IIb Trial; Fullerton Takes 8% Of OMI

May 23, 2011

Starpharma Phase II Trial Selects 1% Vivagel Vaginosis Dose; 3m Develops Phosphagenics Oxycodone Pain Relief Patch; Resonance Trial Backs Fatty Liver Diagnostic; Phylogica Extends Roche Neurologic Disorders Licence; FDA Questions Viralytics Phase II Melanoma Trial Design; Cogstate $1.5m Depression Contract; Cephalon Closing-In On Chemgenex Takeover, 7% Shares To Go; Pharmaxis Requests EU Cystic Fibrosis Trading Halt
Psivida: Alimera Reapplies To FDA For Iluvien For DME; Narhex, China Academy Partner On DG17 For HIV, 7.5m Options; Nanosonics Signs GE Sales Deal; Loses CEO David Radford; Cephalon Takes 76% Of Chemgenex Shares, 86% Options; Uscom Extends European Distribution; Anteo Loses Chairman, Transocean Ceases, ASX 16% Query; Calzada Tells ASX News May Have Pushed Price 92%; Avita Requests Capital Raising Trading Halt; Compumedics Appoints Bob Daspit US Sales Manager; Massachusetts Mutual Life Reduces To 11% Of Novogen; Bionomics Appoints Melanie Young CFO, Co Sec
Bionomics Cashed-Up And Ready To Go; Patrys Contracts Laureate For PAT-LM1 Production; Heartware Investors Keep Tight Rein On Executive Pay; Medivac Completes Metamizer 240SSS Waste System; Verva AGM Approves $2m; Cephalon Creeps Up To 74% Of Chemgenex, Extends Offer Budget Ignores Biotech; CSIRO, NHMRC Safe; Editorial Comment; Ausbiotech Details Budget Impacts, Comments; Neuren Treats 30 Brain Injury Patients, Dose Increased; Centaurus Takes 5% Of Cellestis With Derivatives; Bluechiip Raises $3m For Tracking Device; Biotech Capital Ceases Substantial In Phylogica; UAE Approves Solagran’s Bioeffective A
Bionomics: ‘Neurogenesis Paper Supports BNC210’; Euro Committee Backs Acrux Recuvyra Dog Pain Relief; Phylogica, Pepscan Optimization Collaboration; Starpharma Licences Japan’s Okamoto For Vivagel Condoms; Euro Patent For Healthlinx AGR2 Biomarker; Cephalon Takes 68% Of Chemgenex; Novogen Closes Isoflavone Sale To Marshall Edwards; CBio Tells ASX: Cash Sufficient, Trial Costs, Capital Raising; Solagran Wins Share-Trading Apology From The Age; OMI Requests Acquisition, Capital Raising Trading Halt WEHI Claims ‘Promising’ Phase I Coeliac Trial Results; Novogen EGM Backs Isoflavone Sale To Marshall Edwards; Cephalon Takes 67% Of Chemgenex; Stirling Claims $5m India Telemedcare Deal ; Wilson HTM Ceases Substantial In Cathrx; Jetan Ceases Substantial In Fermiscan WEHI, University Of Melbourne Identify Kufs Disease Gene; Heartware First Quarter Revenue Up 68% To $18m, Loss Up; Cephalon Takes 64% Of Chemgenex ; Helicon Director Graeme Boden Resigns; Stirling Appoints Jeremy Cocks CEO, John Botten Advisor
Psivida: ‘Greater Iluvien Benefit In Veteran DME Patients’; Glaxosmithkline Profit Down 97%, Revenue Falls 20% To $1.5m; Lang Walker Takes 13% Of Neuren; Benitec EU, US Gene Silencing Patents; Australian Lenders Takes 5% Of Atcor Through UBS AG Chemgenex, Mesoblast Welcome Teva Validation Of Cepahlon; Novogen’s Marshall Edwards Raises $US4m; Victorian Government Budgets $7.9m For Innovation; Karmelsonix Appoints Omron Distributor; Ellex Claims Early Sustained AMD Efficacy; Argentina Approves Living Cell Diabecell Trial; Healthlinx Appoints CPC To Assist With FDA Pathway ; Prima Appoints CFO Ian Bangs Joint Co Sec; Bio-Melbourne Briefing: Using Commercialisation Australia
Apr 1, 2011
 		Mar 31, 2011
 		Mar 30, 2011
Mar 29, 2011
 		Mar 28, 2011
 		Mar 25, 2011
Mar 24, 2011
 		Mar 23, 2011
 		Mar 22, 2011
Mar 21, 2011
 		Mar 18, 2011
 		Mar 17, 2011
Mar 16, 2011
Prana: ‘PBT434 Works Upstream Of Dopamine In Parkinson’s’; Japan Tragedy No Impact So Far On Biota, Cellmid; Phosphagenics Commitments Reach $7.1m; NZ Fisher Funds Takes 5% Of Pharmaxis; Australian Ethical Below 5% In QRX; Takes 68% Profit; Manifest Ceases Substantial In Fermiscan, No Comment; Fluorotechnics Changes Board For Acquisition; Hyperion Takes 5% Of Cochlear		 Mar 15, 2011
Biota’s Peter Cook On Agency $300m, Patent Cliff, Share Price; Living Cell Loses Director Robert Finder; Solagran Explains $50m Tomsk Plant		 Mar 14, 2011
Phosphagenics Placement To Raise $5.6m For Oxycodone Patch; Silent Restart For Narhex; Pharmaust EGM To Ratify Placement Issue; Genesis Appoints Daniel Mahnert-Lueg, Graham Chin Directors
Mar 11, 2011
 		Mar 10, 2011
Sirtex On The Move; Refutes AFR Funding Claim; Resonance Expands Novartis Iron Overload Deal; Neuren Pleads Schultz, Presentation To ASX 29% Price Query; Ellex Distributes Staar’s Lenses; M&G Group Increases To 6.1% Of Mesoblast; Phosphagenics Requests ‘Funding Event’ Trading Halt; Biotron Half-Way In Hepatitis C Trial Dosing; IM Medical Meeting To Roll The Board; Safety Medical Explores Three Rivers Copper		 Mar 9, 2011
Mar 8, 2011
Immuron Research Shows Efficacy Against Many HIV Strains; Eastland Share Plan To Raise Up To $1.5m; Compumedics’ $500k Children’s Hospital EEG Contract; Atcor Signs $600k Supply Contract; NHMRC Announces Four More $4m Australia Fellowships; Australian Ethical Takes 7.4% Of Atcor 		Mar 7, 2011
 		Mar 4, 2011
Trouble At Atec, Neopec Mills: Dr Palmer, Dr Mountford Go; Biotechs Win $2.3m Of Commercialisation Australia’s $13m; Federal Government Calls For Patent Standards Submissions; Atcor: ‘15-Year Taiwan Study Backs Central Blood Pressure’; Advanced Surgical Signs Ortho Group Surgeons; Mesoblast Joins S&P ASX300, Wilson HTM Slips From All Ords; Prana’s Prof Ashley Bush Wins $4m NHMRC Fellowship; NHMRC $4m Brings Prof John Quackenbush To Brisbane ; CBio XToll Japanese Patent Granted ; JCP Takes 5.1% Of Resmed; Bio-Melbourne Breakfasts On FDA-Backed Diagnostic Apps
Mar 3, 2011
Questions Raised On Atec; Neopec Safe; Federal Government Report ‘Boosts Clinical Trials Efforts’; Calzada’s Polynovo Completes Animal Burns Trial; Clinuvel Ready For Scenesse Trial For Vitiligo; Starpharma Wins $250k Victoria Agriculture Dendrimer Grant; Phosphagenics Partners On Bovine Mastitis; Giaconda Administrators Appointed; Fabio Pannuti Takes 7.4% Of Helicon; EU Grants Agenix Antibody Patent		 Mar 2, 2011
Ausbiotech Wins Support To Oppose ‘Patent Amendment Bill’; MHRI $500-A-Seat Celebrity Bake-Off For Research Funds; Bone Appoints Peter Young CEO; Bioprospect Requests ‘Strategic Investment’ Trading Halt; Narhex Loses Company Secretary Mourice Garbutt; Karmelsonix To Launch Wholter Asthma Monitor; Pallane ‘Corrective Announcement’		 Mar 1, 2011
February BDI-40 Down 3.4%, ASX200 Up 1.6% - Viralytics Up 47%; Genera Down 36%; Australian Patent For Immuron Influenza Preventative; Bone, IM Medical, Solagran Suspended On Accounts; Karmelsonix Wisconsin Hospital Service Agreement; Universal Biosensors Appoints Paul Wright CEO
Feb 28, 2011
 		Feb 25, 2011
 		Feb 24, 2011
Acrux H1 Revenue Up 16,031% To $90.5m, $57m Profit, 60c Dividend; Optiscan H1 Revenue Up 94% To $1.4m, Turnaround Profit; Virax: Roche Ends Transgene TG4001 Licence; Immuron Expects 50% Travelan Sales Increase; Pallane (Dia-B) To Change Name To Vita For Obesity, Diabetes; Coridon Appoints Neil Finlayson, Dr Julian Chick, Lee Rodne; Avexa To Sell Biomd 20% Of Allied Medical; New Directors; UK Patent For Healthlinx Ovplex Ovarian Cancer Test; Genetic Technologies H1 $4m Maiden Profit; Revenue Up 183%; Australian Patent For Living Cell’s Immupel Encapsulation; Biotron Share Plan To Raise Up To $3.5m; Giaconda Requests ‘Capital Requirements’ Trading Halt
Feb 23, 2011
 		Feb 22, 2011
 		Feb 21, 2011
Feb 18, 2011
 		Feb 17, 2011
 		Feb 16, 2011
Feb 15, 2011
 		Feb 14, 2011
 		Feb 11, 2011
Viralytics’ Cavatak Preclinical Data For Pancreatic Cancer; Progen PG545 Significantly Inhibits Metastases In Mice; Resonance Jumps 104.5% On Pfizer Fibroscreen Deal; Ecobiotics Funds UQ’s Dr Craig Williams For Rainforest Drugs
Feb 10, 2011
 		Feb 9, 2011
Clinuvel Completes US Phase II Scenesse For EPP Study ; Mesoblast EGM Votes For Cephalon And Its $30m; Relevare Reschedules ASX IPO For March 2011; NSW Police Extends Genetic Technologies Forensics Testing; Starpharma Says Reports May Have Pushed Price Above $1; Acuvax Loses CEO Dr William Ardrey, All Changed, Again; Xceed Votes To Divest Boron Molecular; Pharmaust Requests ‘Significant Transaction’ Trading Halt		 Feb 8, 2011
Feb 7, 2011
Phosphagenics’ US Transdermal Psoriasis Collaboration; Phylogica Hopes To Be ‘Cash Sustainable’ By July 2012; Biotron Tells ASX: Phase II Trial Burnt Cash, Capital Raising; Solagran Tells ASX: Legal Fees Burnt Cash, Income Expected; Barleigh Wells Ceases Substantial In Cyclopharm; IM Medical Loses Two More Directors; Stirling Requests Capital Raising Trading Halt		 Feb 4, 2011
WEHI Says Immune Boost Response May Be Key To HIV Cure; Psivida’s Iluvien Significant At 33 Months, But Not 36 Months; Bionomics Files Patents For Memory Enhancing Compounds; GSK Pays Biota $1.2m Relenza Royalty; Xceed Sells Boron For $1.5m To Welvic Australia; Australian Ethical Takes 5.3% Of Atcor; Langley Walker, Group Cease Substantial In Acrux; Anthony Barton Reduces 2.3% In Phylogica; Fermiscan Issues $767k Share Plan Prospectus		 Feb 3, 2011
Feb 2, 2011
 
 		 Feb 1, 2011
 		Jan 31, 2011
Jan 28, 2011
 		Jan 27, 2011
Pharmaxis On The Verge Of Bronchitol Revenue; Bioniche Lists Up 2c To $1.52; Viralytics Says Three More Coxsackieviruses Show Efficacy; Métier Tribeca Expands Phosphagenics’ US Cosmetic Range; Karmelsonix Has One Quarter Cash; Biotron Has Less That Two Quarters Cash; Tissue Therapies Pleads Schultz To 23% Price Fall Query; H1 Loss Up; CBio Appoints EMEA’s Dr Thomas Lönngren Director 		 Jan 25, 2011
FDA Allows 94 More Heartware Bridge-To-Transplant Patients; Heartware Co-Funds Early Intervention Heart Pump Study; US Patent For Progen’s PG500 Series; Pharmaxis Addresses European Outstanding Issues
Jan 24, 2011
QRX Moxduo Trial v Equal Strength Morphine, Oxycodone; Novogen Pleads Schultz To ASX 70% Price Query; Up 50%; Trident Revives Safety Medical, Returns To ASX Tomorrow; Avita Placement Raises $722k; Clinuvel May File In 2011, Stays Focused, Considers New Drugs; LBT Appoints Dr Mike Hirshorn Director; Phylogica Wins Frost & Sullivan Gong		 Jan 21, 2011
Bluechiip Hires ST Microelectronics For Tracking Tags; James Besser Below 5% In Genetic Technologies, Takes $1m Profit; Neurodiscovery Option Placement, Rights Issue For $685k; Neurodiscovery To ASX: Funding May Have Pushed Price 60%; Nasdaq Extends Novogen’s Compliance Period 180 Days		 Jan 20, 2011
Jan 19, 2011
 		Jan 18, 2011
Nusep Share Plan Raises $1m; Narhex Completes DOCA, Directors Change; To Raise $2.5m; Australia Tells Resonance To Reapply For Ferriscan Funding; UBS Takes 6.5% Of CBio		 Jan 17, 2011
Queensland Biotechs Escape Floods Almost Unscathed; Genetic Technologies, Sunrise Medical Settle Patent Dispute; Northcape Takes 5% Of Pharmaxis; Transocean Ceases Substantial In Anteo; First Cape Takes 15% Of Anteo; Immuron Appoints Avexa’s Joe Baini Interim CEO